text,title,id,project_number,terms,administration,organization,mechanism,year,funding,score
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       ",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6229855,K01CA089267,"['cell cell interaction ', ' gene expression ', ' gene mutation ', ' human subject ', ' model design /development ', ' mathematical model ', ' adenocarcinoma ', ' neoplasm /cancer genetics ', ' neoplastic growth ', ' telomere ', ' loss of heterozygosity ', ' tumor progression ', ' clinical research ', ' microarray technology ', ' Barretts esophagus ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2001,118630,0.15594081588085806
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       ",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6514835,K01CA089267,"['cell cell interaction ', ' gene expression ', ' gene mutation ', ' human subject ', ' model design /development ', ' mathematical model ', ' adenocarcinoma ', ' neoplasm /cancer genetics ', ' neoplastic growth ', ' telomere ', ' loss of heterozygosity ', ' tumor progression ', ' clinical research ', ' microarray technology ', ' Barretts esophagus ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2002,121263,0.15594081588085806
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       ",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6633897,K01CA089267,"['cell cell interaction ', ' gene expression ', ' gene mutation ', ' human subject ', ' model design /development ', ' mathematical model ', ' adenocarcinoma ', ' neoplasm /cancer genetics ', ' neoplastic growth ', ' telomere ', ' loss of heterozygosity ', ' tumor progression ', ' clinical research ', ' microarray technology ', ' Barretts esophagus ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2003,123974,0.15594081588085806
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       ",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6751681,K01CA089267,"['cell cell interaction ', ' gene expression ', ' gene mutation ', ' human subject ', ' model design /development ', ' mathematical model ', ' adenocarcinoma ', ' neoplasm /cancer genetics ', ' neoplastic growth ', ' telomere ', ' loss of heterozygosity ', ' tumor progression ', ' clinical research ', ' microarray technology ', ' Barretts esophagus ', ' ']",NCI,FRED HUTCHINSON CANCER RESEARCH CENTER,K01,2004,126767,0.15594081588085806
"EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA    DESCRIPTION  (Applicant's  Description):    The  cell  lineages  in neoplastic       tissues are evolving under the twin dynamics of mutation and clonal expansion.       This  is the basis for both its virulence and our difficulties in treating it.       We  hypothesize  that a subset of the mutations observed in the progression to       cancer  confer  beneficial  selective  effects  on  the cell.  Furthermore, we       hypothesize  that  the  interactions  between  these clonal populations in and       around  the neoplastic tissue determine the progression to cancer.  The aim of       this  project  is  to  identify  these  selective  mutations  and to infer the       interactions  between the mutant clones in Barrett's Esophagus that eventually       lead  to  the development of esophageal adenocarcinoma.  This analysis will be       based  on loss of heterozygosity data, promoter methylation, single nucleotide       polymorphisms,  and  gene  expression  data  for homogeneous subpopulations of       cells  sampled  from  neoplastic  tissue in patients with Barrett's Esophagus.       The  tissue  samples  come  from  biopsies of selected patients in the Seattle       Barrett's  Esophagus  Project  (N=285).   Data mining will be used to identify       mutations  that  are associated with clonal expansion as well as inhibition of       neighboring  clones.    The  order  of  genetic  events  in the progression to       esophageal adenocarcinoma will be determined by phylogenetic reconstruction of       the  cell lineages in the neoplastic tissue of each patient.  Machine learning       techniques,  such  as the EM algorithm, will be employed to infer missing data       and the effects of unsampled mutations. Computational modeling will be used to       generate   comparison  data  for  null  hypotheses  as  well  as  to  generate       experimental  predictions from our understanding of the progression to cancer.       This  is  the first step in my long-term career goal to contribute to medicine       through the use of computational and theoretical methods.  Working at the Fred       Hutchinson  Cancer  Research  Center  will  facilitate  the transition from my       background  in  computer  science  and  evolutionary theory, to an independent       research  program  based on the analysis of cellular and molecular dynamics of       cancer.  The challenge of this project is the integration of diverse molecular       and  epidemiological  data  into  a coherent and detailed understanding of the       progression to cancer in the neoplasm of a model system.                                                                                                                                                                                                       ",EVOLUTIONARY DYNAMICS OF BARRETT'S ESOPHAGUS NEOPLASIA,6886821,K01CA089267,"['cell cell interaction ', ' gene expression ', ' gene mutation ', ' human subject ', ' model design /development ', ' mathematical model ', ' adenocarcinoma ', ' neoplasm /cancer genetics ', ' neoplastic growth ', ' telomere ', ' loss of heterozygosity ', ' neoplastic process ', ' clinical research ', ' microarray technology ', ' Barretts esophagus ', ' ']",NCI,WISTAR INSTITUTE,K01,2005,158490,0.15594081588085806
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. ",A Functional Census of p53 Cancer and Suppressor Mutants,6989008,R01CA112560,"['artificial intelligence ', ' tumor suppressor gene ', ' genetic transcription ', ' gene induction /repression ', ' gene mutation ', ' model design /development ', ' mathematical model ', ' neoplasm /cancer genetics ', ' neoplasm /cancer pharmacology ', ' protein sequence ', ' DNA binding protein ', ' recombinant protein ', ' yeast two hybrid system ', ' p53 gene /protein ', ' molecular biology information system ', ' binding site ', ' genetic screening ', ' computational biology ', ' small molecule ', ' ']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2005,363175,0.12289404999660487
"Text Mining Point Mutations for Genetic Diagnosis Array DESCRIPTION:    Text mining applications seek to alleviate the problems with identifying, searching, and extracting relevant information from large sets of literature. The goal of this proposal is to create a text mining application to extract protein point mutations from biomedical literature. The developed application will be used to extract point mutations from literature discussing human genetic disorders, and the retrieved database of point mutations used to design a DNA microarray chip for prenatal genetic diagnosis. First, the text mining application will be developed using machine learning and statistical natural language processing techniques. Second, the point mutation mining application will be applied to a large set of literature related to genetic disorders, and the retrieved point mutations deposited in an electronic database. This collection of point mutations will be examined to find polymorphisms in genes that are markers for genetic disorders. These polymorphic positions in the human genome will be gathered and used to design a DMA microarray chip that can genotype tens of thousands of single nucleotide polymorphisms. The microarray chip can be used for prenatal genetic diagnosis purposes to screen for hundreds of genetic disorders. ",Text Mining Point Mutations for Genetic Diagnosis Array,6993320,F37LM008883,"['biotechnology ', ' point mutation ', ' information retrieval ', ' technology /technique development ', ' molecular biology information system ', ' microarray technology ', ' predoctoral investigator ', ' ']",NLM,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",F37,2005,45812,0.12032152741952665
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. ",A Functional Census of p53 Cancer and Suppressor Mutants,7103691,R01CA112560,"['small molecule ', ' computational biology ', ' genetic screening ', ' binding sites ', ' molecular biology information system ', ' p53 gene /protein ', ' yeast two hybrid system ', ' recombinant proteins ', ' DNA binding protein ', ' protein sequence ', ' neoplasm /cancer pharmacology ', ' neoplasm /cancer genetics ', ' mathematical model ', ' model design /development ', ' gene mutation ', ' gene induction /repression ', ' genetic transcription ', ' tumor suppressor genes ', ' artificial intelligence ', ' ']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2006,356838,0.12289404999660487
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7313297,R01GM028016,"['driving force ', ' imprint ', ' Computers ', ' Purpose ', ' genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Statistically Significant ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Rate ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Facility Construction Funding Category ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' Standards of Weights and Measures ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Numbers ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Personal Satisfaction ', ' well-being ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Condition ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Class ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Pan Genus ', ' Pan Species ', ' Chimpanzee ', ' Chimp ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2007,258957,0.17881891962294247
"Modeling of Protein Complexes and Missense Mutations    DESCRIPTION (provided by applicant): Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of   cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability.    ",Modeling of Protein Complexes and Missense Mutations,7189836,R01GM073784,"['Cystathionine beta-Synthase ', ' methylcysteine synthase ', ' beta-Thionase ', ' Serine Sulfhydrase ', ' L-Serine hydro-lyase (adding homocysteine) ', ' Cystathionine Synthetase ', ' Cell Cycle Checkpoint ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA Repair ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' Homologous Gene ', ' Homologue ', ' Homolog ', ' GeneHomolog ', ' Enzymes ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Disease Association ', ' Homology Modeling ', ' Cancer Genome Anatomy Project ', ' Scheme ', ' Validation ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' protein folding ', ' Affect ', ' Genes ', ' base ', ' Goals ', ' Procedures ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Surface ', ' Link ', ' Ions ', ' Training ', ' Lac Repressors ', ' Ligands ', ' Individual ', ' Numbers ', ' Literature ', ' Bayesian Method ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Maps ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acids ', ' aminoacid ', ' Membrane Proteins ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Statistical Models ', ' Probabilistic Models ', ' Muramidase ', ' Peptidoglycan N-acetylmuramoylhydrolase ', ' N-Acetylmuramide Glycanhydrolase ', ' Lysozyme ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Peptides ', ' Phenotype ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Proteins ', ' gene product ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Rest ', ' Computer software ', ' computer program/software ', ' Software ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Scientist ', ' Time ', ' Inherited ', ' Hereditary ', ' Complex ', ' Side ', ' System ', ' LOINC Axis 4 System ', ' Location ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' dimer ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' monomer ', ' physical property ', ' protein structure function ', ' Biological Neural Networks ', ' neural network ', ' Missense Mutation ', ' Methylenetetrahydrofolate reductase (NADPH) ', ' Methylenetetrahydrofolate Reductase (NADPH2) ', ' Methylenetetrahydrofolate Reductase ', ' Methylene-THF Reductase (NADPH) ', ' Methylene Tetrahydrofolate Reductase ', ' EC 1.5.1.20 ', ' 5,10-Methylenetetrahydrofolate Reductase (NADPH) ', ' Potential Energy ', ' Structure ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' HIV Protease ', ' HTLV-III Protease ', ' HIV Proteinase ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Modeling ', ' protein protein interaction ', ' Online Mendelian Inheritance In Man ', ' OMIM ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' Resistance ', ' resistant ', ' open source ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' loss of function ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2007,307176,0.23629575906004346
"Text Mining Point Mutations for Genetic Diagnosis Array Text mining applications seek to alleviate the problems with identifying, searching, and extracting relevant information from large sets of literature. The goal of this proposal is to create a text mining application to extract protein point mutations from biomedical literature. The developed application will be used to extract point mutations from literature discussing human genetic disorders, and the retrieved database of point mutations used to design a DMA microarray chip for prenatal genetic diagnosis. First, the text mining application will be developed using machine learning and statistical natural language processing techniques. Second, the point mutation mining application will be applied to a large set of literature related to genetic disorders, and the retrieved point mutations deposited in an electronic database. This collection of point mutations will be examined to find polymorphisms in genes that are markers for genetic disorders. These polymorphic positions in the human genome will be gathered and used to design a DMA microarray chip that can genotype tens of thousands of single nucelotide polymorphisms. The microarray chip can be used for prenatal genetic diagnosis purposes to screen for hundreds of genetic disorders. ",Text Mining Point Mutations for Genetic Diagnosis Array,7156197,F37LM008883,[''],NLM,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",F37,2007,45812,0.11951738609585151
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          ",Improve predictions of structure and function by PredictProtein,7207482,R01LM007329,"['Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Protein Analysis ', ' Range ', ' Resolution ', ' Eukaryotic Cell ', ' Evolution ', ' protein function ', ' Development ', ' developmental ', ' Eye ', ' Eyeball ', ' Point Mutation ', ' Sequence Analysis ', ' Sequence Analyses ', ' SEQ-AN ', ' Output ', ' Affect ', ' Genome ', ' Standards of Weights and Measures ', ' base ', ' density ', ' Goals ', ' Grant ', ' improved ', ' Area ', ' Medical ', ' Screening procedure ', ' screenings ', ' screening ', ' Training ', ' Language ', ' Numbers ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Progress Reports ', ' Funding ', ' Maintenance ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Nucleotides ', ' Phenotype ', ' Prokaryotic Cells ', ' prokaryote ', ' Prokaryotae ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' Testing ', ' Adopted ', ' Investigation ', ' Dimensions ', ' Country ', ' Class ', ' Amino Acid Substitution ', ' Biology ', ' Services ', ' Membrane ', ' membrane structure ', ' protein structure function ', ' Budgets ', ' Structure ', ' novel ', ' Eukaryota ', ' Eukaryote ', ' Devices ', ' Proteome ', ' Code ', ' Coding System ', ' Property ', ' LOINC Axis 2 Property ', ' protein protein interaction ', ' portability ', ' Genomics ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' data modeling ', ' protein structure prediction ', ' design ', ' designing ', ' Linux ', ' Plug-in ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' human disease ', ' ']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2007,323192,0.08919152416035385
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. ",A Functional Census of p53 Cancer and Suppressor Mutants,7253241,R01CA112560,"['Bioinformatics ', ' Bio-Informatics ', ' DNA Binding ', ' DNA Binding Interaction ', ' Cell Cycle Arrest ', ' small molecule ', ' Engineering ', ' Systems Biology ', ' Data ', ' Proliferating ', ' Validation ', ' Killings ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Source Code ', ' Affect ', ' base ', ' Goals ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Site ', ' Area ', ' repaired ', ' repair ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Training ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Numbers ', ' Gene Targeting ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Letters ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Life ', ' Catalogs ', ' programs ', ' Specificity ', ' Stress ', ' Suppressor Mutations ', ' Surveys ', ' Survey Instrument ', ' transcription factor ', ' Work ', ' Yeasts ', ' Techniques ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' mutant ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' Missense Mutation ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Cataloging ', ' Cells ', ' Censuses ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' Protein p53 ', ' p53 Tumor Suppressor ', ' p53 Antigen ', ' Tumor Protein p53 ', ' Protein TP53 ', ' Phosphoprotein pp53 ', ' Phosphoprotein P53 ', ' Oncoprotein p53 ', ' Cellular Tumor Antigen P53 ', ' Antioncogene Protein p53 ', ' Modeling ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' computerized tools ', ' computational tools ', ' design ', ' designing ', ' Cancerous ', ' functional restoration ', ' restore lost function ', ' restore functionality ', ' restore function ', ' tumor ', ' ']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2007,333814,0.12289404999660487
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7351411,R01LM009722,"['tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Score ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' Caring ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Phenotype ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Disruption ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' ']",NLM,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2007,329240,0.24928957014145267
"Genotype/Phenotype Correlations in Lysosomal Storage Diseases    DESCRIPTION (provided by applicant): Our long-term goal is to understand the detailed molecular mechanisms that connect genotype, phenotype and response to therapy in lysosomal storage diseases (LSDs). LSDs are a family of genetic metabolic diseases caused by lysosomal enzyme deficiencies. In this project we use Fabry disease as a model system to develop a bioinformatics-based paradigm to address two fundamental issues: 1) The relationship between genotype and phenotype in LSDs. This task is challenging because in LSDs different mutations in the same enzyme often lead to different disease phenotypes. 2) The relationship between genotype and response to ""pharmacological chaperone"" therapy. Pharmacological chaperones are small-molecule ligands that are used to rescue mutants, resulting in increased enzymatic activity; several Fabry mutations have been shown to be rescueable in this way. The same therapy is likely to be useful for other LSDs, particularly those with neurological involvement, for which enzyme replacement therapy is not viable. The two aims of this application address, at different levels, both issues described above. The first aim, tests the hypothesis that knowing the change that occurs in the protein sequence, together with the structural environment in which it occurs, is sufficient to predict the resulting disease phenotype and response to pharmacological chaperone therapy. This is tested through the rigorous training of classification methods using sequence and structure-derived descriptors for a large set of Fabry mutants of known phenotype. The resulting classification provides a large- scale quantitative description of the correlation between genotype and phenotype. The accuracy of predictions based on this approach is a measure of how much information about the genotype the descriptors contain. The same approach will be used to establish a quantitative correlation between genotype and response to pharmacological chaperone therapy. Finally, applying the classification methods to mutations in other LSDs will test the generality of the approach. The second aim of this application addresses the issue of genotype/phenotype correlation from a biophysical point of view. We test the hypothesis that a combination of factors, mainly folding free energy, ligand binding affinity, and relative pH stability of the mutants determines the disease phenotype and response to pharmacological chaperone therapy. This is done analyzing selected mutants using molecular modeling and molecular dynamics simulations of the enzyme/ligand and enzyme/receptor interactions, as well as, pH stability, and other calculations. The methods used in the second aim are very detailed, but are not applicable at a large scale. Thus, both aims provide complementary views of genotype/phenotype correlation in LSDs. The successful completion of this project will, for the first time, provide a quantitative connection between genotype and phenotype in LSDs and a detailed biophysical description of the molecular mechanisms underlying genotype/phenotype correlations and response to pharmacological chaperone therapy in Fabry disease. Relevance of this research to public health. Lysosomal storage diseases (LSDs) are a group of more than 40 genetic metabolic disorders. Worldwide, the incidence of patients with LSDs is estimated to be ~ 1 in 8,000 live births. Understanding the correlation between genotype, phenotype, and response to treatment in these diseases will help in their diagnosis and treatment, particularly for LSDs that affect the brain, for which no effective treatment is available to date.          ",Genotype/Phenotype Correlations in Lysosomal Storage Diseases,7239204,R21DK078345,"['Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding (Molecular Function) ', ' Molecular Interaction ', ' Binding ', ' Diagnosis ', ' Disease ', ' disease/disorder ', ' Disorder ', ' None or Not Applicable ', ' prevent ', ' preventing ', ' small molecule ', ' Endoplasmic Reticulum ', ' Ergastoplasm ', ' Environment ', ' Address ', ' Enzymes ', ' enzyme deficiency ', ' Affinity ', ' Data ', ' Mutate ', ' Ligand Binding ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' Development ', ' developmental ', ' Feedback ', ' Galactosidase ', ' Output ', ' Affect ', ' Genotype ', ' base ', ' enzyme substrate ', ' Goals ', ' improved ', ' Residual state ', ' Residual ', ' Neurologic ', ' Neurological ', ' Incidence ', ' Chemicals ', ' Training ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' insight ', ' Ligands ', ' Numbers ', ' Molecular Chaperones ', ' Chaperone ', ' Lysosomes ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acids ', ' aminoacid ', ' Metabolic Diseases ', ' metabolism disorder ', ' Thesaurismosis ', ' Metabolic Disorder ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Molecular Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Descriptor ', ' Fabry Disease ', ' ceramide trihexosidosis ', ' alpha galactosidase deficiency ', ' Angiokeratoma Corporis Diffusum ', ' Anderson-Fabry Disease ', ' Patients ', ' Phenotype ', ' Genetic ', ' public health medicine (field) ', ' Public Health ', ' Research ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Time ', ' Complex ', ' Live Birth ', ' enzyme structure ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' protein degradation ', ' Regulatory Protein Degradation ', ' Protein Turnover ', ' Metabolic Protein Degradation ', ' receptor ', ' Receptor Protein ', ' receptor binding ', ' enzyme replacement therapy ', ' Protein Replacement Therapy ', ' family genetics ', ' molecular modeling ', ' Molecular Modeling Protein/Amino Acid Biochemistry ', ' Molecular Modeling Nucleic Acid Biochemistry ', ' Brain ', ' Brain Nervous System ', ' Encephalon ', ' Free Energy ', ' Structure ', ' simulation ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Measures ', ' Relative (related person) ', ' Relative ', ' Lysosomal Storage Diseases ', ' inborn lysosomal enzyme disorder ', ' Lysosomal Enzyme Disorders ', ' response ', ' Classification ', ' Systematics ', ' disease phenotype ', ' design ', ' designing ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' ']",NIDDK,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,R21,2007,127125,0.07491216024628815
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7841085,R01LM009722,"['Acetylation ', ' Bio-Informatics ', ' Bioinformatics ', ' disease/disorder ', ' Disorder ', ' Disease ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Dataset ', ' Data Set ', ' Caring ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Ubiquitination ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Funding ', ' Medicine ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Collaborations ', ' Pharmacogenetics ', ' Phenotype ', ' Genetic ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Disruption ', ' Productivity ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' Post-Translational Protein Processing ', ' tool ', ' gene product ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Computational Biology ', ' programs ', ' Testing ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Hereditary ', ' Inherited ', ' Complex ', ' Score ', ' Amino Acid Substitution ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Catalytic Domain ', ' Structure ', ' Basic Research ', ' Basic Science ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' personnel ', ' Manpower ', ' Human Resources ', ' Position ', ' Positioning Attribute ', ' Catalysis ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Peptide Sequence Determination ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computational tools ', ' computerized tools ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' translational medicine ', ' disease-causing mutation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2008,163321,0.24928957014145267
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7457930,R01GM028016,"['Collection ', ' transmission process ', ' Transmission ', ' Rate ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Facility Construction Funding Category ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' Standards of Weights and Measures ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Numbers ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Personal Satisfaction ', ' well-being ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Condition ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Class ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Pan Genus ', ' Pan Species ', ' Chimpanzee ', ' Chimp ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' Purpose ', ' genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Statistically Significant ', ' Taxon ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2008,254996,0.17881891962294247
"Modeling of Protein Complexes and Missense Mutations Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability. ",Modeling of Protein Complexes and Missense Mutations,7369808,R01GM073784,"['Methylenetetrahydrofolate reductase (NADPH) ', ' Methylenetetrahydrofolate Reductase (NADPH2) ', ' Methylenetetrahydrofolate Reductase ', ' Methylene-THF Reductase (NADPH) ', ' Methylene Tetrahydrofolate Reductase ', ' EC 1.5.1.20 ', ' 5,10-Methylenetetrahydrofolate Reductase (NADPH) ', ' Potential Energy ', ' Structure ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' HIV Protease ', ' HTLV-III Protease ', ' HIV Proteinase ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Modeling ', ' protein protein interaction ', ' Online Mendelian Inheritance In Man ', ' OMIM ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' Resistance ', ' resistant ', ' open source ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' loss of function ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Cystathionine beta-Synthase ', ' methylcysteine synthase ', ' beta-Thionase ', ' Serine Sulfhydrase ', ' L-Serine hydro-lyase (adding homocysteine) ', ' Cystathionine Synthetase ', ' Cell Cycle Checkpoint ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA Repair ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' Homologous Gene ', ' Homologue ', ' Homolog ', ' GeneHomolog ', ' Enzymes ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Disease Association ', ' Homology Modeling ', ' Cancer Genome Anatomy Project ', ' Scheme ', ' Validation ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' protein folding ', ' Affect ', ' Genes ', ' base ', ' Goals ', ' Procedures ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Surface ', ' Link ', ' Ions ', ' Training ', ' Lac Repressors ', ' Ligands ', ' Individual ', ' Numbers ', ' Literature ', ' Bayesian Method ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Maps ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acids ', ' aminoacid ', ' Membrane Proteins ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Statistical Models ', ' Probabilistic Models ', ' Muramidase ', ' Peptidoglycan N-acetylmuramoylhydrolase ', ' N-Acetylmuramide Glycanhydrolase ', ' Lysozyme ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Peptides ', ' Phenotype ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Proteins ', ' gene product ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Rest ', ' Computer software ', ' computer program/software ', ' Software ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Scientist ', ' Time ', ' Inherited ', ' Hereditary ', ' Complex ', ' Side ', ' System ', ' LOINC Axis 4 System ', ' Location ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' dimer ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' monomer ', ' physical property ', ' protein structure function ', ' Biological Neural Networks ', ' neural network ', ' Missense Mutation ', ' ']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2008,307176,0.23629575906004346
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          ",Improve predictions of structure and function by PredictProtein,7389563,R01LM007329,"['Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Protein Analysis ', ' Range ', ' Resolution ', ' Eukaryotic Cell ', ' Evolution ', ' protein function ', ' Development ', ' developmental ', ' Eye ', ' Eyeball ', ' Point Mutation ', ' Sequence Analysis ', ' Sequence Analyses ', ' SEQ-AN ', ' Output ', ' Affect ', ' Genome ', ' Standards of Weights and Measures ', ' base ', ' density ', ' Goals ', ' Grant ', ' improved ', ' Area ', ' Medical ', ' Screening procedure ', ' screenings ', ' screening ', ' Training ', ' Language ', ' Numbers ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Progress Reports ', ' Funding ', ' Maintenance ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Nucleotides ', ' Phenotype ', ' Prokaryotic Cells ', ' prokaryote ', ' Prokaryotae ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' Testing ', ' Adopted ', ' Investigation ', ' Dimensions ', ' Country ', ' Class ', ' Amino Acid Substitution ', ' Biology ', ' Services ', ' Membrane ', ' membrane structure ', ' protein structure function ', ' Budgets ', ' Structure ', ' novel ', ' Eukaryota ', ' Eukaryote ', ' Devices ', ' Proteome ', ' Code ', ' Coding System ', ' Property ', ' LOINC Axis 2 Property ', ' protein protein interaction ', ' portability ', ' Genomics ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' data modeling ', ' protein structure prediction ', ' design ', ' designing ', ' Linux ', ' Plug-in ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' human disease ', ' ']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2008,320418,0.08919152416035385
"Genotype/Phenotype Correlations in Lysosomal Storage Diseases    DESCRIPTION (provided by applicant): Our long-term goal is to understand the detailed molecular mechanisms that connect genotype, phenotype and response to therapy in lysosomal storage diseases (LSDs). LSDs are a family of genetic metabolic diseases caused by lysosomal enzyme deficiencies. In this project we use Fabry disease as a model system to develop a bioinformatics-based paradigm to address two fundamental issues: 1) The relationship between genotype and phenotype in LSDs. This task is challenging because in LSDs different mutations in the same enzyme often lead to different disease phenotypes. 2) The relationship between genotype and response to ""pharmacological chaperone"" therapy. Pharmacological chaperones are small-molecule ligands that are used to rescue mutants, resulting in increased enzymatic activity; several Fabry mutations have been shown to be rescueable in this way. The same therapy is likely to be useful for other LSDs, particularly those with neurological involvement, for which enzyme replacement therapy is not viable. The two aims of this application address, at different levels, both issues described above. The first aim, tests the hypothesis that knowing the change that occurs in the protein sequence, together with the structural environment in which it occurs, is sufficient to predict the resulting disease phenotype and response to pharmacological chaperone therapy. This is tested through the rigorous training of classification methods using sequence and structure-derived descriptors for a large set of Fabry mutants of known phenotype. The resulting classification provides a large- scale quantitative description of the correlation between genotype and phenotype. The accuracy of predictions based on this approach is a measure of how much information about the genotype the descriptors contain. The same approach will be used to establish a quantitative correlation between genotype and response to pharmacological chaperone therapy. Finally, applying the classification methods to mutations in other LSDs will test the generality of the approach. The second aim of this application addresses the issue of genotype/phenotype correlation from a biophysical point of view. We test the hypothesis that a combination of factors, mainly folding free energy, ligand binding affinity, and relative pH stability of the mutants determines the disease phenotype and response to pharmacological chaperone therapy. This is done analyzing selected mutants using molecular modeling and molecular dynamics simulations of the enzyme/ligand and enzyme/receptor interactions, as well as, pH stability, and other calculations. The methods used in the second aim are very detailed, but are not applicable at a large scale. Thus, both aims provide complementary views of genotype/phenotype correlation in LSDs. The successful completion of this project will, for the first time, provide a quantitative connection between genotype and phenotype in LSDs and a detailed biophysical description of the molecular mechanisms underlying genotype/phenotype correlations and response to pharmacological chaperone therapy in Fabry disease. Relevance of this research to public health. Lysosomal storage diseases (LSDs) are a group of more than 40 genetic metabolic disorders. Worldwide, the incidence of patients with LSDs is estimated to be ~ 1 in 8,000 live births. Understanding the correlation between genotype, phenotype, and response to treatment in these diseases will help in their diagnosis and treatment, particularly for LSDs that affect the brain, for which no effective treatment is available to date.          ",Genotype/Phenotype Correlations in Lysosomal Storage Diseases,7388981,R21DK078345,"['Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding (Molecular Function) ', ' Molecular Interaction ', ' Binding ', ' Diagnosis ', ' Disease ', ' disease/disorder ', ' Disorder ', ' None or Not Applicable ', ' prevent ', ' preventing ', ' small molecule ', ' Endoplasmic Reticulum ', ' Ergastoplasm ', ' Environment ', ' Address ', ' Enzymes ', ' enzyme deficiency ', ' Affinity ', ' Data ', ' Mutate ', ' Ligand Binding ', ' Principal Investigator ', ' Characteristics ', ' Molecular ', ' Development ', ' developmental ', ' Feedback ', ' Galactosidase ', ' Output ', ' Affect ', ' Genotype ', ' base ', ' enzyme substrate ', ' Goals ', ' improved ', ' Residual state ', ' Residual ', ' Neurologic ', ' Neurological ', ' Incidence ', ' Chemicals ', ' Training ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' insight ', ' Ligands ', ' Numbers ', ' Molecular Chaperones ', ' Chaperone ', ' Lysosomes ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acids ', ' aminoacid ', ' Metabolic Diseases ', ' metabolism disorder ', ' Thesaurismosis ', ' Metabolic Disorder ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Molecular Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Descriptor ', ' Fabry Disease ', ' ceramide trihexosidosis ', ' alpha galactosidase deficiency ', ' Angiokeratoma Corporis Diffusum ', ' Anderson-Fabry Disease ', ' Patients ', ' Phenotype ', ' Genetic ', ' public health medicine (field) ', ' Public Health ', ' Research ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Time ', ' Complex ', ' Live Birth ', ' enzyme structure ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' protein degradation ', ' Regulatory Protein Degradation ', ' Protein Turnover ', ' Metabolic Protein Degradation ', ' receptor ', ' Receptor Protein ', ' receptor binding ', ' enzyme replacement therapy ', ' Protein Replacement Therapy ', ' family genetics ', ' molecular modeling ', ' Molecular Modeling Protein/Amino Acid Biochemistry ', ' Molecular Modeling Nucleic Acid Biochemistry ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Free Energy ', ' Structure ', ' simulation ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Measures ', ' Relative (related person) ', ' Relative ', ' Lysosomal Storage Diseases ', ' inborn lysosomal enzyme disorder ', ' Lysosomal Enzyme Disorders ', ' response ', ' Classification ', ' Systematics ', ' disease phenotype ', ' design ', ' designing ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' ']",NIDDK,ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI,R21,2008,124583,0.07491216024628815
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7502757,R01LM009722,"['Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' Caring ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Phenotype ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Disruption ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Score ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' ']",NLM,INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS,R01,2008,158863,0.24928957014145267
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. ",A Functional Census of p53 Cancer and Suppressor Mutants,7426313,R01CA112560,"['Bioinformatics ', ' Bio-Informatics ', ' DNA Binding ', ' DNA Binding Interaction ', ' Cell Cycle Arrest ', ' small molecule ', ' Engineering ', ' Systems Biology ', ' Data ', ' Proliferating ', ' Validation ', ' Killings ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Source Code ', ' Affect ', ' base ', ' Goals ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Site ', ' Area ', ' repaired ', ' repair ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Training ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Numbers ', ' Gene Targeting ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Letters ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Life ', ' Catalogs ', ' programs ', ' Specificity ', ' Stress ', ' Suppressor Mutations ', ' Surveys ', ' Survey Instrument ', ' transcription factor ', ' Work ', ' Yeasts ', ' Techniques ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' mutant ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' Missense Mutation ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Cataloging ', ' Cells ', ' Censuses ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' Protein p53 ', ' p53 Tumor Suppressor ', ' p53 Antigen ', ' Tumor Protein p53 ', ' Protein TP53 ', ' Phosphoprotein pp53 ', ' Phosphoprotein P53 ', ' Oncoprotein p53 ', ' Cellular Tumor Antigen P53 ', ' Antioncogene Protein p53 ', ' Modeling ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' computerized tools ', ' computational tools ', ' design ', ' designing ', ' Cancerous ', ' functional restoration ', ' restore lost function ', ' restore functionality ', ' restore function ', ' tumor ', ' ']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2008,335397,0.12289404999660487
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7878232,R01LM009722,"['Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' clinical care ', ' molecular phenotype ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,46511,0.24928957014145267
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          ",Improve predictions of structure and function by PredictProtein,7625220,R01LM007329,"['Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Protein Analysis ', ' Resolution ', ' Evolution ', ' protein function ', ' Development ', ' developmental ', ' Eye ', ' Eyeball ', ' Point Mutation ', ' Sequence Analysis ', ' Sequence Analyses ', ' SEQ-AN ', ' Output ', ' Affect ', ' Genome ', ' base ', ' density ', ' Goals ', ' Grant ', ' improved ', ' Area ', ' Medical ', ' Screening procedure ', ' screenings ', ' screening ', ' Training ', ' Language ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Progress Reports ', ' Funding ', ' Maintenance ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Nucleotides ', ' Phenotype ', ' Prokaryotic Cells ', ' prokaryote ', ' Prokaryotae ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' Testing ', ' Adopted ', ' Investigation ', ' Dimensions ', ' Country ', ' Amino Acid Substitution ', ' Biology ', ' Services ', ' Membrane ', ' membrane structure ', ' protein structure function ', ' Budgets ', ' Structure ', ' novel ', ' Eukaryota ', ' Eukaryote ', ' Devices ', ' Proteome ', ' Code ', ' Coding System ', ' Property ', ' LOINC Axis 2 Property ', ' protein protein interaction ', ' portability ', ' Genomics ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' data modeling ', ' protein structure prediction ', ' design ', ' designing ', ' Linux ', ' Plug-in ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' human disease ', ' ']",NLM,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2009,330166,0.08919152416035385
"Modeling of Protein Complexes and Missense Mutations Amino acid mutations in human proteins are often associated with inherited predispositions to specific diseases. Yet most observed missense polymorphisms, those involving a single nucleotide change leading to a changed amino acid, have not been characterized in terms of their effects on protein structure and function. We hypothesize that many of the most deleterious missense mutations affect protein function in one of two ways: 1) by altering interaction of proteins with other molecules, including other proteins, DMA, and small ligands; or 2) by altering stability of the protein. Both of these mechanisms depend primarily on the location of the mutation and its physical properties: changes in protein interactions are usually caused by mutations in or very near to a binding site; changes in stability are usually caused by mutations of buried hydrophobic residues. The aim of this proposal is to develop a computational system for predicting the functional effects of missense mutations through homology modeling of protein complexes. New functional data on 1000 random mutations in two dimeric enzyme systems will be obtained to train and test the model. The primary application of this computational system will be to genes associated with the development of cancer. Cancer is usually linked to a number of genetic changes, some inherited and others somatic. These include loss of DNA-damage repair, breakdown of cell-cycle checkpoints, and resistance to apoptosis. Each of these processes requires many protein interactions, often in large protein complexes. These interactions may be compromised by missense mutations that alter individual interactions between molecules or mutations that lower protein stability. ",Modeling of Protein Complexes and Missense Mutations,7582317,R01GM073784,"['Cystathionine beta-Synthase ', ' methylcysteine synthase ', ' beta-Thionase ', ' Serine Sulfhydrase ', ' L-Serine hydro-lyase (adding homocysteine) ', ' Cystathionine Synthetase ', ' Cell Cycle Checkpoint ', ' protein complex ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA Repair ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' Homologous Gene ', ' Homologue ', ' Homolog ', ' GeneHomolog ', ' Enzymes ', ' Data Set ', ' Dataset ', ' Data ', ' Disease Association ', ' Homology Modeling ', ' Cancer Genome Anatomy Project ', ' Scheme ', ' Validation ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' protein folding ', ' Affect ', ' Genes ', ' base ', ' Goals ', ' Procedures ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Surface ', ' Link ', ' Ions ', ' Training ', ' Lac Repressors ', ' Ligands ', ' Individual ', ' Literature ', ' Bayesian Method ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Maps ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Amino Acids ', ' aminoacid ', ' Membrane Proteins ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Statistical Models ', ' Probabilistic Models ', ' Muramidase ', ' Peptidoglycan N-acetylmuramoylhydrolase ', ' N-Acetylmuramide Glycanhydrolase ', ' Lysozyme ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Peptides ', ' Phenotype ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Proteins ', ' gene product ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Rest ', ' Computer software ', ' computer program/software ', ' Software ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Scientist ', ' Time ', ' Inherited ', ' Hereditary ', ' Complex ', ' Side ', ' System ', ' LOINC Axis 4 System ', ' Location ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' dimer ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' monomer ', ' physical property ', ' protein structure function ', ' Biological Neural Networks ', ' neural network ', ' Missense Mutation ', ' Methylenetetrahydrofolate reductase (NADPH) ', ' Methylenetetrahydrofolate Reductase (NADPH2) ', ' Methylenetetrahydrofolate Reductase ', ' Methylene-THF Reductase (NADPH) ', ' Methylene Tetrahydrofolate Reductase ', ' EC 1.5.1.20 ', ' 5,10-Methylenetetrahydrofolate Reductase (NADPH) ', ' Potential Energy ', ' Structure ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' HIV Protease ', ' HTLV-III Protease ', ' HIV Proteinase ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Modeling ', ' protein protein interaction ', ' Online Mendelian Inheritance In Man ', ' OMIM ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' Resistance ', ' resistant ', ' open source ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' loss of function ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NIGMS,RESEARCH INST OF FOX CHASE CAN CTR,R01,2009,307176,0.23629575906004346
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7675482,R01LM009722,"['Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' clinical care ', ' molecular phenotype ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,401422,0.24928957014145267
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7584631,R01GM085188,"['Bioinformatics ', ' Bio-Informatics ', ' Binding (Molecular Function) ', ' Molecular Interaction ', ' Binding ', ' protein complex ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' peptide I ', ' RACK1 (peptide) ', ' Data ', ' in vivo ', ' PXXP Motif ', ' Validation ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' base ', ' Goals ', ' improved ', ' Left ', ' Biological ', ' Biochemical ', ' In Vitro ', ' Evaluation ', ' web site ', ' website ', ' Ligands ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' enzyme activity ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Theoretical model ', ' Theoretic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Biological Process ', ' Biological Function ', ' src Homology Region 2 Domain ', ' SH2 Domains ', ' SH3 Domains ', ' SRC Homology Region 3 Domain ', ' Peptides ', ' Play ', ' Proline ', ' L-Proline ', ' Protein Binding ', ' Proteins ', ' gene product ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Electrostatics ', ' Specificity ', ' Testing ', ' Training Support ', ' Yeasts ', ' Complex ', ' Techniques ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Performance ', ' success ', ' Free Energy ', ' Structure ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Proteome ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Code ', ' Coding System ', ' Fungal Genome ', ' yeast genome ', ' Modeling ', ' protein protein interaction ', ' Classification ', ' Systematics ', ' protein aminoacid sequence ', ' peptide sequence ', ' peptide aminoacid sequence ', ' design ', ' designing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' public health relevance ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2009,296287,0.06724251466102339
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7631265,R01GM028016,"['genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Pan Genus ', ' Pan Species ', ' Chimpanzee ', ' Chimp ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2009,259841,0.17881891962294247
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       We are submitting this proposal pursuant to NOT-0D-09-058, NIH Announces the Availability of Recovery Act Funds for Competitive Revision Applications.       Our group focuses on understanding how amino acid substitutions disrupt molecular functions that cause human disease. In our currently funded R01, we are developing methods we call in silico functional profiling. This method works by learning residue-specific protein function and then estimates when it is disrupted. This research funds our efforts to characterize what the underlying molecular disruption a protein mutation is causing and thereby improve accuracy of these approaches. In this competitive revision application, we are proposing to expand our efforts to the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation or transcript splicing. Additionally, we have formed collaborations with genetic data managers and will apply all of our methods to aid in their research and identify new testable hypotheses. We will do this in three supplemental aims. First, we will evaluate genomic features for prediction of regulatory nucleotide substitutions and construct new methods to aid in their classification. Second, we will collaboratively work to develop machine learning methods for classification of nucleotide substitutions that disrupt transcript splicing. Finally, we will work to collaboratively annotate genetic data found in inherited disease, pharmacogenetics and somatic mutations in cancer. Together this Recovery Act proposal will fund two groups in bioinformatics and will support trainees, technical staff, and two faculty members.           7. Narrative In this research, we will identify genetic variants that are likely to disrupt genome function, mRNA transcript processing and protein function. We will develop new methods and databases that will hypothesize the underlying molecular mechanism of genetic disease and genetic phenotypes.",Informatic profiling of clinically relevant mutation,7809730,R01LM009722,"['Data Collection ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' data mining ', ' datamining ', ' Economics ', ' Elements ', ' DNA Resequencing ', ' Resequencing ', ' Data ', ' Dideoxy Chain Termination DNA Sequencing ', ' Sanger Sequencing ', ' Protein Analysis ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Transcript ', ' Molecular ', ' Process ', ' protein function ', ' Faculty ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' Focus Groups ', ' Affect ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genome ', ' base ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Area ', ' Clinical ', ' Variant ', ' Variation ', ' Indium ', ' In element ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Recovery ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Collaborations ', ' Letters ', ' CpG Islands ', ' CpG-Rich Islands ', ' Nucleotides ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' Genetic ', ' Genetic Predisposition to Disease ', ' genetic vulnerability ', ' genetic mechanism of disease ', ' genetic etiology ', ' Inherited Susceptibility ', ' Inherited Predisposition ', ' Genetic Susceptibility ', ' Genetic Predisposition ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' RNA Splicing ', ' Splicing ', ' Messenger RNA ', ' mRNA ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Research Priority ', ' sound ', ' Scientist ', ' Time ', ' transcription factor ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Amino Acid Substitution ', ' Somatic Mutation ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Postdoctoral Fellow ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' American ', ' data management ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Missense Mutation ', ' Informatics ', ' member ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' Generations ', ' Mutation Analysis ', ' Code ', ' Coding System ', ' Modeling ', ' Genomics ', ' Classification ', ' Systematics ', ' genetic variant ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' clinical application ', ' clinical applicability ', ' human disease ', ' disease-causing mutation ', ' molecular phenotype ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2009,145500,0.10605752622728566
"A Functional Census of p53 Cancer and Suppressor Mutants DESCRIPTION (provided by applicant):  The broad, long-term objectives are (1) demonstrate computational and experimental methods cooperating to achieve a functional census of a large mutation sequence space of great medical importance; (2) contribute to our knowledge of p53 functional rescue mechanisms, and so facilitate the search for a small molecule cancer drug that effects an analogous functional rescue of p53; and (3) elucidate part of the systems biology of cancer by characterizing the spectrum of p53 cancer and suppressor mutants across known downstream p53 DNA binding sites. Mutations to the tumor suppressor protein p53 occur in approximately half of all human cancers, and restoring function to a mutationally defective p53 protein is a long-held medical goal. Biological precedence for rescuing p53 cancer mutations is found in second-site p53 cancer suppressor mutations. The analogous p53 pharmacological rescue would save hundreds of thousands of lives annually. Understanding and predicting p53 rescue is an important step toward that goal.      The specific aims are (1) computationally predict all single suppressor mutations for p53 cancer mutants and validate the results experimentally, (2) optimize the rescue effects of known and putative p53 suppressor regions through two or more coordinated mutation changes, and (3) predict and experimentally validate the DNA binding specificity of p53 cancer and suppressor mutants for known p53 DNA binding sites. Our broad strategy is a coordinated computational and experimental attack. We already have experimental p53 functional assays and computational predictors of p53 activity, developed as part of our Preliminary Studies. Computational predictors will be used to focus experimental work into the highest priority areas. Experimental validation of the predictions will lead to a larger training set for machine learning techniques. The larger training set will lead to even more accurate predictions, thus even more focused experimentation. Thus, the interplay between computation and experiment will become ever more efficient as the project progresses. Variations of this basic strategy apply to each of our Specific Aims, which all rely on closely coordinated experiment and computation. ",A Functional Census of p53 Cancer and Suppressor Mutants,7613343,R01CA112560,"['Data Sources ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Binding ', ' DNA Binding Interaction ', ' Cell Cycle Arrest ', ' small molecule ', ' Engineering ', ' Systems Biology ', ' Proliferating ', ' Validation ', ' Killings ', ' Apoptosis ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Source Code ', ' Affect ', ' base ', ' Goals ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Site ', ' Area ', ' repaired ', ' repair ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Training ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' web site ', ' website ', ' Gene Targeting ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Methodology ', ' Method LOINC Axis 6 ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Letters ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Life ', ' Catalogs ', ' programs ', ' Specificity ', ' Stress ', ' Suppressor Mutations ', ' Surveys ', ' Survey Instrument ', ' transcription factor ', ' Work ', ' Yeasts ', ' Techniques ', ' interest ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' mutant ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' Missense Mutation ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Positioning Attribute ', ' Position ', ' Cataloging ', ' Cells ', ' Censuses ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' Protein p53 ', ' p53 Tumor Suppressor ', ' p53 Antigen ', ' Tumor Protein p53 ', ' Protein TP53 ', ' Phosphoprotein pp53 ', ' Phosphoprotein P53 ', ' Oncoprotein p53 ', ' Cellular Tumor Antigen P53 ', ' Antioncogene Protein p53 ', ' Modeling ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' computerized tools ', ' computational tools ', ' design ', ' designing ', ' Cancerous ', ' functional restoration ', ' restore lost function ', ' restore functionality ', ' restore function ', ' tumor ', ' ']",NCI,UNIVERSITY OF CALIFORNIA-IRVINE,R01,2009,342292,0.12289404999660487
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7986659,R01GM028016,"['genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2010,142237,0.17881891962294247
"Population Genetics Theory    DESCRIPTION (provided by applicant): Four areas of theoretical population genetics will be studied. In the first, we will develop mathematical and statistical framework for studying the evolution of genes that affect how other sets of genes interact with one another. This theory helps in understanding conditions under which the genome can be expected to become modular in its production of phenotypes, as well as when synergy between mutations in different genes should be produced by evolution. We shall study how the pattern of interaction between deleterious mutations evolves as a function of the mutation rate, the recombination rate, and the degree of fitness loss of each mutation. We shall also study buildup of statistical association between genes that influence culturally transmitted traits that are associated either through transmission or through fitness. The second area of study concerns the evolution of pathogens such as influenza. Here we build models to predict the accumulation of mutations during epidemics and pandemics in a way that can assist in guiding vaccination strategies. We will develop algorithms that search for potential recombinants and reassortants among a collection of up to 1000 viral sequences. Here we aim to devise a statistical test to indicate whether identified recombinants or reassortants are spurious or statistically significant. Our recent theory of niche construction will form the basis of studies of how pathogens might evolve in response to human actions that they induce, such as use of antibiotics. The final research area will develop multiple-gene models for sex-linked control of genomic imprinting. These will include cis and trans modifiers of imprinting. Fertility selection as well as sex- specific viabilities will be studied in order to clarify the role of multiple paternities, which has been proposed as a driving force in the evolution of genomic imprinting. Genomic data from mammalian species will be analyzed using tools from statistical learning in order to predict which genes are likely to be imprinted. Correlations between DMA sequence properties and predicted imprinting status based on life history characteristics will also be sought.           ",Population Genetics Theory,7869395,R01GM028016,"['genome sequencing ', ' Epidemic ', ' fitness ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Data ', ' Recombinants ', ' Taxon ', ' Collection ', ' transmission process ', ' Transmission ', ' Evolution ', ' Characteristics ', ' sex ', ' Modification ', ' Development ', ' developmental ', ' Fertility ', ' Fecundity ', ' Fecundability ', ' pandemic disease ', ' pandemic ', ' DNA Sequence ', ' Affect ', ' Genes ', ' Population Genetics ', ' Genome ', ' base ', ' Haploidy ', ' Haploid ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Algorithms ', ' Area ', ' Specific qualifier value ', ' Specified ', ' Variant ', ' Variation ', ' Alleles ', ' Allelomorphs ', ' Link ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Laboratories ', ' Genomic Imprinting ', ' Parental Imprinting ', ' Genetic Imprinting ', ' Mammals ', ' Mammalia ', ' Genetic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antigens ', ' immunogen ', ' ATGN ', ' Production ', ' tool ', ' Genetic Recombination ', ' Recombination ', ' DNA recombination (naturally occurring) ', ' DNA Recombination ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Testing ', ' Time ', ' Tweens ', ' Vaccination ', ' Virus ', ' General Viruses ', ' Complex ', ' Pattern ', ' Bacteria ', ' Bacteriophages ', ' bacterial virus ', ' Phages ', ' Viral ', ' Drug Formulations ', ' Formulation ', ' life history ', ' trait ', ' father role ', ' paternity ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' social ', ' influenza epidemic ', ' Flu epidemic ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' response ', ' theories ', ' Genomics ', ' vaccination strategy ', ' pathogen ', ' driving force ', ' imprint ', ' Computers ', ' ']",NIGMS,STANFORD UNIVERSITY,R01,2010,261556,0.17881891962294247
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant):       Informatic profiling of clinically relevant mutation      Many approaches have been developed to predict whether a mutation associated with a disease is actually causative. In contrast to other approaches to predicting deleterious mutations, our approach, called in silico functional profiling, starts with learning residue-specific protein function and then estimates when it is disrupted. This research will continue our efforts to characterize what the underlying molecular disruption a mutation is causing and thereby improve accuracy of these approaches. We will do this by building a database that links clinical observation with molecular phenotype and using this to develop bioinformatic models of mutation. This is particularly relevant to cancer, since many mutations in cancer are both poorly understood and simply associated with cancer. The hypothesis of this proposal is that computational methods that predict a specific residue function using protein sequence and structure can classify known disease-associated mutations based on their function better than existing computational methods, and less expensively than experimental assays. In short, we will describe each phenotypically annotated mutation as possibly affecting catalysis, protein interactions, posttranslational modification and stability of the protein. The structural environments around disease associated mutations can be characterized using a combination of computational biochemical methods based on first principles of biomolecular structure and function and statistical informatics methods. We will continue this research by implementing the following steps: First, we will build a database of how often mutations in cancer, pharmacogenetics, Mendelian and complex disease are disrupted by phosphorylation, stability, catalysis, protein interaction and other posttranslational modifications. Second, we will build a bioinformatic model of disruption using machine learning methods trained with these and other commonly used features. Finally, we will link these to clinical observation by annotating disease causing mutation with an ontology of diseases and integrate these predictions into databases of mutation. Thus, we will link clinical observation with molecular phenotypes by building a useful database and new models of how mutations cause disease.          ",Informatic profiling of clinically relevant mutation,7929905,R01LM009722,"['Acetylation ', ' Bioinformatics ', ' Bio-Informatics ', ' Disease ', ' disease/disorder ', ' Disorder ', ' DNA-Binding Proteins ', ' Environment ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Mutation Spectra ', ' Ontology ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Principal Investigator ', ' Molecular ', ' protein function ', ' Affect ', ' base ', ' Goals ', ' improved ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Link ', ' Training ', ' Laboratories ', ' Laboratory Research ', ' Learning ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Funding ', ' Medicine ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Collaborations ', ' Pharmacogenetics ', ' Genetic ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Productivity ', ' Post-Translational Protein Processing ', ' Protein Modification ', ' Posttranslational Protein Processing ', ' Posttranslational Modifications ', ' Post-Translational Protein Modification ', ' Post-Translational Modifications ', ' Post-Translational Modification Protein/Amino Acid Biochemistry ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' programs ', ' Testing ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Work ', ' Inherited ', ' Hereditary ', ' Complex ', ' Amino Acid Substitution ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' experience ', ' protein structure function ', ' computer science ', ' Informatics ', ' Catalytic Domain ', ' Catalytic Subunit ', ' Catalytic Site ', ' Catalytic Region ', ' Catalytic Core ', ' Structure ', ' Basic Science ', ' Basic Research ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Catalysis ', ' Peptide Sequence Determination ', ' Protein Sequencing Molecular Biology ', ' Protein Sequencing ', ' Protein Sequence Determinations ', ' Amino Acid Sequence Determinations ', ' falls ', ' Modeling ', ' protein protein interaction ', ' Clinical Informatics ', ' cancer classification ', ' disease phenotype ', ' computerized tools ', ' computational tools ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' translational medicine ', ' disease-causing mutation ', ' clinical care ', ' molecular phenotype ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2010,383293,0.24928957014145267
"Computational Strategies for Quantitative Mapping of Genetic Interaction Networks    DESCRIPTION (provided by applicant): Recent studies suggest that many diseases, particularly those that commonly afflict our population, result from interactions among multiple alleles. In an attempt to understand these complex phenotypes, recent experimental efforts in model organisms have focused on measuring such interactions by engineering combinatorial genetic perturbations. Due to the enormous space of possible mutants, brute-force experimental investigation is simply not feasible, and thus, there is a critical need for computational strategies for intelligent exploration of genetic interaction networks. The specific objective of this application is to develop a computational framework for leveraging the existing genomic or proteomic data to enable intelligent direction of combinatorial perturbation studies. The rationale for the proposed research is that although current knowledge of genetic interactions is sparse, the integration of existing genomic and proteomic data can enable the inference of network models that suggest promising candidates for high-throughput interaction screens. Using such computational guidance should enable more efficient characterization of network structure, and ultimately, better understanding of how genes contribute to complex phenotypes.  Based on strong findings in preliminary studies, this objective will be accomplished through two specific aims: (1) development of critical normalization methods and quantitative models for colony array-based interaction assays, and (2) novel machine learning-based approaches for iterative model refinement and optimal interaction screen selection.  The proposed research is innovative because it would represent one of the first efforts to couple genomic data integration and network inference technology with a large-scale experimental effort, where several months of experimental investigation are based entirely on computational direction. Such an approach will yield insight into how combinatorial perturbations can be used to characterize global modularity and organization, and more generally, would serve as a prototype for hybrid computational-experimental strategies in other genomic contexts.      PUBLIC HEALTH RELEVANCE: Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.           Project Narrative: Computational Strategies for Mapping Genetic Interaction Networks Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.",Computational Strategies for Quantitative Mapping of Genetic Interaction Networks,7887777,R01HG005084,"['Coronary heart disease ', ' coronary disorder ', ' Coronary Disease ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Engineering ', ' Systems Biology ', ' Data Set ', ' Dataset ', ' Data ', ' Quantitative Genetics ', ' Study Section ', ' Computer Analysis ', ' computational analysis ', ' Molecular ', ' Development ', ' developmental ', ' Feedback ', ' Affect ', ' Genes ', ' Genome ', ' Imagery ', ' Visualization ', ' base ', ' Goals ', ' Gold ', ' Au element ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Hybrids ', ' Area ', ' Biological ', ' Medical ', ' Alleles ', ' Allelomorphs ', ' Evaluation ', ' Training ', ' insight ', ' Maps ', ' Methods ', ' Genetic Models ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Biological Process ', ' Biological Function ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Collaborations ', ' Organism ', ' living system ', ' Phenotype ', ' Genetic ', ' gene function ', ' Plague ', ' Yersinia pestis disease ', ' Proteins ', ' gene product ', ' Recommendation ', ' Research ', ' Resources ', ' Research Resources ', ' Sensitivity and Specificity ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Technology ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Attention ', ' Investigation ', ' Work ', ' Yeasts ', ' Complex ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' mutant ', ' yeast genetics ', ' Animal Model ', ' model organism ', ' Animal Models and Related Studies ', ' Buffers ', ' Structure ', ' novel ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Chad ', ' Measures ', ' Chromosome Mapping ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Modeling ', ' Property ', ' LOINC Axis 2 Property ', ' high throughput technology ', ' Proteomics ', ' Genomics ', ' Accounting ', ' Communities ', ' disease phenotype ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genetic variant ', ' computer framework ', ' computational framework ', ' data integration ', ' Outcome ', ' Population ', ' Coupling ', ' innovation ', ' innovative ', ' innovate ', ' combinatorial ', ' human disease ', ' network models ', ' prototype ', ' lens ', ' lenses ', ' public health relevance ', ' effective therapy ', ' effective treatment ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NHGRI,UNIVERSITY OF MINNESOTA,R01,2010,273884,0.06287626124954993
"Improve predictions of structure and function by PredictProtein    DESCRIPTION (provided by applicant):       SUMMARY: Over 25,000 researchers in the US and over 50,000 in 120 other countries have exploited the PredictProtein (PP) Internet server to analyze proteins by homology-transfer and by eye novo predictions of protein structure and function. Here, we propose technical and scientific solutions that will improve the functionality of PP and its extension portal META-PP. Many technical changes will remain hidden to users and are required to increase the maintainability, scalability, and portability of these servers. New Graphical User Interfaces are one proposed solution that will visibly impact the service. The scientific solutions address two related tasks pertaining to the prediction of structure and function. The first is to predict the effect of mutations. We propose the development of novel machine learning-based methods to distinguish between mutations that affect structure, function, or have no apparent phenotype. Our final method will be applied to the screening of SNP data from our experimental colleagues at Columbia, as well as to the prediction of SNP effects in public databases. The second major task is the identification of natively unstructured regions and their functional classification. Proteins that do not adopt regular structures in isolation are increasingly becoming an important research area; they may provide a key to the evolution of complexity from prokaryotes to eukaryotes. We propose the development of a machine learning-based identification of features specific to this important class of molecules. We also plan to attack the problem from a very different angle by using predictions of interaction densities inside proteins. The resulting novel tools will allow a proteome-wide analysis of the role of these molecules. All methods will be made available through PP.      RELEVANCE: Information about protein structure adds an entire dimension to protein analysis and genome annotation. This addition is often essential to infer function even for natively unstructured proteins. The PredictProtein server is unique in its combination and exploitation of evolution, structure, and function; many thousands of theoretical, experimental, and clinical researches have benefited from this. The long-term goal of the research proposed here is to improve our ability to use the evolutionary record of amino acid substitutions, i.e. to ultimately understand the amino acid ""language"". The short-term goal is to address two tasks that are closely related to human diseases, namely the distinction between silent and important mutations and the mapping of unstructured proteins onto networks and diseases.          ",Improve predictions of structure and function by PredictProtein,7842572,R01LM007329,"['Services ', ' Membrane ', ' membrane structure ', ' protein structure function ', ' Budgets ', ' Structure ', ' novel ', ' Eukaryota ', ' Eukaryote ', ' Devices ', ' Proteome ', ' Code ', ' Coding System ', ' Property ', ' LOINC Axis 2 Property ', ' protein protein interaction ', ' portability ', ' Genomics ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' data modeling ', ' protein structure prediction ', ' design ', ' designing ', ' Linux ', ' Plug-in ', ' graphical user interface ', ' graphic user interface ', ' Graphical interface ', ' human disease ', ' density ', ' Goals ', ' Grant ', ' improved ', ' Area ', ' Medical ', ' Screening procedure ', ' screenings ', ' screening ', ' Training ', ' Language ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Progress Reports ', ' Funding ', ' Maintenance ', ' Maps ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Nucleotides ', ' Phenotype ', ' Prokaryotic Cells ', ' prokaryote ', ' Prokaryotae ', ' tool ', ' Proteins ', ' gene product ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Solutions ', ' Testing ', ' Adopted ', ' Investigation ', ' Dimensions ', ' Country ', ' Amino Acid Substitution ', ' Biology ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Address ', ' Data Set ', ' Dataset ', ' protein structure ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Protein Analysis ', ' Resolution ', ' Evolution ', ' protein function ', ' Development ', ' developmental ', ' Eye ', ' Eyeball ', ' Point Mutation ', ' Sequence Analysis ', ' Sequence Analyses ', ' SEQ-AN ', ' Output ', ' Affect ', ' Genome ', ' base ', ' ']",NLM,COLUMBIA UNIV NEW YORK MORNINGSIDE,R01,2010,327180,0.08919152416035385
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7741672,R01GM085188,"['Bioinformatics ', ' Bio-Informatics ', ' Binding (Molecular Function) ', ' Molecular Interaction ', ' Binding ', ' protein complex ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' peptide I ', ' RACK1 (peptide) ', ' Data ', ' in vivo ', ' PXXP Motif ', ' Validation ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' base ', ' Goals ', ' improved ', ' Left ', ' Biological ', ' Biochemical ', ' In Vitro ', ' Evaluation ', ' web site ', ' website ', ' Ligands ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' enzyme activity ', ' Amino Acids ', ' aminoacid ', ' Methods ', ' Theoretical model ', ' Theoretic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Biological Process ', ' Biological Function ', ' src Homology Region 2 Domain ', ' SH2 Domains ', ' SH3 Domains ', ' SRC Homology Region 3 Domain ', ' Peptides ', ' Play ', ' Proline ', ' L-Proline ', ' Protein Binding ', ' Proteins ', ' gene product ', ' Research ', ' Role ', ' social role ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Electrostatics ', ' Specificity ', ' Testing ', ' Training Support ', ' Yeasts ', ' Complex ', ' Techniques ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Performance ', ' success ', ' Free Energy ', ' Structure ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Proteome ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Code ', ' Coding System ', ' Fungal Genome ', ' yeast genome ', ' Modeling ', ' protein protein interaction ', ' Classification ', ' Systematics ', ' protein aminoacid sequence ', ' peptide sequence ', ' peptide aminoacid sequence ', ' design ', ' designing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' public health relevance ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2010,292978,0.06724251466102339
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,7937611,R01GM093939,"['Data Analyses ', ' Data Analysis ', ' Pathogenicity ', ' DNA ', ' Deoxyribonucleic Acid ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Data ', ' Collection ', ' Genetic Programming ', ' Genetic Algorithm ', ' Phylogenetic Analysis ', ' Phylogenetics ', ' Evolution ', ' Molecular ', ' Development ', ' developmental ', ' Genes ', ' Genome ', ' base ', ' Goals ', ' improved ', ' Procedures ', ' acronyms ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Area ', ' Language ', ' Libraries ', ' Funding ', ' Maintenance ', ' Amino Acids ', ' aminoacid ', ' Study models ', ' Molecular Sequence Data ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Molecular Evolution ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Immune response ', ' immunoresponse ', ' host response ', ' Peer Review ', ' Phylogeny ', ' pressure ', ' tool ', ' Publications ', ' Scientific Publication ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Computer software ', ' computer program/software ', ' Software ', ' Software Engineering ', ' Computer Software Engineering ', ' Computer Software Development ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Testing ', ' Work ', ' Pattern ', ' System ', ' LOINC Axis 4 System ', ' Viral ', ' Biomedical Research ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Performance ', ' protein structure function ', ' Book Chapters ', ' Animal Model ', ' model organism ', ' Animal Models and Related Studies ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Code ', ' Coding System ', ' Modeling ', ' Genomics ', ' Documentation ', ' Codon Nucleotides ', ' Codon ', ' design ', ' designing ', ' pathogen ', ' Population ', ' combinatorial ', ' user-friendly ', ' wiki ', ' public health relevance ', ' flexibility ', ' flexible ', ' comparative genomics ', ' ']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2010,296413,0.06041009456120367
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8238173,R01LM009722,"['cancer genome ', ' Amino Acid Substitution ', ' Untranslated Regions ', ' UTRs ', ' Pharmacogenetics ', ' disease-causing mutation ', ' Computer software ', ' computer program/software ', ' Software ', ' multidisciplinary ', ' Leadership ', ' Left ', ' Bioinformatics ', ' Bio-Informatics ', ' Structure ', ' Individual ', ' protein structure function ', ' Variant ', ' Variation ', ' career ', ' Feedback ', ' Letters ', ' Inherited ', ' Hereditary ', ' Science ', ' genetic regulatory protein ', ' regulatory gene product ', ' Regulatory Protein ', ' human disease ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Molecular ', ' Modeling ', ' Genomics ', ' Genes ', ' Laboratories ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Genome ', ' clinically relevant ', ' clinical relevance ', ' genome database ', ' Genetic ', ' Affect ', ' Genotype ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Methods ', ' Informatics ', ' tool ', ' Publishing ', ' innovation ', ' innovative ', ' innovate ', ' Algorithms ', ' Staging ', ' Phenotype ', ' Performance ', ' Code ', ' Coding System ', ' Resources ', ' Research Resources ', ' System ', ' LOINC Axis 4 System ', ' Focus Groups ', ' Funding ', ' Goals ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Proteins ', ' gene product ', ' Scientist ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Disease Association ', ' genome sequencing ', ' software development ', ' developing computer software ', ' develop software ', ' disease phenotype ', ' DNA Resequencing ', ' Resequencing ', ' exome ', ' exomes ', ' Classification ', ' Systematics ', ' Human Genome ', ' human whole genome ', ' Biomedical Research ', ' data management ', ' Functional RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Genetic Polymorphism ', ' polymorphism ', ' Polymorphism (Genetics) ', ' user-friendly ', ' Disease model ', ' disorder model ', ' Paper ', ' Research Proposals ', ' Hereditary Disease ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' genetic variant ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Testing ', ' Transcript ', ' Collaborations ', ' Process ', ' Data ', ' Area ', ' novel ', ' Research Personnel ', ' improved ', ' Research ', ' Researchers ', ' Investigators ', ' base ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Data Set ', ' Dataset ', ' Work ', ' Role ', ' social role ', ' Complex ', ' Mutation Analysis ', ' Genetic Sequence Databases ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2011,500661,0.15567112388849605
"Computational Strategies for Quantitative Mapping of Genetic Interaction Networks    DESCRIPTION (provided by applicant): Recent studies suggest that many diseases, particularly those that commonly afflict our population, result from interactions among multiple alleles. In an attempt to understand these complex phenotypes, recent experimental efforts in model organisms have focused on measuring such interactions by engineering combinatorial genetic perturbations. Due to the enormous space of possible mutants, brute-force experimental investigation is simply not feasible, and thus, there is a critical need for computational strategies for intelligent exploration of genetic interaction networks. The specific objective of this application is to develop a computational framework for leveraging the existing genomic or proteomic data to enable intelligent direction of combinatorial perturbation studies. The rationale for the proposed research is that although current knowledge of genetic interactions is sparse, the integration of existing genomic and proteomic data can enable the inference of network models that suggest promising candidates for high-throughput interaction screens. Using such computational guidance should enable more efficient characterization of network structure, and ultimately, better understanding of how genes contribute to complex phenotypes.  Based on strong findings in preliminary studies, this objective will be accomplished through two specific aims: (1) development of critical normalization methods and quantitative models for colony array-based interaction assays, and (2) novel machine learning-based approaches for iterative model refinement and optimal interaction screen selection.  The proposed research is innovative because it would represent one of the first efforts to couple genomic data integration and network inference technology with a large-scale experimental effort, where several months of experimental investigation are based entirely on computational direction. Such an approach will yield insight into how combinatorial perturbations can be used to characterize global modularity and organization, and more generally, would serve as a prototype for hybrid computational-experimental strategies in other genomic contexts.      PUBLIC HEALTH RELEVANCE: Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.           Project Narrative: Computational Strategies for Mapping Genetic Interaction Networks Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.",Computational Strategies for Quantitative Mapping of Genetic Interaction Networks,8133157,R01HG005084,"['Plague ', ' Yersinia pestis disease ', ' Coronary heart disease ', ' coronary disorder ', ' Coronary Disease ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Study Section ', ' Computer Analysis ', ' computational analysis ', ' Phenotype ', ' Genomics ', ' Coupling ', ' Molecular ', ' Affect ', ' human disease ', ' Knowledge ', ' Maps ', ' Organism ', ' living system ', ' effective therapy ', ' effective treatment ', ' public health relevance ', ' Complex ', ' Methods ', ' Accounting ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Medical ', ' Resources ', ' Research Resources ', ' Modeling ', ' base ', ' Genetic ', ' Development ', ' developmental ', ' Outcome ', ' Research ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Measures ', ' Investigation ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Genome ', ' mutant ', ' Animal Model ', ' model organism ', ' Animal Models and Related Studies ', ' Evaluation ', ' prototype ', ' Recommendation ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Proteomics ', ' Gold ', ' Au element ', ' Systems Biology ', ' Yeasts ', ' innovation ', ' innovative ', ' innovate ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Feedback ', ' Property ', ' LOINC Axis 2 Property ', ' Variation (Genetics) ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' insight ', ' Imagery ', ' Visualization ', ' Structure ', ' Population ', ' Hybrids ', ' Attention ', ' Cells ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Collaborations ', ' Data Set ', ' Dataset ', ' Engineering ', ' Genes ', ' Proteins ', ' gene product ', ' Goals ', ' novel ', ' Area ', ' Biological ', ' Work ', ' Communities ', ' Chromosome Mapping ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' lens ', ' lenses ', ' disease phenotype ', ' Genetic Models ', ' genetic variant ', ' high throughput technology ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Sensitivity and Specificity ', ' Alleles ', ' Allelomorphs ', ' Buffers ', ' gene function ', ' genome wide association study ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' Biological Process ', ' Biological Function ', ' combinatorial ', ' Training ', ' Data ', ' Technology ', ' computer framework ', ' computational framework ', ' Gene Structure ', ' Gene Structure/Organization ', ' Gene Organization ', ' Chad ', ' data integration ', ' Quantitative Genetics ', ' network models ', ' yeast genetics ', ' ']",NHGRI,UNIVERSITY OF MINNESOTA,R01,2011,218724,0.06287626124954993
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8178935,U01CA151920,"['cancer genome ', ' Copy Number Polymorphism ', ' copy number variation ', ' Point Mutation ', ' Complementary DNA ', ' cDNA ', ' TP53 gene ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' intestinal epithelium ', ' cancer genomics ', ' oncogenomics ', ' segregation ', ' Racial Segregation ', ' exome ', ' exomes ', ' Somatic Mutation ', ' Atlases ', ' candidate validation ', ' forging ', ' Statistical Study ', ' neoplastic ', ' Colon Carcinoma ', ' Colonic Carcinoma ', ' Colon Cancer ', ' combinatorial ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Systems Biology ', ' cancer diagnosis ', ' Intestines ', ' bowel ', ' Intestinal ', ' authority ', ' small hairpin RNA ', ' short hairpin RNA ', ' shRNA ', ' mathematical model ', ' mathematical modeling ', ' Math Models ', ' Clinical Data ', ' clinical phenotype ', ' Mutate ', ' Medicine ', ' Oncogenes ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncologist ', ' Methylation ', ' Protein Methylation ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Instruction ', ' Publications ', ' Scientific Publication ', ' statistics ', ' patient population ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' gene discovery ', ' discover genes ', ' Methods ', ' Modeling ', ' Data Set ', ' Dataset ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Outcome ', ' outcome forecast ', ' Prognosis ', ' Genetic ', ' In Vitro ', ' Algorithms ', ' Biological ', ' Evaluation ', ' Phenotype ', ' Validation ', ' Clinical ', ' Genes ', ' Diagnostic ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Methodology ', ' Method LOINC Axis 6 ', ' Publishing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Measurement ', ' Diagnosis ', ' United States ', ' Event ', ' Generations ', ' Translations ', ' Data ', ' Biology ', ' mutant ', ' Gene Expression ', ' Surveys ', ' Survey Instrument ', ' Research ', ' Nature ', ' Coupled ', ' Future ', ' tumorigenesis ', ' Oncogenesis ', ' Principal Investigator ', ' novel ', ' Individual ', ' Technology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Goals ', ' Address ', ' Staging ', ' Development ', ' developmental ', ' Engineering ', ' Colorectal Cancer ', ' novel therapeutics ', ' next generation therapeutics ', ' new therapeutics ', ' Variant ', ' Variation ', ' Genomics ', ' experience ', ' Literature ', ' Genome ', ' design ', ' designing ', ' The Cancer Genome Atlas ', ' TCGA ', ' KRAS2 gene ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' Bayesian Analysis ', ' computer studies ', ' computational studies ', ' Large Intestine Carcinoma ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' ']",NCI,STANFORD UNIVERSITY,U01,2011,537462,0.10502725292780575
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,7997221,R01GM085188,"['protein protein interaction ', ' enzyme activity ', ' Validation ', ' Electrostatics ', ' Biological Process ', ' Biological Function ', ' Proline ', ' L-Proline ', ' Classification ', ' Systematics ', ' SH3 Domains ', ' SRC Homology Region 3 Domain ', ' PXXP Motif ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Fungal Genome ', ' yeast genome ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' protein aminoacid sequence ', ' peptide sequence ', ' peptide aminoacid sequence ', ' peptide I ', ' RACK1 (peptide) ', ' Peptides ', ' src Homology Region 2 Domain ', ' SH2 Domains ', ' Theoretical model ', ' Theoretic Models ', ' Code ', ' Coding System ', ' Methods ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Training Support ', ' Ligands ', ' Research ', ' In Vitro ', ' public health relevance ', ' Databases ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Testing ', ' Modeling ', ' Role ', ' social role ', ' Play ', ' in vivo ', ' design ', ' designing ', ' Goals ', ' Evaluation ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Biochemical ', ' protein complex ', ' Complex ', ' Cells ', ' base ', ' Structure ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Disease ', ' disease/disorder ', ' Disorder ', ' Techniques ', ' Binding (Molecular Function) ', ' Molecular Interaction ', ' Binding ', ' Data ', ' improved ', ' Performance ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Proteins ', ' gene product ', ' Computing Methodologies ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Bioinformatics ', ' Bio-Informatics ', ' Specificity ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' success ', ' Yeasts ', ' web site ', ' website ', ' Free Energy ', ' Left ', ' Amino Acids ', ' aminoacid ', ' Biological ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Proteome ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Protein Binding ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2011,289681,0.06724251466102339
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8143338,R01GM093939,"['Likelihood Functions ', ' Codon Nucleotides ', ' Codon ', ' Phylogenetic Analysis ', ' Phylogenetics ', ' Book Chapters ', ' Pathogenicity ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' comparative genomics ', ' Phylogeny ', ' Documentation ', ' Genetic Programming ', ' Genetic Algorithm ', ' Immune response ', ' immunoresponse ', ' host response ', ' Language ', ' Classification ', ' Systematics ', ' Collection ', ' Viral ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Gene Mutation ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' flexibility ', ' flexible ', ' Evolution ', ' Molecular Sequence Data ', ' Study models ', ' user-friendly ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Peer Review ', ' combinatorial ', ' protein structure function ', ' Pattern ', ' Goals ', ' Genomics ', ' Work ', ' Performance ', ' Genome ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' public health relevance ', ' Testing ', ' System ', ' LOINC Axis 4 System ', ' Biomedical Research ', ' Computer software ', ' computer program/software ', ' Software ', ' design ', ' designing ', ' Population ', ' Molecular ', ' Funding ', ' base ', ' improved ', ' Modeling ', ' DNA ', ' Deoxyribonucleic Acid ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Maintenance ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Amino Acids ', ' aminoacid ', ' Data Analyses ', ' Data Analysis ', ' Resources ', ' Research Resources ', ' Code ', ' Coding System ', ' programs ', ' Development ', ' developmental ', ' Genes ', ' Publications ', ' Scientific Publication ', ' Libraries ', ' pressure ', ' tool ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Animal Model ', ' model organism ', ' Animal Models and Related Studies ', ' Procedures ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Area ', ' pathogen ', ' Data ', ' Software Engineering ', ' Computer Software Engineering ', ' Computer Software Development ', ' Molecular Evolution ', ' wiki ', ' acronyms ', ' ']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2011,275732,0.06041009456120367
"Rewiring the yeast brain:  Redundancy and interference in genetic networks    DESCRIPTION (Provided by the applicant)   Abstract: Similar to neural networks in animals, molecular networks in cells can generate bistable or oscillatory dynamics that maintain memories of previous events (e.g. epigenetic switch) or order periodic events (e.g. cell cycle), respectively. In cells, networks of genes interacting with one another through regulatory feedback implement such dynamics. Analogous to learning in brains, cells can """"learn"""" correlations in their environmental signals by encoding such correlations into their gene network dynamics through mutation, a """"re-wiring"""" process that occurs on the timescale of generations. The issue of learning the statistical regularities and correlations of environmental signals is best exemplified by the evolution of """"circadian clocks"""", which are oscillatory gene circuits that have learned to internalize the 24-hour light-dark circadian cycle. Strikingly, circadian clocks have evolved independently multiple times, which suggests there exists some selection pressure and/or evolutionary mechanism that repeatedly favor the convergent evolution of autonomous oscillation. The hypothesis of my research proposal is that certain types of loss-of-function mutations in duplicated genes (known as dominant-negative mutations) can easily generate bistability and oscillation in existing regulatory networks. Gene duplication followed by a loss-of-function mutation can generate a dominant-negative. A dominant negative mutation is a partial loss-of-function mutation that renders a gene duplicate functionally inactive, yet still capable of interacting with the original duplicate, the upstream effectors, and/or downstream targets. Thus, dominant-negatives can easily interfere with the proper regulation and activity of the original duplicate. Because both gene duplication and loss-of-function mutations occur frequently in evolution, this presents an evolutionary mechanism for rapidly generating bistability and autonomous oscillation in gene regulatory networks. My proposed research over the next five years will integrate experiment and theory to understand the extent to which gene duplication and dominant-negative mutations facilitate the evolution of epigenetic switches and circadian clocks in regulatory networks. We will use computer simulation and an experimental directed evolution approach in a tractable, model eukaryote (Saccharomyces cerevisiae) to test the ability of cells to learn the statistical regularities of their coupled environmental signals. Understanding how and why single-cell microbes and parasites have learned to predict their environment is essential for understanding their future evolution to changing host conditions.   Public Health Relevance: The ability of parasites to learn and adapt to changing host conditions and environments presents a challenge to human health. The objective of my research proposal is to understand the capacity of gene networks in single cells to learn and predict the statistical regularities of their environment. Discovering the limitations and abilities of parasites to evolve and anticipate changes in their host environment will be invaluable for the treatment of many human diseases.       ",Rewiring the yeast brain:  Redundancy and interference in genetic networks,8146626,DP2OD008654,"['Duplicate Genes ', ' brain cell ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Yeasts ', ' Circadian Rhythms ', ' diurnal variation ', ' daily biorhythm ', ' circadian process ', ' circadian ', ' Twenty-Four Hour Rhythm ', ' Nyctohemeral Rhythm ', ' Diurnal Rhythm ', ' Dominant-Negative Mutation ', ' Dominant-Negative Mutant ', ' Dominant Negative ', ' Antimorphic mutation ', ' Cell Cycle ', ' Cell Division Cycle ', ' Evolution ', ' loss of function mutation ', ' Eukaryota ', ' Eukaryote ', ' Saccharomyces cerevisiae ', ' S. cerevisiae ', ' S. Cerevisiae [{C0036025}] ', ' S cerevisiae ', "" Brewer's Yeast "", "" Baker's Yeast "", ' Biological Neural Networks ', ' neural network ', ' Learning ', ' Parasites ', ' Human ', ' Modern Man ', ' Man (Taxonomy) ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Memory ', ' Regulation ', ' Testing ', ' Process ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' theories ', ' Environment ', ' Hour ', ' research study ', ' experimental study ', ' experimental research ', ' experiment ', ' Genetic ', ' Modeling ', ' Research Proposals ', ' Event ', ' Research ', ' Future ', ' Animals ', ' Feedback ', ' human disease ', ' Cells ', ' abstracting ', ' Coupled ', ' Microbe ', ' Light ', ' Photoradiation ', ' public health relevance ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Generations ', ' Time ', ' Health ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' pressure ', ' Molecular ', ' Genes ', ' circadian pacemaker ', ' circadian clock ', ' Gene Duplication ', ' directed evolution ', ' ']",OD,DUKE UNIVERSITY,DP2,2011,2355000,0.1263606865615734
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8329613,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' ']",NCI,STANFORD UNIVERSITY,U01,2012,541494,0.10502725292780575
"Protein recognition for modular domains    DESCRIPTION (provided by applicant): Protein is essential for almost every biological process and the interaction between proteins and their interacting partners play critical roles in the functioning cells. Since mutations that disrupt the protein-protein interactions result in many diseases, it is important to understand the biochemical mechanisms of protein recognition, which is important for deciphering protein interaction network and designing potent drugs with high specificity against protein targets. Our long term goal is to develop theoretical models for describing protein binding specificity and reliably predict protein-protein interactions. In the proposed project, we have the following specific aims. Aim 1, we will develop a computational method that combines computer modeling and bioinformatics analysis to characterize the interaction interface between modular domains and their peptide ligands. We will test this method on several modular domains including SH3, SH2 and PDZ domains that bind to specific peptide sequences. Aim 2, we will systematically predict interacting peptides in the yeast genome of all yeast SH3 domains. Aim 3, we will experimentally validate the predictions in vitro to assess the performance of the computational method. We will also conduct in vivo experiments to examine the biological significance of a set of selected domain-peptide interactions.      PUBLIC HEALTH RELEVANCE: Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.           Protein-protein interactions play critical roles in the cell and mutations that disrupt these interactions result in many diseases. It is therefore important to understand the biochemical mechanisms of protein recognition.",Protein recognition for modular domains,8197508,R01GM085188,"['aminoacid ', ' Amino Acids ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cells ', ' Systematics ', ' Classification ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Goals ', ' In Vitro ', ' Ligands ', ' Methods ', ' Theoretic Models ', ' Theoretical model ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Peptides ', ' Play ', ' L-Proline ', ' Proline ', ' Protein Binding ', ' gene product ', ' Proteins ', ' Research ', ' social role ', ' Role ', ' Specificity ', ' Testing ', ' Training Support ', ' Yeasts ', ' yeast genome ', ' Fungal Genome ', ' RACK1 (peptide) ', ' peptide I ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Left ', ' Biological ', ' Biochemical ', ' Evaluation ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' enzyme activity ', ' Biological Function ', ' Biological Process ', ' SH2 Domains ', ' src Homology Region 2 Domain ', ' SRC Homology Region 3 Domain ', ' SH3 Domains ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Electrostatics ', ' Complex ', ' Techniques ', ' Performance ', ' success ', ' Free Energy ', ' Structure ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Proteome ', ' Coding System ', ' Code ', ' Modeling ', ' protein protein interaction ', ' peptide sequence ', ' peptide aminoacid sequence ', ' protein aminoacid sequence ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' protein complex ', ' Data ', ' in vivo ', ' PXXP Motif ', ' Validation ', ' website ', ' web site ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' public health relevance ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2012,289290,0.06724251466102339
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8328943,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exomes ', ' exome ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2012,461516,0.15567112388849605
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8322626,R01GM093939,"['aminoacid ', ' Amino Acids ', ' Biomedical Research ', ' Book Chapters ', ' Systematics ', ' Classification ', ' Codon ', ' Codon Nucleotides ', ' Data Analysis ', ' Data Analyses ', ' Deoxyribonucleic Acid ', ' DNA ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Evolution ', ' Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Language ', ' Libraries ', ' Likelihood Functions ', ' Maintenance ', ' Study models ', ' Molecular Sequence Data ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Peer Review ', ' Phylogeny ', ' pressure ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' computer program/software ', ' Software ', ' Computer software ', ' Computer Software Engineering ', ' Computer Software Development ', ' Software Engineering ', ' Testing ', ' Work ', ' base ', ' improved ', ' Procedures ', ' Area ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Molecular Evolution ', ' immunoresponse ', ' host response ', ' Immune response ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Viral ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Performance ', ' protein structure function ', ' model organism ', ' Animal Models and Related Studies ', ' Animal Model ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Coding System ', ' Code ', ' Modeling ', ' Genomics ', ' Documentation ', ' Pathogenicity ', ' Data ', ' Collection ', ' Genetic Algorithm ', ' Genetic Programming ', ' Phylogenetics ', ' Phylogenetic Analysis ', ' Molecular ', ' developmental ', ' Development ', ' acronyms ', ' designing ', ' design ', ' pathogen ', ' Population ', ' combinatorial ', ' user-friendly ', ' wiki ', ' public health relevance ', ' flexible ', ' flexibility ', ' comparative genomics ', ' ']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2012,274156,0.06041009456120367
"Computational Strategies for Quantitative Mapping of Genetic Interaction Networks    DESCRIPTION (provided by applicant): Recent studies suggest that many diseases, particularly those that commonly afflict our population, result from interactions among multiple alleles. In an attempt to understand these complex phenotypes, recent experimental efforts in model organisms have focused on measuring such interactions by engineering combinatorial genetic perturbations. Due to the enormous space of possible mutants, brute-force experimental investigation is simply not feasible, and thus, there is a critical need for computational strategies for intelligent exploration of genetic interaction networks. The specific objective of this application is to develop a computational framework for leveraging the existing genomic or proteomic data to enable intelligent direction of combinatorial perturbation studies. The rationale for the proposed research is that although current knowledge of genetic interactions is sparse, the integration of existing genomic and proteomic data can enable the inference of network models that suggest promising candidates for high-throughput interaction screens. Using such computational guidance should enable more efficient characterization of network structure, and ultimately, better understanding of how genes contribute to complex phenotypes.  Based on strong findings in preliminary studies, this objective will be accomplished through two specific aims: (1) development of critical normalization methods and quantitative models for colony array-based interaction assays, and (2) novel machine learning-based approaches for iterative model refinement and optimal interaction screen selection.  The proposed research is innovative because it would represent one of the first efforts to couple genomic data integration and network inference technology with a large-scale experimental effort, where several months of experimental investigation are based entirely on computational direction. Such an approach will yield insight into how combinatorial perturbations can be used to characterize global modularity and organization, and more generally, would serve as a prototype for hybrid computational-experimental strategies in other genomic contexts.      PUBLIC HEALTH RELEVANCE: Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.           Project Narrative: Computational Strategies for Mapping Genetic Interaction Networks Many common diseases result from interactions among multiple genes. One approach to studying multigenic interactions is to introduce combinations of mutations in model organisms and observe how they affect the cell. This project proposes to develop computational strategies to guide and interpret these combinatorial perturbation studies, which will ultimately help us better understand and treat multigenic diseases.",Computational Strategies for Quantitative Mapping of Genetic Interaction Networks,8280356,R01HG005084,"['Accounting ', ' Affect ', ' Allelomorphs ', ' Alleles ', ' Attention ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Buffers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cells ', ' Chad ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Communities ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' coronary disorder ', ' Coronary Disease ', ' Coronary heart disease ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Feedback ', ' Genes ', ' Genome ', ' Goals ', ' Au element ', ' Gold ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Hybrids ', ' Maps ', ' Methods ', ' Genetic Models ', ' DNA Molecular Biology ', ' Molecular Biology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' living system ', ' Organism ', ' Phenotype ', ' Yersinia pestis disease ', ' Plague ', ' gene product ', ' Proteins ', ' Recommendation ', ' Research ', ' Research Resources ', ' Resources ', ' Sensitivity and Specificity ', ' Technology ', ' allelic variant ', ' Genetic Variation ', ' Genetic Diversity ', ' Gene variant ', ' Variation (Genetics) ', ' Work ', ' Yeasts ', ' Measures ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' base ', ' Area ', ' Biological ', ' Medical ', ' Evaluation ', ' Training ', ' insight ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Genetic ', ' gene function ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Investigation ', ' Complex ', ' mutant ', ' yeast genetics ', ' model organism ', ' Animal Models and Related Studies ', ' Animal Model ', ' Structure ', ' novel ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Modeling ', ' LOINC Axis 2 Property ', ' Property ', ' high throughput technology ', ' Proteomics ', ' Genomics ', ' Systems Biology ', ' Data ', ' Quantitative Genetics ', ' Study Section ', ' computational analysis ', ' Computer Analysis ', ' Gene Structure/Organization ', ' Gene Organization ', ' Gene Structure ', ' Molecular ', ' developmental ', ' Development ', ' disease phenotype ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' genetic variant ', ' computational framework ', ' computer framework ', ' data integration ', ' Outcome ', ' Population ', ' Coupling ', ' innovative ', ' innovate ', ' innovation ', ' combinatorial ', ' human disease ', ' network models ', ' prototype ', ' lenses ', ' lens ', ' public health relevance ', ' effective treatment ', ' effective therapy ', ' ']",NHGRI,UNIVERSITY OF MINNESOTA,R01,2012,218662,0.06287626124954993
"HyPhy: Molecular Evolutionary Analyses    DESCRIPTION (provided by applicant): Project Description HyPhy (http://www.hyphy.org) is a scriptable software platform designed to enable flexible and powerful analyses of DNA, RNA, codon, amino acid and other types of sequence data in an evolutionary context. Such analyses have become an indispensable component of most research studies that make use of comparative genomic data. Biologists and bioinformaticians increasingly recognize the benefits of molecular evolutionary analyses. Since its initial release in 2001, HyPhy has become a relatively stable and mature product, and has been downloaded by more than 4,500 unique users, integrated into several popular web-based genomic data analysis servers, cited in over 400 peer-reviewed publications and described in three book chapters, in spite of the fact that the development of the package has never been directly funded. This proposal seeks support to improve the quality, performance, reliability, modularity, documentation and feature sets of the HyPhy system. Specific aims can be divided into four major areas: 1. Software engineering, testing, and documentation of the HyPhy codebase. 2. The development of a high-performance engine for phylogenetic maximum likelihood model fitting and inference. 3. Extension of a newly-initiated toolbox for machine learning applications in molecular evolution. 4. Creation and maintenance of a wiki-themed documentation resource.      PUBLIC HEALTH RELEVANCE: Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.           Project Narrative Molecular evolutionary analyses are central to many aspects of basic, translational, and applied biomedical research. Examples include identifying gene mutations that allow pathogens to evade the immune response; prediction of the structure and function of proteins; estimating the evolutionary relatedness of human or other populations; characterizing the magnitude of selective pressure, either natural or artificial, on genes or species.",HyPhy: Molecular Evolutionary Analyses,8542870,R01GM093939,"['aminoacid ', ' Amino Acids ', ' Biomedical Research ', ' Book Chapters ', ' Systematics ', ' Classification ', ' Codon ', ' Codon Nucleotides ', ' Data Analysis ', ' Data Analyses ', ' Deoxyribonucleic Acid ', ' DNA ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Evolution ', ' Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Language ', ' Libraries ', ' Likelihood Functions ', ' Maintenance ', ' Study models ', ' Molecular Sequence Data ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Peer Review ', ' Phylogeny ', ' pressure ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' computer program/software ', ' Software ', ' Computer software ', ' Computer Software Engineering ', ' Computer Software Development ', ' Software Engineering ', ' Testing ', ' Work ', ' base ', ' improved ', ' Procedures ', ' Area ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Molecular Evolution ', ' immunoresponse ', ' host response ', ' Immune response ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Viral ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Performance ', ' protein structure function ', ' model organism ', ' Animal Models and Related Studies ', ' Animal Model ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' Coding System ', ' Code ', ' Modeling ', ' Genomics ', ' Documentation ', ' Pathogenicity ', ' Data ', ' Collection ', ' Genetic Algorithm ', ' Genetic Programming ', ' Phylogenetics ', ' Phylogenetic Analysis ', ' Molecular ', ' developmental ', ' Development ', ' acronyms ', ' designing ', ' design ', ' pathogen ', ' Population ', ' combinatorial ', ' user-friendly ', ' wiki ', ' public health relevance ', ' flexible ', ' flexibility ', ' comparative genomics ', ' ']",NIGMS,NORTH CAROLINA STATE UNIVERSITY RALEIGH,R01,2013,265099,0.06041009456120367
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8534039,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' designing ', ' design ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' ']",NCI,STANFORD UNIVERSITY,U01,2013,508001,0.10502725292780575
"Informatic profiling of clinically relevant mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic profiling of clinically relevant mutation,8526549,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' genetic variant ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exome sequencing ', ' genome annotation ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2013,444076,0.15567112388849605
"Informatics Tools for High-throughput Analysis of Cancer Mutations  PROJECT SUMMARY  Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8606625,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Postions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' alkaline protease inhibitor ', ' MAPI ', ' API ', ' microbial alkaline proteinase inhibitor ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' new approaches ', ' novel strategy ', ' novel approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' public health relevance ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' next generation sequencing ', ' exome sequencing ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2013,289971,0.18887699366737276
"Informatics Tools for High-throughput Analysis of Cancer Mutations     DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics).         PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.            ",Informatics Tools for High-throughput Analysis of Cancer Mutations,8735910,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' alkaline protease inhibitor ', ' MAPI ', ' API ', ' microbial alkaline proteinase inhibitor ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' public health relevance ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' next generation sequencing ', ' exome sequencing ', ' cloud based ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2014,317146,0.18887699366737276
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci    DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer.           ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8727268,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' algorithmic composition ', ' algorithm engineering ', ' Algorithmic Engineering ', ' Algorithmic Design ', ' Algorithm Design ', ' ']",NCI,STANFORD UNIVERSITY,U01,2014,523201,0.10502725292780575
"A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform     DESCRIPTION (provided by applicant): The inception of the BD2K Initiative is a testament to the foresight of NIH and our community. Clearly, the future of biomedicine rests on our collective ability to transform Big Data into intelligible scientific facts. In line with the BD2K objectives,our goal is to revolutionize how we address the universal challenge to discern meaning from unruly data. Capitalizing on our investigators' complementary strengths in computational biology and cardiovascular medicine, we will present a fusion of cutting-edge innovations that are grounded in a cardiovascular research focus, encompassing: (i) on-the-cloud data processing, (ii) crowd sourcing and text-mining data annotation, (iii) protein spatiotemporal dynamics, (iv) multi-omic integration, and (v) multiscale clinical data modeling. Drawing from our decade of experience in creating and refining bioinformatics tools, we propose to amalgamate established Big Data resources into a generalizable model for data annotation and collaborative research, through a new query system and cloud infrastructure for accessing multiple omics repositories, and through computational-supported crowdsourcing initiatives for mining the biomedical literature. We propose to interweave diverse data types for revealing biological networks that coalesce from molecular entities at multiple scales, through machine learning methods for structuring molecular data and defining relationships with drugs and diseases, and through novel algorithms for on-the-cloud integration and pathway visualization of multi-dimensional molecular data. Moreover, we propose to innovate advanced modeling tools to resolve protein dynamics and spatiotemporal molecular mechanisms, through mechanistic modeling of protein properties and 3D protein expression maps, and through Bayesian algorithms that correlate patient phenotypes, health histories, and multi-scale molecular profiles. The utility and customizability o our tools to the broader research population is clearly demonstrated using three archetypical workflows that enable annotations of large lists of genes, transcripts, proteins, or metabolites; powerful analysis of complex protein datasets acquired over time; and seamless aQoregation of diverse molecular, textual and literature data. These workflows will be rigorously validated using data from two significant clinical cohorts, the Jackson Heart Study and the Healthy Elderly Longevity (Wellderly). In parallel, a multifaceted strategy will be implemented to educate and train biomedical investigators, and to engage the public for promoting the overall BD2K initiative. We are convinced that a community-driven BD2K initiative will best realize its scientific potential and transform the research culture in a sustainable manner, exhibiting lasting success beyond the current funding period.         PUBLIC HEALTH RELEVANCE:  The challenges of biomedical Big Data are multifaceted. Biomedical investigators face daunting tasks of storing, analyzing, and distributing large-scale omics data, and aggregating all information to discern mechanistic insights. A coherent effort is required to harness disarrayed Big Data and transform them into intelligible scientific facts, whil engaging the global community via education and outreach programs. This Big Data Science Research proposal is designed to address these challenges by formulating a federated architecture of community-supported tools for enhancing data management, integration and analysis.            ",A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform,8774362,U54GM114833,"['Achievement Attainment ', ' Achievement ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Awareness ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular system (all sites) ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardiovascular system ', ' Communities ', ' Crowding ', ' Aggregated Data ', ' Data Aggregation ', ' Data Analysis ', ' Data Analyses ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Exhibits ', ' facial ', ' faces ', ' Face ', ' Future ', ' Genes ', ' Goals ', ' Half-Life ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Literature ', ' lifespan ', ' life span ', ' Length of Life ', ' Longevity ', ' Maps ', ' Medicine ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' gene product ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' Rest ', ' Science ', ' Time ', ' Translating ', ' Generations ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Organ ', ' improved ', ' Clinical ', ' Biological ', ' Physiologic ', ' Physiological ', ' Training ', ' insight ', ' Funding ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Computational Biology ', ' Knowledge ', ' Scientist ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' Training and Education ', ' data management ', ' experience ', ' success ', ' cohort ', ' Structure ', ' novel ', ' General Public ', ' General Population ', ' Social Support System ', ' Support System ', ' Protein Gene Products ', ' Gene Proteins ', ' Modeling ', ' outreach program ', ' LOINC Axis 2 Property ', ' Property ', ' protein protein interaction ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' data processing ', ' computerized data processing ', ' protein expression ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' protein complex ', ' Address ', ' Data ', ' Tutoring and Outreach ', ' Training and Outreach ', ' Instruction and Outreach ', ' Education and Outreach ', ' Harvest ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Population Research ', ' Protein Dynamics ', ' Clinical Data ', ' Transcript ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' protein metabolite ', ' clinical phenotype ', ' data modeling ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' spatiotemporal ', ' public health relevance ', ' operation ', ' Cloud Infrastructure ', ' Cloud Computing ', ' Software Algorithm ', ' Algorithmic Tools ', ' Algorithmic Software ', ' Jackson Heart Study ', ' Big Data ', ' ']",NIGMS,UNIVERSITY OF CALIFORNIA LOS ANGELES,U54,2014,2106052,0.09034188012626097
"Summer Institute for Statistics of Big Data     DESCRIPTION:  Funding is sought for the Summer Institute for Statistics of Big Data (SISBID) at the University of Washington. This program will provide workshops on the statistical and computational skills needed to access, process, manage, and analyze large biomedical data sets. It will be co-directed by Ali Shojaie and Daniela Witten, faculty in the Department of Biostatistics at University of Washington.  The SISBID program will consist of five 2.5-day in-person courses, or modules, taught at the University of Washington each July. An individual participant can register for whichever set of modules he or she chooses. The five modules are as follows: (1) Accessing Biomedical Big Data; (2) Data Visualization; (3) Supervised Methods for Statistical Machine Learning; (4) Unsupervised Methods for Statistical Machine Learning; (5) Reproducible Research for Biomedical Big Data. Each module will consist of a combination of formal lectures and hands-on computing labs. Participants will work together in teams in order to apply the skills that they develop in each module to important problems drawn from relevant case studies.  The primary audience for SISBID will consist of biomedical scientists who would like to develop the statistical and computational training needed to make use of Biomedical Big Data. The secondary audience will consist of individuals with stronger statistical or computational backgrounds but little exposure to biology, who will learn how to apply their skills to problems associated with Biomedical Big Data. Participants will include advanced undergraduates, graduate students, post-doctoral fellows, and researchers, and will be drawn from industry, government, and academia. In order to ensure that all participants are able to fully engage in the program, participants will be expected to already have some prior background in R programming and statistical inference, which can be obtained by taking two free online courses before the program begins.  Each of the five modules will be co-taught by two instructors. The ten instructors will be drawn from top universities and research centers across the U.S., such as the University of Washington, Rice University, University of Iowa, Johns Hopkins University, MD Anderson Cancer Research Center, Fred Hutchinson Cancer Research Center, and University of North Carolina. They have been selected based on research expertise and excellence in teaching.  Lecture videos and slides will be made freely available online so that individuals who are unable to attend SISBID in person can still benefit from the program.  This proposal specifically requests funds for 55 student / postdoctoral fellow travel scholarships per year, 130 student / postdoctoral fellow registration scholarships per year, instructor travel and stipends, teaching assistant stipends, and PI salary support.         PUBLIC HEALTH RELEVANCE:   In recent years, the biomedical sciences have been inundated by Big Data, such as DNA sequence data and electronic medical records. In principle, it should be possible to use such data for a variety of tasks, such as predicting an individual's risk of developing diabetes or cancer, and tailoring therapies to an individual should he or she become ill. The Summer Institute for Statistics of Big Data will provide biomedical researchers with the computational and statistical training needed in order to take advantage of Big Data, so that they can more effectively use it to understand human diseases and to improve human health.            ",Summer Institute for Statistics of Big Data,8829422,R25EB020380,"['Biology ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' diabetes ', ' Diabetes Mellitus ', ' Environment ', ' Faculty ', ' Government ', ' Health ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Hybrids ', ' Industry ', ' Institutes ', ' Iowa ', ' Learning ', ' Persons ', ' North Carolina ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Rice ', ' Risk ', ' Running ', ' Salaries ', ' Wages ', ' Scholarship ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Statistical Computing ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Training Activity ', ' Training Programs ', ' Travel ', ' United States ', ' Universities ', ' Videotape ', ' Washington ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' case report ', ' Case Study ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Area ', ' Ensure ', ' Training ', ' teacher ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Exposure to ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Slide ', ' instructor ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' biomedical scientist ', ' skills ', ' Participant ', ' member ', ' graduate student ', ' Statistical Methods ', ' Academia ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Center for Cancer Research ', ' NCI Center for Cancer Research ', ' Cancer Center ', ' Collection ', ' Fred Hutchinson Cancer Research Center ', ' Process ', ' website ', ' web site ', ' open source ', ' human disease ', ' public health relevance ', ' Big Data ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' Learning Module ', ' ']",NIBIB,UNIVERSITY OF WASHINGTON,R25,2014,160523,0.11274282688556714
"Mobility Data Integration to Insight     DESCRIPTION (provided by applicant): Mobility is essential for human health. Regular physical activity helps prevent heart disease and stroke, relieves symptoms of depression, and promotes weight loss. Unfortunately, many conditions, such as cerebral palsy, osteoarthritis, and obesity, limit mobility at an enormous personal and societal cost. While vast amounts of data are available from hundreds of research labs and millions of smartphones, there is a dearth of methods for analyzing this massive, heterogeneous dataset.  We propose to establish the National Center for Mobility Data Integration to Insight (the Mobilize Center) to overcome the data science challenges facing mobility big data and biomedical big data in general. Our preliminary work identified four bottlenecks in data science, which drive four Data Science Research Cores.  The Cores include Biomechanical Modeling, Statistical Learning, Behavioral and Social Modeling, and Integrative Modeling and Prediction. Our Cores will produce novel methods to integrate diverse modeling modalities and gain insight from noisy, sparse, heterogeneous, and time-varying big data. Our data-sharing consortia, with clinical, research, and industry partners, will provide mobility data for over ten million people.  Three Driving Biomedical Problems will focus and validate our data science research.  The Mobilize Center will disseminate our novel data science tools to thousands of researchers and create a sustainable data-sharing consortium. We will train tens of thousands of scientists to use data science methods in biomedicine through our in-person and online educational programs. We will establish a cohesive, vibrant, and sustainable National Center through the leadership of an experienced executive team and will help unify the BD2K consortia through our Biomedical Computation Review publication and the Simtk.org resource portal.  The Mobilize Center will lay the groundwork for the next generation of data science systems and revolutionize diagnosis and treatment for millions of people affected by limited mobility.         PUBLIC HEALTH RELEVANCE:  Regular physical activity is essential for human health, yet a broad range of conditions impair mobility. This project will transform human movement research by developing tools for data analysis and creating software that will advance research to prevent, diagnose, and reduce impairments that limit human movement.            ",Mobility Data Integration to Insight,8775015,U54EB020405,"['Affect ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' driving ', ' Automobile Driving ', ' biomechanical ', ' Biomechanics ', ' Biomedical Research ', ' Cerebral Palsy ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' ethical ', ' Ethics ', ' Physical Exercise ', ' Exercise ', ' Non-Trunk ', ' Limbs ', ' Extremities ', ' Limb structure ', ' Fellowship ', ' Gait ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Articulation ', ' Joints ', ' Leadership ', ' Methods ', ' Mission ', ' body movement ', ' Movement ', ' Persons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Degenerative polyarthritis ', ' Pathology ', ' Problem Solving ', ' Public Health ', ' public health medicine (field) ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Running ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Testing ', ' Time ', ' wt-loss ', ' body weight loss ', ' Weight Reduction ', ' Weight Loss ', ' Body Weight decreased ', ' Work ', ' Walking ', ' depressive ', ' depression symptom ', ' Emotional Depression ', ' depressive symptoms ', ' Dataset ', ' Data Set ', ' Injury ', ' base ', ' role model ', ' sensor ', ' improved ', ' Area ', ' Training ', ' Physical activity ', ' insight ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' cognitive function ', ' Scientist ', ' Complex ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' Over weight ', ' Overweight ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Visit ', ' Medical center ', ' experience ', ' social model ', ' cohesion ', ' novel ', ' model-based simulation ', ' models and simulation ', ' Prevention ', ' Modality ', ' social ', ' Modeling ', ' preventing ', ' prevent ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Scholars Program ', ' NCI Scholars Program ', ' Resource Sharing ', ' Monitor ', ' Behavioral ', ' cost ', ' Behavioral Model ', ' data modeling ', ' data integration ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Impairment ', ' public health relevance ', ' industry partner ', ' sharing data ', ' flexible ', ' flexibility ', ' clinical decision-making ', ' Big Data ', ' ']",NIBIB,STANFORD UNIVERSITY,U54,2014,2050748,0.037320809188723165
"Developing Cloud-based tools for Big Neural Data     DESCRIPTION (provided by applicant): Big data has the potential to dramatically advance the electrophysiology biodata sciences in similar ways that it has transformed Genetics. Differences between these two areas dictate separate approaches to apply Big Data tools, and methods in order to provide successful assets to the research community. For one, neural datasets are very heterogeneous by nature. The data is difficult to interpret without knowing specifics about the data acquisition protocol, the experimental paradigm and the physiological state of the recorded subject. Many neural datasets are complemented with complex meta-data sets, which should be an integral component in any effort to integrate and share these data with other researchers. The goal of this project is to develop novel, generalizable Big Data tools to facilitate cloud-base analysis of complex multi-scale neural data. Epilepsy research will be used as a specific use case to guide the development of the tools. A cohort of established senior investigators performing epilepsy research will use and validate these tools in their laboratories. Epilepsy research is currently limited by its narrow focus on single models (animal or human) in individual centers and laboratories. Just as Genetics was revolutionized through Big Data techniques, so too can Epilepsy research be transformed through novel approaches to standardize, share, and mine data across groups of investigators. Over the past several years I have co-developed a NINDS funded cloud-based data platform, ://ieeg.org, giving me a central role in developing Big Data solutions for neural data, such as customized data sharing, large-scale cloud-based data analysis, and search and interrogation techniques for complex data and metadata. My scientific objectives for this project are: (1) to develop generalizable tools to curate, analyze, and interrogate multi-scale neural data, and (2) to create a platform that will galvanize a research community focused on sharing data, and methods to advance Big Data research in the basic and translational neurosciences. Equally important to this proposal, I present a training plan to prepare me for an academic career focused on Big Data in the neurosciences. This plan supplements my background in bioengineering and statistical modeling of neural data with broader data-science expertise in data integration and machine learning, and deeper domain knowledge of the clinical neurosciences. I have assembled a group of collaborators, basic investigators and clinician scientists, who will use the tools developed in this project to analyze and validate their data and methods. I will use the results of this project as the foundation for a R01 Grant application, in which I will expand the developed platform and tools to target other research domains (TBI, Emergency Care, Cardiac), as well as integrate other data-modalities such as Imaging, and Genomics. OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) Page Continuation Format Page         PUBLIC HEALTH RELEVANCE: The goal of this proposal is to advance Big Data research in the neurosciences by developing tools and techniques to interrogate electrophysiology data sets from animal models of human neurological disorders. Development of these tools requires close collaboration between domain experts in Neuroscience, Machine Learning, Statistics and Computer Science. When developed, this platform and these tools will allow investigators to share, collaborate, annotate, standardize and analyze large, complex, multiscale data sets that are a crucial first step in advancing this field.            ",Developing Cloud-based tools for Big Neural Data,8830141,K01ES025436,"['bioengineering ', ' Biomedical Engineering ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Data Analysis ', ' Data Analyses ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Feedback ', ' Foundations ', ' Goals ', ' Health ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' inducement ', ' Incentives ', ' Laboratories ', ' Learning ', ' Methods ', ' Mining ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' living system ', ' Organism ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Science ', ' Solutions ', ' Standardization ', ' statistics ', ' Time ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Series ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Funding ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Techniques ', ' data management ', ' Performance ', ' computer science ', ' cohort ', ' model organism ', ' Animal Models and Related Studies ', ' Animal Model ', ' neural ', ' relating to nervous system ', ' novel ', ' Modality ', ' Genomics ', ' Institution ', ' datamining ', ' data mining ', ' Data ', ' Grant Proposals ', ' Applications Grants ', ' Infrastructure ', ' Research Infrastructure ', ' Computational Technique ', ' Process ', ' Cardiac ', ' Emergency Care ', ' imaging ', ' Image ', ' Metadata ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' data integration ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' data acquisition ', ' comparative ', ' tool development ', ' translational neuroscience ', ' sharing data ', ' Data Provenance ', ' cloud based ', ' Big Data ', ' ']",NIEHS,UNIVERSITY OF PENNSYLVANIA,K01,2014,192201,0.09939901507038518
"Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems     DESCRIPTION (provided by applicant): Abstract Biomedical science, higher education, software and technology are simultaneously undergoing tectonic shifts. The amazing pace of software and technological development are driving equally amazing advances in the ability to acquire massive data sets in the biomedical sciences. These new Big Biomedical data sets come in the form of complex measurements, such as that of the brain, genome, proteome and human biome or massive databases, such as with electronic health records. Big Data issues, such as reproducibility of processing, measurement and analysis techniques, are increasingly complex, and crucial. Across all domains there is a knowledge gap of researchers to analyze and interpret these new data sets and the current higher education model cannot meet the insatiable demand for this training. We propose to make substantial progress on these issues in two domains. Specifically, we propose to use Massive Open Online Courses (MOOCs) to create two series, one in neuroimaging and one in genomics. These series will allow for flexible, student paced, low cost scalable training for tens of thousands of students. Along with these series, we propose the creation of modular Big Data biostatistical content that can be used by students as well as teachers. This effort will be parallel to work on an intelligent tutoring syste called swirl. This application proposes to use swirl to create rich, gamified learning environments for students. All of the material created from this grant will be open access and free.         PUBLIC HEALTH RELEVANCE:  Project narrative: We propose two Massive Open Online Course series in neuroimaging and genomic Big Data analysis as well as the creation of modular Big Data statistics content and content creation for an intelligent tutoring system.            ","Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems",8829370,R25EB020378,"['abstracting ', ' Attention ', ' driving ', ' Automobile Driving ', ' Biology ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' clinical investigation ', ' Clinical Trials ', ' Communities ', ' Cost Analyses ', ' Cost Analysis ', ' Curriculum ', ' Educational Curriculum ', ' Data Analysis ', ' Data Analyses ', ' Data Collection ', ' Education ', ' Educational aspects ', ' Environment ', ' Genes ', ' Genome ', ' Grant ', ' Head ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Learning ', ' Medicine ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Multivariate Analyses ', ' Multivariate Analysis ', ' Persons ', ' Public Health ', ' public health medicine (field) ', ' Public Health Nurses ', ' Public Health Nursing ', ' Racial Stocks ', ' Racial Group ', ' Race ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Solutions ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Technology ', ' Testing ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Generations ', ' Measures ', ' Amaze ', ' TimeLine ', ' Dataset ', ' Data Set ', ' Instructional Models ', ' Educational Models ', ' density ', ' Area ', ' Biological ', ' Medical ', ' Series ', ' Training ', ' teacher ', ' Discipline ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Scientist ', ' Adopted ', ' Dimensions ', ' Complex ', ' Stream ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' meetings ', ' instructor ', ' Services ', ' skills ', ' neuroimaging ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Touch ', ' Touch sensation ', ' Proteome ', ' Modeling ', ' Genomics ', ' Drops ', ' Systems Biology ', ' Data ', ' Molecular Medicine ', ' Resolution ', ' enroll ', ' Enrollment ', ' Principal Investigator ', ' developmental ', ' Development ', ' Electronic Health Record ', ' imaging ', ' Image ', ' cost ', ' process reproducibility ', ' process repeatability ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' multidisciplinary ', ' open source ', ' public health relevance ', ' flexible ', ' flexibility ', ' operation ', ' Big Data ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' Learning Module ', ' ']",NIBIB,JOHNS HOPKINS UNIVERSITY,R25,2014,216000,0.08456762463028059
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions     DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy.         PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.        The written critiques of individual reviewers are provided in essentially unedited form in this section. Please note that these critiques and criteria scores were prepared prior to the meeting and may not have been revised subsequent to any discussions at the review meeting. The ""Resume and Summary of Discussion"" section above summarizes the final opinions of the committee.                ","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8805723,K99CA191093,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Critiques ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Environment ', ' Faculty ', ' Future ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' HeLa ', ' Hela Cells ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Mentors ', ' Mentorship ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' Productivity ', ' gene product ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions, Nucleic Acid (Genetics) ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' statistics ', ' Training Programs ', ' United States ', ' Universities ', ' visual function ', ' Sight ', ' Vision ', ' Writing ', ' Dataset ', ' Data Set ', ' Task Forces ', ' Advisory Committees ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Apoptosis ', ' Point Mutation ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Distal ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Gene Targeting ', ' Sample Size ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' interest ', ' meetings ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' American ', ' Cancer Induction ', ' carcinogenesis ', ' mutant ', ' success ', ' professor ', ' skills ', ' novel ', ' Coding System ', ' Code ', ' Sampling ', ' career development ', ' Genomics ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Normal Cell ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Research Training ', ' Cancer Biology ', ' Cancer Patient ', ' trend ', ' developmental ', ' Development ', ' epigenomics ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' computer based prediction ', ' predictive modeling ', ' Cancer cell line ', ' cancer type ', ' migration ', ' innovative ', ' innovate ', ' innovation ', ' parallel computing ', ' parallel computation ', ' parallel computer ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' responsible research conduct ', ' Regimen ', ' TCGA ', ' The Cancer Genome Atlas ', ' Chip sequencing ', ' Chip seq ', ' Encyclopedia of DNA Elements ', ' Cas nuclease technology ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' ']",NCI,STANFORD UNIVERSITY,K99,2014,116122,0.044363984108982644
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",8774373,U54EB020403,"['Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Acquired Immunodeficiency Syndrome ', ' Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Genes ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human T-Lymphotropic Virus Type III ', ' Human T-Cell Lymphotropic Virus Type III ', ' Human T-Cell Leukemia Virus Type III ', ' Human Immunodeficiency Viruses ', ' HTLV-III ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Articulation ', ' Joints ', ' Learning ', ' Math ', ' Mathematics ', ' Medicine ', ' National Institute of Mental Health ', ' NIMH ', ' National Institute of Mental Health (U.S.) ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Obsessive-Compulsive Neurosis ', ' Obsessive-Compulsive Disorder ', ' Prognosis ', ' outcome forecast ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Schools ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Talents ', ' Training Programs ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Genetic ', ' tool ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuroimaging ', ' novel ', ' Modality ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' chromosome 22q deletion syndrome ', ' Modeling ', ' Genomics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' major depression ', ' Major Depressive Disorder ', ' Institution ', ' Data ', ' NICHD ', ' National Institute of Child Health and Human Development ', ' National Institute on Drug Abuse ', ' NIDA ', ' National Institute of Drug Abuse ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Infrastructure ', ' Research Infrastructure ', ' imaging ', ' Image ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' NIAAA ', ' National Institute on Alcohol Abuse and Alcoholism ', ' innovative ', ' innovate ', ' innovation ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' multi-task ', ' multitask ', ' addictive disorder ', ' addiction ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' Big Data ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2014,2087641,0.07778723406859629
"Informatic Profiling of Clinically Relevant Mutation    DESCRIPTION (provided by applicant): Our group focuses on genetic variants that disrupt molecular functions that cause human disease. In this renewal R01 application, we propose to begin the process of realizing our long-term goals, and to expand our original scope of research to include the challenge of understanding genetic disease mutations and polymorphisms that affect gene expression regulation in noncoding regions. Additionally, we have formed collaborations with genetic data managers and will apply these methods to aid in their research and identify new testable hypotheses. We will do this in three aims. First, we will integrate predictions of protein-disease associations with mutation predictions to develop a new quantitative model of genotype and phenotype. Second, we will integrate each of these together to develop a systems level, molecular function genome annotator with functionality to import into the genome databases. Finally, we will continue to build new methods for characterization of mutations using sequence, function and structure and begin testing our published hypotheses. Each of these aims will include collaboration with the maintainers of genetic datasets to better understand their underlying molecular effects.           PrjctNrrative Tis cmetigrnwlR1aims t nerstn owgntic vritindat iscvrdi gnom sqecin  effortsdisrpts mlclr fnctinad te tsts wetertesemlclr fnctindisrptigvrintsar  mreliklytola to umn gneticdisaseusigbiiformtics.",Informatic Profiling of Clinically Relevant Mutation,8722025,R01LM009722,"['Affect ', ' Algorithms ', ' Biomedical Research ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Feedback ', ' Focus Groups ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Leadership ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Paper ', ' Pharmacogenetics ', ' Phenotype ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' gene product ', ' Proteins ', ' Publishing ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Testing ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Left ', ' Area ', ' Variation ', ' Variant ', ' Individual ', ' Funding ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Staging ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Hereditary ', ' Inherited ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' Amino Acid Substitution ', ' data management ', ' Performance ', ' protein structure function ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' novel ', ' disorder model ', ' Disease model ', ' Mutation Analysis ', ' Coding System ', ' Code ', ' regulatory gene product ', ' Regulatory Protein ', ' genetic regulatory protein ', ' Modeling ', ' developing computer software ', ' develop software ', ' software development ', ' genome database ', ' Genomics ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' Meta-Analysis ', ' Genetic Sequence Databases ', ' Bio-Informatics ', ' Bioinformatics ', ' genome sequencing ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Resequencing ', ' DNA Resequencing ', ' Data ', ' Disease Association ', ' Transcript ', ' Molecular ', ' Process ', ' disease phenotype ', ' cancer genome ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' user-friendly ', ' human disease ', ' disease-causing mutation ', ' exome sequencing ', ' genome annotation ', ' ']",NLM,BUCK INSTITUTE FOR RESEARCH ON AGING,R01,2014,114720,0.15567112388849605
"New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis     DESCRIPTION (provided by applicant)    Maha R Farhat, MD is an Instructor of Medicine at Harvard Medical School on the tenure track and a staff physician in the Department of Pulmonary and Critical Care Medicine at Massachusetts General Hospital. She is completing a masters of biostatistics at the Harvard School of Public Health in 5/2015. She has spent the last 4.5 years acquiring skills in Mycobacterium tuberculosis biology, epidemiology, bioinformatics and biostatistics. She has experience in the analysis of whole genome sequence data, drug resistance data and patient clinical outcome data with the focus of identifying Mycobacterium tuberculosis genetic determinants of drug resistance. She has also developed new methods in this area. Dr. Farhat has 11 publications 5 of which are first author including high impact and highly cited work in the journals Nature Genetics, Genome Medicine and the International Journal of Tuberculosis and Lung Disease. The short term goals of this K01 award are to provide training for Dr. Farhat in critical aspects of data science, computational and evolutionary biology, advanced biostatistics and network science. Dr. Farhat's long term goal is to become a leader in the field of Big Data analysis for infectious diseases. The proposed research as well as the training activities outlined in the proposal will successfully position Dr. Farhat for her first R01 and an independent career as a physician scientist. Environment: Dr. Farhat will perform the interdisciplinary work outlined in this proposal at the distinguished Harvard Departments of Global Health Social Medicine, Biostatistics, Evolutionary biology and the Institute for Quantitative Social Sciences. Dr. Farhat' mentorship team will include two world renowned leaders in the fields of infectious diseases and Big Data, Dr. Megan Murray and Dr. Gary King; and two rising stars in the fields of network Science and evolutionary Biology, Dr. JP Onnela and Dr. Michael Desai. Dr. Murray, the principal mentor on this proposal has mentored over 38 trainees, 9 of which have went on to have independent research careers, and 6 competed successfully for K awards. She is also PI on two recently awarded NIH/NIAID grants a CETR U19 and a TBRU U19 and has over 350 peer reviewed publications. To complement the expertise of her mentors Dr. Farhat will be advised by Dr. Christiani a practicing pulmonary and critical care physician and world renowned researcher in the field of lung and environmental genetics. She will also collaborate and consult with Dr. Merce Crosas, a data scientist, and Dr. Pardis Sabeti, a computational biologist. She will rotate through Dr. Soumya Raychaudhuri's bioinformatics laboratory to diversify her exposure to biomedical Big Data. In addition, she will receive formal training in evolutionary biology, Bayesian and mixed-model biostatistics, computer science, leadership skills and grant writing. The collaborative opportunities, intellectual environment and resources available to Dr. Farhat are outstanding. Research: Infectious diseases continue to be a major cause of morbidity and mortality. Despite the availability of effective antimicrobials, pathogens are successfully evolving new disease phenotypes that allow them to resist killing by these drugs or in other instances cause more severe disease manifestations or wider chains of transmission. Drug resistance (DR) is now common and some bacteria have even become resistant to multiple types or classes of antibiotics6. A key strategy in the fight against emerging pathogen phenotypes in infectious diseases is surveillance, and early personalized therapy to prevent transmission and propagation of these strains. The timely initiation of antibiotic therapy to which the pathogen is sensitive has been shown to be the key factor influencing treatment outcome for a diverse array of infections. Molecular tests that rely on the detection of microbial genetic mutations are particularly promising for surveillance and diagnosis of these pathogen phenotypes but rely on a comprehensive understanding of how mutations associate with these pathogen phenotypes. Currently there is an explosion of data on pathogen whole genome sequences (WGS) that is increasingly generated from clinical laboratories. Data on disease phenotype may also be available, but methods for the analysis and interpretation of these Big Data are lagging. Here I propose tools to aid in this analysis leveraging Big Data sets from Mycobacterium tuberculosis (MTB) and my prior work. Specifically I propose to (1) develop a web-based public interface to several analysis tools, including a statistical learning model that can predict the MTB DR phenotype from its genomic sequence, (2) to develop and study an MTB gene-gene network, based on WGS data, to improve our understanding of the effect of mutation-mutation interactions on the DR phenotype, and (3) study the performance of methods in current use for the association of genotype and phenotype in pathogens, and develop a generalizable power calculator for the best performing method.         PUBLIC HEALTH RELEVANCE    Infectious agents of disease are successfully evolving drug resistance and other adaptations that threaten human health. Understanding the genetic mutations that underlie these disease phenotypes can inform surveillance and diagnostic strategies to combat this threat. Here I propose to develop accessible tools for pathogen genomic analysis that will help identify which genetic mutations are relevant to disease.                ",New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis,9044227,K01ES026835,"['Affect ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antibiotics ', ' Award ', ' Bacteria ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Infectious Disorder ', ' Infectious Diseases and Manifestations ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Complement Proteins ', ' Complement ', ' Critical Care ', ' Data Analysis ', ' Data Analyses ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Genetic Epistasis ', ' Explosion ', ' Future ', ' Genes ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Goals ', ' Grant ', ' Health ', ' General Hospitals ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Infection ', ' Institutes ', ' Laboratories ', ' Leadership ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Maps ', ' Massachusetts ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' mtb ', ' M.tuberculosis ', ' M.tb ', ' M. tuberculosis ', ' M. tb ', ' Mycobacterium tuberculosis ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Peer Review ', ' Phenotype ', ' Phylogeny ', ' Physicians ', ' Public Health ', ' public health medicine (field) ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Public Health Schools ', ' Science ', ' Social Medicine ', ' Social Sciences ', ' Testing ', ' Time ', ' Training Activity ', ' tuberculous spondyloarthropathy ', ' infection due to Mycobacterium tuberculosis ', ' disseminated tuberculosis ', ' disseminated TB ', ' Mycobacterium tuberculosis infection ', ' Mycobacterium tuberculosis (MTB) infection ', ' Mtb infection [{C0041296}] ', ' MTB infection ', ' M.tuberculosis infection ', ' M. tuberculosis infection ', ' Tuberculosis ', ' Work ', ' Writing ', ' Measures ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' Killings ', ' Magazine ', ' Journals ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Collaborations ', ' Genetic ', ' infectious organism ', ' Infectious Agent ', ' Exposure to ', ' tool ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Antibiotic Therapy ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' LOINC Axis 4 System ', ' System ', ' disease severity ', ' Severity of illness ', ' instructor ', ' Consult ', ' experience ', ' gene interaction ', ' Performance ', ' computer science ', ' microbial ', ' Structure ', ' skills ', ' simulation ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Genomics ', ' genetic determinant ', ' Genetic Determinism ', ' Bio-Informatics ', ' Bioinformatics ', ' preventing ', ' prevent ', ' genome sequencing ', ' Low income ', ' global health ', ' DNA Sequence Alteration ', ' Data ', ' Detection ', ' Infectious Diseases / Laboratory ', ' Infectious Diseases Research ', ' International ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Mentored Research Scientist Development Award ', ' NIAID ', ' National Institute of Allergy and Infectious Disease ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' Resolution ', ' Gene Structure/Organization ', ' Gene Organization ', ' Gene Structure ', ' Virulent ', ' Monitor ', ' Transmission ', ' transmission process ', ' Molecular ', ' disease phenotype ', ' fight against ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' designing ', ' design ', ' drug resistant in tuberculosis ', ' drug resistance Mycobacteria Tuberculosis ', ' drug resistance M Tuberculosis ', ' Drug resistant Mycobacteria Tuberculosis ', ' Drug resistant M Tuberculosis ', ' Drug Resistant Tuberculosis ', ' Drug Resistant TB ', ' Drug Resistance Tuberculosis ', ' Drug resistance in tuberculosis ', ' Outcome ', ' Drug-sensitive ', ' pathogen ', ' Computational Science ', ' Population ', ' prospective ', ' resistant ', ' Resistance ', ' anti-microbial ', ' antimicrobial ', ' microbes genome ', ' microbial genome ', ' analytical tool ', ' Microbial Genetics ', ' Network-based ', ' combat ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' Big Data ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIEHS,MASSACHUSETTS GENERAL HOSPITAL,K01,2015,230806,0.11982491889484707
"Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership     DESCRIPTION (provided by applicant): The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The aims to achieve the goals are: 1) Implement an integrated didactic program to enhance student self-efficacy with computational and informatics tool development and use for interrogating and interpreting Big Data, including a two-semester bioinformatics course in Bioinformatics, informed by the expertise of UIUC KnowEnG BD2K Center faculty with additional Special Topics courses available remotely from UIUC. 2) Develop an integrated academic year (Fisk, or partners) and summer research program at the UIUC KnowEnG BD2K Center to assure student exposure to a participation in the life cycle of a `Big Data' research problem. 3) Implement a professional skills development program that assures successful transition of undergraduate participants to a Ph.D. (or MD/PhD Program) in Big Data- reliant biomedical research. 4) Launch a faculty development program in bioinformatics that leads to embracing Big Data problems in courses in multiple disciplines for impact on all Fisk undergraduate STEM majors. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fisk R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.   PUBLIC HEALTH RELEVANCE: The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fis R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.  ",Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership,9049946,R25MD010396,"['Biological Chemistry ', ' Biochemistry ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Communication ', ' Complement Proteins ', ' Complement ', ' Computers ', ' Curriculum ', ' Educational Curriculum ', ' Diving ', ' Education ', ' Educational aspects ', ' Elements ', ' Faculty ', ' Goals ', ' Grant ', ' Health ', ' Illinois ', ' Articulation ', ' Joints ', ' Learning ', ' life course ', ' Life Cycle ', ' Life Cycle Stages ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Program Development ', ' Reading ', ' recruit ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Science ', ' Students ', ' Technology ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Writing ', ' Magazine ', ' Journals ', ' base ', ' career ', ' Biological ', ' Chemicals ', ' Training ', ' Discipline ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Development Plans ', ' Funding ', ' Collaborations ', ' Exposure to ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' posters ', ' programs ', ' cell biology ', ' Cellular biology ', ' Scientist ', ' Oral ', ' LOINC Axis 4 System ', ' System ', ' experience ', ' computer science ', ' Informatics ', ' Base Pairing ', ' Self Efficacy ', ' Manuscripts ', ' skills ', ' Participant ', ' Research Ethics ', ' Proteomics ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' Core Facility ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' R25 Program ', ' R25 Mechanism ', ' Education Projects ', ' Research Training ', ' underserved minority ', ' under-represented minority ', ' Underrepresented Populations ', ' Underrepresented Groups ', ' Underrepresented Minority ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' Minority ', ' innovative ', ' innovate ', ' innovation ', ' data acquisition ', ' tool development ', ' responsible research conduct ', ' sharing data ', ' STEM major ', ' STEM discipline ', ' STEM course ', ' STEM class ', ' STEM field ', ' undergraduate research ', ' Big Data ', ' Teacher Workshop ', ' Faculty Seminar ', ' Faculty Workshop ', ' unique treatment ', ' targeted treatment ', ' tailored treatment ', ' individualized treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' ']",NIMHD,FISK UNIVERSITY,R25,2015,168294,0.12163881736249535
"Summer Institute for Statistics of Big Data DESCRIPTION:  Funding is sought for the Summer Institute for Statistics of Big Data (SISBID) at the University of Washington. This program will provide workshops on the statistical and computational skills needed to access, process, manage, and analyze large biomedical data sets. It will be co-directed by Ali Shojaie and Daniela Witten, faculty in the Department of Biostatistics at University of Washington.  The SISBID program will consist of five 2.5-day in-person courses, or modules, taught at the University of Washington each July. An individual participant can register for whichever set of modules he or she chooses. The five modules are as follows: (1) Accessing Biomedical Big Data; (2) Data Visualization; (3) Supervised Methods for Statistical Machine Learning; (4) Unsupervised Methods for Statistical Machine Learning; (5) Reproducible Research for Biomedical Big Data. Each module will consist of a combination of formal lectures and hands-on computing labs. Participants will work together in teams in order to apply the skills that they develop in each module to important problems drawn from relevant case studies.  The primary audience for SISBID will consist of biomedical scientists who would like to develop the statistical and computational training needed to make use of Biomedical Big Data. The secondary audience will consist of individuals with stronger statistical or computational backgrounds but little exposure to biology, who will learn how to apply their skills to problems associated with Biomedical Big Data. Participants will include advanced undergraduates, graduate students, post-doctoral fellows, and researchers, and will be drawn from industry, government, and academia. In order to ensure that all participants are able to fully engage in the program, participants will be expected to already have some prior background in R programming and statistical inference, which can be obtained by taking two free online courses before the program begins.  Each of the five modules will be co-taught by two instructors. The ten instructors will be drawn from top universities and research centers across the U.S., such as the University of Washington, Rice University, University of Iowa, Johns Hopkins University, MD Anderson Cancer Research Center, Fred Hutchinson Cancer Research Center, and University of North Carolina. They have been selected based on research expertise and excellence in teaching.  Lecture videos and slides will be made freely available online so that individuals who are unable to attend SISBID in person can still benefit from the program.  This proposal specifically requests funds for 55 student / postdoctoral fellow travel scholarships per year, 130 student / postdoctoral fellow registration scholarships per year, instructor travel and stipends, teaching assistant stipends, and PI salary support. PUBLIC HEALTH RELEVANCE:   In recent years, the biomedical sciences have been inundated by Big Data, such as DNA sequence data and electronic medical records. In principle, it should be possible to use such data for a variety of tasks, such as predicting an individual's risk of developing diabetes or cancer, and tailoring therapies to an individual should he or she become ill. The Summer Institute for Statistics of Big Data will provide biomedical researchers with the computational and statistical training needed in order to take advantage of Big Data, so that they can more effectively use it to understand human diseases and to improve human health.",Summer Institute for Statistics of Big Data,8935790,R25EB020380,"['Biology ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' diabetes ', ' Diabetes Mellitus ', ' Environment ', ' Faculty ', ' Government ', ' Health ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Hybrids ', ' Industry ', ' Institutes ', ' Iowa ', ' Learning ', ' Persons ', ' North Carolina ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Rice ', ' Risk ', ' Running ', ' Salaries ', ' Wages ', ' Scholarship ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Statistical Computing ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Training Activity ', ' Training Programs ', ' Travel ', ' United States ', ' Universities ', ' Videotape ', ' Washington ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' case report ', ' Case Study ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Area ', ' Ensure ', ' Training ', ' teacher ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Exposure to ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Slide ', ' instructor ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' biomedical scientist ', ' skills ', ' Participant ', ' member ', ' graduate student ', ' Statistical Methods ', ' Academia ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Center for Cancer Research ', ' NCI Center for Cancer Research ', ' Cancer Center ', ' Collection ', ' Fred Hutchinson Cancer Research Center ', ' Process ', ' website ', ' web site ', ' open source ', ' human disease ', ' Big Data ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' Learning Module ', ' ']",NIBIB,UNIVERSITY OF WASHINGTON,R25,2015,159605,0.11274282688556714
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,8982093,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' disease/disorder ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Parents ', ' great ape ', ' Apes ', ' Pongidae ', ' Research ', ' Risk ', ' Risk Factors ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Strikes ', ' Employee Strikes ', ' Testing ', ' Time ', ' Genetic Variation ', ' Genetic Diversity ', ' Variation (Genetics) ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black or African American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA Synthesis ', ' DNA Replication ', ' DNA biosynthesis ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disease risk ', ' disorder risk ', ' inherited factor ', ' genetic risk factor ', ' developmental disorder ', ' developmental disease/disorder ', ' Admixture ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' Mutation Spectra ', ' Cancer Biology ', ' Collection ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' rare allele ', ' rare variant ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2015,50690,0.23357181072684932
"Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions DESCRIPTION (provided by applicant): The goal of the proposed research training program is to provide me (Dr. Collin Melton) with additional training in areas that will accelerate my career development as I transition from a post-doctoral fellow in Dr. Michael Snyder's lab to an independent tenure track professor. The key elements of this plan are: Candidate: I have extensive training in experimental and computational approaches to studying biomedicine. Areas of additional focus for career development during the K99 mentored post-doctoral research phase include the acquisition of additional experimental skills and supplemental training in cancer biology, human genetics, human genomics, applied statistics, and parallel computing. Additionally, I will receive training in laboratory management, mentorship, and responsible conduct of research. This well-rounded plan will provide me with a skill set that will enable a facile transition from postdoctoral fellow to tenure track faculty. Environment: I have a valuable advisory committee with experts in the areas of genomics, genetics, and cancer biology to ensure my success in this training program and to guide me through the successful acquisition of a faculty job. These include my mentor Dr. Michael Snyder, my co-mentor Dr. James Ford and two advisors, Dr. Hanlee Ji and Dr. Anshul Kundaje. The environment at Stanford University in the Snyder lab and department of Genetics fosters productivity and collaboration with word class facilities, resources, and researchers. Research: My proposed research plan in cancer genomics is timely, relevant, and innovative. The majority of current research in cancer genomics has made groundbreaking progress in understanding the relevant DNA variation that occurs in coding regions of the genome; however, 97-98% of the human genome does not code for protein. This proposal focuses specifically on studying the regulatory regions of the human genome to identify, characterize, and interpret the impact of point mutations in these regulatory regions. The central hypothesis of this proposal is that point mutations in regulatory regions of the human genome drive cancer formation and the functional consequences of these mutations can be predicted using machine learning algorithms. Aim 1 proposes the statistical identification of regulatory regions which are mutated across cancer samples, Aim 2 proposes functional characterization of the prevalent mutations identified in Aim 1, and Aim 3 extends the analysis of characterizing the effects of mutations genome-wide through use of genomics approaches and proposes the use of machine learning to classify novel mutations as either disrupting, activating, or having no effect on regulatory element activity. Through its use of experimental datasets combined with predictive models for functional consequences of individual cancer variation, this research will further the goal of personalized genome interpretation for cancer therapy. PUBLIC HEALTH RELEVANCE: Every cancer patient's disease is caused by unique set of abnormal variation in the human genome. Advancing our understanding this variation aids in the development of new treatments and the proper application of existing treatments. This proposal focuses on understanding a particular type of cancer variation that occurs in regulatory regions of the human genome.","Identification, Characterization, and Prediction of Cancer Driver Mutations in Regulatory Regions",8931936,K99CA191093,"['Algorithms ', ' Allelomorphs ', ' Alleles ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cause of Death ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Elements ', ' Environment ', ' Faculty ', ' Future ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' HeLa ', ' Hela Cells ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Mentors ', ' Mentorship ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' Productivity ', ' gene product ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions, Nucleic Acid (Genetics) ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' statistics ', ' Training Programs ', ' United States ', ' Universities ', ' visual function ', ' Sight ', ' Vision ', ' Dataset ', ' Data Set ', ' Task Forces ', ' Advisory Committees ', ' Programmed Cell Death ', ' Apoptosis Pathway ', ' Apoptosis ', ' Point Mutation ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Distal ', ' Site ', ' Area ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Gene Targeting ', ' Sample Size ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' interest ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' American ', ' Cancer Induction ', ' carcinogenesis ', ' mutant ', ' success ', ' professor ', ' skills ', ' novel ', ' Coding System ', ' Code ', ' Sampling ', ' career development ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Untranslated RNA ', ' Genomics ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Normal Cell ', ' genome sequencing ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Research Training ', ' Cancer Biology ', ' Cancer Patient ', ' trend ', ' developmental ', ' Development ', ' epigenomics ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' Cancer cell line ', ' cancer type ', ' migration ', ' innovative ', ' innovate ', ' innovation ', ' parallel computing ', ' parallel computation ', ' parallel computer ', ' genomewide ', ' genome-wide ', ' responsible research conduct ', ' Regimen ', ' TCGA ', ' The Cancer Genome Atlas ', ' ChIP Sequencing ', ' ChIP-seq ', ' Encyclopedia of DNA Elements ', ' Cas nuclease technology ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' ']",NCI,STANFORD UNIVERSITY,K99,2015,116122,0.04504062239116857
"A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform     DESCRIPTION (provided by applicant): The inception of the BD2K Initiative is a testament to the foresight of NIH and our community. Clearly, the future of biomedicine rests on our collective ability to transform Big Data into intelligible scientific facts. In line with the BD2K objectives,our goal is to revolutionize how we address the universal challenge to discern meaning from unruly data. Capitalizing on our investigators' complementary strengths in computational biology and cardiovascular medicine, we will present a fusion of cutting-edge innovations that are grounded in a cardiovascular research focus, encompassing: (i) on-the-cloud data processing, (ii) crowd sourcing and text-mining data annotation, (iii) protein spatiotemporal dynamics, (iv) multi-omic integration, and (v) multiscale clinical data modeling. Drawing from our decade of experience in creating and refining bioinformatics tools, we propose to amalgamate established Big Data resources into a generalizable model for data annotation and collaborative research, through a new query system and cloud infrastructure for accessing multiple omics repositories, and through computational-supported crowdsourcing initiatives for mining the biomedical literature. We propose to interweave diverse data types for revealing biological networks that coalesce from molecular entities at multiple scales, through machine learning methods for structuring molecular data and defining relationships with drugs and diseases, and through novel algorithms for on-the-cloud integration and pathway visualization of multi-dimensional molecular data. Moreover, we propose to innovate advanced modeling tools to resolve protein dynamics and spatiotemporal molecular mechanisms, through mechanistic modeling of protein properties and 3D protein expression maps, and through Bayesian algorithms that correlate patient phenotypes, health histories, and multi-scale molecular profiles. The utility and customizability o our tools to the broader research population is clearly demonstrated using three archetypical workflows that enable annotations of large lists of genes, transcripts, proteins, or metabolites; powerful analysis of complex protein datasets acquired over time; and seamless aQoregation of diverse molecular, textual and literature data. These workflows will be rigorously validated using data from two significant clinical cohorts, the Jackson Heart Study and the Healthy Elderly Longevity (Wellderly). In parallel, a multifaceted strategy will be implemented to educate and train biomedical investigators, and to engage the public for promoting the overall BD2K initiative. We are convinced that a community-driven BD2K initiative will best realize its scientific potential and transform the research culture in a sustainable manner, exhibiting lasting success beyond the current funding period.         PUBLIC HEALTH RELEVANCE:  The challenges of biomedical Big Data are multifaceted. Biomedical investigators face daunting tasks of storing, analyzing, and distributing large-scale omics data, and aggregating all information to discern mechanistic insights. A coherent effort is required to harness disarrayed Big Data and transform them into intelligible scientific facts, whil engaging the global community via education and outreach programs. This Big Data Science Research proposal is designed to address these challenges by formulating a federated architecture of community-supported tools for enhancing data management, integration and analysis.            ",A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform,8935858,U54GM114833,"['Achievement Attainment ', ' Achievement ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Awareness ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular system (all sites) ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardiovascular system ', ' Communities ', ' Crowding ', ' Aggregated Data ', ' Data Aggregation ', ' Data Analysis ', ' Data Analyses ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Exhibits ', ' facial ', ' faces ', ' Face ', ' Future ', ' Genes ', ' Goals ', ' Half-Life ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Literature ', ' lifespan ', ' life span ', ' Length of Life ', ' Longevity ', ' Maps ', ' Medicine ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' gene product ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' Rest ', ' Science ', ' Time ', ' Translating ', ' Generations ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Organ ', ' improved ', ' Clinical ', ' Biological ', ' Physiologic ', ' Physiological ', ' Training ', ' insight ', ' Funding ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Computational Biology ', ' Knowledge ', ' Scientist ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' Training and Education ', ' data management ', ' experience ', ' success ', ' cohort ', ' Structure ', ' novel ', ' General Public ', ' General Population ', ' Social Support System ', ' Support System ', ' Protein Gene Products ', ' Gene Proteins ', ' Modeling ', ' outreach program ', ' LOINC Axis 2 Property ', ' Property ', ' protein protein interaction ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' data processing ', ' computerized data processing ', ' protein expression ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' protein complex ', ' Address ', ' Data ', ' Tutoring and Outreach ', ' Training and Outreach ', ' Instruction and Outreach ', ' Education and Outreach ', ' Harvest ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Population Research ', ' Protein Dynamics ', ' Clinical Data ', ' Transcript ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' protein metabolite ', ' clinical phenotype ', ' data modeling ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' spatiotemporal ', ' public health relevance ', ' operation ', ' Cloud Infrastructure ', ' Cloud Computing ', ' Software Algorithm ', ' Algorithmic Tools ', ' Algorithmic Software ', ' Jackson Heart Study ', ' Big Data ', ' ']",NIGMS,UNIVERSITY OF CALIFORNIA LOS ANGELES,U54,2015,2748454,0.09034188012626097
"Mobility Data Integration to Insight     DESCRIPTION (provided by applicant): Mobility is essential for human health. Regular physical activity helps prevent heart disease and stroke, relieves symptoms of depression, and promotes weight loss. Unfortunately, many conditions, such as cerebral palsy, osteoarthritis, and obesity, limit mobility at an enormous personal and societal cost. While vast amounts of data are available from hundreds of research labs and millions of smartphones, there is a dearth of methods for analyzing this massive, heterogeneous dataset.  We propose to establish the National Center for Mobility Data Integration to Insight (the Mobilize Center) to overcome the data science challenges facing mobility big data and biomedical big data in general. Our preliminary work identified four bottlenecks in data science, which drive four Data Science Research Cores.  The Cores include Biomechanical Modeling, Statistical Learning, Behavioral and Social Modeling, and Integrative Modeling and Prediction. Our Cores will produce novel methods to integrate diverse modeling modalities and gain insight from noisy, sparse, heterogeneous, and time-varying big data. Our data-sharing consortia, with clinical, research, and industry partners, will provide mobility data for over ten million people.  Three Driving Biomedical Problems will focus and validate our data science research.  The Mobilize Center will disseminate our novel data science tools to thousands of researchers and create a sustainable data-sharing consortium. We will train tens of thousands of scientists to use data science methods in biomedicine through our in-person and online educational programs. We will establish a cohesive, vibrant, and sustainable National Center through the leadership of an experienced executive team and will help unify the BD2K consortia through our Biomedical Computation Review publication and the Simtk.org resource portal.  The Mobilize Center will lay the groundwork for the next generation of data science systems and revolutionize diagnosis and treatment for millions of people affected by limited mobility.         PUBLIC HEALTH RELEVANCE:  Regular physical activity is essential for human health, yet a broad range of conditions impair mobility. This project will transform human movement research by developing tools for data analysis and creating software that will advance research to prevent, diagnose, and reduce impairments that limit human movement.            ",Mobility Data Integration to Insight,8935802,U54EB020405,"['Affect ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' driving ', ' Automobile Driving ', ' biomechanical ', ' Biomechanics ', ' Biomedical Research ', ' Cerebral Palsy ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' Child Human ', ' 0-11 years old ', ' Child ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' ethical ', ' Ethics ', ' Physical Exercise ', ' Exercise ', ' Non-Trunk ', ' Limbs ', ' Extremities ', ' Limb structure ', ' Fellowship ', ' Gait ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Articulation ', ' Joints ', ' Leadership ', ' Methods ', ' Mission ', ' body movement ', ' Movement ', ' Persons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Degenerative polyarthritis ', ' Pathology ', ' Problem Solving ', ' Public Health ', ' public health medicine (field) ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Running ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Testing ', ' Time ', ' wt-loss ', ' body weight loss ', ' Weight Reduction ', ' Weight Loss ', ' Body Weight decreased ', ' Work ', ' Walking ', ' depressive ', ' depression symptom ', ' Emotional Depression ', ' depressive symptoms ', ' Dataset ', ' Data Set ', ' Injury ', ' base ', ' role model ', ' sensor ', ' improved ', ' Area ', ' Training ', ' Physical activity ', ' insight ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' cognitive function ', ' Scientist ', ' Complex ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' Over weight ', ' Overweight ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Visit ', ' Medical center ', ' experience ', ' social model ', ' cohesion ', ' novel ', ' model-based simulation ', ' models and simulation ', ' Prevention ', ' Modality ', ' social ', ' Modeling ', ' Cellular Telephone ', ' Cell Phone ', ' Cellular Phone ', ' preventing ', ' prevent ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Scholars Program ', ' NCI Scholars Program ', ' Resource Sharing ', ' Monitor ', ' Behavioral ', ' cost ', ' Behavioral Model ', ' data modeling ', ' data integration ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Impairment ', ' motor impairment ', ' public health relevance ', ' industry partner ', ' sharing data ', ' flexible ', ' flexibility ', ' clinical decision-making ', ' Big Data ', ' ']",NIBIB,STANFORD UNIVERSITY,U54,2015,2867242,0.037320809188723165
"A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform     DESCRIPTION (provided by applicant): The inception of the BD2K Initiative is a testament to the foresight of NIH and our community. Clearly, the future of biomedicine rests on our collective ability to transform Big Data into intelligible scientific facts. In line with the BD2K objectives,our goal is to revolutionize how we address the universal challenge to discern meaning from unruly data. Capitalizing on our investigators' complementary strengths in computational biology and cardiovascular medicine, we will present a fusion of cutting-edge innovations that are grounded in a cardiovascular research focus, encompassing: (i) on-the-cloud data processing, (ii) crowd sourcing and text-mining data annotation, (iii) protein spatiotemporal dynamics, (iv) multi-omic integration, and (v) multiscale clinical data modeling. Drawing from our decade of experience in creating and refining bioinformatics tools, we propose to amalgamate established Big Data resources into a generalizable model for data annotation and collaborative research, through a new query system and cloud infrastructure for accessing multiple omics repositories, and through computational-supported crowdsourcing initiatives for mining the biomedical literature. We propose to interweave diverse data types for revealing biological networks that coalesce from molecular entities at multiple scales, through machine learning methods for structuring molecular data and defining relationships with drugs and diseases, and through novel algorithms for on-the-cloud integration and pathway visualization of multi-dimensional molecular data. Moreover, we propose to innovate advanced modeling tools to resolve protein dynamics and spatiotemporal molecular mechanisms, through mechanistic modeling of protein properties and 3D protein expression maps, and through Bayesian algorithms that correlate patient phenotypes, health histories, and multi-scale molecular profiles. The utility and customizability o our tools to the broader research population is clearly demonstrated using three archetypical workflows that enable annotations of large lists of genes, transcripts, proteins, or metabolites; powerful analysis of complex protein datasets acquired over time; and seamless aQoregation of diverse molecular, textual and literature data. These workflows will be rigorously validated using data from two significant clinical cohorts, the Jackson Heart Study and the Healthy Elderly Longevity (Wellderly). In parallel, a multifaceted strategy will be implemented to educate and train biomedical investigators, and to engage the public for promoting the overall BD2K initiative. We are convinced that a community-driven BD2K initiative will best realize its scientific potential and transform the research culture in a sustainable manner, exhibiting lasting success beyond the current funding period.         PUBLIC HEALTH RELEVANCE:  The challenges of biomedical Big Data are multifaceted. Biomedical investigators face daunting tasks of storing, analyzing, and distributing large-scale omics data, and aggregating all information to discern mechanistic insights. A coherent effort is required to harness disarrayed Big Data and transform them into intelligible scientific facts, whil engaging the global community via education and outreach programs. This Big Data Science Research proposal is designed to address these challenges by formulating a federated architecture of community-supported tools for enhancing data management, integration and analysis.            ",A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform,9065764,U54GM114833,"['Achievement Attainment ', ' Achievement ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Awareness ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular system (all sites) ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardiovascular system ', ' Communities ', ' Crowding ', ' Aggregated Data ', ' Data Aggregation ', ' Data Analysis ', ' Data Analyses ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Exhibits ', ' facial ', ' faces ', ' Face ', ' Future ', ' Genes ', ' Goals ', ' Half-Life ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Literature ', ' lifespan ', ' life span ', ' Length of Life ', ' Longevity ', ' Maps ', ' Medicine ', ' Methods ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' gene product ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' Rest ', ' Science ', ' Time ', ' Translating ', ' Generations ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Organ ', ' improved ', ' Clinical ', ' Biological ', ' Physiologic ', ' Physiological ', ' Training ', ' insight ', ' Funding ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Computational Biology ', ' Knowledge ', ' Scientist ', ' LOINC Axis 4 System ', ' System ', ' interest ', ' Training and Education ', ' data management ', ' experience ', ' success ', ' cohort ', ' Structure ', ' novel ', ' General Public ', ' General Population ', ' Social Support System ', ' Support System ', ' Protein Gene Products ', ' Gene Proteins ', ' Modeling ', ' outreach program ', ' LOINC Axis 2 Property ', ' Property ', ' protein protein interaction ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' data processing ', ' computerized data processing ', ' protein expression ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' protein complex ', ' Address ', ' Data ', ' Tutoring and Outreach ', ' Training and Outreach ', ' Instruction and Outreach ', ' Education and Outreach ', ' Harvest ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Population Research ', ' Protein Dynamics ', ' Clinical Data ', ' Transcript ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' protein metabolite ', ' clinical phenotype ', ' data modeling ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' spatiotemporal ', ' public health relevance ', ' operation ', ' Cloud Infrastructure ', ' Cloud Computing ', ' Software Algorithm ', ' Algorithmic Tools ', ' Algorithmic Software ', ' Jackson Heart Study ', ' Big Data ', ' ']",NIGMS,UNIVERSITY OF CALIFORNIA LOS ANGELES,U54,2015,647114,0.09034188012626097
"Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy     DESCRIPTION (provided by applicant)     A new electrical biomarker has been identified in high resolution, intracranial electroencephalogram (iEEG) recordings, called a high frequency oscillation (HFO). Studies have suggested this biomarker has great promise to identify seizure networks and improve surgical outcomes for patients with refractory epilepsy. However, translation of HFOs to clinical practice is hampered by many factors such as spatial, temporal and inter-patient variation in HFO detection rates, false positive and false negative detections, and significant background noise. Big data approaches using large numbers of HFOs acquired from many patients are needed to quantify these effects and allow clinical usage of HFOs. This project details a plan in which the candidate's experience quantifying measurement and detection bias in massive high energy nuclear physics datasets will be combined with a multidisciplinary mentor team to address this problem. The combination of training in computational neuroscience, big data network analysis, and translational neural engineering research will be critical to approach this problem and provide a career trajectory for the candidate. The specific aims of this proposal address three specific confounding factors: 1) the false negative HFO detection rate, 2) variations in HFO features not due to epilepsy, and 3) effects of the state of vigilance on HFOs. Each of these aims involve novel big data methods and/or applications generalizable to other situations: 1) estimating false positive detection rates using a combined experimental/simulated data approach, 2) clustering and classification of distributions of data points, rather than of the data points directly, and 3) a general disambiguation statistic to assess meaningful (rather than statistical) difference between distributions.  The applicant's career goal is to become an academic researcher in the analysis and modeling of intracranial EEG data with a focus on translational epilepsy and sleep physiology research. With the rapid advancement in the resolution of clinical EEG, there is already a strong need for this type of research expertise. Thi grant will provide didactic coursework, formal research and methods training, and career guidance from an expert mentor team. The three mentors have appointments spanning Neurology, Anesthesiology, Mathematics, Statistics, Biomedical Engineering, and Electrical Engineering and Computer Science. The candidate will also build and mentor a research team and establish external collaborations.  The University of Michigan is a premier research university with strong programs and training opportunities in biomedical and physical sciences, engineering, translational and academic research, and advanced research computing. This proposal makes extensive use of the University's large computer cluster. The mentor team and an external collaborator will provide candidate access to prerecorded, deidentified data from over 150 patients, estimated to have over 40 million HFOs. The environment and mentor team will provide the training, facilities, and data for the candidate to successfully complete the proposed goals.         PUBLIC HEALTH RELEVANCE    Recent advances in epilepsy research are generating very large datasets in the search for better ways to identify the region of brain responsible for generating seizures. A particular signa known as High Frequency Oscillations found in high resolution intracranial EEG shows great promise for identifying these regions, but clinicians are unable to use the signal due to confounding biases. This project combines big data processing expertise from particle physics, computer science and machine learning to address these confounds, providing a more accurate process to enable clinical translation of this new biomarker and potentially improve clinical outcomes.                ",Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy,9041723,K01ES026839,"['Accounting ', ' Algorithms ', ' Anesthesiology ', ' Appointment ', ' bioengineering ', ' Biomedical Engineering ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Systematics ', ' Classification ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Environment ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Future ', ' Goals ', ' Grant ', ' High Frequency Oscillation ', ' Hybrids ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' Mentorship ', ' Methods ', ' Michigan ', ' Motivation ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurology ', ' Neurosciences ', ' Noise ', ' Nuclear Physics ', ' Patients ', ' physical science ', ' Physics ', ' Physiology ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Seizures ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Sleep ', ' Solutions ', ' statistics ', ' Technology ', ' Training Programs ', ' Translating ', ' Translations ', ' Universities ', ' Work ', ' Research Methods ', ' Research Methodology ', ' Dataset ', ' Data Set ', ' Custom ', ' base ', ' career ', ' computational neuroscience ', ' detector ', ' improved ', ' Area ', ' Chronic ', ' Clinical ', ' Refractory ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Training ', ' Individual ', ' Measurement ', ' Funding ', ' Collaborations ', ' Electrical Engineering ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Techniques ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' experience ', ' computer science ', ' neural ', ' relating to nervous system ', ' expectation ', ' novel ', ' Graph ', ' sleep epilepsy ', ' vigilance ', ' Statistical Methods ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' career development ', ' data processing ', ' computerized data processing ', ' Brain region ', ' Address ', ' Data ', ' Detection ', ' Manpower and Training ', ' Resolution ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Resected ', ' Process ', ' developmental ', ' Development ', ' Electroencephalogram ', ' Outcome ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' scientific computing ', ' spatial temporal variation ', ' public health relevance ', ' patient population ', ' standard of care ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' clinical practice ', ' computer cluster ', ' signal processing ', ' Big Data ', ' ']",NIEHS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,K01,2015,138213,0.06360992187175588
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies.         PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.            ",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,8984471,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Drug Regulations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Kinases ', ' EC 2.7 ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' gene product ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' para-Tyrosine ', ' L-isomer Tyrosine ', ' L-Tyrosine ', ' Tyrosine ', ' Work ', ' Threonine Kinase ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Tyrosine Kinase Growth Factor Receptor ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Pattern ', ' LOINC Axis 4 System ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' LOINC Axis 2 Property ', ' Property ', ' Genomics ', ' drug discovery ', ' Molecular Interaction ', ' Binding ', ' Binding (Molecular Function) ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2015,300000,0.17732211395365816
"The Big DIPA: Data Image Processing and Analysis     DESCRIPTION (provided by applicant): This proposal aims to establish a national short course in Big Data Image Processing & Analysis (BigDIPA) intended to increase the number and overall skills of competent research scientists now encountering large, complex image data sources derived from cutting edge biological/biomedical research approaches. Extraction of knowledge from these imaging sources requires specialized skills and an interdisciplinary mindset. Yet effective training opportunities of this sector of the ""Big Data"" science community are glaringly underappreciated and underserved compared to other big data fields such as omics. UC Irvine is ideally suited to host a short course to address this thematic training deficit on account of the synergistic colocalization between multiple facilities, renowned for development of numerous advanced imaging techniques, and the outstanding instructional environment provided by faculty with collaborative expertise in biological image processing and computer vision, bioinformatics and high performance computational approaches.  Specifically, our BigDIPA proposal assembles an interdisciplinary alliance of faculty experts that can leverage the preeminent imaging resource facilities, such as the Laboratory of Fluorescence Dynamics (LFD) and the Beckman Laser Institute, and fuse these to ongoing campus big data initiatives, e.g. UCI's Data Science Initiative, to create a top-rated training course designed for senior graduate students, postdoctoral researchers, faculty and industry scientists from diverse scientific disciplines who have nascent interests and needs to handle BIG DATA sources beyond their current level of competency.  The course theme is focused to utilize discreet examples drawn from the analysis of complex data acquired from different microscopy imaging modalities employed to investigate dynamics in cellular and tissue processes, including signal transduction networks, development, neuroscience and biomedical applications, and that hereto where hidden or inaccessible to standard methods of analysis. Participants will be guided along the complete acquisition- processing-analysis pipeline through exposure to a coherent progression of topics and issues typically encountered when handling BIG DATA. We believe this training approach will therefore be attractive to a broad and significant untapped pool of researchers from the biological disciplines, biomedical engineering, systems biology, math, biophysics, computer science, bioinformatics and statistics who possess some, but not all, of the requisite competencies to effectively traverse the BD2K landscape. We have designed the course such that skills and experience gained by trainees will be transferable to their own research interests.  The BigDIPA course format will combine didactic lectures on the theory and foundational frameworks that underpin each step, with practical instruction on implementation and hands-on tutorials in image acquisition, large data handling, basic scripting of computational tools, image processing on high performance computing architectures, as well as feature extraction, evaluation and visualization of results. The course is designed to offer an intense learning experience delivered in a compact time frame, and opportunities to foster interdisciplinary interactions through small team exercises. Participants will also be encouraged to take advantage of pre-courses - separate and distinct training opportunities not funded by this proposal - that will be coordinated to directly precede our course. This unique format provides multiple benefits: it provides an efficient mechanism to address individual participant training deficiencies to permit a more productive experience in the BigDIPA course, adds no-cost mutual benefits to independent but synergistic programs, and facilitates recruitment of applicants who frequently feel interested but intimidated due to a perceived lack of prior adequate training.  Beyond providing an intensive on-site training course, all course materials (lecture notes, video lectures and tutorials), tutorial exercises, open source software resources and sample datasets will be made freely available through on-line distribution to maximize outreach and encourage additional contributions of curated training resources solicited from the community.         PUBLIC HEALTH RELEVANCE: We propose to train and expand the cadre of researchers capable of effectively using the deluge of complex BIG DATA being generated by advanced biomedical imaging approaches. These data sources represent a rich source of complex information relevant to many scientific areas of inquiry, and are informative at multiple scales ranging from fundamental biological processes at the cellular level to patient diagnostics for diseases such as cancer or neurological disorders.            ",The Big DIPA: Data Image Processing and Analysis,9044533,R25EB022366,"['Accounting ', ' Engineering / Architecture ', ' Architecture ', ' Life Sciences ', ' Biologic Sciences ', ' Biological Sciences ', ' bioengineering ', ' Biomedical Engineering ', ' Biomedical Research ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' computer vision ', ' Computer Vision Systems ', ' Curriculum ', ' Educational Curriculum ', ' Data Sources ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Education ', ' Educational aspects ', ' Environment ', ' Physical Exercise ', ' Exercise ', ' Faculty ', ' Fluorescence ', ' Foundations ', ' Future ', ' Goals ', ' Industry ', ' Information Sciences ', ' Institutes ', ' Laboratories ', ' Laser Radiation ', ' Laser Electromagnetic ', ' Lasers ', ' Learning ', ' Math ', ' Mathematics ', ' Methods ', ' Microscopy ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' Patients ', ' Problem Solving ', ' recruit ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' Science ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' computer program/software ', ' Software ', ' Computer software ', ' Computer Software Tools ', ' Software Tools ', ' statistics ', ' Time ', ' Work ', ' Imaging Technics ', ' Imaging Procedures ', ' Imaging Techniques ', ' Multidisciplinary Communication ', ' Cross-Disciplinary Communication ', ' Interdisciplinary Communication ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' image processing ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Site ', ' Area ', ' Biological ', ' Evaluation ', ' Training ', ' Discipline ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Funding ', ' Biological Function ', ' Biological Process ', ' Exposure to ', ' Staging ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lecture notes ', ' lectures ', ' programs ', ' Scientist ', ' Complex ', ' Stream ', ' Source ', ' interest ', ' meetings ', ' experience ', ' Performance ', ' transdisciplinary collaboration ', ' interdisciplinary collaboration ', ' biomedical scientist ', ' computer science ', ' high-end computing ', ' High Performance Computing ', ' skills ', ' Participant ', ' Program Announcement ', ' NIH Program Announcements ', ' graduate student ', ' outreach ', ' Modality ', ' Biomedical Technology ', ' Sampling ', ' theories ', ' biomedical imaging ', ' bioimaging ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' imaging method ', ' imaging modality ', ' tissue processing ', ' p50 ', ' Tumor Necrosis Factor Receptor Superfamily Member 5 Gene ', ' TNFRSF5 ', ' MGC9013 ', ' CDW40 ', ' CD40 ', ' Bp50 ', ' TNFRSF5 gene ', ' Address ', ' Systems Biology ', ' Data ', ' NIGMS ', ' National Institute of General Medical Sciences ', ' Research Training ', ' computational analysis ', ' Computer Analysis ', ' Senior Scientist ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Instruction ', ' cost ', ' Knowledge Extraction ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' Imaging technology ', ' data acquisition ', ' open source ', ' demographics ', ' public health relevance ', ' data format ', ' biological systems ', ' flexible ', ' flexibility ', ' Big Data ', ' ']",NIBIB,UNIVERSITY OF CALIFORNIA-IRVINE,R25,2015,161997,0.08383548676080321
"Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data     DESCRIPTION (provided by applicant)    My goal in seeking a K01 Award is to acquire the necessary training to become an independently funded investigator focused on exploiting the power of biomedical Big Data Science to improve outcome following severe injury. I am a trauma surgeon at San Francisco General Hospital, one of the Nation's leading trauma centers, and an Assistant Professor of Surgery at the University of California San Francisco (UCSF). UCSF has recently entered into collaboration with the National Laboratories to study the use of biomedical Big Data in complex clinical conditions and my main mentor, Dr. Mitchell J. Cohen is the lead investigator at UCSF for this collaboration. I believe that given the complexity of the factors that likely affect traum outcome including patient injury patterns, medical co-morbidities, patient biology, and the system of care, trauma provides a solid foundation to study the utility of Big Data Science for solving complex medical questions. To facilitate my growth as an expert in this field, I am proposing to develop a framework for integrating multiple data sources necessary to forecast patient outcomes following trauma. These novel datasets combined with biologic and metadata will then be utilized to create improved metrics that better predict complication risk from modifiable and non-modifiable factors. The net result of this work is a new approach to data ascertainment for measuring outcome, leveraging new data types to improve prediction of patient trajectory, and creating a platform to interface with existing information technology to ultimately be used for an early warning detection system for patients at risk of complications. The future long-term goal of this work would be to identify early patients predicted to do more poorly and then apply refinements to the process of care to minimize complication development. The creation of early warning detection systems has significant theoretic potential to improve quality and ultimately decrease costs. Nearly $30 billion per year in the US is spent on care for the traumatically injured and the development of post-traumatic complications is believed to be major contributor to the overall costs of care. The ability to report performance has been hampered by a lack of standard definitions, reporting bias, access to datasets, and the analysis techniques that fail to account for the highly confounded relationships contributing to patient outcome. This K01 award will provide me with the support necessary to accomplish the following goals: (1) to become an expert in applying biologic big data to trauma care (2) to elucidate the relationship of modifiable factors affecting complication development (3) to gain experience with advanced biostatistical techniques and bioinformatics; and (4) to develop an independent clinical research career. To achieve these goals, I have assembled a multidisciplinary team including Dr. Cohen, a National expert in trauma systems biology and biologic big data, and two co-mentors: Dr. Michael Matthay, a translational research expert in complications after severe illness, and Dr. Alan Hubbard, an expert in advanced biostatistical techniques including biologic big data analysis.         PUBLIC HEALTH RELEVANCE    In the US, trauma is the leading cause of death for those under 45 years old and many of the patients who survive their initial injuries develop complications such as blood clots or pneumonia that contribute to both death and the long-term effects of the trauma. Through leveraging the power of biomedical Big Data, an integrated approach to measuring outcome will be developed utilizing biologic, clinical, and electronic medical record (EMR) data. The goal of this project is to lay the ground work for developing integrated EMR early warning detection systems that could identify those at risk of complications early with the intent to ultimately refie the process of care for this group to minimize complication development.                ",Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data,9043721,K01ES026834,"['Accounting ', ' Affect ', ' Age ', ' Algorithms ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Blood Clotting ', ' Blood coagulation ', ' California ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' co-morbidity ', ' Comorbidity ', ' Complication ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Demographic Aging ', ' Foundations ', ' Future ', ' Patient Care ', ' Patient Care Delivery ', ' Geographic Locations ', ' geographic site ', ' MeSH Descriptors Class 4 ', ' Geographical Location ', ' Geographic Region ', ' Geographic Area ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Hospitalization ', ' Hospitals ', ' General Hospitals ', ' Hybrids ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Longterm Effects ', ' Long-Term Effects ', ' Mentors ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' Mortality ', ' Mortality Vital Statistics ', ' Patients ', ' Play ', ' Pulmonary Inflammation ', ' Pneumonitis ', ' Pneumonia ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' Risk Factors ', ' San Francisco ', ' Science ', ' Technology ', ' Testing ', ' Time ', ' trauma centers ', ' Universities ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Outcome Measure ', ' socioeconomic position ', ' socio-economic position ', ' Socio-economic status ', ' Socioeconomic Status ', ' Dataset ', ' Data Set ', ' Caring ', ' myocardium ischemia ', ' myocardial ischemia/hypoxia ', ' heart ischemia ', ' Ischemic myocardium ', ' Ischemic Heart Disease ', ' Ischemic Heart ', ' Myocardial Ischemia ', ' Injury ', ' base ', ' career ', ' improved ', ' Solid ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Medical ', ' Training ', ' disability ', ' Individual ', ' Funding ', ' Collaborations ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Severities ', ' Complex ', ' Source ', ' Pattern ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' Best Practice Analysis ', ' Benchmarking ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Surgeon ', ' American ', ' experience ', ' Performance ', ' professor ', ' Informatics ', ' high-end computing ', ' High Performance Computing ', ' novel ', ' Reporting ', ' Statistical Methods ', ' Modeling ', ' Cellular Telephone ', ' Cell Phone ', ' Cellular Phone ', ' Bio-Informatics ', ' Bioinformatics ', ' Effectiveness ', ' Address ', ' Systems Biology ', ' Data ', ' Data Element ', ' Detection ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Mentored Research Scientist Development Award ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Characteristics ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' Metadata ', ' cost ', ' injured ', ' care systems ', ' Information Technology ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Trauma ', ' modifiable risk ', ' multidisciplinary ', ' public health relevance ', ' trauma care ', ' cloud based ', ' Big Data ', ' ']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2015,222898,0.0716297166759109
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",8935792,U54EB020403,"['Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Acquired Immunodeficiency Syndrome ', ' Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Genes ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human T-Lymphotropic Virus Type III ', ' Human T-Cell Lymphotropic Virus Type III ', ' Human T-Cell Leukemia Virus Type III ', ' Human Immunodeficiency Viruses ', ' HTLV-III ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Articulation ', ' Joints ', ' Learning ', ' Math ', ' Mathematics ', ' Medicine ', ' National Institute of Mental Health ', ' NIMH ', ' National Institute of Mental Health (U.S.) ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Obsessive-Compulsive Neurosis ', ' Obsessive-Compulsive Disorder ', ' Prognosis ', ' outcome forecast ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Schools ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Talents ', ' Training Programs ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Genetic ', ' tool ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuroimaging ', ' novel ', ' Modality ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' chromosome 22q deletion syndrome ', ' Modeling ', ' Genomics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' major depression ', ' Major Depressive Disorder ', ' Institution ', ' Data ', ' NICHD ', ' National Institute of Child Health and Human Development ', ' National Institute on Drug Abuse ', ' NIDA ', ' National Institute of Drug Abuse ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Infrastructure ', ' Research Infrastructure ', ' imaging ', ' Image ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' NIAAA ', ' National Institute on Alcohol Abuse and Alcoholism ', ' innovative ', ' innovate ', ' innovation ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' multi-task ', ' multitask ', ' addictive disorder ', ' addiction ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' Big Data ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2015,2555730,0.07778723406859629
"Developing Cloud-based tools for Big Neural Data DESCRIPTION (provided by applicant): Big data has the potential to dramatically advance the electrophysiology biodata sciences in similar ways that it has transformed Genetics. Differences between these two areas dictate separate approaches to apply Big Data tools, and methods in order to provide successful assets to the research community. For one, neural datasets are very heterogeneous by nature. The data is difficult to interpret without knowing specifics about the data acquisition protocol, the experimental paradigm and the physiological state of the recorded subject. Many neural datasets are complemented with complex meta-data sets, which should be an integral component in any effort to integrate and share these data with other researchers. The goal of this project is to develop novel, generalizable Big Data tools to facilitate cloud-base analysis of complex multi-scale neural data. Epilepsy research will be used as a specific use case to guide the development of the tools. A cohort of established senior investigators performing epilepsy research will use and validate these tools in their laboratories. Epilepsy research is currently limited by its narrow focus on single models (animal or human) in individual centers and laboratories. Just as Genetics was revolutionized through Big Data techniques, so too can Epilepsy research be transformed through novel approaches to standardize, share, and mine data across groups of investigators. Over the past several years I have co-developed a NINDS funded cloud-based data platform, ://ieeg.org, giving me a central role in developing Big Data solutions for neural data, such as customized data sharing, large-scale cloud-based data analysis, and search and interrogation techniques for complex data and metadata. My scientific objectives for this project are: (1) to develop generalizable tools to curate, analyze, and interrogate multi-scale neural data, and (2) to create a platform that will galvanize a research community focused on sharing data, and methods to advance Big Data research in the basic and translational neurosciences. Equally important to this proposal, I present a training plan to prepare me for an academic career focused on Big Data in the neurosciences. This plan supplements my background in bioengineering and statistical modeling of neural data with broader data-science expertise in data integration and machine learning, and deeper domain knowledge of the clinical neurosciences. I have assembled a group of collaborators, basic investigators and clinician scientists, who will use the tools developed in this project to analyze and validate their data and methods. I will use the results of this project as the foundation for a R01 Grant application, in which I will expand the developed platform and tools to target other research domains (TBI, Emergency Care, Cardiac), as well as integrate other data-modalities such as Imaging, and Genomics. OMB No. 0925-0001/0002 (Rev. 08/12 Approved Through 8/31/2015) Page Continuation Format Page PUBLIC HEALTH RELEVANCE: The goal of this proposal is to advance Big Data research in the neurosciences by developing tools and techniques to interrogate electrophysiology data sets from animal models of human neurological disorders. Development of these tools requires close collaboration between domain experts in Neuroscience, Machine Learning, Statistics and Computer Science. When developed, this platform and these tools will allow investigators to share, collaborate, annotate, standardize and analyze large, complex, multiscale data sets that are a crucial first step in advancing this field.",Developing Cloud-based tools for Big Neural Data,8935817,K01ES025436,"['bioengineering ', ' Biomedical Engineering ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Data Analysis ', ' Data Analyses ', ' Neurophysiology / Electrophysiology ', ' Electrophysiology ', ' Electrophysiology (science) ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Feedback ', ' Foundations ', ' Goals ', ' Health ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' inducement ', ' Incentives ', ' Laboratories ', ' Learning ', ' Methods ', ' Mining ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' living system ', ' Organism ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Science ', ' Solutions ', ' Standardization ', ' statistics ', ' Time ', ' Dataset ', ' Data Set ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Series ', ' Evaluation ', ' Training ', ' Individual ', ' Fostering ', ' Funding ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Scientist ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Techniques ', ' data management ', ' Performance ', ' computer science ', ' cohort ', ' model organism ', ' Animal Models and Related Studies ', ' Animal Model ', ' neural ', ' relating to nervous system ', ' novel ', ' Modality ', ' Genomics ', ' Institution ', ' datamining ', ' data mining ', ' Data ', ' Grant Proposals ', ' Applications Grants ', ' Infrastructure ', ' Research Infrastructure ', ' Computational Technique ', ' Process ', ' Cardiac ', ' Emergency medical care ', ' Emergency healthcare ', ' Emergency health care ', ' Emergency Room care ', ' Emergency Department care ', ' ER care ', ' ED care ', ' Emergency Care ', ' imaging ', ' Image ', ' Metadata ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' data integration ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' data acquisition ', ' comparative ', ' tool development ', ' translational neuroscience ', ' sharing data ', ' Data Provenance ', ' cloud based ', ' Big Data ', ' ']",NIEHS,UNIVERSITY OF PENNSYLVANIA,K01,2015,192201,0.09939901507038518
"Informatics Tools for High-throughput Analysis of Cancer Mutations DESCRIPTION (provided by applicant): Large tumor exome sequencing projects have identified a very large number of mutations whose cancer relevance is not yet understood. To begin to address this need, our team has produced two web applications for high-throughput computational analysis of cancer mutations: the Cancer-Related Analysis of VAriants Toolkit (CRAVAT) and the Mutation Position Imaging Toolbox (MuPIT). CRAVAT accepts millions of mutations in a single batch upload and maps mutations from genomic coordinates to annotated transcripts and proteins. MuPIT currently accepts batch uploads of up to 2500 SNVs and maps from genomic coordinates onto X-ray crystal structures of proteins from Protein Data Bank (PDB). We propose to combine and harden CRAVAT and MuPIT into a single web application, in which we will substantially improve the tools, user interface, software infrastructure, integration with external data resources and tools used by the community, and support for protected data. The scope of all tools in the web application will be broadened to handle analysis of the full range of small-scale mutation consequence types found in cancer exomes.  CRAVAT analysis identifies mutations most likely to have deleterious impact on protein function and those that are most likely to confer a selective advantage to cancer cells (drivers), using classifiers developed by our team. Classifier scores are supplemented with annotations, including population allele frequencies, previous occurrence in tumor tissue types, and gene functional categories, enabling filtering (e.g. removing polymorphisms) and prioritization. Gene-level annotation and scoring, by aggregation of classifier scores from mutations in a cohort is also provided.  MuPIT maps mutations from genomic positions onto to protein structures and provides interactive viewing of mutations in the context of protein structure, and in relation to a variety of annotations. To enable prioritization of interesting mutations and genes, the application provides a preview describing each structure and all available annotations (e.g., binding sites, experimental mutagenesis results, polymorphic and disease- associated variants that have been previously documented). After selecting a PDB of interest, the user is led to an interactive visualization page. An enhanced Jmol applet displays all SNVs mapped onto the structure. Frequently, many SNVs in the input list can be mapped onto a single structure, revealing clustering patterns around key functional sites.  Based only on word-of-mouth, since the debut of the two applications in August 2012, CRAVAT has been utilized by 129 unique users from 39 countries, and it has analyzed 1,136 submitted jobs, totaling 27.9 million mutations. MuPIT has been utilized by 242 unique users from 25 countries, with 720 submitted jobs. (Source: Google Analytics). PUBLIC HEALTH RELEVANCE: The proposed work will harden and develop web applications for the cancer genomics community to interpret small-scale mutations in cancer exomes. They are designed to handle very large number of mutations and to provide analysis targeted at researchers who are not bioinformatics experts. The work will contribute to understanding of the genetic complexity and heterogeneity of tumors and assist in discovery of new approaches for cancer prognosis and treatments.",Informatics Tools for High-throughput Analysis of Cancer Mutations,8910262,U01CA180956,"['Reactive Site ', ' Combining Site ', ' Binding Sites ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Systematics ', ' Classification ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Health ', ' Heterogeneity ', ' histocompatibility typing ', ' Tissue Typing ', ' Tissue Crossmatching ', ' Histocompatibility Testing ', ' Housing ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Professional Positions ', ' Jobs ', ' Occupations ', ' polymorphism ', ' Polymorphism (Genetics) ', ' Genetic Polymorphism ', ' Production ', ' gene product ', ' Proteins ', ' Scientific Publication ', ' Publications ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' computer program/software ', ' Software ', ' Computer software ', ' Technology ', ' Translations ', ' Work ', ' Xrays ', ' X-Rays Radiation ', ' X-Rays ', ' X-Radiation ', ' Radiation, X-Rays, Gamma-Rays ', ' Roentgen Rays ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Privacy ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' prognostic ', ' insight ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Collaborations ', ' Letters ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Source ', ' Pattern ', ' Country ', ' Tumor Tissue ', ' interest ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Missense Mutation ', ' cohort ', ' Informatics ', ' UTRs ', ' Untranslated Regions ', ' Structure ', ' Categories ', ' Position ', ' Positioning Attribute ', ' Mutation Analysis ', ' Network Analysis ', ' Pathway Analysis ', ' high throughput analysis ', ' developing computer software ', ' develop software ', ' software development ', ' Genomics ', ' cancer classification ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' protein structure ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Mutate ', ' Qualifying ', ' Infrastructure ', ' Research Infrastructure ', ' Cancer Center ', ' Cancer Prognosis ', ' computational analysis ', ' Computer Analysis ', ' Transcript ', ' Update ', ' Molecular ', ' protein function ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' web services ', ' oncogenomics ', ' cancer genomics ', ' cancer genome ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' insertion/deletion mutation ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' user-friendly ', ' web interface ', ' tumor ', ' data transmission ', ' data exchange ', ' exomes ', ' exome ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome sequencing ', ' cloud based ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,U01,2015,335363,0.18887699366737276
"Developing integrative approaches for identifying disease-causing genes and dysfunctional networks     DESCRIPTION: Cancer is a consequence of the accumulation of genetic alterations. Large whole-genome scale resequencing projects such as The Cancer Genome Atlas (TCGA) have been launched in an effort to comprehensively catalog the genomic mutations and epigenetic modifications that are associated with cancer. It is essential to identify cancer-causing genes and pathways to gain insight into the disease mechanisms and hence facilitate early diagnosis and optimal treatment. However, identifying cancer-causing genes and their functional pathways remains challenging due to the complex biological interactions and the heterogeneity of diseases. Genetic mutations in disease-causing genes can disturb signaling pathways that impact the expression of a set of genes performing certain biological functions. We refer to a set of such genes as a functional module. We hypothesize that driver mutations, that is, mutations that lead to cancer progression, are likely to affect common disease-associated functional modules, and the causal relationship between the mutations and the perturbed signals of the modules can be reconstructed from gene expression data and protein interaction data. In this project, we will develop a novel approach to infer disease-causing genes and networks by integrating information from multiple types of data including genomic variations, gene expression and protein interactions. We first dynamically identify disease-associated modules that consist of a set of interacting genes, then develop a Bayesian-based approach to infer causative genes from the disease-associated modules. Then, by developing a stochastic search based method, we can determine the paths connecting causative genes and gene modules. As a result, disease- related pathways are inferred from the paths. Furthermore, we will integrate those pathways with the human interactome to discover higher-level disease-associated networks. In addition, we will develop machine learning based classifiers to predict disease types and clinical outcomes utilizing the molecular signatures identified in this project, such as differentially expressed gene modules and causative genes. Our computational framework and classifiers will be made available to the research community via a webserver. The PI serves as the university bioinformatics program director and has extensive teaching and research experience. A goal of this project is also to provide scientific research training to students and o help students to gain biological insight through their involvement with the project. Students will learn practical scientific computing skills from the PI and develop their own computational approaches to solving specific biomedical problems under the guidance of the PI. Thus the project will serve as an effective learning-research model in bioinformatics.         PUBLIC HEALTH RELEVANCE: In this project, we will develop and implement a novel framework to identify causative mutations and pathways and study cancer disease mechanisms by reconstructing signaling pathways. This will help to advance personalized medicine and lead to a greater understanding of cancer mechanisms, which can lay the foundation for improving early diagnosis and treatment planning, as well as the discovery of new therapeutic targets.            ",Developing integrative approaches for identifying disease-causing genes and dysfunctional networks,8880075,R15GM114739,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cataloging ', ' Communities ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Foundations ', ' Gene Cluster ', ' Gene Expression ', ' Genes ', ' Genome ', ' Goals ', ' Heterogeneity ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Protein Phosphorylation ', ' Phosphorylation ', ' gene product ', ' Proteins ', ' Research ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Technology ', ' Universities ', ' Promotor ', ' Promoters (Genetics) ', ' Promoter ', ' Promotor (Genetics) ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' improved ', ' Clinical ', ' Biological ', ' insight ', ' Relapsed Disease ', ' Recurrent disease ', ' Biological Function ', ' Biological Process ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Catalogs ', ' programs ', ' Investigation ', ' Complex ', ' LOINC Axis 4 System ', ' System ', ' early detection ', ' Early Diagnosis ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' Performance ', ' heuristics ', ' knowledgebase ', ' knowledge base ', ' treatment planning ', ' skills ', ' novel ', ' disease risk ', ' disorder risk ', ' Protein Gene Products ', ' Gene Proteins ', ' Single Base Polymorphism ', ' Single Nucleotide Polymorphism ', ' Modeling ', ' Sampling ', ' protein protein interaction ', ' Genomics ', ' ovarian cancer ', ' Ovary Cancer ', ' Malignant Tumor of the Ovary ', ' Malignant Ovarian Tumor ', ' Malignant Ovarian Neoplasm ', ' Malignant neoplasm of ovary ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA-Protein Interaction ', ' Resequencing ', ' DNA Resequencing ', ' DNA Sequence Alteration ', ' Data ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Signature ', ' Expression Profiling ', ' Molecular Profiling ', ' Research Training ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Data ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' whole-genome scan ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide scan ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome-wide scan ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' genome wide analysis ', ' GWAS ', ' genome wide association study ', ' computational framework ', ' computer framework ', ' Bayesian computation ', ' Bayesian Networks ', ' computer based statistical methods ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Population ', ' prospective ', ' innovative ', ' innovate ', ' innovation ', ' early therapy ', ' Early treatment ', ' scientific computing ', ' novel therapeutic target ', ' new therapeutic target ', ' public health relevance ', ' genomewide ', ' genome-wide ', ' disease diagnosis ', ' TCGA ', ' The Cancer Genome Atlas ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' Drug Targeting ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIGMS,UNIVERSITY OF ARKANSAS AT LITTLE ROCK,R15,2015,373520,0.14201746601267956
"Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems DESCRIPTION (provided by applicant): Abstract Biomedical science, higher education, software and technology are simultaneously undergoing tectonic shifts. The amazing pace of software and technological development are driving equally amazing advances in the ability to acquire massive data sets in the biomedical sciences. These new Big Biomedical data sets come in the form of complex measurements, such as that of the brain, genome, proteome and human biome or massive databases, such as with electronic health records. Big Data issues, such as reproducibility of processing, measurement and analysis techniques, are increasingly complex, and crucial. Across all domains there is a knowledge gap of researchers to analyze and interpret these new data sets and the current higher education model cannot meet the insatiable demand for this training. We propose to make substantial progress on these issues in two domains. Specifically, we propose to use Massive Open Online Courses (MOOCs) to create two series, one in neuroimaging and one in genomics. These series will allow for flexible, student paced, low cost scalable training for tens of thousands of students. Along with these series, we propose the creation of modular Big Data biostatistical content that can be used by students as well as teachers. This effort will be parallel to work on an intelligent tutoring syste called swirl. This application proposes to use swirl to create rich, gamified learning environments for students. All of the material created from this grant will be open access and free. PUBLIC HEALTH RELEVANCE:  Project narrative: We propose two Massive Open Online Course series in neuroimaging and genomic Big Data analysis as well as the creation of modular Big Data statistics content and content creation for an intelligent tutoring system.","Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems",8935788,R25EB020378,"['abstracting ', ' Attention ', ' driving ', ' Automobile Driving ', ' Biology ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' clinical investigation ', ' Clinical Trials ', ' Communities ', ' Cost Analyses ', ' Cost Analysis ', ' Curriculum ', ' Educational Curriculum ', ' Data Analysis ', ' Data Analyses ', ' Data Collection ', ' Education ', ' Educational aspects ', ' Environment ', ' Genes ', ' Genome ', ' Grant ', ' Head ', ' Health ', ' Modern Man ', ' Man (Taxonomy) ', ' Human ', ' Laboratories ', ' Learning ', ' Medicine ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Multivariate Analyses ', ' Multivariate Analysis ', ' Persons ', ' Public Health ', ' public health medicine (field) ', ' Public Health Nurses ', ' Public Health Nursing ', ' Racial Stocks ', ' Racial Group ', ' Race ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Science ', ' computer program/software ', ' Software ', ' Computer software ', ' Solutions ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Technology ', ' Testing ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Generations ', ' Measures ', ' Amaze ', ' TimeLine ', ' Dataset ', ' Data Set ', ' Instructional Models ', ' Educational Models ', ' density ', ' Area ', ' Biological ', ' Medical ', ' Series ', ' Training ', ' teacher ', ' Discipline ', ' data repository ', ' clinical data repository ', ' Electronic Database ', ' Electronic Databank ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Scientist ', ' Adopted ', ' Dimensions ', ' Complex ', ' Stream ', ' Techniques ', ' LOINC Axis 4 System ', ' System ', ' meetings ', ' instructor ', ' Services ', ' skills ', ' neuroimaging ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' Touch ', ' Touch sensation ', ' Proteome ', ' Modeling ', ' Genomics ', ' Drops ', ' Systems Biology ', ' Data ', ' Molecular Medicine ', ' Resolution ', ' enroll ', ' Enrollment ', ' Principal Investigator ', ' developmental ', ' Development ', ' Electronic Health Record ', ' imaging ', ' Image ', ' cost ', ' process reproducibility ', ' process repeatability ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' multidisciplinary ', ' open source ', ' flexible ', ' flexibility ', ' operation ', ' Big Data ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' Learning Module ', ' ']",NIBIB,JOHNS HOPKINS UNIVERSITY,R25,2015,212771,0.08456762463028059
"Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci DESCRIPTION (provided by applicant): Colorectal carcinoma (CRC) arises from multiple mutations and genomic aberrations in distinct driver cancer genes that that in concert to spur neoplastic development and phenotype. This inherent genetic complexity greatly complicates both personalized diagnosis and treatment. Previously published studies have confined that large numbers of genes will be mutated or subject to genomic aberrations in CRC. A significant and emerging challenge for the post-genomic era is to identify which of these mutated genes are ""driver"" loci that functionally drive colon cancer development, versus ""passenger"" loci without functional relevance. Finally, it is of the highest priority that one forges these genetic observations with correlations of prognosis and clinical outcome. This can only be done if we better understand the unified biological ramifications of the combined and diverse multigenic driver background which act synergistically to promote CRC tumorigenesis. This proposal details an integrated analysis that will rely on the CRC genomic data generated by the Cancer Genome Atlas Project (TCGA) to discover novel candidate CRC genes and study multigenic CRC driver gene co-mutated / dysregulated modules within the genetic context of other drivers and provide biological validation in a powerful in vitro primary culture CRC model which can be engineered for multiple genetic events.  To accomplish these goals, we will develop and implement novel statistical methodologies for the integrative analysis of multiple TCGA genomic and clinical data sets. The goal is to identify and prioritize novel CRC genes either singly or as co-mutated modules in combination with other known ""driver"" CRC genes. We will use the rich TCGA data set to conduct an integrated CRC genomic analysis of point mutations, gene expression, copy number aberrations and methylation data. We will prioritize the discovery of mutations and other genomic aberrations of these novel CRC genes that are associated with specific clinical stages of disease and other clinical parameters.  These statistical and computational studies will then be directly coupled to rapid and robust functional target validation of candidate loci using our rigorously characterized in vitro primary intestinal culture methodology (Gotani et al, Nature Medicine, 2009), in which we have recently established the transforming activity of established CRC loci such as APC, KRAS and TP53. Genetic deletion and retroviral expression of shRNA, cDNA or mutants thereof will be utilized to evaluate putative individual driver loci, as well as combinatorial oncogene modules. This proposal directly addresses fundamental problems in the exploration and translation of novel colorectal cancer gene discovery in the context of clinical data which is available from TCGA. RELEVANCE (See instructions): Colorectal cancer (CRC) represents the third most commonly diagnosed cancer in the United States. This proposal utilizes a fusion of genomic analysis of a large population of patients, mathematical modeling and culture of intestinal fragments to functionally identify genes that are critical for colon cancer development. These studies have implications for generation of novel diagnostic and therapeutic strategies for colon cancer. ",Integrated Genomic Discovery and Functional Validation of Colorectal Cancer Loci,8916038,U01CA151920,"['Algorithms ', ' Atlases ', ' Biology ', ' cDNA ', ' Complementary DNA ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Large Bowel Carcinoma ', ' Colorectal Carcinomas ', ' Large Intestine Carcinoma ', ' Diagnosis ', ' disease/disorder ', ' Disorder ', ' Disease ', ' Engineering ', ' Future ', ' Gene Expression ', ' Genes ', ' Goals ', ' In Vitro ', ' bowel ', ' Intestinal ', ' Intestines ', ' Literature ', ' Medicine ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Protein Methylation ', ' Methylation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Phenotype ', ' Prognosis ', ' outcome forecast ', ' Scientific Publication ', ' Publications ', ' Publishing ', ' Research ', ' Statistical Study ', ' statistics ', ' Survey Instrument ', ' Surveys ', ' Technology ', ' Translations ', ' United States ', ' Generations ', ' p53 Genes ', ' Tumor Protein p53 Gene ', ' TRP53 ', ' TP53 ', ' P53 ', ' TP53 gene ', ' Racial Segregation ', ' segregation ', ' Dataset ', ' Data Set ', ' Point Mutation ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' intestinal epithelium ', ' Individual ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Measurement ', ' Oncologist ', ' Genetic ', ' Staging ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Somatic Mutation ', ' experience ', ' Sequence Alteration ', ' Genetic mutation ', ' Gene Alteration ', ' DNA mutation ', ' DNA Alteration ', ' Gene Mutation ', ' mutant ', ' authority ', ' novel ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Colon Carcinoma ', ' Modeling ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' mathematical model ', ' Genomics ', ' cancer diagnosis ', ' Oncogenesis ', ' tumorigenesis ', ' v-Ki-RAS2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog ', ' RASK2 ', ' Oncogene K-Ras ', ' Ki-RAS ', ' KRAS2 ', ' KRAS ', ' K-Ras-2 Oncogene ', ' K-Ras 2A ', ' K-RAS2B ', ' K-RAS2A ', ' C-K-RAS ', ' KRAS2 gene ', ' Address ', ' Systems Biology ', ' copy number variation ', ' Copy Number Polymorphism ', ' Data ', ' Mutate ', ' Clinical Data ', ' Validation ', ' Principal Investigator ', ' developmental ', ' Development ', ' Colorectal Cancer ', ' neoplastic ', ' Instruction ', ' clinical phenotype ', ' oncogenomics ', ' cancer genomics ', ' forging ', ' cancer genome ', ' computational studies ', ' computer studies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Coupled ', ' short hairpin RNA ', ' shRNA ', ' small hairpin RNA ', ' combinatorial ', ' next generation therapeutics ', ' new therapeutics ', ' novel therapeutics ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' discover genes ', ' gene discovery ', ' patient population ', ' genomewide ', ' genome-wide ', ' candidate validation ', ' exomes ', ' exome ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome sequencing ', ' algorithmic composition ', ' algorithm engineering ', ' Algorithmic Engineering ', ' Algorithmic Design ', ' Algorithm Design ', ' ']",NCI,STANFORD UNIVERSITY,U01,2015,538358,0.10502725292780575
"Transforming Analytical Learning in the Era of Big Data     DESCRIPTION (provided by applicant): In this dawning era of `Big Data' it is vital to recruit and train the next generation of biomedical data scientists in `Big Data'. The collection of `Big Data' in the biomedical sciences is growing rapidly and has the potential to solve many of today's pressing medical needs including personalized medicine, eradication of disease, and curing cancer. Realizing the benefits of Big Data will require a new generation of leaders in (bio) statistical and computational methods who will be able to develop the approaches and tools necessary to unlock the information contained in large heterogeneous datasets. There is a great need for scientists trained in this specialized, highly heterogeneous, and interdisciplinary new field. Thus, the recruitment of talented undergraduates in science, technology, engineering and mathematics (STEM) programs is vital to our ability to tap into the potential that `Big Data' offer and the challenges that it presents. The University of Michigan Undergraduate Summer Institute: Transforming Analytical Learning in the Era of Big Data will draw from the expertise and experience of faculty from four different departments within four different schools at the University of Michigan: Biostatistics in the School of Public Health, Computer Science in the School of Engineering, Statistics in the College of Literature, Sciences and the Arts, and Information Science in the School of Information. The faculty instructors and mentors have backgrounds in Statistics, Computer Science, Information Science and Biological Sciences. They have active research programs in a broad spectrum of methodological areas including data mining, natural language processing, statistical and machine learning, large-scale optimization, matrix computation, medical computing, health informatics, high-dimensional statistics, distributed computing, missing data, causal inference, data management and integration, signal processing and imaging. The diseases and conditions they study include obesity, cancer, diabetes, cardiovascular disease, neurological disease, kidney disease, injury, macular degeneration and Alzheimer's disease. The areas of biology include neuroscience, genetics, genomics, metabolomics, epigenetics and socio-behavioral science. Undergraduate trainees selected will have strong quantitative skills and a background in STEM. The summer institute will consist of a combination of coursework, to raise the skills and interests of the participants to a sufficient level to consider pursuing graduate studies in `Big Data' science, along with an in depth mentoring component that will allow the participants to research a specific topic/project utilizing `Big Data'. We have witnessed tremendous enthusiasm and response for our pilot offering in 2015 with 153 applications for 20 positions and a yield rate of 80% from the offers we extended. We plan to build on the success of this initial offering in the next three year funding cycle of this grant (2016-2018). The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a no-traditional, action-based learning paradigm. This six week long summer institute will recruit a group of approximately 30 undergraduates nationally and expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material for undergraduate students in this new field across the world.         PUBLIC HEALTH RELEVANCE: We propose a six week long summer institute: ""Transforming Analytical Learning in the Era of Big Data"" to be held at the Department of Biostatistics, University of Michigan, Ann Arbor, with a group of approximately 30 undergraduates recruited nationally, from 2016-2018. We plan to expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty from Biostatistics, Statistics, Computer Science and Engineering, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a Wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material in this new field across the world. The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm.            ",Transforming Analytical Learning in the Era of Big Data,9044118,R25EB022363,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Arts ', ' Behavioral Sciences ', ' Life Sciences ', ' Biologic Sciences ', ' Biological Sciences ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' disease/disorder ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Faculty ', ' Goals ', ' Grant ', ' Information Sciences ', ' Institutes ', ' renal disorder ', ' kidney disorder ', ' Renal Disease ', ' Nephropathy ', ' Kidney Diseases ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Literature ', ' Macular degenerative disease ', ' Macular degeneration ', ' Mentors ', ' Methods ', ' Method LOINC Axis 6 ', ' Methodology ', ' Michigan ', ' natural language understanding ', ' Natural Language Processing ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' recruit ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' Public Health Schools ', ' Science ', ' statistics ', ' Students ', ' Talents ', ' Teaching ', ' Educational process of instructing ', ' Universities ', ' Drug Side Effects ', ' Adverse drug effect ', ' Work ', ' Generations ', ' case report ', ' Case Study ', ' conference ', ' symposium ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Injury ', ' base ', ' Area ', ' Medical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' posters ', ' lectures ', ' programs ', ' Scientist ', ' Oral ', ' Techniques ', ' interest ', ' meetings ', ' instructor ', ' collegiate ', ' college ', ' data management ', ' experience ', ' success ', ' computer science ', ' skills ', ' Participant ', ' member ', ' graduate student ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Statistical Methods ', ' response ', ' Genomics ', ' consumer informatics ', ' Health Informatics ', ' Public Health Informatics ', ' metabolism measurement ', ' metabolomics ', ' datamining ', ' data mining ', ' Data ', ' Collection ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' data integration ', ' grid computing ', ' distributed computing ', ' datagrid ', ' data grid ', ' computational grid ', ' cluster computing ', ' designing ', ' design ', ' next generation ', ' wiki ', ' open source ', ' public health relevance ', ' biomarker ', ' biologic marker ', ' Biological Markers ', ' Science, Technology, Engineering and Math ', ' Science, Technology, Engineering and Mathematics ', ' undergraduate student ', ' signal processing ', ' Big Data ', ' personalized treatment ', ' personalized therapy ', ' personalized medicine ', ' ']",NIBIB,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R25,2015,159359,0.1212833226059418
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,8982803,F31CA200266,"['Cell Multiplication ', ' Cell Growth in Number ', ' Cell Proliferation ', ' Performance ', ' Statistical Bias ', ' novel ', ' Sampling ', ' LOINC Axis 2 Property ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' transcriptome ', ' gene expression signature ', ' gene expression pattern ', ' Gene Expression Profile ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Au element ', ' Gold ', ' Methods ', ' Motivation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' tumor cell metastasis ', ' cancer metastasis ', ' Tumor Cell Migration ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Play ', ' Science ', ' statistics ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Tumor Suppressor Genes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequency ', ' Frequencies (time pattern) ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' Cancer Induction ', ' carcinogenesis ', ' Cellular Proliferation ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2015,43120,0.10587087917782546
"Genomics-based prediction of antibiotic failure in S. aureus infections     DESCRIPTION (provided by applicant)    The Gram positive bacterium Staphylococcus aureus is both an asymptomatic human colonizer and a pathogen that can cause infections in multiple tissue sites, including blood, skin and soft tissue, bone, and internal organs. Methicillin resistant Staphylococcus aureus (MRSA) is a common cause of death by hospital infections (HA-MRSA) and is now also a common community acquired infection (CA-MRSA). Vancomycin (a glycopeptide antibiotic) is the most commonly prescribed drug to treat MRSA infections. High-level resistance (minimal inhibitory concentration (MIC) 16 g/ml) to vancomycin encoded by the mobile vanA gene is rare due to a fitness burden on S. aureus. However, it is more common to encounter strains with mutations conferring intermediate resistance to vancomycin arising from selection during the course of antibiotic therapy. The genetic basis of these vancomycin intermediate S. aureus (VISA) and heterogeneous resistant (hVISA) (MIC 2-8 g/ml) strains involves a large number of different genomic mutations that result in cell wall thickening through changes in cellular signaling and regulation. Routine phenotypic testing in clinical labs probably underestimates the incidence of VISA and hVISA. Due to the fact that mutations in several genes have been linked with VISA, genetic-based detection of intermediate vancomycin resistance has not been developed for routine clinical microbiological use. In our preliminary work, we created an extensive catalog of sequenced clinical and laboratory-selected VISA as well as databases of SNPs and genetic variation in thousands of public S. aureus genomes. In this work we plan to extend these studies toward development of a sequence-based testing protocol that could be used for large numbers of clinical strains. In Specific Aim 1 we plan to extend our knowledge of the mutations that cause VISA by sequencing a panel of 300 novel mutants strains spontaneously selected from 40 S. aureus parent genotypes. We estimate, based on the results of the preliminary data, that this number of strains will be sufficient identify mutations found in 95% of VISA strains. These data will be used for creation of a comprehensive VISA detection assay based on whole genome data with an accuracy of at least 95%. In Specific Aim 2 we will use the information learned from Aim 1 to create a multiplex PCR sequence test for VISA, VRSA and other resistance determinants of S. aureus based on the commercially available Fluidigm platform. We will ultimately aim to have an assay that can be used to monitor systemic MRSA infections, such as bacteremia, to detect development of VISA in its early stages in clinical specimens from the patient. The test will also be able to detect other S. aureus resistance phenotypes and call the genotype of the strain.             PUBLIC HEALTH RELEVANCE    Vancomycin is an antibiotic commonly used to treat methicillin resistant Staphylococcus aureus (MRSA) infections in chronically ill patients. The efficacy of this relatively cheap and well-tolerated therapy is compromised by mutations in the genome of the bacterium. In this project we propose to develop a genetic test based on a library of MRSA genome sequences with known antibiotic susceptibility level that identifies bacteria with diminished resistance to vancomycin.            ",Genomics-based prediction of antibiotic failure in S. aureus infections,9017369,R21AI121860,"['Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antibiotics ', ' bacteraemia ', ' Bacteremia ', ' Bacteria ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' bone ', ' Cataloging ', ' Cause of Death ', ' Cell Wall ', ' Chronically Ill ', ' Evolution ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Gram-Positive Bacteria ', ' University Hospitals ', ' Modern Man ', ' Human ', ' Incidence ', ' Infection ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Libraries ', ' Dimethoxyphenyl Penicillin ', ' 2,6 dimethoxyphenylpenicillin ', ' Methicillin ', ' mortality ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Parents ', ' Patients ', ' Phenotype ', ' Drug Prescribing ', ' Drug Prescriptions ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Software ', ' Computer software ', ' Staph aureus ', ' S.aureus ', ' S. aureus ', ' Staphylococcus aureus ', ' Testing ', ' Body Tissues ', ' Tissues ', ' Vancomycin ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Virulence ', ' Work ', ' Antibiotic Resistance ', ' antibiotic resistant ', ' Resistant to antibiotics ', ' Resistance to antibiotics ', ' Healthcare ', ' health care ', ' Data Set ', ' Dataset ', ' Treatment Failure ', ' therapy failure ', ' Glycopeptide Antibiotics ', ' base ', ' Organ ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' institutional infection ', ' Hospital acquired infection ', ' Hospital Infections ', ' Nosocomial Infections ', ' Community-Acquired Infections ', ' Link ', ' Training ', ' soft tissue ', ' Failure ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' Staging ', ' tool ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Antibiotic Therapy ', ' Research Specimen ', ' Specimen ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Catalogs ', ' Frequencies ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' interest ', ' mutant ', ' pleiotropy ', ' pleiotropic effect ', ' pleiotropism ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' economic cost ', ' Skin Tissue ', ' vancomycin resistant ', ' resistant to vancomycin ', ' resistance to vancomycin ', ' Vancomycin Resistance ', ' Regulation ', ' Modeling ', ' Genomics ', ' Methicillin Resistant S. Aureus ', ' MRSA ', ' methicillin resistant Staphylococcus aureus ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Monitor ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Antibiotic susceptibility ', ' Intermediate resistance ', ' Intermediate resistant ', ' Heteroresistant ', ' Heteroresistance ', ' Vancomycin-resistant S. aureus ', ' Vancomycin-resistant Staphylococcus aureus ', ' Vancomycin-resistant S.aureus ', ' VRSA ', ' pathogen ', ' Resistance ', ' resistant ', ' public health relevance ', ' genetic predictors ', ' clinical sequencing ', ' whole genome ', ' entire genome ', ' ']",NIAID,EMORY UNIVERSITY,R21,2016,234000,0.0741715938342794
"A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform     DESCRIPTION (provided by applicant): The inception of the BD2K Initiative is a testament to the foresight of NIH and our community. Clearly, the future of biomedicine rests on our collective ability to transform Big Data into intelligible scientific facts. In line with the BD2K objectives,our goal is to revolutionize how we address the universal challenge to discern meaning from unruly data. Capitalizing on our investigators' complementary strengths in computational biology and cardiovascular medicine, we will present a fusion of cutting-edge innovations that are grounded in a cardiovascular research focus, encompassing: (i) on-the-cloud data processing, (ii) crowd sourcing and text-mining data annotation, (iii) protein spatiotemporal dynamics, (iv) multi-omic integration, and (v) multiscale clinical data modeling. Drawing from our decade of experience in creating and refining bioinformatics tools, we propose to amalgamate established Big Data resources into a generalizable model for data annotation and collaborative research, through a new query system and cloud infrastructure for accessing multiple omics repositories, and through computational-supported crowdsourcing initiatives for mining the biomedical literature. We propose to interweave diverse data types for revealing biological networks that coalesce from molecular entities at multiple scales, through machine learning methods for structuring molecular data and defining relationships with drugs and diseases, and through novel algorithms for on-the-cloud integration and pathway visualization of multi-dimensional molecular data. Moreover, we propose to innovate advanced modeling tools to resolve protein dynamics and spatiotemporal molecular mechanisms, through mechanistic modeling of protein properties and 3D protein expression maps, and through Bayesian algorithms that correlate patient phenotypes, health histories, and multi-scale molecular profiles. The utility and customizability o our tools to the broader research population is clearly demonstrated using three archetypical workflows that enable annotations of large lists of genes, transcripts, proteins, or metabolites; powerful analysis of complex protein datasets acquired over time; and seamless aQoregation of diverse molecular, textual and literature data. These workflows will be rigorously validated using data from two significant clinical cohorts, the Jackson Heart Study and the Healthy Elderly Longevity (Wellderly). In parallel, a multifaceted strategy will be implemented to educate and train biomedical investigators, and to engage the public for promoting the overall BD2K initiative. We are convinced that a community-driven BD2K initiative will best realize its scientific potential and transform the research culture in a sustainable manner, exhibiting lasting success beyond the current funding period.         PUBLIC HEALTH RELEVANCE:  The challenges of biomedical Big Data are multifaceted. Biomedical investigators face daunting tasks of storing, analyzing, and distributing large-scale omics data, and aggregating all information to discern mechanistic insights. A coherent effort is required to harness disarrayed Big Data and transform them into intelligible scientific facts, whil engaging the global community via education and outreach programs. This Big Data Science Research proposal is designed to address these challenges by formulating a federated architecture of community-supported tools for enhancing data management, integration and analysis.            ",A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform,9087292,U54GM114833,"['Achievement Attainment ', ' Achievement ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Awareness ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Communities ', ' Aggregated Data ', ' Data Aggregation ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Exhibits ', ' facial ', ' faces ', ' Face ', ' Future ', ' Genes ', ' Goals ', ' Half-Life ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Literature ', ' lifespan ', ' life span ', ' Length of Life ', ' Longevity ', ' Maps ', ' Medicine ', ' Mining ', ' Macromolecular Structure ', ' Molecular Structure ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Patients ', ' Phenotype ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Proposals ', ' Research Resources ', ' Resources ', ' Rest ', ' Time ', ' Translating ', ' Generations ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' Organ ', ' improved ', ' Clinical ', ' Biological ', ' Physiologic ', ' Physiological ', ' Training ', ' insight ', ' Funding ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Knowledge ', ' Scientist ', ' System ', ' interest ', ' Training and Education ', ' data management ', ' experience ', ' success ', ' cohort ', ' Structure ', ' novel ', ' General Public ', ' General Population ', ' Social Support System ', ' Support System ', ' Protein Gene Products ', ' Gene Proteins ', ' Modeling ', ' outreach program ', ' Property ', ' protein protein interaction ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' data processing ', ' computerized data processing ', ' protein expression ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' protein complex ', ' Address ', ' Data ', ' Tutoring and Outreach ', ' Training and Outreach ', ' Instruction and Outreach ', ' Education and Outreach ', ' Harvest ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Molecular Profiling ', ' Population Research ', ' Protein Dynamics ', ' Clinical Data ', ' Transcript ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' protein metabolite ', ' clinical phenotype ', ' data modeling ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' innovation ', ' innovative ', ' innovate ', ' spatiotemporal ', ' public health relevance ', ' operation ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' Algorithmic Software ', ' Software Algorithm ', ' Algorithmic Tools ', ' Jackson Heart Study ', ' Big Data ', ' BigData ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' support tools ', ' Data Science ', ' Data Scientist ', ' multiple omics ', ' Big Data to Knowledge ', ' BD2K ', ' data to knowledge ', ' data into knowledge ', ' big biomedical data ', ' ']",NIGMS,UNIVERSITY OF CALIFORNIA LOS ANGELES,U54,2016,4969920,0.09034188012626097
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",9108710,U54EB020403,"['Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Acquired Immunodeficiency Syndrome ', ' Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Genes ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human T-Lymphotropic Virus Type III ', ' Human T-Cell Lymphotropic Virus Type III ', ' Human T-Cell Leukemia Virus Type III ', ' Human Immunodeficiency Viruses ', ' HTLV-III ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Articulation ', ' Joints ', ' Learning ', ' Math ', ' Mathematics ', ' Medicine ', ' NIMH ', ' National Institute of Mental Health ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Obsessive-Compulsive Neurosis ', ' Obsessive-Compulsive Disorder ', ' Prognosis ', ' outcome forecast ', ' Research ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' Schools ', ' Science ', ' Software ', ' Computer software ', ' Talents ', ' Training Programs ', ' Work ', ' Data Set ', ' Dataset ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuro-imaging ', ' neuroimaging ', ' novel ', ' Modality ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' chromosome 22q deletion syndrome ', ' Modeling ', ' Genomics ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Attention deficit hyperactivity disorder ', ' major depression disorder ', ' major depression ', ' clinical depression ', ' Major Depressive Disorder ', ' Institution ', ' Data ', ' NICHD ', ' National Institute of Child Health and Human Development ', ' National Institute on Drug Abuse ', ' NIDA ', ' National Institute of Drug Abuse ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Prognostic Marker ', ' Infrastructure ', ' Research Infrastructure ', ' imaging ', ' Image ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' National Institute on Alcohol Abuse and Alcoholism ', ' NIAAA ', ' innovation ', ' innovative ', ' innovate ', ' multidisciplinary ', ' Computational algorithm ', ' computer algorithm ', ' multitask ', ' multi-task ', ' addiction ', ' addictive disorder ', ' public health relevance ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' Big Data ', ' BigData ', ' Genetic study ', ' cluster merger ', ' merging clusters ', ' web portal ', ' internet portal ', ' Data Science ', ' Data Scientist ', ' diagnostic biomarker ', ' diagnostic marker ', ' Big Data to Knowledge ', ' BD2K ', ' connectome ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2016,2763117,0.07778723406859629
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9156099,R01GM120364,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Goals ', ' Modern Man ', ' Human ', ' Literature ', ' Methods ', ' Structural Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Research Resources ', ' Resources ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Uncertainty ', ' doubt ', ' DNA Sequence ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' experience ', ' Missense Mutation ', ' trait ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Rare Diseases ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' Information Resources ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' protein function ', ' next generation ', ' clinically relevant ', ' clinical relevance ', ' wiki ', ' data structure ', ' human disease ', ' prototype ', ' primary outcome ', ' genome-wide ', ' genomewide ', ' genome scale ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2016,372928,0.21110553409641228
"Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership     DESCRIPTION (provided by applicant): The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The aims to achieve the goals are: 1) Implement an integrated didactic program to enhance student self-efficacy with computational and informatics tool development and use for interrogating and interpreting Big Data, including a two-semester bioinformatics course in Bioinformatics, informed by the expertise of UIUC KnowEnG BD2K Center faculty with additional Special Topics courses available remotely from UIUC. 2) Develop an integrated academic year (Fisk, or partners) and summer research program at the UIUC KnowEnG BD2K Center to assure student exposure to a participation in the life cycle of a `Big Data' research problem. 3) Implement a professional skills development program that assures successful transition of undergraduate participants to a Ph.D. (or MD/PhD Program) in Big Data- reliant biomedical research. 4) Launch a faculty development program in bioinformatics that leads to embracing Big Data problems in courses in multiple disciplines for impact on all Fisk undergraduate STEM majors. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fisk R25 mentors, of value for their broader education and research training goals at UIUC and Mayo. PUBLIC HEALTH RELEVANCE: The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fis R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.  ",Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership,9150655,R25MD010396,"['Biological Chemistry ', ' Biochemistry ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' career track ', ' career pathway ', ' career interest ', ' career aspiration ', ' Career Path ', ' Career Choice ', ' Communication ', ' Complement Proteins ', ' Complement ', ' Computers ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Diving ', ' Elements ', ' Faculty ', ' Goals ', ' Grant ', ' Health ', ' Illinois ', ' Articulation ', ' Joints ', ' Learning ', ' life course ', ' Life Cycle ', ' Life Cycle Stages ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Reading ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Science ', ' Students ', ' Technology ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Writing ', ' Journals ', ' Magazine ', ' base ', ' career ', ' Biological ', ' Chemicals ', ' Training ', ' Discipline ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Development Plans ', ' Funding ', ' Collaborations ', ' Exposure to ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' posters ', ' programs ', ' cell biology ', ' Cellular biology ', ' Scientist ', ' Oral ', ' System ', ' experience ', ' computer science ', ' Informatics ', ' Base Pairing ', ' Self Efficacy ', ' Manuscripts ', ' skills ', ' Participant ', ' Research Ethics ', ' Proteomics ', ' Genomics ', ' Bio-Informatics ', ' Bioinformatics ', ' Address ', ' Core Facility ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' R25 Program ', ' R25 Mechanism ', ' Education Projects ', ' Research Training ', ' underrepresentation of minorities ', ' under-represented minority ', ' under-representation of minorities ', ' Underrepresented Ethnic Minority ', ' Underrepresented Minority ', ' innovation ', ' innovative ', ' innovate ', ' data acquisition ', ' skill acquisition ', ' skill development ', ' tool development ', ' responsible research conduct ', ' sharing data ', ' STEM field ', ' STEM major ', ' STEM discipline ', ' STEM course ', ' STEM class ', ' Teacher Professional Development ', ' teacher development ', ' instructor training ', ' faculty professional development ', ' faculty development ', ' Teacher Training ', ' Teacher Preparation ', ' Teacher Educator ', ' Teacher Education ', ' Faculty Training ', ' Faculty Education ', ' undergraduate research ', ' Big Data ', ' BigData ', ' Faculty Workshop ', ' faculty panel ', ' faculty conference ', ' Teacher Workshop ', ' Faculty Seminar ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored medical treatment ', ' individualized treatment ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' faculty research ', ' summer research ', ' education research ', ' Skills Development ', ' Big Data to Knowledge ', ' BD2K ', ' minority scientist ', ' ']",NIMHD,FISK UNIVERSITY,R25,2016,204941,0.12163881736249535
"The Big DIPA: Data Image Processing and Analysis     DESCRIPTION (provided by applicant): This proposal aims to establish a national short course in Big Data Image Processing & Analysis (BigDIPA) intended to increase the number and overall skills of competent research scientists now encountering large, complex image data sources derived from cutting edge biological/biomedical research approaches. Extraction of knowledge from these imaging sources requires specialized skills and an interdisciplinary mindset. Yet effective training opportunities of this sector of the ""Big Data"" science community are glaringly underappreciated and underserved compared to other big data fields such as omics. UC Irvine is ideally suited to host a short course to address this thematic training deficit on account of the synergistic colocalization between multiple facilities, renowned for development of numerous advanced imaging techniques, and the outstanding instructional environment provided by faculty with collaborative expertise in biological image processing and computer vision, bioinformatics and high performance computational approaches.  Specifically, our BigDIPA proposal assembles an interdisciplinary alliance of faculty experts that can leverage the preeminent imaging resource facilities, such as the Laboratory of Fluorescence Dynamics (LFD) and the Beckman Laser Institute, and fuse these to ongoing campus big data initiatives, e.g. UCI's Data Science Initiative, to create a top-rated training course designed for senior graduate students, postdoctoral researchers, faculty and industry scientists from diverse scientific disciplines who have nascent interests and needs to handle BIG DATA sources beyond their current level of competency.  The course theme is focused to utilize discreet examples drawn from the analysis of complex data acquired from different microscopy imaging modalities employed to investigate dynamics in cellular and tissue processes, including signal transduction networks, development, neuroscience and biomedical applications, and that hereto where hidden or inaccessible to standard methods of analysis. Participants will be guided along the complete acquisition- processing-analysis pipeline through exposure to a coherent progression of topics and issues typically encountered when handling BIG DATA. We believe this training approach will therefore be attractive to a broad and significant untapped pool of researchers from the biological disciplines, biomedical engineering, systems biology, math, biophysics, computer science, bioinformatics and statistics who possess some, but not all, of the requisite competencies to effectively traverse the BD2K landscape. We have designed the course such that skills and experience gained by trainees will be transferable to their own research interests.  The BigDIPA course format will combine didactic lectures on the theory and foundational frameworks that underpin each step, with practical instruction on implementation and hands-on tutorials in image acquisition, large data handling, basic scripting of computational tools, image processing on high performance computing architectures, as well as feature extraction, evaluation and visualization of results. The course is designed to offer an intense learning experience delivered in a compact time frame, and opportunities to foster interdisciplinary interactions through small team exercises. Participants will also be encouraged to take advantage of pre-courses - separate and distinct training opportunities not funded by this proposal - that will be coordinated to directly precede our course. This unique format provides multiple benefits: it provides an efficient mechanism to address individual participant training deficiencies to permit a more productive experience in the BigDIPA course, adds no-cost mutual benefits to independent but synergistic programs, and facilitates recruitment of applicants who frequently feel interested but intimidated due to a perceived lack of prior adequate training.  Beyond providing an intensive on-site training course, all course materials (lecture notes, video lectures and tutorials), tutorial exercises, open source software resources and sample datasets will be made freely available through on-line distribution to maximize outreach and encourage additional contributions of curated training resources solicited from the community. PUBLIC HEALTH RELEVANCE: We propose to train and expand the cadre of researchers capable of effectively using the deluge of complex BIG DATA being generated by advanced biomedical imaging approaches. These data sources represent a rich source of complex information relevant to many scientific areas of inquiry, and are informative at multiple scales ranging from fundamental biological processes at the cellular level to patient diagnostics for diseases such as cancer or neurological disorders.",The Big DIPA: Data Image Processing and Analysis,9150564,R25EB022366,"['Accounting ', ' Engineering / Architecture ', ' Architecture ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biological Sciences ', ' bioengineering ', ' Biomedical Engineering ', ' Biomedical Research ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Communities ', ' computer vision ', ' Computer Vision Systems ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' Data Sources ', ' Disorder ', ' Disease ', ' Environment ', ' Exercise ', ' Faculty ', ' Fluorescence ', ' Foundations ', ' Future ', ' Goals ', ' Health ', ' Industry ', ' Information Sciences ', ' Institutes ', ' Laboratories ', ' Laser Radiation ', ' Laser Electromagnetic ', ' Lasers ', ' Learning ', ' Math ', ' Mathematics ', ' Methods ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' Patients ', ' Problem Solving ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Software ', ' Computer software ', ' Computer Software Tools ', ' Software Tools ', ' statistics ', ' Time ', ' Work ', ' Imaging Techniques ', ' Imaging Technics ', ' Imaging Procedures ', ' Interdisciplinary Communication ', ' Multidisciplinary Communication ', ' Cross-Disciplinary Communication ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' image processing ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Site ', ' Area ', ' Biological ', ' Evaluation ', ' Training ', ' Discipline ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Funding ', ' Biological Function ', ' Biological Process ', ' Exposure to ', ' Staging ', ' Diagnostic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lecture notes ', ' lectures ', ' programs ', ' Scientist ', ' Complex ', ' Stream ', ' Source ', ' interest ', ' meetings ', ' experience ', ' Performance ', ' transdisciplinary collaboration ', ' interdisciplinary collaboration ', ' biomedical scientist ', ' computer science ', ' high-end computing ', ' High Performance Computing ', ' skills ', ' Participant ', ' Program Announcement ', ' NIH Program Announcements ', ' graduate student ', ' outreach ', ' Modality ', ' Biomedical Technology ', ' Sampling ', ' theories ', ' biomedical imaging ', ' bio-imaging ', ' bioimaging ', ' repository ', ' Bio-Informatics ', ' Bioinformatics ', ' imaging method ', ' imaging modality ', ' tissue processing ', ' p50 ', ' Tumor Necrosis Factor Receptor Superfamily Member 5 Gene ', ' TNFRSF5 ', ' MGC9013 ', ' CDW40 ', ' CD40 ', ' Bp50 ', ' TNFRSF5 gene ', ' Address ', ' Systems Biology ', ' Data ', ' NIGMS ', ' National Institute of General Medical Sciences ', ' Research Training ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Senior Scientist ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Instruction ', ' cost ', ' Knowledge Extraction ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' Imaging technology ', ' data acquisition ', ' skill acquisition ', ' skill development ', ' open source ', ' demographics ', ' data format ', ' biological systems ', ' flexibility ', ' flexible ', ' Big Data ', ' BigData ', ' course implementation ', ' learning materials ', ' instructional materials ', ' curricular material ', ' course material ', ' class material ', ' training opportunity ', ' education research ', ' Skills Development ', ' Data Science ', ' Data Scientist ', ' Big Data to Knowledge ', ' BD2K ', ' microscopic imaging ', ' microscopy imaging ', ' microscope imaging ', ' ']",NIBIB,UNIVERSITY OF CALIFORNIA-IRVINE,R25,2016,161997,0.08383548676080321
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9116916,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Drug Regulations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Tyrosine ', ' Work ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Complex ', ' Pattern ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' computational framework ', ' computer framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2016,300000,0.17732211395365816
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9239923,R01NS048453,"['Termination of pregnancy ', ' apraxia ', ' Dyspraxia ', ' Apraxias ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Inhaling ', ' Inhalation ', ' Breathing ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Ataxia ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' Cilia ', ' granule ', ' Cytoplasmic Granules ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Au element ', ' Gold ', ' Modern Man ', ' Human ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Muscle hypotonia ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research Resources ', ' Resources ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Joubert syndrome ', ' Hereditary ', ' Inherited ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit ', ' Digit structure ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' Genetic screening method ', ' novel ', ' Modeling ', ' affection ', ' ocularmotor ', ' ocular motor ', ' oculomotor ', ' disease subtype ', ' disorder subtype ', ' siRNA ', ' Short interfering RNA ', ' Small Interfering RNA ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' ciliogenesis ', ' cilium biogenesis ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Length ', ' Defect ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' Three-dimensional analysis ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' induced pluripotent stem cell ', ' iPSCs ', ' iPSC ', ' iPS ', ' gene discovery ', ' discover genes ', ' population based ', ' stem cell biology ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' exome sequencing ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' accurate diagnosis ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' whole genome ', ' entire genome ', ' ']",NINDS,ROCKEFELLER UNIVERSITY,R01,2016,557723,0.16355562859239955
"Administrative Supplement Request for Transforming Analytical Learning in the Era of Big Data     DESCRIPTION (provided by applicant): In this dawning era of `Big Data' it is vital to recruit and train the next generation of biomedical data scientists in `Big Data'. The collection of `Big Data' in the biomedical sciences is growing rapidly and has the potential to solve many of today's pressing medical needs including personalized medicine, eradication of disease, and curing cancer. Realizing the benefits of Big Data will require a new generation of leaders in (bio) statistical and computational methods who will be able to develop the approaches and tools necessary to unlock the information contained in large heterogeneous datasets. There is a great need for scientists trained in this specialized, highly heterogeneous, and interdisciplinary new field. Thus, the recruitment of talented undergraduates in science, technology, engineering and mathematics (STEM) programs is vital to our ability to tap into the potential that `Big Data' offer and the challenges that it presents. The University of Michigan Undergraduate Summer Institute: Transforming Analytical Learning in the Era of Big Data will draw from the expertise and experience of faculty from four different departments within four different schools at the University of Michigan: Biostatistics in the School of Public Health, Computer Science in the School of Engineering, Statistics in the College of Literature, Sciences and the Arts, and Information Science in the School of Information. The faculty instructors and mentors have backgrounds in Statistics, Computer Science, Information Science and Biological Sciences. They have active research programs in a broad spectrum of methodological areas including data mining, natural language processing, statistical and machine learning, large-scale optimization, matrix computation, medical computing, health informatics, high-dimensional statistics, distributed computing, missing data, causal inference, data management and integration, signal processing and imaging. The diseases and conditions they study include obesity, cancer, diabetes, cardiovascular disease, neurological disease, kidney disease, injury, macular degeneration and Alzheimer's disease. The areas of biology include neuroscience, genetics, genomics, metabolomics, epigenetics and socio-behavioral science. Undergraduate trainees selected will have strong quantitative skills and a background in STEM. The summer institute will consist of a combination of coursework, to raise the skills and interests of the participants to a sufficient level to consider pursuing graduate studies in `Big Data' science, along with an in depth mentoring component that will allow the participants to research a specific topic/project utilizing `Big Data'. We have witnessed tremendous enthusiasm and response for our pilot offering in 2015 with 153 applications for 20 positions and a yield rate of 80% from the offers we extended. We plan to build on the success of this initial offering in the next three year funding cycle of this grant (2016-2018). The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a no-traditional, action-based learning paradigm. This six week long summer institute will recruit a group of approximately 30 undergraduates nationally and expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material for undergraduate students in this new field across the world. PUBLIC HEALTH RELEVANCE: We propose a six week long summer institute: ""Transforming Analytical Learning in the Era of Big Data"" to be held at the Department of Biostatistics, University of Michigan, Ann Arbor, with a group of approximately 30 undergraduates recruited nationally, from 2016-2018. We plan to expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty from Biostatistics, Statistics, Computer Science and Engineering, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a Wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material in this new field across the world. The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm.",Administrative Supplement Request for Transforming Analytical Learning in the Era of Big Data,9243811,R25EB022363,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Arts ', ' Behavioral Sciences ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biological Sciences ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Engineering ', ' Faculty ', ' Goals ', ' Grant ', ' Health ', ' Information Sciences ', ' renal disorder ', ' kidney disorder ', ' Renal Disease ', ' Nephropathy ', ' Kidney Diseases ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Literature ', ' Macular degenerative disease ', ' Macular degeneration ', ' Mentors ', ' Methods ', ' Methodology ', ' Michigan ', ' natural language understanding ', ' Natural Language Processing ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' Public Health Schools ', ' Science ', ' statistics ', ' Students ', ' Talents ', ' Teaching ', ' Educational process of instructing ', ' Universities ', ' Adverse drug effect ', ' Drug Side Effects ', ' Work ', ' Generations ', ' Case Study ', ' case report ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' Injury ', ' base ', ' Area ', ' Medical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' posters ', ' lectures ', ' programs ', ' Scientist ', ' Oral ', ' Techniques ', ' interest ', ' meetings ', ' instructor ', ' collegiate ', ' college ', ' data management ', ' experience ', ' success ', ' computer science ', ' skills ', ' Participant ', ' member ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Statistical Methods ', ' response ', ' Genomics ', ' consumer informatics ', ' Health Informatics ', ' Public Health Informatics ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' datamining ', ' data mining ', ' Administrative Supplement ', ' Data ', ' Collection ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' data integration ', ' distributed computing ', ' datagrid ', ' data grid ', ' cluster computing ', ' designing ', ' design ', ' next generation ', ' wiki ', ' open source ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Science, Technology, Engineering and Mathematics ', ' Science, Technology, Engineering and Math ', ' undergraduate student ', ' signal processing ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Problem Sets ', ' Homework Exercises ', ' summer institute ', ' Data Science ', ' Data Scientist ', ' ']",NIBIB,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R25,2016,159359,0.1212833226059418
"Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems DESCRIPTION (provided by applicant): Abstract Biomedical science, higher education, software and technology are simultaneously undergoing tectonic shifts. The amazing pace of software and technological development are driving equally amazing advances in the ability to acquire massive data sets in the biomedical sciences. These new Big Biomedical data sets come in the form of complex measurements, such as that of the brain, genome, proteome and human biome or massive databases, such as with electronic health records. Big Data issues, such as reproducibility of processing, measurement and analysis techniques, are increasingly complex, and crucial. Across all domains there is a knowledge gap of researchers to analyze and interpret these new data sets and the current higher education model cannot meet the insatiable demand for this training. We propose to make substantial progress on these issues in two domains. Specifically, we propose to use Massive Open Online Courses (MOOCs) to create two series, one in neuroimaging and one in genomics. These series will allow for flexible, student paced, low cost scalable training for tens of thousands of students. Along with these series, we propose the creation of modular Big Data biostatistical content that can be used by students as well as teachers. This effort will be parallel to work on an intelligent tutoring syste called swirl. This application proposes to use swirl to create rich, gamified learning environments for students. All of the material created from this grant will be open access and free. PUBLIC HEALTH RELEVANCE:  Project narrative: We propose two Massive Open Online Course series in neuroimaging and genomic Big Data analysis as well as the creation of modular Big Data statistics content and content creation for an intelligent tutoring system.","Big Data education for the masses: MOOCs, modules, & intelligent tutoring systems",9061684,R25EB020378,"['abstracting ', ' Attention ', ' driving ', ' Automobile Driving ', ' Biology ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Clinical Trials ', ' Communities ', ' Cost Analyses ', ' Cost Analysis ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Collection ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Educational aspects ', ' Education ', ' Environment ', ' Genes ', ' Genome ', ' Grant ', ' Head ', ' Health ', ' Modern Man ', ' Human ', ' Laboratories ', ' Medicine ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Multivariate Analyses ', ' Multivariate Analysis ', ' Persons ', ' Public Health ', ' Public Health Nurses ', ' Public Health Nursing ', ' Racial Stocks ', ' Racial Group ', ' Race ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Science ', ' Software ', ' Computer software ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' Technology ', ' Testing ', ' Time ', ' training module ', ' Training Activity ', ' Training Programs ', ' Universities ', ' Work ', ' Generations ', ' Measures ', ' Amaze ', ' TimeLine ', ' Data Set ', ' Dataset ', ' Educational Models ', ' educational principles ', ' educational practices ', ' educational methods ', ' Instructional Models ', ' density ', ' Area ', ' Biological ', ' Medical ', ' Series ', ' Training ', ' teacher ', ' Discipline ', ' data repository ', ' clinical data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Measurement ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Scientist ', ' Adopted ', ' Dimensions ', ' Complex ', ' Stream ', ' Techniques ', ' System ', ' meetings ', ' instructor ', ' Services ', ' skills ', ' neuro-imaging ', ' neuroimaging ', ' experimental study ', ' experimental research ', ' experiment ', ' research study ', ' novel technologies ', ' new technology ', ' tactile sensation ', ' Touch ', ' Touch sensation ', ' Proteome ', ' Modeling ', ' Genomics ', ' Drops ', ' Systems Biology ', ' Data ', ' Molecular Medicine ', ' Resolution ', ' enroll ', ' Enrollment ', ' Principal Investigator ', ' developmental ', ' Development ', ' Electronic Health Record ', ' imaging ', ' Image ', ' cost ', ' process reproducibility ', ' process repeatability ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' multidisciplinary ', ' open source ', ' flexibility ', ' flexible ', ' operation ', ' Teacher Professional Development ', ' teacher development ', ' instructor training ', ' faculty professional development ', ' faculty development ', ' Teacher Training ', ' Teacher Preparation ', ' Teacher Educator ', ' Teacher Education ', ' Faculty Training ', ' Faculty Education ', ' Big Data ', ' BigData ', ' Learning Module ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' contrast enhanced ', ' educational atmosphere ', ' university atmosphere ', ' training atmosphere ', ' school atmosphere ', ' learning environment ', ' learning atmosphere ', ' intellectual atmosphere ', ' educational environment ', ' education atmosphere ', ' collegiate atmosphere ', ' collegial atmosphere ', ' college atmosphere ', ' classroom environment ', ' hands-on learning ', ' interactive learning ', ' interactive engagement ', ' applied learning ', ' learning materials ', ' instructional materials ', ' curricular material ', ' course material ', ' class material ', ' course module ', ' class module ', ' massive open online courses ', ' Problem Sets ', ' Homework Exercises ', ' tutoring ', ' tutorial support ', ' higher education ', ' Data Science ', ' Data Scientist ', ' Data Analytics ', ' big biomedical data ', ' ']",NIBIB,JOHNS HOPKINS UNIVERSITY,R25,2016,209444,0.08456762463028059
"New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis     DESCRIPTION (provided by applicant)    Maha R Farhat, MD is an Instructor of Medicine at Harvard Medical School on the tenure track and a staff physician in the Department of Pulmonary and Critical Care Medicine at Massachusetts General Hospital. She is completing a masters of biostatistics at the Harvard School of Public Health in 5/2015. She has spent the last 4.5 years acquiring skills in Mycobacterium tuberculosis biology, epidemiology, bioinformatics and biostatistics. She has experience in the analysis of whole genome sequence data, drug resistance data and patient clinical outcome data with the focus of identifying Mycobacterium tuberculosis genetic determinants of drug resistance. She has also developed new methods in this area. Dr. Farhat has 11 publications 5 of which are first author including high impact and highly cited work in the journals Nature Genetics, Genome Medicine and the International Journal of Tuberculosis and Lung Disease. The short term goals of this K01 award are to provide training for Dr. Farhat in critical aspects of data science, computational and evolutionary biology, advanced biostatistics and network science. Dr. Farhat's long term goal is to become a leader in the field of Big Data analysis for infectious diseases. The proposed research as well as the training activities outlined in the proposal will successfully position Dr. Farhat for her first R01 and an independent career as a physician scientist. Environment: Dr. Farhat will perform the interdisciplinary work outlined in this proposal at the distinguished Harvard Departments of Global Health Social Medicine, Biostatistics, Evolutionary biology and the Institute for Quantitative Social Sciences. Dr. Farhat' mentorship team will include two world renowned leaders in the fields of infectious diseases and Big Data, Dr. Megan Murray and Dr. Gary King; and two rising stars in the fields of network Science and evolutionary Biology, Dr. JP Onnela and Dr. Michael Desai. Dr. Murray, the principal mentor on this proposal has mentored over 38 trainees, 9 of which have went on to have independent research careers, and 6 competed successfully for K awards. She is also PI on two recently awarded NIH/NIAID grants a CETR U19 and a TBRU U19 and has over 350 peer reviewed publications. To complement the expertise of her mentors Dr. Farhat will be advised by Dr. Christiani a practicing pulmonary and critical care physician and world renowned researcher in the field of lung and environmental genetics. She will also collaborate and consult with Dr. Merce Crosas, a data scientist, and Dr. Pardis Sabeti, a computational biologist. She will rotate through Dr. Soumya Raychaudhuri's bioinformatics laboratory to diversify her exposure to biomedical Big Data. In addition, she will receive formal training in evolutionary biology, Bayesian and mixed-model biostatistics, computer science, leadership skills and grant writing. The collaborative opportunities, intellectual environment and resources available to Dr. Farhat are outstanding. Research: Infectious diseases continue to be a major cause of morbidity and mortality. Despite the availability of effective antimicrobials, pathogens are successfully evolving new disease phenotypes that allow them to resist killing by these drugs or in other instances cause more severe disease manifestations or wider chains of transmission. Drug resistance (DR) is now common and some bacteria have even become resistant to multiple types or classes of antibiotics6. A key strategy in the fight against emerging pathogen phenotypes in infectious diseases is surveillance, and early personalized therapy to prevent transmission and propagation of these strains. The timely initiation of antibiotic therapy to which the pathogen is sensitive has been shown to be the key factor influencing treatment outcome for a diverse array of infections. Molecular tests that rely on the detection of microbial genetic mutations are particularly promising for surveillance and diagnosis of these pathogen phenotypes but rely on a comprehensive understanding of how mutations associate with these pathogen phenotypes. Currently there is an explosion of data on pathogen whole genome sequences (WGS) that is increasingly generated from clinical laboratories. Data on disease phenotype may also be available, but methods for the analysis and interpretation of these Big Data are lagging. Here I propose tools to aid in this analysis leveraging Big Data sets from Mycobacterium tuberculosis (MTB) and my prior work. Specifically I propose to (1) develop a web-based public interface to several analysis tools, including a statistical learning model that can predict the MTB DR phenotype from its genomic sequence, (2) to develop and study an MTB gene-gene network, based on WGS data, to improve our understanding of the effect of mutation-mutation interactions on the DR phenotype, and (3) study the performance of methods in current use for the association of genotype and phenotype in pathogens, and develop a generalizable power calculator for the best performing method. PUBLIC HEALTH RELEVANCE    Infectious agents of disease are successfully evolving drug resistance and other adaptations that threaten human health. Understanding the genetic mutations that underlie these disease phenotypes can inform surveillance and diagnostic strategies to combat this threat. Here I propose to develop accessible tools for pathogen genomic analysis that will help identify which genetic mutations are relevant to disease.",New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis,9147601,K01ES026835,"['Affect ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antibiotics ', ' Award ', ' Bacteria ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Complement Proteins ', ' Complement ', ' Critical Care ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Genetic Epistasis ', ' Explosion ', ' Future ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Goals ', ' Grant ', ' Health ', ' General Hospitals ', ' Modern Man ', ' Human ', ' Infection ', ' Institutes ', ' Laboratories ', ' Leadership ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Maps ', ' Massachusetts ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' mtb ', ' M.tuberculosis ', ' M.tb ', ' M. tuberculosis ', ' M. tb ', ' Mycobacterium tuberculosis ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Peer Review ', ' Phenotype ', ' Phylogeny ', ' Physicians ', ' Public Health ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Public Health Schools ', ' Science ', ' Social Medicine ', ' Social Sciences ', ' Testing ', ' Time ', ' training module ', ' Training Activity ', ' Tuberculosis ', ' tuberculous spondyloarthropathy ', ' infection due to Mycobacterium tuberculosis ', ' disseminated tuberculosis ', ' disseminated TB ', ' Mycobacterium tuberculosis infection ', ' Mycobacterium tuberculosis (MTB) infection ', ' MTB infection ', ' M.tuberculosis infection ', ' M. tuberculosis infection ', ' Work ', ' Writing ', ' Measures ', ' Treatment outcome ', ' Data Set ', ' Dataset ', ' Killings ', ' Journals ', ' Magazine ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Collaborations ', ' Genetic ', ' infectious organism ', ' Infectious Agent ', ' Exposure to ', ' tool ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Antibiotic Therapy ', ' Diagnostic ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Scientist ', ' System ', ' disease severity ', ' Severity of illness ', ' instructor ', ' Consult ', ' experience ', ' gene interaction ', ' Performance ', ' computer science ', ' microbial ', ' Structure ', ' skills ', ' simulation ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Genomics ', ' genetic determinant ', ' Genetic Determinism ', ' Bio-Informatics ', ' Bioinformatics ', ' preventing ', ' prevent ', ' genome sequencing ', ' Low income ', ' global health ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' DNA Sequence Alteration ', ' Data ', ' Detection ', ' Infectious Diseases / Laboratory ', ' Infectious Diseases Research ', ' International ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Mentored Research Scientist Development Award ', ' NIAID ', ' National Institute of Allergy and Infectious Disease ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' K-Series Research Career Programs ', ' Resolution ', ' Gene Structure/Organization ', ' Gene Organization ', ' Gene Structure ', ' Virulent ', ' Monitor ', ' Transmission ', ' transmission process ', ' Molecular ', ' disease phenotype ', ' fight against ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' designing ', ' design ', ' drug resistant in tuberculosis ', ' drug resistance Mycobacteria Tuberculosis ', ' drug resistance M Tuberculosis ', ' Drug resistant Mycobacteria Tuberculosis ', ' Drug resistant M Tuberculosis ', ' Drug Resistant Tuberculosis ', ' Drug Resistant TB ', ' Drug Resistance Tuberculosis ', ' Drug resistance in tuberculosis ', ' Outcome ', ' Drug-sensitive ', ' pathogen ', ' Population ', ' prospective ', ' Resistance ', ' resistant ', ' antimicrobial ', ' anti-microbial ', ' microbial genome ', ' microbes genome ', ' analytical tool ', ' Microbial Genetics ', ' Network-based ', ' combat ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' tenure track ', ' tenure process ', ' power analysis ', ' Data Science ', ' Data Scientist ', ' pathogen genome ', ' pathogenome ', ' big biomedical data ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NIEHS,MASSACHUSETTS GENERAL HOSPITAL,K01,2016,49355,0.11982491889484707
"Mobility Data Integration to Insight     DESCRIPTION (provided by applicant): Mobility is essential for human health. Regular physical activity helps prevent heart disease and stroke, relieves symptoms of depression, and promotes weight loss. Unfortunately, many conditions, such as cerebral palsy, osteoarthritis, and obesity, limit mobility at an enormous personal and societal cost. While vast amounts of data are available from hundreds of research labs and millions of smartphones, there is a dearth of methods for analyzing this massive, heterogeneous dataset.  We propose to establish the National Center for Mobility Data Integration to Insight (the Mobilize Center) to overcome the data science challenges facing mobility big data and biomedical big data in general. Our preliminary work identified four bottlenecks in data science, which drive four Data Science Research Cores.  The Cores include Biomechanical Modeling, Statistical Learning, Behavioral and Social Modeling, and Integrative Modeling and Prediction. Our Cores will produce novel methods to integrate diverse modeling modalities and gain insight from noisy, sparse, heterogeneous, and time-varying big data. Our data-sharing consortia, with clinical, research, and industry partners, will provide mobility data for over ten million people.  Three Driving Biomedical Problems will focus and validate our data science research.  The Mobilize Center will disseminate our novel data science tools to thousands of researchers and create a sustainable data-sharing consortium. We will train tens of thousands of scientists to use data science methods in biomedicine through our in-person and online educational programs. We will establish a cohesive, vibrant, and sustainable National Center through the leadership of an experienced executive team and will help unify the BD2K consortia through our Biomedical Computation Review publication and the Simtk.org resource portal.  The Mobilize Center will lay the groundwork for the next generation of data science systems and revolutionize diagnosis and treatment for millions of people affected by limited mobility.         PUBLIC HEALTH RELEVANCE:  Regular physical activity is essential for human health, yet a broad range of conditions impair mobility. This project will transform human movement research by developing tools for data analysis and creating software that will advance research to prevent, diagnose, and reduce impairments that limit human movement.            ",Mobility Data Integration to Insight,9103879,U54EB020405,"['Affect ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' driving ', ' Automobile Driving ', ' biomechanical ', ' Biomechanics ', ' Biomedical Research ', ' Cerebral Palsy ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' depression ', ' Mental Depression ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' ethical ', ' Ethics ', ' Exercise ', ' Non-Trunk ', ' Limbs ', ' Extremities ', ' Limb structure ', ' Fellowship ', ' Gait ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Human ', ' Articulation ', ' Joints ', ' Leadership ', ' Methods ', ' Mission ', ' body movement ', ' Movement ', ' Persons ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Degenerative polyarthritis ', ' Pathology ', ' Problem Solving ', ' Public Health ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Running ', ' Software ', ' Computer software ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' stroke ', ' Testing ', ' Time ', ' Body Weight decreased ', ' wt-loss ', ' body weight loss ', ' Weight Reduction ', ' Weight Loss ', ' Work ', ' Walking ', ' Data Set ', ' Dataset ', ' Injury ', ' base ', ' role model ', ' sensor ', ' improved ', ' Area ', ' Training ', ' Physical activity ', ' insight ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' tool ', ' Nature ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' cognitive function ', ' Scientist ', ' Complex ', ' Techniques ', ' System ', ' Over weight ', ' Overweight ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Medical center ', ' experience ', ' social model ', ' cohesion ', ' novel ', ' model-based simulation ', ' models and simulation ', ' Prevention ', ' Modality ', ' social ', ' Modeling ', ' smartphone ', ' smart phone ', ' iPhone ', ' Cellular Telephone ', ' Cell Phone ', ' Cellular Phone ', ' preventing ', ' prevent ', ' biomedical computation ', ' Biomedical Computing ', ' Data ', ' Scholars Program ', ' NCI Scholars Program ', ' Resource Sharing ', ' Behavioral ', ' cost ', ' Behavioral Model ', ' data modeling ', ' data integration ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Impairment ', ' motor impairment ', ' movement limitation ', ' movement impairment ', ' public health relevance ', ' industry partner ', ' industry partnership ', ' industrial partnership ', ' sharing data ', ' flexibility ', ' flexible ', ' clinical decision-making ', ' Big Data ', ' BigData ', ' health data ', ' biomechanical model ', ' biomechanical simulation ', ' biomechanical modeling ', ' biomechanic simulation ', ' biomechanic modeling ', ' massive open online courses ', ' visiting scholar ', ' Data Science ', ' Data Scientist ', ' Accelerometer ', ' activity tracker ', ' activity monitor ', ' accelerometry ', ' Big Data to Knowledge ', ' BD2K ', ' improved outcome ', ' big biomedical data ', ' reduce symptoms ', ' symptom relief ', ' symptom reduction ', ' symptom alleviation ', ' relieves symptoms ', ' fewer symptoms ', ' decrease symptom ', ' ameliorating symptom ', ' alleviate symptom ', ' ']",NIBIB,STANFORD UNIVERSITY,U54,2016,4333045,0.037320809188723165
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9117987,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' Health ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Parents ', ' great ape ', ' Apes ', ' Pongidae ', ' Research ', ' Risk ', ' Risk Factors ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schizophrenia ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Strikes ', ' Employee Strikes ', ' Testing ', ' Time ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Asians ', ' oriental ', ' Generations ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA Synthesis ', ' DNA Replication ', ' DNA biosynthesis ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disease risk ', ' disorder risk ', ' inherited factor ', ' genetic risk factor ', ' developmental disorder ', ' developmental disease/disorder ', ' PhD ', ' Ph.D. ', ' Doctor of Philosophy ', ' Mutation Spectra ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2016,56118,0.23357181072684932
"Summer Institute for Statistics of Big Data DESCRIPTION:  Funding is sought for the Summer Institute for Statistics of Big Data (SISBID) at the University of Washington. This program will provide workshops on the statistical and computational skills needed to access, process, manage, and analyze large biomedical data sets. It will be co-directed by Ali Shojaie and Daniela Witten, faculty in the Department of Biostatistics at University of Washington.  The SISBID program will consist of five 2.5-day in-person courses, or modules, taught at the University of Washington each July. An individual participant can register for whichever set of modules he or she chooses. The five modules are as follows: (1) Accessing Biomedical Big Data; (2) Data Visualization; (3) Supervised Methods for Statistical Machine Learning; (4) Unsupervised Methods for Statistical Machine Learning; (5) Reproducible Research for Biomedical Big Data. Each module will consist of a combination of formal lectures and hands-on computing labs. Participants will work together in teams in order to apply the skills that they develop in each module to important problems drawn from relevant case studies.  The primary audience for SISBID will consist of biomedical scientists who would like to develop the statistical and computational training needed to make use of Biomedical Big Data. The secondary audience will consist of individuals with stronger statistical or computational backgrounds but little exposure to biology, who will learn how to apply their skills to problems associated with Biomedical Big Data. Participants will include advanced undergraduates, graduate students, post-doctoral fellows, and researchers, and will be drawn from industry, government, and academia. In order to ensure that all participants are able to fully engage in the program, participants will be expected to already have some prior background in R programming and statistical inference, which can be obtained by taking two free online courses before the program begins.  Each of the five modules will be co-taught by two instructors. The ten instructors will be drawn from top universities and research centers across the U.S., such as the University of Washington, Rice University, University of Iowa, Johns Hopkins University, MD Anderson Cancer Research Center, Fred Hutchinson Cancer Research Center, and University of North Carolina. They have been selected based on research expertise and excellence in teaching.  Lecture videos and slides will be made freely available online so that individuals who are unable to attend SISBID in person can still benefit from the program.  This proposal specifically requests funds for 55 student / postdoctoral fellow travel scholarships per year, 130 student / postdoctoral fellow registration scholarships per year, instructor travel and stipends, teaching assistant stipends, and PI salary support. PUBLIC HEALTH RELEVANCE:   In recent years, the biomedical sciences have been inundated by Big Data, such as DNA sequence data and electronic medical records. In principle, it should be possible to use such data for a variety of tasks, such as predicting an individual's risk of developing diabetes or cancer, and tailoring therapies to an individual should he or she become ill. The Summer Institute for Statistics of Big Data will provide biomedical researchers with the computational and statistical training needed in order to take advantage of Big Data, so that they can more effectively use it to understand human diseases and to improve human health.",Summer Institute for Statistics of Big Data,9063061,R25EB020380,"['Biology ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' diabetes ', ' Diabetes Mellitus ', ' Environment ', ' Faculty ', ' Government ', ' Health ', ' Modern Man ', ' Human ', ' Hybrids ', ' Industry ', ' Institutes ', ' Iowa ', ' Learning ', ' Persons ', ' North Carolina ', ' Records ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Rice ', ' Risk ', ' Running ', ' Salaries ', ' Wages ', ' Scholarship ', ' Science ', ' Software ', ' Computer software ', ' statistical reasoning ', ' statistical process ', ' Statistical Computing ', ' statistics ', ' Students ', ' Teaching ', ' Educational process of instructing ', ' training module ', ' Training Activity ', ' Training Programs ', ' Travel ', ' United States ', ' Universities ', ' Videotape ', ' Washington ', ' Work ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Case Study ', ' case report ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' Visualization ', ' Imagery ', ' base ', ' improved ', ' Area ', ' Ensure ', ' Training ', ' teacher ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Exposure to ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' lectures ', ' programs ', ' Slide ', ' instructor ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Postdoctoral Fellow ', ' biomedical scientist ', ' skills ', ' Participant ', ' member ', ' graduate student ', ' Statistical Methods ', ' Academia ', ' Data ', ' Center for Cancer Research ', ' NCI Center for Cancer Research ', ' Cancer Center ', ' Collection ', ' Fred Hutchinson Cancer Research Center ', ' Process ', ' website ', ' web site ', ' open source ', ' human disease ', ' Big Data ', ' BigData ', ' Learning Module ', ' Teaching Module ', ' Educational Module ', ' Education Module ', ' data visualization ', ' learning materials ', ' instructional materials ', ' curricular material ', ' course material ', ' class material ', ' online course ', ' online curriculum ', ' E-course ', ' massive open online courses ', ' summer institute ', ' teaching assistant ', ' Applied Skills ', ' big biomedical data ', ' ']",NIBIB,UNIVERSITY OF WASHINGTON,R25,2016,159605,0.11274282688556714
"Transforming Analytical Learning in the Era of Big Data     DESCRIPTION (provided by applicant): In this dawning era of `Big Data' it is vital to recruit and train the next generation of biomedical data scientists in `Big Data'. The collection of `Big Data' in the biomedical sciences is growing rapidly and has the potential to solve many of today's pressing medical needs including personalized medicine, eradication of disease, and curing cancer. Realizing the benefits of Big Data will require a new generation of leaders in (bio) statistical and computational methods who will be able to develop the approaches and tools necessary to unlock the information contained in large heterogeneous datasets. There is a great need for scientists trained in this specialized, highly heterogeneous, and interdisciplinary new field. Thus, the recruitment of talented undergraduates in science, technology, engineering and mathematics (STEM) programs is vital to our ability to tap into the potential that `Big Data' offer and the challenges that it presents. The University of Michigan Undergraduate Summer Institute: Transforming Analytical Learning in the Era of Big Data will draw from the expertise and experience of faculty from four different departments within four different schools at the University of Michigan: Biostatistics in the School of Public Health, Computer Science in the School of Engineering, Statistics in the College of Literature, Sciences and the Arts, and Information Science in the School of Information. The faculty instructors and mentors have backgrounds in Statistics, Computer Science, Information Science and Biological Sciences. They have active research programs in a broad spectrum of methodological areas including data mining, natural language processing, statistical and machine learning, large-scale optimization, matrix computation, medical computing, health informatics, high-dimensional statistics, distributed computing, missing data, causal inference, data management and integration, signal processing and imaging. The diseases and conditions they study include obesity, cancer, diabetes, cardiovascular disease, neurological disease, kidney disease, injury, macular degeneration and Alzheimer's disease. The areas of biology include neuroscience, genetics, genomics, metabolomics, epigenetics and socio-behavioral science. Undergraduate trainees selected will have strong quantitative skills and a background in STEM. The summer institute will consist of a combination of coursework, to raise the skills and interests of the participants to a sufficient level to consider pursuing graduate studies in `Big Data' science, along with an in depth mentoring component that will allow the participants to research a specific topic/project utilizing `Big Data'. We have witnessed tremendous enthusiasm and response for our pilot offering in 2015 with 153 applications for 20 positions and a yield rate of 80% from the offers we extended. We plan to build on the success of this initial offering in the next three year funding cycle of this grant (2016-2018). The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a no-traditional, action-based learning paradigm. This six week long summer institute will recruit a group of approximately 30 undergraduates nationally and expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material for undergraduate students in this new field across the world. PUBLIC HEALTH RELEVANCE: We propose a six week long summer institute: ""Transforming Analytical Learning in the Era of Big Data"" to be held at the Department of Biostatistics, University of Michigan, Ann Arbor, with a group of approximately 30 undergraduates recruited nationally, from 2016-2018. We plan to expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty from Biostatistics, Statistics, Computer Science and Engineering, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a Wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material in this new field across the world. The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm.",Transforming Analytical Learning in the Era of Big Data,9149238,R25EB022363,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Arts ', ' Behavioral Sciences ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biological Sciences ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Engineering ', ' Faculty ', ' Goals ', ' Grant ', ' Health ', ' Information Sciences ', ' renal disorder ', ' kidney disorder ', ' Renal Disease ', ' Nephropathy ', ' Kidney Diseases ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Literature ', ' Macular degenerative disease ', ' Macular degeneration ', ' Mentors ', ' Methods ', ' Methodology ', ' Michigan ', ' natural language understanding ', ' Natural Language Processing ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' recruit ', ' active recruitment ', ' Recruitment Activity ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' Public Health Schools ', ' Science ', ' statistics ', ' Students ', ' Talents ', ' Teaching ', ' Educational process of instructing ', ' Universities ', ' Adverse drug effect ', ' Drug Side Effects ', ' Work ', ' Generations ', ' Case Study ', ' case report ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' Injury ', ' base ', ' Area ', ' Medical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Genetic ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' posters ', ' lectures ', ' programs ', ' Scientist ', ' Oral ', ' Techniques ', ' interest ', ' meetings ', ' instructor ', ' collegiate ', ' college ', ' data management ', ' experience ', ' success ', ' computer science ', ' skills ', ' Participant ', ' member ', ' Prevention ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Statistical Methods ', ' response ', ' Genomics ', ' consumer informatics ', ' Health Informatics ', ' Public Health Informatics ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' datamining ', ' data mining ', ' Data ', ' Collection ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' data integration ', ' distributed computing ', ' datagrid ', ' data grid ', ' cluster computing ', ' designing ', ' design ', ' next generation ', ' wiki ', ' open source ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Science, Technology, Engineering and Mathematics ', ' Science, Technology, Engineering and Math ', ' undergraduate student ', ' signal processing ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Problem Sets ', ' Homework Exercises ', ' summer institute ', ' Data Science ', ' Data Scientist ', ' ']",NIBIB,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R25,2016,160479,0.1212833226059418
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9172003,R01CA208517,"['Affect ', ' Age ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Dorsum ', ' Back ', ' tumors in the brain ', ' Brain Tumors ', ' Brain Neoplasia ', ' Brain Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Body ', ' Cells ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Diagnosis ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Environmental Exposure ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Gene Expression ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Genotype ', ' social group process ', ' Group Processes ', ' In Vitro ', ' Learning ', ' leukemia ', ' Photoradiation ', ' Light ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' Methodology ', ' Minor ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' Processed Genes ', ' Proteins ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Smoking ', ' Syndrome ', ' Testing ', ' Transforming Growth Factor-Beta Family Gene ', ' TGF ', ' TGFbeta ', ' TGF- ', ' TGF-beta ', ' TGF B ', ' Platelet Transforming Growth Factor ', ' Milk Growth Factor ', ' Bone-Derived Transforming Growth Factor ', ' Transforming Growth Factor beta ', ' Weight ', ' Measures ', ' Data Set ', ' Dataset ', ' base ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Training ', ' insight ', ' Individual ', ' p16INK4A Protein ', ' p16INK4 Protein ', ' p16-INK4 ', ' p16(INK4A) ', ' Protein p16 ', ' Protein MTS1 ', ' Protein CDKN2 ', ' Multiple Tumor Suppressor-1 ', ' INK4A Protein ', ' INK4A Gene Product ', ' Cyclin-Dependent Kinase Inhibitor p16 ', ' Cyclin-Dependent Kinase Inhibitor p12 ', ' Cell Cycle Negative Regulator Beta ', ' Cdk4-Associated Protein p16 ', ' CDKN2A Protein ', ' CDK4 Inhibitor ', ' Cyclin-Dependent Kinase Inhibitor 2A ', ' Genetic ', ' tool ', ' Pancreatic Cancer ', ' Pancreas Cancer ', ' Malignant Pancreatic Neoplasm ', ' Malignant neoplasm of pancreas ', ' Knowledge ', ' Hereditary ', ' Inherited ', ' Pattern ', ' Penetrance ', ' p16INK4a ', ' p16INK4A Genes ', ' p16INK4 Genes ', ' p16 Genes ', ' p14ARF ', ' TSG9A ', ' TP16 ', ' MTS1 Genes ', ' MTS1 ', ' INK4A ', ' INK4 ', ' Cyclin-Dependent Kinase Inhibitor 2A Gene ', ' CMM2 ', ' CDKN2A ', ' CDKN2 Genes ', ' CDKN2 ', ' CDK4I ', ' CDKN2A gene ', ' interest ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' Performance ', ' Receptor Protein ', ' receptor ', ' kindred ', ' neural network ', ' Biological Neural Networks ', ' novel ', ' member ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' Modeling ', ' Proteomics ', ' protein expression ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Oncogenesis ', ' tumorigenesis ', ' Address ', ' sunlight exposure ', ' solar exposure ', ' Sun Exposure ', ' Cellular Transformation ', ' metaplastic cell transformation ', ' Data ', ' in vivo ', ' in vivo Model ', ' Cancer Biology ', ' cancer specific gene mutation ', ' Cancer Gene Mutation ', ' Cell Cycle Progression ', ' gene modification ', ' Gene-Modified ', ' Transmission ', ' transmission process ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' epigenomics ', ' feeding ', ' tumor genome ', ' cancer cell genome ', ' cancer genome ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' innovation ', ' innovative ', ' innovate ', ' Oncogenic ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' network models ', ' mutation carrier ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide analysis ', ' overexpression ', ' overexpress ', ' over-expression ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' genome-wide ', ' genomewide ', ' genome scale ', ' non-genetic ', ' nongenetic ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' bead chip ', ' BeadChip ', ' learning network ', ' ']",NCI,MAYO CLINIC ROCHESTER,R01,2016,578620,0.16502161454881356
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics.         PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.            ",Integrative approach for predicting cancer driver genes,9152184,F31CA200266,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Au element ', ' Gold ', ' Methods ', ' Motivation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Neoplasm Metastasis ', ' Play ', ' Science ', ' statistics ', ' Tumor Suppressor Genes ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequencies ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' Cancer Induction ', ' carcinogenesis ', ' Cellular Proliferation ', ' Cell Multiplication ', ' Cell Growth in Number ', ' Cell Proliferation ', ' Performance ', ' Statistical Bias ', ' novel ', ' Sampling ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2016,43576,0.10587087917782546
"Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data     DESCRIPTION (provided by applicant)    My goal in seeking a K01 Award is to acquire the necessary training to become an independently funded investigator focused on exploiting the power of biomedical Big Data Science to improve outcome following severe injury. I am a trauma surgeon at San Francisco General Hospital, one of the Nation's leading trauma centers, and an Assistant Professor of Surgery at the University of California San Francisco (UCSF). UCSF has recently entered into collaboration with the National Laboratories to study the use of biomedical Big Data in complex clinical conditions and my main mentor, Dr. Mitchell J. Cohen is the lead investigator at UCSF for this collaboration. I believe that given the complexity of the factors that likely affect traum outcome including patient injury patterns, medical co-morbidities, patient biology, and the system of care, trauma provides a solid foundation to study the utility of Big Data Science for solving complex medical questions. To facilitate my growth as an expert in this field, I am proposing to develop a framework for integrating multiple data sources necessary to forecast patient outcomes following trauma. These novel datasets combined with biologic and metadata will then be utilized to create improved metrics that better predict complication risk from modifiable and non-modifiable factors. The net result of this work is a new approach to data ascertainment for measuring outcome, leveraging new data types to improve prediction of patient trajectory, and creating a platform to interface with existing information technology to ultimately be used for an early warning detection system for patients at risk of complications. The future long-term goal of this work would be to identify early patients predicted to do more poorly and then apply refinements to the process of care to minimize complication development. The creation of early warning detection systems has significant theoretic potential to improve quality and ultimately decrease costs. Nearly $30 billion per year in the US is spent on care for the traumatically injured and the development of post-traumatic complications is believed to be major contributor to the overall costs of care. The ability to report performance has been hampered by a lack of standard definitions, reporting bias, access to datasets, and the analysis techniques that fail to account for the highly confounded relationships contributing to patient outcome. This K01 award will provide me with the support necessary to accomplish the following goals: (1) to become an expert in applying biologic big data to trauma care (2) to elucidate the relationship of modifiable factors affecting complication development (3) to gain experience with advanced biostatistical techniques and bioinformatics; and (4) to develop an independent clinical research career. To achieve these goals, I have assembled a multidisciplinary team including Dr. Cohen, a National expert in trauma systems biology and biologic big data, and two co-mentors: Dr. Michael Matthay, a translational research expert in complications after severe illness, and Dr. Alan Hubbard, an expert in advanced biostatistical techniques including biologic big data analysis. PUBLIC HEALTH RELEVANCE    In the US, trauma is the leading cause of death for those under 45 years old and many of the patients who survive their initial injuries develop complications such as blood clots or pneumonia that contribute to both death and the long-term effects of the trauma. Through leveraging the power of biomedical Big Data, an integrated approach to measuring outcome will be developed utilizing biologic, clinical, and electronic medical record (EMR) data. The goal of this project is to lay the ground work for developing integrated EMR early warning detection systems that could identify those at risk of complications early with the intent to ultimately refie the process of care for this group to minimize complication development.",Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data,9147595,K01ES026834,"['Accounting ', ' Affect ', ' Age ', ' Algorithms ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Blood Clotting ', ' Blood coagulation ', ' California ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' co-morbidity ', ' Comorbidity ', ' Complication ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Demographic Aging ', ' Foundations ', ' Future ', ' Patient Care Delivery ', ' Patient Care ', ' geographic site ', ' Geographical Location ', ' Geographic Region ', ' Geographic Area ', ' Geographic Locations ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Health ', ' Hospitalization ', ' Hospitals ', ' General Hospitals ', ' Hybrids ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Longterm Effects ', ' Long-Term Effects ', ' Mentors ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' Patients ', ' Play ', ' Pneumonia ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk ', ' Risk Factors ', ' San Francisco ', ' Technology ', ' Testing ', ' Time ', ' trauma centers ', ' Universities ', ' Work ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Outcome Measure ', ' Socioeconomic Status ', ' socioeconomic position ', ' socio-economic position ', ' Socio-economic status ', ' Data Set ', ' Dataset ', ' Caring ', ' Myocardial Ischemia ', ' myocardium ischemia ', ' myocardial ischemia/hypoxia ', ' heart ischemia ', ' cardiac ischemia ', ' Ischemic myocardium ', ' Ischemic Heart Disease ', ' Ischemic Heart ', ' Injury ', ' base ', ' career ', ' improved ', ' Solid ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Medical ', ' Training ', ' disability ', ' Funding ', ' Collaborations ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Knowledge ', ' Severities ', ' Complex ', ' Source ', ' Pattern ', ' Techniques ', ' System ', ' Best Practice Analysis ', ' Benchmarking ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' Surgeon ', ' American ', ' experience ', ' Performance ', ' professor ', ' Informatics ', ' high-end computing ', ' High Performance Computing ', ' novel ', ' Reporting ', ' Statistical Methods ', ' Modeling ', ' smartphone ', ' smart phone ', ' iPhone ', ' Cellular Telephone ', ' Cell Phone ', ' Cellular Phone ', ' Bio-Informatics ', ' Bioinformatics ', ' Effectiveness ', ' Address ', ' Systems Biology ', ' Data ', ' Data Element ', ' Detection ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Mentored Research Scientist Development Award ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Characteristics ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' meta data ', ' Metadata ', ' cost ', ' injured ', ' care systems ', ' Information Technology ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Trauma ', ' modifiable risk ', ' multidisciplinary ', ' trauma care ', ' cloud based ', ' Big Data ', ' BigData ', ' Trauma patient ', ' Data Science ', ' Data Scientist ', ' individual patient ', ' improved outcome ', ' Traumatic injury ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' big biomedical data ', ' ']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2016,222942,0.0716297166759109
"Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy     DESCRIPTION (provided by applicant)     A new electrical biomarker has been identified in high resolution, intracranial electroencephalogram (iEEG) recordings, called a high frequency oscillation (HFO). Studies have suggested this biomarker has great promise to identify seizure networks and improve surgical outcomes for patients with refractory epilepsy. However, translation of HFOs to clinical practice is hampered by many factors such as spatial, temporal and inter-patient variation in HFO detection rates, false positive and false negative detections, and significant background noise. Big data approaches using large numbers of HFOs acquired from many patients are needed to quantify these effects and allow clinical usage of HFOs. This project details a plan in which the candidate's experience quantifying measurement and detection bias in massive high energy nuclear physics datasets will be combined with a multidisciplinary mentor team to address this problem. The combination of training in computational neuroscience, big data network analysis, and translational neural engineering research will be critical to approach this problem and provide a career trajectory for the candidate. The specific aims of this proposal address three specific confounding factors: 1) the false negative HFO detection rate, 2) variations in HFO features not due to epilepsy, and 3) effects of the state of vigilance on HFOs. Each of these aims involve novel big data methods and/or applications generalizable to other situations: 1) estimating false positive detection rates using a combined experimental/simulated data approach, 2) clustering and classification of distributions of data points, rather than of the data points directly, and 3) a general disambiguation statistic to assess meaningful (rather than statistical) difference between distributions.  The applicant's career goal is to become an academic researcher in the analysis and modeling of intracranial EEG data with a focus on translational epilepsy and sleep physiology research. With the rapid advancement in the resolution of clinical EEG, there is already a strong need for this type of research expertise. Thi grant will provide didactic coursework, formal research and methods training, and career guidance from an expert mentor team. The three mentors have appointments spanning Neurology, Anesthesiology, Mathematics, Statistics, Biomedical Engineering, and Electrical Engineering and Computer Science. The candidate will also build and mentor a research team and establish external collaborations.  The University of Michigan is a premier research university with strong programs and training opportunities in biomedical and physical sciences, engineering, translational and academic research, and advanced research computing. This proposal makes extensive use of the University's large computer cluster. The mentor team and an external collaborator will provide candidate access to prerecorded, deidentified data from over 150 patients, estimated to have over 40 million HFOs. The environment and mentor team will provide the training, facilities, and data for the candidate to successfully complete the proposed goals. PUBLIC HEALTH RELEVANCE    Recent advances in epilepsy research are generating very large datasets in the search for better ways to identify the region of brain responsible for generating seizures. A particular signa known as High Frequency Oscillations found in high resolution intracranial EEG shows great promise for identifying these regions, but clinicians are unable to use the signal due to confounding biases. This project combines big data processing expertise from particle physics, computer science and machine learning to address these confounds, providing a more accurate process to enable clinical translation of this new biomarker and potentially improve clinical outcomes.",Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy,9147594,K01ES026839,"['Accounting ', ' Algorithms ', ' Anesthesiology ', ' Appointment ', ' bioengineering ', ' Biomedical Engineering ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Systematics ', ' Classification ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Environment ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Future ', ' Goals ', ' Grant ', ' Health ', ' High Frequency Oscillation ', ' Hybrids ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' Mentorship ', ' Methods ', ' Michigan ', ' Motivation ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurology ', ' Neurosciences ', ' Noise ', ' Nuclear Physics ', ' Patients ', ' physical science ', ' Physics ', ' Physiology ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Seizures ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Sleep ', ' statistics ', ' Technology ', ' Translating ', ' Translations ', ' Universities ', ' Vocational Guidance ', ' executive coaching ', ' career counselor ', ' Vocational Counseling ', ' Occupational Guidance ', ' Career Guidance ', ' Career Counseling ', ' Work ', ' Research Methodology ', ' Research Methods ', ' Data Set ', ' Dataset ', ' Custom ', ' base ', ' career ', ' computational neuroscience ', ' detector ', ' improved ', ' Area ', ' Chronic ', ' Clinical ', ' Refractory ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Training ', ' Individual ', ' Measurement ', ' Funding ', ' Collaborations ', ' Electrical Engineering ', ' tool ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' programs ', ' Event ', ' Techniques ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Operative Surgical Procedures ', ' experience ', ' computer science ', ' neural ', ' relating to nervous system ', ' expectation ', ' novel ', ' Graph ', ' sleep epilepsy ', ' vigilance ', ' Statistical Methods ', ' Network Analysis ', ' Pathway Analysis ', ' Modeling ', ' Sampling ', ' career development ', ' data processing ', ' computerized data processing ', ' Brain region ', ' Address ', ' Data ', ' Detection ', ' Manpower and Training ', ' Resolution ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research enterprise ', ' translation research ', ' Translational Science ', ' Translational Research Enterprise ', ' Translational Research ', ' Resected ', ' Process ', ' developmental ', ' Development ', ' Electroencephalogram ', ' Outcome ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' clinically relevant ', ' clinical relevance ', ' multidisciplinary ', ' scientific computing ', ' spatial temporal variation ', ' patient population ', ' standard of care ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' clinical practice ', ' computer cluster ', ' signal processing ', ' Big Data ', ' BigData ', ' particle physics ', ' flavor physics ', ' training opportunity ', ' improved outcome ', ' big biomedical data ', ' terabyte ', ' ']",NIEHS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,K01,2016,148644,0.06360992187175588
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases.         PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.            ",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9083570,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atlases ', ' Biologic Factor ', ' Biological Factors ', ' Biology ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Parents ', ' Play ', ' polymorphism ', ' Genetic Polymorphism ', ' Probability ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Rest ', ' social role ', ' Role ', ' Selection Bias ', ' Technology ', ' Time ', ' Body Tissues ', ' Tissues ', ' Variation (Genetics) ', ' Genetic Variation ', ' Genetic Diversity ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' Natural Selections ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Machine Learning ', ' Frequencies ', ' Hereditary ', ' Inherited ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' environmental risk ', ' Environmental Factor ', ' Environmental Risk Factor ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Guanine + Cytosine Composition ', ' Pathogenicity ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' genetic evolution ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' sharing data ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' whole genome ', ' entire genome ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2016,300999,0.1267325595934094
"Adapting the Berkeley Big Data Analytics Stack to Genomics and Health Project Summary We propose building a computational platform based on the high performance Berkeley Big Data Analytics Stack (BDAS) to support a new ecosystem of Clinical Decision Support (CDS) applications. This platform will make it faster, easier, and less expensive to develop molecular Clinical Decision Support Systems. These systems require real-time queries of globally distributed data, efficient machine learning on large genomic datasets, and must be secure, fault-tolerant and scalable. BDAS and associated technologies are designed to help us meet these challenges and are therefore ideal building blocks to help us create our computational platform. To encourage the adoption of standards for the querying and sharing of large genomic datasets, we will adapt the BDAS stack to support the standards of the Global Alliance for Genomics and Health (GA4GH). Project Narrative Funding this work will help establish a production quality FOSS implementation of the important Global Alliance for Genomics and Health standards. Without such open-source implementations, a fragmented and proprietary platform ecosystem would slow down innovation as well as divert resources away from the practice of medicine.",Adapting the Berkeley Big Data Analytics Stack to Genomics and Health,9466681,R44GM119858,"['Adoption ', ' Algorithms ', ' Capital ', ' Communities ', ' health services delivery ', ' Healthcare Delivery ', ' health care delivery ', ' Distributed Systems ', ' Feedback ', ' Genome ', ' Health ', ' Industrialization ', ' Industry ', ' Institutes ', ' Leadership ', ' Maintenance ', ' Medicine ', ' Phenotype ', ' Production ', ' Publications ', ' Scientific Publication ', ' Resources ', ' Research Resources ', ' Running ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Technology ', ' Time ', ' Work ', ' Measures ', ' Businesses ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' Dataset ', ' Data Set ', ' Ecological Systems ', ' Ecologic Systems ', ' Ecosystem ', ' base ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Training ', ' Ingestion ', ' Individual ', ' Policies ', ' Funding ', ' Collaborations ', ' Letters ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Source ', ' System ', ' Clinical Decision Support Systems ', ' Services ', ' Performance ', ' Genomics ', ' Provider ', ' Contractor ', ' Data ', ' International ', ' Collection ', ' Small Business Innovation Research ', ' SBIR ', ' Small Business Innovation Research Grant ', ' Molecular ', ' web-based service ', ' web services ', ' distributed data ', ' distributed computing ', ' datagrid ', ' data grid ', ' cluster computing ', ' designing ', ' design ', ' innovation ', ' innovative ', ' innovate ', ' open source ', ' commercialization ', ' Secure ', ' operation ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' Big Data ', ' BigData ', ' precision medicine ', ' Data Analytics ', ' individual patient ', ' Big Data to Knowledge ', ' BD2K ', ' whole genome ', ' entire genome ', ' cloud platform ', ' cloud server ', ' genomic data ', ' petabyte ', ' Apache ', ' ']",NIGMS,"CUROVERSE INNOVATIONS, INC.",R44,2017,1015631,0.060768754747124974
"Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data     DESCRIPTION (provided by applicant)    My goal in seeking a K01 Award is to acquire the necessary training to become an independently funded investigator focused on exploiting the power of biomedical Big Data Science to improve outcome following severe injury. I am a trauma surgeon at San Francisco General Hospital, one of the Nation's leading trauma centers, and an Assistant Professor of Surgery at the University of California San Francisco (UCSF). UCSF has recently entered into collaboration with the National Laboratories to study the use of biomedical Big Data in complex clinical conditions and my main mentor, Dr. Mitchell J. Cohen is the lead investigator at UCSF for this collaboration. I believe that given the complexity of the factors that likely affect traum outcome including patient injury patterns, medical co-morbidities, patient biology, and the system of care, trauma provides a solid foundation to study the utility of Big Data Science for solving complex medical questions. To facilitate my growth as an expert in this field, I am proposing to develop a framework for integrating multiple data sources necessary to forecast patient outcomes following trauma. These novel datasets combined with biologic and metadata will then be utilized to create improved metrics that better predict complication risk from modifiable and non-modifiable factors. The net result of this work is a new approach to data ascertainment for measuring outcome, leveraging new data types to improve prediction of patient trajectory, and creating a platform to interface with existing information technology to ultimately be used for an early warning detection system for patients at risk of complications. The future long-term goal of this work would be to identify early patients predicted to do more poorly and then apply refinements to the process of care to minimize complication development. The creation of early warning detection systems has significant theoretic potential to improve quality and ultimately decrease costs. Nearly $30 billion per year in the US is spent on care for the traumatically injured and the development of post-traumatic complications is believed to be major contributor to the overall costs of care. The ability to report performance has been hampered by a lack of standard definitions, reporting bias, access to datasets, and the analysis techniques that fail to account for the highly confounded relationships contributing to patient outcome. This K01 award will provide me with the support necessary to accomplish the following goals: (1) to become an expert in applying biologic big data to trauma care (2) to elucidate the relationship of modifiable factors affecting complication development (3) to gain experience with advanced biostatistical techniques and bioinformatics; and (4) to develop an independent clinical research career. To achieve these goals, I have assembled a multidisciplinary team including Dr. Cohen, a National expert in trauma systems biology and biologic big data, and two co-mentors: Dr. Michael Matthay, a translational research expert in complications after severe illness, and Dr. Alan Hubbard, an expert in advanced biostatistical techniques including biologic big data analysis. PUBLIC HEALTH RELEVANCE    In the US, trauma is the leading cause of death for those under 45 years old and many of the patients who survive their initial injuries develop complications such as blood clots or pneumonia that contribute to both death and the long-term effects of the trauma. Through leveraging the power of biomedical Big Data, an integrated approach to measuring outcome will be developed utilizing biologic, clinical, and electronic medical record (EMR) data. The goal of this project is to lay the ground work for developing integrated EMR early warning detection systems that could identify those at risk of complications early with the intent to ultimately refie the process of care for this group to minimize complication development.",Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data,9320947,K01ES026834,"['Affect ', ' ages ', ' Age ', ' Algorithms ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Blood Clotting ', ' Blood coagulation ', ' California ', ' Cause of Death ', ' Clinical Study ', ' Clinical Research ', ' co-morbidity ', ' Comorbidity ', ' Complication ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Death ', ' Cessation of life ', ' Foundations ', ' Future ', ' Patient Care Delivery ', ' Patient Care ', ' geographic site ', ' Geographical Location ', ' Geographic Region ', ' Geographic Area ', ' Geographic Locations ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Hospitalization ', ' Hospitals ', ' General Hospitals ', ' Hybrids ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Long-Term Effects ', ' Longterm Effects ', ' Mentors ', ' Methods ', ' Modernization ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Patients ', ' Play ', ' Pneumonia ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk ', ' Risk Factors ', ' San Francisco ', ' Standardization ', ' Technology ', ' Testing ', ' Time ', ' trauma centers ', ' Universities ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Outcome Measure ', ' socioeconomic position ', ' socio-economic position ', ' Socio-economic status ', ' Socioeconomic Status ', ' Dataset ', ' Data Set ', ' Caring ', ' myocardium ischemia ', ' myocardial ischemia/hypoxia ', ' heart ischemia ', ' cardiac ischemia ', ' Ischemic myocardium ', ' Ischemic Heart Disease ', ' Ischemic Heart ', ' Myocardial Ischemia ', ' Injury ', ' base ', ' career ', ' improved ', ' Solid ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Medical ', ' Training ', ' disability ', ' Funding ', ' Collaborations ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Source ', ' Pattern ', ' Techniques ', ' System ', ' Benchmarking ', ' Best Practice Analysis ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Surgeon ', ' Deltastab ', ' Predniocil ', ' Prednihexal ', ' Predni-POS ', ' Predni-H ', ' Prednefrin SF ', ' Predcor ', ' Predate ', ' Predalone ', ' Predaject ', ' Pred Mild ', ' Pred Forte ', ' Pred Fort ', ' Ophtho-Tate ', ' Locaseptil-Neo ', ' Key-Pred ', ' Inflanefran ', ' Inf-Oph ', ' Hydrocortancyl ', ' Hexacortone ', ' Econopred ', ' Diopred ', ' Deltacortilen ', ' Balpred ', ' Articulose-50 ', ' Ak-Tate ', ' American ', ' experience ', ' Performance ', ' professor ', ' Informatics ', ' High Performance Computing ', ' high-end computing ', ' novel ', ' Reporting ', ' Statistical Methods ', ' Modeling ', ' portability ', ' Cellular Phone ', ' smartphone ', ' smart phone ', ' iPhone ', ' Cellular Telephone ', ' Cell Phone ', ' Bioinformatics ', ' Bio-Informatics ', ' Effectiveness ', ' Address ', ' Systems Biology ', ' Data ', ' Data Element ', ' Detection ', ' Mentored Research Scientist Development Award ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Characteristics ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' meta data ', ' Metadata ', ' cost ', ' injured ', ' care systems ', ' Information Technology ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Trauma ', ' modifiable risk ', ' multidisciplinary ', ' demographics ', ' public health relevance ', ' trauma care ', ' cloud based ', ' Big Data ', ' BigData ', ' Trauma patient ', ' Data Science ', ' Data Scientist ', ' individual patient ', ' improved outcome ', ' Traumatic injury ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' big biomedical data ', ' ']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2017,221780,0.0716297166759109
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9324471,K01ES028047,"['anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Award ', ' malignant breast tumor ', ' Breast Cancer ', ' malignant breast neoplasm ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Rodent Ulcer ', ' Basiloma ', ' Basal Cell Epithelioma ', ' Basal cell carcinoma ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Clinical Trials ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' liver carcinoma ', ' Liver Cells Carcinoma ', ' Hepatoma ', ' Hepatocellular cancer ', ' Hepatocellular Carcinoma ', ' Hepatocarcinoma ', ' Primary carcinoma of the liver cells ', ' Mentors ', ' Methods ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Probability ', ' Research ', ' Resources ', ' Research Resources ', ' statistics ', ' Time ', ' Translating ', ' Universities ', ' Work ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' c-myc Genes ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Individual ', ' drug sensitivity ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Therapeutic ', ' Normal tissue morphology ', ' Normal Tissue ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Malignant neoplasm of liver ', ' malignant liver tumor ', ' liver cancer ', ' Hepatic Cancer ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Adopted ', ' Clinic ', ' Source ', ' Pattern ', ' System ', ' Tumor Tissue ', ' Xenograft procedure ', ' xeno-transplantation ', ' xeno-transplant ', ' Xenotransplantation ', ' Xenograft ', ' Heterologous Transplantation ', ' Heterograft ', ' Ewings sarcoma ', "" Ewing's Tumor "", "" Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor "", "" Ewing's Family of Tumours "", ' drug efficacy ', ' novel ', ' Gene Proteins ', ' Protein Gene Products ', ' Code ', ' Coding System ', ' Sampling ', ' response ', ' Proteomics ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' protein expression ', ' Alpha Cell ', ' -cell ', ' Glucagon Secreting Cell ', ' Glucagon Cell ', ' Tissue Sample ', ' Address ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Cancer Biology ', ' Cancer Patient ', ' nonmalignant ', ' Non-Malignant ', ' Validation ', ' Molecular ', ' preclinical ', ' pre-clinical ', ' triple-negative breast cancer ', ' TNBC ', ' triple-negative invasive breast carcinoma ', ' oncogenomics ', ' cancer genomics ', ' Cancer cell line ', ' transcriptomics ', ' mouse model ', ' murine model ', ' tumor ', ' molecular marker ', ' molecular biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' efficacy testing ', ' drug candidate ', ' sharing data ', ' Big Data ', ' BigData ', ' Precision Medicine Initiative ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' personalized cancer therapy ', ' personalized cancer treatment ', ' individualized cancer therapy ', ' Data Science ', ' Data Scientist ', ' genetic signature ', ' gene signatures ', ' individual patient ', ' cancer clinical trial ', ' actionable mutation ', ' driver mutation ', ' Genomic Data Commons ', ' ']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2017,171216,0.13861486539432163
"Genomics-based prediction of antibiotic failure in S. aureus infections     DESCRIPTION (provided by applicant)    The Gram positive bacterium Staphylococcus aureus is both an asymptomatic human colonizer and a pathogen that can cause infections in multiple tissue sites, including blood, skin and soft tissue, bone, and internal organs. Methicillin resistant Staphylococcus aureus (MRSA) is a common cause of death by hospital infections (HA-MRSA) and is now also a common community acquired infection (CA-MRSA). Vancomycin (a glycopeptide antibiotic) is the most commonly prescribed drug to treat MRSA infections. High-level resistance (minimal inhibitory concentration (MIC) 16 g/ml) to vancomycin encoded by the mobile vanA gene is rare due to a fitness burden on S. aureus. However, it is more common to encounter strains with mutations conferring intermediate resistance to vancomycin arising from selection during the course of antibiotic therapy. The genetic basis of these vancomycin intermediate S. aureus (VISA) and heterogeneous resistant (hVISA) (MIC 2-8 g/ml) strains involves a large number of different genomic mutations that result in cell wall thickening through changes in cellular signaling and regulation. Routine phenotypic testing in clinical labs probably underestimates the incidence of VISA and hVISA. Due to the fact that mutations in several genes have been linked with VISA, genetic-based detection of intermediate vancomycin resistance has not been developed for routine clinical microbiological use. In our preliminary work, we created an extensive catalog of sequenced clinical and laboratory-selected VISA as well as databases of SNPs and genetic variation in thousands of public S. aureus genomes. In this work we plan to extend these studies toward development of a sequence-based testing protocol that could be used for large numbers of clinical strains. In Specific Aim 1 we plan to extend our knowledge of the mutations that cause VISA by sequencing a panel of 300 novel mutants strains spontaneously selected from 40 S. aureus parent genotypes. We estimate, based on the results of the preliminary data, that this number of strains will be sufficient identify mutations found in 95% of VISA strains. These data will be used for creation of a comprehensive VISA detection assay based on whole genome data with an accuracy of at least 95%. In Specific Aim 2 we will use the information learned from Aim 1 to create a multiplex PCR sequence test for VISA, VRSA and other resistance determinants of S. aureus based on the commercially available Fluidigm platform. We will ultimately aim to have an assay that can be used to monitor systemic MRSA infections, such as bacteremia, to detect development of VISA in its early stages in clinical specimens from the patient. The test will also be able to detect other S. aureus resistance phenotypes and call the genotype of the strain. PUBLIC HEALTH RELEVANCE    Vancomycin is an antibiotic commonly used to treat methicillin resistant Staphylococcus aureus (MRSA) infections in chronically ill patients. The efficacy of this relatively cheap and well-tolerated therapy is compromised by mutations in the genome of the bacterium. In this project we propose to develop a genetic test based on a library of MRSA genome sequences with known antibiotic susceptibility level that identifies bacteria with diminished resistance to vancomycin.",Genomics-based prediction of antibiotic failure in S. aureus infections,9241329,R21AI121860,"['Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antibiotics ', ' bacteraemia ', ' Bacteremia ', ' Bacteria ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Base Sequence ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Blood Reticuloendothelial System ', ' Blood ', ' bone ', ' Cause of Death ', ' Cell Wall ', ' Chronically Ill ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Evolution ', ' Genes ', ' Genome ', ' Genotype ', ' Goals ', ' Gram-Positive Bacteria ', ' University Hospitals ', ' Modern Man ', ' Human ', ' Incidence ', ' Infection ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Libraries ', ' Methicillin ', ' Dimethoxyphenyl Penicillin ', ' 2,6 dimethoxyphenylpenicillin ', ' mortality ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Parents ', ' Patients ', ' Phenotype ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Computer software ', ' Software ', ' Staphylococcus aureus ', ' Staph aureus ', ' S.aureus ', ' S. aureus ', ' S aureus ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Vancomycin ', ' Genetic Diversity ', ' Genetic Variation ', ' Virulence ', ' Work ', ' antibiotic resistant ', ' antibiotic drug resistance ', ' Resistant to antibiotics ', ' Resistance to antibiotics ', ' Antibiotic Resistance ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' therapy failure ', ' Treatment Failure ', ' Glycopeptide Antibiotics ', ' base ', ' Organ ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' institutional infection ', ' Hospital acquired infection ', ' Hospital Infections ', ' Nosocomial Infections ', ' Community-Acquired Infections ', ' Link ', ' Training ', ' soft tissue ', ' Failure ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Genetic ', ' tool ', ' Antibiotic Therapy ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Specimen ', ' Research Specimen ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Frequencies ', ' Complex ', ' Protocols documentation ', ' Protocol ', ' interest ', ' mutant ', ' pleiotropism ', ' pleiotropy ', ' pleiotropic effect ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' economic cost ', ' Skin Tissue ', ' Vancomycin Resistance ', ' vancomycin resistant ', ' resistant to vancomycin ', ' resistance to vancomycin ', ' Regulation ', ' Modeling ', ' Genomics ', ' methicillin resistant Staphylococcus aureus ', ' Methicillin Resistant S. Aureus ', ' Methicillin Resistant S Aureus ', ' MRSA ', ' Clinical Microbiology ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Monitor ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Antibiotic susceptibility ', ' Intermediate resistant ', ' Heteroresistant ', ' Heteroresistance ', ' Intermediate resistance ', ' Vancomycin-resistant S. aureus ', ' Vancomycin-resistant Staphylococcus aureus ', ' Vancomycin-resistant S.aureus ', ' VRSA ', ' pathogen ', ' Resistance ', ' resistant ', ' public health relevance ', ' genetic predictors ', ' phenotypic data ', ' whole genome ', ' entire genome ', ' ']",NIAID,EMORY UNIVERSITY,R21,2017,195000,0.0741715938342794
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9382414,R35GM124952,"['protein sequence ', ' Primary Protein Structure ', ' Amino Acid Sequence ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disorder ', ' Disease ', ' Drug Design ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Ligands ', ' Methods ', ' Structural Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Pharmacology ', ' Protein Engineering ', ' protein design ', ' genetic protein engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Distal ', ' insight ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2017,335245,0.13491111632773134
"Transforming Analytical Learning in the Era of Big Data     DESCRIPTION (provided by applicant): In this dawning era of `Big Data' it is vital to recruit and train the next generation of biomedical data scientists in `Big Data'. The collection of `Big Data' in the biomedical sciences is growing rapidly and has the potential to solve many of today's pressing medical needs including personalized medicine, eradication of disease, and curing cancer. Realizing the benefits of Big Data will require a new generation of leaders in (bio) statistical and computational methods who will be able to develop the approaches and tools necessary to unlock the information contained in large heterogeneous datasets. There is a great need for scientists trained in this specialized, highly heterogeneous, and interdisciplinary new field. Thus, the recruitment of talented undergraduates in science, technology, engineering and mathematics (STEM) programs is vital to our ability to tap into the potential that `Big Data' offer and the challenges that it presents. The University of Michigan Undergraduate Summer Institute: Transforming Analytical Learning in the Era of Big Data will draw from the expertise and experience of faculty from four different departments within four different schools at the University of Michigan: Biostatistics in the School of Public Health, Computer Science in the School of Engineering, Statistics in the College of Literature, Sciences and the Arts, and Information Science in the School of Information. The faculty instructors and mentors have backgrounds in Statistics, Computer Science, Information Science and Biological Sciences. They have active research programs in a broad spectrum of methodological areas including data mining, natural language processing, statistical and machine learning, large-scale optimization, matrix computation, medical computing, health informatics, high-dimensional statistics, distributed computing, missing data, causal inference, data management and integration, signal processing and imaging. The diseases and conditions they study include obesity, cancer, diabetes, cardiovascular disease, neurological disease, kidney disease, injury, macular degeneration and Alzheimer's disease. The areas of biology include neuroscience, genetics, genomics, metabolomics, epigenetics and socio-behavioral science. Undergraduate trainees selected will have strong quantitative skills and a background in STEM. The summer institute will consist of a combination of coursework, to raise the skills and interests of the participants to a sufficient level to consider pursuing graduate studies in `Big Data' science, along with an in depth mentoring component that will allow the participants to research a specific topic/project utilizing `Big Data'. We have witnessed tremendous enthusiasm and response for our pilot offering in 2015 with 153 applications for 20 positions and a yield rate of 80% from the offers we extended. We plan to build on the success of this initial offering in the next three year funding cycle of this grant (2016-2018). The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a no-traditional, action-based learning paradigm. This six week long summer institute will recruit a group of approximately 30 undergraduates nationally and expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material for undergraduate students in this new field across the world. PUBLIC HEALTH RELEVANCE: We propose a six week long summer institute: ""Transforming Analytical Learning in the Era of Big Data"" to be held at the Department of Biostatistics, University of Michigan, Ann Arbor, with a group of approximately 30 undergraduates recruited nationally, from 2016-2018. We plan to expose them to diverse techniques, skills and problems in the field of Big Data. They will be taught and mentored by a team of interdisciplinary faculty from Biostatistics, Statistics, Computer Science and Engineering, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by UM researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a Wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material in this new field across the world. The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm.",Transforming Analytical Learning in the Era of Big Data,9325011,R25EB022363,"['senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Arts ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biological Sciences ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Engineering ', ' Faculty ', ' Goals ', ' Grant ', ' Information Sciences ', ' Kidney Diseases ', ' renal disorder ', ' kidney disorder ', ' Renal Disease ', ' Nephropathy ', ' Learning ', ' Literature ', ' Macular degeneration ', ' Macular degenerative disease ', ' Mentors ', ' Methods ', ' Methodology ', ' Michigan ', ' Natural Language Processing ', ' natural language understanding ', ' nervous system disorder ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' Neurosciences ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Schools ', ' Public Health Schools ', ' Science ', ' Social Behavior ', ' sociobehavioral ', ' sociobehavior ', ' statistics ', ' Students ', ' Talents ', ' Educational process of instructing ', ' Teaching ', ' Universities ', ' Drug Side Effects ', ' Adverse drug effect ', ' Work ', ' Generations ', ' case report ', ' Case Study ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Injury ', ' base ', ' Area ', ' Medical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Funding ', ' Genetic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' posters ', ' lectures ', ' programs ', ' Scientist ', ' Oral ', ' Techniques ', ' interest ', ' instructor ', ' college ', ' collegiate ', ' data management ', ' experience ', ' success ', ' computer science ', ' skills ', ' Participant ', ' member ', ' Prevention ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Statistical Methods ', ' response ', ' Genomics ', ' Public Health Informatics ', ' consumer informatics ', ' Health Informatics ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' data mining ', ' datamining ', ' Data ', ' Collection ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' data integration ', ' distributed computing ', ' datagrid ', ' data grid ', ' cluster computing ', ' designing ', ' design ', ' next generation ', ' wiki ', ' open source ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' public health relevance ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Science, Technology, Engineering and Mathematics ', ' Science, Technology, Engineering and Math ', ' undergraduate student ', ' undergraduate ', ' signal processing ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' Problem Sets ', ' Homework Exercises ', ' summer institute ', ' Data Science ', ' Data Scientist ', ' high dimensionality ', ' ']",NIBIB,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R25,2017,161633,0.1212833226059418
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9356560,R01GM120364,"['Affect ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Goals ', ' Modern Man ', ' Human ', ' Literature ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' doubt ', ' Uncertainty ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Dimensions ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' experience ', ' AIDS diagnosis ', ' Missense Mutation ', ' trait ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' Information Resources ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' next generation ', ' clinically relevant ', ' clinical relevance ', ' wiki ', ' human disease ', ' prototype ', ' primary outcome ', ' genome-wide ', ' genomewide ', ' genome scale ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2017,343120,0.21110553409641228
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9334146,R01CA208517,"['Affect ', ' ages ', ' Age ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', "" Alzheimer's Disease "", ' Dorsum ', ' Back ', ' Biology ', ' tumors in the brain ', ' Brain Tumors ', ' Brain Neoplasia ', ' Brain Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Body ', ' Cells ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Diagnosis ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Environmental Exposure ', ' Gene Expression ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Genotype ', ' In Vitro ', ' Learning ', ' leukemia ', ' Light ', ' Photoradiation ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Methodology ', ' Minor ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Proteins ', ' Risk ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Smoking ', ' Syndrome ', ' Testing ', ' Transforming Growth Factor-Beta Family Gene ', ' TGF ', ' TGFbeta ', ' TGF- ', ' TGF-beta ', ' TGF B ', ' Platelet Transforming Growth Factor ', ' Milk Growth Factor ', ' Bone-Derived Transforming Growth Factor ', ' Transforming Growth Factor beta ', ' Weight ', ' Generations ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Training ', ' insight ', ' Individual ', ' p16INK4A Protein ', ' p16INK4 Protein ', ' p16-INK4 ', ' p16(INK4A) ', ' Protein p16 ', ' Protein MTS1 ', ' Protein CDKN2 ', ' Multiple Tumor Suppressor-1 ', ' INK4A Protein ', ' INK4A Gene Product ', ' Cyclin-Dependent Kinase Inhibitor p16 ', ' Cyclin-Dependent Kinase Inhibitor p12 ', ' Cell Cycle Negative Regulator Beta ', ' Cdk4-Associated Protein p16 ', ' CDKN2A Protein ', ' CDK4 Inhibitor ', ' Cyclin-Dependent Kinase Inhibitor 2A ', ' Genetic ', ' tool ', ' Malignant neoplasm of pancreas ', ' Pancreatic Cancer ', ' Pancreas Cancer ', ' Malignant Pancreatic Neoplasm ', ' Knowledge ', ' Inherited ', ' Hereditary ', ' Pattern ', ' Penetrance ', ' CDKN2A gene ', ' p16INK4a ', ' p16INK4A Genes ', ' p16INK4 Genes ', ' p16 Genes ', ' p14ARF ', ' TSG9A ', ' TP16 ', ' MTS1 Genes ', ' MTS1 ', ' INK4A ', ' INK4 ', ' Cyclin-Dependent Kinase Inhibitor 2A Gene ', ' CMM2 ', ' CDKN2A ', ' CDKN2 Genes ', ' CDKN2 ', ' CDK4I ', ' interest ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' Performance ', ' receptor ', ' Receptor Protein ', ' kindred ', ' Biological Neural Networks ', ' neural network ', ' novel ', ' member ', ' genetic analysis ', ' Genetic analyses ', ' Code ', ' Coding System ', ' Modeling ', ' Proteomics ', ' Cancer-Predisposing Gene ', ' Cancer Susceptibility Gene ', ' protein expression ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' tumorigenesis ', ' Oncogenesis ', ' Address ', ' Sun Exposure ', ' sunlight exposure ', ' solar exposure ', ' metaplastic cell transformation ', ' Cellular Transformation ', ' Data ', ' in vivo ', ' in vivo Model ', ' Cell Cycle Progression ', ' gene modification ', ' Gene-Modified ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Transmission ', ' transmission process ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' epigenomics ', ' feeding ', ' tumor genome ', ' cancer cell genome ', ' cancer genome ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' innovation ', ' innovative ', ' innovate ', ' Oncogenic ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' network models ', ' mutation carrier ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide screen ', ' genome wide analysis ', ' overexpression ', ' overexpress ', ' over-expression ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' genome-wide ', ' genomewide ', ' genome scale ', ' non-genetic ', ' nongenetic ', ' epidemiologic data ', ' Epidemiology data ', ' Epidemiological data ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' bead chip ', ' BeadChip ', ' learning network ', ' high dimensionality ', ' ']",NCI,MAYO CLINIC ROCHESTER,R01,2017,590577,0.16502161454881356
"Molecular Characterization of Joubert Syndrome     DESCRIPTION (provided by applicant): Congenital ataxia presents in early childhood with non-progressive hypotonia, gross and fine motor delay and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins localize to the cilium. 5] Identified ciliary defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of `Ciliary localization' model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished work we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome sequencing (WES) and genetic mapping on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Begun functional validation of the putative mutations. 5] Developed methods to ultrastructurally interrogate ciliary structure in a high-throughput fashion. The goal of this competing renewal is to identify the remaining `discoverable' genes that when mutated lead to JSRD, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in any proven JSRD gene lead to collapse of the ciliary transition zone by correlating genetic mutations with ultrastructural ciliary defects. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations within a mechanistic framework, and a model that JSRD genes are required for essential ciliary structural components during cerebellar development. PUBLIC HEALTH RELEVANCE: Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations",Molecular Characterization of Joubert Syndrome,9450748,R01NS048453,"['Termination of pregnancy ', ' apraxia ', ' Dyspraxia ', ' Apraxias ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Inhaling ', ' Inhalation ', ' Breathing ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Ataxia ', ' Attention ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' genetic mapping ', ' Total Human and Non-Human Gene Mapping ', ' Linkage Mapping ', ' Gene Mapping Genetics ', ' Gene Mapping ', ' Gene Localization ', ' Chromosome Mapping ', ' Cilia ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Modern Man ', ' Human ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Mental Retardation ', ' Methods ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Muscle hypotonia ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Pregnancy Tests ', ' Probability ', ' Proteins ', ' Publishing ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Resources ', ' Research Resources ', ' Risk ', ' Sonication ', ' Syndrome ', ' Testing ', ' Work ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' Zebrafish ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' pediatric ', ' Childhood ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Complex ', ' Techniques ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' unpublished works ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Mutate ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' gene discovery ', ' discover genes ', ' public health relevance ', ' population based ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome sequencing ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2017,510012,0.18972198342941754
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9301599,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tyrosine ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' computational framework ', ' computer framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2017,300000,0.17732211395365816
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9275505,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Allelomorphs ', ' Alleles ', ' Atlases ', ' Biologic Factor ', ' Biological Factors ', ' Biology ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Parents ', ' Play ', ' Genetic Polymorphism ', ' polymorphism ', ' Probability ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Rest ', ' Role ', ' social role ', ' Selection Bias ', ' Technology ', ' Tissues ', ' Body Tissues ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' Natural Selections ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' sharing data ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' whole genome ', ' entire genome ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2017,300742,0.1267325595934094
"Integrative approach for predicting cancer driver genes     DESCRIPTION (provided by applicant): Carcinogenesis, progression of normal cells to malignant cancer, derives from hallmark capabilities of cancer driven by acquiring (somatic) mutations in ""driver genes"" with a selective advantage for cellular proliferation and potentially metastasis. A major motivation for modern cancer genomics studies is to decipher the genetic architecture of cancer by discovering new driver genes. The most widely-used approaches to predict and prioritize driver genes are based on statistics of mutation frequencies. Several methods have been proposed to identify genes with an excessive number of somatic mutations [9-11], known as significantly mutated genes. I propose to address two major limitations of this approach. First, these methods are insufficiently statistically powered given the amount of sequencing data currently available [15]. I will improve statistical power by leveraging diverse information in cancer genomics currently available into a developed machine learning method. Second, there is little objective clarity about the true effectiveness of these methods [11, 14], since there is no agreed-upon gold standard of driver genes, with the exception of a few well-known drivers. I will develop a framework to compare the effectiveness of driver gene prediction methods, in the absence of a gold standard. Both effectively and efficiently identifying cancer driver genes is a matter of great importance to science funding policy towards cancer genomics. PUBLIC HEALTH RELEVANCE: Large sequencing studies have revolutionized our capability to identify the genetic architecture of cancer. However, effectively integrating this stream of big data to identify specific driver genes has remained troublesome. My proposed research project aims to develop an integrative machine learning method that leverages diverse features in cancer genomics to improve predictions of cancer driver genes, and to utilize a principled approach for evaluating the performance of any such method.",Integrative approach for predicting cancer driver genes,9322626,F31CA200266,"['Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Genes ', ' Gold ', ' Methods ', ' Modernization ', ' Motivation ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Neoplasm Metastasis ', ' tumor cell metastasis ', ' cancer metastasis ', ' Secondary Tumor ', ' Secondary Neoplasm ', ' Metastatic Tumor ', ' Metastatic Neoplasm ', ' Metastatic Mass ', ' Metastatic Lesion ', ' Metastasize ', ' Metastasis ', ' Play ', ' Science ', ' statistics ', ' Supervision ', ' oncosuppressor gene ', ' Tumor Suppressing Genes ', ' Recessive Oncogenes ', ' Oncogenes-Tumor Suppressors ', ' Onco-Suppressor Genes ', ' Emerogenes ', ' Cancer Suppressor Genes ', ' Antioncogenes ', ' Anti-Oncogenes ', ' Tumor Suppressor Genes ', ' base ', ' improved ', ' Malignant ', ' Malignant - descriptor ', ' Evaluation ', ' Policies ', ' Funding ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Research Project Grants ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Stream ', ' Pattern ', ' Somatic Mutation ', ' carcinogenesis ', ' Cancer Induction ', ' Cell Proliferation ', ' Cellular Proliferation ', ' Cell Multiplication ', ' Cell Growth in Number ', ' Gene Mutation ', ' Gene Alteration ', ' Performance ', ' novel ', ' Sampling ', ' Property ', ' Normal Cell ', ' Effectiveness ', ' Address ', ' Data ', ' Mutate ', ' Scheme ', ' Tumor Biology ', ' Characteristics ', ' oncogenomics ', ' cancer genomics ', ' compare effectiveness ', ' public health relevance ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' transcriptome ', ' ']",NCI,JOHNS HOPKINS UNIVERSITY,F31,2017,44044,0.10587087917782546
"Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership     DESCRIPTION (provided by applicant): The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The aims to achieve the goals are: 1) Implement an integrated didactic program to enhance student self-efficacy with computational and informatics tool development and use for interrogating and interpreting Big Data, including a two-semester bioinformatics course in Bioinformatics, informed by the expertise of UIUC KnowEnG BD2K Center faculty with additional Special Topics courses available remotely from UIUC. 2) Develop an integrated academic year (Fisk, or partners) and summer research program at the UIUC KnowEnG BD2K Center to assure student exposure to a participation in the life cycle of a `Big Data' research problem. 3) Implement a professional skills development program that assures successful transition of undergraduate participants to a Ph.D. (or MD/PhD Program) in Big Data- reliant biomedical research. 4) Launch a faculty development program in bioinformatics that leads to embracing Big Data problems in courses in multiple disciplines for impact on all Fisk undergraduate STEM majors. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fisk R25 mentors, of value for their broader education and research training goals at UIUC and Mayo. PUBLIC HEALTH RELEVANCE: The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fis R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.  ",Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership,9303203,R25MD010396,"['Biological Chemistry ', ' Biochemistry ', ' Biomedical Research ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' career track ', ' career pathway ', ' career interest ', ' career aspiration ', ' Career Path ', ' Career Choice ', ' Communication ', ' Complement Proteins ', ' Complement ', ' Computers ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' Elements ', ' Faculty ', ' Goals ', ' Grant ', ' Illinois ', ' Learning ', ' Life Cycle Stages ', ' life course ', ' Life Cycle ', ' Literature ', ' Mathematics ', ' Math ', ' Mentors ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Program Development ', ' Reading ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Science ', ' Students ', ' Technology ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Writing ', ' Magazine ', ' Journals ', ' base ', ' career ', ' Biological ', ' Chemicals ', ' Training ', ' Discipline ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Development Plans ', ' Funding ', ' Collaborations ', ' Exposure to ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' posters ', ' programs ', ' Cellular biology ', ' cell biology ', ' Scientist ', ' Oral ', ' Training and Education ', ' Education and Training ', ' experience ', ' computer science ', ' Informatics ', ' Base Pairing ', ' Self Efficacy ', ' Manuscripts ', ' skills ', ' Participant ', ' Research Ethics ', ' Proteomics ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Address ', ' Systems Biology ', ' Core Facility ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Education Projects ', ' R25 Program ', ' R25 Mechanism ', ' Research Training ', ' underrepresentation of minorities ', ' under-represented minority ', ' under-representation of minorities ', ' Underrepresented Ethnic Minority ', ' Underrepresented Minority ', ' innovation ', ' innovative ', ' innovate ', ' data acquisition ', ' skill acquisition ', ' skill development ', ' tool development ', ' public health relevance ', ' responsible research conduct ', ' sharing data ', ' STEM field ', ' STEM major ', ' STEM discipline ', ' STEM course ', ' STEM class ', ' Teacher Professional Development ', ' teacher development ', ' instructor training ', ' faculty professional development ', ' faculty development ', ' Teacher Training ', ' Teacher Preparation ', ' Teacher Educator ', ' Teacher Education ', ' Faculty Training ', ' Faculty Education ', ' undergraduate student ', ' undergraduate ', ' undergraduate research ', ' Big Data ', ' BigData ', ' Faculty Workshop ', ' faculty panel ', ' faculty conference ', ' Teacher Workshop ', ' Faculty Seminar ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored medical treatment ', ' individualized treatment ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' faculty research ', ' summer research ', ' Big Data to Knowledge ', ' BD2K ', ' minority scientist ', ' Articulation ', ' ']",NIMHD,FISK UNIVERSITY,R25,2017,216000,0.12163881736249535
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9397848,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Natural Language Processing ', ' natural language understanding ', ' Parents ', ' Pongidae ', ' great ape ', ' Apes ', ' Research ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Employee Strikes ', ' Strikes ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disorder risk ', ' disease risk ', ' genetic risk factor ', ' inherited factor ', ' developmental disease/disorder ', ' developmental disorder ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' public health relevance ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2017,510,0.23357181072684932
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",9517179,U54EB020403,"['Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Acquired Immunodeficiency Syndrome ', ' Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Genes ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human T-Lymphotropic Virus Type III ', ' Human T-Cell Lymphotropic Virus Type III ', ' Human T-Cell Leukemia Virus Type III ', ' Human Immunodeficiency Viruses ', ' HTLV-III ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Joints ', ' Learning ', ' Mathematics ', ' Math ', ' Medicine ', ' National Institute of Mental Health ', ' NIMH ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Obsessive-Compulsive Disorder ', ' Obsessive-Compulsive Neurosis ', ' outcome forecast ', ' Prognosis ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schools ', ' Science ', ' Computer software ', ' Software ', ' Talents ', ' Training Programs ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuroimaging ', ' neuro-imaging ', ' novel ', ' organizational structure ', ' Organization Charts ', ' Modality ', ' AIDS/HIV problem ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' chromosome 22q deletion syndrome ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' Modeling ', ' Genomics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Major Depressive Disorder ', ' major depression disorder ', ' major depression ', ' clinical depression ', ' Institution ', ' Data ', ' National Institute of Child Health and Human Development ', ' NICHD ', ' National Institute of Drug Abuse ', ' National Institute on Drug Abuse ', ' NIDA ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Research Infrastructure ', ' Infrastructure ', ' imaging ', ' Image ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' National Institute on Alcohol Abuse and Alcoholism ', ' NIAAA ', ' innovation ', ' innovative ', ' innovate ', ' multidisciplinary ', ' Computational algorithm ', ' computer algorithm ', ' multitask ', ' multi-task ', ' addiction ', ' addictive disorder ', ' public health relevance ', ' multimodality ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' Big Data ', ' BigData ', ' Genetic study ', ' web portal ', ' internet portal ', ' Data Science ', ' Data Scientist ', ' diagnostic biomarker ', ' diagnostic marker ', ' hackathon ', ' hackfest ', ' hack day ', ' Big Data to Knowledge ', ' BD2K ', ' connectome ', ' imaging study ', ' high dimensionality ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2017,81900,0.07778723406859629
"NextGen Random Forests Project Summary/Abstract Building from the PI's current R01, we propose next generation random forests (RF) designed for unprecedented accuracy and computational scalability to meet the challenges of today's complex and big data in the health sciences. Superior accuracy is achieved using super greedy trees which circumvent limitations on local adaptivity imposed by classical tree splitting. We identify a key quantity, forest weights, and show how these can be leveraged for further improvements and generalizability. In one application, improved survival estimators are applied to worldwide esophageal cancer data to develop guidelines for clinical decision making. Richer RF inference is another issue explored. Cutting edge machine learning methods rarely consider the problem of estimating variability. For RF, bootstrapping currently exists as the only tool for reliably estimating condence intervals, but due to heavy computations is rarely applied. We introduce tools to rapidily calculate standard errors based on U-statistic theory. These will be used to increase robustness of esophageal clinical recommendations and to investigate survival temporal trends in cardiovascular disease. In another application, we make use of our new massive data scalability for discovery of tumor and immune regulators of immunotherapy in cancers. This project will set the standard for RF computational performance. Building from the core libraries of the highly accessed R-package randomForestSRC (RF-SRC), software developed under the PIs current R01, we develop open source next generation RF software, RF-SRC Everywhere, Big Data RF-SRC, and HPC RF-SRC. The software will be deployable on a number of popular machine learning workbenches, use distributed data storage technologies, and be optimized for big-p, big-n, and big-np scenarios. Project Narrative We introduce next generation random forests (RF) designed for unprecedented accuracy for complex and big data encountered in the health sciences.",NextGen Random Forests,9383718,R01GM125072,"['Immune Regulators ', ' Immune Mediators/Modulators ', ' Immune Mediators ', ' Biomodulators ', ' Biological Response Modifiers ', ' Blood Reticuloendothelial System ', ' Blood ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' multimodality therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodality Treatment ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Confidence Intervals ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' cardiac failure ', ' Heart failure ', ' Modern Man ', ' Human ', ' Hybrids ', ' Immunotherapy ', ' immune therapy ', ' Immunologically Directed Therapy ', ' In Vitro ', ' Laboratories ', ' Language ', ' Libraries ', ' lymph nodes ', ' lymph gland ', ' Lymph node proper ', ' Lymph Node Reticuloendothelial System ', ' Methods ', ' Methodology ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Patients ', ' outcome forecast ', ' Prognosis ', ' Recommendation ', ' Computer software ', ' Software ', ' statistics ', ' T-Lymphocyte ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' Technology ', ' Thrombosis ', ' Time ', ' Trees ', ' Weight ', ' forest ', ' Guidelines ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Pump ', ' improved ', ' Clinical ', ' Java ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' data storage ', ' data retrieval ', ' Data Storage and Retrieval ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Therapeutic ', ' Atrophic ', ' Atrophy ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Benchmarking ', ' Best Practice Analysis ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Malignant neoplasm of esophagus ', ' oesophageal cancer ', ' Malignant Tumor of the Esophagus ', ' Malignant Esophageal Tumor ', ' Malignant Esophageal Neoplasm ', ' Esophagus Cancer ', ' Esophageal Cancer ', ' parallel processing ', ' Performance ', ' receptor ', ' Receptor Protein ', ' Neoadjuvant Therapy ', ' Neoadjuvant Treatment ', ' Neoadjuvant ', ' NEOADJ ', ' Induction Therapy ', ' novel ', ' Code ', ' Coding System ', ' Modeling ', ' response ', ' theories ', ' software development ', ' developing computer software ', ' develop software ', ' Data ', ' Health Sciences ', ' Receptor Activation ', ' Subgroup ', ' in vivo ', ' Cancer Patient ', ' Clinical Management ', ' Pathologic ', ' Esophageal ', ' developmental ', ' Development ', ' preclinical ', ' pre-clinical ', ' risk prediction model ', ' prognostic model ', ' computer based prediction ', ' predictive modeling ', ' distributed data ', ' designing ', ' design ', ' next generation ', ' Population ', ' Resistance ', ' resistant ', ' open source ', ' mouse model ', ' murine model ', ' therapeutic target ', ' tumor ', ' clinical practice ', ' Interagency Registry for Mechanically Assisted Circulatory Support ', ' Interagency Registry for Mechanical Circulatory Support ', ' INTERMACS ', ' clinical decision-making ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' predicting response ', ' response prediction ', ' predictor of response ', ' predictive response ', ' Time trend ', ' Trends over time ', ' Temporal trend ', ' Immune checkpoint blockade ', ' Checkpoint blockade ', ' ']",NIGMS,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,R01,2017,359872,0.05080573512344636
"Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy     DESCRIPTION (provided by applicant)     A new electrical biomarker has been identified in high resolution, intracranial electroencephalogram (iEEG) recordings, called a high frequency oscillation (HFO). Studies have suggested this biomarker has great promise to identify seizure networks and improve surgical outcomes for patients with refractory epilepsy. However, translation of HFOs to clinical practice is hampered by many factors such as spatial, temporal and inter-patient variation in HFO detection rates, false positive and false negative detections, and significant background noise. Big data approaches using large numbers of HFOs acquired from many patients are needed to quantify these effects and allow clinical usage of HFOs. This project details a plan in which the candidate's experience quantifying measurement and detection bias in massive high energy nuclear physics datasets will be combined with a multidisciplinary mentor team to address this problem. The combination of training in computational neuroscience, big data network analysis, and translational neural engineering research will be critical to approach this problem and provide a career trajectory for the candidate. The specific aims of this proposal address three specific confounding factors: 1) the false negative HFO detection rate, 2) variations in HFO features not due to epilepsy, and 3) effects of the state of vigilance on HFOs. Each of these aims involve novel big data methods and/or applications generalizable to other situations: 1) estimating false positive detection rates using a combined experimental/simulated data approach, 2) clustering and classification of distributions of data points, rather than of the data points directly, and 3) a general disambiguation statistic to assess meaningful (rather than statistical) difference between distributions.  The applicant's career goal is to become an academic researcher in the analysis and modeling of intracranial EEG data with a focus on translational epilepsy and sleep physiology research. With the rapid advancement in the resolution of clinical EEG, there is already a strong need for this type of research expertise. Thi grant will provide didactic coursework, formal research and methods training, and career guidance from an expert mentor team. The three mentors have appointments spanning Neurology, Anesthesiology, Mathematics, Statistics, Biomedical Engineering, and Electrical Engineering and Computer Science. The candidate will also build and mentor a research team and establish external collaborations.  The University of Michigan is a premier research university with strong programs and training opportunities in biomedical and physical sciences, engineering, translational and academic research, and advanced research computing. This proposal makes extensive use of the University's large computer cluster. The mentor team and an external collaborator will provide candidate access to prerecorded, deidentified data from over 150 patients, estimated to have over 40 million HFOs. The environment and mentor team will provide the training, facilities, and data for the candidate to successfully complete the proposed goals. PUBLIC HEALTH RELEVANCE    Recent advances in epilepsy research are generating very large datasets in the search for better ways to identify the region of brain responsible for generating seizures. A particular signa known as High Frequency Oscillations found in high resolution intracranial EEG shows great promise for identifying these regions, but clinicians are unable to use the signal due to confounding biases. This project combines big data processing expertise from particle physics, computer science and machine learning to address these confounds, providing a more accurate process to enable clinical translation of this new biomarker and potentially improve clinical outcomes.",Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy,9322204,K01ES026839,"['Algorithms ', ' Anesthesiology ', ' Appointment ', ' bioengineering ', ' Biomedical Engineering ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Systematics ', ' Classification ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Environment ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Future ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Grant ', ' High Frequency Oscillation ', ' Hybrids ', ' Literature ', ' Mathematics ', ' Math ', ' Mentors ', ' Mentorship ', ' Methods ', ' Michigan ', ' Motivation ', ' nervous system disorder ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' Neurology ', ' Neurosciences ', ' Noise ', ' Nuclear Energy ', ' Atomic Energy ', ' Nuclear Physics ', ' Patients ', ' physical science ', ' Physics ', ' Physiology ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Seizures ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Sleep ', ' statistics ', ' Technology ', ' Translating ', ' Translations ', ' Universities ', ' executive coaching ', ' career counselor ', ' Vocational Counseling ', ' Occupational Guidance ', ' Career Guidance ', ' Career Counseling ', ' Vocational Guidance ', ' Work ', ' Research Methods ', ' Research Methodology ', ' Dataset ', ' Data Set ', ' Custom ', ' base ', ' career ', ' computational neuroscience ', ' detector ', ' improved ', ' Area ', ' Chronic ', ' Clinical ', ' Refractory ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Training ', ' Individual ', ' Measurement ', ' Funding ', ' Collaborations ', ' Electrical Engineering ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Event ', ' Techniques ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' experience ', ' computer science ', ' relating to nervous system ', ' neural ', ' expectation ', ' novel ', ' Graph ', ' vigilance ', ' Excision ', ' resection ', ' Surgical Removal ', ' Removal ', ' Extirpation ', ' Abscission ', ' Statistical Methods ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Sampling ', ' career development ', ' computerized data processing ', ' data processing ', ' Brain region ', ' Address ', ' Data ', ' Detection ', ' Manpower and Training ', ' Resolution ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Process ', ' developmental ', ' Development ', ' Electroencephalogram ', ' Outcome ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' Impairment ', ' clinically relevant ', ' clinical relevance ', ' multidisciplinary ', ' scientific computing ', ' spatial temporal variation ', ' public health relevance ', ' patient population ', ' standard of care ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' clinical practice ', ' computer cluster ', ' signal processing ', ' Big Data ', ' BigData ', ' particle physics ', ' flavor physics ', ' training opportunity ', ' improved outcome ', ' big biomedical data ', ' terabyte ', ' clinical translation ', ' ']",NIEHS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,K01,2017,148964,0.06360992187175588
"Tracing the evolution of the human mutation rate DESCRIPTION (provided by applicant): All genetic variation is created by mutations, changes that arise due to DNA damage or copying mistakes during DNA replication. Mutations are frequent enough that, on average, a child's 3-billion base pair genome contains 74 new genetic variants that are not present in the genome of either parent. Such new mutations confer a higher disease risk than older mutations because they have not passed the test of surviving through several generations of parents and offspring. We aim to pinpoint how the human mutation rate has evolved as humans left Africa and adapted to diverse new environments across the globe.  One specific aim will follow up on my preliminary research which showed that Europeans experienced a mutation rate change after diverging from Africans and Asians. The primary evidence for this change is that European genomes have a higher burden than African or Asian genomes of the mutation type TCCTTC, where the trinucleotide ""TCC"" has experienced a mutation from ""C"" to ""T"" at its central site. We wish to and the genetic basis of this mutation rate change by looking at rare variants in mixed- ancestry Latino and African-American individuals. Specially, we will isolate young genetic variants that probably arose via mutation within the past 10-15 generations, after gene ow from Europe into the Americas had already begun. We will infer the genetic background (European, African, or Native American) upon which each new mutation arose and look for genomic regions where European ances- try correlates strongly with an excess of TCCTTC mutations. These will be the regions most likely to harbor a causal allele that changed the process of mutation accumulation in Europeans. This work has the potential to yield valuable insights into melanoma, a cancer that predominantly affects individuals of European ancestry and whose somatic mutational signature is dominated by TCCTTC.  A second specific aim is to look for other signatures of mutation rate change that have occurred within the human species or, more broadly, within the great apes. We will use a natural language processing technique called Latent Dirichlet Allocation (LDA) to identify collections of mutation types whose rates appear to be under common genetic control. A few mutation types besides TCCTTC show weak signals of rate differentiation between populations, and we will attempt to infer how many separate mutation rate change events are necessary to explain these signals. The admixture mapping technique from Specific Aim I can also be adapted to interrogate the genetic basis of other mutation rate changes that might have occurred in the recent past. These efforts should improve our understanding of the human mutation rate's genetic architecture and how mutation rates differ between populations. PUBLIC HEALTH RELEVANCE: All genetic variation is created by mutations, the copying mistakes that occasionally happen during DNA replication. There is evidence that children born with a higher burden of new mutations are at increased risk for autism, schizophrenia, and serious congenital diseases [1, 2, 3], but it is not well understood how much the human mutation rate varies and what genetic risk factors affect the mutation rate [4]. We aim to follow up on preliminary evidence that the Europeans have a higher mutation rate than Asians or Africans [5], looking for the genetic basis of this rate difference and investigating how often the mutation rate has changed during human evolution.",Tracing the evolution of the human mutation rate,9278228,F32GM116381,"['Acceleration ', ' Affect ', ' Africa ', ' Allelomorphs ', ' Alleles ', ' Americas ', ' Engineering / Architecture ', ' Architecture ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Disorder ', ' Disease ', ' DNA Injury ', ' DNA Damage ', ' Environment ', ' Europe ', ' Evolution ', ' Exhibits ', ' Genes ', ' Genome ', ' hereditary disorder ', ' genetic disorder ', ' Molecular Disease ', ' Genetic Diseases ', ' Genetic Condition ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Natural Language Processing ', ' natural language understanding ', ' Parents ', ' Pongidae ', ' great ape ', ' Apes ', ' Research ', ' Risk ', ' Risk Factors ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Employee Strikes ', ' Strikes ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' oriental ', ' Asians ', ' Generations ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' base ', ' improved ', ' Left ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' insight ', ' Individual ', ' African ', ' European ', ' Bayesian statistics ', ' Bayesian statistical inference ', ' Bayesian statistical analysis ', ' Bayesian spatial analysis ', ' Bayesian network analysis ', ' Bayesian inference ', ' Bayesian Analysis ', ' Native Americans ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Event ', ' Techniques ', ' Somatic Mutation ', ' American ', ' experience ', ' success ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' transition mutation ', ' trait ', ' Base Pairing ', ' offspring ', ' disorder risk ', ' disease risk ', ' genetic risk factor ', ' inherited factor ', ' developmental disease/disorder ', ' developmental disorder ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Cancer Biology ', ' Collection ', ' genomic region ', ' Genomic Segment ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' designing ', ' design ', ' Population ', ' public health relevance ', ' rare variant ', ' rare allele ', ' learning strategy ', ' learning method ', ' learning activity ', ' rate of change ', ' admixture mapping ', ' ']",NIGMS,STANFORD UNIVERSITY,F32,2017,36307,0.23357181072684932
"The Big DIPA: Data Image Processing and Analysis     DESCRIPTION (provided by applicant): This proposal aims to establish a national short course in Big Data Image Processing & Analysis (BigDIPA) intended to increase the number and overall skills of competent research scientists now encountering large, complex image data sources derived from cutting edge biological/biomedical research approaches. Extraction of knowledge from these imaging sources requires specialized skills and an interdisciplinary mindset. Yet effective training opportunities of this sector of the ""Big Data"" science community are glaringly underappreciated and underserved compared to other big data fields such as omics. UC Irvine is ideally suited to host a short course to address this thematic training deficit on account of the synergistic colocalization between multiple facilities, renowned for development of numerous advanced imaging techniques, and the outstanding instructional environment provided by faculty with collaborative expertise in biological image processing and computer vision, bioinformatics and high performance computational approaches.  Specifically, our BigDIPA proposal assembles an interdisciplinary alliance of faculty experts that can leverage the preeminent imaging resource facilities, such as the Laboratory of Fluorescence Dynamics (LFD) and the Beckman Laser Institute, and fuse these to ongoing campus big data initiatives, e.g. UCI's Data Science Initiative, to create a top-rated training course designed for senior graduate students, postdoctoral researchers, faculty and industry scientists from diverse scientific disciplines who have nascent interests and needs to handle BIG DATA sources beyond their current level of competency.  The course theme is focused to utilize discreet examples drawn from the analysis of complex data acquired from different microscopy imaging modalities employed to investigate dynamics in cellular and tissue processes, including signal transduction networks, development, neuroscience and biomedical applications, and that hereto where hidden or inaccessible to standard methods of analysis. Participants will be guided along the complete acquisition- processing-analysis pipeline through exposure to a coherent progression of topics and issues typically encountered when handling BIG DATA. We believe this training approach will therefore be attractive to a broad and significant untapped pool of researchers from the biological disciplines, biomedical engineering, systems biology, math, biophysics, computer science, bioinformatics and statistics who possess some, but not all, of the requisite competencies to effectively traverse the BD2K landscape. We have designed the course such that skills and experience gained by trainees will be transferable to their own research interests.  The BigDIPA course format will combine didactic lectures on the theory and foundational frameworks that underpin each step, with practical instruction on implementation and hands-on tutorials in image acquisition, large data handling, basic scripting of computational tools, image processing on high performance computing architectures, as well as feature extraction, evaluation and visualization of results. The course is designed to offer an intense learning experience delivered in a compact time frame, and opportunities to foster interdisciplinary interactions through small team exercises. Participants will also be encouraged to take advantage of pre-courses - separate and distinct training opportunities not funded by this proposal - that will be coordinated to directly precede our course. This unique format provides multiple benefits: it provides an efficient mechanism to address individual participant training deficiencies to permit a more productive experience in the BigDIPA course, adds no-cost mutual benefits to independent but synergistic programs, and facilitates recruitment of applicants who frequently feel interested but intimidated due to a perceived lack of prior adequate training.  Beyond providing an intensive on-site training course, all course materials (lecture notes, video lectures and tutorials), tutorial exercises, open source software resources and sample datasets will be made freely available through on-line distribution to maximize outreach and encourage additional contributions of curated training resources solicited from the community. PUBLIC HEALTH RELEVANCE: We propose to train and expand the cadre of researchers capable of effectively using the deluge of complex BIG DATA being generated by advanced biomedical imaging approaches. These data sources represent a rich source of complex information relevant to many scientific areas of inquiry, and are informative at multiple scales ranging from fundamental biological processes at the cellular level to patient diagnostics for diseases such as cancer or neurological disorders.",The Big DIPA: Data Image Processing and Analysis,9295026,R25EB022366,"['Engineering / Architecture ', ' Architecture ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biological Sciences ', ' bioengineering ', ' Biomedical Engineering ', ' Biomedical Research ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Biophysics ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' Communities ', ' computer vision ', ' Computer Vision Systems ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Disorder ', ' Disease ', ' Educational aspects ', ' Education ', ' Environment ', ' Exercise ', ' Faculty ', ' Fluorescence ', ' Foundations ', ' Future ', ' Goals ', ' Industry ', ' Information Sciences ', ' Institutes ', ' Laboratories ', ' Lasers ', ' Laser Radiation ', ' Laser Electromagnetic ', ' Learning ', ' Mathematics ', ' Math ', ' Methods ', ' Modernization ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' nervous system disorder ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' Neurosciences ', ' Patients ', ' Problem Solving ', ' Recruitment Activity ', ' recruit ', ' active recruitment ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Schools ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' statistics ', ' Talents ', ' Time ', ' Tissues ', ' Body Tissues ', ' Imaging Technics ', ' Imaging Procedures ', ' Imaging Techniques ', ' Multidisciplinary Communication ', ' Cross-Disciplinary Communication ', ' Interdisciplinary Communication ', ' Competence ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' image processing ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Site ', ' Area ', ' Biological ', ' Evaluation ', ' Training ', ' Discipline ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Funding ', ' Biological Function ', ' Biological Process ', ' Exposure to ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' lecture notes ', ' lectures ', ' programs ', ' Scientist ', ' Complex ', ' Stream ', ' Source ', ' interest ', ' experience ', ' Performance ', ' interdisciplinary collaboration ', ' transdisciplinary collaboration ', ' biomedical scientist ', ' computer science ', ' High Performance Computing ', ' high-end computing ', ' skills ', ' Participant ', ' NIH Program Announcements ', ' Program Announcement ', ' graduate student ', ' outreach ', ' Modality ', ' Biomedical Technology ', ' Sampling ', ' theories ', ' bioimaging ', ' biomedical imaging ', ' bio-imaging ', ' repository ', ' Bioinformatics ', ' Bio-Informatics ', ' imaging modality ', ' imaging method ', ' image-based method ', ' Address ', ' Systems Biology ', ' Data ', ' National Institute of General Medical Sciences ', ' NIGMS ', ' Research Training ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' Instruction ', ' cost ', ' Knowledge Extraction ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' Imaging technology ', ' data acquisition ', ' skill acquisition ', ' skill development ', ' open source ', ' demographics ', ' public health relevance ', ' data format ', ' biological systems ', ' flexibility ', ' flexible ', ' Big Data ', ' BigData ', ' course implementation ', ' learning materials ', ' instructional materials ', ' curricular material ', ' course material ', ' class material ', ' training opportunity ', ' Data Science ', ' Data Scientist ', ' Big Data to Knowledge ', ' BD2K ', ' microscopic imaging ', ' microscopy imaging ', ' microscope imaging ', ' big biomedical data ', ' imaging approach ', ' ']",NIBIB,UNIVERSITY OF CALIFORNIA-IRVINE,R25,2017,161997,0.08383548676080321
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",9302420,U54EB020403,"['Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Acquired Immunodeficiency Syndrome ', ' Algorithms ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Autistic Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Bipolar Disorder ', ' Encephalon ', ' Brain Nervous System ', ' Brain ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Brain Diseases ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Genes ', ' Genome ', ' Goals ', ' History ', ' Recording of previous events ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human T-Lymphotropic Virus Type III ', ' Human T-Cell Lymphotropic Virus Type III ', ' Human T-Cell Leukemia Virus Type III ', ' Human Immunodeficiency Viruses ', ' HTLV-III ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Joints ', ' Learning ', ' Mathematics ', ' Math ', ' Medicine ', ' National Institute of Mental Health ', ' NIMH ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Obsessive-Compulsive Disorder ', ' Obsessive-Compulsive Neurosis ', ' outcome forecast ', ' Prognosis ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schools ', ' Science ', ' Computer software ', ' Software ', ' Talents ', ' Training Programs ', ' Work ', ' Dataset ', ' Data Set ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuroimaging ', ' neuro-imaging ', ' novel ', ' organizational structure ', ' Organization Charts ', ' Modality ', ' AIDS/HIV problem ', ' HIV/AIDS problem ', ' HIV/AIDS ', ' AIDS/HIV ', ' chromosome 22q deletion syndrome ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' Modeling ', ' Genomics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Major Depressive Disorder ', ' major depression disorder ', ' major depression ', ' clinical depression ', ' Institution ', ' Data ', ' National Institute of Child Health and Human Development ', ' NICHD ', ' National Institute of Drug Abuse ', ' National Institute on Drug Abuse ', ' NIDA ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Research Infrastructure ', ' Infrastructure ', ' imaging ', ' Image ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' National Institute on Alcohol Abuse and Alcoholism ', ' NIAAA ', ' innovation ', ' innovative ', ' innovate ', ' multidisciplinary ', ' Computational algorithm ', ' computer algorithm ', ' multitask ', ' multi-task ', ' addiction ', ' addictive disorder ', ' public health relevance ', ' multimodality ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' Big Data ', ' BigData ', ' Genetic study ', ' web portal ', ' internet portal ', ' Data Science ', ' Data Scientist ', ' diagnostic biomarker ', ' diagnostic marker ', ' hackathon ', ' hackfest ', ' hack day ', ' Big Data to Knowledge ', ' BD2K ', ' connectome ', ' imaging study ', ' high dimensionality ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2017,2571864,0.07778723406859629
"New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis     DESCRIPTION (provided by applicant)    Maha R Farhat, MD is an Instructor of Medicine at Harvard Medical School on the tenure track and a staff physician in the Department of Pulmonary and Critical Care Medicine at Massachusetts General Hospital. She is completing a masters of biostatistics at the Harvard School of Public Health in 5/2015. She has spent the last 4.5 years acquiring skills in Mycobacterium tuberculosis biology, epidemiology, bioinformatics and biostatistics. She has experience in the analysis of whole genome sequence data, drug resistance data and patient clinical outcome data with the focus of identifying Mycobacterium tuberculosis genetic determinants of drug resistance. She has also developed new methods in this area. Dr. Farhat has 11 publications 5 of which are first author including high impact and highly cited work in the journals Nature Genetics, Genome Medicine and the International Journal of Tuberculosis and Lung Disease. The short term goals of this K01 award are to provide training for Dr. Farhat in critical aspects of data science, computational and evolutionary biology, advanced biostatistics and network science. Dr. Farhat's long term goal is to become a leader in the field of Big Data analysis for infectious diseases. The proposed research as well as the training activities outlined in the proposal will successfully position Dr. Farhat for her first R01 and an independent career as a physician scientist. Environment: Dr. Farhat will perform the interdisciplinary work outlined in this proposal at the distinguished Harvard Departments of Global Health Social Medicine, Biostatistics, Evolutionary biology and the Institute for Quantitative Social Sciences. Dr. Farhat' mentorship team will include two world renowned leaders in the fields of infectious diseases and Big Data, Dr. Megan Murray and Dr. Gary King; and two rising stars in the fields of network Science and evolutionary Biology, Dr. JP Onnela and Dr. Michael Desai. Dr. Murray, the principal mentor on this proposal has mentored over 38 trainees, 9 of which have went on to have independent research careers, and 6 competed successfully for K awards. She is also PI on two recently awarded NIH/NIAID grants a CETR U19 and a TBRU U19 and has over 350 peer reviewed publications. To complement the expertise of her mentors Dr. Farhat will be advised by Dr. Christiani a practicing pulmonary and critical care physician and world renowned researcher in the field of lung and environmental genetics. She will also collaborate and consult with Dr. Merce Crosas, a data scientist, and Dr. Pardis Sabeti, a computational biologist. She will rotate through Dr. Soumya Raychaudhuri's bioinformatics laboratory to diversify her exposure to biomedical Big Data. In addition, she will receive formal training in evolutionary biology, Bayesian and mixed-model biostatistics, computer science, leadership skills and grant writing. The collaborative opportunities, intellectual environment and resources available to Dr. Farhat are outstanding. Research: Infectious diseases continue to be a major cause of morbidity and mortality. Despite the availability of effective antimicrobials, pathogens are successfully evolving new disease phenotypes that allow them to resist killing by these drugs or in other instances cause more severe disease manifestations or wider chains of transmission. Drug resistance (DR) is now common and some bacteria have even become resistant to multiple types or classes of antibiotics6. A key strategy in the fight against emerging pathogen phenotypes in infectious diseases is surveillance, and early personalized therapy to prevent transmission and propagation of these strains. The timely initiation of antibiotic therapy to which the pathogen is sensitive has been shown to be the key factor influencing treatment outcome for a diverse array of infections. Molecular tests that rely on the detection of microbial genetic mutations are particularly promising for surveillance and diagnosis of these pathogen phenotypes but rely on a comprehensive understanding of how mutations associate with these pathogen phenotypes. Currently there is an explosion of data on pathogen whole genome sequences (WGS) that is increasingly generated from clinical laboratories. Data on disease phenotype may also be available, but methods for the analysis and interpretation of these Big Data are lagging. Here I propose tools to aid in this analysis leveraging Big Data sets from Mycobacterium tuberculosis (MTB) and my prior work. Specifically I propose to (1) develop a web-based public interface to several analysis tools, including a statistical learning model that can predict the MTB DR phenotype from its genomic sequence, (2) to develop and study an MTB gene-gene network, based on WGS data, to improve our understanding of the effect of mutation-mutation interactions on the DR phenotype, and (3) study the performance of methods in current use for the association of genotype and phenotype in pathogens, and develop a generalizable power calculator for the best performing method. PUBLIC HEALTH RELEVANCE    Infectious agents of disease are successfully evolving drug resistance and other adaptations that threaten human health. Understanding the genetic mutations that underlie these disease phenotypes can inform surveillance and diagnostic strategies to combat this threat. Here I propose to develop accessible tools for pathogen genomic analysis that will help identify which genetic mutations are relevant to disease.",New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis,9326841,K01ES026835,"['Affect ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Antibiotics ', ' Award ', ' Bacteria ', ' Biology ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Complement Proteins ', ' Complement ', ' Critical Care ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Genetic Epistasis ', ' Explosion ', ' Future ', ' Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Grant ', ' Health ', ' General Hospitals ', ' Modern Man ', ' Human ', ' Infection ', ' Institutes ', ' Laboratories ', ' Leadership ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Massachusetts ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mycobacterium tuberculosis ', ' mtb ', ' M.tuberculosis ', ' M.tb ', ' M. tuberculosis ', ' M. tb ', ' M tuberculosis ', ' M tb ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Patients ', ' Peer Review ', ' Phenotype ', ' Phylogeny ', ' Physicians ', ' Public Health ', ' Publications ', ' Scientific Publication ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' medical schools ', ' school of medicine ', ' medical college ', ' Public Health Schools ', ' Science ', ' Social Medicine ', ' Social Sciences ', ' Standardization ', ' Testing ', ' Time ', ' training module ', ' Training Activity ', ' tuberculous spondyloarthropathy ', ' infection due to Mycobacterium tuberculosis ', ' disseminated tuberculosis ', ' disseminated TB ', ' Mycobacterium tuberculosis infection ', ' Mycobacterium tuberculosis (MTB) infection ', ' MTB infection ', ' M.tuberculosis infection ', ' M.tb infection ', ' M. tuberculosis infection ', ' M. tb infection ', ' M tuberculosis infection ', ' Tuberculosis ', ' Work ', ' Writing ', ' Measures ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' Killings ', ' Magazine ', ' Journals ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Collaborations ', ' Genetic ', ' Infectious Agent ', ' infectious organism ', ' Exposure to ', ' tool ', ' Antibiotic Therapy ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Diagnostic ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' System ', ' Severity of illness ', ' disease severity ', ' instructor ', ' Consult ', ' experience ', ' gene interaction ', ' Performance ', ' computer science ', ' microbial ', ' Structure ', ' skills ', ' simulation ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' Bioinformatics ', ' Bio-Informatics ', ' prevent ', ' preventing ', ' genome sequencing ', ' Low income ', ' global health ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' International ', ' Mentored Research Scientist Development Award ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' National Institute of Allergy and Infectious Disease ', ' NIAID ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' Resolution ', ' Gene Structure/Organization ', ' Gene Organization ', ' Gene Structure ', ' Virulent ', ' Monitor ', ' Transmission ', ' transmission process ', ' Molecular ', ' disease phenotype ', ' fight against ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' designing ', ' design ', ' drug resistant in tuberculosis ', ' drug resistance Mycobacteria Tuberculosis ', ' drug resistance M Tuberculosis ', ' TB drug resistance ', ' Mtb drug resistance ', ' Drug resistant Mycobacteria Tuberculosis ', ' Drug resistant Mtb ', ' Drug resistant M Tuberculosis ', ' Drug resistance in Mycobacterium Tuberculosis ', ' Drug resistance in Mtb ', ' Drug Resistant Tuberculosis ', ' Drug Resistant TB ', ' Drug Resistance Tuberculosis ', ' Drug resistance in tuberculosis ', ' Outcome ', ' Drug-sensitive ', ' pathogen ', ' Population ', ' prospective ', ' Heritability ', ' Resistance ', ' resistant ', ' antimicrobial ', ' anti-microbial ', ' microbial genome ', ' microbes genome ', ' analytical tool ', ' Microbial Genetics ', ' Network-based ', ' combat ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' tenure track ', ' tenure process ', ' Data Science ', ' Data Scientist ', ' pathogen genome ', ' pathogenome ', ' big biomedical data ', ' whole genome ', ' entire genome ', ' genomic data ', ' ']",NIEHS,HARVARD MEDICAL SCHOOL,K01,2017,225549,0.11982491889484707
"Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing Project Summary/Abstract Clinical data collection is accelerating rapidly, and in the future it will include both provider- and patient- generated data. Hidden within this mass of noisy observational data are clues as to factors influencing disease onset and outcome. Finding ways to exploit this trove of disease data can unlock a new perspective on disease processes. We can tackle disease both from the bottom-up, from experimental data generated in the laboratory, and from the top down, from clinical phenomena observed across human populations. A particularly impactful and prevalent disease is cancer. Each tumor harbors a unique combination of mutations driving a distinct set of oncogenic processes. Targeted therapies have been proposed to pinpoint these mutations, potentially requiring a vast array of therapeutic options. Cancer treatment often fails when drug resistance arises, another result of the complex combinatorial nature of tumor alterations. Combination therapies have been proposed as an approach to interfere with multiple disease signals simultaneously. However, identifying effective drug combinations, and the cancer types in which they are effective, is experimentally infeasible, leading to a push for computational solutions. In this proposal, we combine methods from social sciences and biostatistics to find the causal effect of a drug on cancer onset from observational clinical data. Both increased and decreased cancer rates in drug-takers are of equal interest, as they can inform us of disease processes and provide clinical impact. We are particularly interested in finding drug combinations that impact cancer. These combination effects are unlikely to have been detected, and our clinical data provides a unique resource for observing the effects of tens of thousands of drug combinations. We will pool the resulting causal drug effect estimates across the many cancers present in our data. To gain insight into the cellular processes underlying clinical effect, we will examine the impact of known cancer-causing drugs in vitro, using large public cell line assays. The accompanying goal is to provide Dr. Rachel Melamed with a career development experience to become an independent scientist. Her research will use observational health data to understand the genesis of cancer, prevent the disease, and discover new therapeutic options. This proposal takes advantage of the interdisciplinary strengths of the University of Chicago in computation, biostatistics, and medicine, as well as institutional resources in terms of data access and infrastructure. Dr. Melamed has assembled a team consisting of complementary mentors and collaborators with expertise in computation, statistics, translational medicine, personalized therapy, and cancer therapy. The career development plan focuses on enhancing her statistics and machine learning skills with structured coursework and mentorship, and gaining experience in biomedical applications via applied work and mentorship. This will provide Dr. Melamed with skills to model observational data and to integrate the results with experimental data. Project Narrative Clinical data has been shown to hold patterns relating drugs to cancer onset. Using this data to find drugs that increase cancer rates will provide insight into the disease and an opportunity for preventing some cancer cases. Discovery of drugs, and particularly drug combinations, that reduce cancer rates could suggest low-cost new therapeutic options.",Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing,9324540,K01ES028055,"['anticancer drug ', ' anticancer agent ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Antineoplastic Agents ', ' driving ', ' Automobile Driving ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biological Assay ', ' Biostatistics ', ' Biometrics ', ' Biometry ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Malignant Neoplasms ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Chicago ', ' multimodality therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodality Treatment ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Data Collection ', ' Death ', ' Cessation of life ', ' Disorder ', ' Disease ', ' Drug Combinations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Gene Expression ', ' Goals ', ' Modern Man ', ' Human ', ' In Vitro ', ' Incidence ', ' Investments ', ' Joints ', ' Laboratories ', ' Libraries ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Methodology ', ' Mining ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Drug Prescriptions ', ' Drug Prescribing ', ' Research ', ' Resources ', ' Research Resources ', ' Science ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Social Sciences ', ' statistics ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Work ', ' Measures ', ' Case Series ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Link ', ' insight ', ' Individual ', ' data repository ', ' Databanks ', ' Data Bases ', ' Data Banks ', ' Databases ', ' Development Plans ', ' drug use ', ' Drug usage ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Medical History ', ' disorder onset ', ' disease onset ', ' Onset of illness ', ' cancer prevention ', ' Therapeutic ', ' cancer cell ', ' Malignant Cell ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Event ', ' Clinic ', ' Pattern ', ' interest ', ' experience ', ' life history ', ' Structure ', ' skills ', ' Disease Outcome ', ' novel ', ' disorder risk ', ' disease risk ', ' Self-control as a personality trait ', ' self control ', ' Drug Exposure ', ' Modeling ', ' career development ', ' response ', ' Adverse event ', ' Adverse Experience ', ' Adverse effects ', ' treatment adverse effect ', ' therapy adverse effect ', ' side effect ', ' Treatment Side Effects ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Provider ', ' prevent ', ' preventing ', ' Finding by Cause ', ' Data ', ' Premalignant ', ' precancerous ', ' Pre-Malignant ', ' Research Infrastructure ', ' Infrastructure ', ' in vitro Assay ', ' in vivo ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Data ', ' Molecular ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' cost ', ' Cancer cell line ', ' Population ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' Cancerous ', ' Oncogenic ', ' combinatorial ', ' clinically relevant ', ' clinical relevance ', ' clinical effect ', ' translational medicine ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' tumor ', ' gene discovery ', ' discover genes ', ' FDA approved ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' clinical predictors ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' health data ', ' clinical investigation ', ' training opportunity ', ' Learning Skill ', ' disease heterogeneity ', ' data access ', ' genomic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NIEHS,UNIVERSITY OF CHICAGO,K01,2017,124953,0.005623515458439052
"A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform     DESCRIPTION (provided by applicant): The inception of the BD2K Initiative is a testament to the foresight of NIH and our community. Clearly, the future of biomedicine rests on our collective ability to transform Big Data into intelligible scientific facts. In line with the BD2K objectives,our goal is to revolutionize how we address the universal challenge to discern meaning from unruly data. Capitalizing on our investigators' complementary strengths in computational biology and cardiovascular medicine, we will present a fusion of cutting-edge innovations that are grounded in a cardiovascular research focus, encompassing: (i) on-the-cloud data processing, (ii) crowd sourcing and text-mining data annotation, (iii) protein spatiotemporal dynamics, (iv) multi-omic integration, and (v) multiscale clinical data modeling. Drawing from our decade of experience in creating and refining bioinformatics tools, we propose to amalgamate established Big Data resources into a generalizable model for data annotation and collaborative research, through a new query system and cloud infrastructure for accessing multiple omics repositories, and through computational-supported crowdsourcing initiatives for mining the biomedical literature. We propose to interweave diverse data types for revealing biological networks that coalesce from molecular entities at multiple scales, through machine learning methods for structuring molecular data and defining relationships with drugs and diseases, and through novel algorithms for on-the-cloud integration and pathway visualization of multi-dimensional molecular data. Moreover, we propose to innovate advanced modeling tools to resolve protein dynamics and spatiotemporal molecular mechanisms, through mechanistic modeling of protein properties and 3D protein expression maps, and through Bayesian algorithms that correlate patient phenotypes, health histories, and multi-scale molecular profiles. The utility and customizability o our tools to the broader research population is clearly demonstrated using three archetypical workflows that enable annotations of large lists of genes, transcripts, proteins, or metabolites; powerful analysis of complex protein datasets acquired over time; and seamless aQoregation of diverse molecular, textual and literature data. These workflows will be rigorously validated using data from two significant clinical cohorts, the Jackson Heart Study and the Healthy Elderly Longevity (Wellderly). In parallel, a multifaceted strategy will be implemented to educate and train biomedical investigators, and to engage the public for promoting the overall BD2K initiative. We are convinced that a community-driven BD2K initiative will best realize its scientific potential and transform the research culture in a sustainable manner, exhibiting lasting success beyond the current funding period.         PUBLIC HEALTH RELEVANCE:  The challenges of biomedical Big Data are multifaceted. Biomedical investigators face daunting tasks of storing, analyzing, and distributing large-scale omics data, and aggregating all information to discern mechanistic insights. A coherent effort is required to harness disarrayed Big Data and transform them into intelligible scientific facts, whil engaging the global community via education and outreach programs. This Big Data Science Research proposal is designed to address these challenges by formulating a federated architecture of community-supported tools for enhancing data management, integration and analysis.            ",A Community Effort to Translate Protein Data to Knowledge: An Integrated Platform,9298691,U54GM114833,"['Achievement Attainment ', ' Achievement ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' Algorithms ', ' Engineering / Architecture ', ' Architecture ', ' Awareness ', ' cardiovascular disorder ', ' Cardiovascular Diseases ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cardio-vascular ', ' Cardiovascular system ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Exhibits ', ' facial ', ' faces ', ' Face ', ' Future ', ' Genes ', ' Goals ', ' Half-Life ', ' Health ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Literature ', ' Longevity ', ' lifespan ', ' life span ', ' Length of Life ', ' Maps ', ' Medicine ', ' Mining ', ' Modernization ', ' Molecular Structure ', ' Macromolecular Structure ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Patients ', ' Phenotype ', ' Proteins ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Research Proposals ', ' Resources ', ' Research Resources ', ' Rest ', ' Time ', ' Translating ', ' Generations ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Organ ', ' improved ', ' Clinical ', ' Biological ', ' Physiologic ', ' Physiological ', ' Training ', ' insight ', ' Intuition ', ' Funding ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' computer biology ', ' Knowledge ', ' Scientist ', ' Dimensions ', ' System ', ' interest ', ' Training and Education ', ' Education and Training ', ' data management ', ' experience ', ' success ', ' cohort ', ' Structure ', ' novel ', ' General Population ', ' General Public ', ' Gene Proteins ', ' Protein Gene Products ', ' Modeling ', ' outreach program ', ' Property ', ' protein protein interaction ', ' repository ', ' Bioinformatics ', ' Bio-Informatics ', ' computerized data processing ', ' data processing ', ' protein expression ', ' text searching ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' protein complex ', ' data mining ', ' datamining ', ' Address ', ' Data ', ' Education and Outreach ', ' Tutoring and Outreach ', ' Training and Outreach ', ' Instruction and Outreach ', ' Harvest ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Expression Profiling ', ' Population Research ', ' Population-level research ', ' Population-based research ', ' Protein Analysis ', ' Protein Dynamics ', ' Clinical Data ', ' Transcript ', ' Molecular ', ' Modification ', ' pathway ', ' Pathway interactions ', ' protein metabolite ', ' clinical phenotype ', ' data modeling ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' molecular scale ', ' innovation ', ' innovative ', ' innovate ', ' spatiotemporal ', ' public health relevance ', ' operation ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' Algorithmic Software ', ' Software Algorithm ', ' Algorithmic Tools ', ' Jackson Heart Study ', ' Big Data ', ' BigData ', ' clinical predictors ', ' crowdsourcing ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' learning strategy ', ' learning method ', ' learning activity ', ' support tools ', ' Data Science ', ' Data Scientist ', ' multiple omics ', ' Big Data to Knowledge ', ' BD2K ', ' data to knowledge ', ' data into knowledge ', ' big biomedical data ', ' data resource ', ' ']",NIGMS,UNIVERSITY OF CALIFORNIA LOS ANGELES,U54,2017,5294835,0.09034188012626097
"Multidimensional MRI-based Big Data Analytics to Study Osteoarthritis ABSTRACT This project outlines technical medical image processing and machine learning developments to study the pathogenesis and natural history of osteoarthritis (OA). In the past few years, the availability of public datasets that collect data such as plain radiographs, MRI genomics and patients reported outcomes has allowed the study of disease etiology, potential treatment pathways and predictors of long-range outcomes, showing an increasingly important role of the MRI. Moreover, recent advances in quantitative MRI and medical image processing allow for the extraction of extraordinarily rich arrays of heterogeneous information on the musculoskeletal system, including cartilage and bone morphology, bone shape features, biomechanics, and cartilage biochemical composition.  Osteoarthritis, being a polygenic and multifactorial disease characterized by several phenotypes, seems the perfect candidate for multidimensional analysis and precision medicine. However, accomplish this ambitious task, will require complex analytics and multifactorial data-integration from diverse assessments spanning morphological, biochemical, and biomechanical features. In this project, we propose to fill this gap developing automatic post-processing algorithms to examine cartilage biochemical compositional and morphological features and to apply new multidimensional machine learning to study OA  This Pathway to Independence award application includes a mentored career development plan to transition the candidate, Dr. Valentina Pedoia, into an independent investigator position, as well as an accompanying research plan describing the proposed technical developments for the application of big data analytics to the study of OA. The primary mentor, Dr. Sharmila Majumdar, is a leading expert in the field of quantitative MRI for the study of OA, and the co-mentors, Dr. Adam Ferguson and Dr. Ramakrishna Akella, have extensive experience in the application of machine learning and topological data analysis to big data. The diversified plan of training and the complementary background of these mentors will allow the candidate to develop a unique interdisciplinary profile in the field of musculoskeletal imaging.  The candidate, Dr. Valentina Pedoia, is currently in a post-doctoral level position (Associated Specialist) at the University of California at San Francisco (UCSF), developing MR image post-processing algorithms. The mentoring and career development plan will supplement her image processing background with valuable exposure to machine learning, big data analysis, epidemiological study design, and interdisciplinary collaboration to facilitate her transition to a medical imaging and data scientist independent investigator position. Ultimately, she aims to become a faculty member in a radiology or bioengineering institute, where she can further research technical biomedical imaging and machine learning developments applied to the musculoskeletal system. PROJECT NARRATIVE Morphological and compositional MRI quantifications are widely used tools to detect early cartilage degeneration and to study disease progression of osteoarthritis, a complex and multifactorial disorder. In this project, we propose to develop a fully automatic image post-processing pipeline and multidimensional big data analyses based on machine learning techniques, with the aim to uncover latent information from complex dataset and with the ultimate goal of setting up a platform for OA precision medicine",Multidimensional MRI-based Big Data Analytics to Study Osteoarthritis,9385849,K99AR070902,"['Algorithms ', ' Atlases ', ' Award ', ' Biological Chemistry ', ' Biochemistry ', ' biomechanical ', ' Biomechanics ', ' bioengineering ', ' Biomedical Engineering ', ' bone ', ' California ', ' Cartilaginous Tissue ', ' Cartilage ', ' Chronology ', ' computer vision ', ' Computer Vision Systems ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Disorder ', ' Disease ', ' Elements ', ' Faculty ', ' Gait ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Hybrids ', ' Institutes ', ' arthropathies ', ' joint disorder ', ' arthropathy ', ' arthropathic ', ' Joint Diseases ', ' Knee ', ' Knee joint ', ' Learning ', ' Longitudinal Studies ', ' long-term study ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Medical Imaging ', ' Mentors ', ' Musculoskeletal System ', ' locomotor system ', ' Degenerative polyarthritis ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Patient Outcomes Assessments ', ' Patient Reported Outcomes ', ' Phenotype ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Relaxation ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk Factors ', ' Role ', ' social role ', ' San Francisco ', ' Sex Characteristics ', ' Sex Differences ', ' Syndrome ', ' Time ', ' Tissues ', ' Body Tissues ', ' Universities ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Specialist ', ' Dataset ', ' Data Set ', ' Visualization ', ' Imagery ', ' Natural History ', ' base ', ' image processing ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Training ', ' Lesion ', ' soft tissue ', ' Discipline ', ' Measurement ', ' Development Plans ', ' Disease Progression ', ' Genetic ', ' Exposure to ', ' Morphology ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Knee Osteoarthritis ', ' Dimensions ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' Postdoctoral Fellow ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Early Diagnosis ', ' early detection ', ' experience ', ' parallel processing ', ' interdisciplinary collaboration ', ' transdisciplinary collaboration ', ' kinematics ', ' kinematic model ', ' member ', ' racial difference ', ' race differences ', ' Pathogenesis ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' career development ', ' bioimaging ', ' biomedical imaging ', ' bio-imaging ', ' repository ', ' Genomics ', ' Thick ', ' Thickness ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Symptoms ', ' Data ', ' Validation ', ' developmental ', ' Development ', ' musculoskeletal visualization ', ' musculoskeletal scanning ', ' musculoskeletal imaging ', ' musculoskeletal imaging/visualization/scanning ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' 3D modeling ', ' three-dimensional modeling ', ' image registration ', ' shape description ', ' shape analysis ', ' data integration ', ' designing ', ' design ', ' Outcome ', ' imaging Segmentation ', ' modifiable risk ', ' Big Data ', ' BigData ', ' precision medicine ', ' cartilage degradation ', ' cartilage degeneration ', ' quantitative imaging ', ' imaging biomarker ', ' imaging marker ', ' Data Science ', ' Data Scientist ', ' Data Analytics ', ' connectome ', ' imaging scientist ', ' ']",NIAMS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K99,2017,94041,0.060120223082710283
"Mobility Data Integration to Insight     DESCRIPTION (provided by applicant): Mobility is essential for human health. Regular physical activity helps prevent heart disease and stroke, relieves symptoms of depression, and promotes weight loss. Unfortunately, many conditions, such as cerebral palsy, osteoarthritis, and obesity, limit mobility at an enormous personal and societal cost. While vast amounts of data are available from hundreds of research labs and millions of smartphones, there is a dearth of methods for analyzing this massive, heterogeneous dataset.  We propose to establish the National Center for Mobility Data Integration to Insight (the Mobilize Center) to overcome the data science challenges facing mobility big data and biomedical big data in general. Our preliminary work identified four bottlenecks in data science, which drive four Data Science Research Cores.  The Cores include Biomechanical Modeling, Statistical Learning, Behavioral and Social Modeling, and Integrative Modeling and Prediction. Our Cores will produce novel methods to integrate diverse modeling modalities and gain insight from noisy, sparse, heterogeneous, and time-varying big data. Our data-sharing consortia, with clinical, research, and industry partners, will provide mobility data for over ten million people.  Three Driving Biomedical Problems will focus and validate our data science research.  The Mobilize Center will disseminate our novel data science tools to thousands of researchers and create a sustainable data-sharing consortium. We will train tens of thousands of scientists to use data science methods in biomedicine through our in-person and online educational programs. We will establish a cohesive, vibrant, and sustainable National Center through the leadership of an experienced executive team and will help unify the BD2K consortia through our Biomedical Computation Review publication and the Simtk.org resource portal.  The Mobilize Center will lay the groundwork for the next generation of data science systems and revolutionize diagnosis and treatment for millions of people affected by limited mobility.         PUBLIC HEALTH RELEVANCE:  Regular physical activity is essential for human health, yet a broad range of conditions impair mobility. This project will transform human movement research by developing tools for data analysis and creating software that will advance research to prevent, diagnose, and reduce impairments that limit human movement.            ",Mobility Data Integration to Insight,9333122,U54EB020405,"['Affect ', ' senior citizen ', ' over 65 Elderly ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aged 65 and Over ', ' Elderly ', ' driving ', ' Automobile Driving ', ' biomechanical ', ' Biomechanics ', ' Biomedical Research ', ' Cerebral Palsy ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Systematics ', ' Classification ', ' Clinical Study ', ' Clinical Research ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' diabetes ', ' Diabetes Mellitus ', ' Diagnosis ', ' ethical ', ' Ethics ', ' Exercise ', ' Non-Trunk ', ' Limbs ', ' Extremities ', ' Limb structure ', ' Fellowship ', ' Gait ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Human ', ' Joints ', ' Leadership ', ' Methods ', ' Mission ', ' Movement ', ' body movement ', ' Persons ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Degenerative polyarthritis ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Pathology ', ' Problem Solving ', ' Public Health ', ' Publications ', ' Scientific Publication ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Running ', ' Computer software ', ' Software ', ' stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Testing ', ' Time ', ' wt-loss ', ' body weight loss ', ' Weight Reduction ', ' Weight Loss ', ' Body Weight decreased ', ' Work ', ' Walking ', ' depressive ', ' depression symptom ', ' Emotional Depression ', ' depressive symptoms ', ' Dataset ', ' Data Set ', ' Injury ', ' base ', ' role model ', ' sensor ', ' improved ', ' Area ', ' Training ', ' Physical activity ', ' insight ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' cognitive function ', ' Scientist ', ' Complex ', ' Techniques ', ' System ', ' Overweight ', ' Over weight ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Medical center ', ' experience ', ' social model ', ' cohesion ', ' novel ', ' Prevention ', ' Modality ', ' social ', ' Modeling ', ' Cellular Phone ', ' smartphone ', ' smart phone ', ' iPhone ', ' Cellular Telephone ', ' Cell Phone ', ' prevent ', ' preventing ', ' Biomedical Computing ', ' biomedical computation ', ' Data ', ' NCI Scholars Program ', ' Scholars Program ', ' Resource Sharing ', ' Behavioral ', ' cost ', ' Behavioral Model ', ' data modeling ', ' data integration ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Impairment ', ' motor impairment ', ' movement limitation ', ' movement impairment ', ' public health relevance ', ' industry partner ', ' industry partnership ', ' industrial partnership ', ' sharing data ', ' flexibility ', ' flexible ', ' clinical decision-making ', ' Big Data ', ' BigData ', ' health data ', ' biomechanical model ', ' biomechanical simulation ', ' biomechanical modeling ', ' biomechanic simulation ', ' biomechanic modeling ', ' massive open online courses ', ' visiting scholar ', ' Data Science ', ' Data Scientist ', ' Accelerometer ', ' activity tracker ', ' activity monitor ', ' accelerometry ', ' Big Data to Knowledge ', ' BD2K ', ' improved outcome ', ' reduce symptoms ', ' symptom relief ', ' symptom reduction ', ' symptom alleviation ', ' relieves symptoms ', ' fewer symptoms ', ' decrease symptom ', ' ameliorating symptom ', ' alleviate symptom ', ' online resource ', ' web-based resource ', ' web resource ', ' on-line resource ', ' internet resource ', ' ']",NIBIB,STANFORD UNIVERSITY,U54,2017,3432966,0.037320809188723165
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9675371,K01ES028047,"['Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Award ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Basal cell carcinoma ', ' Rodent Ulcer ', ' Basiloma ', ' Basal Cell Epithelioma ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Clinical Trials ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Gene Expression ', ' Goals ', ' Primary carcinoma of the liver cells ', ' liver carcinoma ', ' Liver Cells Carcinoma ', ' Hepatoma ', ' Hepatocellular cancer ', ' Hepatocellular Carcinoma ', ' Hepatocarcinoma ', ' Mentors ', ' Methods ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Probability ', ' Research ', ' Resources ', ' Research Resources ', ' statistics ', ' Time ', ' Translating ', ' Universities ', ' Work ', ' c-myc Genes ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' Treatment outcome ', ' Data Set ', ' Dataset ', ' base ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Individual ', ' drug sensitivity ', ' data base ', ' Data Bases ', ' Databases ', ' Therapeutic ', ' Normal tissue morphology ', ' Normal Tissue ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Malignant neoplasm of liver ', ' malignant liver tumor ', ' liver cancer ', ' Hepatic Cancer ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Adopted ', ' Clinic ', ' Source ', ' Pattern ', ' System ', ' Tumor Tissue ', ' Xenograft procedure ', ' xeno-transplantation ', ' xeno-transplant ', ' Xenotransplantation ', ' Xenograft ', ' Heterologous Transplantation ', ' Heterograft ', ' Ewings sarcoma ', "" Ewing's Tumor "", "" Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor "", "" Ewing's Family of Tumours "", ' drug efficacy ', ' novel ', ' Gene Proteins ', ' Protein Gene Products ', ' Code ', ' Coding System ', ' Sampling ', ' response ', ' Proteomics ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' protein expression ', ' Tissue Sample ', ' Address ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Cancer Biology ', ' Cancer Patient ', ' nonmalignant ', ' Non-Malignant ', ' Validation ', ' Molecular ', ' preclinical ', ' pre-clinical ', ' triple-negative breast cancer ', ' TNBC ', ' triple-negative invasive breast carcinoma ', ' oncogenomics ', ' cancer genomics ', ' Cancer cell line ', ' transcriptomics ', ' murine model ', ' mouse model ', ' tumor ', ' molecular biomarker ', ' molecular marker ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' efficacy testing ', ' drug candidate ', ' sharing data ', ' BigData ', ' Big Data ', ' Precision Medicine Initiative ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' predictive marker ', ' personalized cancer treatment ', ' individualized cancer therapy ', ' personalized cancer therapy ', ' Data Scientist ', ' Data Science ', ' gene signatures ', ' genetic signature ', ' individual patient ', ' cancer clinical trial ', ' driver mutation ', ' actionable variants ', ' actionable mutation ', ' Genomic Data Commons ', ' Expression Profiling ', ' optimal therapies ', ' optimal treatments ', ' ']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2018,171217,0.13861486539432163
"ENIGMA Center for Worldwide Medicine, Imaging & Genomics     DESCRIPTION (provided by applicant): The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort bringing together 287 scientists and all their vast biomedical datasets, to work on 9 major human brain diseases: schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images, genomes, connectomes and biomarkers on an unprecedented scale, with new kinds of computation for integration, clustering, and learning from complex biodata types. ENIGMA, founded in 2009, performed the largest brain imaging studies in history (N>26,000 subjects; Stein +207 authors, Nature Genetics, 2012) screening genomes and images at 125 institutions in 20 countries. Responding to the BD2K RFA, ENIGMA'S Working Groups target key programmatic goals of BD2K  funders across the NIH, including NIMH, NIBIB, NICHD, NIA, NINDS, NIDA, NIAAA, NHGRI and FIC. ENIGMA creates novel computational algorithms and a new model for Consortium Science to revolutionize the way Big Data is handled, shared and optimized. We unleash the power of sparse machine learning, and high dimensional combinatorics, to cluster and inter-relate genomes, connectomes, and multimodal brain images to discover diagnostic and prognostic markers. The sheer computational power and unprecedented collaboration advances distributed computation on Big Data leveraging US and non-US infrastructure, talents and data. Our projects will better identify factors that resist and promote brain disease, that help diagnosis and prognosis, and identify new mechanisms and drug targets. Our Data Science Research Cores create new algorithms to handle Big Data from (1) Imaging Genomics, (2) Connectomics, and (3) Machine Learning & Clinical Prediction. Led by world leaders in the field who developed major software packages (e.g., Jieping  Ye/SLEP), we prioritize trillions of computations for gene-image clustering, distributed multi-task machine  learning, and new approaches to screen brain connections based on the Partition Problem in mathematics.  Our ENIGMA Training Program offers a world class Summer School coordinated with other BD2K Centers, worldwide scientific exchanges. Challenge-based Workshops and hackathons to stimulate innovation, and Web Portals to disseminate tools and engage scientists in Big Data science.         PUBLIC HEALTH RELEVANCE: The ENIGMA Center for Worldwide Medicine, Imaging and Genomics is an unprecedented global effort uniting 287 scientists from 125 institutions and all their vast biomedical data, to work on 9 major human brain diseases:  schizophrenia, bipolar disorder, major depression, ADHD, OCD, autism, 22q deletion syndrome, HIV/AIDS and addictions. ENIGMA integrates images from multiple modalities, genomes, connectomes and biomarkers on an unimaginable scale, with new computations to integrate, cluster, and learn from complex biodata types.            ","ENIGMA Center for Worldwide Medicine, Imaging & Genomics",9517044,U54EB020403,"['Acquired Immunodeficiency Syndrome ', ' Acquired Immunologic Deficiency Syndrome ', ' Acquired Immuno-Deficiency Syndrome ', ' Acquired Immune Deficiency Syndrome ', ' Acquired Immune Deficiency ', ' AIDS ', ' Algorithms ', ' Autistic Disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Bipolar Disorder ', ' manic depressive illness ', ' manic depressive disorder ', ' bipolar disease ', ' bipolar affective disorder ', ' Manic-Depressive Psychosis ', ' Bipolar Affective Psychosis ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Brain Diseases ', ' Intracranial Central Nervous System Disorders ', ' Intracranial CNS Disorders ', ' Encephalon Diseases ', ' Brain Disorders ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Genes ', ' Genome ', ' Goals ', ' Recording of previous events ', ' History ', ' HIV ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' Human ', ' Modern Man ', ' Joints ', ' Learning ', ' Mathematics ', ' Math ', ' Medicine ', ' National Institute of Mental Health ', ' NIMH ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Obsessive-Compulsive Disorder ', ' Obsessive-Compulsive Neurosis ', ' outcome forecast ', ' Prognosis ', ' Research ', ' Schizophrenia ', ' schizophrenic ', ' dementia praecox ', ' Schizophrenic Disorders ', ' Schools ', ' Science ', ' Computer software ', ' Software ', ' Talents ', ' Training Programs ', ' Work ', ' Data Set ', ' Dataset ', ' base ', ' brain visualization ', ' Brain imaging ', ' Clinical ', ' Training ', ' Workshop ', ' Educational workshop ', ' Collaborations ', ' Genetic ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Country ', ' success ', ' computer science ', ' neuroimaging ', ' neuro-imaging ', ' novel ', ' organizational structure ', ' Organization Charts ', ' Modality ', ' chromosome 22q deletion syndrome ', ' partial monosomy 22q ', ' monosomy 22q ', ' deletion 22q syndrome ', ' del(22q) syndrome ', ' chromosome 22q monosomy ', ' 22q- syndrome ', ' Modeling ', ' Genomics ', ' Attention deficit hyperactivity disorder ', ' attention deficit hyperactive disorder ', ' Predominantly Hyperactive-Impulsive Type Hyperactivity Disorder ', ' Predominantly Hyperactive-Impulsive Type Attention-Deficit Disorder ', ' Hyperkinetic Syndrome ', ' Hyperactivity Disorder NOS ', ' ADHD ', ' AD/HD ', ' Major Depressive Disorder ', ' major depression disorder ', ' major depression ', ' clinical depression ', ' Institution ', ' Data ', ' National Institute of Child Health and Human Development ', ' NICHD ', ' National Institute of Drug Abuse ', ' National Institute on Drug Abuse ', ' NIDA ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Research Infrastructure ', ' Infrastructure ', ' imaging ', ' Image ', ' work group ', ' working group ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' NIBIB ', ' National Institute of Biomedical Imaging and Bioengineering ', ' National Institute of Neurological Diseases and Stroke ', ' NINDS ', ' National Institute of Neurological Disorders and Stroke ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' NIAAA ', ' National Institute on Alcohol Abuse and Alcoholism ', ' innovative ', ' innovate ', ' innovation ', ' multidisciplinary ', ' computer algorithm ', ' Computational algorithm ', ' multi-task ', ' multitask ', ' addictive disorder ', ' addiction ', ' public health relevance ', ' multimodality ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' screening ', ' Drug Targeting ', ' Combinatorics ', ' BigData ', ' Big Data ', ' Genetic study ', ' internet portal ', ' web portal ', ' Data Scientist ', ' Data Science ', ' diagnostic marker ', ' diagnostic biomarker ', ' hackfest ', ' hack day ', ' hackathon ', ' BD2K ', ' Big Data to Knowledge ', ' connectome ', ' imaging study ', ' high dimensionality ', ' ']",NIBIB,UNIVERSITY OF SOUTHERN CALIFORNIA,U54,2018,1454967,0.07778723406859629
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9591863,R01GM126189,"['Algorithms ', ' Architecture ', ' Engineering / Architecture ', ' Biological Sciences ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Classification ', ' Systematics ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Diagnosis ', ' Drug Design ', ' Elements ', ' Freedom ', ' Liberty ', ' Handwriting ', ' Ions ', ' Learning ', ' Ligands ', ' Lipids ', ' Membrane Proteins ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Membrane Protein Gene ', ' Metals ', ' Methods ', ' Methodology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Physics ', ' Proteins ', ' Computer software ', ' Software ', ' Speech ', ' Thermodynamics ', ' Thermodynamic ', ' Psychological Transfer ', ' training transfer ', ' learning transfer ', ' Work ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' cofactor ', ' improved ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Site ', ' Biological ', ' Medical ', ' Chemicals ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Binding Proteins ', ' data base ', ' Data Bases ', ' Databases ', ' root ', ' Plant Roots ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Electrostatics ', ' Dimensions ', ' Complex ', ' Techniques ', ' System ', ' Membrane ', ' membrane structure ', ' mutant ', ' Free Energy ', ' models and simulation ', ' model-based simulation ', ' Future Generations ', ' Bioinformatics ', ' Bio-Informatics ', ' Binding ', ' Molecular Interaction ', ' Address ', ' Affinity ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Ligand Binding ', ' trend ', ' Characteristics ', ' developmental ', ' Development ', ' neglect ', ' next generation ', ' direct application ', ' innovative ', ' innovate ', ' innovation ', ' user-friendly ', ' multi-task ', ' multitask ', ' language processing ', ' Geometry ', ' BigData ', ' Big Data ', ' algebraic topology ', ' metallicity ', ' learning method ', ' learning activity ', ' learning strategy ', ' Data Scientist ', ' Data Science ', ' search engine ', ' high dimensionality ', ' data repository ', ' Databanks ', ' Data Banks ', ' data warehouse ', ' deep learning ', ' ']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2018,319737,0.05719381668893901
"Understanding molecular rules governing protein allostery by deep mutational scanning Project Summary/Abstract Allostery is action at a distance in proteins. It is a property by which perturbation at one site of a protein causes an effect at a distant site of the protein. As nature's biological switches allosteric proteins regulate virtually every major process including catalysis, transcription, transport and signaling. Kinases, G-protein coupled receptors and nuclear receptors are therapeutically important allosteric proteins that play a major role in human health. Disruption of allosteric communication caused by mutations in these proteins is strongly associated with many types of disease abnormalities including cancer. Since the discovery of allostery in the 1960s, the molecular mechanism by which perturbation at one end of a protein is allosterically transmitted to the other end remains a mystery. Understanding molecular rules governing allostery is a fundamental problem in protein biochemistry and biophysics. Such rules may provide a deep insight into how proteins work through interactions between residues. Current approaches to studying allostery, which are biophysical, structural or computational, have two limitations. First, they provide an incomplete picture. Allostery involves the interplay of protein dynamics, structural changes and their effects on function. Probing each independently, as most studies do, does not give a complete understanding. Structure alone cannot explain dynamics, dynamical movement does not imply functional role, and functional studies may not provide insight into the underlying molecular causes. Second, detailed mechanistic studies of individual allosteric proteins while invaluable, are tedious, and cannot be scaled up to investigate many types of allosteric proteins. As a result, unifying heuristic rules would be difficult to infer from such individual case studies. The goal of my research is to develop a generalized, scalable method integrating structure, function and dynamics to understand, quantify and predict molecular drivers of protein allostery. With allosteric transcription factors as a model system, we will determine residues important for allostery (`hotspots') and their connectivity (`pathway') by deep mutational scanning, a method for large-scale functional characterization. We establish a critical link between structure and function by computationally modeling each mutation with Rosetta. We use machine learning on this rich sequence-structure-function dataset to recognize common molecular features (van der Waals, electrostatics, hydrogen bonds etc.) of allosteric hotspot residues, to build a predictive molecular model of allostery. Thus, we integrate high-throughput functional studies, structure-based modeling and machine learning to understand molecular rules governing allostery. Any allosteric protein whose activity can be coupled to a high-throughput screen, of which there are many, is amenable to our approach. Over time as the number and diversity of allosteric protein datasets increases, we expect that the accuracy and generalizability of predictions will continuously improve. Our long-term objective is to be able to (a) predict functional impact of thousands of mutations in disease-associated allosteric proteins revealed by genome sequencing (b) discover novel allosteric sites that improve selectivity and efficacy of drugs. Project Narrative GPCRs, nuclear receptors, ion channels and kinases are allosteric proteins that alone account for 44% of all human protein drug targets. We propose to develop a broad experimental and computational platform to understand molecular mechanism of allostery. This study will pave the way to explaining how dysfunction in allosteric proteins manifests into disease, and developing `smart' (allosteric) drugs that restore normal function.",Understanding molecular rules governing protein allostery by deep mutational scanning,9562195,DP2GM132682,"['Allosteric Site ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Catalysis ', ' Communication ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Hydrogen Bonding ', ' H-bond ', ' Ion Channel ', ' Membrane Channels ', ' Ionic Channels ', ' Methods ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Movement ', ' body movement ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Play ', ' Proteins ', ' Research ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Time ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Work ', ' Case Study ', ' case report ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Site ', ' Biological ', ' Nuclear Receptors ', ' Link ', ' insight ', ' Individual ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Therapeutic ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Electrostatics ', ' Distant ', ' heuristics ', ' drug efficacy ', ' molecular modeling ', ' Molecular Models ', ' Molecular Modeling Protein/Amino Acid Biochemistry ', ' Molecular Modeling Nucleic Acid Biochemistry ', ' Structure ', ' novel ', ' G-Protein-Coupled Receptors ', ' GPCR ', ' G Protein-Coupled Receptor Genes ', ' G Protein-Complex Receptor ', ' Modeling ', ' Property ', ' high throughput screening ', ' High Throughput Assay ', ' genome sequencing ', ' Protein Biochemistry ', ' Protein/Amino Acid Biochemistry ', ' Protein Dynamics ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' virtual ', ' scale up ', ' Coupled ', ' Drug Targeting ', ' mutation scanning ', ' mutation screening ', ' ']",NIGMS,UNIVERSITY OF WISCONSIN-MADISON,DP2,2018,2146877,0.06199536125092891
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9431712,K08HL140203,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Algorithms ', ' Cardiology ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cause of Death ', ' Clinical Informatics ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Coronary Arteriosclerosis ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary heart disease ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' Elements ', ' Environment ', ' Foundations ', ' Genetic Counseling ', ' Genotype ', ' Goals ', ' Gold ', ' General Hospitals ', ' Human ', ' Modern Man ', ' Human Genetics ', ' hypercholesterolemia ', ' Hypercholesteremia ', ' Familial Hypercholesterolemia ', ' familial hyperlipoproteinemia type II ', ' familial hyperlipoproteinemia type 2 ', ' familial hypercholesteremia ', ' familial hyperbetalipoproteinemia ', ' Type II Hyperlipidemia ', ' Type 2 Hyperlipidemia ', ' Hyperlipoproteinemia Type II ', ' Hyperlipoproteinemia Type 2 ', ' Hyperbetalipoproteinemia ', ' Essential Hypercholesterolemia ', ' Institutes ', ' Internal Medicine ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Leadership ', ' Lipids ', ' Low-Density Lipoproteins ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' LDL Cholesterol Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' Massachusetts ', ' Medicine ', ' Mentorship ', ' Methods ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Phenotype ', ' Physicians ', ' Quality Control ', ' Research ', ' Risk ', ' Technology ', ' Testing ', ' Time ', ' United States ', ' Veterans ', ' Work ', ' Generations ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Healthcare ', ' health care ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' prematurity ', ' premature ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Individual ', ' African ', ' Amish ', ' European ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' Family history of ', ' Funding ', ' Ethnicity ', ' Ethnic Origin ', ' Collaborations ', ' Genetic ', ' Exposure to ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' programs ', ' Scientist ', ' Investigation ', ' Clinic ', ' Penetrance ', ' experience ', ' Gene Mutation ', ' Gene Alteration ', ' success ', ' cohort ', ' trait ', ' skills ', ' novel ', ' Prevention strategy ', ' Preventive strategy ', ' Preventative strategy ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' career development ', ' Genomics ', ' heart disease risk ', ' heart disorder risk ', ' cardiac disorder risk ', ' cardiac disease risk ', ' Pathogenicity ', ' metabolomics ', ' metabonomics ', ' metabolism measurement ', ' genome sequencing ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Preventive ', "" Bachelor's Degree "", ' Undergraduate Degree ', ' Baccalaureate Degree ', ' Data ', ' Disease Pathway ', "" Master's Degree "", ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' lifestyle factors ', ' Principal Investigator ', ' developmental ', ' Development ', ' Electronic Health Record ', ' pathway ', ' Pathway interactions ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' National Human Genome Research Institute ', ' biomed informatics ', ' biomedical informatics ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Population ', ' Prevalence ', ' Network-based ', ' human disease ', ' high risk ', ' public health relevance ', ' nongenetic ', ' non-genetic ', ' biorepository ', ' biobank ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' cloud based ', ' precision-based medicine ', ' precision medicine ', ' genomic variation ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' human genomics ', ' full genome ', ' entire genome ', ' whole genome ', ' Preventative therapy ', ' Preventive therapy ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' Risk stratification ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2018,173296,0.12289098788923597
"Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease Project Summary/Abstract Genome-wide association studies have given us many clues about the mutations that cause common genetic diseases, including autoimmune diseases like lupus and rheumatoid arthritis. However, many of the mutations implicated in disease lie outside of the genes themselves and instead lie in the regions controlling expression of the genes, and so probably contribute to disease by producing the wrong amount of the gene in the wrong tissue or at the wrong time. Mutations in regulatory regions are thought to cause disease by altering the binding of regulatory proteins to the DNA, changing the DNA sequence from one that the protein can bind to one that it cannot (or vice versa). However, the ways in which these regulatory proteins control gene expression remains incompletely understood and so it is presently difficult to understand which regulatory protein binds differently to a mutated regulatory region, or how that change in binding affects expression of the regulated genes. In fact, we still do not even know where the regulatory regions are in the tissues we think are dysfunctional in disease. This project aims to better understand how these mutations contribute to autoimmune disease by first increasing our understanding of how regulatory proteins and regulatory regions work to control when and where genes are expressed, and then applying this knowledge to understand genetic disease. First, regulatory regions will be identified in immune cells and their effects on gene expression measured so that mutations that are likely to contribute to disease (those in regulatory regions) can be identified. The relationship between regulatory proteins, regulatory sequence, and gene expression will be learned by creating millions of synthetic regulatory regions and measuring their effect on gene expression, providing many examples of binding sites for each regulatory protein from which to learn. Finally, our new understanding of gene regulation will be applied to determine which genetic mutations change regulatory protein binding and cause disease. This will help us better understand the underlying causes of disease so that new treatments can be developed that target the mutations within each person. The candidate's long term career goals are to better understand how gene regulation works in humans so that we can better understand how the sequence of the genome controls the expression of our genes. The candidate currently works at the Broad Institute, a leading institute in human genetics and genomics with the resources and personnel required of this project. In order to continue to develop as a scientist, the candidate will gain more experience teaching, publish and present his existing findings, gain the necessary skills to work with human cells, and secure a faculty position and funding so that he can continue to make a positive impact on our knowledge of the genome. Project Narrative Certain genetic diseases are thought to be caused by mutations in the DNA that alter the expression of nearby genes. This project will help us to understand how DNA sequence regulates the expression of genes, and aims to apply this knowledge to predict how and why mutations change gene expression and contribute to disease. By better understanding the fundamental causes of disease, we can better design therapeutic interventions.",Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease,9431485,K99HG009920,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Rheumatoid Arthritis ', ' rheumatic arthritis ', ' Atrophic Arthritis ', ' Autoimmune Diseases ', ' autoimmune disorder ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell Separation ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Communities ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Faculty ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Haplotypes ', ' Health ', ' Human ', ' Modern Man ', ' Human Activities ', ' Human Genetics ', ' Institutes ', ' Learning ', ' Libraries ', ' Logic ', ' Maps ', ' Methodology ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Persons ', ' Plasmids ', ' Genetic Polymorphism ', ' polymorphism ', ' Proteins ', ' Publishing ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' Resources ', ' Research Resources ', ' Specificity ', ' Educational process of instructing ', ' Teaching ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Yeasts ', ' Measures ', ' Enhancers ', ' promoter ', ' promotor ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' career ', ' improved ', ' Phase ', ' Biochemical ', ' Link ', ' Susceptibility ', ' Predisposition ', ' Training ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Binding Proteins ', ' Measurement ', ' Funding ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Immune ', ' Immunes ', ' Complex ', ' cell type ', ' System ', ' experience ', ' skills ', ' Human Cell Line ', ' disorder risk ', ' disease risk ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Therapeutic Intervention ', ' intervention therapy ', ' genetic regulatory protein ', ' regulatory gene product ', ' Regulatory Protein ', ' Regulation ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Binding ', ' Molecular Interaction ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Protein Region ', ' Resolution ', ' in vivo ', ' developmental ', ' Development ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' genome wide association study ', ' biochemical model ', ' designing ', ' design ', ' genomewide ', ' genome scale ', ' genome-wide ', ' lupus-like ', ' Secure ', ' rare allele ', ' rare variant ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' genetic predictors ', ' ATACseq ', ' ATAC-seq ', ' human genomics ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NHGRI,"BROAD INSTITUTE, INC.",K99,2018,120204,0.009154388363098736
"SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data Abstract Over 30 million people in the US suffer from genetic diseases or cancers caused by mutations of which ~15% disrupt the regulation of splicing. Alternative splicing (AS) errors have been reported in literature to drive 370 genetic diseases out of ~800 described to date. In addition, due to the recent success of FDA-approved splicing modulators like Nusinersen, along with fascinating pre- clinical results underlining the importance of AS as therapeutic targets; splicing research has become of major interest to pharmaceutical companies. Envisagenics is developing SpliceCoreTM, an innovative cloud-based software platform using biomedical big data for AS analysis to discover new therapies and biomarkers for complex diseases. Our breakthrough platform combines algorithms and databases developed and experimentally validated at Cold Spring Harbor Laboratory (CSHL): SpliceTrapTM, for the detection of splicing activity using RNA-seq data; SpliceDuoTM, for the identification of significant splicing variation across biological samples; SpliceImpact2TM, for the prioritization of biologically relevant AS variants with therapeutic potential; and TXdbTM, a splicing isoform database that connects clients proprietary data to public repositories such as the Cancer Genome Atlas (TCGA). Thanks to the Phase I award SpliceCore was adapted as a cloud-based software, accelerating scalability and adaptation to the fast- evolving market of biomedical Big Data. We now have deployed SpliceCores back-end on three cloud-service providers, increased its overall run-time by a factor of 12, developed tools to discover disease-specific AS isoforms, finalized and tested a machine-learning algorithm to predict the biological impact of AS, and experimentally validated some of our new predictions with a success rate of 82.5%. The goal for Phase II is to accelerate client acquisition through the development of user-interactive applications informed from clients feedback by substantially expanding the platforms knowledgebase and predictive functions with novel AS isoforms extracted from ~37,000 public datasets. Thus, a new version of SpliceCore will be developed to predict regulatory interactions between RNA-binding proteins and their RNA targets to assist in the interpretation of aberrant splicing factors through a collaboration with world renowned HHMI Professor Dr. Tom Tuschl from Rockefeller University and developer of Nusinersen, Professor Dr. Adrian Krainer from CSHL. Envisagenics is targeting the global bioinformatics market valued at $4 billion in 2014 with a CAGR of over 21%. SpliceCore could capture ~10% of the market, identify novel drug targets, and design RNA therapeutics from aberrant splicing events prevalent in cancer and a multitude of genetic diseases while increasing the efficiency of R&D in biopharma. Project Narrative In this SBIR Phase II, Envisagenics will advance the development of SpliceCoreTM, a cloud-based software platform for the discovery of drug-targets and biomarkers using biomedical big data. Therapeutic screens are increasingly focusing on Alternative Splicing (AS), a biological process that regulates gene-product structure and function. Strikingly, 50% of genetic diseases described in literature can be triggered by AS errors. The recent FDA approval of RNA-therapeutic compounds to correct AS errors, combined with increasingly available big datasets and groundbreaking cloud-computing provide a unique opportunity for computerized discovery of AS therapeutics. Envisagenics technology will help biomedical researchers to translate basic science into new therapeutic products for cancer and genetic diseases. By the completion of this project, we will deploy a user-friendly, secured and scalable SpliceCore software, with new functionalities ready for integration into biopharmaceutical Research & Development workflows.",SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data,9465337,R44GM116478,"['Achievement ', ' Achievement Attainment ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Amyotrophic Lateral Sclerosis ', ' Lou Gehrig Disease ', "" Gehrig's Disease "", ' Amyotrophic Lateral Sclerosis Motor Neuron Disease ', ' Award ', ' Back ', ' Dorsum ', ' Biological Products ', ' biotherapeutic agent ', ' biopharmaceutical ', ' Biological Agent ', ' Biologic Products ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Client ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' Face ', ' facial ', ' faces ', ' Feedback ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Immunoprecipitation ', ' Immune Precipitation ', ' Laboratories ', ' Literature ', ' Manuals ', ' Maps ', ' Methods ', ' Spinal Muscular Atrophy ', ' Cruveilhier disease ', ' Aran-Duchenne disease ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Dysmyelopoietic Syndromes ', ' myelodysplasia ', ' Smoldering Leukemia ', ' Refractory anaemia with excess blasts ', ' Refractory Anemia with an Excess of Blasts ', ' Myelodysplastic Syndromes ', ' Nucleotides ', ' Patients ', ' Privatization ', ' Probability ', ' Research ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Ribonucleosides ', ' Risk ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA Splicing ', ' Splicing ', ' Running ', ' Computer software ', ' Software ', ' Specificity ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Translating ', ' Universities ', ' Work ', ' Price ', ' pricing ', ' RNA-Binding Proteins ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' cross-link ', ' crosslink ', ' improved ', ' Phase ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' Failure ', ' data base ', ' Data Bases ', ' Databases ', ' Biological Function ', ' Biological Process ', ' Collaborations ', ' Therapeutic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Protein Splicing ', ' Frequencies ', ' Complex ', ' Event ', ' System ', ' interest ', ' Services ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' professor ', ' knowledge base ', ' knowledgebase ', ' fascinate ', ' Structure ', ' novel ', ' Basic Science ', ' Basic Research ', ' cancer genetics ', ' Reporting ', ' Regulation ', ' Sampling ', ' case control ', ' repository ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' drug discovery ', ' RNA-Binding Protein FUS ', ' hnRNP P2 ', ' Translocated in Liposarcoma Protein ', ' TLS Protein ', ' POMp75 Protein ', ' Fusion Protein in Myxoid Liposarcoma ', ' FUS Protein ', ' Drops ', ' Bioinformatics ', ' Bio-Informatics ', ' Pharmacologic Substance ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' data mining ', ' datamining ', ' Defect ', ' Data ', ' Detection ', ' Memorial Sloan-Kettering Cancer Center ', ' MSKCC ', ' Protein Binding Domain ', ' Protein-Protein Interaction Domain ', ' Protein Binding Motif ', ' Research Infrastructure ', ' Infrastructure ', ' Cancer Cause ', ' Cancer Etiology ', ' Small Business Innovation Research ', ' SBIR ', ' Small Business Innovation Research Grant ', ' Validation ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' preclinical ', ' pre-clinical ', ' pre-clinical study ', ' preclinical study ', ' cost ', ' computerized ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Advanced Development ', ' designing ', ' design ', ' Prevalence ', ' innovative ', ' innovate ', ' innovation ', ' user-friendly ', ' human disease ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic target ', ' commercial application ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' new therapeutic target ', ' FDA approved ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' system architecture ', ' flexible ', ' flexibility ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' Drug Targeting ', ' therapeutic RNA ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' cloud based ', ' BigData ', ' Big Data ', ' FDA Drug Approval ', ' Food and Drug Administration Drug Approval ', ' learning method ', ' learning activity ', ' learning strategy ', ' Predictive Analytics ', ' targeted biomarker ', ' GTEx ', ' Genotype-Tissue Expression Project ', ' gene product ', ' big biomedical data ', ' Cloud Service ', ' petabyte ', ' Serine/Arginine-Rich Splicing Factor 2 ', ' SRSF2 ', ' SC35 ', ' SRSF2 gene ', ' experimental research ', ' experiment ', ' experimental study ', ' service providers ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' data repository ', ' Databanks ', ' Data Banks ', ' data warehouse ', ' ']",NIGMS,"ENVISAGENICS, INC.",R44,2018,940090,0.06473209201912912
"Molecular impact of mutations in monogenic disease and cancer ABSTRACT Nextgenerationgenomescalesequencingofpatientsisnowbecomingroutinefortwoclassesofdisease:rare Mendeliantraitsandcancer.Infavorablecases,thesedataallowidentificationofrelevantmutationsandthus aiddiagnosisandtherapy.Inbothclassesofdisease,themostcommontypeofmutationismissense-single base changes that result in an amino acid substitution in a protein. Uncertainty as to the impact of these mutationsoninvivoproteinactivityhasresultedinaveryconservativeapproachtotheirinterpretationinthe clinic, so causing many missed opportunities for targeted treatment. The goal of this project is to use a combinationofthreestrategiestomaketheinterpretationofthesemutationsmuchmoreapplicableintheclinic. Therearealreadyalargenumberofcomputationalmethodsthatattempttodeterminetheimpactofmissense mutationsonfunction,andthereissubstantialevidencethatthesehaveusefulaccuracy.Theprimarydifficulty isthattheaccuracyinanyparticularcaseisnotreliablycalibrated.Therefore,ourfirstaimistouseacombination ofthesemethodstodevelopanapproachfocusedonmorereliableestimatesfortheprobabilityofhighimpact on protein function (i.e. more confident P values). The second aim is to maximize the utilization of three- dimensionalstructuralinformation,largelyignoredbymostcomputationalmethods.Alargefractionofmissense mutationsintheseclassesofdiseaseactbydestabilizingproteinstructureandknowledgeofstructureallows thesetobeidentifiedwithmuchhigherreliability.Also,structureprovidesaframeworkfordetailedannotation andcomprehensionoffunction.Tofacilitatetheutilizationofstructure,wewillimplementamodelingplatform thatleveragesavailableexperimentalinformationtomaximizethestructuraldataavailableforanalyzingmutation impact. An important aspect of the platform is incorporation of methods for evaluating the reliability of the structuralfeaturesrelevanttoanalysisofeachmutation.Inthethirdaimwewillbuildspecificfunctionalmodels foreachproteinofinterest,integratinginformationfromcurrentdatabases,theliterature,andcommunityinput, soastoprovidetherichestpossiblebackgroundagainstwhichtojudgetheimpactofmutations.Proteopedia,a wellestablishedmediawikiforproteins,willbeusedtoprovideanintegratedviewoftext,data,andstructure.A keycomponentoftheinformationresourcewillbecontributionsfromcurators,whowillprovideannotationand alsosolicitinputfromotherexperts.Thisaspectoftheprojectbuildsonexperiencewithothercrowdsourcing endeavors, including CASP, CAGI and Proteopedia.  There will be three primary outcomes from the project: First,improvedreliabilityfortheinterpretationofmissensemutations.Second,aprototypemutationannotation proceduresuitableforuseinaclinicalsetting.Third,theresourcewillprovideinformationofbenefittoarange ofotherscientists,thusfacilitatingtheanalysisofdiseaserelatedmutations.  NARRATIVE Genome scale DNA sequencing is now contributing to diagnosis and therapy in cases of rare human diseaseandcancer.Fullexploitationofthesedataiscurrentlyhamperedbyinadequateunderstanding ofwhichDNAchangesaffectproteinfunctionsoastocontributetodisease.Thisprojectaimstodevelop themethodsandtoolsneededtoremovethatobstacle.",Molecular impact of mutations in monogenic disease and cancer,9504498,R01GM120364,"['Affect ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Goals ', ' Literature ', ' Methods ', ' Structural Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Play ', ' Probability ', ' Proteins ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Uncertainty ', ' doubt ', ' Comprehension ', ' Protein Domains ', ' Peptide Domain ', ' Tertiary Protein Structure ', ' base ', ' improved ', ' Procedures ', ' Clinical ', ' data base ', ' Data Bases ', ' Databases ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Consensus ', ' Knowledge ', ' Scientist ', ' Dimensions ', ' Clinic ', ' Amino Acid Substitution ', ' interest ', ' AIDS therapy ', ' experience ', ' AIDS diagnosis ', ' Missense Mutation ', ' trait ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' Structure ', ' Reporting ', ' Mutation Analysis ', ' Modeling ', ' protein protein interaction ', ' Address ', ' protein structure ', ' Data ', ' Information Resources ', ' knowledge resources ', ' knowledge resource ', ' information resource ', ' in vivo ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' Molecular ', ' Process ', ' Text ', ' protein function ', ' next generation ', ' clinical relevance ', ' clinically relevant ', ' wiki ', ' human disease ', ' prototype ', ' primary outcome ', ' genomewide ', ' genome scale ', ' genome-wide ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' crowdsource ', ' crowd-sourcing ', ' crowd source ', ' crowdsourcing ', ' learning method ', ' learning activity ', ' learning strategy ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' human model ', ' ']",NIGMS,"UNIV OF MARYLAND, COLLEGE PARK",R01,2018,336086,0.21110553409641228
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9359994,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' apraxia ', ' Dyspraxia ', ' Breathing ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Ataxia ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' Cell Culture Techniques ', ' cell culture ', ' Cells ', ' Cell Body ', ' Cultured Cells ', ' Cilia ', ' Cytoplasmic Granules ', ' granule ', ' Disease ', ' Disorder ', ' Electrons ', ' Negatrons ', ' Negative Beta Particle ', ' Embryo ', ' Embryonic ', ' Face ', ' facial ', ' faces ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Human ', ' Modern Man ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Muscle hypotonia ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Resources ', ' Research Resources ', ' Risk ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Sonication ', ' Mass Spectrum Analysis ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' data base ', ' Data Bases ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Three-dimensional analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' discover genes ', ' gene discovery ', ' population based ', ' stem cell biology ', ' genomewide ', ' genome scale ', ' genome-wide ', ' exomes ', ' exome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' CRISPR/Cas system ', ' CRISPR ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' accurate diagnosis ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' consanguineous family ', ' full genome ', ' entire genome ', ' whole genome ', ' recruit ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2018,510012,0.16355562859239955
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9518680,R01CA208517,"['Affect ', ' Age ', ' ages ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', "" Alzheimer's Disease "", ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', ' Back ', ' Dorsum ', ' Biology ', ' Brain Neoplasms ', ' tumors in the brain ', ' Brain Tumors ', ' Brain Neoplasia ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell growth ', ' Cellular Growth ', ' Cellular Expansion ', ' Cells ', ' Cell Body ', ' Communities ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Diagnosis ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environmental Exposure ', ' Gene Expression ', ' Gene Frequency ', ' allelic frequency ', ' Allele Frequency ', ' Genes ', ' Genome ', ' Genotype ', ' In Vitro ', ' leukemia ', ' Light ', ' Photoradiation ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Methodology ', ' Minor ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Proteins ', ' Risk ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Smoking ', ' Syndrome ', ' Testing ', ' Transforming Growth Factor beta ', ' Transforming Growth Factor-Beta Family Gene ', ' TGF ', ' TGFbeta ', ' TGF- ', ' TGF-beta ', ' TGF B ', ' Platelet Transforming Growth Factor ', ' Milk Growth Factor ', ' Bone-Derived Transforming Growth Factor ', ' Weight ', ' Generations ', ' Measures ', ' Data Set ', ' Dataset ', ' base ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Training ', ' insight ', ' Individual ', ' p16INK4A Protein ', ' p16INK4 Protein ', ' p16-INK4 ', ' p16(INK4A) ', ' Protein p16 ', ' Protein MTS1 ', ' Protein CDKN2 ', ' Multiple Tumor Suppressor-1 ', ' INK4A Protein ', ' INK4A Gene Product ', ' Cyclin-Dependent Kinase Inhibitor p16 ', ' Cyclin-Dependent Kinase Inhibitor p12 ', ' Cell Cycle Negative Regulator Beta ', ' Cdk4-Associated Protein p16 ', ' CDKN2A Protein ', ' CDK4 Inhibitor ', ' Cyclin-Dependent Kinase Inhibitor 2A ', ' Genetic ', ' tool ', ' Malignant neoplasm of pancreas ', ' Pancreatic Cancer ', ' Pancreas Cancer ', ' Malignant Pancreatic Neoplasm ', ' Knowledge ', ' Inherited ', ' Hereditary ', ' Pattern ', ' Penetrance ', ' CDKN2A gene ', ' p16INK4a ', ' p16INK4A Genes ', ' p16INK4 Genes ', ' p16 Genes ', ' p14ARF ', ' TSG9A ', ' TP16 ', ' MTS1 Genes ', ' MTS1 ', ' INK4A ', ' INK4 ', ' Cyclin-Dependent Kinase Inhibitor 2A Gene ', ' CMM2 ', ' CDKN2A ', ' CDKN2 Genes ', ' CDKN2 ', ' CDK4I ', ' interest ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' Performance ', ' receptor ', ' Receptor Protein ', ' kindred ', ' Biological Neural Networks ', ' neural network ', ' novel ', ' member ', ' genetic analysis ', ' Genetic analyses ', ' Code ', ' Coding System ', ' Modeling ', ' Proteomics ', ' Cancer-Predisposing Gene ', ' Cancer Susceptibility Gene ', ' protein expression ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' tumorigenesis ', ' Oncogenesis ', ' Address ', ' Sun Exposure ', ' sunlight exposure ', ' solar exposure ', ' metaplastic cell transformation ', ' Cellular Transformation ', ' Data ', ' in vivo ', ' in vivo Model ', ' cancer specific gene mutation ', ' Cancer Gene Mutation ', ' Cell Cycle Progression ', ' gene modification ', ' Gene-Modified ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Transmission ', ' transmission process ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' epigenomics ', ' feeding ', ' tumor genome ', ' cancer cell genome ', ' cancer genome ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' innovative ', ' innovate ', ' innovation ', ' Oncogenic ', ' next generation diagnostics ', ' new diagnostics ', ' novel diagnostics ', ' network models ', ' mutation carrier ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' genome-wide analysis ', ' overexpress ', ' over-expression ', ' overexpression ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' novel therapeutic intervention ', ' genomewide ', ' genome scale ', ' genome-wide ', ' nongenetic ', ' non-genetic ', ' Epidemiology data ', ' Epidemiological data ', ' epidemiologic data ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' BeadChip ', ' bead chip ', ' high dimensionality ', ' deep learning ', ' ']",NCI,MAYO CLINIC ROCHESTER,R01,2018,601292,0.16502161454881356
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9518337,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' ATGN ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Chromatin ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Immunoglobulin Hypervariable Region ', ' Hypervariable Regions ', ' Hypervariable Loop ', ' Complimentarity Determining Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Transgenic Mice ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' GTP-Binding Protein alpha Subunits, Gs ', ' -Gs ', ' alpha-Gs ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' Stimulatory Gs G-Protein ', ' Regulatory Ns Protein ', ' Gs ', ' Gs ', ' Gs alpha Family G-Protein ', ' GTP-Binding Protein  Subunits, Gs ', ' G(s) ', ' G(s)alpha ', ' G(s),  Subunit ', ' G(s), alpha Subunit ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Infectious Agent ', ' infectious organism ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair enzyme ', ' repair endonuclease ', ' Human Cell Line ', ' response ', ' Immunoglobulin Somatic Hypermutation ', ' somatic hypermutation ', ' Ig Somatic Hypermutation ', ' activation-induced cytidine deaminase ', ' activation-induced deaminase ', ' CDA2 protein ', ' AID protein ', ' AID gene ', ' AICDA protein ', ' AICDA ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' Influenza HA ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experimental research ', ' experiment ', ' experimental study ', ' recruit ', ' ']",NIAID,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",R01,2018,537909,0.15225722621024226
"Probing Hidden Conformational Space and Dynamical States of Circadian Clock Proteins through Rigid Residue Scan and Machine Learning Protein dynamical distribution as ensemble in their phase space is directly linked to allostery. Some triggering events, such as binding process or chemical modification, could cause significant change of protein conformation as well as dynamics distribution. These led to two complementary allosteric models: conformation-driven and dynamics-driven allostery. Mutations of certain amino acid residues could alter distribution of protein conformation or dynamics, and regulate its allosteric function. This suggests that overall space for conformational and dynamical distribution potentially accessible for certain protein is much larger than those of specific structure, such as wild type. Certain perturbation including mutation could cause protein to dwell in additional (referred as hidden) conformational space or dynamical states. Therefore, directing proteins into these hidden states could serve as a novel approach in protein engineering. We propose to apply rigid residue scan method recently developed in our lab and machine learning models for data mining to systematically explore hidden conformational space and dynamical states of proteins with quantitative evaluations based on individual residue assessment. Our long-term goal is to exploit hidden conformational spaces and dynamical states of proteins and develop precise regulations of protein allostery and function. Two parallel and complementary specific aims are proposed to test our hypothesis that many proteins have hidden conformational space and dynamical states inaccessible to the wild type but could be accessed through certain perturbation, and that additional space and states lead to precise allostery regulation or even new protein functions. In Aim 1, we propose to identify residues guiding conformational driven allostery to reach certain hidden conformational space for conformation driven allosteric circadian clock proteins. We will apply rigid residue scan method to efficiently sample hidden conformational space, and develop dimension deduction and Markov state model to theoretically describe protein conformational space. We will also apply machine learning and feature selection methods to develop classification model to quantitatively measure the conformation driven allostery. In Aim 2, we propose to identify residues of dynamics driven allosteric protein as keys to reach hidden dynamical states for dynamics driven allosteric circadian clock proteins. Similarly, we will apply rigid residue scan method to efficiently sample hidden dynamical space, and apply machine learning and feature selection methods to quantitatively measure the dynamics driven allostery. Mutants will be designed for the identified key residues in both aims. These mutants will be subjected to further molecular simulation for validation purpose. Only those computationally validated mutants will be subject to experimental test. We expect that the proposed research will lead to a novel theoretical model of protein allostery and provide computational tools to quantitatively predict the impacts on protein allostery from specific residue, which could benefit experimental study of the circadian clock proteins to design mutants as novel optogenetic tools. Narratives Protein allostery regulates protein functional activities by perturbation at a distant site. Allosteric modulation has become a novel approach to develop optogenetic tools to control biological processes. Here we propose to exploit hidden conformational spaces and dynamical states of proteins and develop precise regulations of protein allostery and function. Our efforts will lead to a novel theoretical model of protein allostery and provide computational tools to quantitatively predict the impacts on protein allostery from specific residue. This could greatly benefit experimental study of the circadian clock proteins to design mutants with new allosteric states as optogenetic tools. ",Probing Hidden Conformational Space and Dynamical States of Circadian Clock Proteins through Rigid Residue Scan and Machine Learning,9516538,R15GM122013,"['Allosteric Regulation ', ' Amino Acids ', ' aminoacid ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cells ', ' Cell Body ', ' Classification ', ' Systematics ', ' Deductibles ', ' Disease ', ' Disorder ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Methods ', ' Methodology ', ' Theoretical model ', ' Theoretic Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Protein Conformation ', ' Protein Engineering ', ' protein design ', ' genetic protein engineering ', ' Proteins ', ' Quantitative Evaluations ', ' Research ', ' Testing ', ' Work ', ' Measures ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' base ', ' Procedures ', ' Site ', ' Phase ', ' Link ', ' Chemicals ', ' Evaluation ', ' Individual ', ' Biological Function ', ' Biological Process ', ' Collaborations ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Dimensions ', ' Event ', ' Scanning ', ' Distant ', ' Clock protein ', ' mutant ', ' Structure ', ' simulation ', ' novel ', ' Regulation ', ' Modeling ', ' Sampling ', ' protein distribution ', ' drug discovery ', ' Binding ', ' Molecular Interaction ', ' Effectiveness ', ' data mining ', ' datamining ', ' Data ', ' Measurable ', ' Protein Dynamics ', ' Validation ', ' Molecular ', ' Process ', ' Modification ', ' protein function ', ' computational studies ', ' computer studies ', ' virtual ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' circadian clock ', ' circadian pacemaker ', ' optogenetics ', ' experimental research ', ' experiment ', ' experimental study ', ' ']",NIGMS,SOUTHERN METHODIST UNIVERSITY,R15,2018,355094,0.03279597511988249
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases Project Summary (unchanged) Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically on and off state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by a diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are:  To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity  To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. Health Narrative (unchanged) Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9700377,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' inhibitor/antagonist ', ' inhibitor ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell growth ', ' Cellular Growth ', ' Cellular Expansion ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Recurrence ', ' Recurrent ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Time ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' developmental ', ' Development ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2018,74718,0.17732211395365816
"Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership     DESCRIPTION (provided by applicant): The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The aims to achieve the goals are: 1) Implement an integrated didactic program to enhance student self-efficacy with computational and informatics tool development and use for interrogating and interpreting Big Data, including a two-semester bioinformatics course in Bioinformatics, informed by the expertise of UIUC KnowEnG BD2K Center faculty with additional Special Topics courses available remotely from UIUC. 2) Develop an integrated academic year (Fisk, or partners) and summer research program at the UIUC KnowEnG BD2K Center to assure student exposure to a participation in the life cycle of a `Big Data' research problem. 3) Implement a professional skills development program that assures successful transition of undergraduate participants to a Ph.D. (or MD/PhD Program) in Big Data- reliant biomedical research. 4) Launch a faculty development program in bioinformatics that leads to embracing Big Data problems in courses in multiple disciplines for impact on all Fisk undergraduate STEM majors. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fisk R25 mentors, of value for their broader education and research training goals at UIUC and Mayo. PUBLIC HEALTH RELEVANCE: The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fis R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.  ",Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership,9503633,R25MD010396,"['Biochemistry ', ' Biological Chemistry ', ' Biomedical Research ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Career Choice ', ' career track ', ' career pathway ', ' career interest ', ' career aspiration ', ' Career Path ', ' Communication ', ' Complement ', ' Complement Proteins ', ' Computers ', ' Educational Curriculum ', ' lesson plans ', ' Curriculum ', ' Elements ', ' Faculty ', ' Goals ', ' Grant ', ' Illinois ', ' Learning ', ' Life Cycle Stages ', ' life course ', ' Life Cycle ', ' Literature ', ' Mathematics ', ' Math ', ' Mentors ', ' Molecular Biology ', ' DNA Molecular Biology ', ' Program Development ', ' Reading ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Science ', ' Students ', ' Technology ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Writing ', ' Magazine ', ' Journals ', ' base ', ' career ', ' Biological ', ' Chemicals ', ' Training ', ' Discipline ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' Development Plans ', ' Funding ', ' Collaborations ', ' Exposure to ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' posters ', ' programs ', ' Cellular biology ', ' cell biology ', ' Scientist ', ' Oral ', ' Training and Education ', ' Education and Training ', ' experience ', ' computer science ', ' Informatics ', ' Base Pairing ', ' Self Efficacy ', ' Manuscripts ', ' skills ', ' Participant ', ' Research Ethics ', ' Proteomics ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Address ', ' Systems Biology ', ' Core Facility ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Education Projects ', ' R25 Program ', ' R25 Mechanism ', ' Research Training ', ' underrepresentation of minorities ', ' under-represented minority ', ' under-representation of minorities ', ' Underrepresented Ethnic Minority ', ' Underrepresented Minority ', ' innovative ', ' innovate ', ' innovation ', ' data acquisition ', ' skill development ', ' skill acquisition ', ' tool development ', ' public health relevance ', ' responsible research conduct ', ' sharing data ', ' STEM major ', ' STEM discipline ', ' STEM course ', ' STEM class ', ' STEM field ', ' teacher development ', ' instructor training ', ' faculty professional development ', ' faculty development ', ' Teacher Training ', ' Teacher Preparation ', ' Teacher Educator ', ' Teacher Education ', ' Faculty Training ', ' Faculty Education ', ' Teacher Professional Development ', ' undergraduate ', ' undergraduate student ', ' undergraduate research ', ' BigData ', ' Big Data ', ' faculty panel ', ' faculty conference ', ' Teacher Workshop ', ' Faculty Seminar ', ' Faculty Workshop ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' faculty research ', ' summer research ', ' BD2K ', ' Big Data to Knowledge ', ' minority scientist ', ' Articulation ', ' recruit ', ' deep learning ', ' ']",NIMHD,FISK UNIVERSITY,R25,2018,216000,0.12163881736249535
"Adapting the Berkeley Big Data Analytics Stack to Genomics and Health Project Summary We propose building a computational platform based on the high performance Berkeley Big Data Analytics Stack (BDAS) to support a new ecosystem of Clinical Decision Support (CDS) applications. This platform will make it faster, easier, and less expensive to develop molecular Clinical Decision Support Systems. These systems require real-time queries of globally distributed data, efficient machine learning on large genomic datasets, and must be secure, fault-tolerant and scalable. BDAS and associated technologies are designed to help us meet these challenges and are therefore ideal building blocks to help us create our computational platform. To encourage the adoption of standards for the querying and sharing of large genomic datasets, we will adapt the BDAS stack to support the standards of the Global Alliance for Genomics and Health (GA4GH). Project Narrative Funding this work will help establish a production quality FOSS implementation of the important Global Alliance for Genomics and Health standards. Without such open-source implementations, a fragmented and proprietary platform ecosystem would slow down innovation as well as divert resources away from the practice of medicine.",Adapting the Berkeley Big Data Analytics Stack to Genomics and Health,9566212,R44GM119858,"['Adoption ', ' Algorithms ', ' Capital ', ' Communities ', ' health care delivery ', ' health services delivery ', ' Healthcare Delivery ', ' Distributed Systems ', ' Feedback ', ' Genome ', ' Health ', ' Industrialization ', ' Industry ', ' Institutes ', ' Leadership ', ' Maintenance ', ' Medicine ', ' Phenotype ', ' Production ', ' Publications ', ' Scientific Publication ', ' Resources ', ' Research Resources ', ' Running ', ' Computer software ', ' Software ', ' Software Tools ', ' Computer Software Tools ', ' Technology ', ' Time ', ' Work ', ' Measures ', ' Businesses ', ' symposium ', ' symposia ', ' summit ', ' convention ', ' conference ', ' Data Set ', ' Dataset ', ' Ecological Systems ', ' Ecologic Systems ', ' Ecosystem ', ' base ', ' Phase ', ' Variation ', ' Variant ', ' Ensure ', ' Training ', ' Ingestion ', ' Individual ', ' Policies ', ' Funding ', ' Collaborations ', ' Letters ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Source ', ' System ', ' Clinical Decision Support Systems ', ' Services ', ' Performance ', ' Genomics ', ' Provider ', ' Contractor ', ' Data ', ' International ', ' Collection ', ' Small Business Innovation Research ', ' SBIR ', ' Small Business Innovation Research Grant ', ' Molecular ', ' web-based service ', ' web services ', ' distributed data ', ' distributed computing ', ' datagrid ', ' data grid ', ' cluster computing ', ' designing ', ' design ', ' innovative ', ' innovate ', ' innovation ', ' open source ', ' commercialization ', ' Secure ', ' operation ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' BigData ', ' Big Data ', ' precision-based medicine ', ' precision medicine ', ' Data Analytics ', ' individual patient ', ' BD2K ', ' Big Data to Knowledge ', ' full genome ', ' entire genome ', ' whole genome ', ' cloud server ', ' cloud platform ', ' genomic data ', ' petabyte ', ' Apache ', ' clinical decision support ', ' ']",NIGMS,"CUROVERSE INNOVATIONS, INC.",R44,2018,999701,0.060768754747124974
"Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing Project Summary/Abstract Clinical data collection is accelerating rapidly, and in the future it will include both provider- and patient- generated data. Hidden within this mass of noisy observational data are clues as to factors influencing disease onset and outcome. Finding ways to exploit this trove of disease data can unlock a new perspective on disease processes. We can tackle disease both from the bottom-up, from experimental data generated in the laboratory, and from the top down, from clinical phenomena observed across human populations. A particularly impactful and prevalent disease is cancer. Each tumor harbors a unique combination of mutations driving a distinct set of oncogenic processes. Targeted therapies have been proposed to pinpoint these mutations, potentially requiring a vast array of therapeutic options. Cancer treatment often fails when drug resistance arises, another result of the complex combinatorial nature of tumor alterations. Combination therapies have been proposed as an approach to interfere with multiple disease signals simultaneously. However, identifying effective drug combinations, and the cancer types in which they are effective, is experimentally infeasible, leading to a push for computational solutions. In this proposal, we combine methods from social sciences and biostatistics to find the causal effect of a drug on cancer onset from observational clinical data. Both increased and decreased cancer rates in drug-takers are of equal interest, as they can inform us of disease processes and provide clinical impact. We are particularly interested in finding drug combinations that impact cancer. These combination effects are unlikely to have been detected, and our clinical data provides a unique resource for observing the effects of tens of thousands of drug combinations. We will pool the resulting causal drug effect estimates across the many cancers present in our data. To gain insight into the cellular processes underlying clinical effect, we will examine the impact of known cancer-causing drugs in vitro, using large public cell line assays. The accompanying goal is to provide Dr. Rachel Melamed with a career development experience to become an independent scientist. Her research will use observational health data to understand the genesis of cancer, prevent the disease, and discover new therapeutic options. This proposal takes advantage of the interdisciplinary strengths of the University of Chicago in computation, biostatistics, and medicine, as well as institutional resources in terms of data access and infrastructure. Dr. Melamed has assembled a team consisting of complementary mentors and collaborators with expertise in computation, statistics, translational medicine, personalized therapy, and cancer therapy. The career development plan focuses on enhancing her statistics and machine learning skills with structured coursework and mentorship, and gaining experience in biomedical applications via applied work and mentorship. This will provide Dr. Melamed with skills to model observational data and to integrate the results with experimental data. Project Narrative Clinical data has been shown to hold patterns relating drugs to cancer onset. Using this data to find drugs that increase cancer rates will provide insight into the disease and an opportunity for preventing some cancer cases. Discovery of drugs, and particularly drug combinations, that reduce cancer rates could suggest low-cost new therapeutic options.",Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing,9482427,K01ES028055,"['Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Chicago ', ' Combined Modality Therapy ', ' multimodality therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodality Treatment ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Data Collection ', ' Cessation of life ', ' Death ', ' Disease ', ' Disorder ', ' Drug Combinations ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Environment ', ' Epidemiology ', ' epidemiological ', ' epidemiologic ', ' Future ', ' Gene Expression ', ' Goals ', ' Human ', ' Modern Man ', ' In Vitro ', ' Incidence ', ' Investments ', ' Joints ', ' Laboratories ', ' Libraries ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Methodology ', ' Mining ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Drug Prescriptions ', ' Drug Prescribing ', ' Research ', ' Resources ', ' Research Resources ', ' Science ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Social Sciences ', ' statistics ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Work ', ' Measures ', ' Case Series ', ' base ', ' Area ', ' Clinical ', ' prematurity ', ' premature ', ' Link ', ' insight ', ' Individual ', ' data base ', ' Data Bases ', ' Databases ', ' Development Plans ', ' drug use ', ' Drug usage ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Medical History ', ' disorder onset ', ' disease onset ', ' Onset of illness ', ' cancer prevention ', ' Therapeutic ', ' cancer cell ', ' Malignant Cell ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Event ', ' Clinic ', ' Pattern ', ' interest ', ' experience ', ' life history ', ' Structure ', ' skills ', ' Disease Outcome ', ' novel ', ' disorder risk ', ' disease risk ', ' Drug Exposure ', ' Modeling ', ' career development ', ' response ', ' Adverse event ', ' Adverse Experience ', ' Adverse effects ', ' treatment adverse effect ', ' therapy adverse effect ', ' side effect ', ' Treatment Side Effects ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Provider ', ' prevent ', ' preventing ', ' Finding by Cause ', ' Data ', ' Premalignant ', ' precancerous ', ' Pre-Malignant ', ' Research Infrastructure ', ' Infrastructure ', ' in vitro Assay ', ' in vivo ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Data ', ' Molecular ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' cost ', ' Cancer cell line ', ' Population ', ' cancer type ', ' innovative ', ' innovate ', ' innovation ', ' Cancerous ', ' Oncogenic ', ' combinatorial ', ' clinical relevance ', ' clinically relevant ', ' clinical effect ', ' translational medicine ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' tumor ', ' discover genes ', ' gene discovery ', ' FDA approved ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' clinical predictors ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted treatment ', ' health data ', ' clinical investigation ', ' training opportunity ', ' Learning Skill ', ' disease heterogeneity ', ' data access ', ' genomic data ', ' experimental research ', ' experiment ', ' experimental study ', ' ']",NIEHS,UNIVERSITY OF CHICAGO,K01,2018,124953,0.005623515458439052
"Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data Big data is now ubiquitous in every field of modern scientific research. Many contemporary applications, such as the recent national microbiome initiative (NMI), greatly demand highly flexible statistical machine learning methods that can produce both interpretable and reproducible results. Thus, it is of paramount importance to identify crucial causal factors that are responsible for the response from a large number of available covariates, which can be statistically formulated as the false discovery rate (FDR) control in general high-dimensional nonlinear models. Despite the enormous applications of shotgun metagenomic studies, most existing investigations concentrate on the study of bacterial organisms. However, viruses and virus-host interactions play important roles in controlling the functions of the microbial communities. In addition, viruses have been shown to be associated with complex diseases. Yet, investigations into the roles of viruses in human diseases are significantly underdeveloped. The objective of this proposal is to develop mathematically rigorous and computationally efficient approaches to deal with highly complex big data and the applications of these approaches to solve fundamental and important biological and biomedical problems. There are four interrelated aims. In Aim 1, we will theoretically investigate the power of the recently proposed model-free knockoffs (MFK) procedure, which has been theoretically justified to control FDR in arbitrary models and arbitrary dimensions. We will also theoretically justify the robustness of MFK with respect to the misspecification of covariate distribution. These studies will lay the foundations for our developments in other aims. In Aim 2, we will develop deep learning approaches to predict viral contigs with higher accuracy, integrate our new algorithm with MFK to achieve FDR control for virus motif discovery, and investigate the power and robustness of our new procedure. In Aim 3, we will take into account the virus-host motif interactions and adapt our algorithms and theories in Aim 2 for predicting virus-host infectious interaction status. In Aim 4, we will apply the developed methods from the first three aims to analyze the shotgun metagenomics data sets in ExperimentHub to identify viruses and virus-host interactions associated with several diseases at some target FDR level. Both the algorithms and results will be disseminated through the web. The results from this study will be important for metagenomics studies under a variety of environments. Big data is ubiquitous in biological research. Identifying causal factors associated with complex diseases or traits from big data is highly important and challenging. New statistical and computational tools will be developed to control False Discovery Rate (FDR) for molecular sequence data based on the novel model-free knockoffs framework. They will be used to detect sequence motifs for viruses and motif-pairs for virus-host interactions, and to analyze multiple metagenomics data sets related to complex diseases.",Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data,9674585,R01GM131407,"['Algorithms ', ' Archaea ', ' Archaeon ', ' Archaeobacteria ', ' Archaebacteria ', ' Attention ', ' Bacteria ', ' Cells ', ' Cell Body ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' type two diabetes ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' MODY ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Disease ', ' Disorder ', ' Environment ', ' Foundations ', ' Genes ', ' Human ', ' Modern Man ', ' Joints ', ' Linear Regressions ', ' Literature ', ' Liver Cirrhosis ', ' Hepatic Cirrhosis ', ' Mathematics ', ' Math ', ' Methods ', ' Modernization ', ' Molecular Sequence Data ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Neurosciences ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Organism ', ' living system ', ' Play ', ' Reproducibility of Results ', ' Reproducibility of Findings ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Role ', ' social role ', ' Sampling Studies ', ' Shotguns ', ' shot gun ', ' Social Sciences ', ' Computer software ', ' Software ', ' Testing ', ' Theoretical Studies ', ' Tissues ', ' Body Tissues ', ' Virus ', ' General Viruses ', ' Work ', ' Healthcare ', ' health care ', ' Data Set ', ' Dataset ', ' Ecological Systems ', ' Ecologic Systems ', ' Ecosystem ', ' base ', ' improved ', ' Procedures ', ' Biological ', ' Nonlinear Models ', ' Non-linear Models ', ' Training ', ' Earth ', ' Planet Earth ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Dimensions ', ' Frequencies ', ' Complex ', ' Genetic Materials ', ' human tissue ', ' Viral ', ' Marines ', ' interest ', ' Consult ', ' Performance ', ' virus identification ', ' trait ', ' virus host interaction ', ' simulation ', ' novel ', ' new technology ', ' novel technologies ', ' Bypass ', ' Modeling ', ' Sampling ', ' response ', ' theories ', ' Genomics ', ' model design ', ' model development ', ' Effectiveness ', ' Address ', ' Length ', ' Data ', ' Reproducibility ', ' Molecular ', ' developmental ', ' Development ', ' Colo-rectal Cancer ', ' Colorectal Cancer ', ' microbiome ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' visualization tool ', ' Visualization software ', ' Coupled ', ' community microbes ', ' microbial community ', ' metagenome sequencing ', ' metagenomic sequencing ', ' biological research ', ' Functional Metagenomics ', ' Metagenomics ', ' user-friendly ', ' human disease ', ' flexible ', ' flexibility ', ' BigData ', ' Big Data ', ' dark matter ', ' Gaussianity model ', ' Gaussianity ', ' Gaussian statistics ', ' Gaussian model ', ' learning method ', ' learning activity ', ' learning strategy ', ' power analysis ', ' high dimensionality ', ' microbiome studies ', ' microbiome science ', ' Microbiomics ', ' microbiome research ', ' deep learning ', ' ']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2018,289700,0.08576415681657736
"Integration of Clinical and Omic Data for Improved Prediction of Patient Outcome Integration of Clinical and Omic Data for Improved Prediction of Patient Outcome PI: Matthew Ruffalo  Sponsors: Ziv Bar-Joseph, Stef Oesterreich A Project Summary This project comprises a data integration and machine learning methodology to improve performance in predicting patient outcome  specically, response to cancer treatments. Multiple disparate data types will be combined for this task, including omic data (somatic mutations, gene expression, methylation), interaction networks, drug target information, and previously-unavailable clinical data, to produce better predictions of response to specic cancer treatments.  The proposed methods will use relationships between genes and proteins (often represented as protein in- teraction networks) to construct composite features from omic data, and use these features as inputs to machine learning algorithms, to improve prediction performance of classication methods when applied to clinically rel- evant prediction tasks. Additionally, this project will use clinical data at a level that is not typically available for breast cancer samples, obtained via the Center for Big Data for Better Health (BD4BH) collaboration between Carnegie Mellon University and the University of Pittsburgh. This data includes time-series clinical data spanning ve years of breast cancer treatment, such as medication administration, laboratory results, pathology reports, symptoms, and other types of data. This clinical data will be integrated into composite features in order to fur- ther improve prediction performance. This feature construction methodology will also allow the investigation of which cellular processes and pathways are most strongly associated with clinical outcomes, such as response to specic treatments and patient survival.  While this approach shows promise in improving classication/prediction performance in clinically relevant tasks such as survival and response to treatment, models learned from these integrated features may still overt the classication task and may not generalize to other cancers or drugs with similar mechanisms of action. As such, this method will integrate cell line expression data from the LINCS project into the predictive features. The LINCS program has proled gene expression changes in cell lines under two broad categories: introduction of small molecules, and gene knockouts. Both sets of data will be used to constrain the sets of genes that are used as features for prediction of response to treatment of certain drugs. A central hypothesis of this proposal is that many cellular processes and cancer types respond in similar ways to such perturbations, allowing the use of a multi-task learning method to identify the commonalities in cellular response to these drugs across cell lines. Such methods will also allow for identication of cell-type-specic and cancer-specic responses to such perturbations, identifying those networks and processes that specically relate to response to treatment in specic cancers. Results will be validated via new in vitro cell line experiments, demonstrating that the constructed features are informative in clinical settings. 1 Integration of Clinical and Omic Data for Improved Prediction of Patient Outcome PI: Matthew Ruffalo  Sponsors: Ziv Bar-Joseph, Stef Oesterreich A Project Narrative This project proposes improvements in targeted cancer treatment, by providing more accurate prediction of re- sponse to cancer drugs based on a patient's specic somatic mutations, differential expression, methylation, and clinical data. This improved performance will be accomplished via feature construction and machine learning techniques, producing patient-specic treatment recommendations of which treatments will be most effective. 1",Integration of Clinical and Omic Data for Improved Prediction of Patient Outcome,9469716,F32CA216937,"['Algorithms ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Line ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Classification ', ' Systematics ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Data Sources ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Gene Expression ', ' Genes ', ' Health ', ' In Vitro ', ' Laboratories ', ' Methods ', ' Methodology ', ' Methylation ', ' Patients ', ' Proteins ', ' Recommendation ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Time ', ' Universities ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Clinical ', ' Biological ', ' Series ', ' Collaborations ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' programs ', ' Investigation ', ' Complex ', ' cell type ', ' Techniques ', ' Somatic Mutation ', ' Performance ', ' knockout gene ', ' novel ', ' Categories ', ' Pathogenesis ', ' Gene Proteins ', ' Protein Gene Products ', ' Biomedical Technology ', ' Pathology Report ', ' Modeling ', ' Sampling ', ' response ', ' Proteomics ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' small molecule ', ' Symptoms ', ' Breast Cancer Treatment ', ' Data ', ' Cancer Patient ', ' Clinical Data ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' Knockout ', ' Knock-out ', ' Process ', ' pathway ', ' Pathway interactions ', ' Output ', ' data integration ', ' Outcome ', ' cancer type ', ' transcriptomics ', ' clinical relevance ', ' clinically relevant ', ' multi-task ', ' multitask ', ' therapeutic response ', ' response to treatment ', ' treatment response ', ' Drug Targeting ', ' BigData ', ' Big Data ', ' transcriptional differences ', ' differentially expressed ', ' differential expression ', ' learning method ', ' learning activity ', ' learning strategy ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' predicting response ', ' experimental research ', ' experiment ', ' experimental study ', ' medication administration ', ' ']",NCI,CARNEGIE-MELLON UNIVERSITY,F32,2018,59038,-0.04346481412511092
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9522439,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cells ', ' Cell Body ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Cyst ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Kidney ', ' renal ', ' Kidney Urinary System ', ' Cystic kidney ', ' Renal Cyst ', ' Kidney Cyst ', ' Methods ', ' Methodology ', ' Mosaicism ', ' mosaic disorders ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Proteins ', ' Role ', ' social role ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Proprotein Convertase 2 ', ' Proinsulin Convertase 2 ', ' Prohormone Convertase 2 ', ' PC2 Protein ', ' PC2 Prohormone Convertase ', ' PC2 Endoprotease ', ' PC2 ', ' Neuroendocrine Convertase PC2 ', ' Endopeptidase PC2 ', ' Autosomal Dominant Polycystic Kidney ', ' Dominant Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Adult Polycystic Kidney Disease ', ' ADPKD ', ' Proprotein Convertase 1 ', ' Proprotein Convertase SPC3 ', ' Proinsulin Convertase 1 ', ' Prohormone Convertase 3 ', ' Prohormone Convertase 1 ', ' PC3 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC1 Endoprotease ', ' PC1 ', ' Neuroendocrine Convertase PC1 ', ' Data Set ', ' Dataset ', ' Fibrocystic liver disease ', ' Cystic disease of liver ', ' Congenital cystic liver disease ', ' polycystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' prognostic ', ' kidney function ', ' Renal function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Chaperone ', ' Molecular Chaperones ', ' Funding ', ' Liver Cyst ', ' Hepatic Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' Severity of illness ', ' disease severity ', ' Penetrance ', ' PRKCSH protein ', ' protein kinase substrate 80KD protein, heavy chain ', ' protein kinase substrate 80K-H ', ' PRKCSH ', ' G19P1 protein ', ' FGF-stimulated p90 ', ' 80K-H protein ', ' Nonsense Mutation ', ' non-sense mutation ', ' mutant ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' End stage renal failure ', ' End-Stage Renal Disease ', ' End-Stage Kidney Disease ', ' ESRD ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' cell assay ', ' Cellular Assay ', ' physiological imaging ', ' Physiologic Imaging ', ' Functional Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' murine model ', ' mouse model ', ' loss of function ', ' treatment development ', ' intervention development ', ' develop therapy ', ' therapy development ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' individualized medicine ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' variant of unknown significance ', ' prognostic tool ', ' mutation scanning ', ' mutation screening ', ' individual patient ', ' molecular diagnostics ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2018,510292,0.08185635525922613
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9494629,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Atlases ', ' Biological Factors ', ' Biologic Factor ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Child ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Chromatin ', ' Communities ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Data Sources ', ' Demographic Factors ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Hereditary Disease ', ' inherited genetic disorder ', ' inherited genetic disease ', ' inherited diseases ', ' inborn error ', ' hereditary disorder ', ' Inherited disorder ', ' Inborn Genetic Diseases ', ' Recording of previous events ', ' History ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Parents ', ' Play ', ' Genetic Polymorphism ', ' polymorphism ', ' Probability ', ' Genetic Recombination ', ' Recombination ', ' DNA Recombination ', ' Research ', ' Resources ', ' Research Resources ', ' Rest ', ' Role ', ' social role ', ' Selection Bias ', ' Technology ', ' Tissues ', ' Body Tissues ', ' Genetic Variation ', ' Genetic Diversity ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' African American ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' Latino ', ' Natural Selections ', ' Data Set ', ' Dataset ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Individual ', ' European ', ' Biological Function ', ' Biological Process ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' genomic region ', ' Genomic Segment ', ' Transmission ', ' transmission process ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' sharing data ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' next generation sequencing ', ' rare allele ', ' rare variant ', ' High-Throughput Sequencing ', ' High-Throughput Nucleotide Sequencing ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' Mendelian disorder ', ' driver mutation ', ' actionable variants ', ' actionable mutation ', ' full genome ', ' entire genome ', ' whole genome ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' human model ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2018,300473,0.1267325595934094
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9527264,K99AG056656,"['Affect ', ' Age ', ' ages ', ' Elderly ', ' senior citizen ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aging ', ' B-Lymphocytes ', ' Bursa-Equivalent Lymphocyte ', ' Bursa-Dependent Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Cell Count ', ' Cell Number ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Cell Body ', ' Centenarian ', ' centenarian human (100+) ', ' 100+ years old ', ' Deoxyribonuclease I ', ' Thymonuclease ', ' Pancreatic DNase ', ' DNase I ', ' DNA Endonuclease ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' DNA Damage ', ' DNA Injury ', ' DNA Transposable Elements ', ' Transposable Elements ', ' DNA Repair ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' Exons ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Goals ', ' Human ', ' Modern Man ', ' Hypersensitivity ', ' Allergy ', ' Immunization ', ' Immunostimulation ', ' Immunological Stimulation ', ' Immunological Sensitization ', ' Immunologic Stimulation ', ' Immunologic Sensitization ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Learning ', ' Mentors ', ' Methods ', ' Study models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Nucleotides ', ' Organism ', ' living system ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Research ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' Role ', ' social role ', ' Software Tools ', ' Computer Software Tools ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Enhancers ', ' promoter ', ' promotor ', ' base ', ' cross-link ', ' crosslink ', ' improved ', ' Site ', ' repair ', ' repaired ', ' Variation ', ' Variant ', ' Evaluation ', ' Stimulus ', ' Individual ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Functional disorder ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' dietary restriction ', ' restricted diet ', ' diet restriction ', ' Frequencies ', ' Protocols documentation ', ' Protocol ', ' Source ', ' cell type ', ' Location ', ' Locus Control Region ', ' Somatic Mutation ', ' repair enzyme ', ' repair endonuclease ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' DNA amplification ', ' Somatic Cell ', ' Mutation Analysis ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' response ', ' theories ', ' Genomic Instability ', ' Genome Instability ', ' RNA amplification ', ' B-Cell Activation ', ' genome sequencing ', ' Defect ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' DNA Replication Damage ', ' DNA Replicating Damage ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutation Spectra ', ' Retrotransposition ', ' Cancer Cause ', ' Cancer Etiology ', ' Collecting Cell ', ' genomic region ', ' Genomic Segment ', ' Process ', ' age dependent ', ' age related ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' insertion/deletion mutation ', ' genomewide ', ' genome scale ', ' genome-wide ', ' single cell sequencing ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' CRISPR/Cas technology ', ' full genome ', ' entire genome ', ' whole genome ', ' single cell technology ', ' ']",NIA,"ALBERT EINSTEIN COLLEGE OF MEDICINE, INC",K99,2018,40760,0.20177922322364664
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9539482,F31HD095571,"['Affect ', ' Amino Acids ', ' aminoacid ', ' Autistic Disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autism ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cataloging ', ' Cell Separation ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cell Survival ', ' Cell Viability ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' Fluorescence ', ' Genes ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Light ', ' Photoradiation ', ' Lipids ', ' Metabolism ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Phosphatidylinositols ', ' PtdIns ', ' Phosphoinositides ', ' Phosphatidyl Inositol ', ' Inositol Phospholipids ', ' Inositol Phosphoglycerides ', ' Inositide Phospholipids ', ' Phosphoric Monoester Hydrolases ', ' Phosphomonoesterases ', ' Phosphohydrolases ', ' Phosphatases ', ' Play ', ' Problem Solving ', ' Proteins ', ' Quality of life ', ' QOL ', ' Risk ', ' Role ', ' social role ', ' Signal Pathway ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Syndrome ', ' Temperature ', ' Testing ', ' Time ', ' Yeasts ', ' Measures ', ' Data Set ', ' Dataset ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variation ', ' Variant ', ' Biochemical ', ' Pythons ', ' Hereditary Mutation ', ' Germline Mutation ', ' Germ-Line Mutation ', ' Susceptibility ', ' Predisposition ', ' Training ', ' insight ', ' Individual ', ' Early Intervention ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Complex ', ' Clinic ', ' Reaction ', ' Techniques ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' novel ', ' PTEN gene ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' high throughput technology ', ' Genomics ', ' Pathogenicity ', ' FRAP1 gene ', ' mammalian target of rapamycin ', ' mTOR ', ' RAFT1 ', ' Mechanistic Target of Rapamycin ', ' FRAP2 ', ' FRAP1 ', ' FKBP12 Rapamycin Complex Associated Protein 1 ', ' FK506 Binding Protein 12-Rapamycin Associated Protein 1 ', ' fitness ', ' autism spectrum disorder ', ' autistic spectrum disorder ', ' Data ', ' Deletion Mutation ', ' Mutate ', ' Protein Biochemistry ', ' Protein/Amino Acid Biochemistry ', ' Resolution ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Ubiquitination ', ' yeast model ', ' Yeast Model System ', ' Characteristics ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' phosphatase and tensin homologue on chromosome ten ', ' mutated in multiple advanced cancers 1 protein ', ' MMAC1 protein ', ' PTEN protein ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' next generation ', ' Outcome ', ' tumorigenic ', ' prospective ', ' Coupled ', ' Coupling ', ' synthetic biology ', ' open source ', ' human disease ', ' mutation carrier ', ' screening ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' accurate diagnosis ', ' genomic variation ', ' Genomic medicine ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' genomic classifier ', ' genomic signature ', ' experimental research ', ' experiment ', ' experimental study ', ' DNAseq ', ' DNA seq ', ' DNA sequencing ', ' ']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2018,44524,0.21665414553331985
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9472091,R01CA163336,"['Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Computing Methodologies ', ' computing method ', ' computer methods ', ' computational methods ', ' computational methodology ', ' DNA ', ' Deoxyribonucleic Acid ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Family ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genome ', ' Glioblastoma ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Goals ', ' knowledge of results ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Recurrence ', ' Recurrent ', ' Research ', ' RNA-Directed DNA Polymerase ', ' Revertase ', ' Reverse Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' RNA Transcriptase ', ' EC 2.7.7.49 ', ' Role ', ' social role ', ' Specificity ', ' Testing ', ' Time ', ' transcription factor ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Work ', ' c-myc Genes ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' telomere ', ' Family member ', ' Mediating ', ' promoter ', ' promotor ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Protein Isoforms ', ' Isoforms ', ' Toxic effect ', ' Toxicities ', ' novel ', ' member ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcriptional Regulation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Binding ', ' Molecular Interaction ', ' TERT gene ', ' telomerase catalytic subunit ', ' Telomere Reverse Transcriptase ', ' TCS1 ', ' EST2 ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' oncogenomics ', ' cancer genomics ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' cancer research ', ' anti-cancer research ', ' anticancer research ', ' computational framework ', ' computer framework ', ' cancer type ', ' Oncogenic ', ' computational resources ', ' computing resources ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic target ', ' therapeutic response ', ' response to treatment ', ' treatment response ', ' genomewide ', ' genome scale ', ' genome-wide ', ' individual patient ', ' recruit ', ' bioinformatics resource ', ' deep learning ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2018,327546,0.14678739468726082
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9509468,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell growth ', ' Cellular Growth ', ' Cellular Expansion ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Model System ', ' Biologic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Names ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Protein Kinase ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Tyrosine Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Testing ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Binding ', ' Molecular Interaction ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2018,300000,0.17732211395365816
"A novel human T-cell platform to define biological effects of genome editing PROJECT SUMMARY Genome editing technologies have extraordinary potential as new genomic medicines that address underlying genetic causes of human disease; however, it remains challenging to predict their long-term safety, because we do not know the consequences of potential side effects of genome editing such as off-target mutations or immunogenicity. Our long-term goal is to understand and predict such unintended biological effects to advance the development of safe and effective therapies. T-cells are an ideal cellular model because: 1) they are highly relevant as the most widely used cells for development of therapeutic genome editing strategies (such as cell- based treatments for HIV and cancer) and 2) mature T-cells encode a diverse T-cell receptor repertoire that can be exploited as built-in cellular barcodes for quantifying clonal expansion or depletion in response to specific treatments. We, therefore, propose the following specific aims: 1) to predict which unintended editing sites have biological effects on human T-cells by integrating large-scale genome-wide activity and epigenomic profiles with state-of-the-art deep learning models and 2) to develop a human primary T-cell platform to detect functional effects of genome editing by measuring clonal representation, off-target mutation frequencies, immunogenicity, or gene expression. If successful, our experimental and predictive framework will profoundly increase confidence in the safety of the next generation of promising genome editing therapies. PROJECT NARRATIVE Genome editing technologies have extraordinary potential as the basis of new genomic medicines that address the underlying genetic causes of human disease; however, it is challenging to predict their long-term safety, because we do not know the consequences of potential unintended side effects of genome editing such as off- target mutations or immunogenicity. To define the biological effects of genome editing strategies, we will develop a human primary T-cell platform to sensitively detect functional effects coupled with an empirically-trained artificial intelligence models to predict them. Together, our platform will significantly improve confidence in safety assessments of promising genome editing therapeutics.",A novel human T-cell platform to define biological effects of genome editing,9678132,U01HL145793,"['Affect ', ' Epitopes ', ' Binding Determinants ', ' Antigenic Determinants ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Engineering ', ' Gene Expression ', ' gene therapy ', ' genetic therapy ', ' gene-based therapy ', ' Genetic Intervention ', ' Gene Transfer Clinical ', ' DNA Therapy ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' HIV ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Immunologic Deficiency Syndromes ', ' immunodeficiency ', ' immune deficiency disorder ', ' hypoimmunity ', ' Immunological Deficiency Syndromes ', ' Immunodeficiency Syndrome ', ' Immunodeficiency Disorder ', ' In Vitro ', ' Maps ', ' Methods ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Phenotype ', ' Proto-Oncogenes ', ' protooncogene ', ' c-ONC ', ' Cellular Oncogene ', ' T-Cell Receptor ', ' Receptors, Antigen, T-Cell ', ' Major Histocompatibility Complex Receptor ', ' MHC Receptor ', ' Ribonucleoproteins ', ' Safety ', ' Standardization ', ' Streptococcus pyogenes ', ' Streptococcus Group A ', ' S.pyogenes ', ' S. pyogenes ', ' S pyogenes ', ' T-Lymphocyte ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' Technology ', ' Testing ', ' Genetic Transcription ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' cytokine ', ' Measures ', ' Site-Directed Mutagenesis ', ' Targeted Modification ', ' Targeted DNA Modification ', ' Site-Specific Mutagenesis ', ' Organizational Change ', ' base ', ' improved ', ' Site ', ' Benign ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Training ', ' Therapeutic ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Peptide Library ', ' DNA Methylation ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' genotoxicity ', ' Peripheral Blood Mononuclear Cell ', ' PBMC ', ' novel ', ' Modeling ', ' response ', ' immunogenic ', ' functional genomics ', ' Adverse effects ', ' treatment adverse effect ', ' therapy adverse effect ', ' side effect ', ' Treatment Side Effects ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' histone modification ', ' Address ', ' Detection ', ' Mature T-Lymphocyte ', ' Mature T-Cell ', ' Regulatory Element ', ' Retroviral Vector ', ' Retrovirus Vector ', ' in vivo ', ' Clonal Expansion ', ' epigenomics ', ' Advanced Development ', ' immunogenicity ', ' next generation ', ' Outcome ', ' Population ', ' Coupled ', ' therapeutic gene ', ' Oncogenic ', ' Cellular model ', ' Cell model ', ' human disease ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic agent development ', ' therapeutic development ', ' effective treatment ', ' effective therapy ', ' genomewide ', ' genome scale ', ' genome-wide ', ' safety testing ', ' comparative genomics ', ' T cell response ', ' adverse consequence ', ' adverse outcome ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' genomic editing ', ' genome editing ', ' learning method ', ' learning activity ', ' learning strategy ', ' Genomic medicine ', ' adaptive immune response ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' TCR repertoire ', ' T-cell receptor repertoire ', ' therapeutic genome editing ', ' deep learning ', ' ']",NHLBI,ST. JUDE CHILDREN'S RESEARCH HOSPITAL,U01,2018,651251,0.046873343038425726
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9564155,R35GM124952,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Cell physiology ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Disease ', ' Disorder ', ' Drug Design ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Goals ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Ligands ', ' Methods ', ' Structural Models ', ' Molecular Conformation ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Pharmacology ', ' Protein Engineering ', ' protein design ', ' genetic protein engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Distal ', ' insight ', ' data base ', ' Data Bases ', ' Databases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' pathway ', ' Pathway interactions ', ' computational framework ', ' computer framework ', ' designing ', ' design ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Treatment Efficacy ', ' Outcome ', ' innovative ', ' innovate ', ' innovation ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental research ', ' experiment ', ' experimental study ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2018,335245,0.13491111632773134
"SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data Abstract Over 30 million people in the US suffer from genetic diseases or cancers caused by mutations of which ~15% disrupt the regulation of splicing. Alternative splicing (AS) errors have been reported in literature to drive 370 genetic diseases out of ~800 described to date. In addition, due to the recent success of FDA-approved splicing modulators like Nusinersen, along with fascinating pre- clinical results underlining the importance of AS as therapeutic targets; splicing research has become of major interest to pharmaceutical companies. Envisagenics is developing SpliceCoreTM, an innovative cloud-based software platform using biomedical big data for AS analysis to discover new therapies and biomarkers for complex diseases. Our breakthrough platform combines algorithms and databases developed and experimentally validated at Cold Spring Harbor Laboratory (CSHL): SpliceTrapTM, for the detection of splicing activity using RNA-seq data; SpliceDuoTM, for the identification of significant splicing variation across biological samples; SpliceImpact2TM, for the prioritization of biologically relevant AS variants with therapeutic potential; and TXdbTM, a splicing isoform database that connects clients proprietary data to public repositories such as the Cancer Genome Atlas (TCGA). Thanks to the Phase I award SpliceCore was adapted as a cloud-based software, accelerating scalability and adaptation to the fast- evolving market of biomedical Big Data. We now have deployed SpliceCores back-end on three cloud-service providers, increased its overall run-time by a factor of 12, developed tools to discover disease-specific AS isoforms, finalized and tested a machine-learning algorithm to predict the biological impact of AS, and experimentally validated some of our new predictions with a success rate of 82.5%. The goal for Phase II is to accelerate client acquisition through the development of user-interactive applications informed from clients feedback by substantially expanding the platforms knowledgebase and predictive functions with novel AS isoforms extracted from ~37,000 public datasets. Thus, a new version of SpliceCore will be developed to predict regulatory interactions between RNA-binding proteins and their RNA targets to assist in the interpretation of aberrant splicing factors through a collaboration with world renowned HHMI Professor Dr. Tom Tuschl from Rockefeller University and developer of Nusinersen, Professor Dr. Adrian Krainer from CSHL. Envisagenics is targeting the global bioinformatics market valued at $4 billion in 2014 with a CAGR of over 21%. SpliceCore could capture ~10% of the market, identify novel drug targets, and design RNA therapeutics from aberrant splicing events prevalent in cancer and a multitude of genetic diseases while increasing the efficiency of R&D in biopharma. Project Narrative In this SBIR Phase II, Envisagenics will advance the development of SpliceCoreTM, a cloud-based software platform for the discovery of drug-targets and biomarkers using biomedical big data. Therapeutic screens are increasingly focusing on Alternative Splicing (AS), a biological process that regulates gene-product structure and function. Strikingly, 50% of genetic diseases described in literature can be triggered by AS errors. The recent FDA approval of RNA-therapeutic compounds to correct AS errors, combined with increasingly available big datasets and groundbreaking cloud-computing provide a unique opportunity for computerized discovery of AS therapeutics. Envisagenics technology will help biomedical researchers to translate basic science into new therapeutic products for cancer and genetic diseases. By the completion of this project, we will deploy a user-friendly, secured and scalable SpliceCore software, with new functionalities ready for integration into biopharmaceutical Research & Development workflows.",SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data,9747570,R44GM116478,"['RNA Splicing ', ' Splicing ', ' Running ', ' Computer software ', ' Software ', ' Specificity ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Translating ', ' Universities ', ' Work ', ' Price ', ' pricing ', ' RNA-Binding Proteins ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' cross-link ', ' crosslink ', ' improved ', ' Phase ', ' Variation ', ' Variant ', ' Biological ', ' Ensure ', ' Failure ', ' data base ', ' Data Bases ', ' Databases ', ' Biological Function ', ' Biological Process ', ' Collaborations ', ' Therapeutic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Protein Splicing ', ' Frequencies ', ' Complex ', ' Event ', ' System ', ' interest ', ' Services ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' professor ', ' knowledge base ', ' knowledgebase ', ' fascinate ', ' Structure ', ' novel ', ' Basic Science ', ' Basic Research ', ' cancer genetics ', ' Reporting ', ' Regulation ', ' Sampling ', ' case control ', ' repository ', ' Meta-Analysis ', ' Meta-Analyses ', ' Data Pooling ', ' Clinical Trial Overviews ', ' drug discovery ', ' RNA-Binding Protein FUS ', ' hnRNP P2 ', ' Translocated in Liposarcoma Protein ', ' TLS Protein ', ' POMp75 Protein ', ' Fusion Protein in Myxoid Liposarcoma ', ' FUS Protein ', ' Drops ', ' Bioinformatics ', ' Bio-Informatics ', ' Pharmacologic Substance ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' data mining ', ' datamining ', ' Defect ', ' Data ', ' Detection ', ' Memorial Sloan-Kettering Cancer Center ', ' MSKCC ', ' Protein Binding Domain ', ' Protein-Protein Interaction Domain ', ' Protein Binding Motif ', ' Research Infrastructure ', ' Infrastructure ', ' Cancer Cause ', ' Cancer Etiology ', ' Small Business Innovation Research ', ' SBIR ', ' Small Business Innovation Research Grant ', ' Validation ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' preclinical ', ' pre-clinical ', ' pre-clinical study ', ' preclinical study ', ' cost ', ' computerized ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Advanced Development ', ' designing ', ' design ', ' Prevalence ', ' innovative ', ' innovate ', ' innovation ', ' user-friendly ', ' human disease ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' novel therapeutics ', ' therapeutic target ', ' commercial application ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' new therapeutic target ', ' FDA approved ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' system architecture ', ' flexible ', ' flexibility ', ' Secure ', ' TCGA ', ' The Cancer Genome Atlas ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' transcriptome sequencing ', ' Drug Targeting ', ' therapeutic RNA ', ' cloud computer ', ' Cloud Infrastructure ', ' Cloud Computing ', ' cloud based ', ' BigData ', ' Big Data ', ' FDA Drug Approval ', ' Food and Drug Administration Drug Approval ', ' learning method ', ' learning activity ', ' learning strategy ', ' Predictive Analytics ', ' targeted biomarker ', ' GTEx ', ' Genotype-Tissue Expression Project ', ' gene product ', ' big biomedical data ', ' Cloud Service ', ' petabyte ', ' Serine/Arginine-Rich Splicing Factor 2 ', ' SRSF2 ', ' SC35 ', ' SRSF2 gene ', ' experimental research ', ' experiment ', ' experimental study ', ' service providers ', ' genetic disorder ', ' genetic condition ', ' Genetic Diseases ', ' data repository ', ' Databanks ', ' Data Banks ', ' data warehouse ', ' Achievement ', ' Achievement Attainment ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Amyotrophic Lateral Sclerosis ', ' Lou Gehrig Disease ', "" Gehrig's Disease "", ' Amyotrophic Lateral Sclerosis Motor Neuron Disease ', ' Award ', ' Back ', ' Dorsum ', ' Biological Products ', ' biotherapeutic agent ', ' biopharmaceutical ', ' Biological Agent ', ' Biologic Products ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Client ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' Face ', ' facial ', ' faces ', ' Feedback ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Immunoprecipitation ', ' Immune Precipitation ', ' Laboratories ', ' Literature ', ' Manuals ', ' Maps ', ' Methods ', ' Spinal Muscular Atrophy ', ' Cruveilhier disease ', ' Aran-Duchenne disease ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Dysmyelopoietic Syndromes ', ' myelodysplasia ', ' Smoldering Leukemia ', ' Refractory anaemia with excess blasts ', ' Refractory Anemia with an Excess of Blasts ', ' Myelodysplastic Syndromes ', ' Nucleotides ', ' Patients ', ' Privatization ', ' Probability ', ' Research ', ' research and development ', ' R&D ', ' R & D ', ' Development and Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Ribonucleosides ', ' Risk ', ' RNA ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' ']",NIGMS,"ENVISAGENICS, INC.",R44,2018,125000,0.06473209201912912
"Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis ABSTRACT This project outlines technical medical image processing and machine learning developments to study the pathogenesis and natural history of osteoarthritis (OA). In the past few years, the availability of public datasets that collect data such as plain radiographs, MRI genomics and patients reported outcomes has allowed the study of disease etiology, potential treatment pathways and predictors of long-range outcomes, showing an increasingly important role of the MRI. Moreover, recent advances in quantitative MRI and medical image processing allow for the extraction of extraordinarily rich arrays of heterogeneous information on the musculoskeletal system, including cartilage and bone morphology, bone shape features, biomechanics, and cartilage biochemical composition.  Osteoarthritis, being a polygenic and multifactorial disease characterized by several phenotypes, seems the perfect candidate for multidimensional analysis and precision medicine. However, accomplish this ambitious task, will require complex analytics and multifactorial data-integration from diverse assessments spanning morphological, biochemical, and biomechanical features. In this project, we propose to fill this gap developing automatic post-processing algorithms to examine cartilage biochemical compositional and morphological features and to apply new multidimensional machine learning to study OA  This Pathway to Independence award application includes a mentored career development plan to transition the candidate, Dr. Valentina Pedoia, into an independent investigator position, as well as an accompanying research plan describing the proposed technical developments for the application of big data analytics to the study of OA. The primary mentor, Dr. Sharmila Majumdar, is a leading expert in the field of quantitative MRI for the study of OA, and the co-mentors, Dr. Adam Ferguson and Dr. Ramakrishna Akella, have extensive experience in the application of machine learning and topological data analysis to big data. The diversified plan of training and the complementary background of these mentors will allow the candidate to develop a unique interdisciplinary profile in the field of musculoskeletal imaging.  The candidate, Dr. Valentina Pedoia, is currently in a post-doctoral level position (Associated Specialist) at the University of California at San Francisco (UCSF), developing MR image post-processing algorithms. The mentoring and career development plan will supplement her image processing background with valuable exposure to machine learning, big data analysis, epidemiological study design, and interdisciplinary collaboration to facilitate her transition to a medical imaging and data scientist independent investigator position. Ultimately, she aims to become a faculty member in a radiology or bioengineering institute, where she can further research technical biomedical imaging and machine learning developments applied to the musculoskeletal system. PROJECT NARRATIVE Morphological and compositional MRI quantifications are widely used tools to detect early cartilage degeneration and to study disease progression of osteoarthritis, a complex and multifactorial disorder. In this project, we propose to develop a fully automatic image post-processing pipeline and multidimensional big data analyses based on machine learning techniques, with the aim to uncover latent information from complex dataset and with the ultimate goal of setting up a platform for OA precision medicine",Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis,9723310,R00AR070902,"['Algorithms ', ' Atlases ', ' Award ', ' Biochemistry ', ' Biological Chemistry ', ' Biomechanics ', ' biomechanical ', ' Biomedical Engineering ', ' bioengineering ', ' bio-engineers ', ' bio-engineered ', ' bone ', ' California ', ' Cartilage ', ' Cartilaginous Tissue ', ' Chronology ', ' Computer Vision Systems ', ' computer vision ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Statistical Data Interpretation ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Disease ', ' Disorder ', ' Elements ', ' Faculty ', ' Gait ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Hybrids ', ' Institutes ', ' arthropathies ', ' joint disorder ', ' arthropathy ', ' arthropathic ', ' Joint Diseases ', ' Knee ', ' Knee joint ', ' Longitudinal Studies ', ' long-term study ', ' Magnetic Resonance Imaging ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Medical Imaging ', ' Mentors ', ' Musculoskeletal System ', ' locomotor system ', ' Degenerative polyarthritis ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Patient Outcomes Assessments ', ' Patient Reported Outcomes ', ' Phenotype ', ' Radiology Specialty ', ' Radiology ', ' General Radiology ', ' Relaxation ', ' Research ', ' Research Design ', ' study design ', ' Study Type ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk Factors ', ' Role ', ' social role ', ' San Francisco ', ' Sex Characteristics ', ' Sex Differences ', ' Syndrome ', ' Time ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Diagnostic radiologic examination ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Specialist ', ' Data Set ', ' Dataset ', ' Visualization ', ' Imagery ', ' Natural History ', ' base ', ' image processing ', ' morphometry ', ' image evaluation ', ' Image Analyses ', ' Image Analysis ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Training ', ' Lesion ', ' soft tissue ', ' Discipline ', ' Measurement ', ' Development Plans ', ' Disease Progression ', ' Genetic ', ' Exposure to ', ' Morphology ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Knee Osteoarthritis ', ' Dimensions ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' Postdoctoral Fellow ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Early Diagnosis ', ' early detection ', ' experience ', ' parallel processing ', ' interdisciplinary collaboration ', ' transdisciplinary collaboration ', ' kinematics ', ' kinematic model ', ' member ', ' racial difference ', ' race differences ', ' Pathogenesis ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' career development ', ' bioimaging ', ' biomedical imaging ', ' bio-imaging ', ' repository ', ' Genomics ', ' Thick ', ' Thickness ', ' Etiology ', ' disease causation ', ' causation ', ' Causality ', ' Symptoms ', ' Data ', ' Validation ', ' developmental ', ' Development ', ' musculoskeletal visualization ', ' musculoskeletal scanning ', ' musculoskeletal imaging ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' 3D modeling ', ' three-dimensional modeling ', ' image registration ', ' shape description ', ' shape analysis ', ' data integration ', ' designing ', ' design ', ' Outcome ', ' imaging Segmentation ', ' modifiable risk ', ' BigData ', ' Big Data ', ' precision-based medicine ', ' precision medicine ', ' cartilage degeneration ', ' cartilage degradation ', ' quantitative imaging ', ' imaging marker ', ' imaging biomarker ', ' Data Scientist ', ' Data Science ', ' Data Analytics ', ' connectome ', ' imaging scientist ', ' deep learning ', ' ']",NIAMS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R00,2018,249000,0.04296640889953015
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9486376,R35GM127087,"['Biology ', ' Computer Simulation ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Disease ', ' Disorder ', ' Elements ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Genes ', ' Regulator Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Maps ', ' Methods ', ' Mission ', ' Statistical Models ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Patients ', ' Phenotype ', ' Pongidae ', ' great ape ', ' Apes ', ' Nucleic Acid Regulatory Sequences ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Risk ', ' Work ', ' species difference ', ' Clinical ', ' Specified ', ' Specific qualifier value ', ' Variation ', ' Variant ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Complex ', ' Pattern ', ' disorder risk ', ' disease risk ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Binding ', ' Molecular Interaction ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Epigenetic Process ', ' To specify ', ' Modification ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' genetic variant ', ' Population ', ' Impairment ', ' combinatorial ', ' mammalian genome ', ' human disease ', ' cellular development ', ' biorepository ', ' biobank ', ' Preventative care ', ' Preventive care ', ' ']",NIGMS,VANDERBILT UNIVERSITY,R35,2018,226333,0.07764059621971087
"NextGen Random Forests Project Summary/Abstract Building from the PI's current R01, we propose next generation random forests (RF) designed for unprecedented accuracy and computational scalability to meet the challenges of today's complex and big data in the health sciences. Superior accuracy is achieved using super greedy trees which circumvent limitations on local adaptivity imposed by classical tree splitting. We identify a key quantity, forest weights, and show how these can be leveraged for further improvements and generalizability. In one application, improved survival estimators are applied to worldwide esophageal cancer data to develop guidelines for clinical decision making. Richer RF inference is another issue explored. Cutting edge machine learning methods rarely consider the problem of estimating variability. For RF, bootstrapping currently exists as the only tool for reliably estimating condence intervals, but due to heavy computations is rarely applied. We introduce tools to rapidily calculate standard errors based on U-statistic theory. These will be used to increase robustness of esophageal clinical recommendations and to investigate survival temporal trends in cardiovascular disease. In another application, we make use of our new massive data scalability for discovery of tumor and immune regulators of immunotherapy in cancers. This project will set the standard for RF computational performance. Building from the core libraries of the highly accessed R-package randomForestSRC (RF-SRC), software developed under the PIs current R01, we develop open source next generation RF software, RF-SRC Everywhere, Big Data RF-SRC, and HPC RF-SRC. The software will be deployable on a number of popular machine learning workbenches, use distributed data storage technologies, and be optimized for big-p, big-n, and big-np scenarios. Project Narrative We introduce next generation random forests (RF) designed for unprecedented accuracy for complex and big data encountered in the health sciences.",NextGen Random Forests,9547466,R01GM125072,"['Biological Response Modifiers ', ' immunomodulatory biologics ', ' Immune Regulators ', ' Immune Mediators/Modulators ', ' Immune Mediators ', ' Biomodulators ', ' Blood ', ' Blood Reticuloendothelial System ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Combined Modality Therapy ', ' multimodality therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodality Treatment ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Confidence Intervals ', ' Flow Cytometry ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Heart failure ', ' cardiac failure ', ' Human ', ' Modern Man ', ' Hybrids ', ' Immunotherapy ', ' immuno therapy ', ' immune-based treatments ', ' immune-based therapies ', ' immune therapy ', ' immune therapeutic interventions ', ' Immunologically Directed Therapy ', ' In Vitro ', ' Laboratories ', ' Language ', ' Libraries ', ' lymph nodes ', ' lymph gland ', ' Lymph node proper ', ' Lymph Node Reticuloendothelial System ', ' Methods ', ' Methodology ', ' Mus ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Patients ', ' outcome forecast ', ' Prognosis ', ' Recommendation ', ' Computer software ', ' Software ', ' statistics ', ' T-Lymphocyte ', ' thymus derived lymphocyte ', ' Thymus-Dependent Lymphocytes ', ' T-Cells ', ' Technology ', ' Thrombosis ', ' Time ', ' Trees ', ' Weight ', ' forest ', ' Guidelines ', ' base ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' tumor progression ', ' Pump ', ' improved ', ' Clinical ', ' Java ', ' data base ', ' Data Bases ', ' Databases ', ' data storage ', ' data retrieval ', ' Data Storage and Retrieval ', ' world wide web ', ' web ', ' WWW ', ' Internet ', ' Therapeutic ', ' Atrophic ', ' Atrophy ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Benchmarking ', ' Best Practice Analysis ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Malignant neoplasm of esophagus ', ' oesophageal cancer ', ' Malignant Tumor of the Esophagus ', ' Malignant Esophageal Tumor ', ' Malignant Esophageal Neoplasm ', ' Esophagus Cancer ', ' Esophageal Cancer ', ' parallel processing ', ' Performance ', ' receptor ', ' Receptor Protein ', ' Neoadjuvant Therapy ', ' Neoadjuvant Treatment ', ' Neoadjuvant ', ' NEOADJ ', ' Induction Therapy ', ' novel ', ' Code ', ' Coding System ', ' Modeling ', ' response ', ' theories ', ' software development ', ' developing computer software ', ' develop software ', ' Data ', ' Health Sciences ', ' Receptor Activation ', ' Subgroup ', ' in vivo ', ' Cancer Patient ', ' Clinical Management ', ' Pathologic ', ' Esophageal ', ' developmental ', ' Development ', ' preclinical ', ' pre-clinical ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' distributed data ', ' designing ', ' design ', ' next generation ', ' Population ', ' resistant ', ' Resistance ', ' open source ', ' murine model ', ' mouse model ', ' therapeutic target ', ' tumor ', ' clinical practice ', ' Interagency Registry for Mechanical Circulatory Support ', ' INTERMACS ', ' Interagency Registry for Mechanically Assisted Circulatory Support ', ' clinical decision-making ', ' BigData ', ' Big Data ', ' learning method ', ' learning activity ', ' learning strategy ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' predicting response ', ' Trends over time ', ' Temporal trend ', ' Time trend ', ' Checkpoint blockade ', ' Immune checkpoint blockade ', ' ']",NIGMS,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,R01,2018,347834,0.05080573512344636
"Mobility Data Integration to Insight     DESCRIPTION (provided by applicant): Mobility is essential for human health. Regular physical activity helps prevent heart disease and stroke, relieves symptoms of depression, and promotes weight loss. Unfortunately, many conditions, such as cerebral palsy, osteoarthritis, and obesity, limit mobility at an enormous personal and societal cost. While vast amounts of data are available from hundreds of research labs and millions of smartphones, there is a dearth of methods for analyzing this massive, heterogeneous dataset.  We propose to establish the National Center for Mobility Data Integration to Insight (the Mobilize Center) to overcome the data science challenges facing mobility big data and biomedical big data in general. Our preliminary work identified four bottlenecks in data science, which drive four Data Science Research Cores.  The Cores include Biomechanical Modeling, Statistical Learning, Behavioral and Social Modeling, and Integrative Modeling and Prediction. Our Cores will produce novel methods to integrate diverse modeling modalities and gain insight from noisy, sparse, heterogeneous, and time-varying big data. Our data-sharing consortia, with clinical, research, and industry partners, will provide mobility data for over ten million people.  Three Driving Biomedical Problems will focus and validate our data science research.  The Mobilize Center will disseminate our novel data science tools to thousands of researchers and create a sustainable data-sharing consortium. We will train tens of thousands of scientists to use data science methods in biomedicine through our in-person and online educational programs. We will establish a cohesive, vibrant, and sustainable National Center through the leadership of an experienced executive team and will help unify the BD2K consortia through our Biomedical Computation Review publication and the Simtk.org resource portal.  The Mobilize Center will lay the groundwork for the next generation of data science systems and revolutionize diagnosis and treatment for millions of people affected by limited mobility.         PUBLIC HEALTH RELEVANCE:  Regular physical activity is essential for human health, yet a broad range of conditions impair mobility. This project will transform human movement research by developing tools for data analysis and creating software that will advance research to prevent, diagnose, and reduce impairments that limit human movement.            ",Mobility Data Integration to Insight,9542295,U54EB020405,"['Affect ', ' Elderly ', ' senior citizen ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Automobile Driving ', ' driving ', ' Biomechanics ', ' biomechanical ', ' Biomedical Research ', ' Cerebral Palsy ', ' Child ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Classification ', ' Systematics ', ' Clinical Research ', ' Clinical Study ', ' Communities ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Data Sources ', ' Diabetes Mellitus ', ' diabetes ', ' Diagnosis ', ' Ethics ', ' ethical ', ' Exercise ', ' Limb structure ', ' Non-Trunk ', ' Limbs ', ' Extremities ', ' Fellowship ', ' Gait ', ' Health ', ' Heart Diseases ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Human ', ' Modern Man ', ' Joints ', ' Leadership ', ' Methods ', ' Mission ', ' Movement ', ' body movement ', ' Persons ', ' Obesity ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Degenerative polyarthritis ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Pathology ', ' Personal Satisfaction ', ' wellbeing ', ' well-being ', ' Problem Solving ', ' Public Health ', ' Publications ', ' Scientific Publication ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' Running ', ' Computer software ', ' Software ', ' Stroke ', ' cerebrovascular accident ', ' cerebral vascular accident ', ' brain attack ', ' Cerebrovascular Stroke ', ' Cerebrovascular Apoplexy ', ' Cerebral Stroke ', ' Brain Vascular Accident ', ' Apoplexy ', ' Testing ', ' Time ', ' Body Weight decreased ', ' wt-loss ', ' body weight loss ', ' Weight Reduction ', ' Weight Loss ', ' Work ', ' Walking ', ' depressive symptoms ', ' depressive ', ' depression symptom ', ' Emotional Depression ', ' Data Set ', ' Dataset ', ' Injury ', ' base ', ' role model ', ' improved ', ' Area ', ' Training ', ' Physical activity ', ' insight ', ' Individual ', ' Workshop ', ' Educational workshop ', ' Fostering ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' cognitive function ', ' Scientist ', ' Complex ', ' Techniques ', ' System ', ' Overweight ', ' Over weight ', ' Medical center ', ' experience ', ' social model ', ' cohesion ', ' novel ', ' models and simulation ', ' model-based simulation ', ' Prevention ', ' Modality ', ' social ', ' Modeling ', ' Cellular Phone ', ' smartphone ', ' smart phone ', ' iPhone ', ' Cellular Telephone ', ' Cell Phone ', ' prevent ', ' preventing ', ' Biomedical Computing ', ' biomedical computation ', ' Data ', ' NCI Scholars Program ', ' Scholars Program ', ' Resource Sharing ', ' Behavioral ', ' cost ', ' Behavioral Model ', ' modeling of the data ', ' model the data ', ' model of data ', ' data modeling ', ' data integration ', ' next generation ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Impairment ', ' movement limitation ', ' movement impairment ', ' motor impairment ', ' public health relevance ', ' industry partnership ', ' industrial partnership ', ' industry partner ', ' sharing data ', ' flexible ', ' flexibility ', ' clinical decision-making ', ' BigData ', ' Big Data ', ' health data ', ' biomechanical simulation ', ' biomechanical modeling ', ' biomechanic simulation ', ' biomechanic modeling ', ' biomechanical model ', ' massive open online courses ', ' visiting scholar ', ' Data Scientist ', ' Data Science ', ' activity tracker ', ' activity monitor ', ' accelerometry ', ' Accelerometer ', ' BD2K ', ' Big Data to Knowledge ', ' improved outcome ', ' symptom relief ', ' symptom reduction ', ' symptom alleviation ', ' relieves symptoms ', ' fewer symptoms ', ' decrease symptom ', ' ameliorating symptom ', ' alleviate symptom ', ' reduce symptoms ', ' web-based resource ', ' web resource ', ' online compendium ', ' on-line resource ', ' on-line compendium ', ' internet resource ', ' online resource ', ' wearable sensor ', ' wearable device ', ' surgical outcome ', ' surgery outcome ', ' societal costs ', ' ']",NIBIB,STANFORD UNIVERSITY,U54,2018,2193870,0.037320809188723165
"Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data     DESCRIPTION (provided by applicant)    My goal in seeking a K01 Award is to acquire the necessary training to become an independently funded investigator focused on exploiting the power of biomedical Big Data Science to improve outcome following severe injury. I am a trauma surgeon at San Francisco General Hospital, one of the Nation's leading trauma centers, and an Assistant Professor of Surgery at the University of California San Francisco (UCSF). UCSF has recently entered into collaboration with the National Laboratories to study the use of biomedical Big Data in complex clinical conditions and my main mentor, Dr. Mitchell J. Cohen is the lead investigator at UCSF for this collaboration. I believe that given the complexity of the factors that likely affect traum outcome including patient injury patterns, medical co-morbidities, patient biology, and the system of care, trauma provides a solid foundation to study the utility of Big Data Science for solving complex medical questions. To facilitate my growth as an expert in this field, I am proposing to develop a framework for integrating multiple data sources necessary to forecast patient outcomes following trauma. These novel datasets combined with biologic and metadata will then be utilized to create improved metrics that better predict complication risk from modifiable and non-modifiable factors. The net result of this work is a new approach to data ascertainment for measuring outcome, leveraging new data types to improve prediction of patient trajectory, and creating a platform to interface with existing information technology to ultimately be used for an early warning detection system for patients at risk of complications. The future long-term goal of this work would be to identify early patients predicted to do more poorly and then apply refinements to the process of care to minimize complication development. The creation of early warning detection systems has significant theoretic potential to improve quality and ultimately decrease costs. Nearly $30 billion per year in the US is spent on care for the traumatically injured and the development of post-traumatic complications is believed to be major contributor to the overall costs of care. The ability to report performance has been hampered by a lack of standard definitions, reporting bias, access to datasets, and the analysis techniques that fail to account for the highly confounded relationships contributing to patient outcome. This K01 award will provide me with the support necessary to accomplish the following goals: (1) to become an expert in applying biologic big data to trauma care (2) to elucidate the relationship of modifiable factors affecting complication development (3) to gain experience with advanced biostatistical techniques and bioinformatics; and (4) to develop an independent clinical research career. To achieve these goals, I have assembled a multidisciplinary team including Dr. Cohen, a National expert in trauma systems biology and biologic big data, and two co-mentors: Dr. Michael Matthay, a translational research expert in complications after severe illness, and Dr. Alan Hubbard, an expert in advanced biostatistical techniques including biologic big data analysis. PUBLIC HEALTH RELEVANCE    In the US, trauma is the leading cause of death for those under 45 years old and many of the patients who survive their initial injuries develop complications such as blood clots or pneumonia that contribute to both death and the long-term effects of the trauma. Through leveraging the power of biomedical Big Data, an integrated approach to measuring outcome will be developed utilizing biologic, clinical, and electronic medical record (EMR) data. The goal of this project is to lay the ground work for developing integrated EMR early warning detection systems that could identify those at risk of complications early with the intent to ultimately refie the process of care for this group to minimize complication development.",Advancing Outcome Metrics in Trauma Surgery Through Utilization of Big Data,9530647,K01ES026834,"['Affect ', ' Age ', ' ages ', ' Algorithms ', ' Biology ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Blood coagulation ', ' Blood Clotting ', ' California ', ' Cause of Death ', ' Clinical Research ', ' Clinical Study ', ' Comorbidity ', ' co-morbidity ', ' Complication ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Foundations ', ' Future ', ' Patient Care ', ' Patient Care Delivery ', ' Geographic Locations ', ' geographic site ', ' Geographical Location ', ' Geographic Region ', ' Geographic Area ', ' Goals ', ' Growth ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Hospitalization ', ' Hospitals ', ' General Hospitals ', ' Hybrids ', ' Laboratories ', ' Lead ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Long-Term Effects ', ' Longterm Effects ', ' Mentors ', ' Methods ', ' Modernization ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Patients ', ' Play ', ' Pneumonia ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Risk ', ' Risk Factors ', ' San Francisco ', ' Standardization ', ' Technology ', ' Testing ', ' Time ', ' trauma centers ', ' Universities ', ' Work ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Outcome Measure ', ' Socioeconomic Status ', ' socioeconomic position ', ' socio-economic position ', ' Socio-economic status ', ' Data Set ', ' Dataset ', ' Caring ', ' Myocardial Ischemia ', ' myocardium ischemia ', ' myocardial ischemia/hypoxia ', ' heart ischemia ', ' coronary ischemia ', ' cardiac ischemia ', ' Ischemic myocardium ', ' Ischemic Heart Disease ', ' Ischemic Heart ', ' Injury ', ' base ', ' career ', ' improved ', ' Solid ', ' Clinical ', ' Physiologic ', ' Physiological ', ' Medical ', ' Training ', ' disability ', ' Funding ', ' Collaborations ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Source ', ' Pattern ', ' Techniques ', ' System ', ' Benchmarking ', ' Best Practice Analysis ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Surgeon ', ' Deltastab ', ' Predniocil ', ' Prednihexal ', ' Predni-POS ', ' Predni-H ', ' Prednefrin SF ', ' Predcor ', ' Predate ', ' Predalone ', ' Predaject ', ' Pred Mild ', ' Pred Forte ', ' Pred Fort ', ' Ophtho-Tate ', ' Locaseptil-Neo ', ' Key-Pred ', ' Inflanefran ', ' Inf-Oph ', ' Hydrocortancyl ', ' Hexacortone ', ' Econopred ', ' Diopred ', ' Deltacortilen ', ' Balpred ', ' Articulose-50 ', ' Ak-Tate ', ' American ', ' experience ', ' Performance ', ' professor ', ' Informatics ', ' High Performance Computing ', ' high-end computing ', ' novel ', ' Reporting ', ' Statistical Methods ', ' Modeling ', ' portability ', ' Bioinformatics ', ' Bio-Informatics ', ' Effectiveness ', ' Address ', ' Systems Biology ', ' Data ', ' Data Element ', ' Detection ', ' Mentored Research Scientist Development Award ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Characteristics ', ' Process ', ' followed up ', ' follow up ', ' Active Follow-up ', ' follow-up ', ' developmental ', ' Development ', ' meta data ', ' Metadata ', ' cost ', ' injured ', ' care services ', ' care systems ', ' risk prediction model ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' predictive modeling ', ' Information Technology ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' novel strategies ', ' Outcome ', ' Trauma ', ' modifiable risk ', ' multidisciplinary ', ' demographics ', ' public health relevance ', ' trauma care ', ' cloud based ', ' BigData ', ' Big Data ', ' Trauma patient ', ' Data Scientist ', ' Data Science ', ' individual patient ', ' improved outcome ', ' Traumatic injury ', ' predictor algorithm ', ' predictive algorithm ', ' prediction algorithm ', ' big biomedical data ', ' iPhone Application ', ' iPhone App ', ' iOS application ', ' iOS app ', ' Smartphone App ', ' Smart Phone Application ', ' Smart Phone App ', ' Cellular Phone Application ', ' Cellular Phone App ', ' Cell phone App ', ' Cell Phone Application ', ' Android Application ', ' Android App ', ' smartphone Application ', ' care costs ', ' ']",NIEHS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",K01,2018,221740,0.0716297166759109
"Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy     DESCRIPTION (provided by applicant)     A new electrical biomarker has been identified in high resolution, intracranial electroencephalogram (iEEG) recordings, called a high frequency oscillation (HFO). Studies have suggested this biomarker has great promise to identify seizure networks and improve surgical outcomes for patients with refractory epilepsy. However, translation of HFOs to clinical practice is hampered by many factors such as spatial, temporal and inter-patient variation in HFO detection rates, false positive and false negative detections, and significant background noise. Big data approaches using large numbers of HFOs acquired from many patients are needed to quantify these effects and allow clinical usage of HFOs. This project details a plan in which the candidate's experience quantifying measurement and detection bias in massive high energy nuclear physics datasets will be combined with a multidisciplinary mentor team to address this problem. The combination of training in computational neuroscience, big data network analysis, and translational neural engineering research will be critical to approach this problem and provide a career trajectory for the candidate. The specific aims of this proposal address three specific confounding factors: 1) the false negative HFO detection rate, 2) variations in HFO features not due to epilepsy, and 3) effects of the state of vigilance on HFOs. Each of these aims involve novel big data methods and/or applications generalizable to other situations: 1) estimating false positive detection rates using a combined experimental/simulated data approach, 2) clustering and classification of distributions of data points, rather than of the data points directly, and 3) a general disambiguation statistic to assess meaningful (rather than statistical) difference between distributions.  The applicant's career goal is to become an academic researcher in the analysis and modeling of intracranial EEG data with a focus on translational epilepsy and sleep physiology research. With the rapid advancement in the resolution of clinical EEG, there is already a strong need for this type of research expertise. Thi grant will provide didactic coursework, formal research and methods training, and career guidance from an expert mentor team. The three mentors have appointments spanning Neurology, Anesthesiology, Mathematics, Statistics, Biomedical Engineering, and Electrical Engineering and Computer Science. The candidate will also build and mentor a research team and establish external collaborations.  The University of Michigan is a premier research university with strong programs and training opportunities in biomedical and physical sciences, engineering, translational and academic research, and advanced research computing. This proposal makes extensive use of the University's large computer cluster. The mentor team and an external collaborator will provide candidate access to prerecorded, deidentified data from over 150 patients, estimated to have over 40 million HFOs. The environment and mentor team will provide the training, facilities, and data for the candidate to successfully complete the proposed goals. PUBLIC HEALTH RELEVANCE    Recent advances in epilepsy research are generating very large datasets in the search for better ways to identify the region of brain responsible for generating seizures. A particular signa known as High Frequency Oscillations found in high resolution intracranial EEG shows great promise for identifying these regions, but clinicians are unable to use the signal due to confounding biases. This project combines big data processing expertise from particle physics, computer science and machine learning to address these confounds, providing a more accurate process to enable clinical translation of this new biomarker and potentially improve clinical outcomes.",Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy,9534672,K01ES026839,"['Algorithms ', ' Anesthesiology ', ' Appointment ', ' Biomedical Engineering ', ' bioengineering ', ' bio-engineers ', ' bio-engineered ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Classification ', ' Systematics ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Engineering ', ' Environment ', ' Epilepsy ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Future ', ' Patient Care ', ' Patient Care Delivery ', ' Goals ', ' Grant ', ' High Frequency Oscillation ', ' Hybrids ', ' Literature ', ' Mathematics ', ' Math ', ' Mentors ', ' Mentorship ', ' Methods ', ' Michigan ', ' Motivation ', ' nervous system disorder ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' Neurology ', ' Neurosciences ', ' Noise ', ' Nuclear Energy ', ' Atomic Energy ', ' Nuclear Physics ', ' Patients ', ' physical science ', ' Physics ', ' Physiology ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Seizures ', ' Signal Transduction ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Sleep ', ' statistics ', ' Technology ', ' Translating ', ' Translations ', ' Universities ', ' Vocational Guidance ', ' executive coaching ', ' career counselor ', ' Vocational Counseling ', ' Occupational Guidance ', ' Career Guidance ', ' Career Counseling ', ' Work ', ' Research Methodology ', ' Research Methods ', ' Data Set ', ' Dataset ', ' Custom ', ' base ', ' career ', ' computational neuroscience ', ' detector ', ' improved ', ' Area ', ' Chronic ', ' Clinical ', ' Refractory ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Training ', ' Individual ', ' Measurement ', ' Funding ', ' Collaborations ', ' Electrical Engineering ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Event ', ' Techniques ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' experience ', ' computer science ', ' relating to nervous system ', ' neural ', ' expectation ', ' novel ', ' Graph ', ' vigilance ', ' Excision ', ' resection ', ' Surgical Removal ', ' Removal ', ' Extirpation ', ' Abscission ', ' Statistical Methods ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Sampling ', ' career development ', ' computerized data processing ', ' data processing ', ' Brain region ', ' Address ', ' Data ', ' Detection ', ' Manpower and Training ', ' Resolution ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Patient-Focused Outcomes ', ' translation research ', ' Translational Science ', ' Translational Research ', ' Process ', ' developmental ', ' Development ', ' Electroencephalogram ', ' Outcome ', ' Population ', ' innovative ', ' innovate ', ' innovation ', ' Impairment ', ' clinical relevance ', ' clinically relevant ', ' multidisciplinary ', ' scientific computing ', ' spatial temporal variation ', ' public health relevance ', ' patient population ', ' standard of care ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' Biological Markers ', ' clinical practice ', ' computer cluster ', ' signal processing ', ' BigData ', ' Big Data ', ' flavor physics ', ' particle physics ', ' training opportunity ', ' improved outcome ', ' big biomedical data ', ' terabyte ', ' clinical translation ', ' surgical outcome ', ' surgery outcome ', ' variation between patients ', ' variability between patients ', ' patient variation ', ' patient variability ', ' ']",NIEHS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,K01,2018,148964,0.06360992187175588
"New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis     DESCRIPTION (provided by applicant)    Maha R Farhat, MD is an Instructor of Medicine at Harvard Medical School on the tenure track and a staff physician in the Department of Pulmonary and Critical Care Medicine at Massachusetts General Hospital. She is completing a masters of biostatistics at the Harvard School of Public Health in 5/2015. She has spent the last 4.5 years acquiring skills in Mycobacterium tuberculosis biology, epidemiology, bioinformatics and biostatistics. She has experience in the analysis of whole genome sequence data, drug resistance data and patient clinical outcome data with the focus of identifying Mycobacterium tuberculosis genetic determinants of drug resistance. She has also developed new methods in this area. Dr. Farhat has 11 publications 5 of which are first author including high impact and highly cited work in the journals Nature Genetics, Genome Medicine and the International Journal of Tuberculosis and Lung Disease. The short term goals of this K01 award are to provide training for Dr. Farhat in critical aspects of data science, computational and evolutionary biology, advanced biostatistics and network science. Dr. Farhat's long term goal is to become a leader in the field of Big Data analysis for infectious diseases. The proposed research as well as the training activities outlined in the proposal will successfully position Dr. Farhat for her first R01 and an independent career as a physician scientist. Environment: Dr. Farhat will perform the interdisciplinary work outlined in this proposal at the distinguished Harvard Departments of Global Health Social Medicine, Biostatistics, Evolutionary biology and the Institute for Quantitative Social Sciences. Dr. Farhat' mentorship team will include two world renowned leaders in the fields of infectious diseases and Big Data, Dr. Megan Murray and Dr. Gary King; and two rising stars in the fields of network Science and evolutionary Biology, Dr. JP Onnela and Dr. Michael Desai. Dr. Murray, the principal mentor on this proposal has mentored over 38 trainees, 9 of which have went on to have independent research careers, and 6 competed successfully for K awards. She is also PI on two recently awarded NIH/NIAID grants a CETR U19 and a TBRU U19 and has over 350 peer reviewed publications. To complement the expertise of her mentors Dr. Farhat will be advised by Dr. Christiani a practicing pulmonary and critical care physician and world renowned researcher in the field of lung and environmental genetics. She will also collaborate and consult with Dr. Merce Crosas, a data scientist, and Dr. Pardis Sabeti, a computational biologist. She will rotate through Dr. Soumya Raychaudhuri's bioinformatics laboratory to diversify her exposure to biomedical Big Data. In addition, she will receive formal training in evolutionary biology, Bayesian and mixed-model biostatistics, computer science, leadership skills and grant writing. The collaborative opportunities, intellectual environment and resources available to Dr. Farhat are outstanding. Research: Infectious diseases continue to be a major cause of morbidity and mortality. Despite the availability of effective antimicrobials, pathogens are successfully evolving new disease phenotypes that allow them to resist killing by these drugs or in other instances cause more severe disease manifestations or wider chains of transmission. Drug resistance (DR) is now common and some bacteria have even become resistant to multiple types or classes of antibiotics6. A key strategy in the fight against emerging pathogen phenotypes in infectious diseases is surveillance, and early personalized therapy to prevent transmission and propagation of these strains. The timely initiation of antibiotic therapy to which the pathogen is sensitive has been shown to be the key factor influencing treatment outcome for a diverse array of infections. Molecular tests that rely on the detection of microbial genetic mutations are particularly promising for surveillance and diagnosis of these pathogen phenotypes but rely on a comprehensive understanding of how mutations associate with these pathogen phenotypes. Currently there is an explosion of data on pathogen whole genome sequences (WGS) that is increasingly generated from clinical laboratories. Data on disease phenotype may also be available, but methods for the analysis and interpretation of these Big Data are lagging. Here I propose tools to aid in this analysis leveraging Big Data sets from Mycobacterium tuberculosis (MTB) and my prior work. Specifically I propose to (1) develop a web-based public interface to several analysis tools, including a statistical learning model that can predict the MTB DR phenotype from its genomic sequence, (2) to develop and study an MTB gene-gene network, based on WGS data, to improve our understanding of the effect of mutation-mutation interactions on the DR phenotype, and (3) study the performance of methods in current use for the association of genotype and phenotype in pathogens, and develop a generalizable power calculator for the best performing method. PUBLIC HEALTH RELEVANCE    Infectious agents of disease are successfully evolving drug resistance and other adaptations that threaten human health. Understanding the genetic mutations that underlie these disease phenotypes can inform surveillance and diagnostic strategies to combat this threat. Here I propose to develop accessible tools for pathogen genomic analysis that will help identify which genetic mutations are relevant to disease.",New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis,9530648,K01ES026835,"['Affect ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Award ', ' Bacteria ', ' Biology ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Communicable Diseases ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Complement ', ' Complement Proteins ', ' Critical Care ', ' Data Analyses ', ' data interpretation ', ' Data Analysis ', ' Statistical Data Interpretation ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Cessation of life ', ' Death ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Drug resistance ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Pharmaceutical Preparations ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Environment ', ' Epidemiology ', ' epidemiological ', ' epidemiologic ', ' Genetic Epistasis ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Explosion ', ' Future ', ' Genes ', ' Medical Genetics ', ' Clinical genetics ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Grant ', ' Health ', ' General Hospitals ', ' Human ', ' Modern Man ', ' Infection ', ' Institutes ', ' Laboratories ', ' Leadership ', ' Lung ', ' pulmonary ', ' Lung Respiratory System ', ' Lung diseases ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Massachusetts ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Mutation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mycobacterium tuberculosis ', ' mtb ', ' M.tuberculosis ', ' M.tb ', ' M. tuberculosis ', ' M. tb ', ' M tuberculosis ', ' M tb ', ' United States National Institutes of Health ', ' National Institutes of Health ', ' NIH ', ' Online Systems ', ' web based ', ' online computer ', ' On-Line Systems ', ' Patients ', ' Peer Review ', ' Phenotype ', ' Phylogeny ', ' Physicians ', ' Public Health ', ' Publications ', ' Scientific Publication ', ' Research ', ' Research Personnel ', ' Researchers ', ' Investigators ', ' Resources ', ' Research Resources ', ' medical schools ', ' school of medicine ', ' medical college ', ' Public Health Schools ', ' Science ', ' Social Medicine ', ' Social Sciences ', ' Standardization ', ' Testing ', ' Time ', ' Training Activity ', ' training module ', ' Tuberculosis ', ' tuberculous spondyloarthropathy ', ' tuberculosis infection ', ' infection due to Mycobacterium tuberculosis ', ' disseminated tuberculosis ', ' disseminated TB ', ' TB infection ', ' Mycobacterium tuberculosis infection ', ' Mycobacterium tuberculosis (MTB) infection ', ' MTB infection ', ' M.tuberculosis infection ', ' M.tb infection ', ' M. tuberculosis infection ', ' M. tb infection ', ' M tuberculosis infection ', ' Work ', ' Writing ', ' Measures ', ' Treatment outcome ', ' Data Set ', ' Dataset ', ' Magazine ', ' Journals ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Training ', ' Collaborations ', ' Genetic ', ' Infectious Agent ', ' infectious organism ', ' Exposure to ', ' tool ', ' Antibiotic Therapy ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Diagnostic ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' System ', ' Severity of illness ', ' disease severity ', ' instructor ', ' Consult ', ' experience ', ' gene interaction ', ' Performance ', ' computer science ', ' microbial ', ' Structure ', ' skills ', ' simulation ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' Bioinformatics ', ' Bio-Informatics ', ' prevent ', ' preventing ', ' genome sequencing ', ' Low income ', ' global health ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' International ', ' Mentored Research Scientist Development Award ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' National Institute of Allergy and Infectious Disease ', ' NIAID ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' Resolution ', ' Gene Structure/Organization ', ' Gene Organization ', ' Gene Structure ', ' Virulent ', ' Monitor ', ' Transmission ', ' transmission process ', ' Molecular ', ' disease phenotype ', ' fight against ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' burden of illness ', ' designing ', ' design ', ' drug resistant in tuberculosis ', ' drug resistant M.tb ', ' drug resistance Mycobacteria Tuberculosis ', ' drug resistance M Tuberculosis ', ' TB drug resistance ', ' Mtb drug resistance ', ' Drug resistant Mycobacteria Tuberculosis ', ' Drug resistant Mtb ', ' Drug resistant M Tuberculosis ', ' Drug resistance in Mycobacterium Tuberculosis ', ' Drug resistance in Mtb ', ' Drug Resistant Tuberculosis ', ' Drug Resistant TB ', ' Drug Resistance Tuberculosis ', ' Drug resistance in tuberculosis ', ' Outcome ', ' Drug-sensitive ', ' pathogen ', ' Population ', ' prospective ', ' Heritability ', ' resistant ', ' Resistance ', ' anti-microbial ', ' antimicrobial ', ' microbes genome ', ' microbial genome ', ' analytical tool ', ' Microbial Genetics ', ' Network-based ', ' combat ', ' public health relevance ', ' genomewide ', ' genome scale ', ' genome-wide ', ' BigData ', ' Big Data ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' personalized medicine ', ' tenure process ', ' tenure track ', ' Data Scientist ', ' Data Science ', ' pathogenome ', ' pathogen genome ', ' big biomedical data ', ' full genome ', ' entire genome ', ' whole genome ', ' genomic data ', ' ']",NIEHS,HARVARD MEDICAL SCHOOL,K01,2018,220530,0.11982491889484707
"Development of New Genome Editing Agents Using RNA Modifying Enzymes Komor  Project Summary/Abstract - Development of New Genome Editing Agents Using RNA Modifying Enzymes  While targeted genome editing, the introduction of a specific modification in genomic DNA, has the potential to allow researchers to study and better understand mechanisms of human genetic diseases, traditional genome editing methods (including CRISPR-Cas9) that rely on the initial introduction of double stranded DNA breaks (DSB) suffer from modest genome editing efficiencies as well as unwanted gene alterations (indels), particularly when attempting to correct point mutations. Recently, a class of genome editing agents called single base editors was developed that does not involve DSBs, but rather uses a dCas9-tethered single-stranded DNA (ssDNA) modifying enzyme to directly chemically modify target nucleobases within a ~5 nucleotide window determined by the protospacer. Two classes of editors have been developed that use cytosine and adenine deamination chemistries to catalyze the conversion of CG base pairs to TA (CBEs), and AT base pairs to GC (ABEs), respectively. Here we propose the development and characterization of new base editors capable of facilitating new point mutations using methylation chemistry. We have use a bioinformatic approach to identify RNA modifying enzymes that have the potential to be repurposed into new base editors, and have rationally designed mutant libraries to use with directed evolution to convert these enzymes into base editors (Aim 1). Concurrently, we are developing a machine learning program that utilizes existing ssDNA modifying enzymes to identify putative mutations that will expand the substrate scope of the identified methyltransferases to ssDNA (Aim 2). Mutations identified from both strategies will then be tested and characterized for base editing in multiple orthogonal systems (Aim 3). The successful completion of the proposed work will represent a significant addition to existing base editing technologies, and will enable researchers to cleanly and efficiently install two additional types of point mutations into the genome of living cells, allowing researchers to quickly and effectively general model systems for the study of human genetic diseases. Komor  Project Narrative - Development of New Genome Editing Agents Using RNA Modifying Enzymes Base editing enables high efficiency genomic point mutation introduction in a variety of cell types and has the potential to allow researchers to better study human genetic diseases. We propose transformative improvements to current base editing technologies that will expand the types of point mutations that can be introduced by base editors. The tools developed here will enable researchers to cleanly and efficiently install additional types of point mutations into the genome of living cells for the study and potential treatment of human genetic diseases.",Development of New Genome Editing Agents Using RNA Modifying Enzymes,9876634,R21GM135736,"['Methylation ', ' transmethylase ', ' methylase ', ' EC 2.1.1 ', ' Methyltransferase ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Program Development ', ' Proteins ', ' Purines ', ' Pyrimidine ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' transfer Ribonucleic acids ', ' tRNA ', ' Triplet Codon-Amino Acid Adaptor ', ' Transfer RNA ', ' Specificity ', ' Technology ', ' Testing ', ' Uracil ', ' Work ', ' Generations ', ' Measures ', ' case report ', ' Case Study ', ' Mediating ', ' Point Mutation ', ' base ', ' Site ', ' Variant ', ' Variation ', ' Link ', ' Chemicals ', ' Lesion ', ' Individual ', ' Directed Molecular Evolution ', ' directed evolution ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' cell type ', ' System ', ' preference ', ' Gene Mutation ', ' Gene Alteration ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' nucleobase ', ' transition mutation ', ' transversion mutation ', ' Base Pairing ', ' novel ', ' Genomics ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Double Strand Break ', ' Mammalian Cell ', ' Modification ', ' Development ', ' developmental ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' design ', ' designing ', ' combat ', ' Genomic DNA ', ' gDNA ', ' genome editing ', ' genomic editing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' Adenine ', ' Vitamin B4 ', ' 1H-Purin-6-amine ', ' adenosine deaminase ', ' Adenosine Aminohydrolase ', ' Adoption ', ' Algorithms ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Body ', ' Cells ', ' Chemistry ', ' Communities ', ' Cytosine ', ' Deamination ', ' Deoxyribonucleic Acid ', ' DNA ', ' DNA Injury ', ' DNA Damage ', ' Single-Stranded DNA ', ' Engineering ', ' Enzyme Gene ', ' Enzymes ', ' E. coli ', ' E coli ', ' Escherichia coli ', ' Evolution ', ' Genome ', ' Modern Man ', ' Human ', ' Human Genetics ', ' In Vitro ', ' Inosine ', ' Libraries ', ' Methods ', ' ']",NIGMS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R21,2019,205479,0.06526979402355713
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9825986,R21CA242861,"['Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Attention ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biology ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' immuno therapy ', ' immune-based treatments ', ' immune-based therapies ', ' immune therapy ', ' immune therapeutic strategy ', ' immune therapeutic regimens ', ' immune therapeutic interventions ', ' immune therapeutic approach ', ' immune drugs ', ' Immunologically Directed Therapy ', ' Immunotherapy ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Monte Carlo simulation ', ' Monte Carlo procedure ', ' Monte Carlo calculation ', ' Monte Carlo algorithm ', ' Monte Carlo Method ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' social role ', ' Role ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Process ', ' Biological Function ', ' cancer immunotherapy ', ' immunotherapy of cancer ', ' immunotherapy for cancer ', ' anticancer immunotherapy ', ' anti-cancer immunotherapy ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Computational Biology ', ' computer biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' neoplastic cell ', ' Tumor Cell ', ' cohort ', ' novel ', ' Positioning Attribute ', ' Position ', ' Code ', ' Coding System ', ' Modeling ', ' response ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' Genomic Segment ', ' genomic region ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' epigenomics ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' immunogenicity ', ' design ', ' designing ', ' Outcome ', ' clinical effect ', ' clinical application ', ' clinical applicability ', ' open source ', ' tumor ', ' genome-wide ', ' genomewide ', ' genome scale ', ' The Cancer Genome Atlas ', ' TCGA ', ' exome sequencing ', ' exome-seq ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' predicting response ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' reference genome ', ' reference assembly ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' checkpoint therapy ', ' immune checkpoint therapy ', ' immune check point therapy ', ' checkpoint inhibitor therapy ', ' checkpoint immunotherapy ', ' check point therapy ', ' check point inhibitor therapy ', ' check point immunotherapy ', ' immune checkpoint blockade ', ' immune check point blockade ', ' checkpoint blockade ', ' check point blockade ', ' neoantigens ', ' neoepitopes ', ' neo-epitopes ', ' neo-antigen ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2019,232291,0.21826324425005916
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,9778816,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cell Body ', ' Cells ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Cyst ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' Renal Cyst ', ' Kidney Cyst ', ' Cystic kidney ', ' Methods ', ' Methodology ', ' mosaic disorders ', ' Mosaicism ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Phenotype ', ' Proteins ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Proinsulin Convertase 2 ', ' Prohormone Convertase 2 ', ' PC2 Protein ', ' PC2 Prohormone Convertase ', ' PC2 Endoprotease ', ' PC2 ', ' Neuroendocrine Convertase PC2 ', ' Endopeptidase PC2 ', ' Proprotein Convertase 2 ', ' Dominant Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Adult Polycystic Kidney Disease ', ' ADPKD ', ' Autosomal Dominant Polycystic Kidney ', ' Proprotein Convertase SPC3 ', ' Proinsulin Convertase 1 ', ' Prohormone Convertase 3 ', ' Prohormone Convertase 1 ', ' PC3 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC1 Endoprotease ', ' PC1 ', ' Neuroendocrine Convertase PC1 ', ' Proprotein Convertase 1 ', ' Dataset ', ' Data Set ', ' polycystic liver disease ', ' Fibrocystic liver disease ', ' Cystic disease of liver ', ' Congenital cystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variant ', ' Variation ', ' Biological ', ' Biochemical ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' prognostic ', ' Renal function ', ' kidney function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Molecular Chaperones ', ' Chaperone ', ' Funding ', ' Hepatic Cyst ', ' Liver Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' Severity of illness ', ' disease severity ', ' Penetrance ', ' PRKCSH protein ', ' protein kinase substrate 80KD protein, heavy chain ', ' protein kinase substrate 80K-H ', ' PRKCSH ', ' G19P1 protein ', ' FGF-stimulated p90 ', ' 80K-H protein ', ' Nonsense Mutation ', ' non-sense mutation ', ' mutant ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' End-Stage Renal Disease ', ' End-Stage Kidney Disease ', ' ESRD ', ' End stage renal failure ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' Cellular Assay ', ' cell assay ', ' Functional Imaging ', ' physiological imaging ', ' Physiologic Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' Grouping ', ' groupings ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' mouse model ', ' murine model ', ' loss of function ', ' therapy development ', ' treatment development ', ' intervention development ', ' develop therapy ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' exome sequencing ', ' exome-seq ', ' screening ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' variant of unknown significance ', ' variant of undetermined significance ', ' variant of uncertain significance ', ' variant of uncertain clinical significance ', ' unclassified variant ', ' prognostic tool ', ' mutation screening ', ' mutation scanning ', ' individual patient ', ' molecular diagnostics ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2019,510292,0.08185635525922613
"Computational evaluation of the causal role of somatic mutations in human aging Project Abstract Although genome instability has long been considered as one of the major causal factors of aging, little is known about the actual number of genome alterations per cell and their effects on aging organisms, most notably humans. In the research proposed here I will take a single cell approach to identify the most common types of somatic mutations, i.e., base substitutions, small INDELS, copy number variation, genome structural variation and retrotranspositions, in human B lymphocytes as a function of age. The overarching goal is then to estimate functional effects of these DNA mutations accumulated during human aging in this particular cell type, which will also serve as a model for studying somatic mutations and their consequences in other cell types. This could never be tested before, because it was never possible to analyze random somatic mutations in a tissue by sequencing bulk DNA from that tissue (mutations are low- abundant), I will achieve this goal by utilizing a new, single-cell, whole genome sequencing (SCWGS) protocol that we developed. In this project I will focus on human B lymphocytes from individuals varying in age from about 30 to over 100 years and determine the genome-wide frequency and location of the different types of mutations in multiple cells from each individual (Aim 1). Preliminary results already show a significant increase of both base substitution mutations and CNVs with age, with a substantial number of these mutations in B cell genomic regions that are potentially functional. Hence, in Aim 2 I will predict the actual functional effects of these potentially functional, age-related mutations using machine learning approaches and integrative network analysis. Finally, in Aim 3 I will empirically test these predictions as to whether the mutation loads observed affect B cell's ability of response to stimulus. Hence, to test the long-standing hypothesis of genome instability as a causal factor in aging ,I will determine age-related mutations in single cells at four levels: (1) number of mutations, mutation spectra and genome distribution in individual cells; (2) potential functional effects of individual mutations, i.e., non-synonymous mutations in exons and mutations in gene regulatory regions; (3) mutations collectively affecting the gene regulatory network; and (4) relationship between mutation load and B cell activation status. In summary, the results of the proposed project will, for the first time uncover possible direct functional effects of somatic mutations on cellular function. Project Narrative Genome instability is considered as one of the major factors of aging and age-related diseases. This research aims to study somatic DNA mutations in normal blood cells (B lymphocytes) of humans of different ages and evaluate the functional effect of these mutations. It will dramatically improve the knowledge of DNA mutations in aging and deepen the understanding of genome instability as a basic aging mechanism in human.",Computational evaluation of the causal role of somatic mutations in human aging,9785353,K99AG056656,"['Affect ', ' Age ', ' ages ', ' Elderly ', ' senior citizen ', ' older person ', ' older adult ', ' later life ', ' late life ', ' geriatric ', ' elders ', ' advanced age ', ' Aging ', ' B-Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Blood Cells ', ' Peripheral Blood Cell ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' centenarian human (100+) ', ' 100+ years old ', ' Centenarian ', ' Thymonuclease ', ' Pancreatic DNase ', ' DNase I ', ' DNA Endonuclease ', ' Deoxyribonuclease I ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' DNA Injury ', ' DNA Damage ', ' Transposable Elements ', ' DNA Transposable Elements ', ' Unscheduled DNA Synthesis ', ' DNA Damage Repair ', ' DNA Repair ', ' Exons ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Allergy ', ' Hypersensitivity ', ' Immunostimulation ', ' Immunological Stimulation ', ' Immunological Sensitization ', ' Immunologic Stimulation ', ' Immunologic Sensitization ', ' Immunization ', ' Laboratories ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Learning ', ' Mentors ', ' Methods ', ' Study models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' living system ', ' Organism ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' social role ', ' Role ', ' Computer Software Tools ', ' Software Tools ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Enhancers ', ' promotor ', ' promoter ', ' base ', ' crosslink ', ' cross-link ', ' improved ', ' Site ', ' repaired ', ' repair ', ' Variant ', ' Variation ', ' Evaluation ', ' Stimulus ', ' Individual ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' dietary restriction ', ' restricted diet ', ' diet restriction ', ' Frequencies ', ' Protocols documentation ', ' Protocol ', ' Source ', ' cell type ', ' Location ', ' Locus Control Region ', ' Somatic Mutation ', ' repair enzyme ', ' repair endonuclease ', "" 5' Untranslated Regions "", ' mRNA Leader Sequences ', "" 5'UTR "", "" 3' Untranslated Regions "", "" 3'UTR "", ' Structure ', ' DNA amplification ', ' Somatic Cell ', ' Mutation Analysis ', ' Code ', ' Coding System ', ' Pathway Analysis ', ' Network Analysis ', ' response ', ' theories ', ' Genomic Instability ', ' Genome Instability ', ' RNA amplification ', ' B-Cell Activation ', ' genome sequencing ', ' Defect ', ' Copy Number Polymorphism ', ' copy number variation ', ' copy number variant ', ' DNA Replication Damage ', ' DNA Replicating Damage ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutation Spectra ', ' Retrotransposition ', ' Cancer Etiology ', ' Cancer Cause ', ' Collecting Cell ', ' Genomic Segment ', ' genomic region ', ' Process ', ' age related ', ' age dependent ', ' nonsynonymous mutation ', ' non-synonymous mutation ', ' insertion/deletion mutation ', ' insertion/deletion ', ' insertion-deletion mutation ', ' insertion-deletion ', ' indel ', ' genome-wide ', ' genomewide ', ' genome scale ', ' single cell sequencing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' whole genome ', ' full genome ', ' entire genome ', ' single cell technology ', ' ']",NIA,ALBERT EINSTEIN COLLEGE OF MEDICINE,K99,2019,135945,0.20177922322364664
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9678589,F30HL146052,"['Actins ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Catalysis ', ' Chemistry ', ' Crystallization ', ' Disorder ', ' Disease ', ' Food or Food Product ', ' Food ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' heart disorder ', ' Cardiac Disorders ', ' Cardiac Diseases ', ' Heart Diseases ', ' Modern Man ', ' Human ', ' bowel ', ' Intestinal ', ' Intestines ', ' Kinetics ', ' Learning ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Membrane Protein Gene ', ' Membrane Proteins ', ' Methods ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Myosins ', ' Myosin Adenosinetriphosphatase ', ' Myosin Adenosine Triphosphatase ', ' Actin-Activated ATPase ', ' Myosin ATPase ', ' Phenotype ', ' Phylogeny ', ' Physics ', ' Proteins ', ' Relaxation ', ' social role ', ' Role ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Solvents ', ' gastric ', ' Stomach ', ' Testing ', ' Time ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' sudden cardiac death ', ' base ', ' sensor ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Biochemical ', ' heart function ', ' function of the heart ', ' cardiac function ', ' insight ', ' Human body ', ' Human Figure ', ' Biological Process ', ' Biological Function ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' millisecond ', ' Msec ', ' Techniques ', ' limb movement ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' Protein Isoforms ', ' Isoforms ', ' Molecular Motors ', ' rat Ran 2 protein ', ' rat Ran-2 antigen ', ' Ran 2 ', ' Speed ', ' Structure ', ' simulation ', ' novel ', ' member ', ' Appearance ', ' Code ', ' Coding System ', ' Regulation ', ' Modeling ', ' Property ', ' Cardiomyopathies ', ' myocardium disorder ', ' myocardium disease ', ' Myocardiopathies ', ' Myocardial Disorder ', ' Myocardial Diseases ', ' Genetic Determinism ', ' genetic determinant ', ' Cardiac Myosins ', ' Cardiac Muscle Myosins ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' Pharmacologic Substance ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Address ', ' Affinity ', ' Data ', ' Drug Binding Site ', ' Motor ', ' Protein Analysis ', ' Protein Region ', ' Resolution ', ' Molecular ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' computerized tools ', ' computational tools ', ' prototype ', ' disease-causing mutation ', ' rare variant ', ' rare allele ', ' biophysical properties ', ' biophysical parameters ', ' biophysical measurement ', ' biophysical characterization ', ' biophysical characteristics ', ' precision medicine ', ' precision-based medicine ', ' Patient risk ', ' Data Science ', ' Congenital cardiomyopathy ', ' Underrepresented Groups ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Risk stratification ', ' ']",NHLBI,WASHINGTON UNIVERSITY,F30,2019,30442,0.008752770381503988
"SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data Abstract Over 30 million people in the US suffer from genetic diseases or cancers caused by mutations of which ~15% disrupt the regulation of splicing. Alternative splicing (AS) errors have been reported in literature to drive 370 genetic diseases out of ~800 described to date. In addition, due to the recent success of FDA-approved splicing modulators like Nusinersen, along with fascinating pre- clinical results underlining the importance of AS as therapeutic targets; splicing research has become of major interest to pharmaceutical companies. Envisagenics is developing SpliceCoreTM, an innovative cloud-based software platform using biomedical big data for AS analysis to discover new therapies and biomarkers for complex diseases. Our breakthrough platform combines algorithms and databases developed and experimentally validated at Cold Spring Harbor Laboratory (CSHL): SpliceTrapTM, for the detection of splicing activity using RNA-seq data; SpliceDuoTM, for the identification of significant splicing variation across biological samples; SpliceImpact2TM, for the prioritization of biologically relevant AS variants with therapeutic potential; and TXdbTM, a splicing isoform database that connects clients proprietary data to public repositories such as the Cancer Genome Atlas (TCGA). Thanks to the Phase I award SpliceCore was adapted as a cloud-based software, accelerating scalability and adaptation to the fast- evolving market of biomedical Big Data. We now have deployed SpliceCores back-end on three cloud-service providers, increased its overall run-time by a factor of 12, developed tools to discover disease-specific AS isoforms, finalized and tested a machine-learning algorithm to predict the biological impact of AS, and experimentally validated some of our new predictions with a success rate of 82.5%. The goal for Phase II is to accelerate client acquisition through the development of user-interactive applications informed from clients feedback by substantially expanding the platforms knowledgebase and predictive functions with novel AS isoforms extracted from ~37,000 public datasets. Thus, a new version of SpliceCore will be developed to predict regulatory interactions between RNA-binding proteins and their RNA targets to assist in the interpretation of aberrant splicing factors through a collaboration with world renowned HHMI Professor Dr. Tom Tuschl from Rockefeller University and developer of Nusinersen, Professor Dr. Adrian Krainer from CSHL. Envisagenics is targeting the global bioinformatics market valued at $4 billion in 2014 with a CAGR of over 21%. SpliceCore could capture ~10% of the market, identify novel drug targets, and design RNA therapeutics from aberrant splicing events prevalent in cancer and a multitude of genetic diseases while increasing the efficiency of R&D in biopharma. Project Narrative In this SBIR Phase II, Envisagenics will advance the development of SpliceCoreTM, a cloud-based software platform for the discovery of drug-targets and biomarkers using biomedical big data. Therapeutic screens are increasingly focusing on Alternative Splicing (AS), a biological process that regulates gene-product structure and function. Strikingly, 50% of genetic diseases described in literature can be triggered by AS errors. The recent FDA approval of RNA-therapeutic compounds to correct AS errors, combined with increasingly available big datasets and groundbreaking cloud-computing provide a unique opportunity for computerized discovery of AS therapeutics. Envisagenics technology will help biomedical researchers to translate basic science into new therapeutic products for cancer and genetic diseases. By the completion of this project, we will deploy a user-friendly, secured and scalable SpliceCore software, with new functionalities ready for integration into biopharmaceutical Research & Development workflows.",SpliceCore: A Cloud-Based Software Platform to Translate Alternative Splicing Events into Therapeutic Targets Using RNA-seq Data,9677178,R44GM116478,"['Achievement ', ' Achievement Attainment ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Amyotrophic Lateral Sclerosis ', ' Lou Gehrig Disease ', "" Gehrig's Disease "", ' Amyotrophic Lateral Sclerosis Motor Neuron Disease ', ' Award ', ' Back ', ' Dorsum ', ' Biological Products ', ' biotherapeutic agent ', ' biopharmaceutical ', ' Biological Agent ', ' Biologic Products ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Client ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' facial ', ' faces ', ' Face ', ' Feedback ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Immune Precipitation ', ' Immunoprecipitation ', ' Laboratories ', ' Literature ', ' Manuals ', ' Maps ', ' Methods ', ' Cruveilhier disease ', ' Aran-Duchenne disease ', ' Spinal Muscular Atrophy ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' myelodysplasia ', ' Smoldering Leukemia ', ' Refractory anaemia with excess blasts ', ' Refractory Anemia with an Excess of Blasts ', ' Myelodysplastic Syndromes ', ' Myelodysplastic Disease ', ' Dysmyelopoietic Syndromes ', ' Nucleotides ', ' Patients ', ' Privatization ', ' Probability ', ' Research ', ' R&D ', ' R & D ', ' Development and Research ', ' research and development ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribonucleosides ', ' Risk ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Splicing ', ' RNA Splicing ', ' Running ', ' Software ', ' Computer software ', ' Specificity ', ' Technology ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Translating ', ' Universities ', ' Work ', ' pricing ', ' Price ', ' RNA-Binding Proteins ', ' Dataset ', ' Data Set ', ' Imagery ', ' Visualization ', ' crosslink ', ' cross-link ', ' improved ', ' Phase ', ' Variant ', ' Variation ', ' Biological ', ' Ensure ', ' Failure ', ' Databases ', ' data base ', ' Data Bases ', ' Biological Process ', ' Biological Function ', ' Collaborations ', ' Therapeutic ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Protein Splicing ', ' Frequencies ', ' Complex ', ' Event ', ' System ', ' interest ', ' Services ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' professor ', ' knowledge base ', ' knowledgebase ', ' fascinate ', ' Structure ', ' novel ', ' Basic Science ', ' Basic Research ', ' cancer genetics ', ' Reporting ', ' Regulation ', ' Sampling ', ' case control ', ' repository ', ' Meta-Analysis ', ' Data Pooling ', ' Clinical Trial Overviews ', ' drug discovery ', ' RNA-Binding Protein FUS ', ' hnRNP P2 ', ' Translocated in Liposarcoma Protein ', ' TLS Protein ', ' POMp75 Protein ', ' Fusion Protein in Myxoid Liposarcoma ', ' FUS Protein ', ' Drops ', ' Bioinformatics ', ' Bio-Informatics ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' Pharmacologic Substance ', ' datamining ', ' data mining ', ' Defect ', ' Data ', ' Detection ', ' Memorial Sloan-Kettering Cancer Center ', ' MSKCC ', ' Protein Binding Domain ', ' Protein-Protein Interaction Domain ', ' Protein Binding Motif ', ' Cancer Etiology ', ' Cancer Cause ', ' Small Business Innovation Research Grant ', ' Small Business Innovation Research ', ' SBIR ', ' Validation ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' pre-clinical ', ' preclinical ', ' preclinical study ', ' pre-clinical study ', ' cost ', ' computerized ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' Advanced Development ', ' design ', ' designing ', ' Prevalence ', ' innovation ', ' innovative ', ' innovate ', ' user-friendly ', ' human disease ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic target ', ' commercial application ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' FDA approved ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' system architecture ', ' flexibility ', ' flexible ', ' Secure ', ' The Cancer Genome Atlas ', ' TCGA ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' Drug Targeting ', ' therapeutic RNA ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' Big Data ', ' BigData ', ' Food and Drug Administration Drug Approval ', ' FDA Drug Approval ', ' learning strategy ', ' learning method ', ' learning activity ', ' Predictive Analytics ', ' targeted biomarker ', ' Genotype-Tissue Expression Project ', ' GTEx ', ' gene product ', ' big biomedical data ', ' large-scale biomedical data ', ' Cloud Service ', ' petabyte ', ' SRSF2 gene ', ' Serine/Arginine-Rich Splicing Factor 2 ', ' SRSF2 ', ' SC35 ', ' experimental study ', ' experimental research ', ' experiment ', ' service providers ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' data warehouse ', ' data repository ', ' Databanks ', ' Data Banks ', ' Infrastructure ', ' machine learning algorithm ', ' ']",NIGMS,"ENVISAGENICS, INC.",R44,2019,488883,0.06473209201912912
"Massively parallel functional analyses of human PTEN variants Project Summary  We are now able to routinely sequence human genomes at single-base resolution. However, our ability to interpret the functional consequences of detected mutations has lagged behind. Computational approaches scale well but have poor accuracy, whereas retrospective analysis of detected variants has high accuracy but does not scale well. In order to solve this problem, a new experimental paradigm has emerged to empirically characterize the effects of mutations with high accuracy at scale. This approach takes advantage of recent and ongoing improvements in DNA synthesis and sequencing, and has the potential to offer unprecedented insight into protein biochemistry and human disease. We believe these insights will prove to be critical for unlocking the potential of genomic medicine.  In this project we seek to comprehensively assess multiple molecular effects of PTEN mutations on protein function, and assess the utility of this data as a predictor for human clinical phenotype. The PTEN protein is a tumor suppressor that is frequently mutated in diverse human cancers and in the germline of some individuals with overgrowth disorders, cancer predisposition syndromes, or autism. Currently, it is impossible to predict the effects of the vast majority of PTEN germline mutations. Since the phenotypic spectrum of PTEN mutation carriers is broad, it would be highly valuable to understand the ways in which phenotypic outcomes arise from PTEN mutation genotypes.  In Aim 1, we will first employ a yeast-based screen to assess the effects all PTEN single amino acid mutations on lipid phosphatase activity, the primary biochemical function of PTEN protein. It is known that several pathogenic variants are destabilized. Therefore, in Aim 2, we will perform a second, independent screen to assess the steady state protein stability of all PTEN single amino acid mutations. In Aim 3, we will use the data derived from this study as well as publically available biochemical information to train a classifier model to predict the relationship between the mutation genotypes and clinical phenotypes observed in humans. These data will increase our fundamental understanding of PTEN function and the role of mutations in diverse disorders, and could provide a valuable clinical tool that would increase the quality of life for PTEN mutation carriers. Project Narrative  Mutations in the gene PTEN are causal for a diverse set of clinical disorders ranging from cancer to autism spectrum disorder. Here, we seek to gain new fundamental insights into the functional relationships between PTEN mutations and clinical presentations by prospectively characterizing the effects of all single amino acid PTEN mutations in parallel. These data will allow the creation of new models that can predict risk of specific PTEN mutations for different clinical outcomes and potentially lead to personalized therapies, early interventions, and optimal outcomes for PTEN mutation carriers.",Massively parallel functional analyses of human PTEN variants,9794010,F31HD095571,"['Affect ', ' Amino Acids ', ' aminoacid ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cataloging ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cell Separation ', ' Cell Viability ', ' Cell Survival ', ' Cell Body ', ' Cells ', ' Disorder ', ' Disease ', ' Fluorescence ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Genotype ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Modern Man ', ' Human ', ' Human Genetics ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Photoradiation ', ' Light ', ' Lipids ', ' Metabolic Processes ', ' Intermediary Metabolism ', ' Metabolism ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Phenotype ', ' PtdIns ', ' Phosphoinositides ', ' Phosphatidyl Inositol ', ' Inositol Phospholipids ', ' Inositol Phosphoglycerides ', ' Inositide Phospholipids ', ' Phosphatidylinositols ', ' Phosphomonoesterases ', ' Phosphohydrolases ', ' Phosphatases ', ' Phosphoric Monoester Hydrolases ', ' Play ', ' Problem Solving ', ' Proteins ', ' QOL ', ' Quality of life ', ' Risk ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Syndrome ', ' Temperature ', ' Testing ', ' Time ', ' Yeasts ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Clinical ', ' Variant ', ' Variation ', ' Biochemical ', ' Pythons ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' Predisposition ', ' Susceptibility ', ' Training ', ' insight ', ' Individual ', ' Early Intervention ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Catalogs ', ' Complex ', ' Clinic ', ' Reaction ', ' Techniques ', ' Tumor Suppressor Proteins ', ' tumor suppressor ', ' DNA biosynthesis ', ' DNA Synthesis ', ' DNA Replication ', ' novel ', ' PTEN gene ', ' Phosphatase and Tensin Homolog Deleted on Chromosome 10 ', ' Phosphatase and Tensin Homolog ', ' PTEN1 ', ' PTEN Hamartoma Tumor Syndrome With Granular Cell Tumor ', ' PTEN Hamartoma Tumor Syndrome ', ' PTEN ', ' PHTS protein ', ' PHTS gene ', ' Mutated in Multiple Advanced Cancers 1 ', ' MMAC1 ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' high throughput technology ', ' Genomics ', ' Pathogenicity ', ' FRAP1 gene ', ' mammalian target of rapamycin ', ' mTOR ', ' RAFT1 ', ' Mechanistic Target of Rapamycin ', ' FRAP2 ', ' FRAP1 ', ' FKBP12 Rapamycin Complex Associated Protein 1 ', ' FK506 Binding Protein 12-Rapamycin Associated Protein 1 ', ' fitness ', ' autism spectrum disorder ', ' autistic spectrum disorder ', "" Kanner's Syndrome "", ' Infantile Autism ', ' Early Infantile Autism ', ' Autistic Disorder ', ' Autism ', ' Data ', ' Deletion Mutation ', ' Mutate ', ' Protein Biochemistry ', ' Protein/Amino Acid Biochemistry ', ' Resolution ', ' Ubiquitination ', ' ubiquitin conjugation ', ' ubiquination ', ' Ubiquitinoylation ', ' Ubiquitilation ', ' Yeast Model System ', ' yeast model ', ' Characteristics ', ' Molecular ', ' Process ', ' protein function ', ' Development ', ' developmental ', ' PTEN protein ', ' phosphatase and tensin homologue on chromosome ten ', ' mutated in multiple advanced cancers 1 protein ', ' MMAC1 protein ', ' Pathway interactions ', ' pathway ', ' clinical phenotype ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' next generation ', ' Outcome ', ' tumorigenic ', ' prospective ', ' Coupled ', ' Coupling ', ' synthetic biology ', ' open source ', ' human disease ', ' mutation carrier ', ' screening ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' accurate diagnosis ', ' genomic variation ', ' Genomic medicine ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' genomic signature ', ' genomic classifier ', ' experimental study ', ' experimental research ', ' experiment ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' ']",NICHD,OREGON HEALTH & SCIENCE UNIVERSITY,F31,2019,45016,0.21665414553331985
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9658531,R35GM127070,"['Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Demography ', ' Evolution ', ' Genes ', ' Population Genetics ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Laboratories ', ' Photoradiation ', ' Light ', ' Maps ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' great ape ', ' Apes ', ' Pongidae ', ' Primates Mammals ', ' Primates ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' statistics ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Genetic Diversity ', ' Genetic Variation ', ' Measures ', ' Enhancers ', ' Natural Selections ', ' promotor ', ' promoter ', ' base ', ' improved ', ' Area ', ' Biochemical ', ' Series ', ' Sample Size ', ' Collaborations ', ' Molecular Evolution ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Pattern ', ' Techniques ', ' computer science ', ' Human Biology ', ' Graph ', ' Reporting ', ' RNA Stability ', ' Sampling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genetic Drift ', ' Genetic Divergence ', ' Genetic Differentiation ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Transcription Initiation ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Regulatory Element ', ' Development ', ' developmental ', ' reconstruction ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' Population ', ' genome annotation ', ' genome analysis ', ' human genomics ', ' CRISPR screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR/Cas9 screen ', ' CRISPR-based screen ', ' CRISPR editing screen ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' ']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2019,479215,0.050870111287866684
"NextGen Random Forests Project Summary/Abstract Building from the PI's current R01, we propose next generation random forests (RF) designed for unprecedented accuracy and computational scalability to meet the challenges of today's complex and big data in the health sciences. Superior accuracy is achieved using super greedy trees which circumvent limitations on local adaptivity imposed by classical tree splitting. We identify a key quantity, forest weights, and show how these can be leveraged for further improvements and generalizability. In one application, improved survival estimators are applied to worldwide esophageal cancer data to develop guidelines for clinical decision making. Richer RF inference is another issue explored. Cutting edge machine learning methods rarely consider the problem of estimating variability. For RF, bootstrapping currently exists as the only tool for reliably estimating condence intervals, but due to heavy computations is rarely applied. We introduce tools to rapidily calculate standard errors based on U-statistic theory. These will be used to increase robustness of esophageal clinical recommendations and to investigate survival temporal trends in cardiovascular disease. In another application, we make use of our new massive data scalability for discovery of tumor and immune regulators of immunotherapy in cancers. This project will set the standard for RF computational performance. Building from the core libraries of the highly accessed R-package randomForestSRC (RF-SRC), software developed under the PIs current R01, we develop open source next generation RF software, RF-SRC Everywhere, Big Data RF-SRC, and HPC RF-SRC. The software will be deployable on a number of popular machine learning workbenches, use distributed data storage technologies, and be optimized for big-p, big-n, and big-np scenarios. Project Narrative We introduce next generation random forests (RF) designed for unprecedented accuracy for complex and big data encountered in the health sciences.",NextGen Random Forests,9706046,R01GM125072,"['Biological Response Modifiers ', ' immunomodulatory biologics ', ' Immune Regulators ', ' Immune Mediators/Modulators ', ' Immune Mediators ', ' Biomodulators ', ' Blood ', ' Blood Reticuloendothelial System ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' multi-modal treatment ', ' multi-modal therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Confidence Intervals ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' cardiac failure ', ' Heart failure ', ' Modern Man ', ' Human ', ' Hybrids ', ' immuno therapy ', ' immune-based treatments ', ' immune-based therapies ', ' immune therapy ', ' immune therapeutic strategy ', ' immune therapeutic regimens ', ' immune therapeutic interventions ', ' immune therapeutic approach ', ' immune drugs ', ' Immunologically Directed Therapy ', ' Immunotherapy ', ' In Vitro ', ' Laboratories ', ' Language ', ' Libraries ', ' lymph gland ', ' Lymph node proper ', ' Lymph Node Reticuloendothelial System ', ' lymph nodes ', ' Methods ', ' Methodology ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Patients ', ' Prognosis ', ' outcome forecast ', ' Recommendation ', ' Software ', ' Computer software ', ' statistics ', ' thymus derived lymphocyte ', ' T-Cells ', ' T-Lymphocyte ', ' Technology ', ' thrombotic disorder ', ' thrombotic disease ', ' Thrombosis ', ' Time ', ' Trees ', ' Weight ', ' forest ', ' Guidelines ', ' base ', ' tumor progression ', ' neoplastic progression ', ' neoplasm progression ', ' cancer progression ', ' Pump ', ' improved ', ' Clinical ', ' Java ', ' Databases ', ' data base ', ' Data Bases ', ' Data Storage and Retrieval ', ' data storage ', ' data retrieval ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Therapeutic ', ' Atrophic ', ' Atrophy ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Immune ', ' Immunes ', ' Complex ', ' Benchmarking ', ' Best Practice Analysis ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' Malignant neoplasm of esophagus ', ' oesophageal cancer ', ' Malignant Tumor of the Esophagus ', ' Malignant Esophageal Tumor ', ' Malignant Esophageal Neoplasm ', ' Esophagus Cancer ', ' Esophageal Cancer ', ' parallel processing ', ' Performance ', ' receptor ', ' Receptor Protein ', ' Neoadjuvant Therapy ', ' Neoadjuvant Treatment ', ' Neoadjuvant ', ' NEOADJ ', ' Induction Therapy ', ' novel ', ' Code ', ' Coding System ', ' Modeling ', ' response ', ' theories ', ' software development ', ' developing computer software ', ' develop software ', ' Data ', ' Health Sciences ', ' Receptor Activation ', ' Subgroup ', ' in vivo ', ' Cancer Patient ', ' Clinical Management ', ' Pathologic ', ' Esophageal ', ' Development ', ' developmental ', ' pre-clinical ', ' preclinical ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' distributed data ', ' design ', ' designing ', ' next generation ', ' Population ', ' Resistance ', ' resistant ', ' open source ', ' mouse model ', ' murine model ', ' therapeutic target ', ' tumor ', ' clinical practice ', ' Interagency Registry for Mechanically Assisted Circulatory Support ', ' Interagency Registry for Mechanical Circulatory Support ', ' INTERMACS ', ' clinical decision-making ', ' Big Data ', ' BigData ', ' learning strategy ', ' learning method ', ' learning activity ', ' predicting response ', ' response prediction ', ' predictor of response ', ' predictive response ', ' prediction of response ', ' Time trend ', ' Trends over time ', ' Temporal trend ', ' immune checkpoint blockade ', ' immune check point blockade ', ' checkpoint blockade ', ' check point blockade ', ' random forest ', ' ']",NIGMS,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,R01,2019,347834,0.05080573512344636
"New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis     DESCRIPTION (provided by applicant)    Maha R Farhat, MD is an Instructor of Medicine at Harvard Medical School on the tenure track and a staff physician in the Department of Pulmonary and Critical Care Medicine at Massachusetts General Hospital. She is completing a masters of biostatistics at the Harvard School of Public Health in 5/2015. She has spent the last 4.5 years acquiring skills in Mycobacterium tuberculosis biology, epidemiology, bioinformatics and biostatistics. She has experience in the analysis of whole genome sequence data, drug resistance data and patient clinical outcome data with the focus of identifying Mycobacterium tuberculosis genetic determinants of drug resistance. She has also developed new methods in this area. Dr. Farhat has 11 publications 5 of which are first author including high impact and highly cited work in the journals Nature Genetics, Genome Medicine and the International Journal of Tuberculosis and Lung Disease. The short term goals of this K01 award are to provide training for Dr. Farhat in critical aspects of data science, computational and evolutionary biology, advanced biostatistics and network science. Dr. Farhat's long term goal is to become a leader in the field of Big Data analysis for infectious diseases. The proposed research as well as the training activities outlined in the proposal will successfully position Dr. Farhat for her first R01 and an independent career as a physician scientist. Environment: Dr. Farhat will perform the interdisciplinary work outlined in this proposal at the distinguished Harvard Departments of Global Health Social Medicine, Biostatistics, Evolutionary biology and the Institute for Quantitative Social Sciences. Dr. Farhat' mentorship team will include two world renowned leaders in the fields of infectious diseases and Big Data, Dr. Megan Murray and Dr. Gary King; and two rising stars in the fields of network Science and evolutionary Biology, Dr. JP Onnela and Dr. Michael Desai. Dr. Murray, the principal mentor on this proposal has mentored over 38 trainees, 9 of which have went on to have independent research careers, and 6 competed successfully for K awards. She is also PI on two recently awarded NIH/NIAID grants a CETR U19 and a TBRU U19 and has over 350 peer reviewed publications. To complement the expertise of her mentors Dr. Farhat will be advised by Dr. Christiani a practicing pulmonary and critical care physician and world renowned researcher in the field of lung and environmental genetics. She will also collaborate and consult with Dr. Merce Crosas, a data scientist, and Dr. Pardis Sabeti, a computational biologist. She will rotate through Dr. Soumya Raychaudhuri's bioinformatics laboratory to diversify her exposure to biomedical Big Data. In addition, she will receive formal training in evolutionary biology, Bayesian and mixed-model biostatistics, computer science, leadership skills and grant writing. The collaborative opportunities, intellectual environment and resources available to Dr. Farhat are outstanding. Research: Infectious diseases continue to be a major cause of morbidity and mortality. Despite the availability of effective antimicrobials, pathogens are successfully evolving new disease phenotypes that allow them to resist killing by these drugs or in other instances cause more severe disease manifestations or wider chains of transmission. Drug resistance (DR) is now common and some bacteria have even become resistant to multiple types or classes of antibiotics6. A key strategy in the fight against emerging pathogen phenotypes in infectious diseases is surveillance, and early personalized therapy to prevent transmission and propagation of these strains. The timely initiation of antibiotic therapy to which the pathogen is sensitive has been shown to be the key factor influencing treatment outcome for a diverse array of infections. Molecular tests that rely on the detection of microbial genetic mutations are particularly promising for surveillance and diagnosis of these pathogen phenotypes but rely on a comprehensive understanding of how mutations associate with these pathogen phenotypes. Currently there is an explosion of data on pathogen whole genome sequences (WGS) that is increasingly generated from clinical laboratories. Data on disease phenotype may also be available, but methods for the analysis and interpretation of these Big Data are lagging. Here I propose tools to aid in this analysis leveraging Big Data sets from Mycobacterium tuberculosis (MTB) and my prior work. Specifically I propose to (1) develop a web-based public interface to several analysis tools, including a statistical learning model that can predict the MTB DR phenotype from its genomic sequence, (2) to develop and study an MTB gene-gene network, based on WGS data, to improve our understanding of the effect of mutation-mutation interactions on the DR phenotype, and (3) study the performance of methods in current use for the association of genotype and phenotype in pathogens, and develop a generalizable power calculator for the best performing method. PUBLIC HEALTH RELEVANCE    Infectious agents of disease are successfully evolving drug resistance and other adaptations that threaten human health. Understanding the genetic mutations that underlie these disease phenotypes can inform surveillance and diagnostic strategies to combat this threat. Here I propose to develop accessible tools for pathogen genomic analysis that will help identify which genetic mutations are relevant to disease.",New Tools for the interpretation of Pathogen Genomic Data with a focus on Mycobacterium tuberculosis,9747894,K01ES026835,"['Affect ', ' Antibiotics ', ' Miscellaneous Antibiotic ', ' Antibiotic Drugs ', ' Antibiotic Agents ', ' Award ', ' Bacteria ', ' Biology ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Infectious Disorder ', ' Infectious Diseases ', ' Infectious Disease Pathway ', ' Communicable Diseases ', ' Complement Proteins ', ' Complement ', ' Critical Care ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' genetic epistases ', ' gene x gene interaction ', ' epistatic relationship ', ' Interaction Deviation ', ' Epistatic Deviation ', ' Epistasis ', ' Genetic Epistasis ', ' Explosion ', ' Future ', ' Genes ', ' Structural Genes ', ' Clinical genetics ', ' Medical Genetics ', ' Genome ', ' Genotype ', ' Geography ', ' Goals ', ' Grant ', ' Health ', ' General Hospitals ', ' Modern Man ', ' Human ', ' Infection ', ' Institutes ', ' Laboratories ', ' Leadership ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' lung disorder ', ' disorder of the lung ', ' disease of the lung ', ' Respiratory System Disorder ', ' Respiratory System Disease ', ' Respiratory Disease ', ' Pulmonary Disorder ', ' Pulmonary Diseases ', ' Lung diseases ', ' Massachusetts ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' mtb ', ' M.tuberculosis ', ' M.tb ', ' M. tuberculosis ', ' M. tb ', ' M tuberculosis ', ' M tb ', ' Mycobacterium tuberculosis ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' web based ', ' online computer ', ' On-Line Systems ', ' Online Systems ', ' Patients ', ' Peer Review ', ' Phenotype ', ' Phylogeny ', ' Physicians ', ' Public Health ', ' Scientific Publication ', ' Publications ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' school of medicine ', ' medical college ', ' medical schools ', ' Public Health Schools ', ' Science ', ' Social Medicine ', ' Social Sciences ', ' Standardization ', ' Testing ', ' Time ', ' training module ', ' Training Activity ', ' tuberculous spondyloarthropathy ', ' tuberculosis infection ', ' infection due to Mycobacterium tuberculosis ', ' disseminated tuberculosis ', ' disseminated TB ', ' TB infection ', ' Mycobacterium tuberculosis infection ', ' Mycobacterium tuberculosis (MTB) infection ', ' MTB infection ', ' M.tuberculosis infection ', ' M.tb infection ', ' M. tuberculosis infection ', ' M. tb infection ', ' M tuberculosis infection ', ' Tuberculosis ', ' Work ', ' Writing ', ' Measures ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' Journals ', ' Magazine ', ' base ', ' career ', ' improved ', ' Area ', ' Clinical ', ' Variant ', ' Variation ', ' Biological ', ' Training ', ' Collaborations ', ' Genetic ', ' Infectious Agent ', ' infectious organism ', ' Exposure to ', ' tool ', ' Antibiotic Therapy ', ' bacterial infectious disease treatment ', ' bacterial disease treatment ', ' Antibiotic Treatment ', ' Diagnostic ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' System ', ' Severity of illness ', ' disease severity ', ' instructor ', ' Consult ', ' experience ', ' gene interaction ', ' Performance ', ' computer science ', ' microbial ', ' Structure ', ' skills ', ' simulation ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' Genomics ', ' Genetic Determinism ', ' genetic determinant ', ' Bioinformatics ', ' Bio-Informatics ', ' preventing ', ' prevent ', ' genome sequencing ', ' Low income ', ' global health ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Detection ', ' Infectious Diseases Research ', ' Infectious Diseases / Laboratory ', ' International ', ' Mentored Research Scientist Development Award ', ' Research Scientist Development Award ', ' Mentored Training Award ', ' K01 Program ', ' K01 Mechanism ', ' K01 Award ', ' National Institute of Allergy and Infectious Disease ', ' NIAID ', ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' Resolution ', ' Gene Structure ', ' Gene Structure/Organization ', ' Gene Organization ', ' Virulent ', ' Monitor ', ' transmission process ', ' Transmission ', ' Molecular ', ' disease phenotype ', ' fight against ', ' burden of illness ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' design ', ' designing ', ' Drug resistance in tuberculosis ', ' drug resistant in tuberculosis ', ' drug resistant M.tb ', ' drug resistance Mycobacteria Tuberculosis ', ' drug resistance M Tuberculosis ', ' TB drug resistance ', ' Mtb drug resistance ', ' Drug resistant Mycobacteria Tuberculosis ', ' Drug resistant Mtb ', ' Drug resistant M Tuberculosis ', ' Drug resistance in Mycobacterium Tuberculosis ', ' Drug resistance in Mtb ', ' Drug Resistant Tuberculosis ', ' Drug Resistant TB ', ' Drug Resistance Tuberculosis ', ' Outcome ', ' Drug-sensitive ', ' pathogen ', ' Population ', ' prospective ', ' Heritability ', ' Resistance ', ' resistant ', ' antimicrobial ', ' anti-microbial ', ' microbial genome ', ' microbes genome ', ' analytical tool ', ' Microbial Genetics ', ' Network-based ', ' combat ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Big Data ', ' BigData ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' tenure track ', ' tenure process ', ' Data Science ', ' pathogen genome ', ' pathogenome ', ' big biomedical data ', ' large-scale biomedical data ', ' whole genome ', ' full genome ', ' entire genome ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' Data Scientist ', ' human pathogen ', ' pathogen genomics ', ' ']",NIEHS,HARVARD MEDICAL SCHOOL,K01,2019,215352,0.11982491889484707
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9741068,R01CA208517,"['Affect ', ' Age ', ' ages ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', "" Alzheimer's Disease "", ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', ' Back ', ' Dorsum ', ' Biology ', ' Brain Neoplasms ', ' tumors in the brain ', ' Brain Tumors ', ' Brain Neoplasia ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Body ', ' Cells ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Diagnosis ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Environmental Exposure ', ' Gene Expression ', ' allelic frequency ', ' Allele Frequency ', ' Gene Frequency ', ' Genes ', ' Genome ', ' Genotype ', ' In Vitro ', ' leukemia ', ' Photoradiation ', ' Light ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' Methodology ', ' Minor ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' Proteins ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Smoking ', ' Syndrome ', ' Testing ', ' Transforming Growth Factor-Beta Family Gene ', ' TGF ', ' TGFbeta ', ' TGF- ', ' TGF-beta ', ' TGF B ', ' Platelet Transforming Growth Factor ', ' Milk Growth Factor ', ' Bone-Derived Transforming Growth Factor ', ' Transforming Growth Factor beta ', ' Weight ', ' Generations ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' Variant ', ' Variation ', ' Biological ', ' Age of Onset ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' Training ', ' insight ', ' Individual ', ' Cyclin-Dependent Kinase Inhibitor 2A ', ' p16INK4A Protein ', ' p16INK4 Protein ', ' p16-INK4 ', ' p16(INK4A) ', ' Protein p16 ', ' Protein MTS1 ', ' Protein CDKN2 ', ' Multiple Tumor Suppressor-1 ', ' INK4A Protein ', ' INK4A Gene Product ', ' Cyclin-Dependent Kinase Inhibitor p16 ', ' Cyclin-Dependent Kinase Inhibitor p12 ', ' Cell Cycle Negative Regulator Beta ', ' Cdk4-Associated Protein p16 ', ' CDKN2A Protein ', ' CDK4 Inhibitor ', ' Genetic ', ' tool ', ' Malignant neoplasm of pancreas ', ' Pancreatic Cancer ', ' Pancreas Cancer ', ' Malignant Pancreatic Neoplasm ', ' Knowledge ', ' Inherited ', ' Hereditary ', ' Pattern ', ' Penetrance ', ' CDKN2A gene ', ' p16INK4a ', ' p16INK4A Genes ', ' p16INK4 Genes ', ' p16 Genes ', ' p14ARF ', ' TSG9A ', ' TP16 ', ' MTS1 Genes ', ' MTS1 ', ' INK4A ', ' INK4 ', ' Cyclin-Dependent Kinase Inhibitor 2A Gene ', ' CMM2 ', ' CDKN2A ', ' CDKN2 Genes ', ' CDKN2 ', ' CDK4I ', ' interest ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' Performance ', ' receptor ', ' Receptor Protein ', ' kindred ', ' novel ', ' member ', ' genetic analysis ', ' Genetic analyses ', ' Code ', ' Coding System ', ' Modeling ', ' Proteomics ', ' Cancer-Predisposing Gene ', ' Cancer Susceptibility Gene ', ' protein expression ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Oncogenesis ', ' tumorigenesis ', ' Address ', ' Sun Exposure ', ' sunlight exposure ', ' solar exposure ', ' metaplastic cell transformation ', ' Cellular Transformation ', ' Data ', ' in vivo ', ' in vivo Model ', ' Cancer Gene Mutation ', ' cancer specific gene mutation ', ' Cell Cycle Progression ', ' Gene-Modified ', ' gene modification ', ' WNT Signaling Pathway ', ' WNT signaling ', ' transmission process ', ' Transmission ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' disease phenotype ', ' epigenomics ', ' feeding ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' innovation ', ' innovative ', ' innovate ', ' Oncogenic ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' network models ', ' mutation carrier ', ' genome-wide analysis ', ' genome-wide identification ', ' genome wide studies ', ' genome wide analysis ', ' overexpression ', ' overexpress ', ' novel therapeutic intervention ', ' novel therapy approach ', ' novel therapeutic approach ', ' new therapy approaches ', ' new therapeutic strategies ', ' new therapeutic intervention ', ' new therapeutic approach ', ' genome-wide ', ' genomewide ', ' genome scale ', ' non-genetic ', ' nongenetic ', ' epidemiologic data ', ' Epidemiology data ', ' Epidemiological data ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' bead chip ', ' BeadChip ', ' high dimensionality ', ' deep learning ', ' convolutional neural network ', ' convolutional neural nets ', ' ConvNet ', ' deep learning algorithm ', ' ']",NCI,MAYO CLINIC ROCHESTER,R01,2019,583253,0.16502161454881356
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9847841,R44GM117961,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Antibodies ', ' Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' Automation ', ' Automobile Driving ', ' driving ', ' Base Sequence ', ' nucleic acid sequence ', ' Nucleotide Sequence ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biotechnology ', ' Biotech ', ' Communities ', ' Data Sources ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Enzyme Gene ', ' Enzymes ', ' Medicine ', ' metabolism disorder ', ' Thesaurismosis ', ' Metabolic Disorder ', ' Metabolic Diseases ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' natural language understanding ', ' Natural Language Processing ', ' Play ', ' protein design ', ' genetic protein engineering ', ' Protein Engineering ', ' Proteins ', ' Reagent ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Standardization ', ' Technology ', ' Generations ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Phase ', ' Link ', ' Training ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Data Quality ', ' Meteor ', ' Inflammatory ', ' Deposition ', ' Deposit ', ' tool ', ' Diagnostic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Protocols documentation ', ' Protocol ', ' Techniques ', ' Structure ', ' novel ', ' peer ', ' Modeling ', ' Sampling ', ' Property ', ' repository ', ' therapeutic protein ', ' protein drug agent ', ' pharmaceutical protein ', ' native protein drug ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' protein structure ', ' Affinity ', ' Data ', ' Collection ', ' Preparation ', ' Modification ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' computerized tools ', ' computational tools ', ' immunogenicity ', ' design ', ' designing ', ' Coupled ', ' Therapeutic antibodies ', ' multitask ', ' multi-task ', ' database structure ', ' data base structure ', ' flexibility ', ' flexible ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' learning strategy ', ' learning method ', ' learning activity ', ' prediction algorithm ', ' predictor algorithm ', ' predictive algorithm ', ' Structural Protein ', ' Drug Screening ', ' data warehouse ', ' data repository ', ' Databanks ', ' Data Banks ', ' data submission ', ' data deposition ', ' deep learning ', ' ']",NIGMS,"PROTABIT, LLC",R44,2019,925531,0.08588080476619434
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9609431,R01CA163336,"['Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Body ', ' Cells ', ' Chromatin ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Deoxyribonucleic Acid ', ' DNA ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Family ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genome ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Glioblastoma ', ' Goals ', ' knowledge of results ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Recurrent ', ' Recurrence ', ' Research ', ' Revertase ', ' Reverse Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' RNA Transcriptase ', ' EC 2.7.7.49 ', ' RNA-Directed DNA Polymerase ', ' social role ', ' Role ', ' Specificity ', ' Testing ', ' Time ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' Work ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' c-myc Genes ', ' telomere ', ' Family member ', ' Mediating ', ' promotor ', ' promoter ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variant ', ' Variation ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Protein Isoforms ', ' Isoforms ', ' Toxic effect ', ' Toxicities ', ' novel ', ' member ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcriptional Control ', ' Transcription Regulation ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' TERT gene ', ' telomerase catalytic subunit ', ' Telomere Reverse Transcriptase ', ' TCS1 ', ' EST2 ', ' Address ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Validation ', ' Molecular ', ' Knock-out ', ' Knockout ', ' resistance mechanism ', ' resistant mechanism ', ' Development ', ' developmental ', ' cancer genomics ', ' oncogenomics ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' computer framework ', ' computational framework ', ' cancer type ', ' Oncogenic ', ' computing resources ', ' computational resources ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' therapeutic target ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' genome-wide ', ' genomewide ', ' genome scale ', ' individual patient ', ' recruit ', ' bioinformatics resource ', ' deep learning ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2019,317385,0.14678739468726082
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,9731524,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Cell Viability ', ' Cell Survival ', ' Communities ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Foundations ', ' Genes ', ' human whole genome ', ' Human Genome ', ' Goals ', ' In Vitro ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Names ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' living system ', ' Organism ', ' Peptides ', ' Transphosphorylases ', ' Phosphotransferase Gene ', ' Kinases ', ' Phosphotransferases ', ' phosphorylase b kinase kinase ', ' hydroxyalkyl protein kinase ', ' glycogen synthase a kinase ', ' Kinase Family Gene ', ' ATP-protein phosphotransferase ', ' Protein Kinase ', ' tyrosyl protein kinase ', ' hydroxyaryl protein kinase ', ' Tyrosylprotein Kinase ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine Kinase ', ' Protein Tyrosine Kinase EEK ', ' Ephrin Type-A Receptor 8 Precursor ', ' Ephrin Type-A Receptor 8 ', ' EPH-and ELK-Related Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' Protein Tyrosine Kinase ', ' Proteins ', ' Publishing ', ' Recurrent ', ' Recurrence ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Tyrosine ', ' Threonine Kinase ', ' Serine/Threonine Protein Kinase Gene ', ' Serine-Threonine Kinases ', ' Serine Kinase ', ' Protein-Threonine Kinase ', ' Protein-Serine Kinase ', ' Protein-Serine-Threonine Kinases ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variant ', ' Variation ', ' Active Sites ', ' Receptor Protein-Tyrosine Kinases ', ' Tyrosine Kinase Receptors ', ' Tyrosine Kinase Linked Receptors ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Receptor Tyrosine Kinase Gene ', ' PTK Receptors ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' System ', ' molecular dynamics ', ' Molecular Dynamics Simulation ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' nonsynonymous mutation ', ' non-synonymous mutation ', ' computer framework ', ' computational framework ', ' Outcome ', ' three dimensional structure ', ' 3D structure ', ' 3-dimensional structure ', ' 3-D structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' predictive test ', ' predictive assay ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2019,300000,0.17732211395365816
"A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data Human monoclonal antibodies are among the fastest growing therapeutic modalities, with over sixty compounds approved by FDA to treat infections, autoimmunity, chronic inflammation and cancer. In combination, these diseases are responsible for the deaths of 50 million people annually, according to the World Health Organization. However, the advent of therapeutic immunologics is expected to significantly reduce the associated morbidity and mortality, particularly for oncologic diseases. Currently, 15 immuno-oncologic (IO) treatments are commercially available and comprise a growing market that is expected to reach $100B by 2022. IO therapeutics effectively attack cancer by selectively binding tumor-specific protein domains on the cell surface, referred to as tumor-associated ectodomains (TAEs). However, many cancers remain insensitive to available IO as effective and safe TAEs are difficult to identify. Standard methods to detect TAEs are costly, time-consuming and limited in their ability to discover novel targets, necessitating the development of innovative technologies to circumvent this burden. RNAseq is currently the most effective method to discover novel splicing isoforms, is high-throughput, sensitive and inexpensive. Envisagenics has been at the forefront of RNAseq- based splicing characterization since the release of its SpliceCore platform. Here, we propose to develop SpliceIO, a novel drug discovery platform that integrates the Envisagenics SpliceCore knowledge base with machine learning algorithms to enable rapid identification of aberrant splicing-derived TAEs using RNAseq data. In this Phase I SBIR proposal, we will develop and apply SpliceIO in the context of Acute Myeloid Leukemia, a cancer particularly resistant to IO but highly associated with splicing mis-regulation and mutations within key spliceosome components. We will identify and validate TAEs in vitro using established leukemia cell lines and patient-derived bone marrow aspirates in collaboration with Dr. Omar Abdel-Wahab from Memorial Sloan Kettering Cancer Center. Collectively, the aims outlined herein will allow us to both develop and validate a novel splicing-dependent TAE identification platform to provide new sources of drug targets while dramatically reducing the time and cost associated with their development. In addition, this will allow Envisagenics to create new partnership opportunities for IO co- development with pharmaceutical companies. If successful, this pipeline can be used to identify drug targets and/or biomarkers for patient stratification in cancer and inflammatory diseases in the context of an SBIR Phase II grant. Despite the recent success of immune-based treatments in melanoma, the majority of cancers remain insensitive and resistant to therapy, necessitating the development of approaches to rapidly identify novel drug targets. Here, we propose to build a target discovery platform that combines our proprietary database of RNA splicing mutations in cancers with machine learning to identify the most clinically-relevant targets for subsequent drug development.",A Software Platform for the Identification of Cell Surface Antigens Using RNA-seq Data,9909639,R43CA246950,"['Alternative Splicing ', ' Alternative RNA Splicing ', ' Alternate Splicing ', ' Antibodies ', ' Monoclonal Antibodies ', ' mAbs ', ' Clinical Treatment Moab ', ' Epitopes ', ' Binding Determinants ', ' Antigenic Determinants ', ' Surface Antigens ', ' Immunological Surface Markers ', ' Immunologic Surface Markers ', ' Cell Surface Antigens ', ' Autoimmunity ', ' Autoimmune Status ', ' Automobile Driving ', ' driving ', ' Bone Marrow ', ' Bone Marrow Reticuloendothelial System ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Death ', ' Cessation of life ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Grant ', ' immuno therapy ', ' immune-based treatments ', ' immune-based therapies ', ' immune therapy ', ' immune therapeutic strategy ', ' immune therapeutic regimens ', ' immune therapeutic interventions ', ' immune therapeutic approach ', ' immune drugs ', ' Immunologically Directed Therapy ', ' Immunotherapy ', ' In Vitro ', ' Infection ', ' Inflammation ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' acute myeloid leukemia ', ' acute granulocytic leukemia ', ' Acute Myelogenous Leukemia ', ' Acute Myeloblastic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myelocytic Leukemia ', ' lymph cell ', ' Lymphocytic ', ' Lymphocyte ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Peptides ', ' Probability ', ' Relapse ', ' Research Resources ', ' Resources ', ' Splicing ', ' RNA Splicing ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Technology ', ' Time ', ' Translations ', ' World Health Organization ', ' Spliceosomes ', ' Tertiary Protein Structure ', ' Protein Domains ', ' Peptide Domain ', ' base ', ' Chronic ', ' Phase ', ' Adult Acute Myeloblastic Leukemia ', ' Adult Acute NonLymphocytic Leukemia ', ' Adult Acute NonLymphoblastic Leukemia ', ' Adult Acute Non-Lymphocytic Leukemia ', ' Adult Acute Non-Lymphoblastic Leukemia ', ' Adult Acute Myeloid Leukemia ', ' Adult Acute Myelogenous Leukemia ', ' Adult Acute Myelocytic Leukemia ', ' Adult Acute Granulocytic Leukemia ', ' Adult ANLL ', ' Adult AML ', ' Adult AGL ', ' Childhood Acute Myeloid Leukemia ', ' Pediatric Acute Myeloid Leukemia ', ' Pediatric Acute Myelogenous Leukemia ', ' Pediatric Acute Myelogeneous Leukemia ', ' Pediatric Acute Myelocytic Leukemia ', ' Pediatric Acute Myeloblastic Leukemia ', ' Pediatric AML ', ' Childhood Acute Myelogenous Leukemia ', ' Childhood Acute Myelogeneous Leukemia ', ' Childhood Acute Myelocytic Leukemia ', ' Childhood Acute Myeloblastic Leukemia ', ' Childhood Acute Granulocytic Leukemia ', ' Childhood AML ', ' Training ', ' Childhood ', ' pediatric ', ' Databases ', ' data base ', ' Data Bases ', ' Collaborations ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Therapeutic ', ' Inflammatory ', ' Aspirate substance ', ' Aspirate ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Event ', ' Source ', ' Techniques ', ' innovative technologies ', ' Performance ', ' Protein Isoforms ', ' Isoforms ', ' success ', ' knowledge base ', ' knowledgebase ', ' novel ', ' Modality ', ' Cell surface ', ' Regulation ', ' Sampling ', ' response ', ' high throughput technology ', ' drug development ', ' immunogenic ', ' Proteomics ', ' drug discovery ', ' RNA Databases ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Pharmacological Substance ', ' Pharmaceuticals ', ' Pharmaceutical Agent ', ' Pharmacologic Substance ', ' Data ', ' Immunooncology ', ' oncoimmunology ', ' immuno oncology ', ' immune-oncology ', ' Memorial Sloan-Kettering Cancer Center ', ' MSKCC ', ' Leukemic Cell ', ' Nonsense-Mediated Decay ', ' Non-sense Mediated Decay ', ' Small Business Innovation Research Grant ', ' Small Business Innovation Research ', ' SBIR ', ' Transcript ', ' Tumor-Derived ', ' Immunologics ', ' Immunologically ', ' Immunological ', ' Immunologic ', ' Immunochemical Immunologic ', ' Development ', ' developmental ', ' therapy resistant ', ' treatment resistance ', ' therapeutic resistance ', ' resistant to therapy ', ' resistance to therapy ', ' cost ', ' human monoclonal antibodies ', ' human monoclonals ', ' human mAbs ', ' humAbs ', ' Hu-mABs ', ' Population ', ' Consumption ', ' Resistance ', ' resistant ', ' clinically relevant ', ' clinical relevance ', ' human disease ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' tumor ', ' therapeutic development ', ' therapeutic agent development ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' FDA approved ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' Drug Targeting ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' patient stratification ', ' stratified patient ', ' tumor heterogeneity ', ' intratumor heterogeneity ', ' intra-tumoral heterogeneity ', ' heterogeneity in tumors ', ' Intratumoral heterogeneity ', ' patient biomarkers ', ' machine learning algorithm ', ' ']",NCI,"ENVISAGENICS, INC.",R43,2019,281778,0.026155794246749933
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9756427,R01GM126189,"['Architecture ', ' Engineering / Architecture ', ' Biological Sciences ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Systematics ', ' Classification ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Drug Design ', ' Elements ', ' Liberty ', ' Freedom ', ' Handwriting ', ' Ions ', ' Learning ', ' Ligands ', ' Lipids ', ' Surface Proteins ', ' Membrane-Associated Proteins ', ' Membrane Protein Gene ', ' Membrane Proteins ', ' Metals ', ' Methods ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Physics ', ' Proteins ', ' Software ', ' Computer software ', ' Speech ', ' Thermodynamic ', ' Thermodynamics ', ' training transfer ', ' learning transfer ', ' Psychological Transfer ', ' Work ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' cofactor ', ' improved ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Site ', ' Biological ', ' Medical ', ' Chemicals ', ' Binding Proteins ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Databases ', ' data base ', ' Data Bases ', ' Plant Roots ', ' root ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Electrostatics ', ' Dimensions ', ' Complex ', ' Techniques ', ' System ', ' 3-Dimensional ', ' 3D ', ' 3-D ', ' Membrane ', ' membrane structure ', ' mutant ', ' Free Energy ', ' models and simulation ', ' model-based simulation ', ' Future Generations ', ' Bioinformatics ', ' Bio-Informatics ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Affinity ', ' Data ', ' Induced Mutation ', ' Induced Sequence Alteration ', ' Induced DNA Alteration ', ' Ligand Binding ', ' trend ', ' Characteristics ', ' Development ', ' developmental ', ' neglect ', ' next generation ', ' direct application ', ' innovation ', ' innovative ', ' innovate ', ' user-friendly ', ' multitask ', ' multi-task ', ' language processing ', ' Geometry ', ' Big Data ', ' BigData ', ' algebraic topology ', ' metallicity ', ' learning strategy ', ' learning method ', ' learning activity ', ' Data Science ', ' search engine ', ' high dimensionality ', ' data warehouse ', ' data repository ', ' Databanks ', ' Data Banks ', ' deep learning ', ' machine learning algorithm ', ' multi-task learning ', ' multitask learning ', ' deep learning algorithm ', ' learning algorithm ', ' ']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2019,319267,0.05719381668893901
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9741127,K01ES028047,"['Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Award ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Basal cell carcinoma ', ' Rodent Ulcer ', ' Basiloma ', ' Basal Cell Epithelioma ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Clinical Trials ', ' Communities ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Gene Expression ', ' Goals ', ' liver carcinoma ', ' Liver Cells Carcinoma ', ' Hepatoma ', ' Hepatocellular cancer ', ' Hepatocellular Carcinoma ', ' Hepatocarcinoma ', ' Primary carcinoma of the liver cells ', ' Mentors ', ' Methods ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Probability ', ' Research ', ' Research Resources ', ' Resources ', ' statistics ', ' Time ', ' Translating ', ' Universities ', ' Work ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' cmyc ', ' c myc ', ' c-myc Genes ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Malignant - descriptor ', ' Malignant ', ' Individual ', ' drug sensitivity ', ' Databases ', ' data base ', ' Data Bases ', ' Therapeutic ', ' Normal tissue morphology ', ' Normal Tissue ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Malignant neoplasm of liver ', ' malignant liver tumor ', ' liver cancer ', ' Hepatic Cancer ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Adopted ', ' Clinic ', ' Source ', ' Pattern ', ' System ', ' Tumor Tissue ', ' Xenograft procedure ', ' xeno-transplantation ', ' xeno-transplant ', ' Xenotransplantation ', ' Xenograft ', ' Heterologous Transplantation ', ' Heterograft ', ' Ewings sarcoma ', "" Ewing's Tumor "", "" Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor "", "" Ewing's Family of Tumours "", ' drug efficacy ', ' novel ', ' Gene Proteins ', ' Protein Gene Products ', ' Code ', ' Coding System ', ' Sampling ', ' response ', ' Proteomics ', ' Meta-Analysis ', ' Data Pooling ', ' Clinical Trial Overviews ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Pharmacogenomics ', ' Bioinformatics ', ' Bio-Informatics ', ' protein expression ', ' Tissue Sample ', ' Address ', ' Data ', ' Molecular Profiling ', ' molecular signature ', ' molecular profile ', ' Molecular Fingerprinting ', ' Cancer Biology ', ' Cancer Patient ', ' Non-Malignant ', ' nonmalignant ', ' Validation ', ' Molecular ', ' pre-clinical ', ' preclinical ', ' triple-negative invasive breast carcinoma ', ' triple-negative breast cancer ', ' TNBC ', ' cancer genomics ', ' oncogenomics ', ' Cancer cell line ', ' Consumption ', ' transcriptomics ', ' mouse model ', ' murine model ', ' tumor ', ' molecular marker ', ' molecular biomarker ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' efficacy testing ', ' drug candidate ', ' data sharing ', ' Big Data ', ' BigData ', ' Precision Medicine Initiative ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' predictive marker ', ' predictive molecular biomarker ', ' predictive biomarkers ', ' personalized cancer therapy ', ' personalized cancer treatment ', ' individualized cancer therapy ', ' Data Science ', ' genetic signature ', ' gene signatures ', ' individual patient ', ' cancer clinical trial ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' Genomic Data Commons ', ' Expression Profiling ', ' optimal treatments ', ' optimal therapies ', ' Big Data Methods ', ' Big Data Tools ', ' Big Data Analytics ', ' ']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2019,170187,0.13861486539432163
"Transforming Analytical Learning in the Era of Big Data PROJECT SUMMARY In this dawning era of `Big Data' it is vital to recruit and train the next generation of biomedical data scientists in `Big Data'. The collection of `Big Data' in the biomedical sciences is growing rapidly and has the potential to solve many of today's pressing medical needs including personalized medicine, eradication of disease, and curing cancer. Realizing the benefits of Big Data will require a new generation of leaders in (bio)statistical and computational methods who will be able to develop the approaches and tools necessary to unlock the information contained in large heterogeneous datasets. There is a great need for scientists trained in this specialized, highly heterogeneous, and interdisciplinary new field of health big data. Thus, the recruitment of talented undergraduates in science, technology, engineering and mathematics (STEM) programs is vital to our ability to tap into the potential that `Big Data' offers and the challenges that it presents. The University of Michigan Undergraduate Summer Institute: Transforming Analytical Learning in the Era of Big Data will primarily draw from the expertise and experience of faculty from three different departments within three different schools at the University of Michigan: Biostatistics in the School of Public Health, Computer Science in the School of Engineering, Statistics in the College of Literature, Sciences and the Arts. The faculty instructors and mentors have backgrounds in Statistics, Computer Science, Information Science, Medicine, Population Health, Social and Biological Sciences. They have active research programs in a broad spectrum of methodological areas including statistical modeling, data mining, natural language processing, statistical and machine learning, large-scale optimization, matrix computation, medical computing, health informatics, high- dimensional statistics, distributed computing, missing data, causal inference, data management and integration, signal processing and medical imaging. The diseases and conditions they study include obesity, diabetes, cardiovascular disease, cancer, neurological disease, kidney disease, injury, macular degeneration and Alzheimer's disease. The areas of biology include neuroscience, genetics, genomics, metabolomics, epigenetics and socio-behavioral science. Undergraduate trainees selected will have strong quantitative skills and a background in STEM. The summer institute will consist of a combination of coursework, to raise the skills and interests of the participants to a sufficient level to consider pursuing graduate studies in `Big Data' science, along with an in depth mentoring component that will allow the participants to research a specific topic/project utilizing `Big Data'. We have witnessed tremendous enthusiasm and success with the current summer program on Big Data led by this team with 164 students trained in the last 4 years (2015-2018) including 90 female students and 30 students from underrepresented minority groups. Fourteen of these participants from the last three years are currently graduate students in Michigan Biostatistics. The ongoing program has gained traction in the national landscape of summer research programs with 20% rate of admission and 80% rate of acceptance among those who are offered this opportunity. The program has consistently received very strong evaluation and our past alumni have become brand ambassadors and advocates for our program. We plan to build on the success and legacy of this program in the next three year funding cycle of this grant (2019-2021). The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm. This six week long summer institute will recruit a group of approximately 45 undergraduates nationally and internationally, with 20 domestic students supported by the requested SIBS funding mechanism and others supported by supplementary institutional and foundation support. We propose to expose the trainees to diverse techniques, skills and problems in the field of health Big Data. They will be taught and mentored by a team of interdisciplinary faculty, reflecting the shared intellectual landscape needed for Big Data research. They will engage in mentored research projects in three primary areas of health big data: Electronic Health Records/Medical Claims, Genomics and Imaging. Some of the projects will be defined in the area of cardiovascular precision medicine, defined by a team of highly quantitative researchers engaged in cardiovascular research that uses big data. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by U-M researchers, outside guests and a professional development workshop to prepare the students for graduate school. We propose an inter-SIBS collaboration with Dordt College summer program trainees who will attend this concluding symposium. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material for undergraduate students in this new field across the world. We will offer multiple professional development opportunities and resources for graduate school preparation to our trainees so that they can reflect and plan beyond their senior year. All of our proposed activities are reflected through our three specific aims: Teaching, Mentoring and Dissemination. PROJECT NARRATIVE We propose a six week long undergraduate summer institute: Transforming Analytical Learning in the Era of Big Data to be held at the Department of Biostatistics, University of Michigan (U-M), Ann Arbor, with a group of approximately 45 undergraduate students recruited nationally and internationally, from 2019-2021. Funding is requested for 20 domestic students with supplementary funding expected to be garnered through institutional resources and private foundation support. The program builds on the success of our existing Big Data Summer Institute (BDSI) supported by a NIH BD2K Courses and Skills grant award that is ending in 2018. We plan to expose program students to diverse techniques, skills and problems in the field of Big Data and Human Health. We enhance our ongoing summer program structure in the current proposal by involving a team of researchers working at the intersection of cardiovascular research and data science with a focus on cardiovascular precision medicine where some of the new mentored research projects will be defined. We primarily focus on three genres of health Big Data arising in Electronic Health Records/Medical Claims, Genomics and Imaging. The trainees will be taught and mentored by a team of interdisciplinary faculty from Biostatistics, Computational Medicine and Bioinformatics, Statistics, Computer Science and Engineering, Information Sciences, Epidemiology and Medicine, reflecting the shared intellectual landscape needed for Big Data research. At the conclusion of the program there will be a concluding capstone symposium showcasing the research of the students via poster and oral presentation. There will be lectures by (U-M) researchers, outside guests and a professional development workshop to prepare the students for graduate school. The resources developed for the summer institute, including lectures, assignments, projects, template codes and datasets will be freely available through a Wiki page so that this format can be replicated anywhere in the world. This democratic dissemination plan will lead to access of teaching and training material in this new field across the world. The overarching goal of our summer institute in big data is to recruit and train the next generation of big data scientists using a non-traditional, action-based learning paradigm and engage them in influential research related to human health.",Transforming Analytical Learning in the Era of Big Data,9733542,R25HL147207,"[""Alzheimer's Disease "", ' senile dementia of the Alzheimer type ', ' primary degenerative dementia ', ' dementia of the Alzheimer type ', ' Primary Senile Degenerative Dementia ', ' Alzheimers disease ', ' Alzheimers Dementia ', "" Alzheimer's "", ' Alzheimer syndrome ', ' Alzheimer sclerosis ', ' Alzheimer disease ', ' Alzheimer Type Dementia ', ' Alzheimer ', ' Arts ', ' Award ', ' Biological Sciences ', ' Life Sciences ', ' Bioscience ', ' Biologic Sciences ', ' Biology ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Engineering ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Faculty ', ' Female ', ' Foundations ', ' Goals ', ' Grant ', ' Health ', ' Modern Man ', ' Human ', ' Influentials ', ' Information Sciences ', ' renal disorder ', ' kidney disorder ', ' Renal Disease ', ' Nephropathy ', ' Kidney Diseases ', ' Learning ', ' Literature ', ' Macular degenerative disease ', ' Macular degeneration ', ' Medical Imaging ', ' Medical Records ', ' Medicine ', ' Mentors ', ' Methods ', ' Methodology ', ' Michigan ', ' Minority Groups ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' natural language understanding ', ' Natural Language Processing ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurosciences ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' Privatization ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Research Resources ', ' Resources ', ' Schools ', ' school of medicine ', ' medical college ', ' medical schools ', ' Public Health Schools ', ' Science ', ' sociobehavioral ', ' sociobehavior ', ' Social Behavior ', ' Social Sciences ', ' statistics ', ' Students ', ' Talents ', ' Teaching ', ' Educational process of instructing ', ' Traction ', ' Universities ', ' Drug Side Effects ', ' Adverse drug effect ', ' Woman ', ' Work ', ' Generations ', ' case report ', ' Case Study ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' Dataset ', ' Data Set ', ' Injury ', ' base ', ' Area ', ' Clinical ', ' Medical ', ' Evaluation ', ' Training ', ' Educational workshop ', ' Workshop ', ' Funding ', ' Research Project Grants ', ' Research Projects ', ' Research Grants ', ' R01 Program ', ' R01 Mechanism ', ' R-Series Research Projects ', ' Collaborations ', ' Genetic ', ' Exposure to ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' posters ', ' lectures ', ' programs ', ' Scientist ', ' Oral ', ' Techniques ', ' interest ', ' instructor ', ' college ', ' collegiate ', ' data management ', ' experience ', ' success ', ' computer science ', ' Structure ', ' skills ', ' Participant ', ' member ', ' Basic Science ', ' Basic Research ', ' graduate student ', ' Prevention ', ' Code ', ' Coding System ', ' Admission activity ', ' Admission ', ' Statistical Methods ', ' Genomics ', ' Public Health Informatics ', ' consumer informatics ', ' Health Informatics ', ' Bioinformatics ', ' Bio-Informatics ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' datamining ', ' data mining ', ' Advocate ', ' Data ', ' Health Sciences ', ' International ', ' Clinical Sciences ', ' Collection ', ' Epigenetic Process ', ' Epigenetic Mechanism ', ' Epigenetic Change ', ' Epigenetic ', ' Funding Mechanisms ', ' Underrepresented Minority ', ' underrepresentation of minorities ', ' under-representation of minorities ', ' Underrepresented Ethnic Minority ', ' Development ', ' developmental ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Image ', ' imaging ', ' burden of illness ', ' years of life lost to disease ', ' years of life lost to disability ', ' disease burden ', ' burden of disease ', ' data integration ', ' cluster computing ', ' distributed computing ', ' datagrid ', ' data grid ', ' design ', ' designing ', ' next generation ', ' wiki ', ' open source ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' network models ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' population health ', ' Science, Technology, Engineering and Mathematics ', ' Science, Technology, Engineering and Math ', ' undergraduate student ', ' undergraduate ', ' signal processing ', ' Big Data ', ' BigData ', ' precision medicine ', ' precision-based medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' underrepresented minority student ', ' URM student ', ' data visualization ', ' student training ', ' Problem Sets ', ' Homework Exercises ', ' summer institute ', ' summer program ', ' summer session ', ' summer research ', ' graduate school preparation ', ' Data Science ', ' Student recruitment ', ' Big Data to Knowledge ', ' BD2K ', ' high dimensionality ', ' recruit ', ' Data Scientist ', ' STEM program ', ' science, technology, engineering and mathematics program ', ' science, technology, engineering and math program ', ' ']",NHLBI,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R25,2019,250974,0.1127122668228637
"A Big Data Approach to BCR ABL Leukemias BCR-ABL1 positive leukemias account for a substantial portion of adult leukemia. Tyrosine kinase  inhibitors (TKIs) have dramatically changed survival outlook. However, current protocols recommend  patients receive TKI chemotherapy agents indefinitely, causing long-term toxicity and substantive  quality of life deficits, leading to decreased TKI compliance. Moreover, >50% of patients who stop  TKIs ultimately relapse and are not as responsive to post-relapse treatment; additionally, mutation  resistance is becoming an increasing issue with TKIs as patients live longer. It is hypothesized  patient heterogeneity within BCR-ABL1 leukemias are a major driving factor on outcome and strongly  influences optimal TKI selection and cessation. However, small cohort size and disease rarity has  impacted large, pragmatic clinical trials, necessitating a big data approach. The overall goal is  to quilt together individual studies to produce a comprehensive view of BCR-ABL1 leukemias that  includes epidemiology, etiology, assessment, and therapy, as well their inter-relationships. With  a comprehensive view, personalized, predictive medicine becomes possible. This project utilizes  literature mining and big data techniques to analyze four major categories: epidemiology (who  gets BCR-ABL1 leukemias, how response correlates to patient characteristics, etc.); etiology (what  factors trigger mutation, mechanisms to improve TKI specificity, preclinical model metrics,  prognostic indicators of recurrence/relapse, etc.); assessment (identifying new  diagnostic/prognostic metrics, improving polymerase chain reaction (PCR) protocols, objective  staging criteria); and treatment (aggregate effect sizes among different therapies, short and  long-term side effect profiles, TKI selection protocols, adjunctive and combination therapies,  criteria for TKI cessation, etc.). The specific aims of the project include: 1) prototype a data  path and construct infrastructure for BCR-ABL1 data curation from literature and/or clinical  sources; 2) construct literature ontological field map to quantify topic depth, aggregate data, and  identify relationships within and between categories; 3) perform exploratory analysis to assess  aggregate statistical power and prototype predictive models for TKI optimization. In summary, the  present project delivers a 21st century, big data approach for BCR-ABL1 leukemia to optimize  clinical management and expedite basic preclinical research. This project is highly relevant to public health as it enables a comprehensive view of BCR ABL  positive leukemia(s) that can optimize clinical management and expedite preclinical research.",A Big Data Approach to BCR ABL Leukemias,9728205,R21CA232249,"['Automobile Driving ', ' driving ', ' Award ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Clinical Trials ', ' Concurrent Studies ', ' Cohort Studies ', ' multi-modal treatment ', ' multi-modal therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Cytogenetics ', ' Aggregated Data ', ' Data Aggregation ', ' Death ', ' Cessation of life ', ' Engineering ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Foundations ', ' Future ', ' Goals ', ' Heterogeneity ', ' Institutes ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' leukemia ', ' acute lymphomatic leukemia ', ' acute lymphogenous leukemia ', ' acute lymphatic leukemia ', ' Precursor Lymphoblastic Leukemia ', ' Precursor Cell Lymphoblastic Leukemia ', ' Acute Lymphoid Leukemia ', ' Acute Lymphoblastic Leukemia ', ' Acute Lymphocytic Leukemia ', ' acute myeloid leukemia ', ' acute granulocytic leukemia ', ' Acute Myelogenous Leukemia ', ' Acute Myeloblastic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myelocytic Leukemia ', ' Chronic Myelogenous Leukemia ', ' Chronic Myelocytic Leukemia ', ' Chronic Granulocytic Leukemia ', ' Chronic Myeloid Leukemia ', ' Literature ', ' pulmonary ', ' Lung Respiratory System ', ' Lung ', ' Maps ', ' Medicine ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Transforming Genes ', ' Cancer-Promoting Gene ', ' Cancer Genes ', ' Oncogenes ', ' Pancreatic ', ' Pancreas ', ' Patients ', ' Polymerase Chain Reaction ', ' Public Health ', ' Publishing ', ' tetraplegic ', ' Tetraplegia ', ' Quadriplegic ', ' Quadriplegia ', ' QOL ', ' Quality of life ', ' Recurrent ', ' Recurrence ', ' Relapse ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Retrospective Studies ', ' Semantics ', ' Specificity ', ' Time ', ' Universities ', ' mobile assistive system ', ' mobile assistive device ', ' mobile assistance system ', ' mobile assistance device ', ' Wheel Chairs ', ' Wheelchairs ', ' case report ', ' Case Study ', ' Decision Modeling ', ' Risk Assessment ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Chronic ', ' Clinical ', ' prognostic ', ' disability ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Sample Size ', ' drug intolerance ', ' Functional disorder ', ' pathophysiology ', ' Physiopathology ', ' Dysfunction ', ' Staging ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Life ', ' Dimensions ', ' Frequencies ', ' Complex ', ' Clinic ', ' Protocols documentation ', ' Protocol ', ' treatment duration ', ' treatment days ', ' Treatment Period ', ' Source ', ' Techniques ', ' experience ', ' drug intolerant ', ' cohort ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' Informatics ', ' Toxic effect ', ' Toxicities ', ' Rare Diseases ', ' orphan disorder ', ' Rare Disorder ', ' Orphan Disease ', ' novel ', ' Categories ', ' disorder risk ', ' disease risk ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Human Resources ', ' personnel ', ' Manpower ', ' Modeling ', ' response ', ' Meta-Analysis ', ' Data Pooling ', ' Clinical Trial Overviews ', ' text mining ', ' literature searching ', ' literature mining ', ' discovery mining ', ' text searching ', ' TK Inhibitors ', ' Protein Tyrosine Kinase Inhibitors ', ' PTK Inhibitors ', ' Tyrosine Kinase Inhibitor ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' treatment compliance ', ' therapy cooperation ', ' therapy compliance ', ' patient cooperation ', ' patient adherence ', ' Patient Compliance ', ' compliance behavior ', ' datamining ', ' data mining ', ' ABL1 gene ', ' c-abl Proto-Oncogenes ', ' c-abl Genes ', ' c-Abl ', ' JTK7 ', ' Abelson Murine Leukemia Viral Oncogene Homolog 1 ', ' ABL1 ', ' Data ', ' Pre-Clinical Model ', ' Preclinical Models ', ' Prognostic Marker ', ' prognostic indicator ', ' prognostic biomarker ', ' Prognosis Marker ', ' Molecular Marker of Prognosis ', ' Cancer Etiology ', ' Cancer Cause ', ' Clinical Management ', ' Ontology ', ' Patient-Focused Outcomes ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Characteristics ', ' pre-clinical ', ' preclinical ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' Outcome ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' adult leukemia ', ' Resistance ', ' resistant ', ' pre-clinical research ', ' preclinical research ', ' lexical ', ' chemotherapy ', ' novel diagnostics ', ' next generation diagnostics ', ' new diagnostics ', ' comparative ', ' prototype ', ' population based ', ' resistance mutation ', ' resistant mutation ', ' relational database ', ' Big Data ', ' BigData ', ' Data Analytics ', ' Pragmatic clinical trial ', ' database schema ', ' rare cancer ', ' rare tumor ', ' rare malignancy ', ' cancers that are rare ', ' personalized predictions ', ' personalized predictors ', ' individualized predictions ', ' Individualized Predictors ', ' Infrastructure ', ' side effect ', ' ']",NCI,GEORGIA INSTITUTE OF TECHNOLOGY,R21,2019,167262,0.1088485057865689
"Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership     DESCRIPTION (provided by applicant): The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The aims to achieve the goals are: 1) Implement an integrated didactic program to enhance student self-efficacy with computational and informatics tool development and use for interrogating and interpreting Big Data, including a two-semester bioinformatics course in Bioinformatics, informed by the expertise of UIUC KnowEnG BD2K Center faculty with additional Special Topics courses available remotely from UIUC. 2) Develop an integrated academic year (Fisk, or partners) and summer research program at the UIUC KnowEnG BD2K Center to assure student exposure to a participation in the life cycle of a `Big Data' research problem. 3) Implement a professional skills development program that assures successful transition of undergraduate participants to a Ph.D. (or MD/PhD Program) in Big Data- reliant biomedical research. 4) Launch a faculty development program in bioinformatics that leads to embracing Big Data problems in courses in multiple disciplines for impact on all Fisk undergraduate STEM majors. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fisk R25 mentors, of value for their broader education and research training goals at UIUC and Mayo. PUBLIC HEALTH RELEVANCE: The overall goal of the proposed Fisk- UIUC KnowEnG R25 program is to recruit and retain a cadre of under-represented minority scientists prepared to compete for PhD training in biomedical research with already acquired confidence in the use of Big Data. The proposed partnership with the KnowEnG BD2K Center at UIUC will permit curricular enhancements and summer research opportunities for Fisk trainees while, at the same time, reciprocally training natural scientists and mathematics majors in complementary computer and informatics sciences and providing computer science and mathematics undergraduates with essential systems, molecular and cell biology/biochemistry background at Fisk University to provide context for cutting edge genomics, proteomics, and individualized medicine research reliant on Big Data. In addition to curricular and research training program elements, Fisk students will have remote access to seminar courses to increase efficacy in communicating BD2K-based technologies and their applications. Didactic work and undergraduate research experiences will be complemented by an individualized student development plan for honing professional skills, deep understanding of the responsible conduct of research, and wrap-around mentoring to assure subsequent successful entry into competitive BD2K aligned PhD-granting programs. UIUC-hosted summer workshops for faculty will increase confidence in use of Big Data tools, leading to innovations in STEM courses that embrace Big Data, impacting all Fisk STEM undergraduates. Research collaborations between Fisk and BD2K partner faculty also will be fostered. The proposed program will increase both didactic and research experiences in Big Data for Fisk University undergraduates while preparing them for successful entry into PhD-granting programs in related disciplines at research intensive universities. Our KnowEnG partnership also will increase Fisk faculty capacity in Big Data use and foster faculty research collaborations, thus introducing Big Data into course-embedded research, impacting all Fisk University STEM Majors. Reciprocally, our KnowEnG UIUC faculty partners will enrich their holistic mentoring skills of URM trainees based on interactions with Fis R25 mentors, of value for their broader education and research training goals at UIUC and Mayo.  ",Fisk University/UIUC-Mayo KnowENG BD2K Center R25 Partnership,9729464,R25MD010396,"['Research Ethics ', ' Proteomics ', ' Genomics ', ' Bioinformatics ', ' Bio-Informatics ', ' Address ', ' Systems Biology ', ' Core Facility ', ' Doctor of Philosophy ', ' PhD ', ' Ph.D. ', ' Education Projects ', ' R25 Program ', ' R25 Mechanism ', ' Research Training ', ' Underrepresented Minority ', ' underrepresentation of minorities ', ' under-representation of minorities ', ' Underrepresented Ethnic Minority ', ' computerized tools ', ' computational tools ', ' innovation ', ' innovative ', ' innovate ', ' data acquisition ', ' skill acquisition ', ' skill development ', ' tool development ', ' public health relevance ', ' responsible research conduct ', ' data sharing ', ' STEM field ', ' science, technology, engineering and mathematics major ', ' science, technology, engineering and mathematics field ', ' science, technology, engineering and mathematics discipline ', ' science, technology, engineering and mathematics course ', ' science, technology, engineering and mathematics class ', ' science, technology, engineering and math major ', ' science, technology, engineering and math field ', ' science, technology, engineering and math discipline ', ' science, technology, engineering and math course ', ' science, technology, engineering and math class ', ' STEM major ', ' STEM discipline ', ' STEM course ', ' STEM class ', ' Teacher Professional Development ', ' teacher development ', ' instructor training ', ' faculty professional development ', ' faculty development ', ' Teacher Training ', ' Teacher Preparation ', ' Teacher Educator ', ' Teacher Education ', ' Faculty Training ', ' Faculty Education ', ' undergraduate student ', ' undergraduate ', ' undergraduate research ', ' Big Data ', ' BigData ', ' Faculty Workshop ', ' faculty panel ', ' faculty conference ', ' Teacher Workshop ', ' Faculty Seminar ', ' individualized medicine ', ' unique treatment ', ' tailored treatment ', ' tailored therapy ', ' tailored medical treatment ', ' individualized treatment ', ' individualized therapy ', ' individualized patient treatment ', ' customized treatment ', ' customized therapy ', ' faculty research ', ' summer research ', ' Big Data to Knowledge ', ' BD2K ', ' minority scientist ', ' Articulation ', ' recruit ', ' deep learning ', ' Big Data Methods ', ' Big Data Tools ', ' Big Data Analytics ', ' informatics\xa0tool ', ' Biochemistry ', ' Biological Chemistry ', ' Biomedical Research ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' career track ', ' career pathway ', ' career interest ', ' career aspiration ', ' Career Path ', ' Career Choice ', ' Communication ', ' Complement Proteins ', ' Complement ', ' Computers ', ' lesson plans ', ' Curriculum ', ' Educational Curriculum ', ' Elements ', ' Faculty ', ' Goals ', ' Grant ', ' Illinois ', ' Learning ', ' life course ', ' Life Cycle ', ' Life Cycle Stages ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' DNA Molecular Biology ', ' Molecular Biology ', ' Program Development ', ' Reading ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Science ', ' Students ', ' Technology ', ' Time ', ' Training Programs ', ' Universities ', ' Work ', ' Writing ', ' Journals ', ' Magazine ', ' base ', ' career ', ' Biological ', ' Chemicals ', ' Training ', ' Discipline ', ' Educational workshop ', ' Workshop ', ' Fostering ', ' Development Plans ', ' Funding ', ' Collaborations ', ' Exposure to ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' posters ', ' programs ', ' Cellular biology ', ' cell biology ', ' Scientist ', ' Oral ', ' Training and Education ', ' Education and Training ', ' experience ', ' computer science ', ' Informatics ', ' Base Pairing ', ' Self Efficacy ', ' Manuscripts ', ' skills ', ' Participant ', ' ']",NIMHD,FISK UNIVERSITY,R25,2019,216000,0.12163881736249535
"Id3 and VSMC in Murine and Human Atherosclerosis Despite major advances in prevention and treatment of atherosclerotic cardiovascular disease (ASCVD), it remains a major cause of deaths worldwide. As ASCVD is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and impact on this unmet residual risk. One such human polymorphism in the ID3 gene (rs11574) was associated with ASCVD in 3 distinct human cohorts. Notably, this SNP significantly attenuates ID3 function and studies in pre-clinical models confirm a critical role for ID3 in atheroprotection. We have previously shown that loss of ID3 inhibits vascular smooth muscle cell (VSMC) proliferation and promotes VSMC expression of inflammatory factors, processes linked to increase atherosclerosis. In collaboration with Dr. Gary Owens, we have generated a mouse model with VSMC lineage tracing and VSMC-specific deletion of ID3 to study ID3-dependent VSMC specific changes during the course of lesion development in the context of the whole animal. We have developed a comprehensive CyTOF panel to identify and quantitate key cellular and intracellular changes in VSMC and other lesional cells in the aorta during the course of atherosclerosis development in these mice. To translate murine findings to humans, we have utilized CRISPR/Cas9 genetic engineering to knock out ID3 and produce the full allelic series of rs11574 in human cells and validated a reproducible system for differentiation of human inducible pluripotent stem cells (iPSCs) to VSMC. We will quantify the changes in VSMC phenotype in iPSC-derived VSMC with the full allelic series of rs11574. To further translate murine findings to humans, intravascular ultrasound virtual histology (IVUS-VH) will be measured in human coronary arteries and analyzed with cutting edge image analysis techniques in collaboration with Dr. Milan Sonka at the University of Iowa. As such, our group is uniquely poised to dissect the role of this ASCVD-associated SNP and translate findings to humans. We hypothesize: that loss of ID3 in VSMCs will inhibit VSMC growth and promote a phenotype that exacerbates vessel wall inflammation and atherosclerosis lesion development; that human ID3 encoded by the risk allele aggravates these atherogenic VSMC functions; and that human subjects with the risk allele have larger coronary plaques with increased fatty deposits, necrotic cores and calcification compared to subjects homozygous for the common allele. As atherosclerotic cardiovascular disease (ASCVD) is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and further impact on ASCVD morbidity and mortality. Human ID3 gene polymorphism at rs11574 is associated with ASCVD in three unique human cohorts. Preliminary data supports a key role for ID3 in vascular smooth muscle cell biology linked to ASCVD. In the current proposal, we will utilize a novel mouse model with VSMC lineage tracing and specific deletion of ID3 to elucidate the role of ID3 in promoting atherogenic VSMCs. We will then utilize CRISPR/Cas9 gene editing in human inducible pluripotent stem cell-derived VSMCs to identify the VSMC processes altered by the ID3 gene mutation linked to CVD. Lastly, we will determine if this ID3 gene mutation, alone or in combination with other gene mutations are associated with the amount and type of atherosclerotic plaque in human coronary arteries as measured by intravascular ultrasound virtual histology. Results have the potential to lead to novel targeted therapy for atherosclerosis.",Id3 and VSMC in Murine and Human Atherosclerosis,9801966,R01HL148109,"['Alanine ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Animals ', ' Aorta ', ' Apolipoprotein E ', ' ApoE ', ' Apo-E ', ' Arteries ', ' Atherosclerosis ', ' atherosclerotic vascular disease ', ' atherosclerotic disease ', ' atheromatosis ', ' Atherosclerotic Cardiovascular Disease ', ' Atheroscleroses ', ' Automobile Driving ', ' driving ', ' Biology ', ' Blood Vessels ', ' vascular ', ' Cause of Death ', ' cell adhesion protein ', ' Cell Adhesion Molecule Gene ', ' Adhesion Molecule ', ' Cell Adhesion Molecules ', ' Cell Number ', ' Cell Count ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Cell Body ', ' Cells ', ' diabetes ', ' Diabetes Mellitus ', ' Disorder ', ' Disease ', ' vulnerable plaque ', ' atherosclerotic plaque ', ' atherosclerotic lesions ', ' atherosclerosis plaque ', ' Atheromatous plaque ', ' Atheromatous degeneration ', ' Atheromatous ', ' Atheroma ', ' Arterial Fatty Streaks ', ' Arterial Fatty Streak ', ' Gene Expression ', ' Genes ', ' genetically engineered ', ' Recombinant DNA Technology ', ' Genetic Engineering Molecular Biology ', ' Genetic Engineering Biotechnology ', ' Genetic Engineering ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Heart ', ' Histology ', ' Modern Man ', ' Human ', ' indexing ', ' Inflammation ', ' Iowa ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Null Cells ', ' Null Lymphocytes ', ' macrophage ', ' Minor ', ' Morbidity ', ' Morbidity - disease rate ', ' mortality ', ' Multivariate Analyses ', ' Multivariate Analysis ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Vascular Smooth Muscle ', ' Necrotic ', ' Necrosis ', ' Phenotype ', ' polymorphism ', ' Genetic Polymorphism ', ' study design ', ' Study Type ', ' Research Design ', ' Risk ', ' social role ', ' Role ', ' Testing ', ' L-Threonine ', ' Threonine ', ' Translating ', ' ultrasound scanning ', ' ultrasound imaging ', ' ultrasound ', ' sound measurement ', ' sonography ', ' sonogram ', ' diagnostic ultrasound ', ' Ultrasound Test ', ' Ultrasound Medical Imaging ', ' Ultrasound Diagnosis ', ' Ultrasonogram ', ' Ultrasonic Imaging ', ' Medical Ultrasound ', ' Echotomography ', ' Echography ', ' Ultrasonography ', ' Universities ', ' Vascular Cell Adhesion Molecule ', ' VCAM-1 ', ' VCAM ', ' Inducible Cell Adhesion Molecule 110 ', ' INCAM-110 ', ' CD106 Antigens ', ' CD106 ', ' Vascular Cell Adhesion Molecule-1 ', ' Measures ', ' Mediating ', ' promotor ', ' promoter ', ' calcification ', ' Calcified ', ' human subject ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Coronary artery ', ' Heart artery ', ' Cardiac artery ', ' Medial ', ' Residual state ', ' Residual ', ' Variant ', ' Variation ', ' Series ', ' Link ', ' Lesion ', ' Stimulus ', ' Coronary Stenosis ', ' Coronary Artery Stenosis ', ' Inflammation Mediators ', ' inflammatory mediator ', ' Collaborations ', ' Cell Lineage ', ' Attenuated ', ' Inflammatory ', ' Deposition ', ' Deposit ', ' oxidized low density lipoprotein ', ' oxidized LDL ', ' ox-LDL ', ' OxLDL ', ' Cellular biology ', ' cell biology ', ' Immune ', ' Immunes ', ' Techniques ', ' System ', ' dimer ', ' Gene Mutation ', ' Gene Alteration ', ' Reverse Transcriptase Polymerase Chain Reaction ', ' reverse transcriptase PCR ', ' RTPCR ', ' RT-PCR ', ' cohort ', ' novel ', ' Participant ', ' Prevention ', ' Single Nucleotide Polymorphism ', ' Single Base Polymorphism ', ' Cytometry ', ' Modeling ', ' Pluripotent Stem Cells ', ' Proteomics ', ' Genomics ', ' Smooth Muscle Myocytes ', ' Smooth Muscle Tissue Cell ', ' Smooth Muscle Cells ', ' Leiomyocyte ', ' Molecular Interaction ', ' Binding ', ' Thickness ', ' Thick ', ' Data ', ' Pre-Clinical Model ', ' Preclinical Models ', ' Reproducibility ', ' Genetic Risk ', ' Characteristics ', ' Molecular ', ' Knock-out ', ' Knockout ', ' Process ', ' Development ', ' developmental ', ' Image ', ' imaging ', ' virtual ', ' vascular smooth muscle cell proliferation ', ' Heritability ', ' mouse model ', ' murine model ', ' new therapeutic target ', ' novel therapy target ', ' novel therapeutic target ', ' novel pharmacotherapy target ', ' novel druggable target ', ' novel drug target ', ' new therapy target ', ' new pharmacotherapy target ', ' new druggable target ', ' new drug target ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' risk variant ', ' risk locus ', ' risk loci ', ' risk genotype ', ' risk gene ', ' risk allele ', ' Risk-associated variant ', ' genome editing ', ' genomic editing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' Multi-Ethnic Study of Atherosclerosis ', ' Tumor-infiltrating immune cells ', ' T cell tumor trafficking ', ' T cell infiltration ', ' Immune infiltrates ', ' coronary artery calcium ', ' coronary calcium ', ' coronary plaque ', ' machine learning algorithm ', ' ']",NHLBI,UNIVERSITY OF VIRGINIA,R01,2019,687622,0.045021781326330605
"Deep learning-based approach to identify non-coding cancer drivers that alter chromatin conformation Summary Most variants obtained from tumor whole-genome sequences (WGS) occur in non- coding regions of the genome. Although variants in protein-coding regions have received the majority of attention, numerous studies have now noted the importance of non- coding variants in cancer. Identification of functional non-coding variants that drive tumor growth remains a challenge and a bottleneck for the use of whole-genome sequencing in the clinic. Cancer drivers are generally identified by the high frequency at which their mutations occur across patients. However, mutation rate is highly heterogeneous in non- coding regions and many non-driver elements show higher mutation frequency than others, such as regions bound by transcription factors in melanoma or regions replicating late during cell division in colon cancer. In this proposal, we will use high- throughput pooled CRISPR screen and novel computational methods to predict non- coding cancer drivers. We will quantitatively measure the impact of thousands of non- coding mutations using our innovative high-throughput CRISPR screen that directly ties modifications in the native context of the non-coding genome (i.e. not a reporter assay) to a cancer relevant phenotype (cell growth). The results of the screen will be used as training data for the development of NC_Driver, a computational cancer driver prediction tool. NC_Driver will integrate the signals of high functional impact with the recurrence of variants across multiple tumor samples to identify the non-coding mutations under positive selection in cancer. We will identify drivers in promoters, enhancers and CTCF insulators. CTCF insulators are the most mutated yet least studied regulatory elements in the cancer genome. Using this integrative experimental and computational approach, we will identify high-confidence candidate drivers. Finally, we will perform functional evaluation of prioritized non-coding drivers in colorectal and prostate cancers. We will use CRISPR/Cas9 genome editing in patient-derived cell cultures to test 20 high-ranking candidate driver promoter/enhancer/insulator mutations. Overall, this proposal addresses the critical need to identify drivers in the non-coding genome and over long- term enable the maximal benefit of genome sequencing for each patient. Project Narrative Cancer genomes contain thousands of mutations but only a few of them play an important role in cancer proliferation and are called drivers. Most of the mutations occur in regions of the genome that do not make proteins, yet the majority of previous studies have focused on protein-coding regions. In this proposal, we will use integrative computational and experimental approaches to identify drivers in the non-protein-coding regions of the genome.",Deep learning-based approach to identify non-coding cancer drivers that alter chromatin conformation,9831005,R01CA218668,"['Accounting ', ' Attention ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cell culture ', ' Cell Culture Techniques ', ' Cell division ', ' Cellular Growth ', ' Cellular Expansion ', ' cell growth ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Cell Viability ', ' Cell Survival ', ' Cell Body ', ' Cells ', ' Chromatin ', ' Colon ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Disorder ', ' Disease ', ' Dissection ', ' Elements ', ' Gene Expression ', ' Genes ', ' Genome ', ' Heterogeneity ', ' Institutes ', ' Learning ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Parents ', ' Patients ', ' Phenotype ', ' Play ', ' Prostatic Gland ', ' Prostate Gland ', ' Prostate ', ' Proteins ', ' Recurrent ', ' Recurrence ', ' Research ', ' social role ', ' Role ', ' Running ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Testing ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' Enhancers ', ' promotor ', ' promoter ', ' DNA Sequence ', ' base ', ' Variant ', ' Variation ', ' Evaluation ', ' Training ', ' Genetic ', ' Reporter ', ' tool ', ' Nature ', ' Malignant neoplasm of prostate ', ' Prostatic Cancer ', ' Prostate Cancer ', ' Prostate CA ', ' Malignant prostatic tumor ', ' Malignant Tumor of the Prostate ', ' Catalogs ', ' Frequencies ', ' Clinic ', ' Xenograft procedure ', ' xeno-transplantation ', ' xeno-transplant ', ' Xenotransplantation ', ' Xenograft ', ' Heterologous Transplantation ', ' Heterograft ', ' Benchmarking ', ' Best Practice Analysis ', ' Somatic Mutation ', ' tumor growth ', ' cohort ', ' Structure ', ' novel ', ' Colon Carcinoma ', ' cancer in the colon ', ' Colonic Carcinoma ', ' Colon Cancer ', ' Code ', ' Coding System ', ' Sampling ', ' high throughput screening ', ' High Throughput Assay ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Oncogenesis ', ' tumorigenesis ', ' genome sequencing ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Cancer Patient ', ' Screening Result ', ' Transcript ', ' Validation ', ' Modification ', ' Development ', ' developmental ', ' Colorectal Cancer ', ' Colo-rectal Cancer ', ' tumor microenvironment ', ' cancer microenvironment ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' knock-down ', ' knockdown ', ' tumorigenic ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' tumor ', ' colon cancer cell line ', ' colorectal cancer cell line ', ' colo-rectal cancer cell line ', ' genome-wide ', ' genomewide ', ' genome scale ', ' biobank ', ' biorepository ', ' Targeted Resequencing ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' Statistical Algorithm ', ' Statistics Algorithm ', ' precision medicine ', ' precision-based medicine ', ' genome editing ', ' genomic editing ', ' CRISPR/Cas technology ', ' Cas nuclease technology ', ' CRISPR/Cas9 technology ', ' CRISPR/Cas9 ', ' CRISPR/Cas method ', ' CRISPR-based tool ', ' CRISPR-based technology ', ' CRISPR-based technique ', ' CRISPR-based method ', ' CRISPR-CAS-9 ', ' CRISPR technology ', ' CRISPR technique ', ' CRISPR methodology ', ' CRISPR method ', ' Knock-in ', ' knockin ', ' tumor heterogeneity ', ' intratumor heterogeneity ', ' intra-tumoral heterogeneity ', ' heterogeneity in tumors ', ' Intratumoral heterogeneity ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' CRISPR screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR/Cas9 screen ', ' CRISPR-based screen ', ' CRISPR editing screen ', ' deep learning ', ' ']",NCI,WEILL MEDICAL COLL OF CORNELL UNIV,R01,2019,113967,0.08071171432194386
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9653955,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' ATGN ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B-cell ', ' B-Cells ', ' B cells ', ' B cell ', ' B blood cells ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Chromatin ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' Virus-HIV ', ' Lymphadenopathy-Associated Virus ', ' LAV-HTLV-III ', ' Human Immunodeficiency Viruses ', ' Acquired Immunodeficiency Syndrome Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' AIDS Virus ', ' HIV ', ' Modern Man ', ' Human ', ' Immunity ', ' Immunoglobulin Hypervariable Region ', ' Hypervariable Regions ', ' Hypervariable Loop ', ' Complimentarity Determining Region ', ' Complementarity Determining Regions ', ' Immune Globulins ', ' Immunoglobulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' influenza infection ', ' flu infection ', ' Grippe ', ' Influenza ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Transgenic Mice ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' social role ', ' Role ', ' gastric ', ' Stomach ', ' Testing ', ' Time ', ' Vaccines ', ' B lymphoma ', ' B-Cell Lymphomas ', ' Mediating ', ' -Gs ', ' alpha-Gs ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' Stimulatory Gs G-Protein ', ' Regulatory Ns Protein ', ' Gs ', ' Gs ', ' Gs alpha Family G-Protein ', ' GTP-Binding Protein  Subunits, Gs ', ' G(s) ', ' G(s)alpha ', ' G(s),  Subunit ', ' G(s), alpha Subunit ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Solid Neoplasm ', ' Solid Tumor ', ' Structure of germinal center of lymph node ', ' Germinal Center ', ' Immune response ', ' immunoresponse ', ' host response ', ' Immunological response ', ' Infectious Agent ', ' infectious organism ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair enzyme ', ' repair endonuclease ', ' Human Cell Line ', ' response ', ' Immunoglobulin Somatic Hypermutation ', ' somatic hypermutation ', ' Ig Somatic Hypermutation ', ' activation-induced cytidine deaminase ', ' activation-induced deaminase ', ' CDA2 protein ', ' AID protein ', ' AID gene ', ' AICDA protein ', ' AICDA ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' Computer Analysis ', ' computer analyses ', ' computational analysis ', ' computational analyses ', ' Gene-Modified ', ' gene modification ', ' Validation ', ' Molecular ', ' Process ', ' Development ', ' developmental ', ' genetic variant ', ' genomic variant ', ' allelic variant ', ' allele variant ', ' Gene variant ', ' B lymphoid malignancy ', ' B cell malignancy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' Influenza Hemagglutinin ', ' influenza virus hemagglutinin ', ' influenza virus HA ', ' flu hemagglutinin ', ' flu HA ', ' Influenza HA ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' Knock-in ', ' knockin ', ' experimental study ', ' experimental research ', ' experiment ', ' recruit ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2019,587448,0.15225722621024226
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9740714,R01GM076275,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Gene Expression ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' Modern Man ', ' Human ', ' Ions ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' living system ', ' Organism ', ' Pathology ', ' Patients ', ' Peptides ', ' Play ', ' Proteins ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Research Resources ', ' Resources ', ' Ribonucleic Acid ', ' RNA Gene Products ', ' Non-Polyadenylated RNA ', ' RNA ', ' Computer Software Tools ', ' Software Tools ', ' Specificity ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Zinc Finger Motifs ', ' Zinc Finger Domain ', ' Zinc Fingers ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Link ', ' Individual ', ' Binding Proteins ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Biological Process ', ' Biological Function ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Complex ', ' Pattern ', ' interest ', ' Somatic Mutation ', ' preference ', ' Animal Model ', ' model organism ', ' model of animal ', ' Animal Models and Related Studies ', ' knowledge base ', ' knowledgebase ', ' Structure ', ' novel ', ' Proteome ', ' Code ', ' Coding System ', ' Sampling ', ' Property ', ' software development ', ' developing computer software ', ' develop software ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Binding ', ' DNA bound ', ' DNA Binding Interaction ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' DNA-Protein Interaction ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Protein Analysis ', ' Ligand Binding ', ' cancer genome ', ' tumor genome ', ' cancer cell genome ', ' virtual ', ' Population ', ' human disease ', ' tumor ', ' disease-causing mutation ', ' learning strategy ', ' learning method ', ' learning activity ', ' predictive tools ', ' experimental study ', ' experimental research ', ' experiment ', ' Infrastructure ', ' ']",NIGMS,PRINCETON UNIVERSITY,R01,2019,312660,0.09056100085204799
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9731187,U01CA227544,"['Affect ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Cell Body ', ' Cells ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Disorder ', ' Disease ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Feedback ', ' flow cytophotometry ', ' Flow Microfluorometry ', ' Flow Microfluorimetry ', ' Flow Cytofluorometry ', ' Flow Cytofluorometries ', ' Flow Cytometry ', ' Gene Expression ', ' Genes ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Libraries ', ' Maps ', ' Malignant Melanoma ', ' melanoma ', ' Methods ', ' Methodology ', ' Model System ', ' Biologic Models ', ' Biological Models ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Phenotype ', ' Protein Phosphorylation ', ' Phosphorylation ', ' Play ', ' Proteins ', ' Reagent ', ' Research ', ' social role ', ' Role ', ' Signal Pathway ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Technology ', ' Testing ', ' Translating ', ' Work ', ' Generations ', ' Measures ', ' Proto-Oncogene Proteins c-akt ', ' related to A and C-protein ', ' rac protein kinase ', ' proto-oncogene protein akt ', ' proto-oncogene protein RAC ', ' c-akt protein ', ' RAC-PK protein ', ' Protein Kinase B ', ' Akt protein ', ' AKT ', ' base ', ' Gene Dosage ', ' Gene Copy Number ', ' Link ', ' Measurement ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Complex ', ' Pattern ', ' Techniques ', ' Gene Mutation ', ' Gene Alteration ', ' Gene Proteins ', ' Protein Gene Products ', ' Therapeutic Intervention ', ' intervention therapy ', ' Regulation ', ' Modeling ', ' response ', ' Proteomics ', ' mathematical model ', ' mathematical modeling ', ' mathematic model ', ' Math Models ', ' Normal Cell ', ' Address ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Predictive Cancer Model ', ' Cancer Cell Growth ', ' Molecular ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' predictive modeling ', ' prognostic model ', ' prediction model ', ' computer based prediction ', ' design ', ' designing ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' cancer type ', ' Resistance ', ' resistant ', ' cell behavior ', ' cellular behavior ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' Breast Epithelial Cells ', ' mammary epithelial cells ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' Breast Cancer cell line ', ' Breast tumor cell line ', ' phosphoproteomics ', ' phospho-proteomics ', ' CRISPR library ', ' CRISPR/Cas9 library ', ' CRISPR-based library ', ' proteomic signature ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2019,608348,0.08365369730905468
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,9726144,R01CA249758,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Attention ', ' malignant breast neoplasm ', ' malignant breast tumor ', ' Breast Cancer ', ' Non-Small-Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Nonsmall Cell Lung Carcinoma ', ' Non-Small Cell Lung Cancer ', ' NSCLC - Non-Small Cell Lung Cancer ', ' NSCLC ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' computing method ', ' computer methods ', ' computer based method ', ' computational methods ', ' computational methodology ', ' Computing Methodologies ', ' Data Sources ', ' Death ', ' Cessation of life ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Family ', ' Foundations ', ' spongioblastoma multiforme ', ' glioblastoma multiforme ', ' Grade IV Astrocytoma ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytic Neoplasm ', ' Glioblastoma ', ' Health ', ' treatment provider ', ' medical personnel ', ' healthcare personnel ', ' health workforce ', ' health provider ', ' health care worker ', ' health care personnel ', ' Healthcare worker ', ' Healthcare Providers ', ' Health Care Providers ', ' Health Personnel ', ' History ', ' Recording of previous events ', ' Laboratories ', ' Medical Records ', ' Malignant Melanoma ', ' melanoma ', "" men's "", ' men ', ' Methods ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' natural language understanding ', ' Natural Language Processing ', ' Pathology ', ' Patients ', ' Public Health ', ' Recurrent ', ' Recurrence ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Semantics ', ' Technology ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Tweens ', ' Universities ', ' Vermont ', ' Woman ', ' Work ', ' Electronic Medical Record ', ' Computerized Medical Record ', ' Measures ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Medical ', ' Link ', ' Malignant neoplasm of lung ', ' lung cancer ', ' Pulmonary malignant Neoplasm ', ' Pulmonary Cancer ', ' Malignant Tumor of the Lung ', ' Drug usage ', ' drug use ', ' Collaborations ', ' Genetic ', ' cancer cell ', ' Malignant Cell ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Pattern ', ' Clinical Decision Support Systems ', ' Somatic Mutation ', ' Medical center ', ' Performance ', ' novel ', ' Second Primary Cancers ', ' secondary cancer ', ' Secondary Malignant Neoplasm ', ' Secondary Malignancy ', ' Second Cancer ', ' Pathology Report ', ' Statistical Methods ', ' Modeling ', ' response ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Bioinformatics ', ' Bio-Informatics ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Cancer Etiology ', ' Cancer Cause ', ' Cancer Patient ', ' Clinical Data ', ' Ontology ', ' Smoking Status ', ' Translational Research ', ' translation research ', ' Translational Science ', ' Tumor Pathology ', ' Validation ', ' Pathologic ', ' Characteristics ', ' resistance mechanism ', ' resistant mechanism ', ' Development ', ' developmental ', ' Colorectal Cancer ', ' Colo-rectal Cancer ', ' electronic data ', ' Pathway interactions ', ' pathway ', ' genetic profiling ', ' anticancer research ', ' cancer research ', ' anti-cancer research ', ' design ', ' designing ', ' Outcome ', ' Resistance development ', ' developing resistance ', ' Resistant development ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' Resistance ', ' resistant ', ' demographics ', ' tumor ', ' treatment response ', ' therapeutic response ', ' response to treatment ', ' treatment strategy ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' screening ', ' precision medicine ', ' precision-based medicine ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' targeted cancer therapy ', ' clinically actionable ', ' learning strategy ', ' learning method ', ' learning activity ', ' power analysis ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' ']",NCI,DARTMOUTH COLLEGE,R01,2019,375150,0.041361326121242985
"Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing Project Summary/Abstract Clinical data collection is accelerating rapidly, and in the future it will include both provider- and patient- generated data. Hidden within this mass of noisy observational data are clues as to factors influencing disease onset and outcome. Finding ways to exploit this trove of disease data can unlock a new perspective on disease processes. We can tackle disease both from the bottom-up, from experimental data generated in the laboratory, and from the top down, from clinical phenomena observed across human populations. A particularly impactful and prevalent disease is cancer. Each tumor harbors a unique combination of mutations driving a distinct set of oncogenic processes. Targeted therapies have been proposed to pinpoint these mutations, potentially requiring a vast array of therapeutic options. Cancer treatment often fails when drug resistance arises, another result of the complex combinatorial nature of tumor alterations. Combination therapies have been proposed as an approach to interfere with multiple disease signals simultaneously. However, identifying effective drug combinations, and the cancer types in which they are effective, is experimentally infeasible, leading to a push for computational solutions. In this proposal, we combine methods from social sciences and biostatistics to find the causal effect of a drug on cancer onset from observational clinical data. Both increased and decreased cancer rates in drug-takers are of equal interest, as they can inform us of disease processes and provide clinical impact. We are particularly interested in finding drug combinations that impact cancer. These combination effects are unlikely to have been detected, and our clinical data provides a unique resource for observing the effects of tens of thousands of drug combinations. We will pool the resulting causal drug effect estimates across the many cancers present in our data. To gain insight into the cellular processes underlying clinical effect, we will examine the impact of known cancer-causing drugs in vitro, using large public cell line assays. The accompanying goal is to provide Dr. Rachel Melamed with a career development experience to become an independent scientist. Her research will use observational health data to understand the genesis of cancer, prevent the disease, and discover new therapeutic options. This proposal takes advantage of the interdisciplinary strengths of the University of Chicago in computation, biostatistics, and medicine, as well as institutional resources in terms of data access and infrastructure. Dr. Melamed has assembled a team consisting of complementary mentors and collaborators with expertise in computation, statistics, translational medicine, personalized therapy, and cancer therapy. The career development plan focuses on enhancing her statistics and machine learning skills with structured coursework and mentorship, and gaining experience in biomedical applications via applied work and mentorship. This will provide Dr. Melamed with skills to model observational data and to integrate the results with experimental data. Project Narrative Clinical data has been shown to hold patterns relating drugs to cancer onset. Using this data to find drugs that increase cancer rates will provide insight into the disease and an opportunity for preventing some cancer cases. Discovery of drugs, and particularly drug combinations, that reduce cancer rates could suggest low-cost new therapeutic options.",Using clinical data to identify FDA-approved drugs for cancer prevention and therapeutic repurposing,9699483,K01ES028055,"['Antineoplastic Agents ', ' anticancer drug ', ' anticancer agent ', ' anti-cancer drug ', ' Tumor-Specific Treatment Agents ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Cancer Drug ', ' Antineoplastics ', ' Antineoplastic Drugs ', ' Anti-Cancer Agents ', ' Automobile Driving ', ' driving ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biometry ', ' Biostatistics ', ' Biometrics ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Chicago ', ' multi-modal treatment ', ' multi-modal therapy ', ' combined treatment ', ' combined modality treatment ', ' combination therapy ', ' Multimodal Treatment ', ' Multimodal Therapy ', ' Combined Modality Therapy ', ' Data Collection ', ' Death ', ' Cessation of life ', ' Disorder ', ' Disease ', ' Drug Combinations ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Environment ', ' epidemiological ', ' epidemiologic ', ' Epidemiology ', ' Future ', ' Gene Expression ', ' Goals ', ' Modern Man ', ' Human ', ' In Vitro ', ' Incidence ', ' Investments ', ' Joints ', ' Laboratories ', ' Libraries ', ' Medicine ', ' Mentors ', ' Mentorship ', ' Methods ', ' Methodology ', ' Mining ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Patients ', ' Drug Prescribing ', ' Drug Prescriptions ', ' Research ', ' Research Resources ', ' Resources ', ' Science ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Social Sciences ', ' statistics ', ' Body Tissues ', ' Tissues ', ' Universities ', ' Work ', ' Measures ', ' Case Series ', ' base ', ' Area ', ' Clinical ', ' premature ', ' prematurity ', ' Link ', ' insight ', ' Individual ', ' Databases ', ' data base ', ' Data Bases ', ' Development Plans ', ' Drug usage ', ' drug use ', ' Medical History ', ' Personal Medical History Epidemiology ', ' Personal Medical History ', ' Onset of illness ', ' disorder onset ', ' disease onset ', ' cancer prevention ', ' Therapeutic ', ' cancer cell ', ' Malignant Cell ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Scientist ', ' Complex ', ' Event ', ' Clinic ', ' Pattern ', ' interest ', ' experience ', ' life history ', ' Structure ', ' skills ', ' Disease Outcome ', ' novel ', ' disorder risk ', ' disease risk ', ' Drug Exposure ', ' Modeling ', ' career development ', ' response ', ' Adverse event ', ' Adverse Experience ', ' Genomics ', ' cancer therapy ', ' anticancer therapy ', ' anti-cancer therapy ', ' Malignant Neoplasm Treatment ', ' Malignant Neoplasm Therapy ', ' Cancer Treatment ', ' Provider ', ' preventing ', ' prevent ', ' Data ', ' Premalignant ', ' precancerous ', ' Pre-Malignant ', ' in vitro Assay ', ' in vivo ', ' Clinical Data ', ' Molecular ', ' Process ', ' follow-up ', ' followup ', ' followed up ', ' follow up ', ' active followup ', ' Active Follow-up ', ' Development ', ' developmental ', ' Pathway interactions ', ' pathway ', ' cost ', ' Cancer cell line ', ' Population ', ' cancer type ', ' innovation ', ' innovative ', ' innovate ', ' Cancerous ', ' Oncogenic ', ' combinatorial ', ' clinically relevant ', ' clinical relevance ', ' clinical effect ', ' translational medicine ', ' novel therapeutics ', ' novel therapy ', ' novel drugs ', ' novel drug treatments ', ' next generation therapeutics ', ' new therapy ', ' new therapeutics ', ' new drugs ', ' new drug treatments ', ' tumor ', ' gene discovery ', ' discover genes ', ' FDA approved ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' clinical predictors ', ' targeted treatment ', ' targeted therapy ', ' targeted therapeutic agents ', ' targeted therapeutic ', ' targeted drug treatments ', ' targeted drug therapy ', ' health data ', ' clinical investigation ', ' training opportunity ', ' Learning Skill ', ' disease heterogeneity ', ' data access ', ' genomic data ', ' genomic dataset ', ' genomic data-set ', ' experimental study ', ' experimental research ', ' experiment ', ' Infrastructure ', ' econometrics ', ' side effect ', ' ']",NIEHS,UNIVERSITY OF CHICAGO,K01,2019,124953,0.005623515458439052
"High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms     DESCRIPTION (provided by applicant): Mutations are the ultimate source of genetic variation and one of the driving forces of evolution. Both the absolute mutation rate and the relative rate among mutation subtypes fluctuate along the genome, affected by adjacent nucleotide motifs and local features such as GC content and replication timing. Characterizing regional variation of mutation patterns is critical for understanding genome evolution and to identify variants causing genetic diseases. However, mutation rate and molecular spectrum are difficult to measure at high resolution, genomewide, and in an unbiased fashion. Estimates based on common variants and between- species substitutions are confounded by natural selection, population demographic history, and biased gene conversion (BGC). Methods relying on incidence rates of monogenic diseases or finding de novo variants by trio sequencing can inform global trends, but do not provide sufficient data to assess fine-scale local parameters. This study will overcome these limitations by using the extremely rare variants (ERVs) as a new data source to characterize patterns of recent germline variation in humans. ERVs, defined in this study as singletons in 30,000 samples, are becoming available via large-scale whole-genome sequencing (WGS) of population samples. Unlike common variants or substitutions, ERVs arose very recently and are largely unaffected by selection, BGC, etc. We will analyze 200-300 million singleton variants observed in 30,000 subjects at 20-30X coverage. The regional distribution of ERV subtypes will establish a quantitative atlas of the rate and spectrum of human germline mutations mostly unaltered by selection. We will share this resource with the research community and apply it to determine the impact of local genomic features and epigenomic attributes. We will use the systematic departures between ERVs and variants of higher frequencies (polymorphisms and substitutions) to infer local effects of selection, and this may uncover hitherto unknown functional regions of the genome. By comparing mutation signatures in ERVs with those in somatic variations observed in diverse cancers we will attribute distinct mutational signatures to known biochemical processes and thus infer the major contributors to new germline mutations in the human genome. This subtype-specific atlas will also be used to predict the probability of observing every possible single-base mutation in the genome, thus facilitating the interpretation of candidate causal variants of human diseases. We will assess mutation pattern differences among European Americans, African Americans and Latinos, and seek to discover genetic modifiers of germline mutation rate by finding functionally damaging mutations that show increased ERV counts in the surrounding genomic region, potentially identifying both known and previous unknown ""mutator"" genes that play a role in transmission fidelity in humans. This research will provide an essential resource to study the genesis and maintenance of germline mutations in humans. Understanding such a fundamental process will be the basis for a deeper understanding of human evolution and diseases. PUBLIC HEALTH RELEVANCE: We will study the patterns of inherited mutations in humans using approximately 250 million extremely rare DNA variants in human populations. Our results will allow the prediction of the rate of new mutations at every site in the genome based on features of the surrounding DNA sequence, thus providing a common resource to study the arrival and maintenance of mutations in humans. Understanding such a basic process is important for answering fundamental questions in human evolution, the cause of inherited diseases, and the role of DNA abnormality in cancer and aging.",High-resolution map of human germline mutation patterns and inference of mutagenic mechanisms,9702844,R01GM118928,"['Affect ', ' Aging ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Atlases ', ' Biological Factors ', ' Biologic Factor ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' youngster ', "" childrens' "", ' children ', ' Children (0-21) ', ' Child Youth ', ' 0-11 years old ', ' Child ', ' Chromatin ', ' Communities ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Data Sources ', ' Demographic Factors ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Evolution ', ' Family ', ' Foundations ', ' Future ', ' Gene Conversion ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' inherited genetic disorder ', ' inherited genetic disease ', ' inherited diseases ', ' inborn error ', ' hereditary disorder ', ' Inherited disorder ', ' Inborn Genetic Diseases ', ' Hereditary Disease ', ' History ', ' Recording of previous events ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Incidence ', ' Maintenance ', ' Maps ', ' Methods ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Nucleotides ', ' Parents ', ' Play ', ' polymorphism ', ' Genetic Polymorphism ', ' Probability ', ' Recombination ', ' DNA Recombination ', ' Genetic Recombination ', ' Research ', ' Research Resources ', ' Resources ', ' Rest ', ' social role ', ' Role ', ' Selection Bias ', ' Technology ', ' Body Tissues ', ' Tissues ', ' Genetic Diversity ', ' Genetic Variation ', ' Weight ', ' Generations ', ' Measures ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' black American ', ' Black Populations ', ' Afroamerican ', ' Afro American ', ' African American ', ' Latino ', ' Natural Selections ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' density ', ' improved ', ' Site ', ' Variant ', ' Variation ', ' Germ-Line Mutation ', ' Hereditary Mutation ', ' Germline Mutation ', ' Individual ', ' European ', ' Biological Process ', ' Biological Function ', ' Genetic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Inherited ', ' Hereditary ', ' Complex ', ' Dependence ', ' Source ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' American ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Modeling ', ' Sampling ', ' repository ', ' Genomics ', ' Guanine + Cytosine Composition ', ' Guanine + Cytosine Content ', ' GC Content ', ' GC Composition ', ' G+C Content ', ' G+C Compositions ', ' Pathogenicity ', ' Mismatch Repair ', ' Post-Replication Mismatch Repair ', ' genome sequencing ', ' Address ', ' Biochemical Process ', ' Data ', ' Resolution ', ' Resource Sharing ', ' Genomic Segment ', ' genomic region ', ' transmission process ', ' Transmission ', ' trend ', ' Molecular ', ' Process ', ' epigenomics ', ' Population ', ' driving force ', ' human disease ', ' prototype ', ' public health relevance ', ' genome-wide ', ' genomewide ', ' genome scale ', ' data sharing ', ' next generation sequencing ', ' nextgen sequencing ', ' next gen sequencing ', ' NGS system ', ' NGS Method ', ' rare variant ', ' rare allele ', ' High-Throughput Nucleotide Sequencing ', ' High-Throughput Sequencing ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' human model ', ' web server ', ' causal variant ', ' causative variant ', ' causative mutation ', ' causal mutation ', ' causal gene ', ' causal allele ', ' ']",NIGMS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,R01,2019,300191,0.1267325595934094
"Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease Project Summary/Abstract Genome-wide association studies have given us many clues about the mutations that cause common genetic diseases, including autoimmune diseases like lupus and rheumatoid arthritis. However, many of the mutations implicated in disease lie outside of the genes themselves and instead lie in the regions controlling expression of the genes, and so probably contribute to disease by producing the wrong amount of the gene in the wrong tissue or at the wrong time. Mutations in regulatory regions are thought to cause disease by altering the binding of regulatory proteins to the DNA, changing the DNA sequence from one that the protein can bind to one that it cannot (or vice versa). However, the ways in which these regulatory proteins control gene expression remains incompletely understood and so it is presently difficult to understand which regulatory protein binds differently to a mutated regulatory region, or how that change in binding affects expression of the regulated genes. In fact, we still do not even know where the regulatory regions are in the tissues we think are dysfunctional in disease. This project aims to better understand how these mutations contribute to autoimmune disease by first increasing our understanding of how regulatory proteins and regulatory regions work to control when and where genes are expressed, and then applying this knowledge to understand genetic disease. First, regulatory regions will be identified in immune cells and their effects on gene expression measured so that mutations that are likely to contribute to disease (those in regulatory regions) can be identified. The relationship between regulatory proteins, regulatory sequence, and gene expression will be learned by creating millions of synthetic regulatory regions and measuring their effect on gene expression, providing many examples of binding sites for each regulatory protein from which to learn. Finally, our new understanding of gene regulation will be applied to determine which genetic mutations change regulatory protein binding and cause disease. This will help us better understand the underlying causes of disease so that new treatments can be developed that target the mutations within each person. The candidate's long term career goals are to better understand how gene regulation works in humans so that we can better understand how the sequence of the genome controls the expression of our genes. The candidate currently works at the Broad Institute, a leading institute in human genetics and genomics with the resources and personnel required of this project. In order to continue to develop as a scientist, the candidate will gain more experience teaching, publish and present his existing findings, gain the necessary skills to work with human cells, and secure a faculty position and funding so that he can continue to make a positive impact on our knowledge of the genome. Project Narrative Certain genetic diseases are thought to be caused by mutations in the DNA that alter the expression of nearby genes. This project will help us to understand how DNA sequence regulates the expression of genes, and aims to apply this knowledge to predict how and why mutations change gene expression and contribute to disease. By better understanding the fundamental causes of disease, we can better design therapeutic interventions.",Learning the rules of enhancer activity to understand non-coding genetic variation in autoimmune disease,9695242,K99HG009920,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Rheumatoid Arthritis ', ' rheumatic arthritis ', ' Atrophic Arthritis ', ' Autoimmune Diseases ', ' autoimmune disorder ', ' Binding Sites ', ' Reactive Site ', ' Combining Site ', ' Biochemistry ', ' Biological Chemistry ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' cultured cell line ', ' Strains Cell Lines ', ' CellLine ', ' Cell Line ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' cell sorting ', ' Cell Separation Technology ', ' Cell Segregation ', ' Cell Isolation ', ' Cell Separation ', ' Cell Body ', ' Cells ', ' Chromatin ', ' Communities ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' Diagnosis ', ' Disorder ', ' Disease ', ' Deoxyribonucleic Acid ', ' DNA ', ' Faculty ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' Genome ', ' human whole genome ', ' Human Genome ', ' Goals ', ' ontogeny ', ' Tissue Growth ', ' Generalized Growth ', ' Growth ', ' Haplotypes ', ' Health ', ' Modern Man ', ' Human ', ' Human Activities ', ' Human Genetics ', ' Institutes ', ' Learning ', ' Libraries ', ' Logic ', ' Maps ', ' Methodology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Persons ', ' Plasmids ', ' polymorphism ', ' Genetic Polymorphism ', ' Proteins ', ' Publishing ', ' genetic regulatory element ', ' Regulatory Regions ', ' Nucleic Acid Regulator Regions ', ' Nucleic Acid Regulatory Sequences ', ' Research ', ' Research Resources ', ' Resources ', ' Specificity ', ' Teaching ', ' Educational process of instructing ', ' Testing ', ' Time ', ' Body Tissues ', ' Tissues ', ' Transcription factor genes ', ' Transcription Factor Proto-Oncogene ', ' General Transcription Factors ', ' General Transcription Factor Gene ', ' Basal transcription factor genes ', ' Basal Transcription Factor ', ' transcription factor ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Yeasts ', ' Measures ', ' Enhancers ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' career ', ' improved ', ' Phase ', ' Biochemical ', ' Link ', ' Predisposition ', ' Susceptibility ', ' Training ', ' Binding Proteins ', ' bound protein ', ' Protein Binding ', ' Ligand Binding Protein Gene ', ' Ligand Binding Protein ', ' Measurement ', ' Funding ', ' Reporter ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Scientist ', ' Immune ', ' Immunes ', ' Complex ', ' cell type ', ' System ', ' experience ', ' skills ', ' Human Cell Line ', ' disorder risk ', ' disease risk ', ' Human Resources ', ' personnel ', ' Manpower ', ' Positioning Attribute ', ' Position ', ' Therapeutic Intervention ', ' intervention therapy ', ' genetic regulatory protein ', ' regulatory gene product ', ' Regulatory Protein ', ' Regulation ', ' Modeling ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Molecular Interaction ', ' Binding ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Mutate ', ' Protein Region ', ' Resolution ', ' in vivo ', ' Development ', ' developmental ', ' genome wide association study ', ' whole genome association study ', ' whole genome association studies ', ' whole genome association analysis ', ' genomewide association study ', ' genomewide association studies ', ' genomewide association scan ', ' genome wide association studies ', ' genome wide association scan ', ' genome wide association ', ' GWAS ', ' GWA study ', ' biochemical model ', ' design ', ' designing ', ' Lupus ', ' genome-wide ', ' genomewide ', ' genome scale ', ' Secure ', ' rare variant ', ' rare allele ', ' personalized medicine ', ' personalized treatment ', ' personalized therapy ', ' personalization of treatment ', ' genetic predictors ', ' ATAC-seq ', ' ATACseq ', ' human genomics ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' ']",NHGRI,"BROAD INSTITUTE, INC.",K99,2019,90935,0.009154388363098736
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9683394,F32GM131573,"['Affect ', ' Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biological Assay ', ' Biologic Assays ', ' Bioassay ', ' Assay ', ' Biology ', ' Malignant Neoplasms ', ' neoplasm/cancer ', ' malignancy ', ' Malignant Tumor ', ' Cancers ', ' Communities ', ' Complement Proteins ', ' Complement ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Evolution ', ' Gene Expression ', ' Gene Regulation Process ', ' Gene Regulation ', ' Gene Action Regulation ', ' Gene Expression Regulation ', ' Genes ', ' trans acting element ', ' regulatory gene ', ' Transcriptional Regulatory Elements ', ' Regulator Genes ', ' Genome ', ' Goals ', ' Laboratories ', ' Libraries ', ' Literature ', ' Mission ', ' Modernization ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' New York ', ' Pathology ', ' Phenotype ', ' Play ', ' Proteins ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Ribosomes ', ' transfer Ribonucleic acids ', ' tRNA ', ' Triplet Codon-Amino Acid Adaptor ', ' Transfer RNA ', ' social role ', ' Role ', ' Software ', ' Computer software ', ' Stress ', ' Testing ', ' Transcription ', ' RNA Expression ', ' Gene Transcription ', ' Genetic Transcription ', ' mRNA Translation ', ' Genetic Translation ', ' Translations ', ' Universities ', ' Genetic Diversity ', ' Genetic Variation ', ' Work ', ' Generations ', ' Measures ', ' Protein Coding Region ', ' ORFs ', ' Open Reading Frames ', ' promotor ', ' promoter ', ' Site ', ' Variant ', ' Variation ', ' Biological ', ' Evaluation ', ' Training ', ' insight ', ' Genetic ', ' tool ', ' Nature ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Frequencies ', ' Scanning ', ' interest ', ' Nutrient ', ' novel ', ' cancer genetics ', ' Code ', ' Coding System ', ' Regulation ', ' Modeling ', ' response ', ' Untranslated RNA ', ' noncoding ', ' Nontranslated RNA ', ' Noncoding RNA ', ' Non-translated RNA ', ' Non-Coding RNA ', ' Non-Coding ', ' Functional RNA ', ' Genomics ', ' mRNA Decay ', ' mRNA Degradation ', ' mRNA Transcript Degradation ', ' work performance ', ' job performance ', ' Performance at work ', ' genome sequencing ', ' Address ', ' Systems Biology ', ' fitness ', ' Data ', ' Human Pathology ', ' Regulatory Element ', ' Translation Initiation ', ' Translational Regulation ', ' Development ', ' developmental ', ' environmental change ', ' Population ', ' Coupled ', ' analytical tool ', ' multidisciplinary ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' collaborative environment ', ' peer-group environment ', ' peer-group atmosphere ', ' interdisciplinary environment ', ' interdisciplinary atmosphere ', ' interactive environment ', ' interactive atmosphere ', ' collaborative atmosphere ', ' business-friendly environment ', ' Business-Friendly Atmosphere ', ' mutation screening ', ' mutation scanning ', ' actionable mutation ', ' driver mutation ', ' actionable variants ', ' whole genome ', ' full genome ', ' entire genome ', ' ribosome profiling ', ' ribosome footprint profiling ', ' Ribo-seq ', ' experimental study ', ' experimental research ', ' experiment ', ' Expression Profiling ', ' preservation ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' ']",NIGMS,NEW YORK UNIVERSITY,F32,2019,61226,0.20091819715970052
"Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data Big data is now ubiquitous in every field of modern scientific research. Many contemporary applications, such as the recent national microbiome initiative (NMI), greatly demand highly flexible statistical machine learning methods that can produce both interpretable and reproducible results. Thus, it is of paramount importance to identify crucial causal factors that are responsible for the response from a large number of available covariates, which can be statistically formulated as the false discovery rate (FDR) control in general high-dimensional nonlinear models. Despite the enormous applications of shotgun metagenomic studies, most existing investigations concentrate on the study of bacterial organisms. However, viruses and virus-host interactions play important roles in controlling the functions of the microbial communities. In addition, viruses have been shown to be associated with complex diseases. Yet, investigations into the roles of viruses in human diseases are significantly underdeveloped. The objective of this proposal is to develop mathematically rigorous and computationally efficient approaches to deal with highly complex big data and the applications of these approaches to solve fundamental and important biological and biomedical problems. There are four interrelated aims. In Aim 1, we will theoretically investigate the power of the recently proposed model-free knockoffs (MFK) procedure, which has been theoretically justified to control FDR in arbitrary models and arbitrary dimensions. We will also theoretically justify the robustness of MFK with respect to the misspecification of covariate distribution. These studies will lay the foundations for our developments in other aims. In Aim 2, we will develop deep learning approaches to predict viral contigs with higher accuracy, integrate our new algorithm with MFK to achieve FDR control for virus motif discovery, and investigate the power and robustness of our new procedure. In Aim 3, we will take into account the virus-host motif interactions and adapt our algorithms and theories in Aim 2 for predicting virus-host infectious interaction status. In Aim 4, we will apply the developed methods from the first three aims to analyze the shotgun metagenomics data sets in ExperimentHub to identify viruses and virus-host interactions associated with several diseases at some target FDR level. Both the algorithms and results will be disseminated through the web. The results from this study will be important for metagenomics studies under a variety of environments. Big data is ubiquitous in biological research. Identifying causal factors associated with complex diseases or traits from big data is highly important and challenging. New statistical and computational tools will be developed to control False Discovery Rate (FDR) for molecular sequence data based on the novel model-free knockoffs framework. They will be used to detect sequence motifs for viruses and motif-pairs for virus-host interactions, and to analyze multiple metagenomics data sets related to complex diseases.",Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data,9753295,R01GM131407,"['Algorithms ', ' Archaea ', ' Archaeon ', ' Archaeobacteria ', ' Archaebacteria ', ' Attention ', ' Bacteria ', ' Cell Body ', ' Cells ', ' type two diabetes ', ' type II DM ', ' type 2 DM ', ' maturity onset diabetes ', ' ketosis resistant diabetes ', ' adult onset diabetes ', ' Type II diabetes ', ' Type II Diabetes Mellitus ', ' Type 2 diabetes ', ' Type 2 Diabetes Mellitus ', ' T2DM ', ' T2D ', ' T2 DM ', ' Stable Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Noninsulin Dependent Diabetes Mellitus ', ' Noninsulin Dependent Diabetes ', ' Non-Insulin Dependent Diabetes ', ' NIDDM ', ' Maturity-Onset Diabetes Mellitus ', ' Ketosis-Resistant Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' Disorder ', ' Disease ', ' Environment ', ' Foundations ', ' Genes ', ' Modern Man ', ' Human ', ' Joints ', ' Linear Regressions ', ' Literature ', ' Hepatic Cirrhosis ', ' Liver Cirrhosis ', ' Math ', ' Mathematics ', ' Methods ', ' Modernization ', ' Molecular Sequence Data ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Neurosciences ', ' obese population ', ' obese person ', ' obese people ', ' obese ', ' corpulentia ', ' corpulency ', ' corpulence ', ' adiposity ', ' Obesity ', ' living system ', ' Organism ', ' Play ', ' Reproducibility of Findings ', ' Reproducibility of Results ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' social role ', ' Role ', ' Sampling Studies ', ' shot gun ', ' Shotguns ', ' Social Sciences ', ' Software ', ' Computer software ', ' Testing ', ' Theoretical Studies ', ' Body Tissues ', ' Tissues ', ' General Viruses ', ' Virus ', ' Work ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' Ecosystem ', ' Ecological Systems ', ' Ecologic Systems ', ' base ', ' improved ', ' Procedures ', ' Biological ', ' Non-linear Models ', ' Nonlinear Models ', ' Training ', ' Planet Earth ', ' Earth ', ' Internet ', ' world wide web ', ' web ', ' WWW ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Investigation ', ' Dimensions ', ' Frequencies ', ' Complex ', ' Genetic Materials ', ' human tissue ', ' Viral ', ' Marines ', ' interest ', ' Consult ', ' Performance ', ' virus identification ', ' trait ', ' virus host interaction ', ' simulation ', ' novel ', ' new technology ', ' novel technologies ', ' Bypass ', ' Modeling ', ' Sampling ', ' response ', ' theories ', ' Genomics ', ' model design ', ' model development ', ' Effectiveness ', ' Address ', ' Length ', ' Data ', ' Reproducibility ', ' Molecular ', ' Development ', ' developmental ', ' Colorectal Cancer ', ' Colo-rectal Cancer ', ' microbiome ', ' computerized tools ', ' computational tools ', ' design ', ' designing ', ' Visualization software ', ' visualization tool ', ' Coupled ', ' microbial community ', ' community microbes ', ' metagenomic sequencing ', ' metagenome sequencing ', ' biological research ', ' Metagenomics ', ' Functional Metagenomics ', ' user-friendly ', ' human disease ', ' flexibility ', ' flexible ', ' Big Data ', ' BigData ', ' dark matter ', ' Gaussian model ', ' Gaussianity model ', ' Gaussianity ', ' Gaussian statistics ', ' learning strategy ', ' learning method ', ' learning activity ', ' power analysis ', ' high dimensionality ', ' microbiome research ', ' microbiome studies ', ' microbiome science ', ' Microbiomics ', ' deep learning ', ' deep learning algorithm ', ' contig ', ' ']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2019,279949,0.08576415681657736
"Unraveling molecular and system-level mechanisms of human disease-associated protein mutations Project Summary Although a quickly expanding catalogue of protein mutations have been discovered, including those that cause human diseases or confer drug resistance, mechanistic understanding and prediction of functional consequences of these mutations remain rather limited. There is a critical need to develop novel, multiscale computational frameworks that are rigorous and generalizable to help close the ever-increasing gap between phenotypic data and mechanistic knowledge about the mutations and to develop effective therapeutic strategies.  My long-term research goals are two folds: (1) to unravel how a change in protein sequence ripples through various aspects of molecular and system-levels to a change in cellular function and cause human diseases or confer drug resistance; and (2) to translate learned mechanistic knowledge to effective drug-design strategies for human diseases and drug resistance. Toward these goals I propose to advance and combine the strengths of computational molecular biology (structural modeling and design for proteins or protein interactions) and computational systems biology (pathway/network-level topology and dynamics) and follow a novel, formal paradigm to develop methods that systematically identify mechanisms underlying various stages of consequence propagation (from conformation, molecular and system-level variables, to cellular functions, where intermediates can be skipped if necessary). In the forward direction of propagating consequences, I will determine, explain and understand mutational consequences at various levels with machine learning, causal analysis, and combinatorial optimization, starting with known or modelled changes at various levels. In the inverse direction of designing consequences, I will follow known or learned mechanistic hypotheses and develop efficient combinatorial optimization methods to design mutagenesis experiments or screen / design ligands for desired perturbations at various levels, which would test and refine corresponding hypotheses directly and translate mechanistic hypotheses to therapeutic strategies. Mechanisms underlying distal (potentially allosteric) mutations, multiple mutations within a protein or across proteins as well as systems pharmacology strategies will also be rigorously determined in the process.  The expected outcomes from the innovative project will include two main components. The first will be both biophysical principles of proteins and integrative understanding of biomedical systems, which will be organized in a database for public access. The second will be translating mechanistic insights into therapeutic intervention strategies to treat diseases. In particular, targeted experiments (mutagenesis or ligand-binding) will be designed following known or discovered mechanistic hypotheses. This project will involve close collaboration with structural biologists and clinician-scientists who are active collaborators of the PI. Project Narrative Genetic mutations, many of which lead to protein mutations, are often associated with human diseases: they often directly cause diseases or contribute to their progressions. Understanding mechanisms by which these mutations lead to significant functional consequences is of extreme importance to developing effective therapeutics to cure diseases and ameliorate drug resistance.",Unraveling molecular and system-level mechanisms of human disease-associated protein mutations,9774239,R35GM124952,"['Amino Acid Sequence ', ' protein sequence ', ' Primary Protein Structure ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Subcellular Process ', ' Cellular Process ', ' Cellular Physiology ', ' Cellular Function ', ' Cell Process ', ' Cell Function ', ' Cell physiology ', ' Disorder ', ' Disease ', ' Drug Design ', ' resistant to Drug ', ' resistance to Drug ', ' drug resistant ', ' Drug resistance ', ' Goals ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Ligands ', ' Methods ', ' Structural Models ', ' conformational state ', ' conformation ', ' Molecular Stereochemistry ', ' Molecular Configuration ', ' Molecular Conformation ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Pharmacology ', ' protein design ', ' genetic protein engineering ', ' Protein Engineering ', ' Proteins ', ' Research ', ' Testing ', ' Translating ', ' Mutagenesis Molecular Biology ', ' Genetics-Mutagenesis ', ' Mutagenesis ', ' Distal ', ' insight ', ' Databases ', ' data base ', ' Data Bases ', ' Collaborations ', ' Therapeutic ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Catalogs ', ' Scientist ', ' System ', ' novel ', ' Therapeutic Intervention ', ' intervention therapy ', ' Modeling ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Disease Resistance ', ' resistant to disease ', ' resistant disease ', ' resistance to disease ', ' Computational Molecular Biology ', ' Systems Biology ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Structural Biologist ', ' Ligand Binding ', ' Molecular ', ' Process ', ' Pathway interactions ', ' pathway ', ' computer framework ', ' computational framework ', ' design ', ' designing ', ' Treatment Efficacy ', ' therapy efficacy ', ' therapeutically effective ', ' therapeutic efficacy ', ' intervention efficacy ', ' Outcome ', ' innovation ', ' innovative ', ' innovate ', ' human disease ', ' Combinatorial Optimization ', ' phenotypic data ', ' experimental study ', ' experimental research ', ' experiment ', ' ']",NIGMS,TEXAS ENGINEERING EXPERIMENT STATION,R35,2019,335245,0.13491111632773134
"Genomic sequencing to aid diagnosis in pediatric and prenatal practice: Examining clinical utility, ethical implications, payer coverage, and data integration in a diverse population. PROJECT SUMMARY I propose to gain experience in what are becoming the next big topics in genomic medicine  the integration of big data using data science in order to achieve precision health  what could be summed up as data science of the future. These topics emerge from - but go beyond - the narrower concept of precision medicine as the use of genetic information for treatment decisions. The goal is to develop experience in data science and precision health so that my work can serve as a bridge between my field of economics and these fields - and begin to prepare for the future challenges as they emerge. PROJECT NARRATIVE Both data science and precision health will be critical components of future health care interventions and impact patients, providers, and society. Big Data using data science includes the aggregation and analysis of data across platforms (includes information from, e.g. genetic testing, biosensors, wearables, and electronic health records, with such data analyzed using, e.g. artificial intelligence and machine learning). Precision Health uses a big data approach to focus on disease prevention and detection throughout ones lifetime.","Genomic sequencing to aid diagnosis in pediatric and prenatal practice: Examining clinical utility, ethical implications, payer coverage, and data integration in a diverse population.",9929780,U01HG009599,"['Artificial Intelligence ', ' Machine Intelligence ', ' Computer Reasoning ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' Diagnosis ', ' Economics ', ' ethical ', ' Ethics ', ' Future ', ' Goals ', ' Health ', ' Patients ', ' Societies ', ' Work ', ' health care ', ' Healthcare ', ' population diversity ', ' heterogeneous population ', ' diverse populations ', ' Population Heterogeneity ', ' Clinical ', ' Childhood ', ' pediatric ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Source ', ' experience ', ' Biosensor ', ' biological sensor ', ' prenatal ', ' unborn ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' disorder prevention ', ' disease prevention ', ' Intervention ', ' interventional strategy ', ' Intervention Strategies ', ' Genomics ', ' Provider ', ' Detection ', ' Sum ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' data integration ', ' Big Data ', ' BigData ', ' precision medicine ', ' precision-based medicine ', ' genetic information ', ' informal learning ', ' informal instruction ', ' informal education ', ' formal learning ', ' Data Science ', ' Genomic medicine ', ' Precision Health ', ' ']",NHGRI,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",U01,2019,166973,0.06517195057811126
"Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model PROJECT SUMMARY / ABSTRACT Rare monogenic forms of common diseases have provided key fundamental insights about common disease. However, genetic, environmental, and stochastic elements influence risk for disease. Familial hypercholesterolemia (FH), an autosomal dominant disorder afflicting 1 in 250 linked to severe increases in LDL cholesterol and premature coronary heart disease (CHD) risk, is an ideal model to characterize modifiers of disease. Despite the presence of a strong genetic driver of hypercholesterolemia from FH mutations, we recently observed that half do not have the expected severe hypercholesterolemia. In this proposal, we outline several methods to discover and dissect the genetic and non-genetic factors influencing CHD risk conferred by FH mutations in humans and determine whether knowledge of these factors can improve risk discrimination among those with FH mutations. Our approach harnesses several multi-dimensional datasets: whole genome sequences, metabolomics, and cross-sectional and longitudinal cardiovascular phenotypes. In Aim 1, we will aggregate and curate 75,000 deep (30X) whole genome sequences and cardiovascular phenotypes. In Aim 2, we will discover genetic and non-genetic modifiers of LDL cholesterol and CHD risk in FH and evaluate their metabolomic consequences. In Aim 3, we will develop a method incorporating genetics and longitudinal non- genetic exposures for CHD risk stratification among ~4,000 with FH mutations in the Million Veteran Program. In addition to the proposed Aims, this five-year proposal outlines a comprehensive strategy for the principal investigator's (PI's) scientific and professional development in academic cardiovascular medicine. The research strategy builds upon the PI's prior research experience and clinical training. In addition to an undergraduate degree in Molecular Biology and master's degree in Biomedical Informatics, he completed post- graduate medical training in Internal Medicine and Cardiovascular Medicine. He recently developed a new preventive/genetic cardiology clinic focusing on the evaluation and management of those with or a family history of premature CHD, including those with FH, at Massachusetts General Hospital (MGH). This proposal now focuses on expanding his scientific skills in human genetics and genomics into new domains: integrative genomics, statistical genetics, clinical informatics, and risk modeling. The career development goals will be at achieved through a multi-faceted approach involving mentorship, collaboration, didactic coursework, conferences, and scientific investigation. This work will take place in a unique training environment comprised of MGH and the Broad Institute. Successful completion of this career development award will result in improved fundamental understanding of the determinants of CHD, result in the PI's transition to an independent physician-scientist, and provide a solid foundation from which he will apply for R01-level funding. PROJECT NARRATIVE / PUBLIC HEALTH RELEVANCE Cardiovascular disease, largely due to coronary heart disease (CHD), remains the leading cause of death in the United States and now worldwide despite current advances. Familial hypercholesterolemia is a relative common genetic disorder characterized by severe hypercholesterolemia and premature CHD but many carrying these mutations do not develop these consequences. This proposal seeks to define and characterize the factors modifying CHD risk among those with FH mutations; success has the potential to broadly identify new mechanisms of CHD and novel strategies for prevention.",Understanding modifiers of mendelian mutation penetrance using familial hypercholesterolemia as a model,9609507,K08HL140203,"['Adult ', ' adulthood ', ' Adult Human ', ' 21+ years old ', ' Affect ', ' Cardiology ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cardiovascular system ', ' circulatory system ', ' Heart Vascular ', ' Cardiovascular Organ System ', ' Cardiovascular Body System ', ' Cardiovascular ', ' Cause of Death ', ' Clinical Informatics ', ' virtual simulation ', ' in silico ', ' computerized simulation ', ' computerized modeling ', ' computer based models ', ' computational simulation ', ' computational models ', ' computational modeling ', ' Mathematical Models and Simulations ', ' Mathematical Model Simulation ', ' Computerized Models ', ' Computer based Simulation ', ' Computer Models ', ' Computer Simulation ', ' coronary arterial disease ', ' atherosclerotic coronary disease ', ' Coronary Atherosclerosis ', ' Coronary Artery Disorder ', ' Coronary Artery Disease ', ' Coronary Arteriosclerosis ', ' coronary disorder ', ' atherosclerotic heart disease ', ' Coronary Disease ', ' Coronary heart disease ', ' Cognitive Discrimination ', ' Discrimination ', ' Disorder ', ' Disease ', ' Elements ', ' Environment ', ' Foundations ', ' Genetic Counseling ', ' Genotype ', ' Goals ', ' Gold ', ' General Hospitals ', ' Modern Man ', ' Human ', ' Human Genetics ', ' Hypercholesteremia ', ' hypercholesterolemia ', ' familial hyperlipoproteinemia type II ', ' familial hyperlipoproteinemia type 2 ', ' familial hypercholesteremia ', ' familial hyperbetalipoproteinemia ', ' Type II Hyperlipidemia ', ' Type 2 Hyperlipidemia ', ' Hyperlipoproteinemia Type II ', ' Hyperlipoproteinemia Type 2 ', ' Hyperbetalipoproteinemia ', ' Essential Hypercholesterolemia ', ' Familial Hypercholesterolemia ', ' Institutes ', ' Internal Medicine ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Leadership ', ' Lipids ', ' beta-Lipoproteins ', ' LDL Lipoproteins ', ' LDL ', ' Low-Density Lipoproteins ', ' beta-Lipoprotein Cholesterol ', ' Low Density Lipoprotein Cholesterol ', ' LDL Cholesterol ', ' LDL Cholesterol Lipoproteins ', ' Massachusetts ', ' Medicine ', ' Mentorship ', ' Methods ', ' statistical linear models ', ' statistical linear mixed models ', ' Probability Models ', ' Probabilistic Models ', ' Statistical Models ', ' DNA Molecular Biology ', ' Molecular Biology ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' National Institutes of Health ', ' NIH ', ' United States National Institutes of Health ', ' Phenotype ', ' Physicians ', ' Quality Control ', ' Research ', ' Risk ', ' Technology ', ' Testing ', ' Time ', ' United States ', ' Veterans ', ' Work ', ' Generations ', ' symposia ', ' summit ', ' convention ', ' conference ', ' symposium ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Solid ', ' Clinical ', ' premature ', ' prematurity ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Biochemical ', ' Medical ', ' Link ', ' Evaluation ', ' Training ', ' insight ', ' Individual ', ' African ', ' Amish ', ' European ', ' Family history of ', ' Family Medical History Epidemiology ', ' Family Medical History ', ' Funding ', ' Ethnic Origin ', ' Ethnicity ', ' Collaborations ', ' Genetic ', ' Exposure to ', ' Knowledge ', ' Catalogs ', ' programs ', ' Scientist ', ' Investigation ', ' Clinic ', ' Penetrance ', ' experience ', ' Gene Mutation ', ' Gene Alteration ', ' success ', ' cohort ', ' trait ', ' skills ', ' novel ', ' Prevention strategy ', ' Preventive strategy ', ' Preventative strategy ', ' disorder risk ', ' disease risk ', ' Environmental Risk Factor ', ' environmental risk ', ' Environmental Factor ', ' Prevention ', ' Positioning Attribute ', ' Position ', ' genetic analysis ', ' Genetic analyses ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' career development ', ' Genomics ', ' heart disease risk ', ' heart disorder risk ', ' cardiac disorder risk ', ' cardiac disease risk ', ' Pathogenicity ', ' metabonomics ', ' metabolism measurement ', ' metabolomics ', ' genome sequencing ', ' Mediator of activation protein ', ' Mediator of Activation ', ' Mediator ', ' Preventive ', "" Bachelor's Degree "", ' Undergraduate Degree ', ' Baccalaureate Degree ', ' Data ', ' Disease Pathway ', "" Master's Degree "", ' K-Series Research Career Programs ', ' Research Career Program ', ' K-Awards ', ' Career Development Programs K-Series ', ' Career Development Awards and Programs ', ' Career Development Awards ', ' in vivo ', ' lifestyle factors ', ' life-style factor ', ' Principal Investigator ', ' Development ', ' developmental ', ' Electronic Health Record ', ' electronic healthcare record ', ' electronic health care record ', ' Pathway interactions ', ' pathway ', ' National Heart, Lung, and Blood Institute ', ' NHLBI ', ' National Human Genome Research Institute ', ' National Center for Human Genome Research ', ' NHGRI ', ' biomedical informatics ', ' biomed informatics ', ' next generation ', ' novel strategies ', ' novel strategy ', ' novel approaches ', ' new approaches ', ' Population ', ' Prevalence ', ' Network-based ', ' human disease ', ' high risk ', ' public health relevance ', ' non-genetic ', ' nongenetic ', ' biobank ', ' biorepository ', ' Cloud Computing ', ' cloud computer ', ' Cloud Infrastructure ', ' cloud based ', ' precision medicine ', ' precision-based medicine ', ' genomic variation ', ' Mendelian disorder ', ' single-gene disorder ', ' single-gene disease ', ' monogenic disorder ', ' monogenic disease ', ' Mendelian genetic disorder ', ' Mendelian disease ', ' human genomics ', ' whole genome ', ' full genome ', ' entire genome ', ' Preventive therapy ', ' Preventative therapy ', ' Trans-Omics for Precision Medicine ', ' TOPMed ', ' Risk stratification ', ' DNA sequencing ', ' DNAseq ', ' DNA seq ', ' Genetic Diseases ', ' genetic disorder ', ' genetic condition ', ' machine learning algorithm ', ' risk prediction model ', ' ']",NHLBI,MASSACHUSETTS GENERAL HOSPITAL,K08,2019,170003,0.12289098788923597
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9749889,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' apraxia ', ' Dyspraxia ', ' Breathing ', ' inspiration ', ' Respiratory Inspiration ', ' Respiratory Aspiration ', ' Ataxia ', ' Dyssynergia ', ' Coordination Impairment ', ' Ataxy ', ' cell culture ', ' Cell Culture Techniques ', ' Cell Body ', ' Cells ', ' Cultured Cells ', ' Cilia ', ' granule ', ' Cytoplasmic Granules ', ' Disorder ', ' Disease ', ' Negatrons ', ' Negative Beta Particle ', ' Electrons ', ' Embryonic ', ' Embryo ', ' facial ', ' faces ', ' Face ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Modern Man ', ' Human ', ' renal ', ' Kidney Urinary System ', ' Kidney ', ' heavy metal lead ', ' heavy metal Pb ', ' Pb element ', ' Lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' Murine ', ' Mice Mammals ', ' Mice ', ' Mus ', ' Muscular Hypotonia ', ' Muscle Tone Poor ', ' Muscle Hypotony ', ' Hypotonia ', ' Hypomyotonia ', ' Decreased Muscle Tone ', ' Muscle hypotonia ', ' genome mutation ', ' Genetic defect ', ' Genetic Change ', ' Genetic Alteration ', ' Mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Research Resources ', ' Resources ', ' Risk ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Sonication ', ' Mass Spectrum Analyses ', ' Mass Spectrum ', ' Mass Spectroscopy ', ' Mass Spectrometry ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrum Analysis ', ' Syndrome ', ' Testing ', ' Work ', ' Zebra Fish ', ' Zebra Danio ', ' Danio rerio ', ' Brachydanio rerio ', ' Zebrafish ', ' base ', ' Brain imaging ', ' brain visualization ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variant ', ' Variation ', ' Series ', ' Training ', ' Cerebellar vermis structure ', ' vermis ', ' insight ', ' Individual ', ' Cerebrum ', ' cerebral ', ' Databases ', ' data base ', ' Data Bases ', ' Congenital cerebellar hypoplasia ', ' Cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Joubert syndrome ', ' cerebelloparenchymal disorder IV ', ' cerebellar vermis agenesis ', ' Joubert-Boltshauser syndrome ', ' Inherited ', ' Hereditary ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit structure ', ' Digit ', ' Gene Mutation ', ' Gene Alteration ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' Genetic screening method ', ' genetic testing ', ' gene-based testing ', ' gene testing ', ' novel ', ' Modeling ', ' affection ', ' oculomotor ', ' ocularmotor ', ' ocular motor ', ' disorder subtype ', ' disease subtype ', ' disease subgroups ', ' Small Interfering RNA ', ' siRNA ', ' Short interfering RNA ', ' Pathogenicity ', ' Bioinformatics ', ' Bio-Informatics ', ' cilium biogenesis ', ' ciliogenesis ', ' genome sequencing ', ' Candidate Disease Gene ', ' Candidate Gene ', ' Length ', ' Defect ', ' DNA Sequence Alteration ', ' genomic alteration ', ' Sequence Alteration ', ' Genetic mutation ', ' DNA mutation ', ' DNA Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' Enrollment ', ' enroll ', ' Validation ', ' WNT Signaling Pathway ', ' WNT signaling ', ' Molecular ', ' Knock-out ', ' Knockout ', ' Development ', ' developmental ', ' Neurodevelopmental Disorder ', ' Neurological Development Disorder ', ' Cerebellar malformation ', ' Cerebellum malformation ', ' reconstruction ', ' knock-down ', ' knockdown ', ' Three-dimensional analysis ', ' 3D analysis ', ' 3-dimensional analysis ', ' 3-D analysis ', ' Retinal ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' gene discovery ', ' discover genes ', ' population based ', ' stem cell biology ', ' genome-wide ', ' genomewide ', ' genome scale ', ' exome ', ' exomes ', ' transcriptome sequencing ', ' RNAseq ', ' RNA sequencing ', ' RNA Seq ', ' exome sequencing ', ' exome-seq ', ' screening ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' CRISPR/Cas system ', ' CRISPR ', ' accurate diagnosis ', ' consanguineous family ', ' consanguineous\xa0kindreds ', ' consanguineous pedigree ', ' whole genome ', ' full genome ', ' entire genome ', ' recruit ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2019,510012,0.16355562859239955
"Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis ABSTRACT This project outlines technical medical image processing and machine learning developments to study the pathogenesis and natural history of osteoarthritis (OA). In the past few years, the availability of public datasets that collect data such as plain radiographs, MRI genomics and patients reported outcomes has allowed the study of disease etiology, potential treatment pathways and predictors of long-range outcomes, showing an increasingly important role of the MRI. Moreover, recent advances in quantitative MRI and medical image processing allow for the extraction of extraordinarily rich arrays of heterogeneous information on the musculoskeletal system, including cartilage and bone morphology, bone shape features, biomechanics, and cartilage biochemical composition.  Osteoarthritis, being a polygenic and multifactorial disease characterized by several phenotypes, seems the perfect candidate for multidimensional analysis and precision medicine. However, accomplish this ambitious task, will require complex analytics and multifactorial data-integration from diverse assessments spanning morphological, biochemical, and biomechanical features. In this project, we propose to fill this gap developing automatic post-processing algorithms to examine cartilage biochemical compositional and morphological features and to apply new multidimensional machine learning to study OA  This Pathway to Independence award application includes a mentored career development plan to transition the candidate, Dr. Valentina Pedoia, into an independent investigator position, as well as an accompanying research plan describing the proposed technical developments for the application of big data analytics to the study of OA. The primary mentor, Dr. Sharmila Majumdar, is a leading expert in the field of quantitative MRI for the study of OA, and the co-mentors, Dr. Adam Ferguson and Dr. Ramakrishna Akella, have extensive experience in the application of machine learning and topological data analysis to big data. The diversified plan of training and the complementary background of these mentors will allow the candidate to develop a unique interdisciplinary profile in the field of musculoskeletal imaging.  The candidate, Dr. Valentina Pedoia, is currently in a post-doctoral level position (Associated Specialist) at the University of California at San Francisco (UCSF), developing MR image post-processing algorithms. The mentoring and career development plan will supplement her image processing background with valuable exposure to machine learning, big data analysis, epidemiological study design, and interdisciplinary collaboration to facilitate her transition to a medical imaging and data scientist independent investigator position. Ultimately, she aims to become a faculty member in a radiology or bioengineering institute, where she can further research technical biomedical imaging and machine learning developments applied to the musculoskeletal system. PROJECT NARRATIVE Morphological and compositional MRI quantifications are widely used tools to detect early cartilage degeneration and to study disease progression of osteoarthritis, a complex and multifactorial disorder. In this project, we propose to develop a fully automatic image post-processing pipeline and multidimensional big data analyses based on machine learning techniques, with the aim to uncover latent information from complex dataset and with the ultimate goal of setting up a platform for OA precision medicine",Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis,9742424,R00AR070902,"['Algorithms ', ' Atlases ', ' Award ', ' Biochemistry ', ' Biological Chemistry ', ' Biomechanics ', ' biomechanical ', ' Biomedical Engineering ', ' bioengineering ', ' bio-engineers ', ' bio-engineered ', ' bone ', ' California ', ' Cartilaginous Tissue ', ' Cartilage ', ' Chronology ', ' computer vision ', ' Computer Vision Systems ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' statistical analysis ', ' Statistical Data Analysis ', ' Statistical Data Analyses ', ' Statistical Data Interpretation ', ' Disorder ', ' Disease ', ' Elements ', ' Faculty ', ' Gait ', ' Goals ', ' Health ', ' Modern Man ', ' Human ', ' Hybrids ', ' Institutes ', ' joint disorder ', ' arthropathy ', ' arthropathic ', ' Joint Diseases ', ' arthropathies ', ' Knee ', ' Knee joint ', ' longterm study ', ' long-term study ', ' Longitudinal Studies ', ' Zeugmatography ', ' Nuclear Magnetic Resonance Imaging ', ' NMR Tomography ', ' NMR Imaging ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' MRI ', ' MR Tomography ', ' MR Imaging ', ' Magnetic Resonance Imaging ', ' Medical Imaging ', ' Mentors ', ' locomotor system ', ' Musculoskeletal System ', ' osteoarthritic ', ' hypertrophic arthritis ', ' degenerative joint disease ', ' Osteoarthrosis ', ' Osteoarthritis ', ' Degenerative Arthritis ', ' Degenerative polyarthritis ', ' Patient Reported Outcomes ', ' Patient Outcomes Assessments ', ' Phenotype ', ' Radiology ', ' General Radiology ', ' Radiology Specialty ', ' Relaxation ', ' Research ', ' study design ', ' Study Type ', ' Research Design ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Risk Factors ', ' social role ', ' Role ', ' San Francisco ', ' Syndrome ', ' Time ', ' Body Tissues ', ' Tissues ', ' Universities ', ' X-Ray Medical Imaging ', ' X-Ray Imaging ', ' Roentgenography ', ' Radiography ', ' Diagnostic X-Ray Radiology ', ' Diagnostic X-Ray ', ' Diagnostic Radiology ', ' Conventional X-Ray ', ' Diagnostic radiologic examination ', ' Specialist ', ' Dataset ', ' Data Set ', ' Imagery ', ' Visualization ', ' Natural History ', ' base ', ' image processing ', ' morphometry ', ' Image Analysis ', ' image evaluation ', ' Image Analyses ', ' Clinical ', ' Phase ', ' Variant ', ' Variation ', ' Biochemical ', ' Medical ', ' Training ', ' Lesion ', ' soft tissue ', ' Discipline ', ' Measurement ', ' Development Plans ', ' Disease Progression ', ' Genetic ', ' Exposure to ', ' Morphology ', ' Shapes ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' Knowledge ', ' Knee Osteoarthritis ', ' knee joint osteoarthritis ', ' knee joint OA ', ' knee OA ', ' Dimensions ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' 3-Dimensional ', ' 3D ', ' 3-D ', ' Postdoctoral Fellow ', ' post-doctoral ', ' post-doc ', ' Research Associate ', ' Postdoc ', ' Early Diagnosis ', ' early detection ', ' experience ', ' parallel processing ', ' interdisciplinary collaboration ', ' transdisciplinary collaboration ', ' kinematics ', ' kinematic model ', ' member ', ' racial difference ', ' race differences ', ' Pathogenesis ', ' epidemiology study ', ' epidemiologic investigation ', ' Epidemiology Research ', ' Epidemiological Studies ', ' Epidemiologic Studies ', ' Epidemiologic Research ', ' Positioning Attribute ', ' Position ', ' Modeling ', ' career development ', ' bioimaging ', ' biomedical imaging ', ' bio-imaging ', ' repository ', ' Genomics ', ' Thickness ', ' Thick ', ' disease causation ', ' causation ', ' Causality ', ' Etiology ', ' Symptoms ', ' Data ', ' Validation ', ' Development ', ' developmental ', ' musculoskeletal imaging ', ' musculoskeletal visualization ', ' musculoskeletal scanning ', ' Image ', ' imaging ', ' Pathway interactions ', ' pathway ', ' three-dimensional modeling ', ' 3D modeling ', ' 3-D modeling ', ' image registration ', ' shape analysis ', ' shape description ', ' data integration ', ' design ', ' designing ', ' Outcome ', ' imaging Segmentation ', ' modifiable risk ', ' Big Data ', ' BigData ', ' precision medicine ', ' precision-based medicine ', ' cartilage degradation ', ' cartilage degeneration ', ' quantitative imaging ', ' imaging biomarker ', ' imaging-based marker ', ' imaging-based biomarker ', ' imaging-based biological marker ', ' imaging marker ', ' connectome ', ' imaging scientist ', ' deep learning ', ' Data Scientist ', ' Big Data Methods ', ' Big Data Tools ', ' Big Data Analytics ', ' multidimensional data ', ' high dimensional data ', ' Sex Differences ', ' sex-specific differences ', ' sex-related differences ', ' sex-dependent differences ', ' ']",NIAMS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R00,2019,249000,0.04296640889953015
"Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy     DESCRIPTION (provided by applicant)     A new electrical biomarker has been identified in high resolution, intracranial electroencephalogram (iEEG) recordings, called a high frequency oscillation (HFO). Studies have suggested this biomarker has great promise to identify seizure networks and improve surgical outcomes for patients with refractory epilepsy. However, translation of HFOs to clinical practice is hampered by many factors such as spatial, temporal and inter-patient variation in HFO detection rates, false positive and false negative detections, and significant background noise. Big data approaches using large numbers of HFOs acquired from many patients are needed to quantify these effects and allow clinical usage of HFOs. This project details a plan in which the candidate's experience quantifying measurement and detection bias in massive high energy nuclear physics datasets will be combined with a multidisciplinary mentor team to address this problem. The combination of training in computational neuroscience, big data network analysis, and translational neural engineering research will be critical to approach this problem and provide a career trajectory for the candidate. The specific aims of this proposal address three specific confounding factors: 1) the false negative HFO detection rate, 2) variations in HFO features not due to epilepsy, and 3) effects of the state of vigilance on HFOs. Each of these aims involve novel big data methods and/or applications generalizable to other situations: 1) estimating false positive detection rates using a combined experimental/simulated data approach, 2) clustering and classification of distributions of data points, rather than of the data points directly, and 3) a general disambiguation statistic to assess meaningful (rather than statistical) difference between distributions.  The applicant's career goal is to become an academic researcher in the analysis and modeling of intracranial EEG data with a focus on translational epilepsy and sleep physiology research. With the rapid advancement in the resolution of clinical EEG, there is already a strong need for this type of research expertise. Thi grant will provide didactic coursework, formal research and methods training, and career guidance from an expert mentor team. The three mentors have appointments spanning Neurology, Anesthesiology, Mathematics, Statistics, Biomedical Engineering, and Electrical Engineering and Computer Science. The candidate will also build and mentor a research team and establish external collaborations.  The University of Michigan is a premier research university with strong programs and training opportunities in biomedical and physical sciences, engineering, translational and academic research, and advanced research computing. This proposal makes extensive use of the University's large computer cluster. The mentor team and an external collaborator will provide candidate access to prerecorded, deidentified data from over 150 patients, estimated to have over 40 million HFOs. The environment and mentor team will provide the training, facilities, and data for the candidate to successfully complete the proposed goals. PUBLIC HEALTH RELEVANCE    Recent advances in epilepsy research are generating very large datasets in the search for better ways to identify the region of brain responsible for generating seizures. A particular signa known as High Frequency Oscillations found in high resolution intracranial EEG shows great promise for identifying these regions, but clinicians are unable to use the signal due to confounding biases. This project combines big data processing expertise from particle physics, computer science and machine learning to address these confounds, providing a more accurate process to enable clinical translation of this new biomarker and potentially improve clinical outcomes.",Epileptic biomarkers and big data: identifying brain regions to resect in patients with refractory epilepsy,9752624,K01ES026839,"['Algorithms ', ' Anesthesiology ', ' Appointment ', ' Biomedical Engineering ', ' bioengineering ', ' bio-engineers ', ' bio-engineered ', ' Biophysics ', ' biophysical sciences ', ' biophysical principles ', ' biophysical foundation ', ' Brain ', ' Encephalon ', ' Brain Nervous System ', ' Systematics ', ' Classification ', ' data interpretation ', ' Data Analysis ', ' Data Analyses ', ' drug/agent ', ' Pharmaceutic Preparations ', ' Medication ', ' Drugs ', ' Pharmaceutical Preparations ', ' Engineering ', ' Environment ', ' epileptogenic ', ' epileptiform ', ' epilepsia ', ' Seizure Disorder ', ' Epileptics ', ' Epileptic Seizures ', ' Epilepsy ', ' Future ', ' Patient Care Delivery ', ' Patient Care ', ' Goals ', ' Grant ', ' High Frequency Oscillation ', ' Hybrids ', ' Literature ', ' Math ', ' Mathematics ', ' Mentors ', ' Mentorship ', ' Methods ', ' Michigan ', ' Motivation ', ' neurological disease ', ' Neurological Disorders ', ' Neurologic Disorders ', ' Nervous System Diseases ', ' nervous system disorder ', ' Neurology ', ' Neurosciences ', ' Noise ', ' Atomic Energy ', ' Nuclear Energy ', ' Nuclear Physics ', ' Patients ', ' physical science ', ' Physics ', ' Research ', ' Researchers ', ' Investigators ', ' Research Personnel ', ' Seizures ', ' biological signal transduction ', ' Signaling ', ' Signal Transduction Systems ', ' Intracellular Communication and Signaling ', ' Cell Signaling ', ' Cell Communication and Signaling ', ' Signal Transduction ', ' Sleep ', ' statistics ', ' Technology ', ' Translating ', ' Translations ', ' Universities ', ' executive coaching ', ' career counselor ', ' Vocational Counseling ', ' Occupational Guidance ', ' Career Guidance ', ' Career Counseling ', ' Vocational Guidance ', ' Work ', ' Research Methods ', ' Research Methodology ', ' Dataset ', ' Data Set ', ' Custom ', ' base ', ' career ', ' computational neuroscience ', ' detector ', ' improved ', ' Area ', ' Chronic ', ' Clinical ', ' Refractory ', ' Variant ', ' Variation ', ' Physiological ', ' Physiologic ', ' Training ', ' Individual ', ' Measurement ', ' Funding ', ' Collaborations ', ' Electrical Engineering ', ' tool ', ' Machine Learning ', ' support vector machine ', ' statistical learning ', ' kernel methods ', ' programs ', ' Event ', ' Techniques ', ' Operative Surgical Procedures ', ' surgery ', ' Surgical Procedure ', ' Surgical Interventions ', ' Surgical ', ' Operative Procedures ', ' experience ', ' computer science ', ' relating to nervous system ', ' neural ', ' expectation ', ' novel ', ' Graph ', ' vigilance ', ' Excision ', ' resection ', ' Surgical Removal ', ' Removal ', ' Extirpation ', ' Abscission ', ' Statistical Methods ', ' Pathway Analysis ', ' Network Analysis ', ' Modeling ', ' Sampling ', ' career development ', ' data processing ', ' computerized data processing ', ' Brain region ', ' Address ', ' Data ', ' Detection ', ' Manpower and Training ', ' Resolution ', ' Patient-Focused Outcomes ', ' Patient-Centered Outcomes ', ' Patient outcome ', ' Translational Research ', ' translation research ', ' Translational Science ', ' Process ', ' Development ', ' developmental ', ' Electroencephalogram ', ' Outcome ', ' Population ', ' innovation ', ' innovative ', ' innovate ', ' Impairment ', ' clinically relevant ', ' clinical relevance ', ' multidisciplinary ', ' scientific computing ', ' spatial temporal variation ', ' public health relevance ', ' patient population ', ' standard of care ', ' Biological Markers ', ' biomarker ', ' biologic marker ', ' bio-markers ', ' clinical practice ', ' computer cluster ', ' signal processing ', ' Big Data ', ' BigData ', ' particle physics ', ' flavor physics ', ' training opportunity ', ' improved outcome ', ' big biomedical data ', ' large-scale biomedical data ', ' terabyte ', ' clinical translation ', ' surgery outcome ', ' surgical outcome ', ' patient variability ', ' variation between patients ', ' variability between patients ', ' patient variation ', ' Big Data Methods ', ' Big Data Tools ', ' Big Data Analytics ', ' sleep physiology ', ' ']",NIEHS,UNIVERSITY OF MICHIGAN AT ANN ARBOR,K01,2019,148964,0.06360992187175588
"Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data Limitless replicative potential is a key hallmark of cancer and critically depends on telomere maintenance. Many cancers thus aberrantly reactivate the telomerase reverse transcriptase (TERT), a catalytic subunit of the telomerase complex that elongates telomere. It has been recently discovered that this common path to immortality in multiple cancers is through two activating point mutations in the TERT promoter (TERTp), found in more than 50 different cancer types, often at strikingly high frequencies, e.g. roughly 83% in glioblastomas (GBM) and 71% in melanomas. In the previous funding period, the PI has identified the molecular function of these highly recurrent mutations, demonstrating that the transcription factor (TF) GABP binds the mutant TERTp with exquisite specificity, but not the wild-type TERTp. The high prevalence of TERTp mutations across multiple cancer types and the selectivity of GABP recruitment to mutant TERTp thus provide an unprecedented opportunity for treating a large number of cancer patients with minimal toxicity to healthy cells. Despite the clear significance of this opportunity, however, several important questions surrounding the molecular functions and modulators of TERTp mutations remain poorly understood, hindering the development of effective and safe therapeutic strategies.  Our long-term goal is to establish a rigorous computational framework for understanding the aberrant transcriptional and epigenetic networks in cancers and to apply the resulting knowledge to devise novel therapeutic strategies that account for the genetic background of individual patients and that can a priori predict and avoid potential resistance mechanisms. The objective of our current renewal proposal is to develop powerful computational methods for transforming our knowledge about the non-coding TERTp mutations into an effective and safe molecular target. At the same time, the resulting methods will help resolve several outstanding challenges in the field of transcriptional gene regulation and have broad applications in cancer genomics. We will accomplish our objective my pursuing the following Aims: (1) Develop and test a computational framework for inferring sequence features that determine the distinct and shared binding patterns of paralogous TFs; (2) Develop and validate integrative tools for discovering the molecular basis of genetic interactions between germline variations and oncogenic mutations; (3) Develop and apply computational methods for studying the role of DNA helical phase between adjacent binding motifs in recruiting ETS factors to chromatin; (4) Perform a systematic genomic characterization of the effects of knocking out GABPB1L in TERTp-mutant cancer cells and healthy cells. The results of this proposal will have a broad impact on cancer research by providing powerful tools for studying paralogous oncogenic TFs and revealing novel insights into a highly promising therapeutic strategy. The proposed research will provide computational and bioinformatic resources for studying the binding pattern of paralogous oncogenic transcription factors. It will provide a computational framework for inferring the function of non-coding regulatory mutations and studying their interaction with common genetic variants. As an important application, we will systematically analyze a novel therapeutic strategy that has the potential to treat effectively a large number of patients across multiple cancer types harboring the recently discovered TERT promoter mutations.",Predicting Transcriptional and Epigenetic Networks in Cancer from Sequencing Data,9831048,R01CA163336,"['cancer research ', ' anticancer research ', ' computational framework ', ' computer framework ', ' cancer type ', ' Oncogenic ', ' computational resources ', ' computing resources ', ' new drug treatments ', ' new drugs ', ' new therapeutics ', ' new therapy ', ' next generation therapeutics ', ' novel drug treatments ', ' novel drugs ', ' novel therapy ', ' novel therapeutics ', ' therapeutic target ', ' response to treatment ', ' therapeutic response ', ' treatment response ', ' genome scale ', ' genomewide ', ' genome-wide ', ' individual patient ', ' recruit ', ' bio-informatics resource ', ' bioinformatics resource ', ' deep learning ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cells ', ' Cell Body ', ' Chromatin ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' DNA ', ' Deoxyribonucleic Acid ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Family ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genome ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Goals ', ' knowledge of results ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Recurrence ', ' Recurrent ', ' Research ', ' RNA-Directed DNA Polymerase ', ' EC 2.7.7.49 ', ' RNA Transcriptase ', ' RNA-Dependent DNA Polymerase ', ' Reverse Transcriptase ', ' Revertase ', ' Role ', ' social role ', ' Specificity ', ' Testing ', ' Time ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Work ', ' c-myc Genes ', ' c myc ', ' cmyc ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' telomere ', ' Family member ', ' Mediating ', ' promotor ', ' promoter ', ' Telomerase ', ' Point Mutation ', ' base ', ' Phase ', ' Variation ', ' Variant ', ' Link ', ' insight ', ' Individual ', ' Funding ', ' Therapeutic ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Frequencies ', ' Complex ', ' Pattern ', ' Techniques ', ' Somatic Mutation ', ' dimer ', ' mutant ', ' Isoforms ', ' Protein Isoforms ', ' Toxicities ', ' Toxic effect ', ' novel ', ' member ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' Telomere Maintenance ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' Molecular Interaction ', ' Binding ', ' EST2 ', ' TCS1 ', ' Telomere Reverse Transcriptase ', ' telomerase catalytic subunit ', ' TERT gene ', ' Address ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' High Prevalence ', ' Molecular Target ', ' Cancer Patient ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' Validation ', ' Molecular ', ' Knockout ', ' Knock-out ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' oncogenomics ', ' cancer genomics ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' anti-cancer research ', ' ']",NCI,UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN,R01,2020,326848,0.14678739468726082
"Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers PROJECT SUMMARY As a computational biologist, my long-term goal is to develop methods and tools to discover new or better therapeutics for cancers. In the past few years, I have identified drug-repositioning candidates for a number of primary cancers using Big Data approaches. These candidates have been validated successfully in preclinical mouse models. To maximize the utility of Big Data, I plan to translate the findings into therapeutics; therefore, I propose to develop methods to utilize transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers. Current preclinical and clinical approaches including the NCI MATCH trial select therapies primarily based on actionable mutations, yet patients may have no actionable mutations or multiple actionable mutations that are hard to prioritize, suggesting the need for other different types of molecular biomarkers. The recent efforts have enabled the large-scale identification of various types of molecular biomarkers through correlating drug sensitivity with molecular profiles of pre-treatment cancer cell lines. Computational methods to match these biomarkers to individual patients to inform therapy in the clinic are thus in high demand. The objective of this award is therefore to develop computational approaches to identify therapeutics for individual patients by leveraging large-scale biomarkers identified from cancer cell lines. Through conducing this research, I expect to expand my knowledge in cancer clinical trials, cancer genomics, cancer biology, and statistics. To achieve the goal, I have gathered seven renowned experts from different fields related to Big Data Science as mentors/advisors/collaborators: Primary Mentor Dr. Atul Butte in translational bioinformatics from UCSF, Co-mentor Dr. Samuel So in cancer biology from Stanford University, Co-mentor Dr. Mark Segal in statistics from UCSF, Advisor Dr. Andrei Goga in cancer biology from UCSF, Advisor Dr. Laura Esserman in breast cancer trials from UCSF, Collaborator Dr. John Gordan in liver cancer trials from UCSF and Collaborator Dr. Xin Chen in cancer biology from UCSF. With the support from my world- class mentors, advisors and collaborators, this award will prepare me to be a leader in developing big data methods that are broadly impactful. PROJECT NARRATIVE One goal of the precision medicine initiative is to select optimal therapies for individual cancer patients based on their molecular and clinical profiles. Current preclinical and clinical approaches select therapies primarily based on actionable mutations. This work is expected to employ the protein/gene expression based biomarkers computed from public databases to inform individualized cancer therapy.","Integrating transcriptomic, proteomic and pharmacogenomic data to inform individualized therapy in cancers",9925076,K01ES028047,"['Antineoplastic Agents ', ' Anti-Cancer Agents ', ' Antineoplastic Drugs ', ' Antineoplastics ', ' Cancer Drug ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Tumor-Specific Treatment Agents ', ' anti-cancer drug ', ' anticancer agent ', ' anticancer drug ', ' Award ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Basal cell carcinoma ', ' Basal Cell Epithelioma ', ' Basiloma ', ' Rodent Ulcer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Clinical Trials ', ' Communities ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Gene Expression ', ' Goals ', ' Primary carcinoma of the liver cells ', ' Hepatocarcinoma ', ' Hepatocellular Carcinoma ', ' Hepatocellular cancer ', ' Hepatoma ', ' Liver Cells Carcinoma ', ' liver carcinoma ', ' Mentors ', ' Methods ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Probability ', ' Research ', ' Resources ', ' Research Resources ', ' statistics ', ' Time ', ' Translating ', ' Universities ', ' Work ', ' c-myc Genes ', ' c myc ', ' cmyc ', ' v-myc Avian Myelocytomatosis Viral Oncogene Cellular Homolog ', ' Treatment outcome ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Individual ', ' drug sensitivity ', ' Data Bases ', ' data base ', ' Databases ', ' Therapeutic ', ' Normal Tissue ', ' Normal tissue morphology ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' Hepatic Cancer ', ' liver cancer ', ' malignant liver tumor ', ' Malignant neoplasm of liver ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Scientist ', ' Adopted ', ' Clinic ', ' Source ', ' Pattern ', ' System ', ' Tumor Tissue ', ' Heterograft ', ' Heterologous Transplantation ', ' Xenograft ', ' Xenotransplantation ', ' xeno-transplant ', ' xeno-transplantation ', ' Xenograft procedure ', "" Ewing's Family of Tumours "", "" Ewing's Sarcoma/Peripheral Primitive Neuroectodermal Tumor "", "" Ewing's Tumor "", ' Ewings sarcoma ', ' drug efficacy ', ' novel ', ' Protein Gene Products ', ' Gene Proteins ', ' Coding System ', ' Code ', ' Sampling ', ' response ', ' Proteomics ', ' Meta-Analysis ', ' Cancer Treatment ', ' Malignant Neoplasm Therapy ', ' Malignant Neoplasm Treatment ', ' anti-cancer therapy ', ' anticancer therapy ', ' cancer therapy ', ' Pharmacogenomics ', ' Bio-Informatics ', ' Bioinformatics ', ' protein expression ', ' Tissue Sample ', ' Address ', ' Data ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Cancer Biology ', ' Cancer Patient ', ' nonmalignant ', ' Non-Malignant ', ' Validation ', ' Molecular ', ' preclinical ', ' pre-clinical ', ' TNBC ', ' triple-negative breast cancer ', ' triple-negative invasive breast carcinoma ', ' oncogenomics ', ' cancer genomics ', ' Cancer cell line ', ' Consumption ', ' transcriptomics ', ' murine model ', ' mouse model ', ' tumor ', ' molecular biomarker ', ' molecular marker ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' efficacy testing ', ' drug candidate ', ' data sharing ', ' BigData ', ' Big Data ', ' Precision Medicine Initiative ', ' customized therapy ', ' customized treatment ', ' individualized patient treatment ', ' individualized therapy ', ' individualized treatment ', ' patient specific therapies ', ' patient specific treatment ', ' tailored medical treatment ', ' tailored therapy ', ' tailored treatment ', ' unique treatment ', ' individualized medicine ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' predictive biomarkers ', ' predictive molecular biomarker ', ' predictive marker ', ' individualized cancer therapy ', ' personalized cancer treatment ', ' personalized cancer therapy ', ' gene signatures ', ' genetic signature ', ' individual patient ', ' oncology clinical trial ', ' cancer clinical trial ', ' actionable variants ', ' actionable mutation ', ' Genomic Data Commons ', ' Expression Profiling ', ' optimal therapies ', ' optimal treatments ', ' Big Data Analytics ', ' Big Data Tools ', ' Big Data Methods ', ' learning classifier ', ' big-data science ', ' oncotype ', ' ']",NIEHS,MICHIGAN STATE UNIVERSITY,K01,2020,169087,0.13861486539432163
"Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management PROJECT SUMMARY/ABSTRACT Lung cancer is the second-most common type of cancer and the leading cause of cancer death in men and women. Among the different types of lung cancer, non-small cell lung cancer (NSCLC) is the most common type and it constitutes 85% to 90% of all lung cancer cases. Current cancer research has shown that multiple somatic mutations affect the sensitivity of patients to various drugs used for NSCLC treatment. These mutations are essential factors for determining the most effective, personalized treatment for each NSCLC patient; however, most NSCLC patients develop resistance to these targeted therapies in their first year of treatment. Many mechanisms of this resistance are still unknown. Designing and prescribing better targeted therapies for NSCLC patients requires further understanding, particularly with respect to the relationship between NSCLC tumors pathological and clinical findings, genetic profiles, and targeted therapy responses/resistance. Currently, there is no computational method to connect observations and findings from pathology reports, medical records, somatic mutations, and the targeted therapy resistance. This project provides a plan to build a novel computational method to identify statistically significant associations between the pathological findings of NSCLC tumors and the presence of clinically-actionable somatic mutations. Furthermore, these associations, in combination with an innovative set of feature analysis from pathology reports and electronic medical records, will be leveraged to build and validate a machine-learning model to identify NSCLC patients with clinically-actionable somatic mutations. Finally, the associated clinical, pathological, and genetic findings for NSCLC patients will be used in a new machine-learning framework to predict patients time-to-resistance to targeted therapies. The required data to build and validate the proposed models in this project will be obtained through a collaboration with the Department of Pathologys Laboratory for Clinical Genomics and Advanced Technologies at Dartmouth-Hitchcock Medical Center. In addition to internal validation, the investigators in this proposal established a collaboration with the Department of Pathology at the University of Vermont Medical Center to apply and validate the developed models on an external data source. Upon successful implementation of this bioinformatics approach, the developed models will be able to reveal statistically significant links between clinical and pathological findings, clinically-actionable somatic mutations, and targeted-therapy responses for a better understanding of NSCLC tumor development and treatment. The proposed approach will provide an accurate, fast, and inexpensive pre- selection method for screening NSCLC patients with clinically-actionable mutations for translational research and precision medicine. Furthermore, the proposed machine-learning method to identify NSCLC patients resistance to targeted therapies will help healthcare providers to select the best treatment strategies for these patients, improve their health outcomes, and establish this precision medicine paradigm for other types of cancer. PROJECT NARRATIVE Resistance to targeted therapies severely limits the ability to treat non-small cell lung cancer (NSCLC) patients. This project proposes a novel computational approach to find statistically-significant links between pathological and clinical findings, clinically-actionable mutations, and targeted-therapy responses for NSCLC patients. The outcomes of this proposal can assist healthcare providers to identify the most effective strategy for NSCLC treatment, improve public health, and promote precision medicine.",Clinicopathologic and Genetic Profiling through Machine Learning and Natural Language Processing for Precision Lung Cancer Management,10023259,R01CA249758,"['Affect ', ' Architecture ', ' Engineering / Architecture ', ' Attention ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Non-Small-Cell Lung Carcinoma ', ' NSCLC ', ' NSCLC - Non-Small Cell Lung Cancer ', ' Non-Small Cell Lung Cancer ', ' Nonsmall Cell Lung Carcinoma ', ' nonsmall cell lung cancer ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Data Sources ', ' Cessation of life ', ' Death ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Family ', ' Foundations ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Health ', ' Health Personnel ', ' Health Care Providers ', ' Healthcare Providers ', ' Healthcare worker ', ' health care personnel ', ' health care worker ', ' health provider ', ' health workforce ', ' healthcare personnel ', ' medical personnel ', ' treatment provider ', ' Recording of previous events ', ' History ', ' Laboratories ', ' Medical Records ', ' melanoma ', ' Malignant Melanoma ', ' men ', "" men's "", ' Methods ', ' Methodology ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Natural Language Processing ', ' natural language understanding ', ' Pathology ', ' Patients ', ' Public Health ', ' Recurrence ', ' Recurrent ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Semantics ', ' Technology ', ' Testing ', ' Time ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Vermont ', ' Woman ', ' Work ', ' Computerized Medical Record ', ' Electronic Medical Record ', ' Information Retrieval ', ' Information extraction ', ' Measures ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Clinical ', ' Medical ', ' Link ', ' Malignant Tumor of the Lung ', ' Pulmonary Cancer ', ' Pulmonary malignant Neoplasm ', ' lung cancer ', ' Malignant neoplasm of lung ', ' drug use ', ' Drug usage ', ' Collaborations ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Pattern ', ' Clinical Decision Support Systems ', ' Somatic Mutation ', ' Medical center ', ' Performance ', ' novel ', ' Second Cancer ', ' Secondary Malignancy ', ' Secondary Malignant Neoplasm ', ' secondary cancer ', ' Second Primary Cancers ', ' Pathology Report ', ' Statistical Methods ', ' Modeling ', ' response ', ' Genomics ', ' Cancer Treatment ', ' Malignant Neoplasm Therapy ', ' Malignant Neoplasm Treatment ', ' anti-cancer therapy ', ' anticancer therapy ', ' cancer therapy ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Cancer Cause ', ' Cancer Etiology ', ' Cancer Patient ', ' Clinical Data ', ' Ontology ', ' Smoking Status ', ' Translational Science ', ' translation research ', ' Translational Research ', ' Tumor Pathology ', ' Validation ', ' Pathologic ', ' Characteristics ', ' resistant mechanism ', ' resistance mechanism ', ' developmental ', ' Development ', ' Colo-rectal Cancer ', ' Colorectal Cancer ', ' electronic data ', ' pathway ', ' Pathway interactions ', ' genetic profiling ', ' anti-cancer research ', ' cancer research ', ' anticancer research ', ' designing ', ' design ', ' Outcome ', ' Resistant development ', ' developing resistance ', ' Resistance development ', ' cancer type ', ' innovate ', ' innovative ', ' innovation ', ' resistant ', ' Resistance ', ' demographics ', ' tumor ', ' response to treatment ', ' therapeutic response ', ' treatment response ', ' treatment strategy ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' screening ', ' precision-based medicine ', ' precision medicine ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' targeted cancer therapy ', ' clinically actionable ', ' power analysis ', ' actionable variants ', ' actionable mutation ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' machine learning method ', ' ']",NCI,DARTMOUTH COLLEGE,R01,2020,375150,0.041361326121242985
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,10260680,R21CA242861,"['cancer cell genome ', ' tumor genome ', ' cancer genome ', ' immunogenicity ', ' designing ', ' design ', ' Outcome ', ' clinical effect ', ' clinical applicability ', ' clinical application ', ' open source ', ' tumor ', ' genome scale ', ' genomewide ', ' genome-wide ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome-seq ', ' exome sequencing ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' reference assembly ', ' reference genome ', ' entire genome ', ' full genome ', ' whole genome ', ' check point immunotherapy ', ' check point inhibitor therapy ', ' check point inhibitory therapy ', ' check point therapy ', ' checkpoint immunotherapy ', ' checkpoint inhibitor therapy ', ' checkpoint inhibitory therapy ', ' immune check point therapy ', ' immune checkpoint therapy ', ' checkpoint therapy ', ' check point blockade ', ' checkpoint blockade ', ' immune check point blockade ', ' immune checkpoint blockade ', ' neo-antigen ', ' neo-epitopes ', ' neoepitopes ', ' neoantigens ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' large data sets ', ' large datasets ', ' driver mutation ', ' Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Attention ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biology ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Monte Carlo Method ', ' Monte Carlo algorithm ', ' Monte Carlo calculation ', ' Monte Carlo procedure ', ' Monte Carlo simulation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Role ', ' social role ', ' Testing ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Function ', ' Biological Process ', ' anti-cancer immunotherapy ', ' anticancer immunotherapy ', ' immune-based cancer therapies ', ' immunotherapy for cancer ', ' immunotherapy of cancer ', ' cancer immunotherapy ', ' machine learned ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' Tumor Cell ', ' neoplastic cell ', ' cohort ', ' novel ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' genomic region ', ' Genomic Segment ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' epigenomics ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2020,177000,0.21826324425005916
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary Fundamental challenges that hinder the current understanding of biomolecular systems are their tremendous complexity, high dimensionality and excessively large data sets associated with their geometric modeling and simulations. These challenges call for innovative strategies for handling massive biomolecular datasets. Topology, in contrast to geometry, provides a unique tool for dimensionality reduction and data simplification. However, traditional topology typically incurs with excessive reduction in geometric information. Persistent homology is a new branch of topology that is able to bridge traditional topology and geometry, but suffers from neglecting biological information. Built upon PIs recent work in the topological data analysis of biomolecules, this project will explore how to integrate topological data analysis and machine learning to significantly improve the current state-of-the-art predictions of protein-ligand binding and mutation impact established in the PIs preliminary studies. These improvements will be achieved through developing physics-embedded topological methodologies and advanced deep learning architectures for tackling heterogeneous biomolecular data sets arising from a variety of physical and biological considerations. Finally, the PI will establish robust databases and online servers for the proposed predictions. Project Narrative The project concerns the integration of topological data analysis and machine learning architectures for the predictions of protein-ligand binding affinities and mutation induced protein stability changes from massive data sets. This new data approach has considerable impact for future generation methods in computational biophysics and drug design.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,9989158,R01GM126189,"['Architecture ', ' Engineering / Architecture ', ' Biological Sciences ', ' Biologic Sciences ', ' Bioscience ', ' Life Sciences ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Classification ', ' Systematics ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Diagnosis ', ' Drug Design ', ' Elements ', ' Freedom ', ' Liberty ', ' Handwriting ', ' Ions ', ' Learning ', ' Ligands ', ' Lipids ', ' Membrane Proteins ', ' Membrane Protein Gene ', ' Membrane-Associated Proteins ', ' Surface Proteins ', ' Metals ', ' Methods ', ' Methodology ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Physics ', ' Proteins ', ' Computer software ', ' Software ', ' Speech ', ' Thermodynamics ', ' Thermodynamic ', ' Psychological Transfer ', ' learning transfer ', ' training transfer ', ' Work ', ' Dataset ', ' Data Set ', ' DNA Sequence ', ' base ', ' cofactor ', ' improved ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Site ', ' Biological ', ' Medical ', ' Chemicals ', ' Ligand Binding Protein ', ' Ligand Binding Protein Gene ', ' Protein Binding ', ' bound protein ', ' Binding Proteins ', ' Data Bases ', ' data base ', ' Databases ', ' root ', ' Plant Roots ', ' tool ', ' machine learned ', ' Machine Learning ', ' Electrostatics ', ' Dimensions ', ' Complex ', ' Techniques ', ' System ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' membrane structure ', ' Membrane ', ' mutant ', ' Free Energy ', ' model-based simulation ', ' models and simulation ', ' Future Generations ', ' Bio-Informatics ', ' Bioinformatics ', ' Molecular Interaction ', ' Binding ', ' Address ', ' Affinity ', ' Data ', ' Induced DNA Alteration ', ' Induced Sequence Alteration ', ' Induced Mutation ', ' Ligand Binding ', ' trend ', ' Characteristics ', ' developmental ', ' Development ', ' neglect ', ' next generation ', ' direct application ', ' innovate ', ' innovative ', ' innovation ', ' user-friendly ', ' multi-task ', ' multitask ', ' language processing ', ' Geometry ', ' BigData ', ' Big Data ', ' algebraic topology ', ' metallicity ', ' learning activity ', ' learning method ', ' learning strategy ', ' Data Science ', ' search engine ', ' high dimensionality ', ' Data Banks ', ' Databanks ', ' data depository ', ' data repository ', ' data warehouse ', ' deep learning ', ' machine learned algorithm ', ' machine learning algorithm ', ' multitask learning ', ' multi-task learning ', ' deep learning algorithm ', ' learning algorithm ', ' large data sets ', ' large datasets ', ' data diversity ', ' diverse data ', ' ']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2020,318777,0.05719381668893901
"Genetic determinants of 4D genome folding in human cardiac development PROJECT SUMMARY A major unanswered question is how chromatin topology coordinates human development and cellular differentiation, and how genome folding is differentially regulated in human disease. It is thought that three- dimensional (3D) chromatin organization is driven by transcriptional regulators, but fundamental mechanisms of this regulation as it relates to disease-relevant human cells have not been well explored. We propose to elucidate the temporally dynamic 3D nucleome (4DN) that underlies human cardiac differentiation, its molecular underpinnings, and the impact of mutations that underly defective 4DN organization in human congenital heart disease (CHD). CHDs are the most common birth defect and arise from abnormal heart development. The genetic basis of CHD is largely mutations in genes encoding chromatin modifiers (e.g. WDR5, KMT2D) and transcription factors (TFs, e.g. TBX5, GATA4), many of which also cause adult-onset arrhythmias. The impact of CHD mutations on the 4DN has not been explored. We hypothesize that 3D genome folding is highly regulated during cardiac differentiation and is impacted by disease-causing mutations in transcriptional regulators and non-coding elements. We will use iPS cell models and machine learning to elucidate dynamic 3D chromatin organization in human cardiomyocytes and endothelial cells during normal and diseased cardiac differentiation. We propose 3 specific aims: Aim 1: Establish a kilobase-scale 4D map of genome folding in human cardiomyocytes (CM) and endothelial cell (EC) differentiation. We will use directed differentiation of human iPS cells towards the two major cell types of the developing heart: CMs and ECs, and using microC across a fine time course of differentiation we will define at kilobase scale the 3D organization of the genome, capturing the states of developmental intermediates and the final differentiated cells. This aim will generate an essential integrated 4DN template for discovery in cardiac differentiation. In Aim 2: we will Determine the regulatory and disease-related basis for cardiac 3D chromatin organization. We will perform microC in iPS cell lines with CHD-associated mutations in transcriptional regulators, differentiated into CMs and ECs. These findings will establish the degree to which CHD is caused by abnormal genome folding and chromatin states, with important relevance to other human cardiovascular diseases. Finally, Aim 3 will address High-throughput screening of millions of CHD and synthetic non- coding mutations with a deep-learning model of dynamic genome folding. We will build a deep-learning model predicting 3D chromatin contact frequencies across cardiac differentiation at kilobase-resolution. By introducing thousands of CHD patient deletions and other non-coding mutations in silico, we will prioritize variants likely to interact with transcriptional regulators to cause disease through disrupted genome folding. Several candidates will be validated in engineered iPS cells differentiated into CMs and ECs. These results will provide a novel platform for computational discovery of disease variant impact across diverse human diseases PROJECT NARRATIVE Congenital heart defects are present in 1-2 out of 100 births, and are caused by mutations in genes that may control the 3-dimensional organization of chromosomes. We will use human cellular models and Artificial Intelligence to understand how chromosome organization is controlled during heart development and altered by disease processes. This will reveal fundamental concepts of gene regulation and may lead to a better understanding congenital heart defects towards improving diagnosis and treatment.",Genetic determinants of 4D genome folding in human cardiac development,10118056,U01HL157989,"['human pluripotent stem cell ', ' model of human ', ' human model ', ' deep learning ', ' computing platform ', ' computational platform ', ' in silico ', ' machine learning method ', ' stem cell model ', ' Congenital Abnormality ', ' Birth Defects ', ' Congenital Anatomic Abnormality ', ' Congenital Anatomical Abnormality ', ' Congenital Defects ', ' Congenital Deformity ', ' Congenital Malformation ', ' Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Architecture ', ' Engineering / Architecture ', ' Arrhythmia ', ' Cardiac Arrhythmia ', ' Heart Arrhythmias ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Birth ', ' Parturition ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Cell Differentiation process ', ' Cell Differentiation ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Cells ', ' Cell Body ', ' Child ', ' 0-11 years old ', ' Child Youth ', ' Children (0-21) ', ' children ', "" childrens' "", ' youngster ', ' Chromatin ', ' Complement ', ' Complement Proteins ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Elements ', ' Engineering ', ' Family ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Heart ', ' Congenital Heart Defects ', ' Congenital Cardiac Defects ', ' congenital cardiac anomalies ', ' Heart Diseases ', ' Cardiac Diseases ', ' Cardiac Disorders ', ' heart disorder ', ' Histones ', ' Human ', ' Modern Man ', ' Human Development ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Maps ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Phenotype ', ' Proteins ', ' Time ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Work ', ' Measures ', ' Enhancers ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' congenital cardiac abnormality ', ' congenital cardiac disease ', ' congenital cardiac disorder ', ' congenital cardiac malformation ', ' congenital heart abnormality ', ' congenital heart anomaly ', ' congenital heart disease ', ' congenital heart malformation ', ' congenital heart disorder ', ' improved ', ' Variation ', ' Variant ', ' Endothelial Cells ', ' Cardiac Muscle Cells ', ' Cardiocyte ', ' Heart Muscle Cells ', ' Heart myocyte ', ' cardiomyocyte ', ' Cardiac Myocytes ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Complex ', ' cell type ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' CTCF protein ', ' DNA-binding protein CTCF ', ' CCCTC-binding factor ', ' Structure ', ' Human Biology ', ' novel ', ' Chromosomal Organization ', ' Chromosomal Structure ', ' Chromosome Organization ', ' Chromosome Structures ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' High Throughput Assay ', ' high throughput screening ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' cohesin ', ' genetic determinant ', ' Genetic Determinism ', ' histone modification ', ' heart development ', ' heart formation ', ' cardiogenesis ', ' Chromatin Remodeling Complex ', ' chromatin modifier ', ' Chromatin Remodeling Factor ', ' SMARCA2 ', ' SMARCA2 gene ', ' Address ', ' Data ', ' Mutate ', ' Regulatory Element ', ' Resolution ', ' Molecular ', ' Process ', ' Cardiac ', ' developmental ', ' Development ', ' stem cell differentiation ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' Cellular model ', ' Cell model ', ' human disease ', ' disease-causing mutation ', ' ChIP Sequencing ', ' chromatin immunoprecipitation-sequencing ', ' ChIP-seq ', ' Cardiac development ', ' ATACseq ', ' ATAC-seq ', ' GATA binding protein 4 ', ' GATA4 ', ' GATA4 transcription factor ', ' GATA4 gene ', ' Cardiac Abnormalities ', ' Cardiac Malformation ', ' Cardiac defect ', ' Heart Malformation ', ' heart defect ', ' Heart Abnormalities ', ' ']",NHLBI,J. DAVID GLADSTONE INSTITUTES,U01,2020,742240,0.07873368074761647
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,9882227,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B blood cells ', ' B cell ', ' B cells ', ' B-Cells ', ' B-cell ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Chromatin ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Complimentarity Determining Region ', ' Hypervariable Loop ', ' Hypervariable Regions ', ' Immunoglobulin Hypervariable Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' Grippe ', ' flu infection ', ' influenza infection ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Transgenic Mice ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' G(s), alpha Subunit ', ' G(s),  Subunit ', ' G(s)alpha ', ' G(s) ', ' GTP-Binding Protein  Subunits, Gs ', ' Gs alpha Family G-Protein ', ' Gs ', ' Gs ', ' Regulatory Ns Protein ', ' Stimulatory Gs G-Protein ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' alpha-Gs ', ' -Gs ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' infectious organism ', ' Infectious Agent ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair endonuclease ', ' repair enzyme ', ' Human Cell Line ', ' response ', ' Ig Somatic Hypermutation ', ' somatic hypermutation ', ' Immunoglobulin Somatic Hypermutation ', ' AICDA ', ' AICDA protein ', ' AID gene ', ' AID protein ', ' CDA2 protein ', ' activation-induced deaminase ', ' activation-induced cytidine deaminase ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' Influenza HA ', ' flu HA ', ' flu hemagglutinin ', ' influenza virus HA ', ' influenza virus hemagglutinin ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experiment ', ' experimental research ', ' experimental study ', ' recruit ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,591815,0.15225722621024226
"Predicting and analyzing variation in cellular interactomes Project Summary Over the last two decades, significant experimental efforts have determined large sets of reference interactions for humans and other model organisms, along with substantial knowledge about the binding specificities of proteins, including for a large fraction of human transcription factors (TFs). The resulting data have proven to be an incredibly useful resource for understanding how cells function; nevertheless, they do not capture how molecular interactions and networks are different from the reference across individuals. Indeed, while human genomes in both healthy and disease populations are rapidly being sequenced, the corresponding individual-specific interaction networks remain largely unexamined; this represents a major gap in our knowledge, as mutations that alter molecular interactions underlie a wide range of human diseases. Further, the substantial amount of genetic variation across populations makes it infeasible in the near term to experimentally determine per-individual interaction networks. Thus our long-term goal is to develop computational methods to uncover whether and how mutations within coding and non-coding portions of the genome perturb cellular interactions and networks. Our specific aims are: (1) We will develop computational structure-based approaches to identify and catalog, at proteome-scale, variations within proteins that are likely to impact their ability to bind with DNA, RNA, small molecules, peptides or ions, thereby providing a comprehensive resource for analyzing protein interaction variation. (2) We will develop novel structure-based and probabilistic methods to predict how DNA-binding specificities are altered when a TF is mutated; since mutated TFs have been linked to numerous diseases, this will be a great aid in understanding disease networks and pathology. (3) We will develop new methods to uncover non-coding somatic mutations that alter human regulatory networks in cancer; this is a critical step towards ultimately uncovering patient-specific cancer networks. Overall by pursuing these aimswhich integrate mutational information with existing knowledge about reference interactions, interfaces and specificitieswe will develop novel computational methods that will significantly advance our understanding of molecular interactions perturbed in disease and healthy contexts. Narrative The proposed research will yield new software tools that predict whether specific genetic mutations alter molecular interactions and networks. Since many human diseases are caused by mutations that affect molecular interactions, this research will expand our understanding of the underlying basis of disease and will provide new avenues for diagnosis and treatment.",Predicting and analyzing variation in cellular interactomes,9896829,R01GM076275,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Diagnosis ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Gene Expression ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Human ', ' Modern Man ', ' Ions ', ' Methods ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Organism ', ' living system ', ' Pathology ', ' Patients ', ' Peptides ', ' Play ', ' Proteins ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Research ', ' Resources ', ' Research Resources ', ' RNA ', ' Non-Polyadenylated RNA ', ' RNA Gene Products ', ' Ribonucleic Acid ', ' Software Tools ', ' Computer Software Tools ', ' Specificity ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Mutagenesis ', ' Genetics-Mutagenesis ', ' Mutagenesis Molecular Biology ', ' Zinc Fingers ', ' Zinc Finger Domain ', ' Zinc Finger Motifs ', ' Mediating ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Link ', ' Individual ', ' Ligand Binding Protein ', ' Ligand Binding Protein Gene ', ' Protein Binding ', ' bound protein ', ' Binding Proteins ', ' Biological Function ', ' Biological Process ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Knowledge ', ' Catalogs ', ' Complex ', ' Pattern ', ' interest ', ' Somatic Mutation ', ' preference ', ' Animal Models and Related Studies ', ' model of animal ', ' model organism ', ' Animal Model ', ' knowledgebase ', ' knowledge base ', ' Structure ', ' novel ', ' Proteome ', ' Coding System ', ' Code ', ' Sampling ', ' Property ', ' develop software ', ' developing computer software ', ' software development ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Bio-Informatics ', ' Bioinformatics ', ' DNA Binding Interaction ', ' DNA bound ', ' DNA Binding ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' DNA-Protein Interaction ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Mutate ', ' Protein Analysis ', ' Ligand Binding ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' virtual ', ' Population ', ' human disease ', ' tumor ', ' disease-causing mutation ', ' predictive tools ', ' experiment ', ' experimental research ', ' experimental study ', ' Infrastructure ', ' machine learning method ', ' ']",NIGMS,PRINCETON UNIVERSITY,R01,2020,312660,0.09056100085204799
"Big Data Predictive Phylogenetics with Bayesian Learning Big Data Predictive Phylogenetics with Bayesian Learning Abstract Andrew Holbrook, Ph.D., is a Bayesian statistician with a broad background in applied, theoretical and compu- tational data science. His proposed research Big Data Predictive Phylogenetics with Bayesian Learning tackles viral outbreak forecasting by combining Bayesian phylogenetic modeling with exible, `self-exciting' stochastic process models. The development and publication of open-source, high-performance computing software for his models will facilitate fast epidemiological eld response in a big data setting. Dr. Holbrook will apply his method- ology to the reconstruction of the 2015-2016 Zika virus epidemic in the Americas, focusing on identifying key geographical routes of transmission and phylogenetic clades with enhanced infectiousness.  Candidate: Dr. Holbrook is Postdoctoral Scholar at the UCLA Department of Human Genetics. He earned his Ph.D. in Statistics from the Department of Statistics at UC Irvine, during which time he completed his dissertation Geometric Bayes, an investigation into Bayesian modeling and computing on abstract mathematical spaces, and simultaneously participated in scientic collaborations at the UC Irvine Alzheimer's Disease Research Center. The proposed career development plan will establish Dr. Holbrook as an independent leader in data intensive viral epidemiology by 1) facilitating coursework to build biological domain knowledge, 2) affording Dr. Holbrook the opportunity to lead his own project while remaining under the expert oversight of UCLA Prof. Marc Suchard, M.D., Ph.D., and 3) allowing Dr. Holbrook to continue his focus on quantitative viral epidemiology once he has moved to a faculty commitment.  Mentors: During the rst three years of the award period, Dr. Holbrook will work closely with Prof. Suchard, continuing their current schedule of weekly meetings. Prof. Suchard is a leading expert in both Bayesian phylo- genetics and high-performance statistical computing; and with his medical background, Prof. Suchard will advise Dr. Holbrook in his expansion of domain knowledge in viral epidemiology. As secondary mentor, Prof. Kristian Andersen, Ph.D., of the Scripps Institute will advise Dr. Holbrook in the impactful application of his statistical and computational methodologies to the 2015-2016 Zika virus epidemic. Dr. Holbrook and Profs. Suchard and Andersen will maintain their collaborations after the postdoctoral period.  Research: Bayesian phylogenetics successfully reconstructs evolutionary histories but fails to predict viral spread. Self-exciting point processes are devoid of biological insight and fail to account for geographic networks of diffusion. Aim 1 addresses deciencies in these two complementary viral epidemiological modeling techniques by innovating a combined model where the phylogenetic and self-excitatory components support each other. Aim 2 makes widespread adoption a reality by publishing open-source, massively parallel computing software suitable for big data analysis. Aim 3 reconstructs the 2015-2016 Zika epidemic, learns key geographical routes of transmission and identies phylogenetic clades with enhanced infectiousness. Project Narrative Tracking and predicting viral outbreaks remains an open epidemiological problem with deadly consequences. Dr. Holbrook will attack the problem with his Bayesian phylogenetic Hawkes processes, a class of models tailored to simultaneously reconstruct evolutionary histories and predict viral diffusion dynamics. With the mentorship of Profs. Marc Suchard (primary) and Kristian Andersen (secondary), Dr. Holbrook will develop open-source, high-performance computing software and apply his statistical computing methodology to the analysis of the 2015-2016 Zika virus epidemic of the Americas, learning key routes of transmission and identifying phylogenetic clades with enhanced infectiousness.",Big Data Predictive Phylogenetics with Bayesian Learning,10039150,K25AI153816,"['Accounting ', ' Adoption ', ' Air ', "" Alzheimer's Disease "", ' AD dementia ', ' Alzheimer ', ' Alzheimer Type Dementia ', ' Alzheimer disease ', ' Alzheimer sclerosis ', ' Alzheimer syndrome ', "" Alzheimer's "", "" Alzheimer's disease dementia "", ' Alzheimers Dementia ', ' Alzheimers disease ', ' Primary Senile Degenerative Dementia ', ' dementia of the Alzheimer type ', ' primary degenerative dementia ', ' senile dementia of the Alzheimer type ', ' Americas ', ' Award ', ' Behavior ', ' Biology ', ' Computing Methodologies ', ' computational methodology ', ' computational methods ', ' computer based method ', ' computer methods ', ' computing method ', ' Dangerousness ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Diffusion ', ' Disease Outbreaks ', ' Outbreaks ', ' Earthquakes ', ' Epidemic ', ' Epidemiology ', ' epidemiologic ', ' epidemiological ', ' Evolution ', ' Faculty ', ' Geography ', ' Goals ', ' Health ', ' Recording of previous events ', ' History ', ' Human Genetics ', ' Influenza ', ' Grippe ', ' flu infection ', ' influenza infection ', ' Institutes ', ' Joints ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Learning ', ' Mathematics ', ' Math ', ' Mentors ', ' Mentorship ', ' Methodology ', ' Phylogeny ', ' Publications ', ' Scientific Publication ', ' Publishing ', ' Research ', ' Ships ', ' Computer software ', ' Software ', ' Statistical Computing ', ' statistical process ', ' statistical reasoning ', ' statistics ', ' Stochastic Processes ', ' stochastic method ', ' Testing ', ' Time ', ' Travel ', ' Work ', ' Generations ', ' Schedule ', ' Biological ', ' Medical ', ' Evaluation ', ' Failure ', ' insight ', ' Individual ', ' Development Plans ', ' Viral Activity ', ' Viral Function ', ' Viral Physiology ', ' Collaborations ', ' Knowledge ', ' Scientist ', ' Investigation ', ' Complex ', ' Event ', ' Route ', ' Pattern ', ' Techniques ', ' Viral ', ' meetings ', ' Performance ', ' high-end computing ', ' High Performance Computing ', ' Speed ', ' Structure ', ' novel ', ' Modeling ', ' career development ', ' Free Will ', ' response ', ' Herd Immunity ', ' Address ', ' Data ', ' M.D. ', ' Doctor of Medicine ', ' Ph.D. ', ' PhD ', ' Doctor of Philosophy ', ' Epidemiologist ', ' Phylogenetics ', ' Phylogenetic Analysis ', ' Viral Epidemiology ', ' Transmission ', ' transmission process ', ' Process ', ' developmental ', ' Development ', ' reconstruction ', ' epidemiological model ', ' blind ', ' pathogen ', ' innovate ', ' innovative ', ' innovation ', ' open source ', ' parallel computation ', ' parallel computing ', ' parallel computer ', ' flexible ', ' flexibility ', ' Bayesian adaptive designs ', ' Bayesian adaptive models ', ' Bayesian belief network ', ' Bayesian belief updating model ', ' Bayesian framework ', ' Bayesian hierarchical model ', ' Bayesian network model ', ' Bayesian nonparametric models ', ' Bayesian spatial data model ', ' Bayesian spatial image models ', ' Bayesian spatial models ', ' Bayesian statistical models ', ' Bayesian tracking algorithms ', ' Bayesian Modeling ', ' BigData ', ' Big Data ', ' Data Science ', ' ZIKV ', ' zikav ', ' Zika Virus ', ' Bayesian machine learning ', ' Bayesian learning ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ZIKA ', ' ']",NIAID,UNIVERSITY OF CALIFORNIA LOS ANGELES,K25,2020,106467,0.07583982170152709
"Id3 and VSMC in Murine and Human Atherosclerosis Despite major advances in prevention and treatment of atherosclerotic cardiovascular disease (ASCVD), it remains a major cause of deaths worldwide. As ASCVD is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and impact on this unmet residual risk. One such human polymorphism in the ID3 gene (rs11574) was associated with ASCVD in 3 distinct human cohorts. Notably, this SNP significantly attenuates ID3 function and studies in pre-clinical models confirm a critical role for ID3 in atheroprotection. We have previously shown that loss of ID3 inhibits vascular smooth muscle cell (VSMC) proliferation and promotes VSMC expression of inflammatory factors, processes linked to increase atherosclerosis. In collaboration with Dr. Gary Owens, we have generated a mouse model with VSMC lineage tracing and VSMC-specific deletion of ID3 to study ID3-dependent VSMC specific changes during the course of lesion development in the context of the whole animal. We have developed a comprehensive CyTOF panel to identify and quantitate key cellular and intracellular changes in VSMC and other lesional cells in the aorta during the course of atherosclerosis development in these mice. To translate murine findings to humans, we have utilized CRISPR/Cas9 genetic engineering to knock out ID3 and produce the full allelic series of rs11574 in human cells and validated a reproducible system for differentiation of human inducible pluripotent stem cells (iPSCs) to VSMC. We will quantify the changes in VSMC phenotype in iPSC-derived VSMC with the full allelic series of rs11574. To further translate murine findings to humans, intravascular ultrasound virtual histology (IVUS-VH) will be measured in human coronary arteries and analyzed with cutting edge image analysis techniques in collaboration with Dr. Milan Sonka at the University of Iowa. As such, our group is uniquely poised to dissect the role of this ASCVD-associated SNP and translate findings to humans. We hypothesize: that loss of ID3 in VSMCs will inhibit VSMC growth and promote a phenotype that exacerbates vessel wall inflammation and atherosclerosis lesion development; that human ID3 encoded by the risk allele aggravates these atherogenic VSMC functions; and that human subjects with the risk allele have larger coronary plaques with increased fatty deposits, necrotic cores and calcification compared to subjects homozygous for the common allele. As atherosclerotic cardiovascular disease (ASCVD) is a heritable and polygenic disorder, identification of ASCVD-associated single nucleotide polymorphisms (SNP) in humans and elucidation of their effect on ASCVD biology is needed to fully understand and further impact on ASCVD morbidity and mortality. Human ID3 gene polymorphism at rs11574 is associated with ASCVD in three unique human cohorts. Preliminary data supports a key role for ID3 in vascular smooth muscle cell biology linked to ASCVD. In the current proposal, we will utilize a novel mouse model with VSMC lineage tracing and specific deletion of ID3 to elucidate the role of ID3 in promoting atherogenic VSMCs. We will then utilize CRISPR/Cas9 gene editing in human inducible pluripotent stem cell-derived VSMCs to identify the VSMC processes altered by the ID3 gene mutation linked to CVD. Lastly, we will determine if this ID3 gene mutation, alone or in combination with other gene mutations are associated with the amount and type of atherosclerotic plaque in human coronary arteries as measured by intravascular ultrasound virtual histology. Results have the potential to lead to novel targeted therapy for atherosclerosis.",Id3 and VSMC in Murine and Human Atherosclerosis,10004164,R01HL148109,"['Alanine ', ' Alleles ', ' Allelomorphs ', ' Amino Acids ', ' aminoacid ', ' Animals ', ' Aorta ', ' Apolipoprotein E ', ' Apo-E ', ' ApoE ', ' Arteries ', ' Atherosclerosis ', ' Atheroscleroses ', ' Atherosclerotic Cardiovascular Disease ', ' atheromatosis ', ' atherosclerotic disease ', ' atherosclerotic vascular disease ', ' Automobile Driving ', ' driving ', ' Biology ', ' Blood Vessels ', ' vascular ', ' Cause of Death ', ' Cell Adhesion Molecules ', ' Adhesion Molecule ', ' Cell Adhesion Molecule Gene ', ' cell adhesion protein ', ' Cell Count ', ' Cell Number ', ' cell growth ', ' Cellular Expansion ', ' Cellular Growth ', ' Cell physiology ', ' Cell Function ', ' Cell Process ', ' Cellular Function ', ' Cellular Physiology ', ' Cellular Process ', ' Subcellular Process ', ' Cells ', ' Cell Body ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Arterial Fatty Streak ', ' Arterial Fatty Streaks ', ' Atheroma ', ' Atheromatous ', ' Atheromatous degeneration ', ' Atheromatous plaque ', ' atherosclerosis plaque ', ' atherosclerotic lesions ', ' atherosclerotic plaque ', ' vulnerable plaque ', ' Gene Expression ', ' Genes ', ' Genetic Engineering ', ' Genetic Engineering Biotechnology ', ' Genetic Engineering Molecular Biology ', ' Recombinant DNA Technology ', ' genetically engineered ', ' Growth ', ' Generalized Growth ', ' Tissue Growth ', ' ontogeny ', ' Heart ', ' Histology ', ' Human ', ' Modern Man ', ' indexing ', ' Inflammation ', ' Iowa ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Null Lymphocytes ', ' Null Cells ', ' macrophage ', ' Minor ', ' Morbidity - disease rate ', ' Morbidity ', ' mortality ', ' Multivariate Analysis ', ' Multivariate Analyses ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Vascular Smooth Muscle ', ' Necrosis ', ' Necrotic ', ' Phenotype ', ' Genetic Polymorphism ', ' polymorphism ', ' Research Design ', ' Study Type ', ' study design ', ' Risk ', ' Role ', ' social role ', ' Testing ', ' Threonine ', ' L-Threonine ', ' Translating ', ' Ultrasonography ', ' Echography ', ' Echotomography ', ' Medical Ultrasound ', ' Ultrasonic Imaging ', ' Ultrasonogram ', ' Ultrasound Diagnosis ', ' Ultrasound Medical Imaging ', ' Ultrasound Test ', ' diagnostic ultrasound ', ' sonogram ', ' sonography ', ' sound measurement ', ' ultrasound ', ' ultrasound imaging ', ' ultrasound scanning ', ' Universities ', ' Vascular Cell Adhesion Molecule-1 ', ' CD106 ', ' CD106 Antigens ', ' INCAM-110 ', ' Inducible Cell Adhesion Molecule 110 ', ' VCAM ', ' VCAM-1 ', ' Vascular Cell Adhesion Molecule ', ' Measures ', ' Mediating ', ' promotor ', ' promoter ', ' Calcified ', ' calcification ', ' human subject ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Cardiac artery ', ' Heart artery ', ' Coronary artery ', ' Medial ', ' Residual ', ' Residual state ', ' Variation ', ' Variant ', ' Series ', ' Link ', ' Lesion ', ' Stimulus ', ' Coronary Artery Stenosis ', ' Coronary Stenosis ', ' inflammatory mediator ', ' Inflammation Mediators ', ' Collaborations ', ' Cell Lineage ', ' Attenuated ', ' Inflammatory ', ' Deposit ', ' Deposition ', ' OxLDL ', ' ox-LDL ', ' oxidized LDL ', ' oxidized low density lipoprotein ', ' cell biology ', ' Cellular biology ', ' Immunes ', ' Immune ', ' Techniques ', ' System ', ' dimer ', ' Gene Alteration ', ' Gene Mutation ', ' RT-PCR ', ' RTPCR ', ' reverse transcriptase PCR ', ' Reverse Transcriptase Polymerase Chain Reaction ', ' cohort ', ' novel ', ' Participant ', ' Prevention ', ' Single Base Polymorphism ', ' single nucleotide variant ', ' Single Nucleotide Polymorphism ', ' Cytometry ', ' Modeling ', ' Pluripotent Stem Cells ', ' Proteomics ', ' Genomics ', ' Leiomyocyte ', ' Smooth Muscle Cells ', ' Smooth Muscle Tissue Cell ', ' Smooth Muscle Myocytes ', ' Molecular Interaction ', ' Binding ', ' Thickness ', ' Thick ', ' Data ', ' Preclinical Models ', ' Pre-Clinical Model ', ' Reproducibility ', ' Genetic Risk ', ' Characteristics ', ' Molecular ', ' Knockout ', ' Knock-out ', ' Process ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' virtual ', ' vascular smooth muscle cell proliferation ', ' Heritability ', ' murine model ', ' mouse model ', ' new drug target ', ' new druggable target ', ' new pharmacotherapy target ', ' new therapy target ', ' novel drug target ', ' novel druggable target ', ' novel pharmacotherapy target ', ' novel therapeutic target ', ' novel therapy target ', ' new therapeutic target ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' Risk-associated variant ', ' risk allele ', ' risk gene ', ' risk genotype ', ' risk loci ', ' risk locus ', ' risk variant ', ' genomic editing ', ' genome editing ', ' CRISPR method ', ' CRISPR methodology ', ' CRISPR technique ', ' CRISPR technology ', ' CRISPR-CAS-9 ', ' CRISPR-based method ', ' CRISPR-based technique ', ' CRISPR-based technology ', ' CRISPR-based tool ', ' CRISPR/Cas method ', ' CRISPR/Cas9 ', ' CRISPR/Cas9 technology ', ' Cas nuclease technology ', ' Clustered Regularly Interspaced Short Palindromic Repeats method ', ' Clustered Regularly Interspaced Short Palindromic Repeats methodology ', ' Clustered Regularly Interspaced Short Palindromic Repeats technique ', ' Clustered Regularly Interspaced Short Palindromic Repeats technology ', ' CRISPR/Cas technology ', ' Multi-Ethnic Study of Atherosclerosis ', ' Immune infiltrates ', ' T cell infiltration ', ' T cell tumor trafficking ', ' immune cell infiltrate ', ' immune infiltration ', ' intratumoral immune cell ', ' tumor immune cell ', ' Tumor-infiltrating immune cells ', ' coronary calcium ', ' coronary artery calcium ', ' coronary plaque ', ' machine learned algorithm ', ' machine learning algorithm ', ' ']",NHLBI,UNIVERSITY OF VIRGINIA,R01,2020,671017,0.045021781326330605
"ADPKD: Disease Spectrum & Genotype-Phenotype Correlations Autosomal dominant polycystic kidney disease (ADPKD) is a common monoallelic disorder associated with progressive cyst development and resulting in end stage renal failure (ESRD) in 50% of patients by 60y. However, there is considerable phenotypic variability, extending from in utero onset to patients with adequate renal function into old age. Autosomal dominant polycystic liver disease (ADPLD), as traditionally defined, results in PLD with minimal renal cysts. Classically there have been considered two ADPKD genes, PKD1 and PKD2, encoding PC1 and PC2, and two ADPLD genes, PRKCSH and SEC63, but in the past few years greater genetic heterogeneity has been described, with nine genes now implicated overall. Recent data also indicates an overlap in etiology and pathogenesis associated with ADPKD and ADPLD, with the efficient biogenesis and localization of the PC-complex central to both disorders. During the last funding period we identified a novel gene, GANAB, which is associated with both disorders, where the encoded protein, GII is involved in the maturation and trafficking of PC1.  In this proposal we will take advantage of advances in next generation sequencing (NGS) methodologies, and large populations of ADPKD and ADPLD patients that have been assembled and screened for the classic genes, to hunt for novel genes for these disorders (Aim 1). The phenotype associated with these genes will be characterized (Aim 3) along with their mechanism of action (Aim 2). NGS methods will be perfected to screen the segmentally duplicated locus, PKD1, and to identify missed mutations at the known loci, including those present in just some cells due to mosaicism (Aim 1). The significance of many PKD1 nontruncating variants has been difficult to evaluate (classed as variants of unknown significance; VUS), but recently evidence that some are incompletely penetrant alleles partially explains phenotypic variability in PKD1 populations. In Aim 2 improved in silico predictions, in combination with machine learning, will improve the understanding of the pathogenicity and penetrance of VUS. A cellular assay of the biogenesis and trafficking of this PC-complex will also be employed to quantify the penetrance of VUS. The mechanism of pathogenesis will be explored in animal models with ultralow penetrant (ULP) Pkd1 or Pkd2 alleles. Employing the large clinically, imaging, and genetically well-defined populations phenotypic groupings of patients will be defined that will then be compared to the genic and PKD1 allelic groups (Aim 3). This iterative process will allow the Variant Score (VS) associated with each PKD1 VUS to be refined. In a separate population the revised VS, alone and in combination with clinical, functional, and imaging data, will be employed to generate a comprehensive, predictive algorithm for ADPKD (Aim 3). Disease modifiers to severe disease, via biallelic ADPKD, and due to alleles at other loci will also be identified and characterized in the cellular assay and in vivo in combination with the Pkd1 hypomorphic, RC model. The final aim will exploit the newly identified information that some PKD1 and PKD2 VUS are rescuable, folding mutations that in a maturation-fostering environment can traffic and function appropriately. A screening scheme based on the level of cell surface PC1 will be improved and new chaperone drugs specific for the PC complex will be sought in collaboration with Sanford Burnham Prebys. A second mutation group that will be explored therapeutically are nonsense mutations. A cellular assay for readthrough efficiency is being developed and will be used for screening. Identified chaperone or readthrough drugs will be tested in available mouse models. Overall this proposal will better explain the etiology and the genetic causes of phenotypic variability in ADPKD/ADPLD, develop better prognostic tools for individual selection of patients for treatment that are now becoming available, and explore allele based treatments for ADPKD. ADPKD and ADPLD are genetic diseases associated with cyst development and loss of function in the kidney and liver cysts, where the disease severity varies greatly between patients. Here we will identify new genes that cause these disorders and evaluate mutations in silico, in a cellular assay, and in whole animals to better predict the disease course in each patient. Treatment options associated with the type of individual patient mutations will also be explored, bringing individualized medicine to these diseases.",ADPKD: Disease Spectrum & Genotype-Phenotype Correlations,10148997,R01DK058816,"['Age ', ' ages ', ' Alleles ', ' Allelomorphs ', ' Animals ', ' Biogenesis ', ' Origin of Life ', ' Budgets ', ' Cells ', ' Cell Body ', ' Cyst ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Environment ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Cystic kidney ', ' Kidney Cyst ', ' Renal Cyst ', ' Methods ', ' Methodology ', ' Mosaicism ', ' mosaic disorders ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Phenotype ', ' Proteins ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Proprotein Convertase 2 ', ' Endopeptidase PC2 ', ' Neuroendocrine Convertase PC2 ', ' PC2 ', ' PC2 Endoprotease ', ' PC2 Prohormone Convertase ', ' PC2 Protein ', ' Prohormone Convertase 2 ', ' Proinsulin Convertase 2 ', ' Autosomal Dominant Polycystic Kidney ', ' ADPKD ', ' Adult Polycystic Kidney Disease ', ' Autosomal Dominant Polycystic Kidney Disease ', ' Dominant Polycystic Kidney Disease ', ' Neuroendocrine Convertase PC1 ', ' PC1 ', ' PC1 Endoprotease ', ' PC1 Prohormone Convertase ', ' PC3 Endoprotease ', ' PC3 Prohormone Convertase ', ' Prohormone Convertase 1 ', ' Prohormone Convertase 3 ', ' Proinsulin Convertase 1 ', ' Proprotein Convertase SPC3 ', ' Proprotein Convertase 1 ', ' Congenital cystic liver disease ', ' Cystic disease of liver ', ' Fibrocystic liver disease ', ' polycystic liver disease ', ' protein folding ', ' base ', ' dosage ', ' improved ', ' Hepatic ', ' Clinical ', ' Variation ', ' Variant ', ' Biological ', ' Biochemical ', ' Germline Mutation ', ' Hereditary Mutation ', ' Germ-Line Mutation ', ' prognostic ', ' kidney function ', ' Renal function ', ' insight ', ' Individual ', ' Fostering ', ' Patient Selection ', ' Genetic Heterogeneity ', ' Chaperone ', ' Molecular Chaperones ', ' Funding ', ' Liver Cyst ', ' Hepatic Cyst ', ' Collaborations ', ' Therapeutic ', ' Genetic ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Severities ', ' Complex ', ' Event ', ' disease severity ', ' Severity of illness ', ' Penetrance ', ' 80K-H protein ', ' FGF-stimulated p90 ', ' G19P1 protein ', ' PRKCSH ', ' protein kinase substrate 80K-H ', ' protein kinase substrate 80KD protein, heavy chain ', ' PRKCSH protein ', ' non-sense mutation ', ' Nonsense Mutation ', ' mutant ', ' Animal Models and Related Studies ', ' model of animal ', ' model organism ', ' Animal Model ', ' trafficking ', ' novel ', ' Cell surface ', ' Pathogenesis ', ' Modeling ', ' Pathogenicity ', ' ESRD ', ' End-Stage Kidney Disease ', ' End-Stage Renal Disease ', ' End stage renal failure ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Defect ', ' Data ', ' in vitro Assay ', ' in vivo ', ' cell assay ', ' Cellular Assay ', ' Physiologic Imaging ', ' physiological imaging ', ' Functional Imaging ', ' Other Genetics ', ' Scheme ', ' Process ', ' groupings ', ' Grouping ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' in utero ', ' early onset ', ' disease phenotype ', ' Population ', ' murine model ', ' mouse model ', ' loss of function ', ' develop therapy ', ' intervention development ', ' treatment development ', ' therapy development ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' customized therapy ', ' customized treatment ', ' individualized patient treatment ', ' individualized therapy ', ' individualized treatment ', ' patient specific therapies ', ' patient specific treatment ', ' tailored medical treatment ', ' tailored therapy ', ' tailored treatment ', ' unique treatment ', ' individualized medicine ', ' unclassified variant ', ' variant of uncertain clinical significance ', ' variant of uncertain significance ', ' variant of undetermined significance ', ' variant of unknown significance ', ' prognostic tool ', ' mutation scanning ', ' mutation screening ', ' individual patient ', ' molecular diagnostics ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' in silico ', ' large data sets ', ' large datasets ', ' ']",NIDDK,MAYO CLINIC ROCHESTER,R01,2020,15035,0.08185635525922613
"Imaging signatures of genetic mutations in glioblastoma using machine learning Glioblastoma (GB) is the most common and aggressive malignant adult brain tumor, with grim prognosis and heterogeneous molecular and imaging profiles. Although the currently applicable treatment options (i.e., surgery, radiotherapy, chemotherapy) have expanded during the last 20 years, there is no substantial improvement in the OS rates. The major obstacle in treating GBM patients is the heterogeneity of their molecular landscape. Determination of molecular targets requires ex vivo postoperative tissue analyses, which are limited in assessing the tumor's spatial heterogeneity (sampling error due to single sample histopathological and molecular analysis) and temporal heterogeneity (not possible to continuously assess the molecular transformation of the tumor during treatment). Herein we propose to develop quantitative imaging phenomic (QIP) markers of a range of mutations of interest in GB. We will build on prior work on EGFR, IDH1 mutations and MGMT methylation QIP signatures, and develop an extensive panel of imaging signatures of 10 gene mutations, as well as MGMT promoter methylation, using machine learning methods applied to relatively routine clinical mpMRI (standard plus diffusion tensor and perfusion protocols). Availability of such biomarkers can contribute to non-invasive i) patient stratification into appropriate treatments, ii) measurement of individual molecular characteristics. In particular, we propose to carry out the following specific aims: Specific Aim 1 (SA1): To develop the enabling methodologies for constructing Quantitative Imaging Phenomic signatures of GB mutations Specific Aim 2 (SA2): Establish QIP signatures of 10 mutations of interest in gliomas, plus MGMT promoter status, using next generation sequencing (NGS). We will use 709 datasets. Specific Aim 3 (SA3): Characterize the molecular heterogeneity of GB using QIP signatures, leveraging the NGS samples of SA1, as well as a new sample that we will genotype, adding to a total of 600 tumor samples obtained from 4 different locations per patient from 150 patients. The first 150 tissue samples are already analyzed as part of ongoing work. Specific Aim 4 (SA4): Integrate our methods into the Cancer Imaging Phenomics Toolkit (CaPTk), in order to allow easy access to them by users This project will investigate the relationship between imaging characteristics of glioblastoma and its underlying genetic mutations/variants. As such, it aims to develop a number of imaging signatures of mutations that are important in GBM, using 1,159 (709 patients plus an additional 450 tissue samples of 150 of these patients obtained from different locations in the tumor) analyzed via next generation sequencing. The primary motivation of this work is to develop the imaging analytics methodologies and associated biomarkers that will allow us to evaluate the spatial, temporal and molecular heterogeneity of glioblastoma, thereby assisting in patient stratification and treatment.",Imaging signatures of genetic mutations in glioblastoma using machine learning,9893291,R01NS042645,"['Adult ', ' 21+ years old ', ' Adult Human ', ' adulthood ', ' Atlases ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Biopsy ', ' Brain Neoplasms ', ' Brain Neoplasia ', ' Brain Tumors ', ' tumors in the brain ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Diagnosis ', ' Diffusion ', ' Genes ', ' Genotype ', ' Glioblastoma ', ' Grade IV Astrocytic Neoplasm ', ' Grade IV Astrocytic Tumor ', ' Grade IV Astrocytoma ', ' glioblastoma multiforme ', ' spongioblastoma multiforme ', ' Glioma ', ' Glial Cell Tumors ', ' Glial Neoplasm ', ' Glial Tumor ', ' Neuroglial Neoplasm ', ' Neuroglial Tumor ', ' glial-derived tumor ', ' neuroglia neoplasm ', ' neuroglia tumor ', ' Growth ', ' Generalized Growth ', ' Tissue Growth ', ' ontogeny ', ' Heterogeneity ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Methods ', ' Methodology ', ' Methylation ', ' Motivation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Perfusion ', ' Phenotype ', ' Postoperative Period ', ' Post-Operative ', ' Postoperative ', ' outcome forecast ', ' Prognosis ', ' Radiation therapy ', ' Radiotherapeutics ', ' Radiotherapy ', ' radiation treatment ', ' radio-therapy ', ' treatment with radiation ', ' Epidermal Growth Factor Receptor ', ' EGF Receptor ', ' EGFR ', ' ERBB Protein ', ' Epidermal Growth Factor Receptor Kinase ', ' Epidermal Growth Factor Receptor Protein-Tyrosine Kinase ', ' Epidermal Growth Factor-Urogastrone Receptors ', ' HER1 ', ' TGF-alpha Receptor ', ' Transforming Growth Factor alpha Receptor ', ' Urogastrone Receptor ', ' c-erbB-1 ', ' c-erbB-1 Protein ', ' erbB-1 ', ' erbB-1 Proto-Oncogene Protein ', ' erbBl ', ' proto-oncogene protein c-erbB-1 ', ' Sampling Errors ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Spatial Distribution ', ' Survival Rate ', ' Testing ', ' Tissues ', ' Body Tissues ', ' Work ', ' Measures ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Image Analyses ', ' image evaluation ', ' image interpretation ', ' Image Analysis ', ' Clinical ', ' Malignant ', ' Malignant - descriptor ', ' Variation ', ' Variant ', ' Evaluation ', ' Individual ', ' Measurement ', ' Descriptor ', ' Morphology ', ' Infiltration ', ' machine learned ', ' Machine Learning ', ' programs ', ' Complex ', ' Protocol ', ' Protocols documentation ', ' Texture ', ' Pattern ', ' Location ', ' Operative Procedures ', ' Surgical ', ' Surgical Interventions ', ' Surgical Procedure ', ' surgery ', ' Operative Surgical Procedures ', ' interest ', ' Gene Alteration ', ' Gene Mutation ', ' Receptor Protein ', ' receptor ', ' tumor growth ', ' Modeling ', ' Sampling ', ' Tissue Sample ', ' DNA-6-O-Methylguanine[protein]-L-Cysteine S-Methyltransferase ', ' EC 2.1.1.63 ', ' Guanine-O(6)-Alkyltransferase ', ' MGMT ', ' Methylated-DNA Protein-Cysteine Methyltransferase ', ' Methylated-DNA-Protein-Cysteine S-Methyltransferase ', ' Methylguanine-DNA Methyltransferase Gene ', ' O(6)-AGT ', ' O(6)-Alkylguanine-DNA Alkyltransferase ', ' O(6)-MeG-DNA Methyltransferase ', ' O(6)-Methylguanine DNA Transmethylase ', ' O(6)-Methylguanine Methyltransferase ', ' O(6)-Methylguanine-DNA Methyltransferase ', ' O6-Alkylguanine DNA Alkyltransferase ', ' alkylguanine DNA alkyltransferase ', ' methylguanine DNA methyltransferase ', ' MGMT gene ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Analysis ', ' Molecular Fingerprinting ', ' molecular profile ', ' molecular signature ', ' Molecular Profiling ', ' Molecular Target ', ' Stratification ', ' Subgroup ', ' Therapeutic Clinical Trial ', ' in vivo ', ' Ligand Binding ', ' Characteristics ', ' Molecular ', ' molecule imaging ', ' molecular imaging ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' clinical phenotype ', ' rapid growth ', ' designing ', ' design ', ' oncologic imaging ', ' oncology imaging ', ' tumor imaging ', ' cancer imaging ', ' clinical relevance ', ' clinically relevant ', ' chemotherapy ', ' tumor ', ' standard of care ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' phenomics ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' Radiogenomics ', ' personalized diagnosis ', ' precise diagnostics ', ' precision diagnostics ', ' personalized diagnostics ', ' quantitative imaging ', ' clinically actionable ', ' gene signatures ', ' genetic signature ', ' individual patient ', ' stratified patient ', ' patient stratification ', ' Intratumoral heterogeneity ', ' heterogeneity in tumors ', ' intra-tumoral heterogeneity ', ' intratumor heterogeneity ', ' tumor heterogeneity ', ' radiomics ', ' predictive signature ', ' clinical imaging ', ' routine imaging ', ' Individualized Predictors ', ' individualized predictions ', ' personalized predictors ', ' personalized predictions ', ' deep learning ', ' machine learning method ', ' ']",NINDS,UNIVERSITY OF PENNSYLVANIA,R01,2020,670422,0.0017617805142430853
"Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations PROJECT SUMMARY/ABSTRACT  Myosins are a diverse and ubiquitous class of molecular motors that are responsible for generating much of the macroscopic force in the human body. The human genome encodes 38 different isoforms of myosin, and members of this group act as force sensors or generators for a diverse set of processes throughout the body. To serve this wide array of functions, each myosin isoform has been biophysically tuned for its physiological role. In fact, the tuning is so precise that missense variants in one myosin isoform, !-cardiac myosin, can cause a congenital cardiomyopathy that is the leading cause of sudden cardiac death in people under 30. And yet, it is unknown how particular variants cause disease, or how to infer the pathogenic potential for novel mutations.  Large differences in functional properties between myosin isoforms are not the result of large differences in coding sequence or overall topology. Neither foreknowledge of phylogeny nor crystal structure is sufcient to predict an isoform's biophysical properties. Furthermore, mutations causing disease frequently occur in regions of the protein far from the site of their deleterious effects. Poor understanding of the biophysical regulation of motor function has hampered the development of pharmaceuticals and the interpretation of human genomic data.  My goal is to establish a mechanistic understanding of myosin motors that is capable of predicting if and how sequence variation changes biophysical properties and can cause cardiac disease. Since myosin kinetics are not apparent from sequence or overall structure, they must be determined by other factors. I hypothesize that kinetic differences result from differences in the allosteric networks in these proteins. Allosteric network in this context refers to the coordinated conformational uctuations that give protein regulation the appearance of action at a distance. To test this hypothesis, we will use our unique combination of enormous computational power for molecular simulation and cutting-edge machine learning tools for analyzing protein allostery.  Aim 1 is to identify the biophysical determinants of myosin isoforms' differing speeds. To test our hypothesis that allosteric networks are responsible for modulating dynamics, I will use molecular simulations of different myosin isoforms and compare their allosteric networks with biochemical data about their properties. Aim 1 directly addresses outstanding questions about normal molecular-biological function of the heart, putting it in line with NHLBI overarching objective #1.  Aim 2 is to determine the difference, at atomic resolution, between healthy and diseased !-cardiac myosin. I hypothesize that the pathogenicity of variants with an unknown molecular etiology is a consequence of allosteric disruption, and will use our computational tools to test this hypothesis by simulating a set of known-pathogenic variants. This aim uses techniques from data science to understand the genetic determinants of health, and will apply equally well to rare alleles in under-represented groups as to majority groups. It is directly addresses NHLBI overarching objectives #3, #4, and #7. PROJECT NARRATIVE  Myosins are a closely-related group of molecules that are responsible for generating much of the force in the human body, including the heartbeat, the movement of limbs, and driving food through the stomach and intestines. Small changes to the myosin genes can have large effects: in healthy people, these give rise to different myosins that perform different functions, and mutations in some myosin genes can give rise to diseases that cause of sudden cardiac death. This proposal aims to learn, at the level of atoms and interatomic bonds, why and how these subtle changes to the myosin gene can create such large effects in the protein's function.",Physics-based precision medicine: computationally phenotyping myosin isoforms and cardiomyopathy mutations,9881184,F30HL146052,"['Actins ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Catalysis ', ' Chemistry ', ' Crystallization ', ' Disease ', ' Disorder ', ' Food ', ' Food or Food Product ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Heart Diseases ', ' Cardiac Diseases ', ' Cardiac Disorders ', ' heart disorder ', ' Human ', ' Modern Man ', ' Intestines ', ' Intestinal ', ' bowel ', ' Kinetics ', ' Learning ', ' Membrane Proteins ', ' Membrane Protein Gene ', ' Membrane-Associated Proteins ', ' Surface Proteins ', ' Methods ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Myosin ATPase ', ' Actin-Activated ATPase ', ' Myosin Adenosine Triphosphatase ', ' Myosin Adenosinetriphosphatase ', ' Myosins ', ' Phenotype ', ' Phylogeny ', ' Physics ', ' Proteins ', ' Relaxation ', ' Role ', ' social role ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Solvents ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' sudden cardiac death ', ' base ', ' improved ', ' Site ', ' Surface ', ' Clinical ', ' Variation ', ' Variant ', ' Physiologic ', ' Physiological ', ' Biochemical ', ' cardiac function ', ' function of the heart ', ' heart function ', ' insight ', ' Human Figure ', ' Human body ', ' Biological Function ', ' Biological Process ', ' tool ', ' machine learned ', ' Machine Learning ', ' Msec ', ' millisecond ', ' Techniques ', ' limb movement ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' Isoforms ', ' Protein Isoforms ', ' Molecular Motors ', ' Ran 2 ', ' rat Ran-2 antigen ', ' rat Ran 2 protein ', ' Speed ', ' Structure ', ' simulation ', ' novel ', ' member ', ' Appearance ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' Property ', ' Myocardial Diseases ', ' Myocardial Disorder ', ' Myocardiopathies ', ' myocardium disease ', ' myocardium disorder ', ' Cardiomyopathies ', ' genetic determinant ', ' Genetic Determinism ', ' Cardiac Muscle Myosins ', ' Cardiac Myosins ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' Pharmaceutical Agent ', ' Pharmaceuticals ', ' Pharmacological Substance ', ' Pharmacologic Substance ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Address ', ' Affinity ', ' Data ', ' Drug Binding Site ', ' Motor ', ' Protein Analysis ', ' Protein Region ', ' Resolution ', ' Molecular ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' computational tools ', ' computerized tools ', ' prototype ', ' disease-causing mutation ', ' rare allele ', ' rare variant ', ' biophysical characteristics ', ' biophysical characterization ', ' biophysical measurement ', ' biophysical parameters ', ' biophysical properties ', ' precision-based medicine ', ' precision medicine ', ' Patient risk ', ' Data Science ', ' Congenital cardiomyopathy ', ' Underrepresented Groups ', ' entire genome ', ' full genome ', ' whole genome ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' Risk stratification ', ' force sensor ', ' ']",NHLBI,WASHINGTON UNIVERSITY,F30,2020,48719,0.008752770381503988
"Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis ABSTRACT This project outlines technical medical image processing and machine learning developments to study the pathogenesis and natural history of osteoarthritis (OA). In the past few years, the availability of public datasets that collect data such as plain radiographs, MRI genomics and patients reported outcomes has allowed the study of disease etiology, potential treatment pathways and predictors of long-range outcomes, showing an increasingly important role of the MRI. Moreover, recent advances in quantitative MRI and medical image processing allow for the extraction of extraordinarily rich arrays of heterogeneous information on the musculoskeletal system, including cartilage and bone morphology, bone shape features, biomechanics, and cartilage biochemical composition.  Osteoarthritis, being a polygenic and multifactorial disease characterized by several phenotypes, seems the perfect candidate for multidimensional analysis and precision medicine. However, accomplish this ambitious task, will require complex analytics and multifactorial data-integration from diverse assessments spanning morphological, biochemical, and biomechanical features. In this project, we propose to fill this gap developing automatic post-processing algorithms to examine cartilage biochemical compositional and morphological features and to apply new multidimensional machine learning to study OA  This Pathway to Independence award application includes a mentored career development plan to transition the candidate, Dr. Valentina Pedoia, into an independent investigator position, as well as an accompanying research plan describing the proposed technical developments for the application of big data analytics to the study of OA. The primary mentor, Dr. Sharmila Majumdar, is a leading expert in the field of quantitative MRI for the study of OA, and the co-mentors, Dr. Adam Ferguson and Dr. Ramakrishna Akella, have extensive experience in the application of machine learning and topological data analysis to big data. The diversified plan of training and the complementary background of these mentors will allow the candidate to develop a unique interdisciplinary profile in the field of musculoskeletal imaging.  The candidate, Dr. Valentina Pedoia, is currently in a post-doctoral level position (Associated Specialist) at the University of California at San Francisco (UCSF), developing MR image post-processing algorithms. The mentoring and career development plan will supplement her image processing background with valuable exposure to machine learning, big data analysis, epidemiological study design, and interdisciplinary collaboration to facilitate her transition to a medical imaging and data scientist independent investigator position. Ultimately, she aims to become a faculty member in a radiology or bioengineering institute, where she can further research technical biomedical imaging and machine learning developments applied to the musculoskeletal system. PROJECT NARRATIVE Morphological and compositional MRI quantifications are widely used tools to detect early cartilage degeneration and to study disease progression of osteoarthritis, a complex and multifactorial disorder. In this project, we propose to develop a fully automatic image post-processing pipeline and multidimensional big data analyses based on machine learning techniques, with the aim to uncover latent information from complex dataset and with the ultimate goal of setting up a platform for OA precision medicine",Multidimensional MRI-based Non-Euclidean Deep Learning to Study Osteoarthritis,9934128,R00AR070902,"['Algorithms ', ' Atlases ', ' Award ', ' Biochemistry ', ' Biological Chemistry ', ' Biomechanics ', ' biomechanical ', ' Biomedical Engineering ', ' bio-engineered ', ' bio-engineers ', ' bioengineering ', ' bone ', ' California ', ' Cartilage ', ' Cartilaginous Tissue ', ' Chronology ', ' Computer Vision Systems ', ' computer vision ', ' Data Analyses ', ' Data Analysis ', ' data interpretation ', ' Statistical Data Interpretation ', ' Statistical Data Analyses ', ' Statistical Data Analysis ', ' statistical analysis ', ' Disease ', ' Disorder ', ' Elements ', ' Faculty ', ' Gait ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Hybrids ', ' Institutes ', ' arthropathies ', ' Joint Diseases ', ' arthropathic ', ' arthropathy ', ' joint disorder ', ' Knee ', ' Knee joint ', ' Longitudinal Studies ', ' long-term study ', ' longitudinal outcome studies ', ' longterm study ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' Medical Imaging ', ' Mentors ', ' Musculoskeletal System ', ' locomotor system ', ' Degenerative polyarthritis ', ' Degenerative Arthritis ', ' Osteoarthritis ', ' Osteoarthrosis ', ' degenerative joint disease ', ' hypertrophic arthritis ', ' osteoarthritic ', ' Patient Outcomes Assessments ', ' Patient Reported Measures ', ' Patient Reported Outcomes ', ' Phenotype ', ' Radiology Specialty ', ' General Radiology ', ' Radiology ', ' Relaxation ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Risk Factors ', ' Role ', ' social role ', ' San Francisco ', ' Syndrome ', ' Time ', ' Tissues ', ' Body Tissues ', ' Universities ', ' Diagnostic radiologic examination ', ' Conventional X-Ray ', ' Diagnostic Radiology ', ' Diagnostic X-Ray ', ' Diagnostic X-Ray Radiology ', ' Radiography ', ' Roentgenography ', ' X-Ray Imaging ', ' X-Ray Medical Imaging ', ' Xray imaging ', ' Xray medical imaging ', ' conventional Xray ', ' diagnostic Xray ', ' diagnostic Xray radiology ', ' Specialist ', ' Dataset ', ' Data Set ', ' Natural History ', ' base ', ' image processing ', ' morphometry ', ' Clinical ', ' Phase ', ' Variation ', ' Variant ', ' Biochemical ', ' Medical ', ' Training ', ' Lesion ', ' soft tissue ', ' Discipline ', ' Measurement ', ' Development Plans ', ' Disease Progression ', ' Genetic ', ' Exposure to ', ' Morphology ', ' Shapes ', ' tool ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' knee OA ', ' knee joint OA ', ' knee joint osteoarthritis ', ' Knee Osteoarthritis ', ' Dimensions ', ' Complex ', ' Event ', ' Scanning ', ' Source ', ' Techniques ', ' 3-D ', ' 3D ', ' three dimensional ', ' 3-Dimensional ', ' Postdoc ', ' Research Associate ', ' post-doc ', ' post-doctoral ', ' Postdoctoral Fellow ', ' early detection ', ' Early Diagnosis ', ' experience ', ' parallel processing ', ' transdisciplinary collaboration ', ' interdisciplinary collaboration ', ' kinematic model ', ' kinematics ', ' member ', ' race differences ', ' racial difference ', ' Pathogenesis ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Epidemiological Studies ', ' Epidemiology Research ', ' epidemiologic investigation ', ' epidemiology study ', ' Position ', ' Positioning Attribute ', ' Modeling ', ' career development ', ' bio-imaging ', ' biomedical imaging ', ' bioimaging ', ' depository ', ' repository ', ' Genomics ', ' Thickness ', ' Thick ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Symptoms ', ' Data ', ' Validation ', ' developmental ', ' Development ', ' musculoskeletal scanning ', ' musculoskeletal visualization ', ' musculoskeletal imaging ', ' imaging ', ' Image ', ' pathway ', ' Pathway interactions ', ' 3-D modeling ', ' 3D modeling ', ' three-dimensional modeling ', ' image registration ', ' shape description ', ' shape analysis ', ' data integration ', ' designing ', ' design ', ' Outcome ', ' imaging Segmentation ', ' modifiable risk ', ' BigData ', ' Big Data ', ' precision-based medicine ', ' precision medicine ', ' cartilage degeneration ', ' cartilage degradation ', ' quantitative imaging ', ' imaging marker ', ' imaging-based biological marker ', ' imaging-based biomarker ', ' imaging-based marker ', ' imaging biomarker ', ' connectome ', ' imaging scientist ', ' deep learning ', ' Data Scientist ', ' Big Data Analytics ', ' Big Data Tools ', ' Big Data Methods ', ' high dimensional data ', ' multidimensional datasets ', ' multidimensional data ', ' Differences between sexes ', ' Differs between sexes ', ' Sexual differences ', ' sex-dependent differences ', ' sex-related differences ', ' sex-specific differences ', ' Sex Differences ', ' Visualization ', ' data heterogeneity ', ' data set heterogeneity ', ' dataset heterogeneity ', ' heterogeneous data ', ' heterogeneous data sets ', ' heterogeneous datasets ', ' heterogenous data sets ', ' heterogenous datasets ', ' heterogenous data ', ' algorithm development ', ' feature extraction ', ' ']",NIAMS,"UNIVERSITY OF CALIFORNIA, SAN FRANCISCO",R00,2020,249000,0.04296640889953015
"NextGen Random Forests Project Summary/Abstract Building from the PI's current R01, we propose next generation random forests (RF) designed for unprecedented accuracy and computational scalability to meet the challenges of today's complex and big data in the health sciences. Superior accuracy is achieved using super greedy trees which circumvent limitations on local adaptivity imposed by classical tree splitting. We identify a key quantity, forest weights, and show how these can be leveraged for further improvements and generalizability. In one application, improved survival estimators are applied to worldwide esophageal cancer data to develop guidelines for clinical decision making. Richer RF inference is another issue explored. Cutting edge machine learning methods rarely consider the problem of estimating variability. For RF, bootstrapping currently exists as the only tool for reliably estimating condence intervals, but due to heavy computations is rarely applied. We introduce tools to rapidily calculate standard errors based on U-statistic theory. These will be used to increase robustness of esophageal clinical recommendations and to investigate survival temporal trends in cardiovascular disease. In another application, we make use of our new massive data scalability for discovery of tumor and immune regulators of immunotherapy in cancers. This project will set the standard for RF computational performance. Building from the core libraries of the highly accessed R-package randomForestSRC (RF-SRC), software developed under the PIs current R01, we develop open source next generation RF software, RF-SRC Everywhere, Big Data RF-SRC, and HPC RF-SRC. The software will be deployable on a number of popular machine learning workbenches, use distributed data storage technologies, and be optimized for big-p, big-n, and big-np scenarios. Project Narrative We introduce next generation random forests (RF) designed for unprecedented accuracy for complex and big data encountered in the health sciences.",NextGen Random Forests,9929599,R01GM125072,"['Biological Response Modifiers ', ' Biomodulators ', ' Immune Mediators ', ' Immune Mediators/Modulators ', ' Immune Regulators ', ' immunomodulatory biologics ', ' Blood ', ' Blood Reticuloendothelial System ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cardiovascular Diseases ', ' cardiovascular disorder ', ' Combined Modality Therapy ', ' Multimodal Therapy ', ' Multimodal Treatment ', ' combination therapy ', ' combined modality treatment ', ' combined treatment ', ' multi-modal therapy ', ' multi-modal treatment ', ' Confidence Intervals ', ' Esophagus ', ' Flow Cytometry ', ' Flow Cytofluorometries ', ' Flow Cytofluorometry ', ' Flow Microfluorimetry ', ' Flow Microfluorometry ', ' flow cytophotometry ', ' Heart failure ', ' cardiac failure ', ' Human ', ' Modern Man ', ' Hybrids ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' In Vitro ', ' Laboratories ', ' Language ', ' Libraries ', ' lymph nodes ', ' Lymph Node Reticuloendothelial System ', ' Lymph node proper ', ' Lymphatic nodes ', ' lymph gland ', ' lymphnodes ', ' Methods ', ' Methodology ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Patients ', ' outcome forecast ', ' Prognosis ', ' Recommendation ', ' Computer software ', ' Software ', ' statistics ', ' T-Lymphocyte ', ' T-Cells ', ' thymus derived lymphocyte ', ' Technology ', ' Thrombosis ', ' thrombotic disease ', ' thrombotic disorder ', ' Time ', ' Trees ', ' Weight ', ' forest ', ' Guidelines ', ' base ', ' cancer progression ', ' neoplasm progression ', ' neoplastic progression ', ' tumor progression ', ' Pump ', ' improved ', ' Clinical ', ' Java ', ' Data Bases ', ' data base ', ' Databases ', ' data retrieval ', ' data storage ', ' Data Storage and Retrieval ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Therapeutic ', ' Atrophy ', ' Atrophic ', ' tool ', ' machine learned ', ' Machine Learning ', ' Immunes ', ' Immune ', ' Best Practice Analysis ', ' Benchmarking ', ' Operative Procedures ', ' Surgical ', ' Surgical Interventions ', ' Surgical Procedure ', ' surgery ', ' Operative Surgical Procedures ', ' Esophageal Cancer ', ' Esophagus Cancer ', ' Malignant Esophageal Neoplasm ', ' Malignant Esophageal Tumor ', ' Malignant Tumor of the Esophagus ', ' oesophageal cancer ', ' Malignant neoplasm of esophagus ', ' parallel processing ', ' Performance ', ' Receptor Protein ', ' receptor ', ' Induction Therapy ', ' NEOADJ ', ' Neoadjuvant ', ' Neoadjuvant Treatment ', ' Neoadjuvant Therapy ', ' Immunomodulation ', ' immune modulation ', ' immune regulation ', ' immune regulator ', ' immunologic reactivity control ', ' immunomodulatory ', ' immunoregulatory ', ' immunoregulation ', ' novel ', ' Coding System ', ' Code ', ' Modeling ', ' response ', ' theories ', ' develop software ', ' developing computer software ', ' software development ', ' Data ', ' Health Sciences ', ' Receptor Activation ', ' Subgroup ', ' in vivo ', ' Cancer Patient ', ' Clinical Management ', ' Pathologic ', ' developmental ', ' Development ', ' preclinical ', ' pre-clinical ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' distributed data ', ' designing ', ' design ', ' next generation ', ' Population ', ' resistant ', ' Resistance ', ' open source ', ' murine model ', ' mouse model ', ' therapeutic target ', ' tumor ', ' clinical practice ', ' INTERMACS ', ' Interagency Registry for Mechanical Circulatory Support ', ' Interagency Registry for Mechanically Assisted Circulatory Support ', ' clinical decision-making ', ' BigData ', ' Big Data ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' Temporal trend ', ' Trends over time ', ' Time trend ', ' check point blockade ', ' checkpoint blockade ', ' immune check point blockade ', ' immune checkpoint blockade ', ' random forest ', ' complex data  ', ' machine learning method ', ' ']",NIGMS,UNIVERSITY OF MIAMI SCHOOL OF MEDICINE,R01,2020,347834,0.05080573512344636
"Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different cancer phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. We have identified 4 large, multi- generational kindreds with a founder CDKN2A deleterious mutation (L16R, 47T>G). Our preliminary observations demonstrate that this mutant has lower expression and decreased ability to regulate cell cycle progression compared to wild type protein. Our sequencing studies of kindred members with different cancer phenotypes have identified potential variants in novel genes that modify risk (LGR6, a co-receptor of Wnt signaling and COL11A1, which participates in oncogenic signaling, including TGFbeta). We will determine the ability of the p16 mutant to promote transformation and how it is influenced by interaction with the above candidate modifier genes, LGR6 or COL11A1, in pancreatic cancer and melanoma. We will also develop novel computational models using machine deep learning, to generate networks that capture high dimensional features to integrate gene, biology, and cancer phenotype. This approach will be extended to kindreds with other CDKN2A mutations. Our Specific Aims are to: (1) Identify genotypes of potential modifier genes in multiple kindreds that feature pancreatic cancer and melanoma and known to carry CDKN2A germline mutations. We will use genome wide variant coverage of germline DNA from CDKN2A carriers from the 4 large L16R kindreds, plus additional members in 42 other similar CDKN2A kindreds. We will identify candidate modifier genes in the kindreds by rule-based statistical genetic analysis of genotypes. (2) Define the impact of CDKN2A L16R mutation on the function of p16 and its interplay with candidate modifier genes. We will elucidate the biological significance of mutations in CDKN2A and candidate modifier genes using functional and high throughput methodologies by analyzing the mechanism underlying the interplay between p16 and modifier genes; define new pathways cooperating with this interplay using a combination of genome wide studies to assess transformation in cells carrying p16 mutant or wild-type background using well established in vitro and in vivo models. (3) Develop a deep learning network model to integrate genetic, biological and epidemiological data to accurately infer pancreatic cancer and melanoma phenotypes and age of onset in mutation carriers. We will apply a convolutional neural network, a deep learning algorithm in the training dataset, develop a back-propagation algorithm to fine tune weights, and construct mutation-gene networks to capture high-dimensional features for each disease subclass. We will acquire and disseminate new knowledge and tools to the scientific community. Our integrated methods and approach will bring insight into how different cancer phenotypes can occur with identical predisposing mutations, which can be applied to other cancer syndromes with similar challenges. PROJECT NARRATIVE This proposal addresses Provocative Question #2. We will use innovative approaches to investigate how CDKN2A (which encodes p16) mutation carriers develop different phenotypes (pancreatic cancer vs melanoma vs no cancer), and include both genetic and non-genetic factors. Using 4 large, multi-generational kindreds with a founder CDKN2A deleterious mutation and other kindreds, we will define the mechanism underlying the interplay between CDKN2A and other factors. We will develop novel computational models using machine deep learning, that integrate gene, biology, and cancer phenotype. We will share our new knowledge and tools with the scientific community, and bring insights to apply to other challenging cancer syndromes.",Determinants of pancreatic cancer and malignant melanoma phenotypes in CDKN2A hereditary kindreds,9978727,R01CA208517,"['Affect ', ' Age ', ' ages ', ' Algorithms ', ' Alleles ', ' Allelomorphs ', ' Back ', ' Dorsum ', ' Biology ', ' Brain Neoplasms ', ' Brain Neoplasia ', ' Brain Tumors ', ' tumors in the brain ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' cell growth ', ' Cellular Expansion ', ' Cellular Growth ', ' Cells ', ' Cell Body ', ' Communities ', ' Diagnosis ', ' Discrimination ', ' Cognitive Discrimination ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environmental Exposure ', ' Gene Expression ', ' Gene Frequency ', ' Allele Frequency ', ' allelic frequency ', ' Genes ', ' Genome ', ' Genotype ', ' In Vitro ', ' leukemia ', ' Light ', ' Photoradiation ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Methodology ', ' Minor ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Proteins ', ' Risk ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Smoking ', ' Syndrome ', ' Testing ', ' Transforming Growth Factor beta ', ' Bone-Derived Transforming Growth Factor ', ' Milk Growth Factor ', ' Platelet Transforming Growth Factor ', ' TGF B ', ' TGF-beta ', ' TGF- ', ' TGFbeta ', ' TGF ', ' Transforming Growth Factor-Beta Family Gene ', ' Weight ', ' Generations ', ' Measures ', ' Dataset ', ' Data Set ', ' base ', ' Variation ', ' Variant ', ' Biological ', ' Age of Onset ', ' Germline Mutation ', ' Hereditary Mutation ', ' Germ-Line Mutation ', ' Training ', ' insight ', ' Individual ', ' CDK4 Inhibitor ', ' CDKN2A Protein ', ' Cdk4-Associated Protein p16 ', ' Cell Cycle Negative Regulator Beta ', ' Cyclin-Dependent Kinase Inhibitor p12 ', ' Cyclin-Dependent Kinase Inhibitor p16 ', ' INK4A Gene Product ', ' INK4A Protein ', ' Multiple Tumor Suppressor-1 ', ' Protein CDKN2 ', ' Protein MTS1 ', ' Protein p16 ', ' p16(INK4A) ', ' p16-INK4 ', ' p16INK4 Protein ', ' p16INK4A Protein ', ' Cyclin-Dependent Kinase Inhibitor 2A ', ' Genetic ', ' tool ', ' Malignant Pancreatic Neoplasm ', ' Pancreas Cancer ', ' Pancreatic Cancer ', ' pancreatic malignancy ', ' Malignant neoplasm of pancreas ', ' Knowledge ', ' Hereditary ', ' Inherited ', ' Pattern ', ' Penetrance ', ' CDK4I ', ' CDKN2 ', ' CDKN2 Genes ', ' CDKN2A ', ' CMM2 ', ' Cyclin-Dependent Kinase Inhibitor 2A Gene ', ' INK4 ', ' INK4A ', ' MTS1 ', ' MTS1 Genes ', ' TP16 ', ' TSG9A ', ' p14ARF ', ' p16 Genes ', ' p16INK4 Genes ', ' p16INK4A Genes ', ' p16INK4a ', ' CDKN2A gene ', ' interest ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' Performance ', ' Receptor Protein ', ' receptor ', ' kindred ', ' novel ', ' member ', ' Genetic analyses ', ' genetic analysis ', ' Coding System ', ' Code ', ' Modeling ', ' Proteomics ', ' Cancer Susceptibility Gene ', ' Cancer-Predisposing Gene ', ' protein expression ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Oncogenesis ', ' tumorigenesis ', ' Address ', ' solar exposure ', ' sunlight exposure ', ' Sun Exposure ', ' Cellular Transformation ', ' metaplastic cell transformation ', ' Data ', ' in vivo ', ' in vivo Model ', ' cancer specific gene mutation ', ' Cancer Gene Mutation ', ' Cell Cycle Progression ', ' gene modification ', ' Gene-Modified ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Transmission ', ' transmission process ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' disease phenotype ', ' epigenomics ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' innovate ', ' innovative ', ' innovation ', ' Oncogenic ', ' new diagnostics ', ' next generation diagnostics ', ' novel diagnostics ', ' network models ', ' mutation carrier ', ' genome wide analysis ', ' genome wide studies ', ' genome-wide identification ', ' genome-wide analysis ', ' overexpress ', ' overexpression ', ' new therapeutic approach ', ' new therapeutic intervention ', ' new therapeutic strategies ', ' new therapy approaches ', ' novel therapeutic approach ', ' novel therapy approach ', ' novel therapeutic intervention ', ' genome scale ', ' genomewide ', ' genome-wide ', ' nongenetic ', ' non-genetic ', ' Epidemiological data ', ' Epidemiology data ', ' epidemiologic data ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' BeadChip ', ' bead chip ', ' high dimensionality ', ' deep learning ', ' ConvNet ', ' convolutional network ', ' convolutional neural nets ', ' convolutional neural network ', ' deep learning algorithm ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', "" Alzheimer's brain "", "" Alzheimer's disease brain "", ' ']",NCI,MAYO CLINIC ROCHESTER,R01,2020,590577,0.16502161454881356
"A Big Data Approach to BCR ABL Leukemias BCR-ABL1 positive leukemias account for a substantial portion of adult leukemia. Tyrosine kinase  inhibitors (TKIs) have dramatically changed survival outlook. However, current protocols recommend  patients receive TKI chemotherapy agents indefinitely, causing long-term toxicity and substantive  quality of life deficits, leading to decreased TKI compliance. Moreover, >50% of patients who stop  TKIs ultimately relapse and are not as responsive to post-relapse treatment; additionally, mutation  resistance is becoming an increasing issue with TKIs as patients live longer. It is hypothesized  patient heterogeneity within BCR-ABL1 leukemias are a major driving factor on outcome and strongly  influences optimal TKI selection and cessation. However, small cohort size and disease rarity has  impacted large, pragmatic clinical trials, necessitating a big data approach. The overall goal is  to quilt together individual studies to produce a comprehensive view of BCR-ABL1 leukemias that  includes epidemiology, etiology, assessment, and therapy, as well their inter-relationships. With  a comprehensive view, personalized, predictive medicine becomes possible. This project utilizes  literature mining and big data techniques to analyze four major categories: epidemiology (who  gets BCR-ABL1 leukemias, how response correlates to patient characteristics, etc.); etiology (what  factors trigger mutation, mechanisms to improve TKI specificity, preclinical model metrics,  prognostic indicators of recurrence/relapse, etc.); assessment (identifying new  diagnostic/prognostic metrics, improving polymerase chain reaction (PCR) protocols, objective  staging criteria); and treatment (aggregate effect sizes among different therapies, short and  long-term side effect profiles, TKI selection protocols, adjunctive and combination therapies,  criteria for TKI cessation, etc.). The specific aims of the project include: 1) prototype a data  path and construct infrastructure for BCR-ABL1 data curation from literature and/or clinical  sources; 2) construct literature ontological field map to quantify topic depth, aggregate data, and  identify relationships within and between categories; 3) perform exploratory analysis to assess  aggregate statistical power and prototype predictive models for TKI optimization. In summary, the  present project delivers a 21st century, big data approach for BCR-ABL1 leukemia to optimize  clinical management and expedite basic preclinical research. This project is highly relevant to public health as it enables a comprehensive view of BCR ABL  positive leukemia(s) that can optimize clinical management and expedite preclinical research.",A Big Data Approach to BCR ABL Leukemias,9869875,R21CA232249,"['Automobile Driving ', ' driving ', ' Award ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Clinical Trials ', ' Cohort Studies ', ' Concurrent Studies ', ' Combined Modality Therapy ', ' Multimodal Therapy ', ' Multimodal Treatment ', ' combination therapy ', ' combined modality treatment ', ' combined treatment ', ' multi-modal therapy ', ' multi-modal treatment ', ' Cytogenetics ', ' Data Aggregation ', ' Aggregated Data ', ' Cessation of life ', ' Death ', ' Engineering ', ' Epidemiology ', ' epidemiologic ', ' epidemiological ', ' Foundations ', ' Future ', ' Goals ', ' Heterogeneity ', ' Institutes ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' leukemia ', ' Acute Lymphocytic Leukemia ', ' Acute Lymphoblastic Leukemia ', ' Acute Lymphoid Leukemia ', ' Precursor Cell Lymphoblastic Leukemia ', ' Precursor Lymphoblastic Leukemia ', ' acute lymphatic leukemia ', ' acute lymphogenous leukemia ', ' acute lymphomatic leukemia ', ' Acute Myelocytic Leukemia ', ' AML - Acute Myeloid Leukemia ', ' Acute Myeloblastic Leukemia ', ' Acute Myelogenous Leukemia ', ' acute granulocytic leukemia ', ' acute myeloid leukemia ', ' Chronic Myeloid Leukemia ', ' Chronic Granulocytic Leukemia ', ' Chronic Myelocytic Leukemia ', ' Chronic Myelogenous Leukemia ', ' Literature ', ' Lung ', ' Lung Respiratory System ', ' pulmonary ', ' Maps ', ' Medicine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Oncogenes ', ' Cancer Genes ', ' Cancer-Promoting Gene ', ' Transforming Genes ', ' Pancreas ', ' Pancreatic ', ' Patients ', ' Polymerase Chain Reaction ', ' Public Health ', ' Publishing ', ' Quadriplegia ', ' Quadriplegic ', ' Tetraplegia ', ' tetraplegic ', ' Quality of life ', ' QOL ', ' Recurrence ', ' Recurrent ', ' Relapse ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Retrospective Studies ', ' Semantics ', ' Specificity ', ' Time ', ' Universities ', ' Wheelchairs ', ' Wheel Chairs ', ' mobile assistance device ', ' mobile assistance system ', ' mobile assistive device ', ' mobile assistive system ', ' case report ', ' Case Study ', ' Decision Modeling ', ' Risk Assessment ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Chronic ', ' Clinical ', ' prognostic ', ' disability ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Sample Size ', ' drug intolerance ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Staging ', ' machine learned ', ' Machine Learning ', ' Life ', ' Dimensions ', ' Frequencies ', ' Complex ', ' Clinic ', ' Protocol ', ' Protocols documentation ', ' Treatment Period ', ' treatment days ', ' treatment duration ', ' Source ', ' Techniques ', ' experience ', ' cohort ', ' Animal Models and Related Studies ', ' model of animal ', ' model organism ', ' Animal Model ', ' Informatics ', ' Toxicities ', ' Toxic effect ', ' Orphan Disease ', ' Rare Disorder ', ' orphan disorder ', ' Rare Diseases ', ' novel ', ' Categories ', ' disease risk ', ' disorder risk ', ' Epidemiologic Research ', ' Epidemiologic Studies ', ' Epidemiological Studies ', ' Epidemiology Research ', ' epidemiologic investigation ', ' epidemiology study ', ' Manpower ', ' personnel ', ' Human Resources ', ' Modeling ', ' response ', ' Meta-Analysis ', ' discovery mining ', ' literature mining ', ' literature searching ', ' text mining ', ' text searching ', ' PTK Inhibitors ', ' Protein Tyrosine Kinase Inhibitors ', ' TK Inhibitors ', ' Tyrosine Kinase Inhibitor ', ' Causality ', ' causation ', ' disease causation ', ' Etiology ', ' Patient Compliance ', ' patient adherence ', ' patient cooperation ', ' therapy compliance ', ' therapy cooperation ', ' treatment compliance ', ' compliance behavior ', ' datamining ', ' data mining ', ' ABL1 ', ' Abelson Murine Leukemia Viral Oncogene Homolog 1 ', ' JTK7 ', ' c-Abl ', ' c-abl Genes ', ' c-abl Proto-Oncogenes ', ' ABL1 gene ', ' Data ', ' Preclinical Models ', ' Pre-Clinical Model ', ' Molecular Marker of Prognosis ', ' Prognosis Marker ', ' prognostic biomarker ', ' prognostic indicator ', ' Prognostic Marker ', ' Cancer Cause ', ' Cancer Etiology ', ' Clinical Management ', ' Ontology ', ' Patient outcome ', ' Patient-Centered Outcomes ', ' Patient-Focused Outcomes ', ' Characteristics ', ' preclinical ', ' pre-clinical ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' Outcome ', ' cancer type ', ' innovate ', ' innovative ', ' innovation ', ' adult leukemia ', ' resistant ', ' Resistance ', ' preclinical research ', ' pre-clinical research ', ' lexical ', ' chemotherapy ', ' new diagnostics ', ' next generation diagnostics ', ' novel diagnostics ', ' comparative ', ' prototype ', ' population based ', ' resistant mutation ', ' resistance mutation ', ' relational database ', ' BigData ', ' Big Data ', ' Data Analytics ', ' Pragmatic clinical trial ', ' database schema ', ' cancers that are rare ', ' rare malignancy ', ' rare tumor ', ' rare cancer ', ' Individualized Predictors ', ' individualized predictions ', ' personalized predictors ', ' personalized predictions ', ' Infrastructure ', ' side effect ', ' data curation ', ' ']",NCI,GEORGIA INSTITUTE OF TECHNOLOGY,R21,2020,190454,0.1088485057865689
"Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts Project Summary The success of the ongoing battle with coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends crucially on the availability of effective diagnostics, vaccines, antibody therapeutics, and small-molecular drugs. Although SARS-CoV-2 mutates slower than the viruses that cause the flu and the common cold, it has had more than 8300 observed single mutations on its genome of 29,900 nucleotides by June 1, 2020. We show that these mutations might have devastating effects on COVID-19 diagnostics, vaccines, antibody therapeutics, and small-molecular drugs (J. Chem. Inf. Model. In press). We will develop new artificial intelligence (AI) to forecast SARS-CoV-2 future mutations. Leveraging on state-of-art methods developed under the present R01 award, we will design mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs. The CPUs and GPUs requested in this supplement will be essential for my lab to continue the research of the present R01 award and to apply the methods developed in this award to attack fundamental problems in combating COVID-19. Project Narrative The project concerns the forecasting of SARS-CoV-2 mutations and the design of mutation- resistant vaccines, antibody therapeutics, and small-molecular drugs using artificial intelligence (AI) and advanced mathematics. The requested CPUs and GPUs will enable us to addresses potential threats in combating COVID-19.",Synergistic integration of topology and machine learning for the predictions of protein-ligand binding affinities and mutation impacts,10189006,R01GM126189,"['inhibitor/antagonist ', ' inhibitor ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Attention ', ' Award ', ' Cells ', ' Cell Body ', ' Common Cold ', ' Acute Nasopharyngitis ', ' Conflict (Psychology) ', ' Conflict ', ' Crystallization ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Evolution ', ' Future ', ' Genome ', ' Goals ', ' Grant ', ' Heterogeneity ', ' Peptidyl-Dipeptidase A ', ' Angiotensin Converting Enzyme ', ' Angiotensin I-Converting Enzyme ', ' CD143 Antigens ', ' Carboxycathepsin ', ' Dipeptidyl Peptidase A ', ' Kininase A ', ' Kininase II ', ' Mathematics ', ' Math ', ' Medicine ', ' Methods ', ' Mission ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Proteins ', ' Recurrence ', ' Recurrent ', ' Research ', ' Rhinovirus ', ' RNA Viruses ', ' Time ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Vaccines ', ' Virulence ', ' Virus ', ' Work ', ' Diagnostic tests ', ' protein folding ', ' base ', ' improved ', ' Site ', ' Phase ', ' Coronaviridae ', ' corona virus ', ' Coronavirus ', ' Failure ', ' Ligand Binding Protein ', ' Ligand Binding Protein Gene ', ' Protein Binding ', ' bound protein ', ' Binding Proteins ', ' drug use ', ' Drug usage ', ' news ', ' Therapeutic ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Adopted ', ' Viral ', ' experience ', ' Receptor Protein ', ' receptor ', ' receptor bound ', ' receptor binding ', ' success ', ' develop a vaccine ', ' development of a vaccine ', ' vaccine formulation ', ' vaccine development ', ' antigen antibody binding ', ' Manuscripts ', ' Structure ', ' Reporting ', ' Modeling ', ' Influenza A ', ' Influenza Viruses Type A ', ' Influenzavirus A ', ' Orthomyxovirus Type A ', ' Type A Influenza ', ' Influenza A virus ', ' Molecular Interaction ', ' Binding ', ' SARS ', ' SARS coronavirus disease ', ' SARS-CoV disease ', ' Severe Acute Respiratory Syndrome CoV disease ', ' Severe Acute Respiratory Syndrome coronavirus disease ', ' Severe Acute Respiratory Syndrome ', ' SARS Virus ', ' SARS corona virus ', ' SARS-Associated Coronavirus ', ' SARS-CoV ', ' SARS-Related Coronavirus ', ' Severe Acute Respiratory Syndrome Virus ', ' Severe Acute Respiratory Syndrome corona virus ', ' Severe Acute Respiratory Syndrome coronavirus ', ' severe acute respiratory syndrome-CoV ', ' SARS coronavirus ', ' Address ', ' Affinity ', ' Diagnostic Reagent ', ' Induced DNA Alteration ', ' Induced Sequence Alteration ', ' Induced Mutation ', ' Mutate ', ' NIGMS ', ' National Institute of General Medical Sciences ', ' Molecular ', ' Process ', ' Modification ', ' developmental ', ' Development ', ' pandemic ', ' pandemic disease ', ' reconstruction ', ' designing ', ' design ', ' flu ', ' Therapeutic antibodies ', ' combat ', ' resistant mutation ', ' resistance mutation ', ' Preventative measure ', ' Preventive measure ', ' Preventative vaccine ', ' Prophylactic vaccine ', ' Preventive vaccine ', ' autoencoding neural network ', ' autoencoder ', ' COVID19 ', ' corona virus disease 2019 ', ' coronavirus disease 2019 ', ' COVID-19 ', ' 2019 novel coronavirus ', ' SARS-CoV-2 ', ' SARS-CoV2 ', ' SARS-associated coronavirus 2 ', ' SARS-coronavirus-2 ', ' SARS-related coronavirus 2 ', ' Severe acute respiratory syndrome coronavirus 2 ', ' Wuhan coronavirus ', ' 2019-nCoV ', ' COVID19 vaccine ', ' corona virus disease 2019 vaccine ', ' coronavirus disease 2019 vaccine ', ' COVID-19 vaccine ', ' ']",NIGMS,MICHIGAN STATE UNIVERSITY,R01,2020,116389,0.1572576641178806
"A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions PROJECT SUMMARY Cancer genomes typically harbor a substantial number of somatic mutations. Relatively few driver mutations actually alter the function of proteins in tumor cells, whereas most mutations are considered to be functionally neutral passenger mutations. Over the past decade, the search for cancer driver mutations has focused on coding regions and several mutational significance algorithms have been developed for coding mutations. The contribution of mutations in noncoding regulatory regions to tumor formation largely remains unknown and current mutational significance algorithms are not designed to detect driver mutations in noncoding regions, due to biological differences between coding and noncoding mutations. The emerging availability of large whole- genome sequencing datasets (e.g. PCAWG and HMF datasets) creates an ample opportunity to develop new mutational significance algorithms that are particularly designed for the interpretation of noncoding regions. Recently, we have developed a new statistical approach that identifies driver mutations in coding regions based on the nucleotide context. Critically, consideration of the nucleotide context around mutations does not require prior knowledge for functional consequences associated with these mutations. Hence, we hypothesize that generalizing our nucleotide context model to noncoding regions will uncover novel noncoding driver mutations that cannot be detected using the mutational significance approaches currently available. For this purpose, we will develop a statistical framework that incorporates the biological differences between coding and noncoding mutations and that is specifically designed to detect driver mutations in noncoding regions. Specifically, we will consider the context-dependent distribution of passenger mutations, modeling of the background mutation rate, accurately partition the background mutation rate, model the sequence composition of the reference genome, and account for coverage fluctuation. We will then combine these statistical components by computing an independent product of their underlying probabilities. We will derive a significance p-value using a Monte-Carlo simulation approach, and use FDR for multiple hypothesis test correction. This strategy will allow us to accurately estimate the significance of somatic mutations in noncoding genomic regions. We will next apply this statistical framework to whole-genome sequencing data of 5,523 tumor patients, thereby deriving a comprehensive list of candidate driver mutations in noncoding regions. Finally, we will investigate whether noncoding mutations are overrepresented in transcription factor binding sites, regulate gene expression levels, induce alternative splicing, or affect epigenomic states. Upon the completion of this project, we will have developed and applied a statistical framework for discovery of significant somatic mutations in noncoding regions, and defined the mutational landscape of the non-coding cancer genome. All aspects of the methods developed and applied in this project will be made open source and developed in an online platform. PROJECT NARRATIVE While coding cancer driver mutations have been characterized in detail over the past decade, the contribution of noncoding mutations to tumor formation remains - apart from few examples (e.g. mutations in TERT promoters) - largely unknown. Recently, large-scale whole-genome sequencing datasets have been made available, but a major bottleneck for the biological and clinical interpretation of these cancer whole-genome cohorts is the lack of statistical models that identify driver mutations in noncoding regions. We developed a new statistical approach that characterizes driver mutations based on their surrounding nucleotide context in coding regions, and herein we propose a concrete plan to generalize our computational model to noncoding regions, apply our model to aggregated whole-genome sequencing data of 5,523 tumor patients (PCAWG, HMF datasets), and define the noncoding driver and passenger mutational landscape for biological discovery and focused clinical application.",A statistical framework to systematically characterize cancer driver mutations in noncoding genomic regions,9957082,R21CA242861,"['Affect ', ' Algorithms ', ' Alternative Splicing ', ' Alternate Splicing ', ' Alternative RNA Splicing ', ' Attention ', ' Binding Sites ', ' Combining Site ', ' Reactive Site ', ' Biology ', ' malignant breast neoplasm ', ' Breast Cancer ', ' malignant breast tumor ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Immunotherapy ', ' Immune mediated therapy ', ' Immunologically Directed Therapy ', ' immune therapeutic approach ', ' immune therapeutic interventions ', ' immune therapeutic regimens ', ' immune therapeutic strategy ', ' immune therapy ', ' immune-based therapies ', ' immune-based treatments ', ' immuno therapy ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Monte Carlo Method ', ' Monte Carlo algorithm ', ' Monte Carlo calculation ', ' Monte Carlo procedure ', ' Monte Carlo simulation ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Nucleotides ', ' Patients ', ' Play ', ' Probability ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Role ', ' social role ', ' Testing ', ' transcription factor ', ' Basal Transcription Factor ', ' Basal transcription factor genes ', ' General Transcription Factor Gene ', ' General Transcription Factors ', ' Transcription Factor Proto-Oncogene ', ' Transcription factor genes ', ' Mediating ', ' promotor ', ' promoter ', ' Dataset ', ' Data Set ', ' base ', ' Clinical ', ' Biological ', ' Biological Function ', ' Biological Process ', ' anti-cancer immunotherapy ', ' anticancer immunotherapy ', ' immune-based cancer therapies ', ' immunotherapy for cancer ', ' immunotherapy of cancer ', ' cancer immunotherapy ', ' machine learned ', ' Machine Learning ', ' computer biology ', ' Computational Biology ', ' Knowledge ', ' Pattern ', ' Somatic Mutation ', ' mutant ', ' Tumor Cell ', ' neoplastic cell ', ' cohort ', ' novel ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Microsatellite Instability ', ' genome sequencing ', ' Address ', ' Data ', ' Stratification ', ' genomic region ', ' Genomic Segment ', ' Process ', ' protein function ', ' developmental ', ' Development ', ' epigenomics ', ' cancer cell genome ', ' tumor genome ', ' cancer genome ', ' immunogenicity ', ' designing ', ' design ', ' Outcome ', ' clinical effect ', ' clinical applicability ', ' clinical application ', ' open source ', ' tumor ', ' genome scale ', ' genomewide ', ' genome-wide ', ' TCGA ', ' The Cancer Genome Atlas ', ' exome-seq ', ' exome sequencing ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' prediction of response ', ' predictive response ', ' predictor of response ', ' response prediction ', ' predicting response ', ' reference assembly ', ' reference genome ', ' entire genome ', ' full genome ', ' whole genome ', ' check point immunotherapy ', ' check point inhibitor therapy ', ' check point inhibitory therapy ', ' check point therapy ', ' checkpoint immunotherapy ', ' checkpoint inhibitor therapy ', ' checkpoint inhibitory therapy ', ' immune check point therapy ', ' immune checkpoint therapy ', ' checkpoint therapy ', ' check point blockade ', ' checkpoint blockade ', ' immune check point blockade ', ' immune checkpoint blockade ', ' neo-antigen ', ' neo-epitopes ', ' neoepitopes ', ' neoantigens ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' large data sets ', ' large datasets ', ' driver mutation ', ' ']",NCI,DANA-FARBER CANCER INST,R21,2020,193576,0.21826324425005916
"Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer Title: Reverse Sensitivity Analysis for Identifying Proteomics Signatures of Cancer Abstract Cancer is a complex disease in which genetic disruptions in cell signaling networks are known to play a significant role. A major aim of cancer systems biology is to build models that can predict the impact of these genetic disruptions to guide therapeutic interventions (i.e. personalized medicine). A prominent driver of cancer cell growth is signaling pathway deregulation from mutations in key regulatory nodes and loss/gain in gene copy number (CNV). However, current mathematical modeling approaches do not adequately capture the impact of these genetic changes. Reasons for this include the poorly understood layers of regulation between gene expression and protein activity, and limitations in most modeling and protein measurement technologies. In addition, there is a paucity of overarching hypotheses that can link specific gene expression or mutation patterns to the cancer phenotype. Recent work by our group has resolved some of the technical challenges that have hindered the application of proteomics technologies to cancer systems biology research. It has also suggested a new approach for using quantitative proteomics data to understand mechanisms driving cancer cell behavior. Using an ultrasensitive, targeted proteomics platform that can measure both abundance and phosphorylation of proteins present at only hundreds of copies per cell, we found that signaling pathways appeared to be controlled by only a limited number of key nodes whose activity is tightly regulated through low abundance and feedback phosphorylation. We propose to build on these findings by critically testing the hypothesis that CNV and genetic mutations dysregulate signaling pathways in cancer by shifting control from tightly regulated nodes to poorly regulated ones. This will be done by systematically identifying key regulatory nodes of normal and cancer cells using CRISPRa/i screens, determine the relationship between protein abundance and signaling pathway activities using ultrasensitive targeted proteomics and phosphoproteomics and then use these data to semi-automatically generate mathematical models of the functional topology of the signaling pathways. Specifically, we propose to: 1) Use targeted CRISPR gene perturbation libraries to identify the regulatory topologies of signaling pathways important in cancer and how they are disrupted by common cancer mutations, 2) Use the CRISPR perturbation and proteomics data to semi-automatically build predictive models of cancer cell signaling pathways, and 3) Combine modeling and perturbation screens to understand how feedback regulation in cancer contributes to drug resistance. This work will result in simplified, computationally tractable yet mechanistic models of signaling pathways and provide network maps of feedback and crosstalk circuits that can be used to rapidly map the regulatory state of cells. Most important, it will provide a generic platform for translating protein abundance and phosphorylation patterns into a state snapshot of cancers that can lead to predicting their response to specific drugs. Narrative Cancer is an extremely complex disease which is frequently caused by signaling pathway deregulation from genetic mutation or loss/gain in gene copy number. Modern analytical techniques have provided a wealth of data on the molecular changes associated with cancer mutations, but it has been extremely difficult to use this information to design targeted therapies. We propose a new methodology that combines CRISPR-based targeted screens, advanced proteomics technologies, and a new mathematical modeling approach for identifying proteomics signatures of altered signaling pathways in cancer that can be used to build predictive models and explore mechanisms of drug resistance.",Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer,9923630,U01CA227544,"['Affect ', ' Automobile Driving ', ' driving ', ' Behavior ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cells ', ' Cell Body ', ' Disease ', ' Disorder ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Feedback ', ' Flow Cytometry ', ' Flow Cytofluorometries ', ' Flow Cytofluorometry ', ' Flow Microfluorimetry ', ' Flow Microfluorometry ', ' flow cytophotometry ', ' Gene Expression ', ' Genes ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Libraries ', ' Maps ', ' melanoma ', ' Malignant Melanoma ', ' Methods ', ' Methodology ', ' Biological Models ', ' Biologic Models ', ' Model System ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Phosphorylation ', ' Protein Phosphorylation ', ' Play ', ' Proteins ', ' Reagent ', ' Research ', ' Role ', ' social role ', ' Signal Pathway ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Technology ', ' Testing ', ' Translating ', ' Work ', ' Generations ', ' Measures ', ' AKT ', ' Akt protein ', ' Protein Kinase B ', ' RAC-PK protein ', ' c-akt protein ', ' proto-oncogene protein RAC ', ' proto-oncogene protein akt ', ' rac protein kinase ', ' related to A and C-protein ', ' Proto-Oncogene Proteins c-akt ', ' base ', ' Gene Copy Number ', ' Gene Dosage ', ' Link ', ' Measurement ', ' Genetic ', ' Malignant Cell ', ' cancer cell ', ' tool ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Pattern ', ' Techniques ', ' Gene Alteration ', ' Gene Mutation ', ' Protein Gene Products ', ' Gene Proteins ', ' intervention therapy ', ' Therapeutic Intervention ', ' Regulation ', ' Modeling ', ' response ', ' Proteomics ', ' Math Models ', ' mathematic model ', ' mathematical modeling ', ' mathematical model ', ' Normal Cell ', ' Address ', ' Systems Biology ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Mutate ', ' Predictive Cancer Model ', ' Cancer Cell Growth ', ' Molecular ', ' developmental ', ' Development ', ' pathway ', ' Pathway interactions ', ' computer based prediction ', ' prediction model ', ' prognostic model ', ' predictive modeling ', ' designing ', ' design ', ' new approaches ', ' novel approaches ', ' novel strategy ', ' novel strategies ', ' cancer type ', ' resistant ', ' Resistance ', ' cellular behavior ', ' cell behavior ', ' screening ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' mammary epithelial cells ', ' Breast Epithelial Cells ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' targeted drug therapy ', ' targeted drug treatments ', ' targeted therapeutic ', ' targeted therapeutic agents ', ' targeted therapy ', ' targeted treatment ', ' Breast tumor cell line ', ' Breast Cancer cell line ', ' phospho-proteomics ', ' phosphoproteomics ', ' CRISPR-based library ', ' CRISPR/Cas9 library ', ' Clustered Regularly Interspaced Short Palindromic Repeats library ', ' CRISPR library ', ' proteomic signature ', ' experiment ', ' experimental research ', ' experimental study ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NCI,BATTELLE PACIFIC NORTHWEST LABORATORIES,U01,2020,801231,0.08365369730905468
"A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions Project summary There is a fundamental gap in our understanding of how mutations are preferentially targeted to the variable (V) regions of the Immunoglobulin (Ig) loci during somatic hypermutation (SHM). The persistence of this gap has limited our understanding of the mutagenic mechanisms involving activation-induced deaminase (AID) in the immune response and in the role of AID in mis-targeting mutations leading to B-cell lymphomas and other cancers. The long-term goal of the proposed research is to understand the global targeting of mutations in immunity that are required to protect us from infections. As high-throughput data from human antibody immune responses became available, it provided us with new opportunities to generate hypotheses to explain the underlying mechanisms of SHM. We now propose to generate further hypotheses using computational models applied to additional databases and to validate these hypotheses using cellular and animal experiments. Our objective is to understand what directs SHM across the many human Ig heavy chain V-regions. Our central hypothesis is that the V-region SHM process is highly dependent on a DNA sequence signature(s) that drives mutations in a largely deterministic fashion. This hypothesis is supported by our preliminary results using human in vivo data from a few human V region genes and has begun to be validated using independent databases and experiments in human B cell lines. The rationale is that evaluations of computational data based upon biological mechanisms, together with appropriate biological experiments, will reveal the key differences between IGHV regions (IGHV 3-23, 4-34, 1-18, 1-02, etc.) that lead to the dominance of each of those V regions in the responses to medically important antigens. Our hypothesis will be tested by pursuing two specific aims: 1) identify the extent to which a DNA signature determines the mutation process in four individual human IGHV genes that are important in disease responses; 2) examine the relationship between AID hotspots and Pol hotspots across all the other human V region genes, thus rigorously defining a mutation targeting signature. Both aims will also entail studying human V region genes and modifications of them in human cell lines and in mice expressing a human V region to further confirm the signature and identify molecular mechanisms in vivo. Our approach is innovative because the computational models we are proposing will be mechanistically motivated focusing on the interaction between AID and Pol hotspots, thus testing molecular mechanisms as opposed to classic statistical models using whole V region sequences that ignore the underlying biology. In addition, to focus on mechanisms we will leverage new high-throughput data from human V regions that have not undergone antigen selection. Our results will be highly relevant to human IgV repertoire analyses from immune responses that are currently hard to interpret and will help future vaccine and therapeutic antibody development, as well as help to understand mutations in human malignancies where AID plays a key role. Project narrative The proposed research is relevant to public health because understanding the targeting of AID-mediated mutations across many human heavy chain V-regions will make it possible to develop vaccines that will lead more rapidly to better and more broadly protective antibodies to infectious agents and reveal the risk factors in the development of B-cell malignancies and gastric and other solid tumors where AID is implicated.",A combined computational and experimental approach to the evolution and role of the DNA sequence environment in targeting mutations to antibody V regions,10090262,R01AI132507,"['Affect ', ' Alleles ', ' Allelomorphs ', ' Antibodies ', ' Antibody Affinity ', ' antigen antibody affinity ', ' Antigens ', ' immunogen ', ' Autoimmunity ', ' Autoimmune Status ', ' B-Lymphocytes ', ' B blood cells ', ' B cell ', ' B cells ', ' B-Cells ', ' B-cell ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Cell Line ', ' CellLine ', ' Strains Cell Lines ', ' cultured cell line ', ' Chromatin ', ' Disease ', ' Disorder ', ' DNA ', ' Deoxyribonucleic Acid ', ' Environment ', ' Enzyme Activation ', ' Evolution ', ' Family ', ' Feedback ', ' Future ', ' Genes ', ' Goals ', ' HIV ', ' AIDS Virus ', ' Acquired Immune Deficiency Syndrome Virus ', ' Acquired Immunodeficiency Syndrome Virus ', ' Human Immunodeficiency Viruses ', ' LAV-HTLV-III ', ' Lymphadenopathy-Associated Virus ', ' Virus-HIV ', ' Human ', ' Modern Man ', ' Immunity ', ' Complementarity Determining Regions ', ' Complimentarity Determining Region ', ' Hypervariable Loop ', ' Hypervariable Regions ', ' Immunoglobulin Hypervariable Region ', ' Immunoglobulins ', ' Immune Globulins ', ' Heavy-Chain Immunoglobulins ', ' Infection ', ' Influenza ', ' Grippe ', ' flu infection ', ' influenza infection ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Transgenic Mice ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Play ', ' Public Health ', ' Research ', ' Risk Factors ', ' Role ', ' social role ', ' Stomach ', ' gastric ', ' Testing ', ' Time ', ' Vaccines ', ' B-Cell Lymphomas ', ' B lymphoma ', ' Mediating ', ' G(s), alpha Subunit ', ' G(s),  Subunit ', ' G(s)alpha ', ' G(s) ', ' GTP-Binding Protein  Subunits, Gs ', ' Gs alpha Family G-Protein ', ' Gs ', ' Gs ', ' Regulatory Ns Protein ', ' Stimulatory Gs G-Protein ', ' alpha Subunit Stimulatory GTP-Binding Protein ', ' alpha-Gs ', ' -Gs ', ' GTP-Binding Protein alpha Subunits, Gs ', ' DNA Sequence ', ' base ', ' density ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Medical ', ' Animal Experiments ', ' Evaluation ', ' Individual ', ' Data Bases ', ' data base ', ' Databases ', ' Solid Tumor ', ' Solid Neoplasm ', ' Germinal Center ', ' Structure of germinal center of lymph node ', ' Immunological response ', ' host response ', ' immunoresponse ', ' Immune response ', ' infectious organism ', ' Infectious Agent ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Event ', ' Pattern ', ' Techniques ', ' Location ', ' neutralizing antibody ', ' human data ', ' repair endonuclease ', ' repair enzyme ', ' Human Cell Line ', ' response ', ' Ig Somatic Hypermutation ', ' somatic hypermutation ', ' Immunoglobulin Somatic Hypermutation ', ' AICDA ', ' AICDA protein ', ' AID gene ', ' AID protein ', ' CDA2 protein ', ' activation-induced deaminase ', ' activation-induced cytidine deaminase ', ' Post-Replication Mismatch Repair ', ' Mismatch Repair ', ' chromatin modification ', ' Polymerase ', ' B-Cell Development ', ' Data ', ' Mutate ', ' in vivo ', ' in vivo Model ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' gene modification ', ' Gene-Modified ', ' Validation ', ' Molecular ', ' Process ', ' developmental ', ' Development ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' B cell malignancy ', ' B lymphoid malignancy ', ' Outcome ', ' innovate ', ' innovative ', ' innovation ', ' Influenza HA ', ' flu HA ', ' flu hemagglutinin ', ' influenza virus HA ', ' influenza virus hemagglutinin ', ' Influenza Hemagglutinin ', ' Therapeutic antibodies ', ' spatial relationship ', ' vaccine response ', ' knockin ', ' Knock-in ', ' experiment ', ' experimental research ', ' experimental study ', ' recruit ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIAID,ALBERT EINSTEIN COLLEGE OF MEDICINE,R01,2020,38074,0.15225722621024226
"Functional Annotation of Natural and Disease Variants in Tryosine Kinases     DESCRIPTION (provided by applicant): Protein tyrosine kinases are dynamic molecular switches that toggle between a catalytically ""on"" and ""off"" state to turn on and off signals responsible for cell growth and survival. While the tyrosine kinase switch is tightly regulated by  diverse array of structural mechanisms in normal states, in many disease states, the switch is permanently turned on or off due, in part, to mutations in the tyrosine kinase domain. Although genome sequencing studies have revealed the mutational patterns of tyrosine kinases from many different disease types, understanding the structural and functional impact of these mutations is a challenge because many recurrent mutations occur far from the active site (distal mutations) and the residue networks that contribute to the complex modes of tyrosine kinase allosteric regulation are not fully understood. Our long term goal is to understand the relationships connecting sequence, structure, function, regulation and disease in protein kinases using a combination of computational and experimental approaches. Our objective in this proposal, which is the next logical step toward attainment of our long-term goal, is to delineate the residue interaction networks that contribute to the unique modes of allosteric regulation in tyrosine kinases, and to develop a computational framework for predicting mutation impact using the evolutionary and allosteric properties encoded in three dimensional structures. The central hypothesis is that distal mutations alter evolutionarily conserved allosteric networks in tyrosine kinases, and delineating the allosteric networks unique to tyrosine kinases will provide context for predicting and testing disease mutation impact. The specific aims are: * To identify and characterize natural sequence and structural variants associated with tight  allosteric control of tyrosine kinase activity * To develop a computational framework for predicting mutation impact on kinase activation and to  experimentally validate computational predictions using selected receptor tyrosine kinases as  model systems Successful completion of these aims is expected to reveal novel activating mutations in putative allosteric sites in the tyrosine kinase domain, and pinpoint key residues and interactions for functional studies. These outcomes, in turn, are expected to have major biomedical impact by accelerating the functional characterization of the mutated tyrosine kinome, which is emerging as a major target for personalized medicine. Finally, by providing detailed mechanistic annotation of mutations identified in genome sequencing studies, this proposal will address a fundamental NIH roadmap problem in translational medicine of converting genomic discoveries into therapeutic strategies. PUBLIC HEALTH RELEVANCE: Protein tyrosine kinases are a biomedically important class of proteins that are abnormally regulated in many human diseases including cancer, diabetes, and inflammatory disorders, to name but a few. They have been the focus of many drug discovery efforts and genome sequencing studies because of the therapeutic potential of targeting mutated tyrosine kinases for personalized therapy. By providing functional annotation of natural and disease mutations in tyrosine kinases, the proposed studies will accelerate the targeting of mutated tyrosine kinases for drug discovery and personalized therapy.",Functional Annotation of Natural and Disease Variants in Tryosine Kinases,10145865,R01GM114409,"['Allosteric Regulation ', ' Allosteric Site ', ' Antineoplastic Agents ', ' Anti-Cancer Agents ', ' Antineoplastic Drugs ', ' Antineoplastics ', ' Cancer Drug ', ' Neoplastic Disease Chemotherapeutic Agents ', ' Tumor-Specific Treatment Agents ', ' anti-cancer drug ', ' anticancer agent ', ' anticancer drug ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' cell growth ', ' Cellular Expansion ', ' Cellular Growth ', ' Cell Survival ', ' Cell Viability ', ' Communities ', ' Diabetes Mellitus ', ' diabetes ', ' Disease ', ' Disorder ', ' Drug resistance ', ' drug resistant ', ' resistance to Drug ', ' resistant to Drug ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Foundations ', ' Genes ', ' Human Genome ', ' human whole genome ', ' Goals ', ' In Vitro ', ' Biological Models ', ' Biologic Models ', ' Model System ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Names ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Organism ', ' living system ', ' Peptides ', ' Phosphotransferases ', ' Kinases ', ' Phosphotransferase Gene ', ' Transphosphorylases ', ' Protein Kinase ', ' ATP-protein phosphotransferase ', ' Kinase Family Gene ', ' glycogen synthase a kinase ', ' hydroxyalkyl protein kinase ', ' phosphorylase b kinase kinase ', ' Protein Tyrosine Kinase ', ' EPH- and ELK-Related Tyrosine Kinase ', ' EPH-and ELK-Related Kinase ', ' Ephrin Type-A Receptor 8 ', ' Ephrin Type-A Receptor 8 Precursor ', ' Protein Tyrosine Kinase EEK ', ' Tyrosine Kinase ', ' Tyrosine-Protein Kinase Receptor EEK ', ' Tyrosine-Specific Protein Kinase ', ' Tyrosylprotein Kinase ', ' hydroxyaryl protein kinase ', ' tyrosyl protein kinase ', ' Proteins ', ' Publishing ', ' Recurrence ', ' Recurrent ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Testing ', ' Tyrosine ', ' Protein-Serine-Threonine Kinases ', ' Protein-Serine Kinase ', ' Protein-Threonine Kinase ', ' Serine Kinase ', ' Serine-Threonine Kinases ', ' Serine/Threonine Protein Kinase Gene ', ' Threonine Kinase ', ' base ', ' improved ', ' Distal ', ' Site ', ' Variation ', ' Variant ', ' Active Sites ', ' PTK Receptors ', ' Receptor Tyrosine Kinase Gene ', ' Transmembrane Receptor Protein Tyrosine Kinase ', ' Tyrosine Kinase Linked Receptors ', ' Tyrosine Kinase Receptors ', ' Receptor Protein-Tyrosine Kinases ', ' insight ', ' Therapeutic ', ' Inflammatory ', ' machine learned ', ' Machine Learning ', ' Complex ', ' Pattern ', ' System ', ' Molecular Dynamics Simulation ', ' molecular dynamics ', ' mutant ', ' Structure ', ' novel ', ' Regulation ', ' Modeling ', ' Property ', ' Genomics ', ' drug discovery ', ' Pathogenicity ', ' Molecular Interaction ', ' Binding ', ' genome sequencing ', ' Address ', ' Drug Binding Site ', ' Mutate ', ' Ontology ', ' Tyrosine Kinase Domain ', ' Molecular ', ' non-synonymous mutation ', ' nonsynonymous mutation ', ' computational framework ', ' computer framework ', ' Outcome ', ' 3-D structure ', ' 3-dimensional structure ', ' 3D structure ', ' three dimensional structure ', ' translational medicine ', ' human disease ', ' public health relevance ', ' personalization of treatment ', ' personalized therapy ', ' personalized treatment ', ' personalized medicine ', ' predictive assay ', ' predictive test ', ' learning classifier ', ' ']",NIGMS,UNIVERSITY OF GEORGIA,R01,2020,9815,0.17732211395365816
"The adaptive potential of translational regulation Project Summary/Abstract  Our current understanding of the adaptive effects of mutation is largely limited to alterations in protein coding sequence and disruption of transcriptional cis-regulatory promoters. Very little is known about how mutations alter translation, or the role these mutations play in adaptation and evolution. This project seeks to address this gap by identifying the functional effect of mutations on translation. To accomplish this I will first identify mutations that arise from adaptation to various nutrient limited environments. I will then use expression profiling (e.g. RNA-seq, ribosome profiling, and RATE-seq) to identify the effect these mutations have on translation, as well as other levels of gene expression. This will provide insight into the magnitude of effect mutations have on translation and their relative rate. Furthermore, to fully characterize the role synonymous mutations have on fitness I will be using a deep scanning synonymous mutation library. To understand the role tRNA abundance plays in the fitness effect of a given synonymous mutations, I will also be evaluating fitness within tRNA under- and over-expression backgrounds. Because of the closely coupled nature of translation rates and mRNA decay, I will also characterize the effect synonymous mutations have on mRNA decay using RATE-seq. My analysis of the functional effects of these mutations on gene expression, particularly within the genetic background and environment in which they arose, will allow for the development of a machine learning algorithm that can use sequence and annotation features to predict the effect of a mutation on gene expression. This tool will aid future research into the effect mutations have of gene expression by allowing the identification of high-confidence candidates for further evaluation.  This project will be conducted at New York Universitys Center for Genomics and Systems Biology, whose mission is to answer otherwise intractable biological questions using applied experimental and computational approaches. The Center houses numerous facilities and cores that will be instrumental in the performance of this work. The collaborative atmosphere and multi-disciplinary nature of NYUs research communities that will enable me to stay abreast of developments in related fields and to rapidly communicate my research to interested parties. I will be trained under the guidance of Dr. David Gresham, an excellent researcher working on complementing long-term evolution experiments with gene expression studies to characterize the adaptive potential of the regulation of gene expression. Project Narrative The translation of mRNA into protein is a critical step in gene expression that is tightly regulated with mis-regulation of translation being a hallmark of many human pathologies. Understanding how mutations can alter the regulation of translation is an understudied but important aspect of adaptation and evolution. Ultimately, without an understanding of the adaptive potential of translation we have an incomplete, and imperfect, picture of the underlying genetic causes of numerous forms of cancer and genetic diseases.",The adaptive potential of translational regulation,9893712,F32GM131573,"['Affect ', ' Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Malignant Neoplasms ', ' Cancers ', ' Malignant Tumor ', ' malignancy ', ' neoplasm/cancer ', ' Communities ', ' Complement ', ' Complement Proteins ', ' Disease ', ' Disorder ', ' Elements ', ' Environment ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Goals ', ' Laboratories ', ' Libraries ', ' Literature ', ' Mission ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' New York ', ' Pathology ', ' Phenotype ', ' Play ', ' Proteins ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Ribosomes ', ' Transfer RNA ', ' Triplet Codon-Amino Acid Adaptor ', ' tRNA ', ' transfer Ribonucleic acids ', ' Role ', ' social role ', ' Computer software ', ' Software ', ' Stress ', ' Testing ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Translation ', ' mRNA Translation ', ' Translations ', ' Universities ', ' Genetic Variation ', ' Genetic Diversity ', ' Work ', ' Generations ', ' Measures ', ' Open Reading Frames ', ' ORFs ', ' Protein Coding Region ', ' promotor ', ' promoter ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Evaluation ', ' Training ', ' insight ', ' Genetic ', ' tool ', ' Nature ', ' machine learned ', ' Machine Learning ', ' Frequencies ', ' Scanning ', ' interest ', ' Nutrient ', ' novel ', ' cancer genetics ', ' Coding System ', ' Code ', ' Regulation ', ' Modeling ', ' response ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genomics ', ' mRNA Decay ', ' mRNA Degradation ', ' mRNA Transcript Degradation ', ' job performance ', ' work performance ', ' Performance at work ', ' genome sequencing ', ' Address ', ' Systems Biology ', ' fitness ', ' Data ', ' Human Pathology ', ' Regulatory Element ', ' Translation Initiation ', ' Translational Regulation ', ' developmental ', ' Development ', ' environmental change ', ' Population ', ' Coupled ', ' analytical tool ', ' multidisciplinary ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' Business-Friendly Atmosphere ', ' business-friendly environment ', ' collaborative atmosphere ', ' interactive atmosphere ', ' interactive environment ', ' interdisciplinary atmosphere ', ' interdisciplinary environment ', ' peer-group atmosphere ', ' peer-group environment ', ' collaborative environment ', ' mutation scanning ', ' mutation screening ', ' entire genome ', ' full genome ', ' whole genome ', ' Ribo-seq ', ' ribosome footprint profiling ', ' ribosome profiling ', ' experiment ', ' experimental research ', ' experimental study ', ' Expression Profiling ', ' preservation ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' machine learned algorithm ', ' machine learning algorithm ', ' driver mutation ', ' ']",NIGMS,NEW YORK UNIVERSITY,F32,2020,65310,0.20091819715970052
"The Evolution of Gene Regulation and Human Disease PROJECT SUMMARY Genetic variants that disrupt the functionality of regulatory sequences, and thereby alter gene expression levels, are major contributors to both evolutionary divergence between species and differences in risk for complex disease among humans. However, due to the complexity of the gene regulatory programs encoded in mammalian genomes and their rapid turnover between species, evaluating the function of non-protein-coding mutations is challenging. This is a major roadblock to tracing the evolution of human-specific biology. In addition, since the majority of disease-associated variants are non-coding, it impairs our ability to map the genetics of complex disease.  The long-term mission of my lab is to interpret the complex gene regulatory programs encoded in the human genome and accurately model the effects of genetic mutations to these elements on phenotypes relevant to disease and human evolution. We work toward these goals by integrating cutting-edge machine learning, statistical modeling of evolution, and the analysis of genotypes and phenotypes from large-scale clinical biobanks. In particular, my lab is uniquely well positioned to build on our previous work to address the following fundamental questions:  1. How have evolutionary transitions on the human-lineage modified the genomein particular gene  regulatory programsto produce human-specific biology? And how do these modifications relate to  human-specific disease risk?  2. What are the combinatorial rules underlying how TF binding patterns specify precise control of gene  regulation? And how do these gene regulatory programs evolve between species?  3. How do genetic and epigenetic mechanisms interact to specify the dynamic gene regulatory programs  that drive cellular development? And how are these programs perturbed in disease?  4. How can we interpret non-protein-coding mutations identified in patient genomes to inform treatment  and preventative care? Our work will produce much-needed methods for understanding the effects of mutations to gene regulatory regions and identify mutations responsible for differences in disease risk between human populations. PROJECT NARRATIVE The genetic mutations that distinguish humans from other great apes and that influence risk for complex disease are mostly found outside of genes. Many of these mutations influence when and where genes are expressed. However, we do not know how to interpret the effects of most such mutations on gene regulation, disease risk, or human evolution, we will develop computational models that leverage machine learning, evolutionary patterns, and large-scale clinical biobanks to identify mutations that disrupt proper control of genes and lead to disease.",The Evolution of Gene Regulation and Human Disease,9904747,R35GM127087,"['Biology ', ' Disease ', ' Disorder ', ' Elements ', ' Evolution ', ' Gene Expression ', ' Gene Expression Regulation ', ' Gene Action Regulation ', ' Gene Regulation ', ' Gene Regulation Process ', ' Genes ', ' Regulator Genes ', ' Transcriptional Regulatory Elements ', ' regulatory gene ', ' trans acting element ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Genotype ', ' Goals ', ' Human ', ' Modern Man ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Maps ', ' Methods ', ' Mission ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Patients ', ' Phenotype ', ' Pongidae ', ' Apes ', ' great ape ', ' Nucleic Acid Regulatory Sequences ', ' Nucleic Acid Regulator Regions ', ' Regulatory Regions ', ' genetic regulatory element ', ' Risk ', ' Work ', ' species difference ', ' Clinical ', ' Specified ', ' Specific qualifier value ', ' Variation ', ' Variant ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' programs ', ' Complex ', ' Pattern ', ' disease risk ', ' disorder risk ', ' Position ', ' Positioning Attribute ', ' Coding System ', ' Code ', ' Modeling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Molecular Interaction ', ' Binding ', ' Address ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Epigenetic ', ' Epigenetic Change ', ' Epigenetic Mechanism ', ' Epigenetic Process ', ' To specify ', ' Modification ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Population ', ' Impairment ', ' combinatorial ', ' mammalian genome ', ' human disease ', ' cellular development ', ' biorepository ', ' biobank ', ' Preventative care ', ' Preventive care ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' ']",NIGMS,VANDERBILT UNIVERSITY,R35,2020,86356,0.07764059621971087
"Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database PROJECT SUMMARY Therapeutic antibodies, specialized enzymes for drug manufacturing, small molecule drug screening agents, and other proteins have been instrumental in advancing biotechnology and medicine. Protein therapeutics alone represents a rapidly growing $100+ billion market with broad applications in the treatment of cancer, inflammatory and metabolic diseases, and numerous other disorders. Most of the antibodies and other protein therapeutics developed in the last several years have been engineered, leading to improvements in important properties such as efficacy, binding affinity, expression, stability, and immunogenicity. However, improving protein properties through sequence modification remains a challenging task. Artificial intelligence (AI), which has been enormously successful in several fields (e.g., image recognition, self-driving cars, natural language processing), is now being applied to protein engineering and has the potential to transform this field as well. AI and machine learning (ML) can take advantage of large and diverse datasets to identify correlations, predict beneficial mutations, and explore novel protein sequences in ways that are not possible using other techniques. Other advantages include the ability to simultaneously optimize multiple protein properties and explore sequence space more efficiently. In Phases I and II of this project, we developed the ProtaBank database as a central repository to store, organize, and annotate protein mutation data spanning a broad range of properties. ProtaBank is the largest and only database actively collecting such a comprehensive set of sequence mutation data and is growing rapidly due to the wealth of data being generated with advanced automation and next-generation sequencing techniques. ProtaBank's depth and breadth makes it an ideal data source to train ML models. This proposal aims to create the ProtaBank AI Platform to enable the use of AI and ML tools to apply the data in ProtaBank to engineer proteins. The platform will provide fully customizable computational tools and will invoke protein-specific knowledge to properly prepare data for use with ML models. An interface to popular ML frameworks will be provided so that scientists can use these techniques to discover new predictive algorithms and enhance their ability to design proteins with the desired properties. Specific aims include: (1) integrating peer validated ML methods and proprietary technology for protein engineering into the ProtaBank AI Platform, (2) developing dynamic ML dataset creation tools, (3) expanding and improving the ProtaBank database by reaching out to scientists to contribute data, (4) enhancing our data deposition tools, and (5) integrating ProtaBank with the Protein Data Bank structure database and other databases. ! Project Narrative Protein engineering has enabled significant advances in health care by playing a key role in the development of antibodies and other protein therapeutics (e.g., for the treatment of cancer, inflammatory and metabolic diseases, and other disorders), highly selective enzymes for drug manufacturing, and novel proteins for use in diagnostics and the identification of new small molecule drugs. This project will enable the power of artificial intelligence (AI) to be applied to accelerate the engineering of proteins with new and improved properties. AI approaches can capitalize on the large amounts of protein mutation data being generated and stored in our recently developed ProtaBank protein mutation database to transform the way in which protein therapeutics and reagents are discovered and developed.!",Advancing Protein Engineering Using Artificial Intelligence and the ProtaBank Mutation Database,9994932,R44GM117961,"['Amino Acid Sequence ', ' Primary Protein Structure ', ' protein sequence ', ' Antibodies ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Automation ', ' Automobile Driving ', ' driving ', ' Base Sequence ', ' Nucleotide Sequence ', ' nucleic acid sequence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biotechnology ', ' Biotech ', ' Communities ', ' Data Sources ', ' Disease ', ' Disorder ', ' Pharmaceutical Preparations ', ' Drugs ', ' Medication ', ' Pharmaceutic Preparations ', ' drug/agent ', ' Engineering ', ' Enzymes ', ' Enzyme Gene ', ' Medicine ', ' Metabolic Diseases ', ' Metabolic Disorder ', ' Thesaurismosis ', ' metabolism disorder ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Natural Language Processing ', ' natural language understanding ', ' Play ', ' Protein Engineering ', ' genetic protein engineering ', ' protein design ', ' Proteins ', ' Reagent ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Standardization ', ' Technology ', ' Generations ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Phase ', ' Link ', ' Training ', ' insight ', ' Data Bases ', ' data base ', ' Databases ', ' Meteor ', ' Inflammatory ', ' Deposit ', ' Deposition ', ' tool ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Scientist ', ' Protocol ', ' Protocols documentation ', ' Techniques ', ' Structure ', ' novel ', ' peer ', ' Modeling ', ' Sampling ', ' Property ', ' depository ', ' repository ', ' native protein drug ', ' pharmaceutical protein ', ' protein drug agent ', ' therapeutic protein ', ' Cancer Treatment ', ' Malignant Neoplasm Therapy ', ' Malignant Neoplasm Treatment ', ' anti-cancer therapy ', ' anticancer therapy ', ' cancer therapy ', ' Molecular Interaction ', ' Binding ', ' small molecule ', ' protein structures ', ' proteins structure ', ' protein structure ', ' Affinity ', ' Data ', ' Collection ', ' Preparation ', ' Modification ', ' developmental ', ' Development ', ' imaging ', ' Image ', ' computational tools ', ' computerized tools ', ' immunogenicity ', ' designing ', ' design ', ' Coupled ', ' Therapeutic antibodies ', ' multi-task ', ' multitask ', ' data base structure ', ' database structure ', ' flexible ', ' flexibility ', ' NGS Method ', ' NGS system ', ' next gen sequencing ', ' nextgen sequencing ', ' next generation sequencing ', ' learning activity ', ' learning method ', ' learning strategy ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' Drug Screening ', ' Data Banks ', ' Databanks ', ' data depository ', ' data repository ', ' data warehouse ', ' data deposition ', ' data submission ', ' deep learning ', ' machine learning method ', ' ']",NIGMS,"PROTABIT, LLC",R44,2020,462766,0.08588080476619434
"The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy Project Summary: The long-term goal of this research program is to develop a rigorously experimentally validated all-atom computational model of the cardiac thin filament (CTF) bound to myosin S1 which provides a unique and accessible platform to identify novel, high resolution disease mechanisms linked to Hypertrophic Cardiomyopathy (HCM). In the prior funding period, we refined and extended our existing CTF computational model and successfully employed it to identify unique and clinically relevant allosteric disease mechanisms including HCM mutation-induced changes in myofilament Ca2+ kinetics, mutation-specific molecular causes of differential cardiac remodeling and disease progression. This included an in vivo validation via the development of a novel transgenic mouse model of cTnT-linked dilated cardiomyopathy and a predictive algorithm to determine the pathogenicity of cTnT mutations that out-performed existing computational approaches in a preliminary test. The key to these advances has been the ability of the current model to precisely identify and locate allosteric changes caused by mutations throughout all components of the CTF followed by closely coupled experimental validation and eventual in vivo model correlation. We now propose to significantly expand the biological complexity of the model to include myosin S1, the molecular motor that drives contraction and the second most common genetic cause of HCM. This important and challenging advance will facilitate a deeper understanding of disease pathogenesis by, for the first time, incorporating the role of molecular allosteric mechanisms between myosin S1 and thin filament. This new computational  experimental platform will be used for both mechanistic insight (for example used for the identification of novel myofilament disease targets,) and the development of a comprehensive deep-learning predictive algorithm to assign pathogenicity to both myosin and thin filament HCM mutations. The latter represents the first use of high-resolution structure, dynamics and function to predict HCM disease allele pathogenicity, a central challenge in the clinical management of these complex patients. Both the training and testing components of the deep learning development will utilize data from the highly annotated and curated SHaRe HCM registry thus greatly improving translational power. Two Specific Aims will be pursued: Aim 1 will utilize state of the art rare event simulation methods developed in one of our groups and refinement of existing unstructured domains of the CTF via FRET to establish the new model. Aim 2 will employ an extensive program of computational analysis and subsequent in vitro validation using pathogenic, variants of unknown significance and non- pathogenic HCM alleles derived from SHaRe to provide inputs to the machine learning environment for algorithm development. Novel disease mechanisms for myosin and thin filament HCM that include crosstalk between the two components will also be explored. Elucidation of these mechanisms can be the basis for robust molecular approaches to disease. Precision medicine and molecular medicine are concepts that aim to employ a patients genetic structure to discern the best medical treatments for disease. Hypertrophic cardiomyopathy is a genetic disease that afflicts 1/500 people. This application translates our knowledge of the molecular level effects of cardiac tissue mutation to disease and will aim to lead to eventual treatment.",The interaction of myosin and the thin filament: how mutations cause allosteric dysfunction and their connection to genetic cardiomyopathy,10071638,R01HL107046,"['Alleles ', ' Allelomorphs ', ' Artificial Intelligence ', ' AI system ', ' Computer Reasoning ', ' Machine Intelligence ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Biology ', ' Biophysics ', ' biophysical foundation ', ' biophysical principles ', ' biophysical sciences ', ' Breath Tests ', ' breath analysis ', ' Differential Scanning Calorimetry ', ' Calorimetric Differential Thermal Analysis ', ' Dilated Cardiomyopathy ', ' Congestive Cardiomyopathy ', ' Translating ', ' Work ', ' Generations ', ' Anisotropy ', ' Fluorescence Anisotropy ', ' Dataset ', ' Data Set ', ' base ', ' improved ', ' Site ', ' Variation ', ' Variant ', ' Biological ', ' Physiologic ', ' Physiological ', ' Medical ', ' Link ', ' Training ', ' insight ', ' Individual ', ' Disease Progression ', ' Funding ', ' Dysfunction ', ' Physiopathology ', ' pathophysiology ', ' Functional disorder ', ' Descriptor ', ' Genetic ', ' Contracting Opportunities ', ' Contracts ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' programs ', ' Complex ', ' Event ', ' Distant ', ' Techniques ', ' System ', ' computational quantum chemistry ', ' quantum chemistry ', ' success ', ' FRET ', ' Frster Resonance Energy Transfer ', ' Fluorescence Resonance Energy Transfer ', ' Molecular Motors ', ' Structure ', ' simulation ', ' novel ', ' Pathogenesis ', ' Modeling ', ' Sampling ', ' response ', ' Pathogenicity ', ' Genetic Structures ', ' Thick Filament ', ' Thin Filament ', ' Address ', ' Data ', ' Induced DNA Alteration ', ' Induced Sequence Alteration ', ' Induced Mutation ', ' Molecular Medicine ', ' Motor ', ' Protein Dynamics ', ' Resolution ', ' in vivo ', ' in vivo Model ', ' Clinical Management ', ' computational analyses ', ' computational analysis ', ' computer analyses ', ' Computer Analysis ', ' Validation ', ' Molecular ', ' Cardiac ', ' developmental ', ' Development ', ' next generation ', ' Coupled ', ' C-terminal ', ' clinical relevance ', ' clinically relevant ', ' murine model ', ' mouse model ', ' stopped-flow fluorescence ', ' precision-based medicine ', ' precision medicine ', ' unclassified variant ', ' variant of uncertain clinical significance ', ' variant of uncertain significance ', ' variant of undetermined significance ', ' variant of unknown significance ', ' classroom environment ', ' college atmosphere ', ' collegial atmosphere ', ' collegiate atmosphere ', ' education atmosphere ', ' educational environment ', ' intellectual atmosphere ', ' learning atmosphere ', ' learning environment ', ' school atmosphere ', ' training atmosphere ', ' university atmosphere ', ' educational atmosphere ', ' predictive algorithm ', ' predictor algorithm ', ' prediction algorithm ', ' experiment ', ' experimental research ', ' experimental study ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' deep learning ', ' neural network ', ' machine learned algorithm ', ' machine learning algorithm ', ' automated analysis ', ' familial cardiomyopathy ', ' genetic cardiomyopathy ', ' hereditary cardiomyopathy ', ' inherited cardiomyopathy ', ' Computerized Models ', ' computational modeling ', ' computational models ', ' computer based models ', ' computerized modeling ', ' Computer Models ', ' algorithm development ', ' Hypertrophic Cardiomyopathy ', ' Asymmetric Septal Hypertrophy ', ' Cardiomyopathy familial hypertrophic ', ' Hereditary ventricular hypertrophy ', ' Hypertrophic Obstructive Cardiomyopathy ', ' Idiopathic Hypertrophic Subvalvular Stenosis ', ' Idiopathic hypertrophic subaortic stenosis ', ' hypertrophic myocardiopathy ', ' cell motility ', ' Cell Locomotion ', ' Cell Migration ', ' Cell Movement ', ' Cellular Migration ', ' Cellular Motility ', ' Motility ', ' Chemistry ', ' Disease ', ' Disorder ', ' Engineering ', ' Enzymes ', ' Enzyme Gene ', ' Goals ', ' Grant ', ' Hand ', ' Human ', ' Modern Man ', ' In Vitro ', ' Kinetics ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Manuals ', ' Methods ', ' Methodology ', ' Transgenic Mice ', ' Microfilaments ', ' Actin Filaments ', ' Myofilaments ', ' Molecular Conformation ', ' Molecular Configuration ', ' Molecular Stereochemistry ', ' conformation ', ' conformational state ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Myosin ATPase ', ' Actin-Activated ATPase ', ' Myosin Adenosine Triphosphatase ', ' Myosin Adenosinetriphosphatase ', ' Myosins ', ' Patients ', ' Perception ', ' phosphorescence ', ' Play ', ' Protein Conformation ', ' Proteins ', ' Registries ', ' Research ', ' Resources ', ' Research Resources ', ' Role ', ' social role ', ' Sarcomeres ', ' Technology ', ' Testing ', ' Thinness ', ' Leanness ', ' Time ', ' Tissues ', ' Body Tissues ', ' ']",NHLBI,UNIVERSITY OF ARIZONA,R01,2020,585711,0.11429310107724709
"Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study SUMMARY Alzheimers disease and related dementias (ADRDs) are typically the result of neurodegenerative processes that begin 15-20 years before clinical diagnosis. Despite this lengthy subclinical phase and advances in early diagnostic technologies including cerebrospinal fluid (CSF) biomarkers, brain MRIs, and positron emission tomography (PET) measures there are no scalable biomarkers to identify individuals with preclinical disease, which may offer the best time window for intervention. Specifically, because brain MRI and PET tests are resource-intensive and CSF sampling is invasive, there is urgent need for biomarkers based on blood samples, which can be non-invasively collected even in centers lacking highly specialized technology. The mitochondrial genome (mtDNA), unlike the stable nuclear genome, is dynamic and accumulates somatic mutations over the lifespan. Mutations in the mtDNA can be induced by oxidative stress and lead to declining mitochondrial function as we age; in turn, less functional mitochondria generate higher levels of oxidative stress, which induces chronic inflammation and tissue injury in specific organs including the brain. Yet, no study has investigated mtDNA mutations as early predictors of ADRD. We hypothesize that individuals with higher levels and faster accumulation of blood mtDNA mutations have greater cognitive decline and preclinical ADRD brain imaging changes during midlife, and that these mtDNA biomarkers will predict ADRD diagnosis in older adults. We will test our hypotheses by leveraging the NHLBI-funded Coronary Artery Risk Development In young Adults (CARDIA) study. CARDIA is a multicenter, community-based, longitudinal cohort that recruited 5,115 black and white young adults (mean age 25 years), followed them up at least every five years, and is preparing to conduct its examination Year 35 (Y35) visit in 2020/21 (mean age 60 years) when over 3,000 participants are expected to return. We will use state-of-the-art deep sequencing technology to measure mtDNA mutations in CARDIA blood samples collected at Y15, Y25, and Y35. In Aim 1, we will determine whether higher levels of mtDNA mutations and their accumulation over time are associated with greater cognitive decline in midlife. In Aim 2, we will determine whether mtDNA mutations are associated with structural, physiological, and functional MRI phenotypes of preclinical ADRD as well as with sensitive MRI-based markers of accelerated brain aging and preclinical ADRD constructed by our team using contemporary machine learning techniques. Finally, in Aim 3, we will test the clinical utility of these mtDNA mutation biomarkers in identifying individuals at risk of future ADRD in four older cohorts that have large numbers of longitudinally identified, clinically-diagnosed ADRD. Our focus on longitudinal measures of blood mtDNA, cognitive function, and MRI changes over a 10- year period during midlife, combined with characterization of their clinical utility in older populations, is highly innovative. If successful, our study may help initiate possible future interventions in early midlife and reduce the public health and medical burden of AD and dementia. PUBLIC HEALTH STATEMENT This study has high potential for characterizing novel blood-based biomarkers to identify preclinical ADRD and test their utility in predicting clinical ADRD. No other study has a similar design with repeated blood mtDNA mutations, cognitive assessments, and brain imaging data during midlife, a critical time window for interventions to prevent clinical ADRD development. By also using data from four large cohorts of older adults, we can determine the clinical utility of these mtDNA biomarkers to predict clinical ADRD and move the field closer toward the NIHs goal of personalized health interventions.",Blood mitochondrial DNA biomarkers of midlife cognitive decline and adverse brain imaging changes - A longitudinal investigation in the CARDIA populationbased cohort study,10055446,R01AG069120,"['Age ', ' ages ', ' Elderly ', ' advanced age ', ' elders ', ' geriatric ', ' late life ', ' later life ', ' older adult ', ' older person ', ' senior citizen ', ' Aging ', "" Alzheimer's Disease "", ' AD dementia ', ' Alzheimer ', ' Alzheimer Type Dementia ', ' Alzheimer disease ', ' Alzheimer sclerosis ', ' Alzheimer syndrome ', "" Alzheimer's "", "" Alzheimer's disease dementia "", ' Alzheimers Dementia ', ' Alzheimers disease ', ' Primary Senile Degenerative Dementia ', ' dementia of the Alzheimer type ', ' primary degenerative dementia ', ' senile dementia of the Alzheimer type ', ' Blood ', ' Blood Reticuloendothelial System ', ' Brain ', ' Brain Nervous System ', ' Encephalon ', ' Cerebrospinal Fluid ', ' cerebral spinal fluid ', ' spinal fluid ', ' Clinical Markers ', ' Cohort Studies ', ' Concurrent Studies ', ' Communities ', ' Diagnosis ', ' Disease ', ' Disorder ', ' Mitochondrial DNA ', ' mtDNA ', ' Future ', ' Genome ', ' Goals ', ' Health ', ' Inflammation ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Longevity ', ' Length of Life ', ' life span ', ' lifespan ', ' Magnetic Resonance Imaging ', ' MR Imaging ', ' MR Tomography ', ' MRI ', ' Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance ', ' NMR Imaging ', ' NMR Tomography ', ' Nuclear Magnetic Resonance Imaging ', ' Zeugmatography ', ' middle age ', ' mid life ', ' mid-life ', ' middle aged ', ' midlife ', ' Mitochondria ', ' mitochondrial ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' United States National Institutes of Health ', ' NIH ', ' National Institutes of Health ', ' Nerve Degeneration ', ' Neuron Degeneration ', ' neural degeneration ', ' neurodegeneration ', ' neurodegenerative ', ' neurological degeneration ', ' neuronal degeneration ', ' Patients ', ' Phenotype ', ' Positron-Emission Tomography ', ' PET ', ' PET Scan ', ' PET imaging ', ' PETSCAN ', ' PETT ', ' Positron Emission Tomography Medical Imaging ', ' Positron Emission Tomography Scan ', ' Rad.-PET ', ' positron emission tomographic (PET) imaging ', ' positron emission tomographic imaging ', ' positron emitting tomography ', ' Public Health ', ' Research ', ' Research Design ', ' Study Type ', ' study design ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Resources ', ' Research Resources ', ' Risk ', ' Role ', ' social role ', ' Technology ', ' Testing ', ' Time ', ' Work ', ' Measures ', ' base ', ' Organ ', ' Blood Sample ', ' Blood specimen ', ' brain visualization ', ' Brain imaging ', ' Chronic ', ' Solid ', ' Clinical ', ' Phase ', ' Physiologic ', ' Physiological ', ' Medical ', ' Link ', ' insight ', ' brain atrophy ', ' cortical atrophy ', ' cerebral atrophy ', ' Individual ', ' adult youth ', ' young adulthood ', ' young adult ', ' Oxidative Stress ', ' Funding ', ' clinical Diagnosis ', ' tool ', ' Cognitive Disturbance ', ' Cognitive Impairment ', ' Cognitive decline ', ' Cognitive function abnormal ', ' Disturbance in cognition ', ' cognitive dysfunction ', ' cognitive loss ', ' Impaired cognition ', ' Diagnostic ', ' machine learned ', ' Machine Learning ', ' Functional MRI ', ' fMRI ', ' Functional Magnetic Resonance Imaging ', ' programs ', ' cognitive function ', ' Investigation ', ' Pattern ', ' Techniques ', ' Nuclear ', ' Somatic Mutation ', ' Visit ', ' experience ', ' cohort ', ' Structure ', ' novel ', ' Participant ', ' Environmental Factor ', ' environmental risk ', ' Environmental Risk Factor ', ' Sampling ', ' Intervention Strategies ', ' interventional strategy ', ' Intervention ', ' mtDNA mutation ', ' mitochondrial DNA mutation ', ' preventing ', ' prevent ', ' genome sequencing ', ' Address ', ' Data ', ' Cognitive ', ' Older Population ', ' Process ', ' Active Follow-up ', ' active followup ', ' follow up ', ' followed up ', ' followup ', ' follow-up ', ' developmental ', ' Development ', ' preclinical ', ' pre-clinical ', ' mitochondrial genome ', ' NHLBI ', ' National Heart, Lung, and Blood Institute ', ' deep sequencing ', ' age dependent ', ' age related ', ' designing ', ' design ', ' aged ', ' prospective ', ' innovate ', ' innovative ', ' innovation ', ' aged brain ', ' aging brain ', ' Alzheimer risk factor ', ' alzheimer risk ', "" Alzheimer's disease risk "", ' Framingham Heart Study ', ' critical period ', ' population based ', ' bio-markers ', ' biologic marker ', ' biomarker ', ' Biological Markers ', ' clinical risk ', ' epigenome ', ' clinical predictors ', ' predictive biomarkers ', ' predictive molecular biomarker ', ' predictive marker ', ' cognitive assessment ', ' cognitive testing ', ' Coronary Artery Risk Development in Young Adults ', ' Coronary Artery Risk Development in Young Adults Study ', ' entire genome ', ' full genome ', ' whole genome ', ' TOPMed ', ' Trans-Omics for Precision Medicine ', ' blood-based marker ', ' blood-based biomarker ', ' Long-term cohort ', ' Longterm cohort ', ' Longitudinal cohort ', ' recruit ', ' AD related dementia ', ' ADRD ', ' Alzheimer related dementia ', "" Alzheimer's disease related dementia "", ' risk factor for dementia ', ' risk for dementia ', ' dementia risk ', ' injury to tissue ', ' tissue injury ', ' ']",NIA,COLUMBIA UNIVERSITY HEALTH SCIENCES,R01,2020,852784,0.04834748610535386
"Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data Big data is now ubiquitous in every field of modern scientific research. Many contemporary applications, such as the recent national microbiome initiative (NMI), greatly demand highly flexible statistical machine learning methods that can produce both interpretable and reproducible results. Thus, it is of paramount importance to identify crucial causal factors that are responsible for the response from a large number of available covariates, which can be statistically formulated as the false discovery rate (FDR) control in general high-dimensional nonlinear models. Despite the enormous applications of shotgun metagenomic studies, most existing investigations concentrate on the study of bacterial organisms. However, viruses and virus-host interactions play important roles in controlling the functions of the microbial communities. In addition, viruses have been shown to be associated with complex diseases. Yet, investigations into the roles of viruses in human diseases are significantly underdeveloped. The objective of this proposal is to develop mathematically rigorous and computationally efficient approaches to deal with highly complex big data and the applications of these approaches to solve fundamental and important biological and biomedical problems. There are four interrelated aims. In Aim 1, we will theoretically investigate the power of the recently proposed model-free knockoffs (MFK) procedure, which has been theoretically justified to control FDR in arbitrary models and arbitrary dimensions. We will also theoretically justify the robustness of MFK with respect to the misspecification of covariate distribution. These studies will lay the foundations for our developments in other aims. In Aim 2, we will develop deep learning approaches to predict viral contigs with higher accuracy, integrate our new algorithm with MFK to achieve FDR control for virus motif discovery, and investigate the power and robustness of our new procedure. In Aim 3, we will take into account the virus-host motif interactions and adapt our algorithms and theories in Aim 2 for predicting virus-host infectious interaction status. In Aim 4, we will apply the developed methods from the first three aims to analyze the shotgun metagenomics data sets in ExperimentHub to identify viruses and virus-host interactions associated with several diseases at some target FDR level. Both the algorithms and results will be disseminated through the web. The results from this study will be important for metagenomics studies under a variety of environments. Big data is ubiquitous in biological research. Identifying causal factors associated with complex diseases or traits from big data is highly important and challenging. New statistical and computational tools will be developed to control False Discovery Rate (FDR) for molecular sequence data based on the novel model-free knockoffs framework. They will be used to detect sequence motifs for viruses and motif-pairs for virus-host interactions, and to analyze multiple metagenomics data sets related to complex diseases.",Adaptive Reproducible High-Dimensional Nonlinear Inference for Big Biological Data,9923688,R01GM131407,"['Algorithms ', ' Archaea ', ' Archaebacteria ', ' Archaeobacteria ', ' Archaeon ', ' Attention ', ' Bacteria ', ' Cells ', ' Cell Body ', ' Non-Insulin-Dependent Diabetes Mellitus ', ' Adult-Onset Diabetes Mellitus ', ' Ketosis-Resistant Diabetes Mellitus ', ' Maturity-Onset Diabetes Mellitus ', ' NIDDM ', ' Non-Insulin Dependent Diabetes ', ' Noninsulin Dependent Diabetes ', ' Noninsulin Dependent Diabetes Mellitus ', ' Slow-Onset Diabetes Mellitus ', ' Stable Diabetes Mellitus ', ' T2 DM ', ' T2D ', ' T2DM ', ' Type 2 Diabetes Mellitus ', ' Type 2 diabetes ', ' Type II Diabetes Mellitus ', ' Type II diabetes ', ' adult onset diabetes ', ' ketosis resistant diabetes ', ' maturity onset diabetes ', ' type 2 DM ', ' type II DM ', ' type two diabetes ', ' Disease ', ' Disorder ', ' Environment ', ' Foundations ', ' Genes ', ' Human ', ' Modern Man ', ' Joints ', ' Linear Regressions ', ' Literature ', ' Liver Cirrhosis ', ' Hepatic Cirrhosis ', ' Mathematics ', ' Math ', ' Methods ', ' Modernization ', ' Molecular Sequence Data ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Neurosciences ', ' Obesity ', ' adiposity ', ' corpulence ', ' corpulency ', ' corpulentia ', ' obese ', ' obese people ', ' obese person ', ' obese population ', ' Organism ', ' living system ', ' Play ', ' Reproducibility of Results ', ' Reproducibility of Findings ', ' Research ', ' Research Personnel ', ' Investigators ', ' Researchers ', ' Role ', ' social role ', ' Sampling Studies ', ' Shotguns ', ' shot gun ', ' Social Sciences ', ' Computer software ', ' Software ', ' Testing ', ' Theoretical Studies ', ' Tissues ', ' Body Tissues ', ' Virus ', ' Work ', ' health care ', ' Healthcare ', ' Dataset ', ' Data Set ', ' Ecologic Systems ', ' Ecological Systems ', ' Ecosystem ', ' base ', ' improved ', ' Procedures ', ' Biological ', ' Nonlinear Models ', ' Non-linear Models ', ' Training ', ' Earth ', ' Planet Earth ', ' WWW ', ' web ', ' world wide web ', ' Internet ', ' Investigation ', ' Dimensions ', ' Frequencies ', ' Complex ', ' Genetic Materials ', ' human tissue ', ' Viral ', ' interest ', ' Consult ', ' Performance ', ' identification of viruses ', ' virus identification ', ' trait ', ' virus host interaction ', ' simulation ', ' novel ', ' novel technologies ', ' new technology ', ' Bypass ', ' Modeling ', ' Sampling ', ' response ', ' theories ', ' Genomics ', ' model design ', ' model development ', ' Effectiveness ', ' Address ', ' Length ', ' Data ', ' Reproducibility ', ' Molecular ', ' developmental ', ' Development ', ' Colo-rectal Cancer ', ' Colorectal Cancer ', ' microbiome ', ' computational tools ', ' computerized tools ', ' designing ', ' design ', ' visualization tool ', ' Visualization software ', ' Coupled ', ' community microbes ', ' microbial community ', ' metagenome sequencing ', ' metagenomic sequencing ', ' biological research ', ' Functional Metagenomics ', ' Metagenomics ', ' user-friendly ', ' human disease ', ' flexible ', ' flexibility ', ' BigData ', ' Big Data ', ' dark matter ', ' Gaussian statistics ', ' Gaussianity ', ' Gaussianity model ', ' Gaussian model ', ' learning activity ', ' learning method ', ' learning strategy ', ' power analysis ', ' high dimensionality ', ' Microbiomics ', ' microbiome science ', ' microbiome studies ', ' microbiome research ', ' deep learning ', ' deep learning algorithm ', ' contig ', ' statistical and machine learning ', ' machine learning method ', ' ']",NIGMS,UNIVERSITY OF SOUTHERN CALIFORNIA,R01,2020,276700,0.08576415681657736
"Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation To be fully understood, the human genome must be considered in the context of evolution. The activities that have dominated human genomics for three decades  such as genome sequencing and annotation, interrogation with high-throughput biochemical assays, and the identification of associations between genetic variants and diseases  have been enormously informative, but these descriptive studies must eventually be understood within the theoretical framework of evolutionary genetics. We must continue to press forward from the what? to the why? and how? of human genetics.  The goal of my laboratory is to interpret high-throughput genomic data from an evolutionary perspective. Drawing from ideas and techniques in molecular evolution, population genetics, statistics, and computer science, we aim both to understand the evolutionary forces that have shaped human genomes, and to use evolution to shed light on the phenotypic importance of particular sequences. Our recent activities have focused in three major areas: (1)  reconstruction  of  features  of  human  evolution  based  on  genome  sequences;  (2)  prediction  of  the  fitness consequences  of  human  mutations;  and  (3)  the  study  of  transcriptional  regulation  and  its  evolution  in primates.   We have reported major findings in each of these areas, including the existence of gene flow from early modern humans to Eastern Neandertals, a map of fitness consequences for mutations across the human genome, and an analysis showing that the architecture of transcription initiation is highly similar at enhancers and promoters in the human genome.  Here we propose to extend our research substantially in each of these areas, working together with a broad range  of  experimental  and  theoretical  collaborators.    Our  new  goals  include  the  development  of  improved methods for reconstructing human demography, with a focus on ancient gene flow; extensions of our ancestral recombination graph (ARG) sampling methods to accommodate much larger samples sizes, with applications in association mapping and the detection of natural selection; two complementary machine-learning approaches for  improving  the  prediction  of  fitness  consequences  from  sequence  data;  an  experimental  collaboration  to leverage CRISPR-Cas9 screens in characterizing noncoding mutations; a multi-pronged study of the sequence determinants of RNA stability and their implications for the evolution of transcription units; and development of a new probabilistic model for turnover of regulatory elements.  Together, these projects will address a wide variety of fundamental questions about the function and evolution of sequences in the human genome. Vast quantities of genomic data are now available to describe patterns of genetic variation within  human populations and across species, and various measures of biochemical activity along the human  genome. These data need to be interpreted in light of the fundamental forces of mutation,  recombination, natural selection, and genetic drift that have shaped genetic variation. This  proposal describes a series of projects that make use of new computational, statistical, and  theoretical methods to address fundamental questions in human evolutionary genetics, including how  humans arose   from our archaic hominin and ape cousins, how human populations diverged from one  another, how new mutations influence human health and fitness, and how regulatory sequences  contribute to unique aspects of human biology.","Evolutionary Human Genomics: Demography, Natural Selection, and Transcriptional Regulation",9876220,R35GM127070,"['Architecture ', ' Engineering / Architecture ', ' Biological Assay ', ' Assay ', ' Bioassay ', ' Biologic Assays ', ' Demography ', ' Evolution ', ' Genes ', ' Population Genetics ', ' Genome ', ' Human Genome ', ' human whole genome ', ' Goals ', ' Health ', ' Human ', ' Modern Man ', ' Human Genetics ', ' Laboratories ', ' Light ', ' Photoradiation ', ' Maps ', ' Methods ', ' Statistical Models ', ' Probabilistic Models ', ' Probability Models ', ' statistical linear mixed models ', ' statistical linear models ', ' Modernization ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Phenotype ', ' Pongidae ', ' Apes ', ' great ape ', ' Primates ', ' Primates Mammals ', ' Genetic Recombination ', ' DNA Recombination ', ' Recombination ', ' Research ', ' statistics ', ' Genetic Transcription ', ' Gene Transcription ', ' RNA Expression ', ' Transcription ', ' Genetic Variation ', ' Genetic Diversity ', ' Measures ', ' Enhancers ', ' Natural Selections ', ' promotor ', ' promoter ', ' base ', ' improved ', ' Area ', ' Biochemical ', ' Series ', ' Sample Size ', ' Collaborations ', ' Molecular Evolution ', ' Genetic ', ' machine learned ', ' Machine Learning ', ' Pattern ', ' Techniques ', ' computer science ', ' Human Biology ', ' Graph ', ' Reporting ', ' RNA Stability ', ' Sampling ', ' Functional RNA ', ' Non-Coding ', ' Non-Coding RNA ', ' Non-translated RNA ', ' Noncoding RNA ', ' Nontranslated RNA ', ' noncoding ', ' Untranslated RNA ', ' Genetic Differentiation ', ' Genetic Divergence ', ' Genetic Drift ', ' Transcription Regulation ', ' Transcriptional Control ', ' Transcriptional Regulation ', ' Transcription Initiation ', ' genome sequencing ', ' Address ', ' fitness ', ' Data ', ' Detection ', ' Regulatory Element ', ' developmental ', ' Development ', ' reconstruction ', ' Gene variant ', ' allele variant ', ' allelic variant ', ' genomic variant ', ' genetic variant ', ' Population ', ' genome annotation ', ' genome analysis ', ' human genomics ', ' CRISPR editing screen ', ' CRISPR-based screen ', ' CRISPR/Cas9 screen ', ' clustered regularly interspaced short palindromic repeats screen ', ' CRISPR screen ', ' genomic data-set ', ' genomic dataset ', ' genomic data ', ' genetic condition ', ' genetic disorder ', ' Genetic Diseases ', ' ']",NIGMS,COLD SPRING HARBOR LABORATORY,R35,2020,479215,0.050870111287866684
"Molecular Characterization of Joubert Syndrome Project Summary Congenital ataxia presents in early childhood with non-progressive hypotonia, gross motor, fine motor and cognitive delays. These disorders are distinct from the progressive ataxias because of the presence of congenital cerebellar malformations and because they are typically inherited recessively. Joubert Syndrome and Related Disorders (JSRD) constitute a major subset of these conditions, consisting of a cerebellar midline (vermis) malformation, a nearly pathognomonic Molar Tooth sign on brain Imaging (MTI) and co-existent oculomotor apraxia and episodic breathing dysrhythmias. In our published data, we have: 1] Identified ten unique genetic causes of JSRD (nearly half of the published causes), 2] Generated genotype-phenotype correlations involving cerebellar, retinal, renal, hepatic, digit, and cerebral manifestations. 3] Identified common founder mutations that allow for population-based screening. 4] Discovered that JSRD encoded proteins frequently localize to the cilium. 5] Identified ciliary transition zone (TZ) defects in cells with JSRD mutations. 6] Performed siRNA cell-based screens for defective ciliogenesis to prioritize candidate JSRD genes. 7] Generated and characterized multiple zebrafish, mouse and human cell culture models for JSRD. 8] Defined the concept of Ciliary localization model, in which one JSRD gene is required for ciliary localization of other JSRD proteins. In our unpublished data we have: 1] Recruited an additional 200 JSRD patients without molecular diagnosis. 2] Performed whole exome (WES) and whole genome sequencing (WGS) on an additional 100 JSRD families. 3] Identified an additional 12 novel likely JSRD candidate genes. 4] Generated IPSCs and cerebellar organoids from mutation-positive and negative families to aid in functional analysis and gene discovery using RNAseq. 5] Begun functional validation of the putative mutations. 6] Developed methods to interrogate ciliary structure in a high-throughput fashion with electron microscopy (EM). The goal of this competing renewal is to identify the remaining discoverable genes that lead to JSRD when lost, functionally validate mutations within the pathogenetic framework, and test the hypothesis that mutations in JSRD genes lead to collapse of the ciliary TZ. Because the majority of patients still have unknown cause of disease, this renewal aims to advance knowledge through molecular characterization of new genes, using newly evolving high-throughput techniques, integrated bioinformatics, and a unique resource of consanguineous families recruited world-wide. We further aim to validate these mutations in patient cells, within a mechanistic framework that JSRD genes are required for essential ciliary structural components during cerebellar development. Project Narrative Joubert syndrome is a genetically and phenotypically heterogeneous neurodevelopmental disorder unified by defects of the cellular primary cilium. This work will identify new genetic causes and dissect ciliary defects associated with genetic mutations.",Molecular Characterization of Joubert Syndrome,9988508,R01NS048453,"['Termination of pregnancy ', ' Apraxias ', ' Dyspraxia ', ' apraxia ', ' Breathing ', ' Respiratory Aspiration ', ' Respiratory Inspiration ', ' inspiration ', ' Ataxia ', ' Ataxy ', ' Coordination Impairment ', ' Dyssynergia ', ' Cell Culture Techniques ', ' cell culture ', ' Cells ', ' Cell Body ', ' Cultured Cells ', ' Cilia ', ' Cytoplasmic Granules ', ' granule ', ' Disease ', ' Disorder ', ' Electrons ', ' Negative Beta Particle ', ' Negatrons ', ' Embryo ', ' Embryonic ', ' Face ', ' faces ', ' facial ', ' Family ', ' Genes ', ' Genotype ', ' Goals ', ' Gold ', ' Human ', ' Modern Man ', ' Kidney ', ' Kidney Urinary System ', ' renal ', ' Lead ', ' Pb element ', ' heavy metal Pb ', ' heavy metal lead ', ' Methods ', ' Electron Microscopy ', ' Scanning Electron Microscopy ', ' Middle East ', ' Molar tooth ', ' Morphogenesis ', ' morphogenetic process ', ' Mus ', ' Mice ', ' Mice Mammals ', ' Murine ', ' Muscle hypotonia ', ' Decreased Muscle Tone ', ' Hypomyotonia ', ' Hypotonia ', ' Muscle Hypotony ', ' Muscle Tone Poor ', ' Muscular Hypotonia ', ' Mutation ', ' Genetic Alteration ', ' Genetic Change ', ' Genetic defect ', ' genome mutation ', ' Organoids ', ' Patients ', ' Phenotype ', ' Probability ', ' Proteins ', ' Publishing ', ' Resources ', ' Research Resources ', ' Retina ', ' Risk ', ' Signal Transduction ', ' Cell Communication and Signaling ', ' Cell Signaling ', ' Intracellular Communication and Signaling ', ' Signal Transduction Systems ', ' Signaling ', ' biological signal transduction ', ' Sonication ', ' Mass Spectrum Analysis ', ' Mass Photometry/Spectrum Analysis ', ' Mass Spectrometry ', ' Mass Spectroscopy ', ' Mass Spectrum ', ' Mass Spectrum Analyses ', ' Syndrome ', ' Testing ', ' Work ', ' Zebrafish ', ' Brachydanio rerio ', ' Danio rerio ', ' Zebra Danio ', ' Zebra Fish ', ' base ', ' brain visualization ', ' Brain imaging ', ' Hepatic ', ' Clinical ', ' Microscopic ', ' Variation ', ' Variant ', ' Series ', ' Training ', ' vermis ', ' Cerebellar vermis structure ', ' insight ', ' Individual ', ' cerebral ', ' Cerebrum ', ' Data Bases ', ' data base ', ' Databases ', ' Cerebellar hypoplasia ', ' Congenital cerebellar hypoplasia ', ' Genetic ', ' Morphology ', ' machine learned ', ' Machine Learning ', ' Knowledge ', ' Joubert-Boltshauser syndrome ', ' cerebellar vermis agenesis ', ' cerebelloparenchymal disorder IV ', ' Joubert syndrome ', ' Hereditary ', ' Inherited ', ' Severities ', ' cell type ', ' Techniques ', ' fetal ', ' Digit ', ' Digit structure ', ' Gene Alteration ', ' Gene Mutation ', ' mutant ', ' early childhood ', ' cohort ', ' Transmission Electron Microscopy ', ' Structure ', ' novel ', ' Modeling ', ' affection ', ' ocular motor ', ' ocularmotor ', ' oculomotor ', ' disease subgroups ', ' disease subtype ', ' disorder subtype ', ' Short interfering RNA ', ' siRNA ', ' Small Interfering RNA ', ' Pathogenicity ', ' Bio-Informatics ', ' Bioinformatics ', ' ciliogenesis ', ' cilium biogenesis ', ' genome sequencing ', ' Candidate Gene ', ' Candidate Disease Gene ', ' Length ', ' Defect ', ' DNA Alteration ', ' DNA mutation ', ' Genetic mutation ', ' Sequence Alteration ', ' genomic alteration ', ' DNA Sequence Alteration ', ' Data ', ' Molecular Diagnosis ', ' Motor ', ' Protein Analysis ', ' Cognitive ', ' enroll ', ' Enrollment ', ' Validation ', ' WNT signaling ', ' WNT Signaling Pathway ', ' Molecular ', ' Knockout ', ' Knock-out ', ' developmental ', ' Development ', ' Neurological Development Disorder ', ' Neurodevelopmental Disorder ', ' Cerebellum malformation ', ' Cerebellar malformation ', ' reconstruction ', ' knockdown ', ' knock-down ', ' 3-D analysis ', ' 3-dimensional analysis ', ' 3D analysis ', ' Three-dimensional analysis ', ' loss of function mutation ', ' founder mutation ', ' malformation ', ' discover genes ', ' gene discovery ', ' population based ', ' stem cell biology ', ' genome scale ', ' genomewide ', ' genome-wide ', ' exomes ', ' exome ', ' RNA Seq ', ' RNA sequencing ', ' RNAseq ', ' transcriptome sequencing ', ' exome-seq ', ' exome sequencing ', ' screening ', ' CRISPR ', ' CRISPR/Cas system ', ' Clustered Regularly Interspaced Short Palindromic Repeats ', ' accurate diagnosis ', ' consanguineous kindreds ', ' consanguineous pedigree ', ' consanguineous family ', ' entire genome ', ' full genome ', ' whole genome ', ' recruit ', ' gene testing ', ' gene-based testing ', ' genetic testing ', ' ']",NINDS,"UNIVERSITY OF CALIFORNIA, SAN DIEGO",R01,2020,510012,0.16355562859239955
